FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Kangovi, S Long, JA Emanuel, E AF Kangovi, Shreya Long, Judith A. Emanuel, Ezekiel TI Community Health Workers Combat Readmission SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID GENERAL MEDICINE PATIENTS C1 [Kangovi, Shreya; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kangovi, Shreya; Long, Judith A.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Emanuel, Ezekiel] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Long, Judith A.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Emanuel, Ezekiel] Univ Penn, Off Provost, Philadelphia, PA 19104 USA. [Emanuel, Ezekiel] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Kangovi, S (reprint author), 423 Guardian Dr,Blockley Hall,13th Floor, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu NR 12 TC 12 Z9 12 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD DEC 10 PY 2012 VL 172 IS 22 BP 1756 EP 1757 DI 10.1001/2013.jamainternmed.82 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 052LE UT WOS:000312198300015 PM 23128914 ER PT J AU Shen, KZ Johnson, SW AF Shen, Ke-Zhong Johnson, Steven W. TI Chronic dopamine depletion augments the functional expression of K-ATP channels in the rat subthalamic nucleus SO NEUROSCIENCE LETTERS LA English DT Article DE ATP-sensitive K+ channel; Subthalamic nucleus; N-Methyl-D-aspartate; Sulfonylurea; Tolbutamide; Brain slice ID SENSITIVE POTASSIUM CHANNELS; NEURONS IN-VITRO; PARKINSONS-DISEASE; BASAL GANGLIA; BRAIN; 6-HYDROXYDOPAMINE; RESPONSES; PALLIDUM; PATHWAY; GABA AB Symptoms of Parkinson's disease caused by dopamine depletion are associated with burst firing in the subthalamic nucleus (STN). Moreover, regularization or suppression of STN neuronal activity is thought to improve symptoms of Parkinson's disease. We reported recently that N-methyl-D-aspartate (NMDA) receptor stimulation of rat STN neurons evokes ATP-sensitive K+ (K-ATP) current via a Ca2+-and nitric oxide-dependent mechanism. The present studies were done to determine whether or not K-ATP channel function in STN neurons is altered in a model of chronic dopamine depletion. Brain slices were prepared from rats with unilateral dopamine depletion caused by intracerebral 6-hydroxydopamine (6-OHDA) injections. Whole-cell patch-clamp recordings showed that NMDA evoked more outward current at -70 mV and greater positive slope conductance in STN neurons located ipsilateral to 6-OHDA treatment compared to neurons located contralateral. Moreover, extracellular, loose-patch recordings showed that NMDA increased spontaneous firing rate in STN neurons in slices from normal rats, whereas NMDA produced a tolbutamide-sensitive inhibition of firing rate in STN neurons located ipsilateral to 6-OHDA treatment. These results show that K-ATP channel function in STN neurons is up-regulated by chronic dopamine deficiency. We suggest that K-ATP channel activation in the STN might benefit symptoms of Parkinson's disease. Published by Elsevier Ireland Ltd. C1 [Shen, Ke-Zhong; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Johnson, Steven W.] Portland VA Med Ctr, Portland, OR 97207 USA. RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM johnsost@ohsu.edu FU USPHS [NS38715]; Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center FX This work was supported by USPHS grant NS38715 and by the Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center. NR 25 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD DEC 7 PY 2012 VL 531 IS 2 BP 104 EP 108 DI 10.1016/j.neulet.2012.10.030 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 058CX UT WOS:000312612800009 PM 23127848 ER PT J AU Han, D Ybanez, MD Johnson, HS McDonald, JN Mesropyan, L Sancheti, H Martin, G Martin, A Lim, AM Dara, L Cadenas, E Tsukamoto, H Kaplowitz, N AF Han, Derick Ybanez, Maria D. Johnson, Heather S. McDonald, Jeniece N. Mesropyan, Lusine Sancheti, Harsh Martin, Gary Martin, Alanna Lim, Atalie M. Dara, Lily Cadenas, Enrique Tsukamoto, Hidekazu Kaplowitz, Neil TI Dynamic Adaptation of Liver Mitochondria to Chronic Alcohol Feeding in Mice BIOGENESIS, REMODELING, AND FUNCTIONAL ALTERATIONS SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SKELETAL-MUSCLE MITOCHONDRIA; CHRONIC ETHANOL-CONSUMPTION; RAT-LIVER; ENERGY-METABOLISM; DEPENDENT HEPATOTOXICITY; SUPEROXIDE ANION; SWIFT INCREASE; FAT DIET; NECROSIS; EXERCISE AB Liver mitochondria undergo dynamic alterations following chronic alcohol feeding to mice. Intragastric alcohol feeding to mice resulted in 1) increased state III respiration (109% compared with control) in isolated liver mitochondria, probably due to increased levels of complexes I, IV, and V being incorporated into the respiratory chain; 2) increased mitochondrial NAD(+) and NADH levels (similar to 2-fold), with no change in the redox status; 3) alteration in mitochondrial morphology, with increased numbers of elongated mitochondria; and 4) enhanced mitochondrial biogenesis in the liver, which corresponded with an up-regulation of PGC-1 alpha (peroxisome proliferator-activated receptor gamma coactivator-1 alpha). Oral alcohol feeding to mice, which is associated with less liver injury and steatosis, slightly enhanced respiration in isolated liver mitochondria (30.8% compared with control), lower than the striking increase caused by intragastric alcohol feeding. Mitochondrial respiration increased with both oral and intragastric alcohol feeding despite extensive N-acetylation of mitochondrial proteins. The alcohol-induced mitochondrial alterations are probably an adaptive response to enhance alcohol metabolism in the liver. Isolated liver mitochondria from alcohol-treated mice had a greater rate of acetaldehyde metabolism and respiration when treated with acetaldehyde than control. Aldehyde dehydrogenase-2 levels were unaltered in response to alcohol, suggesting that the greater acetaldehyde metabolism by isolated mitochondria from alcohol-treated mice was due to increased mitochondrial respiration that regenerated NAD(+), the rate-limiting substrate in alcohol/acetaldehyde metabolism. Overall, our work suggests that mitochondrial plasticity in the liver may be an important adaptive response to the metabolic stress caused by alcohol intake and could potentially play a role in many other vital functions performed by the liver. C1 [Han, Derick; Lim, Atalie M.; Dara, Lily; Kaplowitz, Neil] Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, Los Angeles, CA 90089 USA. [Lim, Atalie M.; Dara, Lily; Kaplowitz, Neil] Univ So Calif, Keck Sch Med, So Calif Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90089 USA. [Sancheti, Harsh; Cadenas, Enrique] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA. [Martin, Gary; Martin, Alanna] Occidental Coll, Dept Biol, Los Angeles, CA 90041 USA. [Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, Los Angeles, CA 90089 USA. [Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA. [Tsukamoto, Hidekazu] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90089 USA. RP Han, D (reprint author), Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, 2011 Zonal Ave,HMR 101, Los Angeles, CA 90089 USA. EM derickh@usc.edu OI Sancheti, Harsh/0000-0001-8084-4550 FU National Institutes of Health Grant [AA016911, AA14428, P50AA11999] FX This work was supported, in whole or in part, by National Institutes of Health Grant AA016911 (to D. H.), AA14428 (to N. K.), and P50AA11999 (to H. T.). NR 57 TC 24 Z9 24 U1 0 U2 10 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 7 PY 2012 VL 287 IS 50 BP 42165 EP 42179 DI 10.1074/jbc.M112.377374 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 051CT UT WOS:000312103000054 PM 23086958 ER PT J AU Norton, WE McCannon, CJ Schall, MW Mittman, BS AF Norton, Wynne E. McCannon, C. Joseph Schall, Marie W. Mittman, Brian S. TI A stakeholder-driven agenda for advancing the science and practice of scale-up and spread in health SO IMPLEMENTATION SCIENCE LA English DT Article DE Scale-up; Spread; Healthcare; Public health; Improvement; Implementation; Dissemination; Health systems research; Healthcare delivery ID INTERNATIONAL HEALTH; IMPROVEMENT; CARE; RECOMMENDATIONS; ORGANIZATIONS; INNOVATIONS; SERVICES AB Background: Although significant advances have been made in implementation science, comparatively less attention has been paid to broader scale-up and spread of effective health programs at the regional, national, or international level. To address this gap in research, practice and policy attention, representatives from key stakeholder groups launched an initiative to identify gaps and stimulate additional interest and activity in scale-up and spread of effective health programs. We describe the background and motivation for this initiative and the content, process, and outcomes of two main phases comprising the core of the initiative: a state-of-the-art conference to develop recommendations for advancing scale-up and spread and a follow-up activity to operationalize and prioritize the recommendations. The conference was held in Washington, D. C. during July 2010 and attended by 100 representatives from research, practice, policy, public health, healthcare, and international health communities; the follow-up activity was conducted remotely the following year. Discussion: Conference attendees identified and prioritized five recommendations (and corresponding sub-recommendations) for advancing scale-up and spread in health: increase awareness, facilitate information exchange, develop new methods, apply new approaches for evaluation, and expand capacity. In the follow-up activity, 'develop new methods' was rated as most important recommendation; expanding capacity was rated as least important, although differences were relatively minor. Summary: Based on the results of these efforts, we discuss priority activities that are needed to advance research, practice and policy to accelerate the scale-up and spread of effective health programs. C1 [Norton, Wynne E.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA. [McCannon, C. Joseph; Schall, Marie W.] Inst Healthcare Improvement, Cambridge, MA 02138 USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, VA Ctr Implementat Practice & Res Support, North Hills, CA 91343 USA. RP Norton, WE (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, 1665 Univ Blvd, Birmingham, AL 35294 USA. EM wenorton@uab.edu OI Mittman, Brian/0000-0003-3589-9178 FU Agency for Healthcare Research and Quality [1R13HS019422-01]; Commonwealth Fund [20100353]; Veterans Health Administration; Quality Enhancement Research Initiative; John A. Hartford Foundation; Patrick and Catherine Weldon Donaghue Medical Research Foundation FX The state-of-the-art conference on scale-up/spread was supported by grant 1R13HS019422-01 from the Agency for Healthcare Research and Quality (PI: McCannon); grant #20100353 from the Commonwealth Fund (PI: McCannon); funding from The Veterans Health Administration, Quality Enhancement Research Initiative, The John A. Hartford Foundation, and The Patrick and Catherine Weldon Donaghue Medical Research Foundation. Views expressed in this paper do not necessarily reflect the official policies of the Department of Health and Human Services or Department of Veterans Affairs; nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government. NR 33 TC 6 Z9 6 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD DEC 6 PY 2012 VL 7 AR 118 DI 10.1186/1748-5908-7-118 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 104AY UT WOS:000315962700001 PM 23216748 ER PT J AU Winters-Stone, KM Li, FZ Horak, F Luoh, SW Bennett, JA Nail, L Dieckmann, N AF Winters-Stone, Kerri M. Li, Fuzhong Horak, Fay Luoh, Shiuh-Wen Bennett, Jill A. Nail, Lillian Dieckmann, Nathan TI Comparison of tai chi vs. strength training for fall prevention among female cancer survivors: study protocol for the GET FIT trial SO BMC CANCER LA English DT Article DE Resistance training; Exercise; Physical function; Postural stability; Muscle strength; Chemotherapy; Neoplasm; Fracture ID RANDOMIZED CONTROLLED-TRIAL; LOWER-EXTREMITY FUNCTION; RECEIVING ADJUVANT CHEMOTHERAPY; PHYSICAL PERFORMANCE BATTERY; BREAST-CANCER; OLDER-ADULTS; EXERCISE PROGRAM; BODY-COMPOSITION; ENERGY-BALANCE; WOMENS HEALTH AB Background: Women with cancer are significantly more likely to fall than women without cancer placing them at higher risk of fall-related fractures, other injuries and disability. Currently, no evidence-based fall prevention strategies exist that specifically target female cancer survivors. The purpose of the GET FIT (Group Exercise Training for Functional Improvement after Treatment) trial is to compare the efficacy of two distinct types of exercise, tai chi versus strength training, to prevent falls in women who have completed treatment for cancer. The specific aims of this study are to: 1) Determine and compare the efficacy of both tai chi training and strength training to reduce falls in older female cancer survivors, 2) Determine the mechanism(s) by which tai chi and strength training each reduces falls and, 3) Determine whether or not the benefits of each intervention last after structured training stops. Methods/Design: We will conduct a three-group, single-blind, parallel design, randomized controlled trial in women, aged 50-75 years old, who have completed chemotherapy for cancer comparing 1) tai chi 2) strength training and 3) a placebo control group of seated stretching exercise. Women will participate in supervised study programs twice per week for six months and will be followed for an additional six months after formal training stops. The primary outcome in this study is falls, which will be prospectively tracked by monthly self-report. Secondary outcomes are maximal leg strength measured by isokinetic dynamometry, postural stability measured by computerized dynamic posturography and physical function measured by the Physical Performance Battery, all measured at baseline, 3, 6 and 12 months. The sample for this trial (N=429, assuming 25% attrition) will provide adequate statistical power to detect at least a 47% reduction in the fall rate over 1 year by being in either of the 2 exercise groups versus the control group. Discussion: The GET FIT trial will provide important new knowledge about preventing falls using accessible and implementable exercise interventions for women following chemotherapy for cancer. ClinicalTrials.gov NCT01635413 C1 [Winters-Stone, Kerri M.; Bennett, Jill A.; Nail, Lillian; Dieckmann, Nathan] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA. [Winters-Stone, Kerri M.; Luoh, Shiuh-Wen; Bennett, Jill A.; Nail, Lillian] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA. [Li, Fuzhong] Oregon Res Inst, Eugene, OR 97403 USA. [Horak, Fay] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. [Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR 97239 USA. RP Winters-Stone, KM (reprint author), Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA. EM wintersk@ohsu.edu OI Li, Fuzhong/0000-0001-6644-4702 FU NCI NIH HHS [R01 CA163474]; NIA NIH HHS [R37 AG006457] NR 78 TC 9 Z9 10 U1 7 U2 41 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD DEC 5 PY 2012 VL 12 AR 577 DI 10.1186/1471-2407-12-577 PG 10 WC Oncology SC Oncology GA 067CJ UT WOS:000313270100001 PM 23217054 ER PT J AU Volpp, KG Shea, JA Small, DS Basner, M Zhu, JS Norton, L Ecker, A Novak, C Bellini, LM Dine, CJ Mollicone, DJ Dinges, DF AF Volpp, Kevin G. Shea, Judy A. Small, Dylan S. Basner, Mathias Zhu, Jingsan Norton, Laurie Ecker, Adrian Novak, Cristina Bellini, Lisa M. Dine, C. Jessica Mollicone, Daniel J. Dinges, David F. TI Effect of a Protected Sleep Period on Hours Slept During Extended Overnight In-hospital Duty Hours Among Medical Interns A Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID VIGILANCE TEST PVT; PSYCHOMOTOR VIGILANCE; DOSE-RESPONSE; WORK; RESTRICTION; ALERTNESS; MORTALITY; RECOVERY; DURATION; REFORM AB Context A 2009 Institute of Medicine report recommended protected sleep periods for medicine trainees on extended overnight shifts, a position reinforced by new Accreditation Council for Graduate Medical Education requirements. Objective To evaluate the feasibility and consequences of protected sleep periods during extended duty. Design, Setting, and Participants Randomized controlled trial conducted at the Philadelphia VA Medical Center medical service and Oncology Unit of the Hospital of the University of Pennsylvania (2009-2010). Of the 106 interns and senior medical students who consented, 3 were not scheduled on any study rotations. Among the others, 44 worked at the VA center, 16 at the university hospital, and 43 at both. Intervention Twelve 4-week blocks were randomly assigned to either a standard intern schedule (extended duty overnight shifts of up to 30 hours; equivalent to 1200 overnight intern shifts at each site), or a protected sleep period (protected time from 12: 30 AM to 5: 30 AM with handover of work cell phone; equivalent to 1200 overnight intern shifts at each site). Participants were asked to wear wrist actigraphs and complete sleep diaries. Main Outcome Measures Primary outcome was hours slept during the protected period on extended duty overnight shifts. Secondary outcome measures included hours slept during a 24-hour period (noon to noon) by day of call cycle and Karolinska sleepiness scale. Results For 98.3% of on-call nights, cell phones were signed out as designed. At the VA center, participants with protected sleep had a mean 2.86 hours (95% CI, 2.57-3.10 hours) of sleep vs 1.98 hours (95% CI, 1.68-2.28 hours) among those who did not have protected hours of sleep (P<.001). At the university hospital, participants with protected sleep had a mean 3.04 hours (95% CI, 2.77-3.45 hours) of sleep vs 2.04 hours (95% CI, 1.79-2.24) among those who did not have protected sleep (P<.001). Participants with protected sleep were significantly less likely to have call nights with no sleep: 5.8% (95% CI, 3.0%-8.5%) vs 18.6% (95% CI, 13.9%-23.2%) at the VA center (P<.001) and 5.9% (95% CI, 3.1%-8.7%) vs 14.2% (95% CI, 9.9%-18.4%) at the university hospital (P=.001). Participants felt less sleepy after on-call nights in the intervention group, with Karolinska sleepiness scale scores of 6.65 (95% CI, 6.35-6.97) vs 7.10 (95% CI, 6.85-7.33; P=.01) at the VA center and 5.91 (95% CI, 5.64-6.16) vs 6.79 (95% CI, 6.57-7.04; P<.001) at the university hospital. Conclusions For internal medicine services at 2 hospitals, implementation of a protected sleep period while on call resulted in an increase in overnight sleep duration and improved alertness the next morning. C1 [Volpp, Kevin G.; Shea, Judy A.; Norton, Laurie; Novak, Cristina] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Shea, Judy A.; Zhu, Jingsan; Norton, Laurie; Novak, Cristina; Bellini, Lisa M.; Dine, C. Jessica] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Basner, Mathias; Ecker, Adrian; Dinges, David F.] Univ Penn, Perelman Sch Med, Dept Psychiat, Div Sleep & Chronobiol, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Shea, Judy A.; Small, Dylan S.; Zhu, Jingsan; Norton, Laurie; Novak, Cristina] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Mollicone, Daniel J.] Pulsar Informat Inc, Philadelphia, PA USA. RP Volpp, KG (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu RI Emchi, Karma/Q-1952-2016 FU Veterans Affairs Health Services Research and Development Service [08-429]; National Institutes of Health [NR004281] FX This work was funded by educational grant 08-429 from the Veterans Affairs Health Services Research and Development Service. Dr Dinges was also supported in part by grant NR004281 from the National Institutes of Health. NR 34 TC 13 Z9 13 U1 2 U2 21 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 5 PY 2012 VL 308 IS 21 BP 2208 EP 2217 DI 10.1001/jama.2012.34490 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 047HI UT WOS:000311829500012 PM 23212498 ER PT J AU Shaheen, NJ Weinberg, DS Denberg, TD Chou, R Qaseem, A Shekelle, P AF Shaheen, Nicholas J. Weinberg, David S. Denberg, Thomas D. Chou, Roger Qaseem, Amir Shekelle, Paul CA Amer Coll Phys TI Upper Endoscopy for Gastroesophageal Reflux Disease: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ESOMEPRAZOLE 40 MG; SEVERE EROSIVE ESOPHAGITIS; OPEN-ACCESS ENDOSCOPY; QUALITY-OF-LIFE; BARRETTS-ESOPHAGUS; UNITED-STATES; GASTROINTESTINAL ENDOSCOPY; GASTRIC CARDIA; TIME TRENDS; SURVEILLANCE AB Background: Upper endoscopy is commonly used in the diagnosis and management of gastroesophageal reflux disease (GERD). Evidence demonstrates that it is indicated only in certain situations, and inappropriate use generates unnecessary costs and exposes patients to harms without improving outcomes. Methods: The Clinical Guidelines Committee of the American College of Physicians reviewed evidence regarding the indications for, and yield of, upper endoscopy in the setting of GERD, and to highlight how clinicians can increase the delivery of high-value health care. Best Practice Advice 1: Upper endoscopy is indicated in men and women with heartburn and alarm symptoms (dysphagia, bleeding, anemia, weight loss, and recurrent vomiting). Best Practice Advice 2: Upper endoscopy is indicated in men and women with: Typical GERD symptoms that persist despite a therapeutic trial of 4 to 8 weeks of twice-daily proton-pump inhibitor therapy. Severe erosive esophagitis after a 2-month course of proton-pump inhibitor therapy to assess healing and rule out Barrett esophagus. Recurrent endoscopy after this follow-up examination is not indicated in the absence of Barrett esophagus. History of esophageal stricture who have recurrent symptoms of dysphagia. Best Practice Advice 3: Upper endoscopy may be indicated: In men older than 50 years with chronic GERD symptoms (symptoms for more than 5 years) and additional risk factors (nocturnal reflux symptoms, hiatal hernia, elevated body mass index, tobacco use, and intra-abdominal distribution of fat) to detect esophageal adenocarcinoma and Barrett esophagus. For surveillance evaluation in men and women with a history of Barrett esophagus. In men and women with Barrett esophagus and no dysplasia, surveillance examinations should occur at intervals no more frequently than 3 to 5 years. More frequent intervals are indicated in patients with Barrett esophagus and dysplasia. Ann Intern Med. 2012; 157: 808-816. www.annals.org For author affiliations, see end of text. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Harvard Vanguard Med Associates, Auburndale, MA 02466 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. RI Shaheen, Nicholas/A-1898-2013 FU National Cancer Institute [U54CA163060, U54CA156733] FX Financial support for the development of this best practice advice paper comes exclusively from the ACP's operating budget. Dr. Shaheen is supported by the National Cancer Institute (grant U54CA163060 and U54CA156733). NR 73 TC 50 Z9 52 U1 0 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 4 PY 2012 VL 157 IS 11 BP 808 EP + DI 10.7326/0003-4819-157-11-201212040-00008 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 049RC UT WOS:000312000100006 PM 23208168 ER PT J AU Dietrich, EA Gebhard, KH Fasching, CE Giacaman, RA Kappes, JC Ross, KF Herzberg, MC AF Dietrich, Elizabeth A. Gebhard, Kristin H. Fasching, Claudine E. Giacaman, Rodrigo A. Kappes, John C. Ross, Karen F. Herzberg, Mark C. TI Short Communication HIV Type 1 Escapes Inactivation by Saliva via Rapid Escape into Oral Epithelial Cells SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID PERMISSIVE CELLS; KERATINOCYTES; TRANSMISSION; INFECTION AB Saliva contains anti-HIV-1 factors, which show unclear efficacy in thwarting mucosal infection. When incubated in fresh, unfractionated whole saliva, infectious HIV-1 IIIb and BaL (X4- and R5-tropic, respectively) persisted from 4 to at least 30 min in a saliva concentration-dependent manner. In salivary supernatant for up to 6 h, both infectious HIV-1 strains "escaped" into immortalized oral epithelial cells; infectious BaL showed selectively enhanced escape in the presence of saliva. Fluorescently labeled HIV-1 virus-like particles entered oral epithelial cells within minutes of exposure. Using a previously unrecognized mechanism, therefore, strains of HIV-1 escape inactivation by saliva via rapid uptake into oral epithelial cells. C1 [Herzberg, Mark C.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA. [Dietrich, Elizabeth A.; Gebhard, Kristin H.; Fasching, Claudine E.; Giacaman, Rodrigo A.; Ross, Karen F.; Herzberg, Mark C.] Minneapolis VA Med Ctr, Mucosal & Vaccine Res Ctr, Minneapolis, MN USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. RP Herzberg, MC (reprint author), Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, 17-164 Moos Tower,515 Delaware St SE, Minneapolis, MN 55455 USA. EM mcherzb@umn.edu RI Giacaman, Rodrigo/A-9811-2010 OI Giacaman, Rodrigo/0000-0003-3362-5173 FU NIH/ NIDCR [R01DE015503, R21DE015506]; Minneapolis VA Medical Center; UAB Center for AIDS Research Virology and Sequencing Cores [P30-AI-27767]; Genetically Defined Microbe and Expression Core of the UAB Mucosal HIV and Immunobiology Center [R24 DK-64400]; Veterans Affairs, Research Service FX The support of NIH/ NIDCR R01DE015503 (M. C. H.), R21DE015506 (K. F. R.), and funds from the Minneapolis VA Medical Center by J.C.K. and M. C. H. is greatly appreciated. Research in J.C.K.'s laboratory was supported by the UAB Center for AIDS Research Virology and Sequencing Cores (P30-AI-27767), the Genetically Defined Microbe and Expression Core of the UAB Mucosal HIV and Immunobiology Center (R24 DK-64400), and a Merit Review Award from the Veterans Affairs, Research Service. NR 16 TC 5 Z9 5 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD DEC PY 2012 VL 28 IS 12 BP 1574 EP 1578 DI 10.1089/aid.2011.0069 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 047FW UT WOS:000311825000007 PM 22077822 ER PT J AU Utech, AE Tadros, EM Hayes, TG Garcia, JM AF Utech, Anne E. Tadros, Eiriny M. Hayes, Teresa G. Garcia, Jose M. TI Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE LA English DT Article DE Inflammation; Anorexia; Interleukin-6; TNF-alpha; Testosterone ID RESTING ENERGY-EXPENDITURE; TUMOR-BEARING RATS; CELL LUNG-CANCER; PROINFLAMMATORY CYTOKINES; SYMPTOM ASSESSMENT; TERMINAL CANCER; SERUM-LEVELS; WEIGHT-LOSS; FOOD-INTAKE; HYPOGONADISM AB Background Cancer can lead to weight loss, anorexia, and poor nutritional status, which are associated with decreased survival in cancer patients. Methods Male cancer patients (n=136) were followed for a mean time of 4.5 years. Variables were obtained at baseline: cancer stage, albumin, hemoglobin, tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6, bioavailable testosterone, appetite questionnaire, and weight change from baseline to 18 months. Primary statistical tests included Kaplan-Meier survival analysis and Cox proportional hazard regression (PHREG). Results Univariate PHREG showed that cancer stage, albumin, hemoglobin, TNF-alpha, IL-6, and weight change were each significantly associated with mortality risk (P<0.05), but bioavailable testosterone was not. Multivariate PHREG analysis established that weight change and albumin were jointly statistically significant even after adjusting for stage. Conclusion In this sample of male oncology patients, cancer stage, serum albumin, and weight loss predicted survival. High levels of inflammatory markers and hemoglobin are associated with increased mortality, but do not significantly improve the ability to predict survival above and beyond cancer stage, albumin, and weight loss. C1 [Utech, Anne E.; Tadros, Eiriny M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Hayes, Teresa G.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Div Hematol & Oncol, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA. RP Garcia, JM (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA. EM jgarcia1@bcm.edu FU Dept. of Veterans Affairs [BX000507, CX000174]; Abbott; Aeterna Zentaris; Helsinn Therapeutics FX This material is based upon work supported by the Dept. of Veterans Affairs (MREP, SCVAHNCDA, MERIT awards BX000507 and CX000174). Dr. Garcia receives research support from Abbott, Aeterna Zentaris, and Helsinn Therapeutics. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia, and Muscle [35]. NR 35 TC 26 Z9 26 U1 0 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 2190-5991 J9 J CACHEXIA SARCOPENI JI J. Caxhexia Sarcopenia Muscle PD DEC PY 2012 VL 3 IS 4 BP 245 EP 251 DI 10.1007/s13539-012-0075-5 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 218WV UT WOS:000324464200005 PM 22648739 ER PT J AU Corro, G Rocco, CA De Candia, C Catano, G Turk, G Mangano, A Aulicino, PC Bologna, R Sen, L AF Corro, Guillermo Rocco, Carlos A. De Candia, Cristian Catano, Gabriel Turk, Gabriela Mangano, Andrea Aulicino, Paula C. Bologna, Rosa Sen, Luisa TI Genetic and Functional Analysis of HIV Type 1 nef Gene Derived from Long-Term Nonprogressor Children: Association of Attenuated Variants with Slow Progression to Pediatric AIDS SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; PERINATAL INFECTION; STRUCTURAL DEFECTS; REPEAT SEQUENCES; NATURAL-HISTORY; TRANSGENIC MICE; T-CELLS; TRANSMISSION; REPLICATION AB Among persons infected by HIV-1, the rate of progression to AIDS is multifactorial being affected by host and viral factors, including the HIV-encoded negative factor (Nef). Our aim was to define whether variations in the nef gene as well as its functions may be associated with slower HIV disease course in infected children. The proviral HIV-1 nef gene was cloned, sequenced, and compared in children with contrasting disease course: 10 long-term nonprogressors (LTNP) and six rapid progressor (RP). The CD4 and MHC-I down-modulation ability of nef alleles derived from LTNP and RP children was analyzed. We observed that only one of our 10 LTNP had a protective genetic background, and out of them, 40% had defective nef genes, carrying substitutions at the (AWLEAQ(56-61)) and the (Rxx(22-24)) domains, and that those alleles were unable of down-regulate CD4 and MHC-I. The emergence or presence of Nef L58V substitution was associated with viral attenuation, indicated by a reduction in HIV viral loads, a persistent preservation of CD4(+) T cell counts, and lack of AIDS-related symptoms. Our results demonstrate that HIV-1 perinatally infected children carrying functionally defective nef HIV-1 strains have prolonged asymptomatic phases without therapy, suggesting a relevant role of CD4 and MHC-I down-modulation Nef domains on in vivo HIV-1 pathogenesis and pediatric immunodeficiency outcome. C1 [Corro, Guillermo; Rocco, Carlos A.; Mangano, Andrea; Aulicino, Paula C.; Sen, Luisa] Hosp Pediat Prof Dr Juan P Garran, Lab Biol Celular & Retrovirus, Buenos Aires, DF, Argentina. [Corro, Guillermo; Mangano, Andrea; Aulicino, Paula C.; Sen, Luisa] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina. [De Candia, Cristian; Turk, Gabriela] Univ Buenos Aires, Natl Reference Ctr AIDS, Buenos Aires, DF, Argentina. [Catano, Gabriel] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [Catano, Gabriel] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Bologna, Rosa] Hosp Pediat Prof Dr Juan P Garrahan, Serv Infectol, Buenos Aires, DF, Argentina. RP Corro, G (reprint author), 1881 Combate Pozos St,C1245AAM, Buenos Aires, DF, Argentina. EM gcorro2@gmail.com NR 54 TC 6 Z9 6 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD DEC PY 2012 VL 28 IS 12 BP 1617 EP 1626 DI 10.1089/aid.2012.0020 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 047FW UT WOS:000311825000013 PM 22583022 ER PT J AU Srivastava, MK Dubinett, S Sharma, S AF Srivastava, Minu K. Dubinett, Steven Sharma, Sherven TI Targeting MDSCs enhance therapeutic vaccination responses against lung cancer SO ONCOIMMUNOLOGY LA English DT Editorial Material DE immune suppression; immunotherapy; lung cancer; myeloid-derived suppressor cells ID SUPPRESSOR-CELLS; BONE-MARROW AB Myeloid-derived suppressor cells (MDSCs) are important regulators of immune responses. These cells suppress the cytotoxic activities of natural killer (NK)-cell and T-cell effectors and promote tumor growth. We demonstrated that depleting MDSCs improve therapeutic responses to vaccination in a murine model of lung cancer. This approach may prove beneficial against tumors in which MDSC exert prominent immunosuppressive effects. C1 [Srivastava, Minu K.; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Lung Canc Res Program, Los Angeles, CA 90095 USA. [Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Srivastava, Minu K.; Dubinett, Steven; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Lung Canc Res Program, Los Angeles, CA 90095 USA. EM ssharma@mednet.ucla.edu FU NCATS NIH HHS [UL1 TR000124] NR 8 TC 10 Z9 10 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2162-4011 J9 ONCOIMMUNOLOGY JI OncoImmunology PD DEC PY 2012 VL 1 IS 9 BP 1650 EP 1651 DI 10.4161/onci.21970 PG 2 WC Oncology; Immunology SC Oncology; Immunology GA 108GY UT WOS:000316281700035 PM 23264925 ER PT J AU Uebel, M AF Uebel, Michael TI Psychoanalysis and the Question of Violence: From Masochism to Shame SO AMERICAN IMAGO LA English DT Article ID WORLD-WAR-II; TRAINING PSYCHOTHERAPISTS; MENTAL-HEALTH; GUILT; MIND; ZEN; EMBARRASSMENT; PERSPECTIVES; ATTRIBUTES; COMPASSION C1 US Dept Vet Affairs, Cent Texas Vet Hlth Care Syst, Washington, DC 20420 USA. RP Uebel, M (reprint author), US Dept Vet Affairs, Cent Texas Vet Hlth Care Syst, Washington, DC 20420 USA. NR 133 TC 0 Z9 0 U1 1 U2 3 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 0065-860X J9 AM IMAGO JI Am. Imago PD WIN PY 2012 VL 69 IS 4 BP 473 EP 505 PG 33 WC Humanities, Multidisciplinary SC Arts & Humanities - Other Topics GA 099YP UT WOS:000315662200003 ER PT J AU Saunders, GH Chisolm, TH Wallhagen, MI AF Saunders, Gabrielle H. Chisolm, Theresa H. Wallhagen, Margaret I. TI Older Adults and Hearing Help-Seeking Behaviors SO AMERICAN JOURNAL OF AUDIOLOGY LA English DT Article DE adults; aging; amplification or hearing aids; auditory rehabilitation; hearing loss; outcomes ID QUALITY-OF-LIFE; NEGATIVE CONSEQUENCES; URINARY-INCONTINENCE; IMPAIRMENT; AID; POPULATION; PEOPLE; CARE; AGE; DETERMINANTS AB Purpose: To review the current literature on help seeking for hearing health care among older adults. Method: The authors conducted a literature review regarding help seeking for hearing-related communication difficulties as well as for other chronic medical conditions. Results: Untreated hearing loss can lead to numerous negative secondary consequences; uptake and use of hearing aids remain low, despite the fact that hearing aids provide an effective treatment option for older adults with hearing loss. The authors describe models relevant to understanding the help-seeking and decision-making behaviors of older adults with hearing loss and discuss recommendations for future research. Conclusion: Because of the considerable overlap in factors associated with help-seeking behaviors across chronic medical conditions and because help-seeking behaviors are complex, help seeking should be examined within the framework of a multifactorial model, such as the health belief model or the transtheoretical stages of change model. C1 [Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Chisolm, Theresa H.] Univ S Florida, Tampa, FL USA. [Wallhagen, Margaret I.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. RP Saunders, GH (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. EM Gabrielle.saunders@va.gov NR 48 TC 21 Z9 23 U1 3 U2 16 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1059-0889 J9 AM J AUDIOL JI Am. J. Audiol. PD DEC PY 2012 VL 21 IS 2 BP 331 EP 337 DI 10.1044/1059-0889(2012/12-0028) PG 7 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 083HY UT WOS:000314455400020 PM 23233518 ER PT J AU Ford, EC de Los Santos, LF Pawlicki, T Sutlief, S Dunscombe, P AF Ford, E. C. de Los Santos, L. Fong Pawlicki, T. Sutlief, S. Dunscombe, P. TI Consensus recommendations for incident learning database structures in radiation oncology SO MEDICAL PHYSICS LA English DT Article DE patient safety; radiation therapy; brachytherapy; incident learning ID IMPROVING PATIENT SAFETY; RADIOTHERAPY; THERAPY; ERRORS; SYSTEM; RISK AB Purpose: Incident learning plays a key role in improving quality and safety in a wide range of industries and medical disciplines. However, implementing an effective incident learning system is complex, especially in radiation oncology. One current barrier is the lack of technical standards to guide users or developers. This report, the product of an initiative by the Work Group on Prevention of Errors in Radiation Oncology of the American Association of Physicists in Medicine, provides technical recommendations for the content and structure of incident learning databases in radiation oncology. Methods: A panel of experts was assembled and tasked with developing consensus recommendations in five key areas: definitions, process maps, severity scales, causality taxonomy, and data elements. Experts included representatives from all major North American radiation oncology organizations as well as users and developers of public and in-house reporting systems with over two decades of collective experience. Recommendations were developed that take into account existing incident learning systems as well as the requirements of outside agencies. Results: Consensus recommendations are provided for the five major topic areas. In the process mapping task, 91 common steps were identified for external beam radiation therapy and 88 in brachytherapy. A novel feature of the process maps is the identification of "safety barriers," also known as critical control points, which are any process steps whose primary function is to prevent errors or mistakes from occurring or propagating through the radiotherapy workflow. Other recommendations include a ten-level medical severity scale designed to reflect the observed or estimated harm to a patient, a radiation oncology-specific root causes table to facilitate and regularize root-cause analyses, and recommendations for data elements and structures to aid in development of electronic databases. Also presented is a list of key functional requirements of any reporting system. Conclusions: Incident learning is recognized as an invaluable tool for improving the quality and safety of treatments. The consensus recommendations in this report are intended to facilitate the implementation of such systems within individual clinics as well as on broader national and international scales. (C) 2012 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4764914] C1 [Ford, E. C.] Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA. [de Los Santos, L. Fong] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA. [Pawlicki, T.] Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA. [Sutlief, S.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Dunscombe, P.] Univ Calgary, Dept Oncol, Calgary, AB T2N 1N4, Canada. RP Ford, EC (reprint author), Univ Washington, Med Ctr, Dept Radiat Oncol, Box 356043,1959 NE Pacific St, Seattle, WA 98195 USA. EM eford@uw.edu FU American Association of Physicists in Medicine FX The American Association of Physicists in Medicine is acknowledged for funding the members and guests of the WGPE who attended the Workshop. The partnering organizations, mentioned above, are also acknowledged for their support of this endeavor by sponsoring their representatives. Corbi Foster and Noel Crisman-Fillhart, from AAPM Headquarters provided much of the logistical support of the Workshop. Finally all the participants are recognized for their active involvement and contributions to this effort. WGPE members and guests, fully sponsored by the AAPM, were: Peter Dunscombe, Luis Fong de Los Santos, Eric Ford, Anne Greener, Jennifer Johnson, Ajay Kapur, Janaki Krishnamoorthy, Sasa Mutic, Todd Pawlicki, Steven Sutlief, Stephanie Terezakis M.D., Bruce Thomadsen. Representatives of partnering organizations were: Jean-Pierre Bissonnette (COMP), Jim Deye (NIH), Rachel Hackett (AAMD), Sandra Hayden (ASRT), James Hevezi (ACR), Ola Holmberg (IAEA), Jatinder Palta (ASTRO/NROR), Emily Wilson (ASTRO). Dr. Barrett Caldwell served as a consultant to the Causal Taxonomies group. The authors also acknowledge valuable discussions with Peter Gabriel, M.D. and Edna Volz, MS of the University of Pennsylvania, and Howard Bergendahl, M.S., J.D. (Bergendahl Institute, LLC). This report has been reviewed and approved by the AAPM. References to AAPM Task Group-100 have been reviewed and approved by the TG-100 writing group and parent committees within AAPM. NR 30 TC 33 Z9 33 U1 0 U2 4 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD DEC PY 2012 VL 39 IS 12 BP 7272 EP 7290 DI 10.1118/1.4764914 PG 19 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 049FJ UT WOS:000311967400011 PM 23231278 ER PT J AU Cloud, LJ Rosenblatt, A Margolis, RL Ross, CA Pillai, JA Corey-Bloom, J Tully, HM Bird, T Panegyres, PK Nichter, CA Higgins, DS Helmers, SL Factor, SA Jones, R Testa, CM AF Cloud, Leslie J. Rosenblatt, Adam Margolis, Russel L. Ross, Christopher A. Pillai, Jagan A. Corey-Bloom, Jody Tully, Hannah M. Bird, Thomas Panegyres, Peter K. Nichter, Charles A. Higgins, Donald S., Jr. Helmers, Sandra L. Factor, Stewart A. Jones, Randi Testa, Claudia M. TI Seizures in Juvenile Huntington's Disease: Frequency and Characterization in a Multicenter Cohort SO MOVEMENT DISORDERS LA English DT Article DE Huntington's disease; juvenile Huntington's disease; seizures ID EARLY-ONSET; AGE AB Little is known about the epilepsy that often occurs in the juvenile form of Huntington's disease (HD), but is absent from the adult-onset form. The primary aim of this study was to characterize the seizures in juvenile HD (JHD) subjects with regard to frequency, semiology, defining EEG characteristics, and response to antiepileptic agents. A multicenter, retrospective cohort was identified by database query and/or chart review. Data on age of HD onset, primary HD manifestations, number of CAG repeats, the presence or absence of seizures, seizure type(s), antiepileptic drugs used, subjects' response to antiepileptic drugs (AEDs), and EEG results were assembled, where available. Ninety subjects with genetically confirmed JHD were included. Seizures were present in 38% of subjects and were more likely to occur with younger ages of HD onset. Generalized tonic-clonic seizures were the most common seizure type, followed by tonic, myoclonic, and staring spells. Multiple seizure types commonly occurred within the same individual. Data on EEG findings and AED usage are presented. Seizure risk in JHD increases with younger age of HD onset. Our ability to draw firm conclusions about defining EEG characteristics and response to AEDs was limited by the retrospective nature of the study. Future prospective studies are required. (C) 2012 Movement Disorder Society C1 [Cloud, Leslie J.; Rosenblatt, Adam; Testa, Claudia M.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA. [Rosenblatt, Adam] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA. [Margolis, Russel L.; Ross, Christopher A.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol,Dept Neurol, Baltimore, MD 21205 USA. [Margolis, Russel L.; Ross, Christopher A.] Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD USA. [Pillai, Jagan A.; Corey-Bloom, Jody] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Tully, Hannah M.; Bird, Thomas] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Tully, Hannah M.] Seattle Childrens Hosp, Seattle, WA USA. [Bird, Thomas] Univ Washington, Geriatr Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Panegyres, Peter K.] Neurodegenerat Disorders Res Pty Ltd, Subiaco, WA, Australia. [Nichter, Charles A.; Higgins, Donald S., Jr.] Albany Med Coll, Dept Neurol, Albany, NY 12208 USA. [Higgins, Donald S., Jr.] Samuel Stratton VA Med Ctr, Neurol Serv, Albany, NY USA. [Helmers, Sandra L.; Factor, Stewart A.; Jones, Randi] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. RP Cloud, LJ (reprint author), Virginia Commonwealth Univ, Dept Neurol, 1001 E Broad St,Suite 222,POB 980539, Richmond, VA 23298 USA. EM lcloud@vcu.edu RI Ross, Christopher/H-8395-2013 NR 10 TC 13 Z9 13 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD DEC PY 2012 VL 27 IS 14 BP 1797 EP 1800 DI 10.1002/mds.25237 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 089GN UT WOS:000314899000018 PM 23124580 ER PT J AU Mata, IF Checkoway, H Hutter, CM Samii, A Roberts, JW Kim, HM Agarwal, P Alvarez, V Ribacoba, R Pastor, P Lorenzo-Betancor, O Infante, J Sierra, M Gomez-Garre, P Mir, P Ritz, B Rhodes, SL Colcher, A Van Deerlin, V Chung, KA Quinn, JF Yearout, D Martinez, E Farin, FM Wan, JY Edwards, KL Zabetian, CP AF Mata, Ignacio F. Checkoway, Harvey Hutter, Carolyn M. Samii, Ali Roberts, John W. Kim, Hojoong M. Agarwal, Pinky Alvarez, Victoria Ribacoba, Renee Pastor, Pau Lorenzo-Betancor, Oswaldo Infante, Jon Sierra, Maria Gomez-Garre, Pilar Mir, Pablo Ritz, Beate Rhodes, Shannon L. Colcher, Amy Van Deerlin, Vivianna Chung, Kathryn A. Quinn, Joseph F. Yearout, Dora Martinez, Erica Farin, Federico M. Wan, Jia Y. Edwards, Karen L. Zabetian, Cyrus P. TI Common Variation in the LRRK2 Gene is a Risk Factor for Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; LRRK2; SNP ID GENOME-WIDE ASSOCIATION; EXONIC VARIANTS; METAANALYSIS; MUTATIONS; REGION; SNCA AB Background: Common variants in the LRRK2 gene influence the risk of Parkinson's disease (PD) in Asians, but whether the same is true in European-derived populations is less clear. Methods: We genotyped 66 LRRK2 tagging single-nucleotide polymorphisms (SNPs) in 575 PD patients and 689 controls from the northwestern United States (tier 1). PD-associated SNPs (P < .05) were then genotyped in an independent sample of 3617 cases and 2512 controls from the United States and Spain (tier 2). Logistic regression was used to model additive SNP genotype effects adjusted for age and sex among white individuals. Results: Two regions showed independent association with PD in tier 1, and SNPs in both regions were successfully replicated in tier 2 (rs10878226, combined odds ratio [OR], 1.20; 95% confidence interval [CI], 1.08-1.33; P = 6.3 x 10(-4); rs11176013, OR, 0.89; CI, 0.83-0.95; P = 4.6 x 10(-4)). Conclusions: Our data suggest that common variation within LRRK2 conveys susceptibility for PD in individuals of European ancestry. (C) 2012 Movement Disorder Society C1 [Mata, Ignacio F.; Samii, Ali; Kim, Hojoong M.; Yearout, Dora; Martinez, Erica; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Mata, Ignacio F.; Samii, Ali; Kim, Hojoong M.; Yearout, Dora; Martinez, Erica; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Checkoway, Harvey; Farin, Federico M.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Hutter, Carolyn M.; Wan, Jia Y.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Hutter, Carolyn M.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Program, Seattle, WA 98104 USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Agarwal, Pinky] Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Alvarez, Victoria] Hosp Univ Cent Asturias, Inst Invest Nefrol IRSINFRIAT, Genet Mol Lab, Oviedo, Spain. [Ribacoba, Renee] Hosp Univ Cent Asturias, Dept Neurol, Oviedo, Spain. [Pastor, Pau; Lorenzo-Betancor, Oswaldo] Univ Navarra, Ctr Appl Med Res, Div Neurosci, Neurogenet Lab, E-31080 Pamplona, Spain. [Pastor, Pau; Lorenzo-Betancor, Oswaldo] Univ Navarra, Dept Neurol, Clin Univ Navarra, Sch Med, E-31080 Pamplona, Spain. [Pastor, Pau; Lorenzo-Betancor, Oswaldo; Infante, Jon; Gomez-Garre, Pilar; Mir, Pablo] Inst Salud Carlos III, CIBERNED, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain. [Infante, Jon; Sierra, Maria] Marques de Valdecilla Univ Hosp, Dept Neurol, Santander, Spain. [Gomez-Garre, Pilar; Mir, Pablo] Univ Seville, CSIC, Hosp Univ Virgen del Rocio,Inst Biomed Sevilla IB, Unidad Trastornos Movimiento,Serv Neurol & Neurof, Seville, Spain. [Ritz, Beate; Rhodes, Shannon L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA 90024 USA. [Ritz, Beate] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Colcher, Amy] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Van Deerlin, Vivianna] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Chung, Kathryn A.; Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. RP Mata, IF (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM nachofm@u.washington.edu; zabetian@u.washington.edu RI Pastor, Pau/C-9834-2009; Ritz, Beate/E-3043-2015; IBIS, MOVIMIENTO/P-3309-2015; Mir, Pablo/C-8662-2013 OI Pastor, Pau/0000-0002-7493-8777; Mir, Pablo/0000-0003-1656-302X FU BLRD VA [I01 BX000531]; NIEHS NIH HHS [P01 ES016732, P30 ES007033, P42 ES004696, R01 ES010544, U54 ES012078]; NINDS NIH HHS [P50 NS038367, P50 NS053488, P50 NS062684, R01 NS065070] NR 20 TC 0 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD DEC PY 2012 VL 27 IS 14 BP 1822 EP 1825 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 089GN UT WOS:000314899000024 PM 23115130 ER PT J AU Coleman, CN Hrdina, C Casagrande, R Cliffer, KD Mansoura, MK Nystrom, S Hatchett, R Caro, JJ Knebel, AR Wallace, KS Adams, SA AF Coleman, C. Norman Hrdina, Chad Casagrande, Rocco Cliffer, Kenneth D. Mansoura, Monique K. Nystrom, Scott Hatchett, Richard Caro, J. Jaime Knebel, Ann R. Wallace, Katherine S. Adams, Steven A. TI User-Managed Inventory: An Approach to Forward-Deployment of Urgently Needed Medical Countermeasures for Mass-Casualty and Terrorism Incidents SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE medical countermeasures; user-managed inventory; nuclear ID NUCLEAR DETONATION; SCARCE RESOURCES; SURGE CAPACITY; HEALTH; ALLOCATION AB The user-managed inventory (UMI) is an emerging idea for enhancing the current distribution and maintenance system for emergency medical countermeasures (MCMs). It increases current capabilities for the dispensing and distribution of MCMs and enhances local/regional preparedness and resilience. In the UMI, critical MCMs, especially those in routine medical use ("dual utility") and those that must be administered soon after an incident before outside supplies can arrive, are stored at multiple medical facilities (including medical supply or distribution networks) across the United States. The medical facilities store a sufficient cache to meet part of the surge needs but not so much that the resources expire before they would be used in the normal course of business. In an emergency, these extra supplies can be used locally to treat casualties, including evacuees from incidents in other localities. This system, which is at the interface of local/regional and federal response, provides response capacity before the arrival of supplies from the Strategic National Stockpile (SNS) and thus enhances the local/regional medical responders' ability to provide life-saving MCMs that otherwise would be delayed. The UMI can be more cost-effective than stockpiling by avoiding costs due to drug expiration, disposal of expired stockpiled supplies, and repurchase for replacement. (Disaster Med Public Health Preparedness. 2012; 6:408-414) C1 [Coleman, C. Norman; Hrdina, Chad; Cliffer, Kenneth D.; Mansoura, Monique K.; Nystrom, Scott; Hatchett, Richard; Knebel, Ann R.] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA. [Coleman, C. Norman] NCI, Radiat Res Program, NIH, Bethesda, MD 20892 USA. [Casagrande, Rocco] Gryphon Sci, Takoma Pk, MD USA. [Caro, J. Jaime] UnitedBiosource Corp, Lexington, MA USA. [Caro, J. Jaime] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Caro, J. Jaime] McGill Univ, Div Gen Internal Med, Montreal, PQ, Canada. [Wallace, Katherine S.] US Dept Vet Affairs, Off Operat Secur & Preparedness, Washington, DC USA. [Adams, Steven A.] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. RP Coleman, CN (reprint author), 6130 Execut Blvd, Rockville, MD 20852 USA. EM Norman.Coleman@nih.gov NR 16 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD DEC PY 2012 VL 6 IS 4 BP 408 EP 414 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 083WY UT WOS:000314497800015 PM 23241473 ER PT J AU Easler, JJ Zureikat, A Papachristou, GI AF Easler, Jeffrey J. Zureikat, Amer Papachristou, Georgios I. TI An update on minimally invasive therapies for pancreatic necrosis SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Review DE acute pancreatitis; endoscopic necrosectomy; infected pancreatic necrosis; minimally invasive techniques; necrosectomy; necrosis; pancreas; pancreatic fluid collections; pancreatic necrosis; walled-off pancreatic necrosis ID INFECTED NECROTIZING PANCREATITIS; STANDARD PERCUTANEOUS DRAINAGE; ACUTE BILIARY PANCREATITIS; DUAL MODALITY DRAINAGE; ENDOSCOPIC NECROSECTOMY; RETROPERITONEAL APPROACH; RADIOLOGICAL PROCEDURES; SURGICAL-MANAGEMENT; CATHETER DRAINAGE; REDUCES LENGTH AB Pancreatic necrosis is a local complication of severe acute pancreatitis associated with multiple organ dysfunction, infection and increased mortality. While surgery is the mainstay for invasive management, studies have demonstrated that delaying necrosectomy translates to improved patient outcomes. Minimally invasive therapies have been described both for early and late management of necrotic pancreatic collections and fall into three broad categories: endoscopic, radiology assisted percutaneous drainage and laparoscopic or retroperitoneal surgical techniques. Such interventions may serve as temporizing measures delaying necrosectomy, but more importantly, as best demonstrated in recent randomized controlled trials, can serve as alternative approaches resulting in improved patient outcomes. Access to these techniques is based on their availability at expert centers. Minimally invasive therapies have increased in popularity, with a general consensus among experts being that reduced complications and mortality rates are realized by approaches other than open necrosectomy. However, additional well-designed, randomized trials are needed. C1 [Easler, Jeffrey J.; Papachristou, Georgios I.] Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Zureikat, Amer] Univ Pittsburgh Med, Div Gastrointestinal Surg, Pittsburgh, PA USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. EM papachri@pitt.edu NR 44 TC 4 Z9 4 U1 0 U2 12 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1747-4124 J9 EXPERT REV GASTROENT JI Expert Rev. Gastroenterol. Hepatol. PD DEC PY 2012 VL 6 IS 6 BP 745 EP 753 DI 10.1586/EGH.12.48 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 083JZ UT WOS:000314460900016 PM 23237259 ER PT J AU Fried-Oken, M Rowland, C Daniels, D Dixon, M Fuller, B Mills, C Noethe, G Small, J Still, K Oken, B AF Fried-Oken, Melanie Rowland, Charity Daniels, Darlene Dixon, Mayling Fuller, Bret Mills, Carolyn Noethe, Glory Small, Jeon Still, Kevin Oken, Barry TI AAC to Support Conversation in Persons with Moderate Alzheimer's Disease SO AUGMENTATIVE AND ALTERNATIVE COMMUNICATION LA English DT Article DE AAC; Alzheimer's disease; Dementia; Aided conversation ID MEMORY AIDS; DEMENTIA; ADULTS; PREVALENCE; DIAGNOSIS; STATE AB Even though we know that external memory aids support communication in Alzheimer's disease, the components of the communication aids for individuals with Alzheimer's disease have not been studied systematically. The goal of these two pilot experiments was to examine differences in conversational performance of adults with Alzheimer's disease related to the presence and absence of an aid, the type of symbol embedded in the aid, and the presence or absence of voice output. In Experiment 1, 30 adults with moderate-to-severe Alzheimer's disease participated in 10-min conversations with and without personalized AAC boards. There was no effect of AAC, regardless of symbol type, and a deleterious effect of voice output. In Experiment 2, modified spaced-retrieval training preceded conversations, standardized prompts were presented, and semantically-based dependent variables were examined. For the 11 participants in the second experiment, there was a significant effect of AAC, showing that the presence of AAC was associated with greater use of targeted words during personal conversations. We discuss new information about the contribution of AAC for persons with Alzheimer's disease, and demonstrate how the applied research process evolves over the course of a long-term commitment to a scientific investigation. C1 [Fried-Oken, Melanie; Rowland, Charity; Daniels, Darlene; Dixon, Mayling; Mills, Carolyn; Noethe, Glory; Still, Kevin; Oken, Barry] Oregon Hlth & Sci Univ, Portland, OR 97207 USA. [Fuller, Bret] Portland VA Med Ctr, Portland, OR USA. [Small, Jeon] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Fried-Oken, M (reprint author), Oregon Hlth & Sci Univ, POB 574, Portland, OR 97207 USA. EM friedm@ohsu.edu FU U.S. Department of Health and Human Services, National Institutes of Health [R21 HD47754, P30 AG008017]; U.S. Department of Education, National Institute on Disability and Rehabilitation Research [H133G040176]; Oregon Tax Check-Off Alzheimer's Research Grant FX We acknowledge support from the U.S. Department of Health and Human Services, National Institutes of Health grant R21 HD47754 and P30 AG008017; the U.S. Department of Education, National Institute on Disability and Rehabilitation Research grant H133G040176; and the 2004 Oregon Tax Check-Off Alzheimer's Research Grant. We thank the participants and their caregivers for inviting us into their homes and permitting us to document their conversations. NR 47 TC 5 Z9 5 U1 4 U2 27 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0743-4618 EI 1477-3848 J9 AUGMENT ALTERN COMM JI Augment. Altern. Commun. PD DEC PY 2012 VL 28 IS 4 BP 219 EP 231 DI 10.3109/07434618.2012.732610 PG 13 WC Audiology & Speech-Language Pathology; Rehabilitation SC Audiology & Speech-Language Pathology; Rehabilitation GA 077DO UT WOS:000314008300003 PM 23256854 ER PT J AU Pham, PCT Pham, PMT Pham, PTT AF Pham, Phuong-Chi T. Pham, Phuong-Mai T. Pham, Phuong-Thu T. TI Patients with diabetes mellitus Type 2 and hypomagnesemia may have enhanced glomerular filtration via hypocalcemia SO CLINICAL NEPHROLOGY LA English DT Article DE hypomagnesemia; diabetes mellitus; glomerular hyperfiltration; hypocalcemia ID HUMAN MAGNESIUM-DEFICIENCY; LOWER SERUM MAGNESIUM; PARATHYROID-HORMONE; CALCIUM; VASOCONSTRICTION; HYPERFILTRATION; RESISTANCE; INSULIN; KIDNEY AB Introduction: Hypomagnesemia and glomerular hyperfiltration are commonly observed in patients with diabetes mellitus Type 2 (DM2). In the current study, we examined the relationship between hypomagnesemia and glomerular filtration rates in DM2 patients. Materials and methods: Data were obtained for DM2 patients without documented kidney disease seen at UCLA-Olive View Medical Center during January through March 2001. Data for hemoglobin, hemoglobin A1C (HbA1C), routine electrolytes, lipid profiles, urinalyses, history of hypertension, and pharmacy profiles were retrieved. Estimation of glomerular filtration rate (eGFR) was based on the CKD-epi formula. Multivariate analyses were performed to determine the correlations between eGFR and clinical factors including age, gender, history of hypertension, the use of diuretics, renin angiotensin system (RAS) inhibitors, acetylsalicylic acid, and statins, serum calcium, magnesium, hemoglobin, HbA1C, lipid profile, and degree of proteinuria. Results: 550 patients (54% females) with mean age 57.5 +/- 11.0 years and eGFR 95.7 +/- 14.8 ml/min/1.73 m(2) were included. Multivariate analysis revealed negative correlations with eGFR for age (Pearson-correlation-coefficient: -0.7, p < 0.0001), hypertension (-0.32, p < 0.0001), magnesium (-0.21, p < 0.0001), calcium (-0.13, p = 0.009), proteinuria (-0.17, p < 0.0001), and the use of RAS inhibitors (-0.21, p < 0.0001), and diuretics (-0.24, p < 0.0001) and a positive correlation for HbA1C (0.28, p < 0.0001). Further analysis of the interaction between serum magnesium and calcium, defined as magnesium x calcium (Mg x Ca), revealed a more significant correlation with eGFR than either cation alone (-0.24, p < 0.0001). Conclusions: Serum magnesium, calcium, and (Mg x Ca) all had significant negative correlations with eGFR. In particular, (Mg x Ca) had the strongest correlation with eGFR. C1 [Pham, Phuong-Chi T.] Olive View UCLA Med Ctr, Div Nephrol & Hypertens, Sylmar, CA 91342 USA. [Pham, Phuong-Mai T.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Dept Internal Med, North Hills, CA USA. [Pham, Phuong-Thu T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Pham, PCT (reprint author), Olive View UCLA Med Ctr, Div Nephrol & Hypertens, 14445 Olive View Dr,2B-182, Sylmar, CA 91342 USA. EM pham.pchi@ucla.edu NR 28 TC 3 Z9 3 U1 0 U2 3 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD DEC PY 2012 VL 78 IS 6 BP 442 EP 448 DI 10.5414/CN107525 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 068YF UT WOS:000313401400003 PM 23073059 ER PT J AU Canolty, RT Ganguly, K Carmena, JM AF Canolty, Ryan T. Ganguly, Karunesh Carmena, Jose M. TI Task-Dependent Changes in Cross-Level Coupling between Single Neurons and Oscillatory Activity in Multiscale Networks SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID FIELD POTENTIAL OSCILLATIONS; PRIMATE MOTOR CORTEX; SENSORIMOTOR CORTEX; PARIETAL CORTEX; CELL ASSEMBLIES; ORIENTATION SELECTIVITY; GAMMA OSCILLATIONS; PREFRONTAL CORTEX; BETA-OSCILLATIONS; WORKING-MEMORY AB Understanding the principles governing the dynamic coordination of functional brain networks remains an important unmet goal within neuroscience. How do distributed ensembles of neurons transiently coordinate their activity across a variety of spatial and temporal scales? While a complete mechanistic account of this process remains elusive, evidence suggests that neuronal oscillations may play a key role in this process, with different rhythms influencing both local computation and long-range communication. To investigate this question, we recorded multiple single unit and local field potential (LFP) activity from microelectrode arrays implanted bilaterally in macaque motor areas. Monkeys performed a delayed center-out reach task either manually using their natural arm (Manual Control, MC) or under direct neural control through a brain-machine interface (Brain Control, BC). In accord with prior work, we found that the spiking activity of individual neurons is coupled to multiple aspects of the ongoing motor beta rhythm (10-45 Hz) during both MC and BC, with neurons exhibiting a diversity of coupling preferences. However, here we show that for identified single neurons, this beta-to-rate mapping can change in a reversible and task-dependent way. For example, as beta power increases, a given neuron may increase spiking during MC but decrease spiking during BC, or exhibit a reversible shift in the preferred phase of firing. The within-task stability of coupling, combined with the reversible cross-task changes in coupling, suggest that task-dependent changes in the beta-to-rate mapping play a role in the transient functional reorganization of neural ensembles. We characterize the range of task-dependent changes in the mapping from beta amplitude, phase, and inter-hemispheric phase differences to the spike rates of an ensemble of simultaneously-recorded neurons, and discuss the potential implications that dynamic remapping from oscillatory activity to spike rate and timing may hold for models of computation and communication in distributed functional brain networks. C1 [Canolty, Ryan T.; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, San Francisco, CA USA. [Ganguly, Karunesh] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Carmena, Jose M.] Univ Calif Berkeley, UCB UCSF Joint Grad Grp Bioengn, Berkeley, CA 94720 USA. RP Canolty, RT (reprint author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu FU NIH NINDS [1K99NS070627-01A1]; NSF [CBET-0954243]; DARPA [N66001-10-C-2008] FX This work was supported by grants from the NIH NINDS (1K99NS070627-01A1 to RTC), NSF (CBET-0954243 to JMC), and a DARPA Contract N66001-10-C-2008 to JMC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 80 TC 15 Z9 15 U1 0 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD DEC PY 2012 VL 8 IS 12 AR e1002809 DI 10.1371/journal.pcbi.1002809 PG 23 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA 062EI UT WOS:000312901500016 PM 23284276 ER PT J AU Sze, JA Goodkind, MS Gyurak, A Levenson, RW AF Sze, Jocelyn A. Goodkind, Madeleine S. Gyurak, Anett Levenson, Robert W. TI Aging and Emotion Recognition: Not Just a Losing Matter SO PSYCHOLOGY AND AGING LA English DT Article DE aging; emotion recognition; empathic accuracy; social interaction ID AGE-RELATED DIFFERENCES; ADULT LIFE-SPAN; EMPATHIC ACCURACY; FACIAL EXPRESSIONS; SOCIOEMOTIONAL SELECTIVITY; PHYSIOLOGICAL LINKAGE; MARITAL INTERACTION; GENDER-DIFFERENCES; SOCIAL COGNITION; SEX-DIFFERENCES AB Past studies on emotion recognition and aging have found evidence of age-related decline when emotion recognition was assessed by having participants detect single emotions depicted in static images of full or partial (e.g., eye region) faces. These tests afford good experimental control but do not capture the dynamic nature of real-world emotion recognition, which is often characterized by continuous emotional judgments and dynamic multimodal stimuli. Research suggests that older adults often perform better under conditions that better mimic real-world social contexts. We assessed emotion recognition in young, middle-aged, and older adults using two traditional methods (single emotion judgments of static images of faces and eyes) and an additional method in which participants made continuous emotion judgments of dynamic, multimodal stimuli (videotaped interactions between young, middle-aged, and older couples). Results revealed an Age x Test interaction. Largely consistent with prior research, we found some evidence that older adults performed worse than young adults when judging single emotions from images of faces (for sad and disgust faces only) and eyes (for older eyes only), with middle-aged adults falling in between. In contrast, older adults did better than young adults on the test involving continuous emotion judgments of dyadic interactions, with middle-aged adults falling in between. In tests in which target stimuli differed in age, emotion recognition was not facilitated by an age match between participant and target. These findings are discussed in terms of theoretical and methodological implications for the study of aging and emotional processing. C1 [Sze, Jocelyn A.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Goodkind, Madeleine S.] VA Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA. [Goodkind, Madeleine S.; Gyurak, Anett] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Gyurak, Anett] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA. [Levenson, Robert W.] Univ Calif Berkeley, Inst Personal & Social Res, Dept Psychol, Berkeley, CA 94720 USA. RP Levenson, RW (reprint author), Univ Calif Berkeley, Inst Personal & Social Res, Dept Psychol, 4143 Tolman Hall MC 5050, Berkeley, CA 94720 USA. EM boblev@socrates.berkeley.edu FU NIA NIH HHS [R37 AG017766, R37-AG017766, R01 AG041762] NR 82 TC 14 Z9 14 U1 2 U2 39 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0882-7974 J9 PSYCHOL AGING JI Psychol. Aging PD DEC PY 2012 VL 27 IS 4 BP 940 EP 950 DI 10.1037/a0029367 PG 11 WC Gerontology; Psychology, Developmental SC Geriatrics & Gerontology; Psychology GA 067PB UT WOS:000313306500020 PM 22823183 ER PT J AU O'Neil, CK Hanlon, JT Marcum, ZA AF O'Neil, Christine K. Hanlon, Joseph T. Marcum, Zachary A. TI Adverse Effects of Analgesics Commonly Used by Older Adults With Osteoarthritis: Focus on Non-Opioid and Opioid Analgesics SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Review DE adverse drug events; aged; analgesics; osteoarthritis ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EMERGENCY-DEPARTMENT VISITS; ELDERLY-PATIENTS; KNEE OSTEOARTHRITIS; UNITED-STATES; CYCLO-OXYGENASE-2 INHIBITORS; PHARMACOLOGICAL MANAGEMENT; ACETAMINOPHEN ABSORPTION; MYOCARDIAL-INFARCTION; OARSI RECOMMENDATIONS AB Background: Osteoarthritis (OA) is the most common cause of disability in older adults, and although analgesic use can be helpful, it can also result in adverse drug events. Objective: To review the recent literature to describe potential adverse drug events associated with analgesics commonly used by older adults with OA. Methods: To identify articles for this review, a systematic search of the English-language literature from January 2001 to June 2012 was conducted using PubMed, MEDLINE, EBSCO, and the Cochrane Database of Systematic Reviews for publications related to the medical management of OA. Search terms used were "analgesics," "acetaminophen," "nonsteroidal anti-inflammatory drugs" (NSAIDs), "opioids," "pharmacokinetics," "pharmacodynamics," and "adverse drug events." The search was restricted to those articles that concerned humans aged >= 65 years. A manual search of the reference lists from identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify additional articles. From these, the authors identified those studies that examined analgesic use in older adults. Results: There are limited data to suggest that non-frail elders are more likely than their younger counterparts to develop acetaminophen-induced hepatotoxicity. However, decreased hepatic phase II metabolism in frail elders may result in increased risk of hepatotoxicity. It is now well established that older adults are at higher risk of NSAID-induced gastrointestinal toxicity and renal insufficiency. Insofar as opioids, the data that suggest an increased risk of falls, fractures, or delirium need to be tempered by the potential risk of inadequately treating severe chronic OA-related pain. Conclusions: Acetaminophen is the mainstay frontline analgesic for treating OA-related pain in older adults. NSAIDs should be limited to short-term use only, and for moderate to severe OA-related pain, opioids may be preferable in individuals without substance abuse or dependence issues. (Am J Geriatr Pharmacother. 2012;10: 331-342)(C) 2012 Elsevier HS Journals, Inc. All rights reserved. C1 [O'Neil, Christine K.] Duquesne Univ, Dept Pharm Practice, Sch Pharm, Pittsburgh, PA 15219 USA. [Hanlon, Joseph T.; Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Marcum, Zachary A.] Univ Pittsburgh, Geriatr Pharmaceut Outcomes & Geroinformat Res &, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.; Marcum, Zachary A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med Geriatr, 3471 5th Ave,Ste 500, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu FU National Institute on Aging [R56AG 027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056, R01AG028050]; National Institute of Nursing Research grant [R01 NR010135]; Agency for Healthcare Research and Quality grants [R01 HS017695, K12 HS019461, R01HS018721]; VA Health Services Research grant [IIR-06-062] FX Supported in part by National Institute on Aging grants and contracts (R56AG 027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056, and R01AG028050), a National Institute of Nursing Research grant (R01 NR010135), Agency for Healthcare Research and Quality grants (R01 HS017695, K12 HS019461, and R01HS018721), and a VA Health Services Research grant (IIR-06-062). Dr. O'Neil helped with the literature search, study design, data collection, data interpretation, and writing of the manuscript. Dr. Marcum helped with the literature search, table creation, study design, data collection, data interpretation, and writing of the manuscript. Dr. Hanlon helped with the study design, data collection, data interpretation, and writing of the manuscript. NR 67 TC 50 Z9 54 U1 2 U2 27 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD DEC PY 2012 VL 10 IS 6 BP 331 EP 342 DI 10.1016/j.amjopharm.2012.09.004 PG 12 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 064NT UT WOS:000313083000001 PM 23036838 ER PT J AU Brown, A Hirsch, R Laor, T Hannon, MJ Levesque, MC Starz, T Francis, K Kwoh, CK AF Brown, Amanda Hirsch, Raphael Laor, Tal Hannon, Michael J. Levesque, Marc C. Starz, Terence Francis, Kimberly Kwoh, C. Kent TI Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging? SO ARTHRITIS CARE & RESEARCH LA English DT Article ID EARLY RHEUMATOID-ARTHRITIS; AMERICAN-COLLEGE; SELECT CATEGORIES; FOLLOW-UP; RHEUMATOLOGY/EUROPEAN LEAGUE; DISEASE; CHILDREN; CRITERIA; THERAPY; CLASSIFICATION AB Objective Up to 90% of adults with rheumatoid arthritis (RA) in clinical remission have persistent synovitis and/or bone marrow lesions (BMLs) on magnetic resonance imaging (MRI). MRI findings in patients with juvenile idiopathic arthritis (JIA) in clinical remission have not been described. We utilized 3T MRI with contrast enhancement to examine JIA patients with hand and/or wrist involvement who were in clinical remission and compared them with a cohort of adult RA patients. Methods In total, 11 JIA patients and 10 RA patients with arthritis involving the hands and/or wrists were identified by their primary rheumatologist as being in physician-defined clinical remission, having no signs or symptoms of active arthritis and no medication changes for at least 6 months. A study rheumatologist performed a joint evaluation for tenderness, swelling, and limitation of motion, and study participants self-reported tender joint counts. The participants underwent MRI with intravenous contrast enhancement of 1 hand and wrist with a history of prior symptoms. A pediatric musculoskeletal radiologist blinded to the clinical data scored the MRIs for synovitis, tenosynovitis, and/or BMLs. Results Sixty-three percent of the JIA cohort and 70% of the RA cohort had MRI findings of synovitis, BMLs, and/or tenosynovitis. All pediatric patients with MRI abnormalities had normal physician tender and swollen joint counts. The patients' self-report of painful joint counts did not predict MRI abnormalities. Conclusion Over one-half of the patients in clinical remission had MRI evidence of persistent inflammation, defined as the presence of synovitis, tenosynovitis, or BMLs. A substantial portion of patients with JIA may have subclinical disease despite clinical remission. C1 [Brown, Amanda] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Hirsch, Raphael; Francis, Kimberly] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. [Hirsch, Raphael; Hannon, Michael J.; Levesque, Marc C.; Starz, Terence; Francis, Kimberly; Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Laor, Tal] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Laor, Tal] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Kwoh, C. Kent] VA Pittsburgh Healthcare, Pittsburgh, PA USA. RP Kwoh, CK (reprint author), S702 BSTWR,200 Lothrop St, Pittsburgh, PA 15206 USA. EM kwoh@pitt.edu FU Children's Hospital of Pittsburgh; NIH [R21-AR-056690, T32-AR-052282, P60-AR-054731] FX Supported in part by the Children's Hospital of Pittsburgh. Dr. Hirsch's work was supported by the NIH (grants R21-AR-056690 and T32-AR-052282). Dr. Kwoh's work was supported by the NIH (grant P60-AR-054731). NR 45 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD DEC PY 2012 VL 64 IS 12 BP 1846 EP 1854 DI 10.1002/acr.21774 PG 9 WC Rheumatology SC Rheumatology GA 045NZ UT WOS:000311704800008 PM 22740386 ER PT J AU Richards, JS Cannon, GW Hayden, CL Amdur, RL Lazaro, D Mikuls, TR Reimold, AM Caplan, L Johnson, DS Schwab, P Cherascu, BN Kerr, GS AF Richards, J. Steuart Cannon, Grant W. Hayden, Candace L. Amdur, Richard L. Lazaro, Deana Mikuls, Ted R. Reimold, Andreas M. Caplan, Liron Johnson, Dannette S. Schwab, Pascale Cherascu, Bogdan N. Kerr, Gail S. TI Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID HEALTH-ASSESSMENT QUESTIONNAIRE; HIP FRACTURE; DISEASE-ACTIVITY; MEDICATION ADHERENCE; OSTEOPOROTIC WOMEN; RISK; PERSISTENCE; ALENDRONATE; DATABASES; RATES AB Objective Pharmacy Benefits Management program data for patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were linked with clinical data to determine bisphosphonate adherence and persistence among US veterans with rheumatoid arthritis (RA) and to determine factors associated with adherence. Methods The primary outcome measures were the duration of bisphosphonate therapy and the medication possession ratio (MPR). Patients with an MPR <0.80 were classified as nonadherent. Potential covariates considered in the analysis included patient demographics, RA disease activity and severity parameters, and factors associated with osteoporosis risk. Associations of patient factors with duration of therapy and adherence were examined using multivariable regression modeling. Results Bisphosphonates were prescribed to 573 (41.5%) of 1,382 VARA subjects. The mean +/- SD duration of therapy for bisphosphonates was 39.2 +/- 31.4 months. A longer duration of therapy correlated with older age, more years of education, and dual x-ray absorptiometry testing. The mean +/- SD MPR of VARA subjects for bisphosphonate therapy was 0.69 +/- 0.28; 302 (52.7%) were nonadherent. In multivariate analyses, nonadherence with bisphosphonate therapy was associated with a longer duration of RA disease (odds ratio [OR] 1.02, 95% confidence interval [95% CI] 1.001.04) and duration of bisphosphonate therapy >32 months (OR 1.63, 95% CI 1.042.57). Whites were less likely to have a low MPR compared with nonwhites (OR 0.52, 95% CI 0.300.88). Conclusion Nonadherence with bisphosphonates was common in this cohort of RA patients and was associated with nonwhite ethnicity, a longer duration of RA disease, and a greater duration of bisphosphonate therapy. C1 [Richards, J. Steuart; Amdur, Richard L.] VA Med Ctr, Washington, DC USA. [Richards, J. Steuart; Amdur, Richard L.] Georgetown Univ, Washington, DC USA. [Cannon, Grant W.; Hayden, Candace L.] George E Whalen VA Med Ctr, Salt Lake City, UT USA. [Cannon, Grant W.; Hayden, Candace L.] Univ Utah, Salt Lake City, UT USA. [Lazaro, Deana] Brooklyn VA, New York, NY USA. [Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Reimold, Andreas M.] VA Med Ctr, Dallas, TX USA. [Reimold, Andreas M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. [Johnson, Dannette S.] DO GV Sonny Montgomery VA Med Ctr, Jackson, MS USA. [Johnson, Dannette S.] Univ Mississippi, Jackson, MS USA. [Schwab, Pascale] Portland VA, Portland, OR USA. [Cherascu, Bogdan N.] Iowa City VA, Iowa City, IA USA. [Kerr, Gail S.] Howard Univ, Washington, DC 20059 USA. [Kerr, Gail S.] Georgetown Univ, VA Med Ctr, Washington, DC USA. RP Richards, JS (reprint author), DC VA Med Ctr, 50 Irving St NW, Washington, DC 20422 USA. EM john.richards1@va.gov FU VA Health Services Research and Development grant [SHP 08-172] FX Supported by a VA Health Services Research and Development grant (SHP 08-172). NR 31 TC 8 Z9 9 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD DEC PY 2012 VL 64 IS 12 BP 1864 EP 1870 DI 10.1002/acr.21777 PG 7 WC Rheumatology SC Rheumatology GA 045NZ UT WOS:000311704800010 PM 22740421 ER PT J AU Crane, PK Carle, A Gibbons, LE Insel, P Mackin, RS Gross, A Jones, RN Mukherjee, S Curtis, SM Harvey, D Weiner, M Mungas, D AF Crane, Paul K. Carle, Adam Gibbons, Laura E. Insel, Philip Mackin, R. Scott Gross, Alden Jones, Richard N. Mukherjee, Shubhabrata Curtis, S. McKay Harvey, Danielle Weiner, Michael Mungas, Dan CA Alzheimer's Dis Neuroimaging TI Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Memory; psychometrics; longitudinal analysis; cognition; hippocampus ID ITEM RESPONSE THEORY; MILD COGNITIVE IMPAIRMENT; DIAGNOSIS; DEMENTIA; NETWORK; DECLINE; MODEL AB We sought to develop and evaluate a composite memory score from the neuropsychological battery used in the Alzheimer's Disease (AD) Neuroimaging Initiative (ADNI). We used modern psychometric approaches to analyze longitudinal Rey Auditory Verbal Learning Test (RAVLT, 2 versions), AD Assessment Schedule - Cognition (ADAS-Cog, 3 versions), Mini-Mental State Examination (MMSE), and Logical Memory data to develop ADNI-Mem, a composite memory score. We compared RAVLT and ADAS-Cog versions, and compared ADNI-Mem to RAVLT recall sum scores, four ADAS-Cog-derived scores, the MMSE, and the Clinical Dementia Rating Sum of Boxes. We evaluated rates of decline in normal cognition, mild cognitive impairment (MCI), and AD, ability to predict conversion from MCI to AD, strength of association with selected imaging parameters, and ability to differentiate rates of decline between participants with and without AD cerebrospinal fluid (CSF) signatures. The second version of the RAVLT was harder than the first. The ADAS-Cog versions were of similar difficulty. ADNI-Mem was slightly better at detecting change than total RAVLT recall scores. It was as good as or better than all of the other scores at predicting conversion from MCI to AD. It was associated with all our selected imaging parameters for people with MCI and AD. Participants with MCI with an AD CSF signature had somewhat more rapid decline than did those without. This paper illustrates appropriate methods for addressing the different versions of word lists, and demonstrates the additional power to be gleaned with a psychometrically sound composite memory score. C1 [Crane, Paul K.; Gibbons, Laura E.; Mukherjee, Shubhabrata; Curtis, S. McKay] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Carle, Adam] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Carle, Adam] Univ Cincinnati, Coll Arts & Sci, Cincinnati, OH 45229 USA. [Insel, Philip; Mackin, R. Scott; Weiner, Michael] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Gross, Alden; Jones, Richard N.] Hebrew Senior Life, Inst Aging Res, Dept Psychiat, Boston, MA 02131 USA. [Harvey, Danielle] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA. [Mungas, Dan] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. RP Crane, PK (reprint author), Univ Washington, Harborview Med Ctr, Box 359780,325 9th Ave, Seattle, WA 98104 USA. EM pcrane@u.washington.edu; gibbonsl@u.washington.edu RI Kowall, Neil/G-6364-2012; Preda, Adrian /K-8889-2013; Saykin, Andrew/A-1318-2007; Crane, Paul/C-8623-2014; Jones, Richard/J-3488-2013 OI Kowall, Neil/0000-0002-6624-0213; Preda, Adrian /0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532; Jones, Richard/0000-0002-1049-218X; Crane, Paul/0000-0003-4278-7465; Mukherjee, Shubhabrata/0000-0003-2522-2884 FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering; NIH [P30 AG010129, K01 AG030514, R01 AG029672, P50 AG05136, R13 AG030995]; Dana Foundation. Data management FX Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation. Data management and the specific analyses reported here wer\e supported by NIH grant R01 AG029672 (Paul Crane, PI), P50 AG05136 (Murray Raskind, PI), and R13 AG030995 (Dan Mungas, PI). NR 25 TC 66 Z9 67 U1 1 U2 16 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2012 VL 6 IS 4 BP 502 EP 516 DI 10.1007/s11682-012-9186-z PG 15 WC Neuroimaging SC Neurosciences & Neurology GA 061VL UT WOS:000312878200003 PM 22782295 ER PT J AU Gibbons, LE Carle, AC Mackin, RS Harvey, D Mukherjee, S Insel, P Curtis, SM Mungas, D Crane, PK AF Gibbons, Laura E. Carle, Adam C. Mackin, R. Scott Harvey, Danielle Mukherjee, Shubhabrata Insel, Philip Curtis, S. McKay Mungas, Dan Crane, Paul K. CA Alzheimer's Dis Neuroimaging TI A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Executive function; Mild cognitive impairment; Item response theory; Composite scores ID EPISODIC MEMORY; BIOMARKER SIGNATURE; CONVERSION; DEMENTIA; MCI; HETEROGENEITY; DECLINE AB The Alzheimer's Disease Neuroimaging Initiative (ADNI) measures abilities broadly related to executive function (EF), including WAIS-R Digit Symbol Substitution, Digit Span Backwards, Trails A and B, Category Fluency, and Clock Drawing. This study investigates whether a composite executive function measure based on these multiple indicators has better psychometric characteristics than the widely used individual components. We applied item response theory methods to 800 ADNI participants to derive an EF composite score (ADNI-EF) from the above measures. We then compared ADNI-EF with component measures in 390 longitudinally-followed participants with mild cognitive impairment (MCI) with respect to: (1) Ability to detect change over time; (2) Ability to predict conversion to dementia; (3) Strength of cross-sectional association with MRI-derived measures of structures involved in frontal systems, and (4) Strength of baseline association with cerebrospinal fluid (CSF) levels of amyloid beta(1-42), total tau, and phosphorylated tau(181P). ADNI-EF showed the greatest change over time, followed closely by Category Fluency. ADNI-EF needed a 40 % smaller sample size to detect change. ADNI-EF was the strongest predictor of AD conversion. ADNI-EF was the only measure significantly associated with all the MRI regions, though other measures were more strongly associated in a few of the regions. ADNI-EF was associated with all the CSF measures. ADNI-EF appears to be a useful composite measure of EF in MCI, as good as or better than any of its composite parts. This study demonstrates an approach to developing a psychometrically sophisticated composite score from commonly-used tests. C1 [Gibbons, Laura E.; Mukherjee, Shubhabrata; Curtis, S. McKay; Crane, Paul K.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Carle, Adam C.] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Carle, Adam C.] Univ Cincinnati, Coll Arts & Sci, Cincinnati, OH 45229 USA. [Mackin, R. Scott; Insel, Philip] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Harvey, Danielle] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA. [Mungas, Dan] UC Davis Med Ctr, Dept Neurol3, Sacramento, CA 95817 USA. RP Gibbons, LE (reprint author), Univ Washington, Harborview Med Ctr, Box 359780,325 9th Ave, Seattle, WA 98104 USA. EM gibbonsl@washington.edu RI ; Kowall, Neil/G-6364-2012; Preda, Adrian /K-8889-2013; Saykin, Andrew/A-1318-2007; Crane, Paul/C-8623-2014 OI Mukherjee, Shubhabrata/0000-0003-2522-2884; Kowall, Neil/0000-0002-6624-0213; Preda, Adrian /0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532; Crane, Paul/0000-0003-4278-7465 FU National Institute on Aging [R01 AG 029672, P50 AG05136, R13 AG030995]; National Institute of Mental Health [K08MH081065]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; NIH [P30 AG010129, K01 AG030514]; Dana Foundation FX Supported by grants R01 AG 029672 (P Crane), P50 AG05136 (Raskind), and R13 AG030995 (Mungas) from the National Institute on Aging, and K08MH081065 (Mackin) from the National Institute of Mental Health.; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation. NR 45 TC 58 Z9 58 U1 5 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2012 VL 6 IS 4 BP 517 EP 527 DI 10.1007/s11682-012-9176-1 PG 11 WC Neuroimaging SC Neurosciences & Neurology GA 061VL UT WOS:000312878200004 PM 22644789 ER PT J AU Ramanan, VK Kim, S Holohan, K Shen, L Nho, K Risacher, SL Foroud, TM Mukherjee, S Crane, PK Aisen, PS Petersen, RC Weiner, MW Saykin, AJ AF Ramanan, Vijay K. Kim, Sungeun Holohan, Kelly Shen, Li Nho, Kwangsik Risacher, Shannon L. Foroud, Tatiana M. Mukherjee, Shubhabrata Crane, Paul K. Aisen, Paul S. Petersen, Ronald C. Weiner, Michael W. Saykin, Andrew J. CA ADNI TI Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Memory; Psychometrics; Alzheimer's disease; Mild cognitive impairment; Pathway analysis; Genome-wide association study ID MILD COGNITIVE IMPAIRMENT; MINI-MENTAL STATE; STATISTICAL-METHODS; MULTIPLE-SCLEROSIS; QUANTITATIVE TRAIT; APOLIPOPROTEIN-E; SET ENRICHMENT; TYPE-4 ALLELE; AXON GUIDANCE; OLDER-ADULTS AB Memory deficits are prominent features of mild cognitive impairment (MCI) and Alzheimer's disease (AD). The genetic architecture underlying these memory deficits likely involves the combined effects of multiple genetic variants operative within numerous biological pathways. In order to identify functional pathways associated with memory impairment, we performed a pathway enrichment analysis on genome-wide association data from 742 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants. A composite measure of memory was generated as the phenotype for this analysis by applying modern psychometric theory to item-level data from the ADNI neuropsychological test battery. Using the GSA-SNP software tool, we identified 27 canonical, expertly-curated pathways with enrichment (FDR-corrected p-value < 0.05) against this composite memory score. Processes classically understood to be involved in memory consolidation, such as neurotransmitter receptor-mediated calcium signaling and long-term potentiation, were highly represented among the enriched pathways. In addition, pathways related to cell adhesion, neuronal differentiation and guided outgrowth, and glucose- and inflammation-related signaling were also enriched. Among genes that were highly-represented in these enriched pathways, we found indications of coordinated relationships, including one large gene set that is subject to regulation by the SP1 transcription factor, and another set that displays co-localized expression in normal brain tissue along with known AD risk genes. These results 1) demonstrate that psychometrically-derived composite memory scores are an effective phenotype for genetic investigations of memory impairment and 2) highlight the promise of pathway analysis in elucidating key mechanistic targets for future studies and for therapeutic interventions. C1 [Ramanan, Vijay K.; Kim, Sungeun; Holohan, Kelly; Shen, Li; Nho, Kwangsik; Risacher, Shannon L.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN USA. [Ramanan, Vijay K.; Holohan, Kelly; Foroud, Tatiana M.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA. [Ramanan, Vijay K.] Indiana Univ Sch Med, Med Scientist Training Program, Indianapolis, IN USA. [Kim, Sungeun; Shen, Li; Nho, Kwangsik; Foroud, Tatiana M.; Saykin, Andrew J.] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN USA. [Mukherjee, Shubhabrata; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA. [Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Petersen, Ronald C.] Mayo Clin Minnesota, Dept Neurol, Rochester, MN USA. [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Saykin, AJ (reprint author), Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN USA. EM asaykin@iupui.edu RI Kowall, Neil/G-6364-2012; Preda, Adrian /K-8889-2013; Saykin, Andrew/A-1318-2007; Crane, Paul/C-8623-2014 OI Kowall, Neil/0000-0002-6624-0213; Preda, Adrian /0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532; Crane, Paul/0000-0003-4278-7465; Mukherjee, Shubhabrata/0000-0003-2522-2884; Shen, Li/0000-0002-5443-0503 FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; NIH [P30 AG010129, K01 AG030514]; Dana Foundation; NSF [IIS-1117335]; NIA [R13 AG030995, R01 AG19771, P30 AG10133, R01 AG029672] FX Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation. Data management and the specific analyses reported here were supported by NSF IIS-1117335 (Shen), NIA R13 AG030995 (Mungas), NIA R01 AG19771 (Saykin), P30 AG10133 (Saykin/Ghetti), and R01 AG029672 (Crane). The authors declare that they have no conflict of interest. NR 79 TC 25 Z9 25 U1 2 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2012 VL 6 IS 4 BP 634 EP 648 DI 10.1007/s11682-012-9196-x PG 15 WC Neuroimaging SC Neurosciences & Neurology GA 061VL UT WOS:000312878200013 PM 22865056 ER PT J AU Mukherjee, S Trittschuh, E Gibbons, LE Mackin, RS Saykin, A Crane, PK AF Mukherjee, Shubhabrata Trittschuh, Emily Gibbons, Laura E. Mackin, R. Scott Saykin, Andrew Crane, Paul K. CA Alzheimer's Dis Neuroimaging TI Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Memory; Executive functioning; Alzheimer's disease; Phenotype; Genetic analyses; Psychometrics ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; DYSFUNCTION; CONSORTIUM; BIOMARKERS; PHENOTYPES; DIAGNOSIS; PATTERNS; PROGRESS AB Previous investigators have suggested the existence of distinct cognitive phenotypes of Alzheimer's disease (AD): a dysexecutive subgroup with executive functioning worse than memory and an amnesic subgroup with memory worse than executive functioning. We evaluated data from the AD Neuroimaging Initiative. We assigned people with AD to dysexecutive and amnesic subgroups using single indicators, and analogously using the ADNI-Mem and ADNI-EF composite scores developed using modern psychometric approaches. We evaluated associations between subgroup membership, APOE genotype, and single nucleotide polymorphisms (SNPs) are associated with AD, and brain vascular disease defined as white matter hyperintensities (WMH) and MRI-identified infarcts. We hypothesized that APOE epsilon 4 and alleles associated with higher risk for AD would predict amnesic subgroup membership; alleles associated with higher WMH or infarct burden would predict dysexecutive subgroup membership. Classification agreement between the two approaches was only fair (kappa = 0.23). There was no relationship between APOE alleles and the dysexecutive or amnesic phenotypes defined by either categorization approach. There were 58 AD-related and 25 WMH- or infarct-related SNPs for which odds ratios were > 1.5 or < 0.67 for dysexecutive vs. amnesic subgroup defined by either categorization approach. Higher proportions of SNPs had odds ratios in the hypothesized direction for the subgroups defined by the modern psychometric approach for AD-related (58 % vs. 38 %, p-value < 0.001) and brain vascular disease-related SNPs (48 vs. 32 %, p-value = 0.01). Genetic variation may underlie differential performance in memory and executive functioning among people with AD. Modern psychometric composite scores produced group assignments with more SNP associations in the hypothesized direction. C1 [Mukherjee, Shubhabrata; Gibbons, Laura E.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA. [Trittschuh, Emily] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Trittschuh, Emily] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Mackin, R. Scott] San Francisco VA Med Ctr, CIND, San Francisco, CA USA. [Saykin, Andrew] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN USA. RP Mukherjee, S (reprint author), Box 359780,325 9th Ave, Seattle, WA 98104 USA. EM smukherj@u.washington.edu RI Kowall, Neil/G-6364-2012; Preda, Adrian /K-8889-2013; Saykin, Andrew/A-1318-2007; Crane, Paul/C-8623-2014 OI Kowall, Neil/0000-0002-6624-0213; Preda, Adrian /0000-0003-3373-2438; Saykin, Andrew/0000-0002-1376-8532; Crane, Paul/0000-0003-4278-7465; Mukherjee, Shubhabrata/0000-0003-2522-2884 FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; NIH [P30 AG010129, K01 AG030514, R01 AG029672, R13 AG030995]; NIA [P50 AG05136] FX Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514. Data management and the specific analyses reported here were supported by NIH grant R01 AG029672 (Paul Crane, PI), R13 AG030995 (Mungas), and P50 AG05136 (Raskind), from the NIA. NR 37 TC 5 Z9 5 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2012 VL 6 IS 4 BP 649 EP 660 DI 10.1007/s11682-012-9207-y PG 12 WC Neuroimaging SC Neurosciences & Neurology GA 061VL UT WOS:000312878200014 PM 23161456 ER PT J AU Nield, M Hoo, GWS AF Nield, Margaret Hoo, Guy W. Soo TI Real-Time Telehealth for COPD Self-Management Using Skype (TM) SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE Social support; Dyspnea; Breathing strategy; Telecommunication ID OBSTRUCTIVE PULMONARY-DISEASE; SOCIAL SUPPORT; HOME TELEHEALTH; DYSPNEA; HEALTH; STATEMENT; OUTCOMES AB The utility of real-time interactive voice and video telehealth for teaching pursed-lips breathing (PLB) in chronic obstructive pulmonary disease (COPD) is unknown. This was a pilot study to determine its feasibility and efficacy on the key variables of social support and dyspnea. A randomized control study design with repeated measures (baseline, 4 and 12 weeks) was used. All participants in the control and intervention groups received PLB instruction at baseline, but only the intervention group received one weekly PLB reinforcement session for 4 weeks via home computer and Skype (TM) software. Outcome measures were Medical Outcomes Study Social Support Survey and dyspnea assessment (visual analogue scales for intensity and distress, modified Borg after six-minute walk distance, and Shortness of Breath Questionnaire for activity-associated dyspnea). A total of 22 participants with COPD (mean FEV1 % predicted = 56) were randomized; 16 (9 telehealth, 7 control) completed the protocol. Intent-to-treat analysis at week 4, but not week 12, demonstrated significantly improved total social support (P = 0.02) and emotional/informational subscale (P = 0.03) scores. Dyspnea intensity decreased (P = 0.08) for the intervention group with a minimal clinical important difference of 10.4 units. Analysis of only participants who completed the protocol demonstrated a significant decrease in dyspnea intensity (P = <0.01) for the intervention group at both week 4 and 12. Real-time telehealth is a feasible, innovative approach for PLB instruction in the home with outcomes of improved social support and decreased dyspnea. C1 [Nield, Margaret] VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. [Hoo, Guy W. Soo] Univ Calif Los Angeles, W Los Angeles VA Healthcare Ctr, Pulm & Crit Care Sect, Los Angeles, CA USA. [Hoo, Guy W. Soo] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Nield, M (reprint author), VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,111Q, Los Angeles, CA 90073 USA. EM pegnield@gmail.com FU Breathe California of Los Angeles County; National Institutes of Health [P20 NR010671-01] FX Margaret Nield has no conflict of interest to disclose. Guy W. Soo Hoo is a member of the board of Breathe California of Los Angeles County. The funding sources (Breathe California of Los Angeles County and in part by National Institutes of Health [Grant P20 NR010671-01]) had no role in the design or conduct of the study, collection, management, analysis or interpretation of the data or preparation, review or approval of the manuscript. The authors are responsible for the content and the writing of this paper. NR 37 TC 13 Z9 13 U1 2 U2 25 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD DEC PY 2012 VL 9 IS 6 BP 611 EP 619 DI 10.3109/15412555.2012.708067 PG 9 WC Respiratory System SC Respiratory System GA 056PO UT WOS:000312503400006 PM 22946768 ER PT J AU Springelkamp, H Lee, K Ramdas, WD Vingerling, JR Hofman, A Klaver, CCW Sonka, M Abramoff, MD Jansonius, NM AF Springelkamp, Henriet Lee, Kyungmoo Ramdas, Wishal D. Vingerling, Johannes R. Hofman, Albert Klaver, Caroline C. W. Sonka, Milan Abramoff, Michael D. Jansonius, Nomdo M. TI Optimizing the Information Yield of 3-D OCT in Glaucoma SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; FIBER LAYER THICKNESS; SPECTRAL-DOMAIN OCT; OPEN-ANGLE GLAUCOMA; CIRRUS HD-OCT; NERVE HEAD; STRATUS OCT; REPRODUCIBILITY; EYES; REPEATABILITY AB PURPOSE. To determine, first, which regions of 3-D optical coherence tomography (OCT) volumes can be segmented completely in the majority of subjects and, second, the relationship between analyzed area and thickness measurement test-retest variability. METHODS. Three-dimensional OCT volumes (6X6 mm) centered around the fovea and optic nerve head (ONH) of 925 Rotterdam Study participants were analyzed; 44 participants were scanned twice. Volumes were segmented into 10 layers, and we determined the area where all layers could be identified in at least 95% (macula) or 90% (ONH) of subjects. Macular volumes were divided in 2 x 2, 4 x 4, 6 x 6, 8 x 8, or 68 blocks. We placed two circles around the ONH; the ONH had to fit into the smaller circle, and the larger circle had to fit into the segmentable part of the volume. The area between the circles was divided in 3 to 12 segments. We determined the test-retest variability (coefficient of repeatability) of the retinal nerve fiber layer (RNFL) and ganglion cell layer (RGCL) thickness measurements as a function of size of blocks/segments. RESULTS. Eighty-two percent of the macular volume could be segmented in at least 95% of subjects; for the ONH, this was 65% in at least 90%. The radii of the circles were 1.03 and 1.84 mm. Depending on the analyzed area, median test-retest variability ranged from 8% to 15% for macular RNFL, 11% to 22% for macular RGCL, 5% to 11% for the two together, and 18% to 22% for ONH RNFL. CONCLUSIONS. Test-retest variability hampers a detailed analysis of 3-D OCT data. Combined macular RNFL and RGCL thickness averaged over larger areas had the best test-retest variability. (Invest Ophthalmol Vis Sci. 2012; 53: 8162-8171) DOI:10.1167/iovs.12-10551 C1 [Springelkamp, Henriet; Ramdas, Wishal D.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands. [Springelkamp, Henriet; Ramdas, Wishal D.; Vingerling, Johannes R.; Hofman, Albert; Klaver, Caroline C. W.; Jansonius, Nomdo M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Lee, Kyungmoo; Sonka, Milan; Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA. [Abramoff, Michael D.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA. [Abramoff, Michael D.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA. [Abramoff, Michael D.] US Dept Vet Affairs, Iowa City, IA USA. [Jansonius, Nomdo M.] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, Groningen, Netherlands. RP Abramoff, MD (reprint author), Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci PFP 11205, Iowa City, IA 52242 USA. EM michael-abramoff@uiowa.edu RI Klaver, Caroline/A-2013-2016 FU Rotterdam: Stichting Lijf en Leven, Krimpen aan de Lek, The Netherlands; MD Fonds, Utrecht, The Netherlands; Rotterdamse Vereniging Blindenbelangen, Rotterdam, The Netherlands; Stichting Oogfonds Nederland, Utrecht, The Netherlands; Blindenpenning, Amsterdam, The Netherlands; Blindenhulp, The Hague, The Netherlands; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn, The Netherlands; Landelijke Stichting voor Blinden en Slechtzienden, Utrecht, The Netherlands; Swart van Essen, Rotterdam, The Netherlands; Stichting Winckel-Sweep, Utrecht, The Netherlands; Henkes Stichting, Rotterdam, The Netherlands; Lameris Ootech BV, Nieuwegein, The Netherlands; Medical Workshop, de Meern, The Netherlands; Topcon Europe BV, Capelle aan de IJssel, The Netherlands; Heidelberg Engineering, Dossenheim, Germany; Iowa: National Institute of Health [EY019112] FX Supported by Rotterdam: Stichting Lijf en Leven, Krimpen aan de Lek; MD Fonds, Utrecht; Rotterdamse Vereniging Blindenbelangen, Rotterdam; Stichting Oogfonds Nederland, Utrecht; Blindenpenning, Amsterdam; Blindenhulp, The Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn; Landelijke Stichting voor Blinden en Slechtzienden, Utrecht; Swart van Essen, Rotterdam; Stichting Winckel-Sweep, Utrecht; Henkes Stichting, Rotterdam; Lameris Ootech BV, Nieuwegein; Medical Workshop, de Meern; Topcon Europe BV, Capelle aan de IJssel; all in The Netherlands; and Heidelberg Engineering, Dossenheim, Germany; Iowa: National Institute of Health Grant EY019112. The authors alone are responsible for the content and writing of the paper. NR 40 TC 3 Z9 3 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD DEC PY 2012 VL 53 IS 13 BP 8162 EP 8171 DI 10.1167/iovs.12-10551 PG 10 WC Ophthalmology SC Ophthalmology GA 064EX UT WOS:000313056000034 PM 23154462 ER PT J AU Lin, F Vance, DE Gleason, CE Heidrich, SM AF Lin, Feng Vance, David E. Gleason, Carey E. Heidrich, Susan M. TI Caring for Older Adults with Mild Cognitive Impairment An Update for Nurses SO JOURNAL OF GERONTOLOGICAL NURSING LA English DT Article ID MINI-MENTAL-STATE; OF-THE-LITERATURE; ALZHEIMERS-DISEASE; INSTRUMENTAL ACTIVITIES; NEUROPSYCHIATRIC SYMPTOMS; SIGNIFICANT OTHERS; PHYSICAL-ACTIVITY; GROUP-THERAPY; RATING-SCALE; DEMENTIA AB Mild cognitive impairment (MCI) is a mild decline in single or multiple cognitive domains, while global cognition and basic activities of daily living remain intact. Nurses play an important role in early detection of MCI and providing care to maintain maximum independence for individuals with MCI. This article seeks to provide nurses with a review of the most recent research regarding the etiology and diagnosis of MCI, related risk and protective factors, patient and family experiences, and current interventions. This update provides research evidence to inform nursing practice of MCI care. C1 [Lin, Feng] Univ Rochester, Med Ctr, Sch Nursing, Rochester, NY 14642 USA. [Vance, David E.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [Gleason, Carey E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Heidrich, Susan M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Lin, F (reprint author), Univ Rochester, Med Ctr, Sch Nursing, HWH 2W128,601 Elmwood Ave, Rochester, NY 14642 USA. EM vankee_lin@urmc.rochester.edu OI Vance, David/0000-0002-0498-6263 FU NIA NIH HHS [P50 AG033514] NR 107 TC 1 Z9 1 U1 3 U2 13 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0098-9134 J9 J GERONTOL NURS JI J. Gerontol. Nurs. PD DEC PY 2012 VL 38 IS 12 BP 22 EP 37 DI 10.3928/00989134-20121112-99 PG 19 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA 064AQ UT WOS:000313043700006 PM 23189995 ER PT J AU Orman, JA Geyer, D Jones, J Schneider, EB Grafman, J Pugh, MJ DuBose, J AF Orman, Jean A. Geyer, Dennis Jones, John Schneider, Eric B. Grafman, Jordan Pugh, Mary Jo DuBose, Joseph TI Epidemiology of moderate-to-severe penetrating versus closed traumatic brain injury in the Iraq and Afghanistan wars SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article DE Traumatic and penetrating brain injury; military; epidemiology; Operation Enduring Freedom/Iraqi Freedom; Operation New Dawn ID COMBAT WOUNDS; FREEDOM; HOSPITALIZATIONS; BATTLEFIELD AB BACKGROUND: US combat operations in Iraq and Afghanistan have resulted in a greater proportion of service members with head and neck wounds caused by explosions compared with that of previous wars. Although penetrating traumatic brain injury (TBI) is frequently associated with these wounds, the epidemiology of penetrating TBI from these conflicts has not been well described. METHODS: The Joint Theater Trauma Registry was queried for January 2003 through December 2010 to identify all patients with moderate-to-severe brain injury with a maximum Abbreviated Injury Scale (AIS) score of the head of 3 or greater and a diagnosis of penetrating or closed TBI in accordance with the Department of Defense Traumatic Brain Injury Surveillance definition. The epidemiology of these injuries was examined, including demographics, TBI severity, overall injury severity, and surgical interventions provided. RESULTS: A total of 1,255 TBI patients (774 penetrating, 481 closed) meeting criteria were identified. Penetrating brain injuries were more severe, more likely to be battle related, and less likely to be isolated injuries than a group of moderate-to-severe closed TBIs within the same range of anatomic injury severity. During the 5-year period of the Iraq war with the largest numbers of TBIs (2004-2008), the numbers of penetrating TBIs exceeded closed TBIs by a ratio of 2:1. During the 3-year period of the Afghanistan war with the greatest numbers of TBIs (2008-2010), the ratio of penetrating to closed TBIs was substantially lower, approximately 1.3:1. CONCLUSION: This study represents the first comprehensive report on the epidemiology of moderate-to-severe penetrating and closed TBIs resulting from the wars in Iraq and Afghanistan using Joint Theater Trauma Registry data. With the maturing theater of conflicts, penetrating TBIs were substantially less predominant compared with closed TBIs. While this finding may reflect changes in the use of protective measures and tactics or improvements in diagnosis of closed TBIs, additional research is needed to identify the reason for this shift and the subsequent effect on outcome after combat-related TBIs. (J Trauma Acute Care Surg. 2012;73: S496-S502. Copyright (C) 2012 by Lippincott Williams & Wilkins) C1 [Orman, Jean A.] USA, Inst Surg Res, ATTN MCMR SRR, Ft Sam Houston, TX 78234 USA. [Orman, Jean A.; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Geyer, Dennis] San Antonio Mil Med Ctr, Dept Surg, Neurosurg Serv, San Antonio, TX USA. [Pugh, Mary Jo] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Schneider, Eric B.] Johns Hopkins Sch Med, Ctr Surg Trials & Outcomes Res, Baltimore, MD USA. [DuBose, Joseph] Univ Maryland Med Syst, R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA. [Jones, John] Northwestern Univ, Rehabil Inst Chicago, Chicago, IL 60611 USA. [Grafman, Jordan] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. RP Orman, JA (reprint author), USA, Inst Surg Res, ATTN MCMR SRR, 3698 Chambers Pass, Ft Sam Houston, TX 78234 USA. EM Jean.A.Orman@amedd.army.mil OI Grafman, Jordan H./0000-0001-8645-4457; Pugh, Mary Jo/0000-0003-4196-7763 FU South Texas Veterans Healthcare System FX We acknowledge JTTR for providing data for this study and Ms. Susan West and Ms. Celina Garcia of the JTTR staff for their invaluable assistance in preparing the data set. Some work for this study was supported by resources of the South Texas Veterans Healthcare System. NR 38 TC 9 Z9 10 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD DEC PY 2012 VL 73 SU 5 BP S496 EP S502 DI 10.1097/TA.0b013e318275473c PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 056QT UT WOS:000312506900020 PM 23192076 ER PT J AU Tsai, J Rosenheck, RA Decker, SE Desai, RA Harpaz-Rotem, I AF Tsai, Jack Rosenheck, Robert A. Decker, Suzanne E. Desai, Rani A. Harpaz-Rotem, Ilan TI Trauma Experience Among Homeless Female Veterans: Correlates and Impact on Housing, Clinical, and Psychosocial Outcomes SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; WOMEN VETERANS; COOCCURRING DISORDERS; SUBSTANCE-ABUSE; MENTAL-HEALTH; RISK-FACTORS; VICTIMIZATION; ASSOCIATION; THERAPY AB This study examined lifetime exposure to traumatic events as reported by 581 homeless female veterans enrolled in a Homeless Women Veterans Program across 11 sites to characterize the types of trauma they experienced; their correlation with baseline characteristics; and their association with housing, clinical outcomes, and psychosocial functioning over a 1-year treatment period. Almost all participants endorsed multiple types and episodes of traumatic events. Among the most common were having someone close experience a serious or life-threatening illness (82%) and rape (67%). Exploratory factor analysis revealed 6 potential trauma categories: being robbed, experiencing accident or disasters, illness or death of others, combat, sexual assault, and physical assault. At baseline, trauma from sexual assault was associated with more days homeless (beta = .18, p < .001), trauma from accidents or disasters was associated with poorer physical health (beta = -.23, p < .001), and trauma from being robbed was related to greater use of drugs (beta = .22, p < .001). Trauma reported at baseline, however, was not predictive of 1-year outcomes, suggesting type and frequency of trauma does not negatively affect the housing gains homeless women veterans can achieve through homeless services. C1 [Tsai, Jack; Rosenheck, Robert A.; Decker, Suzanne E.; Harpaz-Rotem, Ilan] Vet Affairs New England Mental Illness, Res Educ & Clin Ctr, West Haven, CT USA. [Tsai, Jack; Rosenheck, Robert A.; Decker, Suzanne E.; Desai, Rani A.; Harpaz-Rotem, Ilan] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Rosenheck, Robert A.; Desai, Rani A.] Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT USA. [Desai, Rani A.] US Dept Vet Affairs, NE Program Evaluat Ctr, West Haven, CT USA. [Harpaz-Rotem, Ilan] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. RP Tsai, J (reprint author), VACT, 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM Jack.Tsai@yale.edu RI Tsai, Jack/D-3889-2013 OI Tsai, Jack/0000-0002-0329-648X NR 37 TC 4 Z9 4 U1 1 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2012 VL 25 IS 6 BP 624 EP 632 DI 10.1002/jts.21750 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 051TW UT WOS:000312151400003 PM 23225030 ER PT J AU Snider, AJ Wu, BX Jenkins, RW Sticca, JA Kawamori, T Hannun, YA Obeid, LM AF Snider, Ashley J. Wu, Bill X. Jenkins, Russell W. Sticca, Jonathan A. Kawamori, Toshihiko Hannun, Yusuf A. Obeid, Lina M. TI Loss of neutral ceramidase increases inflammation in a mouse model of inflammatory bowel disease SO PROSTAGLANDINS & OTHER LIPID MEDIATORS LA English DT Article DE Ceramide; Ceramidase; Sphingosine-1-phosphate; Colitis; Neutrophil; Inflammation ID SPHINGOSINE KINASE 1; COLLAGEN-INDUCED ARTHRITIS; ACID CERAMIDASE; TNF-ALPHA; ALKALINE CERAMIDASE; CHRONIC ACTIVATION; PGE(2) PRODUCTION; RECEPTOR AGONIST; T-CELLS; SPHINGOSINE-1-PHOSPHATE AB Sphingolipids are emerging as important mediators of immune and inflammatory responses. We have previously demonstrated that sphingosine-1-phosphate (S1P) and its synthetic enzyme sphingosine kinase-1 (SK1) play an important role in inflammatory bowel disease. S1P generation is dependent on SK phosphorylation of sphingosine. Generation of sphingosine results only from the breakdown of ceramide by ceramidases (CDase). In this study, we set out to determine the role of neutral CDase (nCDase) in S1P generation and inflammatory bowel disease. To this end, we established nCDase expression is increased in patients with ulcerative colitis. Using the dextran sulfate sodium (DSS)-induced colitis model, we determined nCDase activity increased in colon epithelium, but not submucosa, in wild-type (WT) mice. Following DSS, ceramide levels were elevated in colon epithelium from WT and nCDase(-/-) mice, while S1P levels were significantly elevated only in the epithelium of nCDase(-/-) mice. Similarly, cyclooxygenase-2 (Cox-2) levels were significantly elevated only in the epithelium of nCDase(-/-) mice. Neutral CDase(-/-) mice also exhibited higher endotoxin levels in circulation, as well as higher circulating levels of S1P. This increase in S1P in nCDase(-/-) mice was accompanied by a marked leukocytosis, most notably circulating neutrophils and lymphocytes. Taken together these data demonstrate that loss of nCDase results in an unexpected increase in S1P generation in inflammation, and suggests that nCDase may actually protect against inflammation. Published by Elsevier Inc. C1 [Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Wu, Bill X.; Jenkins, Russell W.; Sticca, Jonathan A.; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Obeid, Lina M.] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), SUNY Stony Brook, Med Ctr, Dept Med, Hlth Sci Ctr L4, Stony Brook, NY 11794 USA. EM Lina.Obeid@stonybrookmedicine.edu OI obeid, lina/0000-0002-0734-0847 FU Veterans Affairs Merit Award; Career Development Award; NIH [GM062887] FX This work was supported by a Veterans Affairs Merit Award (LMO) and Career Development Award (AJS), as well as NIH Grant GM062887 (LMO). Lipid analyses provided by the Lipidomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313) and the Lipidomics Core in the SC Lipidomics and Pathobiology COBRE, Department Biochemistry, MUSC (P20 RR017677). We thank Dr. Richard Proia (NIDDK, Bethesda, MD, USA) for providing the nCDase-/- mice, George Washington and the COBRE Animal Pathobiology Core, as well as Margaret H. Romano and the Core Histology Laboratory at MUSC for their technical assistance. NR 43 TC 9 Z9 11 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-8823 J9 PROSTAG OTH LIPID M JI Prostaglandins Other Lipid Mediat. PD DEC PY 2012 VL 99 IS 3-4 BP 124 EP 130 DI 10.1016/j.prostaglandins.2012.08.003 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 056SN UT WOS:000312511800008 PM 22940715 ER PT J AU Simpson, TL Stappenbeck, CA Varra, AA Moore, SA Kaysen, D AF Simpson, Tracy L. Stappenbeck, Cynthia A. Varra, Alethea A. Moore, Sally A. Kaysen, Debra TI Symptoms of Posttraumatic Stress Predict Craving Among Alcohol Treatment Seekers: Results of a Daily Monitoring Study SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE alcohol craving; PTSD; daily monitoring; self-medication hypothesis ID ECOLOGICAL MOMENTARY ASSESSMENT; SUBSTANCE USE DISORDERS; TIMELINE FOLLOW BACK; PTSD CHECKLIST; CUE REACTIVITY; PSYCHOMETRIC PROPERTIES; DRINKING PATTERNS; FEMALE VETERANS; NEGATIVE AFFECT; SEXUAL ASSAULT AB Alcohol use disorders (AUDs) and Posttraumatic Stress Disorder (PTSD) commonly co-occur. Craving for alcohol is a common aspect of AUD, with and without PTSD, and is one of the key predictors of continued problematic alcohol use among treatment seekers. The present study sought to investigate the self-medication hypothesis using daily Interactive Voice Response (IVR) reports to examine the relationships between PTSD symptomatology and both same-day and next-day alcohol craving. Twenty-nine individuals with an AUD (26 of whom screened positive for PTSD) entering AUD treatment provided daily IVR data for up to 28 days regarding their alcohol use, craving, and 7 symptoms of PTSD. Given the nested nature of daily data, generalized estimating equations using a negative binomial distribution and a log link function were used to test hypotheses. Results suggest that days with greater overall PTSD severity are associated with greater alcohol craving, and greater reports of startle and anger/irritability were particularly associated with same-day craving. The next-day results suggest that the combination of the 7 PTSD symptoms did not predict next-day craving. However, greater distress from nightmares the previous night, emotional numbing, and hypervigilance predicted greater next-day craving, while greater anger/irritability predicted lower next-day craving. These findings highlight the importance of assessing the relationship between specific symptoms of PTSD and alcohol cravings in order to increase our understanding of the functional interplay among them for theory building. Additionally, clinicians may be better able to refine treatment decisions to more efficiently break the cycle between PTSD-related distress and AUD symptoms. C1 [Simpson, Tracy L.; Stappenbeck, Cynthia A.; Varra, Alethea A.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Simpson, Tracy L.; Varra, Alethea A.; Moore, Sally A.; Kaysen, Debra] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Moore, Sally A.] Evidence Based Treatment Ctr Seattle PLLC, Seattle, WA USA. RP Simpson, TL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Tracy.Simpson@va.gov NR 70 TC 22 Z9 22 U1 4 U2 16 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD DEC PY 2012 VL 26 IS 4 BP 724 EP 733 DI 10.1037/a0027169 PG 10 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 059CM UT WOS:000312682000005 PM 22369221 ER PT J AU Jonker, MA Sauerhammer, TM Faucher, LD Schurr, MJ Kudsk, KA AF Jonker, Mark A. Sauerhammer, Tina M. Faucher, Lee D. Schurr, Michael J. Kudsk, Kenneth A. TI Bilateral versus Unilateral Bronchoalveolar Lavage for the Diagnosis of Ventilator-Associated Pneumonia SO SURGICAL INFECTIONS LA English DT Article ID NOSOCOMIAL PNEUMONIA; QUANTITATIVE CULTURES; RANDOMIZED-TRIAL; TRAUMA PATIENTS; RISK-FACTORS; BLIND; EFFICACY; BRONCHOSCOPY; MANAGEMENT; ACCURACY AB Background: Ventilator-associated pneumonia (VAP) complicates the clinical course of critically injured intubated patients. Bronchoscopic bronchoalveolar lavage (BAL) represents an invasive and accurate means of VAP diagnosis. Unilateral and blinded techniques offer less invasive alternatives to bronchoscopic BAL. This study evaluated clinical criteria as well as unilateral directed versus bilateral BAL for VAP diagnosis. Methods: A retrospective chart review of 113 consecutive intubated trauma patients with clinically suspected VAP undergoing unilateral versus bilateral BAL was performed with comparison of positive culture results (>10(4) colony-forming units [CFU]/mL). Culture results were compared with chest radiograph (CXR) infiltrates and white blood cell (WBC) count elevation. Results: Bilateral BAL was more likely to be positive than unilateral BAL (50.4% vs. 25.5%). In 37.1% of bilateral BALs, there was discordance between the sides of positivity or the bacteria isolated. A CXR infiltrate and WBC count elevation did not predict positive BAL. Conclusions: Clinical indicators of VAP are inaccurate, and bilateral bronchoscopic BAL is more likely than unilateral BAL to provide a positive sample in intubated trauma patients. Techniques that do not sample both lungs reliably should be avoided for diagnosis in this patient population. C1 [Jonker, Mark A.; Sauerhammer, Tina M.; Faucher, Lee D.; Schurr, Michael J.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU National Institute of Health (NIH) [R01 GM53439]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service FX This research is supported by National Institute of Health (NIH) Grant R01 GM53439.; This material is also based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service. The contents of this article do not represent the views of the Dept. of Veterans Affairs or the United States Government. NR 32 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 J9 SURG INFECT JI Surg. Infect. PD DEC PY 2012 VL 13 IS 6 BP 391 EP 395 DI 10.1089/sur.2011.081 PG 5 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA 061GF UT WOS:000312835800008 PM 23240724 ER PT J AU Mader, BJ Pivtoraiko, VN Flippo, HM Klocke, BJ Roth, KA Mangieri, LR Shacka, JJ AF Mader, Burton J. Pivtoraiko, Violetta N. Flippo, Hilary M. Klocke, Barbara J. Roth, Kevin A. Mangieri, Leandra R. Shacka, John J. TI Rotenone Inhibits Autophagic Flux Prior to Inducing Cell Death SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE Rotenone; autophagy; lysosome; cell death; Parkinson's disease; SH-SY5Y ID LYSOSOMAL DEGRADATION PATHWAY; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; MEMBRANE PERMEABILIZATION; DOPAMINERGIC-NEURONS; SH-SY5Y CELLS; DYSFUNCTION; APOPTOSIS; MODELS; CLEARANCE AB Rotenone, which selectively inhibits mitochondrial complex I, induces oxidative stress, alpha-synuclein accumulation, and dopaminergic neuron death, principal pathological features of Parkinson's disease. The autophagy-lysosome pathway degrades damaged proteins and organelles for the intracellular maintenance of nutrient and energy balance. While it is known that rotenone causes autophagic vacuole accumulation, the mechanism by which this effect occurs has not been thoroughly investigated. Treatment of differentiated SH-SY5Y cells with rotenone (10 mu M) induced the accumulation of autophagic vacuoles at 6 h and 24 h as indicated by Western blot analysis for microtubule associated protein-light chain 3-II (MAP-LC3-II). Assessment of autophagic flux at these time points indicated that autophagic vacuole accumulation resulted from a decrease in their effective lysosomal degradation, which was substantiated by increased levels of autophagy substrates p62 and alpha-synuclein. Inhibition of lysosomal degradation may be explained by the observed decrease in cellular ATP levels, which in turn may have caused the observed concomitant increase in acidic vesicle pH. The early (6 h) effects of rotenone on cellular energetics and autophagy-lysosome pathway function preceded the induction of cell death and apoptosis. These findings indicate that the classical mitochondrial toxin rotenone has a pronounced effect on macroautophagy completion that may contribute to its neurotoxic potential. C1 [Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Shacka, JJ (reprint author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, SC 930G4,1530 3rd Ave S, Birmingham, AL 35294 USA. EM shacka@uab.edu RI di Ronza, Alberto/H-7674-2016 OI di Ronza, Alberto/0000-0002-9813-5143; Mangieri, Leandra/0000-0001-8981-0103; Roth, Kevin/0000-0002-0643-995X FU VA Merit Award [1 101 BX000957-01]; NIH R01s (National) [NS35107, NS41962, CA134773] FX J.J.S. is supported by a VA Merit Award 1 101 BX000957-01. K.A.R. is supported by NIH R01s (National NS35107, NS41962, and CA134773. We also thank the UAB Neuroscience Core facilities (NS047466 and NS057098) for technical assistance. NR 41 TC 25 Z9 25 U1 2 U2 20 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD DEC PY 2012 VL 3 IS 12 BP 1063 EP 1072 DI 10.1021/cn300145z PG 10 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA 057LH UT WOS:000312564400010 PM 23259041 ER PT J AU Blevins, JE Moralejo, DH Wolden-Hanson, TH Thatcher, BS Ho, JM Kaiyala, KJ Matsumoto, K AF Blevins, James E. Moralejo, Daniel H. Wolden-Hanson, Tami H. Thatcher, Brendan S. Ho, Jacqueline M. Kaiyala, Karl J. Matsumoto, Kozo TI Alterations in activity and energy expenditure contribute to lean phenotype in Fischer 344 rats lacking the cholecystokinin-1 receptor gene SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE satiety; meal size; cholecystokinin; CCK1 receptors ID DEPENDENT DIABETES-MELLITUS; C-FOS EXPRESSION; TOKUSHIMA FATTY RAT; QUANTITATIVE-TRAIT LOCUS; INDUCED OBESE RATS; BRAIN-STEM NUCLEI; FOOD-INTAKE; BODY-WEIGHT; MICE LACKING; A RECEPTORS AB Blevins JE, Moralejo DH, Wolden-Hanson TH, Thatcher BS, Ho JM, Kaiyala KJ, Matsumoto K. Alterations in activity and energy expenditure contribute to lean phenotype in Fischer 344 rats lacking the cholecystokinin-1 receptor gene. Am J Physiol Regul Integr Comp Physiol 303: R1231-R1240, 2012. First published October 31, 2012; doi:10.1152/ajpregu.00393.2012.-CCK is hypothesized to inhibit meal size by acting at CCK1 receptors (CCK1R) on vagal afferent neurons that innervate the gastrointestinal tract and project to the hindbrain. Earlier studies have shown that obese Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which carry a spontaneous null mutation of the CCK1R, are hyperphagic and obese. Recent findings show that rats with CCK1R-null gene on a Fischer 344 background (Cck1r(-/-)) are lean and normophagic. In this study, the metabolic phenotype of this rat strain was further characterized. As expected, the CCK1R antagonist, devazepide, failed to stimulate food intake in the Cck1r(-/-) rats. Both Cck1r(+/+) and Cck1r(-/-) rats became diet-induced obese (DIO) when maintained on a high-fat diet relative to chow-fed controls. Cck1r(-/-) rats consumed larger meals than controls during the dark cycle and smaller meals during the light cycle. These effects were accompanied by increased food intake, total spontaneous activity, and energy expenditure during the dark cycle and an apparent reduction in respiratory quotient during the light cycle. To assess whether enhanced responsiveness to anorexigenic factors may contribute to the lean phenotype, we examined the effects of melanotan II (MTII) on food intake and body weight. We found an enhanced effect of MTII in Cck1r(-/-) rats to suppress food intake and body weight following both central and peripheral administration. These results suggest that the lean phenotype is potentially driven by increases in total spontaneous activity and energy expenditure. C1 [Moralejo, Daniel H.] Univ Texas MD Anderson Canc Ctr, Dept Vet Sci, Bastrop, TX USA. [Blevins, James E.; Wolden-Hanson, Tami H.; Thatcher, Brendan S.; Ho, Jacqueline M.] VA Puget Sound Hlth Care Syst, Off Res & Dev, Med Res Serv, Dept Vet Affairs Med Ctr, Seattle, WA USA. [Blevins, James E.; Ho, Jacqueline M.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Kaiyala, Karl J.] Univ Washington, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA. [Matsumoto, Kozo] Kyoto Sangyo Univ, Fac Life Sci, Dept Anim Med Sci, Kyoto 603, Japan. RP Moralejo, DH (reprint author), UT MD Anderson Canc Ctr, Dept Vet Sci, Michale E Keeling Ctr Comparat Med & Res, 650 Cool Water Dr, Bastrop, TX 78602 USA. EM moralejo@uw.edu FU Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA); VA Puget Sound Health Care System Rodent Metabolic and Behavioral Phenotyping Core; biomedical research core program of the National Institutes of Health (NIH) Diabetes Research Center at the University of Washington; American Diabetes Association [1-05-JF-32]; Department of VA Merit Review Research Program, NIH [DK-17047, RO1DK-61516, P30DK017047-31, P30KD017047-31689] FX This material is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA), the VA Puget Sound Health Care System Rodent Metabolic and Behavioral Phenotyping Core, the biomedical research core program of the National Institutes of Health (NIH) Diabetes Research Center at the University of Washington, and the American Diabetes Association. The research in our laboratory has been supported by the Department of VA Merit Review Research Program, NIH Grants DK-17047, RO1DK-61516, P30DK017047-31, and P30KD017047-31689, and by the Junior Faculty Award 1-05-JF-32 by the American Diabetes Association. NR 56 TC 4 Z9 4 U1 1 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD DEC PY 2012 VL 303 IS 12 BP R1231 EP R1240 DI 10.1152/ajpregu.00393.2012 PG 10 WC Physiology SC Physiology GA 057SQ UT WOS:000312584700003 PM 23115121 ER PT J AU Kim, KS Kim, MJ Kononen, E Lounatmaa, K Summanen, P Finegold, SM AF Kim, Keun-Sung Kim, Min-Ju Kononen, Eija Lounatmaa, Kari Summanen, Paula Finegold, Sydney M. TI Single nucleotide polymorphisms are randomly dispersed and mostly synonymous in partial rpoB and cpn60 genes of Campylobacter showae human isolates SO ANAEROBE LA English DT Article DE Campylobacter showae; 16S rRNA gene; rpoB gene; cpn60 gene; SNPs AB The partial 16S rRNA, rpoB, and cpn60 genes congruently allow this study to identify all the eight isolates as the species Campylobacter showae. To our knowledge, this is the first report to reveal the interspecies and intraspecies sequence variations present in the three genes of the C. showae isolates. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Kim, Keun-Sung; Kim, Min-Ju] Chung Ang Univ, Dept Food Sci & Technol, Ansung 456756, Kyungki Do, South Korea. [Kononen, Eija] Natl Inst Hlth & Welf, Bacteriol Unit, Helsinki, Finland. [Kononen, Eija] Univ Turku, Inst Dent, Turku, Finland. [Lounatmaa, Kari] Oy Lounatmaa Ltd, Helsinki, Finland. [Summanen, Paula] W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. [Finegold, Sydney M.] W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect, Los Angeles, CA 90073 USA. [Finegold, Sydney M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Finegold, Sydney M.] Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. RP Kim, KS (reprint author), Chung Ang Univ, Dept Food Sci & Technol, Ansung 456756, Kyungki Do, South Korea. EM keunsung@cau.ac.kr FU DOD [W81XWH-0510134]; VA Merit Review funds FX This work has been supported, in part, by DOD Grant # W81XWH-0510134 and by VA Merit Review funds. NR 5 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD DEC PY 2012 VL 18 IS 6 BP 626 EP 629 DI 10.1016/j.anaerobe.2012.09.006 PG 4 WC Microbiology SC Microbiology GA 056FK UT WOS:000312473600012 PM 23022203 ER PT J AU Thoma, B Pizzi, L McDaniel, C Li, J Mearns, E Wordell, C Cavarocchi, N AF Thoma, Brandi Pizzi, Laura McDaniel, Cara Li, Julius Mearns, Elizabeth Wordell, Cindy Cavarocchi, Nicholas TI DEXMEDETOMIDINE VERSUS PROPOFOL AND MIDAZOLAM IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY SO CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT 42nd Critical Care Congress of the Society-of-Critical-Care-Medicine CY JAN 19-23, 2013 CL San Juan, PR SP Soc Crit Care Medi C1 [Thoma, Brandi; McDaniel, Cara; Wordell, Cindy] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Pizzi, Laura; Mearns, Elizabeth] Thomas Jefferson Univ, Sch Pharm, Philadelphia, PA USA. [Li, Julius] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD DEC PY 2012 VL 40 IS 12 SU S MA 1120 BP U302 EP U302 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA 050HZ UT WOS:000312045701386 ER PT J AU Tanner, JM Friedlander, AH Chang, TI AF Tanner, J. M. Friedlander, A. H. Chang, T. I. TI Bilateral bifid mandibular condyles diagnosed with three-dimensional reconstruction SO DENTOMAXILLOFACIAL RADIOLOGY LA English DT Article DE bifid mandibular condyle ID BEAM COMPUTED-TOMOGRAPHY; TEMPOROMANDIBULAR-JOINT; POPULATION AB Bifid mandibular condyles (BMCs) are rare anomalies. The overwhelming majority of prior reports described their predominantly unilateral occurrence diagnosed by panoramic radiography. We present an even rarer case of bilateral BMC initially identified by panoramic radiography and confirmed with colour-enhanced three-dimensional CT. These images substantiate the theory that the secondary condyles arise from the neck of the mandible (Lopez-Lopez et al. Bifid condyle: review of the literature of the last 10 years and report of two cases. Cianio 2010; 28: 136-140). Dentomaxillofacial Radiology (2012) 41, 691-695. doi: 10.1259/dmfr/15030240 C1 [Tanner, J. M.; Chang, T. I.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Los Angeles, CA 90073 USA. RP Chang, TI (reprint author), VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, 11301 Wilshire Blvd W160, Los Angeles, CA 90073 USA. EM Tina.Chang2@va.gov NR 16 TC 0 Z9 0 U1 0 U2 1 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0250-832X J9 DENTOMAXILLOFAC RAD JI Dentomaxillofac. Radiol. PD DEC PY 2012 VL 41 IS 8 BP 691 EP 695 DI 10.1259/dmfr/15030240 PG 5 WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging GA 056TM UT WOS:000312514300012 PM 22241877 ER PT J AU Kamnaksh, A Kwon, SK Kovesdi, E Ahmed, F Barry, ES Grunberg, NE Long, J Agoston, D AF Kamnaksh, Alaa Kwon, Sook-Kyung Kovesdi, Erzsebet Ahmed, Farid Barry, Erin S. Grunberg, Neil E. Long, Joseph Agoston, Denes TI Neurobehavioral, cellular, and molecular consequences of single and multiple mild blast exposure SO ELECTROPHORESIS LA English DT Article DE Blast; Cumulative effect; Neurobehavior; Protein biomarkers; Traumatic brain injury ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPAL SLICE CULTURES; ENDOTHELIAL GROWTH-FACTOR; ISCHEMIA/REPERFUSION INJURY; ADULT HIPPOCAMPUS; COMBAT VETERANS; IRAQI FREEDOM; NEUROGENESIS; PTSD AB Mild traumatic brain injury, caused by the exposure to single or repeated blast overpressure, is a principal concern due to its pathological complexity and neurobehavioral similarities with posttraumatic stress disorder. In this study, we exposed rats to a single or multiple (five total; administered on consecutive days) mild blasts, assessed their behavior at 1 and 16 days postinjury) and performed histological and protein analyses of brains and plasma at an early (2 h) and a late (22 days) termination time point. One day postinjury, multiple-injured (MI) rats showed the least general locomotion and the most depression- and anxiety-related behaviors among the experimental groups; there were no such differences at 16 days. However, at the later time point, both injured groups displayed elevated levels of select protein biomarkers. Histology showed significantly increased numbers of TUNEL+ (terminal-deoxy-transferase-mediated dUTP nick-end labeling)-positive cells in the dorsal and ventral hippocampus (DHC and VHC) of both injured groups as early as 2 h after injury. At 22 days, the increase was limited to the VHC of MI animals. Our findings suggest that the exposure to mild blast overpressure triggers early hippocampal cell death as well as neuronal, glial, and vascular damage that likely contribute to significant, albeit transient increases in depression- and anxiety-related behaviors. However, the severity of the observed pathological changes in MI rats failed to support the hypothesized cumulative effect of repeated injury. We infer that at this blast frequency, a potential conditioning phenomenon counteracts with and reduces the extent of subsequent damage in MI rats. C1 [Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Sch Med, Bethesda, MD 20814 USA. [Kamnaksh, Alaa; Kwon, Sook-Kyung; Ahmed, Farid; Barry, Erin S.; Grunberg, Neil E.; Agoston, Denes] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA. [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA. [Barry, Erin S.; Grunberg, Neil E.] Walter Reed Army Inst Res, Dept Med & Clin Psychol, Silver Spring, MD USA. [Long, Joseph] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA. RP Agoston, D (reprint author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM vagoston@usuhs.edu FU Center for Neuroscience and Regenerative Medicine [G1703F] FX We thank the Neurotrauma Team at the Walter Reed Army Institute of Research for their technical help during the exposures. This work was supported by the Center for Neuroscience and Regenerative Medicine grant number G1703F. The views, opinions, and/or findings contained herein are those of the authors and should not be construed as an official position, policy, or decision of the Department of the Army or the Department of Defense. Animal handling and treatments were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide to the Care and Use of Laboratory Animals, National Research Council. The facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. NR 68 TC 20 Z9 21 U1 1 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0173-0835 J9 ELECTROPHORESIS JI Electrophoresis PD DEC PY 2012 VL 33 IS 24 SI SI BP 3680 EP 3692 DI 10.1002/elps.201200319 PG 13 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 057FT UT WOS:000312548900011 PM 23161523 ER PT J AU Aleksic, M Liddy, N Molloy, PE Pumphrey, N Vuidepot, A Chang, KM Jakobsen, BK AF Aleksic, Milos Liddy, Nathaniel Molloy, Peter E. Pumphrey, Nick Vuidepot, Annelise Chang, Kyong-Mi Jakobsen, Bent K. TI Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE Immunotherapy; T-cell; Thymic selection; Tumor immunology ID MEDULLARY EPITHELIAL-CELLS; GENE-EXPRESSION; HUMAN THYMUS; ANTIGEN; PEPTIDES; SINGLE; CRYSTALLIZATION; RECOGNITION; LYMPHOCYTES; VACCINATION AB T-cell destiny during thymic selection depends on the affinity of the TCR for autologous peptide ligands presented in the context of MHC molecules. This is a delicately balanced process; robust binding leads to negative selection, yet some affinity for the antigen complex is required for positive selection. All TCRs of the resulting repertoire thus have some intrinsic affinity for an MHC type presenting an assortment of peptides. Generally, TCR affinities of peripheral T cells will be low toward self-derived peptides, as these would have been presented during thymic selection, whereas, by serendipity, binding to pathogen-derived peptides that are encountered de novo could be stronger. A crucial question in assessing immunotherapeutic strategies for cancer is whether natural TCR repertoires have the capacity for efficiently recognizing tumor-associated peptide antigens. Here, we report a comprehensive comparison of TCR affinities to a range of HLA-A2 presented antigens. TCRs that bind viral antigens fall within a strikingly higher affinity range than those that bind cancer-related antigens. This difference may be one of the key explanations for tumor immune escape and for the deficiencies of T-cell vaccines against cancer. C1 [Aleksic, Milos; Liddy, Nathaniel; Molloy, Peter E.; Pumphrey, Nick; Vuidepot, Annelise; Jakobsen, Bent K.] Immunocore Ltd, Abingdon OX14 4RX, Oxon, England. [Chang, Kyong-Mi] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chang, Kyong-Mi] Univ Penn, Philadelphia, PA 19104 USA. RP Jakobsen, BK (reprint author), Immunocore Ltd, 57C Milton Pk, Abingdon OX14 4RX, Oxon, England. EM bent.jakobsen@immunocore.com FU Immunocore Ltd., Abingdon, United Kingdom; NIH [AI047519]; Abramson Cancer Center FACS facility; Philadelphia VA Medical Research FX We would like to thank Peter Bader, Debbie Baker, Giovanna Bossi, Scott Burrows, Enzo Cerundolo, Sophie Conchon, Linda Hibbert, Erik Hooijberg John Miles, Yasuharu Nishimura, Samantha Paston, Jim Riley, Andrew Sewell, Robert Thimme, and Cassian Yee for providing T-cell clones; Hyosun Cho for work on the HCV-specific T cell lines; Conor Hayes, Qin Su, and Arsen Volkov for isolating TCR chains by RACE-PCR; Brian Cameron, Emma Gostick, Nikolai Lissin, Tara Mahon, and Alex Powlesland for protein production and SPR measurements; and Joanne Oates and Karen Pulford for assistance in manuscript preparation. This work was funded by Immunocore Ltd., Abingdon, United Kingdom. K.C. is also supported in part by: NIH AI047519, Abramson Cancer Center FACS facility and Philadelphia VA Medical Research. The contents of the publications/presentations do not represent the views of the VA or the US government. NR 36 TC 56 Z9 56 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD DEC PY 2012 VL 42 IS 12 BP 3174 EP 3179 DI 10.1002/eji.201242606 PG 6 WC Immunology SC Immunology GA 057FJ UT WOS:000312547800014 PM 22949370 ER PT J AU Kind, AJH Jensen, L Barczi, S Bridges, A Kordahl, R Smith, MA Asthana, S AF Kind, Amy J. H. Jensen, Laury Barczi, Steve Bridges, Alan Kordahl, Rebecca Smith, Maureen A. Asthana, Sanjay TI Low-Cost Transitional Care With Nurse Managers Making Mostly Phone Contact With Patients Cut Rehospitalization At A VA Hospital SO HEALTH AFFAIRS LA English DT Article ID CONTROLLED-TRIAL; HEART-FAILURE; VETERANS; DEMENTIA; INTERVENTION; VALIDATION; MEDICARE; PROGRAM; QUALITY AB The Coordinated-Transitional Care (C-TraC) Program was designed to improve care coordination and outcomes among veterans with high-risk conditions discharged to community settings from the William S. Middleton Memorial Veterans Hospital, in Madison, Wisconsin. Under the program, patients work with nurse case managers on care and health issues, including medication reconciliation, before and after hospital discharge, with all contacts made by phone once the patient is at home. Patients who received the C-TraC protocol experienced one-third fewer rehospitalizations than those in a baseline comparison group, producing an estimated savings of $1,225 per patient net of programmatic costs. This model requires a relatively small amount of resources to operate and may represent a viable alternative for hospitals seeking to offer improved transitional care as encouraged by the Affordable Care Act. In particular, the model may be attractive for providers in rural areas or other care settings challenged by wide geographic dispersion of patients or by constrained resources. C1 [Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, Coordinated Transit Care Program C TraC, GRECC, Madison, WI USA. [Kind, Amy J. H.; Barczi, Steve; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Div Geriatr & Gerontol, Madison, WI 53706 USA. [Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Kordahl, Rebecca] William S Middleton Mem Vet Adm Med Ctr, Patient Care Serv, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Hlth Innovat Program, Madison, WI 53706 USA. RP Kind, AJH (reprint author), William S Middleton Mem Vet Adm Med Ctr, Coordinated Transit Care Program C TraC, GRECC, Madison, WI USA. EM ajk@medicine.wisc.edu FU VA Transformation-21 Grant, "Patient-Centric Alternatives to Institutional Extended Care"; Madison VA Geriatrics Research, Education, and Clinical Center (GRECC) [2012-08]; National Institute on Aging [K23AG034551]; National Institute on Aging, in partnership with the American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; University of Wisconsin School of Medicine and Public Health's Health Innovation Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research; Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health [1UL1RR025011]; VA Office of Geriatrics and Extended Care in the VA Central Office; Veterans Integrated Service Network 12; William S. Middleton Memorial Veterans Hospital FX Some of the information in this article was presented as a poster at the annual meeting of the American Geriatrics Society, Seattle, Washington, May 3, 2012. The design, implementation, and assessment of the C-TraC Program and the writing of this article were supported by a VA Transformation-21 Grant, "Patient-Centric Alternatives to Institutional Extended Care," and the Madison VA Geriatrics Research, Education, and Clinical Center (GRECC-Manuscript No. 2012-08); and were funded through the National Institute on Aging Paul B. Beeson Patient-Oriented Research Career Development Award (K23AG034551 [PI Kind], National Institute on Aging, in partnership with the American Federation for Aging Research, the John A. Hartford Foundation, the Atlantic Philanthropies, and the Starr Foundation). Additional support was provided by the University of Wisconsin School of Medicine and Public Health's Health Innovation Program; the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research; and the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (Grant No. 1UL1RR025011). No funding source had a role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. The authors acknowledge Ken Shay, Barbara Hyduke, and Karen Massey in the VA Office of Geriatrics and Extended Care in the VA Central Office and the leadership of both the Veterans Integrated Service Network 12 and the William S. Middleton Memorial Veterans Hospital for their support of the C-TraC Program; Peggy Munson for Institutional Review Board assistance; Sheila Kelly and Megan Carey for data abstraction; and Colleen Brown, Andrea Gilmore, Melissa Hovanes, Brock Polnaszek, and Joanna Wong for manuscript formatting and graphics. NR 27 TC 25 Z9 26 U1 1 U2 18 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD DEC PY 2012 VL 31 IS 12 BP 2659 EP 2668 DI 10.1377/hlthaff.2012.0366 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 057ZA UT WOS:000312602100009 PM 23213150 ER PT J AU Park, JD Metlay, J Asch, JM Asch, DA AF Park, James D. Metlay, Jessica Asch, Jeremy M. Asch, David A. TI The New York Times Readers' Opinions About Paying People to Take Their Medicine SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE chronic disease management; health policy; health promotion; media; qualitative methods ID FINANCIAL INCENTIVES; HEALTH; ACCEPTABILITY; SMOKING AB Background. There has been considerable interest in using financial incentives to help people improve their health. However, paying people to improve their health touches on strongly held views about personal responsibility. Method. The New York Times printed two articles in June 2010 about patient financial incentives, which resulted in 394 comments from their online audience. The authors systematically analyzed those online responses to news media in order to understand the range of themes that were expressed regarding the use of financial incentives to improve health. Results. The New York Times online readers revealed a broad range of attitudes about paying individuals to be healthy. Many comments reflected disdain for financial incentives, describing them as "absurd" or "silly." Other comments reflected the notion that financial incentives reward individuals for being irresponsible toward their health. Many individuals communicated concerns that paying individuals for healthy behaviors may weaken their internal drive to be healthy. A smaller set of comments conveyed support for financial incentives, recognizing it as a small sum to pay to prevent or offset higher costs related to chronic diseases. Conclusions. Although a measurable group of individuals supported financial incentives, most readers revealed negative perceptions of these approaches and an appeal for greater personal responsibility for individual health. Despite experimental success of financial incentives, negative perceptions may limit their public acceptability and uptake. C1 [Park, James D.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Metlay, Jessica] Vassar Coll, Poughkeepsie, NY 12601 USA. [Asch, Jeremy M.] Brandeis Univ, Waltham, MA USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Park, JD (reprint author), Univ Penn, Div Gen Internal Med, 1005 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jdpark@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X FU PHS HHS [T32-HP-10026] NR 26 TC 3 Z9 3 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD DEC PY 2012 VL 39 IS 6 BP 725 EP 731 DI 10.1177/1090198111428645 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 057JM UT WOS:000312559300010 PM 22467634 ER PT J AU Huynh, TN Weigt, SS Sugar, CA Shapiro, S Kleerup, EC AF Huynh, Thanh N. Weigt, S. Sam Sugar, Catherine A. Shapiro, Shelley Kleerup, Eric C. TI Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit SO JOURNAL OF CRITICAL CARE LA English DT Article DE Pulmonary hypertension; Intensive care unit; Pulmonary artery catheterization ID CRITICALLY-ILL PATIENTS; RIGHT HEART-FAILURE; ARTERIAL-HYPERTENSION; PROSTACYCLIN; MANAGEMENT; DISEASE; CATHETER; INFUSION; THERAPY AB Purpose: Patients with pulmonary hypertension (PH) can decompensate to the point where they require care in the intensive care unit (ICU). Our objective is to examine the outcomes and characteristics of patients with PH admitted to the ICU. Methods: This is a retrospective study of 99 patients with PH who were admitted to the medical ICU of a single tertiary care center. Baseline characteristics, interventions during ICU admission, and ICU and 6-month outcome were documented. Univariate and multivariate logistic regressions were used to evaluate association of patient characteristics with mortality. Results: Intensive care unit mortality was 30%, and 6-month mortality was 40%. Acute Physiology and Chronic Health Evaluation II score, World Health Organization Group 3 PH, and preexisting treatment with a prostacyclin at time of ICU admission were associated with worse outcome. Patients who received cardiopulmonary resuscitation had 100% mortality. The requirement for mechanical ventilation and dialysis was also associated with increased mortality. Pulmonary artery catheter placement was associated with reduced mortality, specifically if it was placed early during ICU admission and if associated with a change in the present management. Conclusions: Mortality is high in critically ill patients with PH. The identification of prognostic baseline characteristics and interventions in the ICU is important and warrants further investigation. (C) 2012 Elsevier Inc. All rights reserved. C1 [Huynh, Thanh N.; Weigt, S. Sam; Kleerup, Eric C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Shapiro, Shelley] Univ Calif Los Angeles, Dept Cardiol, VA Greater Healthcare Syst, Los Angeles, CA 90095 USA. RP Huynh, TN (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, BOX 951690,37-131 CHS, Los Angeles, CA 90095 USA. EM thuynh@mednet.ucla.edu FU NCRR NIH HHS [L30 RR033215] NR 23 TC 7 Z9 7 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 J9 J CRIT CARE JI J. Crit. Care PD DEC PY 2012 VL 27 IS 6 AR 739.e7 DI 10.1016/j.jcrc.2012.08.006 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 057YF UT WOS:000312599800034 PM 23089677 ER PT J AU Velmurugan, K Bouchard, R Mahaffey, G Pugazhenthi, S AF Velmurugan, Kalpana Bouchard, Ron Mahaffey, Gregory Pugazhenthi, Subbiah TI Neuroprotective actions of Glucagon-like peptide-1 in differentiated human neuroprogenitor cells SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's disease; apoptosis; CREB; glucagon-like peptide-1; human neuroprogenitor cells; signal transduction ID ELEMENT-BINDING PROTEIN; NEURAL STEM-CELLS; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; PROMOTES NEUROGENESIS; DIABETES-MELLITUS; DOWN-REGULATION; BCL-2 PROMOTER; CREB AB Glucagon-like peptide-1 (GLP-1)-based therapies are currently available for the treatment of type 2 diabetes, based on their actions on pancreatic beta cells. GLP-1 is also known to exert neuroprotective actions. To determine its mechanism of action, we developed a neuron-rich cell culture system by differentiating human neuroprogenitor cells in the presence of a combination of neurotrophins and retinoic acid. The neuronal nature of these cells was characterized by neurogenesis pathway-specific array. GLP-1 receptor expression was seen mainly in the neuronal population. Culture of neurons in the presence of A beta oligomers resulted in the induction of apoptosis as shown by the activation of caspase-3 and caspase-6. Exendin-4, a long-acting analog of GLP-1, protected the neurons from apoptosis induced by A beta oligomers. Exendin-4 stimulated cyclic AMP response element binding protein phosphorylation, a regulatory step in its activation. A transient transfection assay showed induction of a reporter linked to CRE site-containing human brain-derived neurotrophic factor promoter IV, by the growth factor through multiple signaling pathways. The anti-apoptotic action of exendin-4 was lost following down-regulation of cAMP response element binding protein. Withdrawal of neurotrophins resulted in the loss of neuronal phenotype of differentiated neuroprogenitor cells, which was prevented by incubation in the presence of exendin-4. Diabetes is a risk factor in the pathogenesis of Alzheimer's disease. Our findings suggest that GLP-1-based therapies can decrease the incidence of Alzheimer's disease among aging diabetic population. C1 [Velmurugan, Kalpana; Bouchard, Ron; Pugazhenthi, Subbiah] Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO USA. [Velmurugan, Kalpana; Bouchard, Ron; Mahaffey, Gregory; Pugazhenthi, Subbiah] Univ Colorado Denver, Dept Med, Aurora, CO 80045 USA. RP Pugazhenthi, S (reprint author), Univ Colorado Denver, Denver VA Med Ctr, Mail Stop 8106,12801 E 17th Ave, Aurora, CO 80045 USA. EM subbiah.pugazhenthi@ucdenver.edu FU Veterans Administration [NEUD-004-07F] FX This work was carried out with the use of resources and facilities at Denver VA Medical Center. This study was supported by Merit Review grant NEUD-004-07F from the Veterans Administration (to S. P.). RT-PCR analysis was performed at the University of Colorado Cancer Center Core Facility. Digital deconvolution microscopy was carried out at the VA Microscopy Core Facility. Authors declare that there is no conflict of interest associated with this manuscript. NR 48 TC 18 Z9 18 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD DEC PY 2012 VL 123 IS 6 BP 919 EP 931 DI 10.1111/jnc.12036 PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 051WK UT WOS:000312158500004 PM 23020846 ER PT J AU O'Hare, AM Walker, R Haneuse, S Crane, PK McCormick, WC Bowen, JD Larson, EB AF O'Hare, Ann M. Walker, Rod Haneuse, Sebastian Crane, Paul K. McCormick, Wayne C. Bowen, James D. Larson, Eric B. TI Relationship Between Longitudinal Measures of Renal Function and Onset of Dementia in a Community Cohort of Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; renal function; eGFR; variability; trajectory ID CHRONIC KIDNEY-DISEASE; COGNITIVE FUNCTION; IMPAIRMENT; ALBUMINURIA; HEALTH; DECLINE; RISK; MICROALBUMINURIA; ASSOCIATION; POPULATION AB Objectives To evaluate the association between dynamic measures of renal function ascertained over time and onset of dementia. Design Prospective community cohort study. Setting Group Health, Seattle, Washington. Participants Two thousand nine hundred sixty-eight adults aged 65 and older followed for the development of dementia over a median of 6.0 years (interquartile range 3.110.1 years). Measurements Time-varying measures of renal function were constructed based on 49,340 serum creatinine measurements and included average estimated glomerular filtration rate (eGFR), eGFR trajectory, and variability in eGFR around this trajectory over 5-year exposure windows. The association between these three eGFR exposure measures and risk of dementia was estimated using a Cox regression model adjusted for other participant characteristics. Time-varying measures of urine protein by dipstick were also adjusted for in sensitivity analyses. Results Participants with a lower eGFR had a higher incidence of dementia, but this did not reach statistical significance in adjusted analyses (omnibus P = .14). There were trends toward a higher adjusted incidence of dementia in participants with positive eGFR trajectories (omnibus P = .07) and greater variability in eGFR (omnibus P = .04) over time. The results of sensitivity analyses, including those in which time-varying measures of proteinuria were included, were consistent with those of the primary analysis. Conclusion In a community cohort of older adults followed for a median of 6 years, strong associations were not found between measures of kidney disease severity and progression and incident dementia. J Am Geriatr Soc 60:2215-2222, 2012. C1 [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA 98119 USA. [O'Hare, Ann M.; Crane, Paul K.; McCormick, Wayne C.; Larson, Eric B.] Univ Washington, Dept Med, Seattle, WA USA. [Haneuse, Sebastian] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Bowen, James D.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA. RP O'Hare, AM (reprint author), VA Puget Sound Healthcare Syst, Dept Med, 1160 S Columbian Way, Seattle, WA 98119 USA. EM Ann.OHare@va.gov RI Crane, Paul/C-8623-2014 OI Crane, Paul/0000-0003-4278-7465 FU National Institutes of Health [U01 AG006781, 1K23AG28980] FX This work was supported by National Institutes of Health Grants U01 AG006781 (PI: Larson) and 1K23AG28980 (PI: O'Hare). NR 32 TC 7 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2012 VL 60 IS 12 BP 2215 EP 2222 DI 10.1111/j.1532-5415.2012.04238.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 056AY UT WOS:000312460500003 PM 23231548 ER PT J AU Pierluissi, E Mehta, KM Kirby, KA Boscardin, WJ Fortinsky, RH Palmer, RM Landefeld, CS AF Pierluissi, Edgar Mehta, Kala M. Kirby, Katharine A. Boscardin, W. John Fortinsky, Richard H. Palmer, Robert M. Landefeld, C. Seth TI Depressive Symptoms After Hospitalization in Older Adults: Function and Mortality Outcomes SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE depression symptoms; hospitalized older adults; elderly; function; mortality ID CONGESTIVE-HEART-FAILURE; RANDOMIZED-CONTROLLED-TRIAL; ELDERLY MEDICAL INPATIENTS; ACUTE CORONARY SYNDROME; MYOCARDIAL-INFARCTION; MAJOR DEPRESSION; HEALTH; CARE; DISEASE; ILLNESS AB Objectives To determine the relationship between depressive symptoms after hospitalization and survival and functional outcomes. Design Secondary analysis of a prospective cohort study. Setting General medical service of two urban, teaching hospitals in Ohio. Participants Hospitalized individuals aged 70 and older. Measurements Ten depressive symptoms, instrumental activities of daily living (IADLs), and basic activities of daily living (ADLs) were measured at hospital discharge and 1, 3, 6, and 12 months later. Participant-specific changes in depressive symptoms (slopes) were determined using all data points. Four groups were also defined according to number of depressive symptoms (=3 symptoms, low; 410 symptoms, high) at discharge and follow-up: lowlow, lowhigh, highlow, and highhigh. Mortality was measured 3, 6, and 12 months after hospital discharge. Results Participant-specific discharge depressive symptoms and change in depressive symptoms over time (slopes) were associated (P < .05) with functional and mortality outcomes. At 1 year, more participants in the lowlow depressive symptom group (49%) were alive and independent in IADLs and ADLs than in the lowhigh group (37%, P = .02), and more participants in the highlow group (39%) were alive and independent in IADLs and ADLs than in the highhigh group (19%, P < .001). Conclusion Number of depressive symptoms and change in number of depressive symptoms during the year after discharge were associated with functional and mortality outcomes in hospitalized older adults. Fewer participants with persistently high or increasing depressive symptoms after hospitalization were alive and functionally independent 1 year later than participants with decreasing or persistently low symptoms, respectively. J Am Geriatr Soc 60:2254-2262, 2012. C1 [Pierluissi, Edgar; Mehta, Kala M.; Kirby, Katharine A.; Boscardin, W. John] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94110 USA. [Mehta, Kala M.; Boscardin, W. John] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA. [Fortinsky, Richard H.] Univ Connecticut, Ctr Aging, Farmington, CT USA. [Palmer, Robert M.] Univ Pittsburgh, Div Geriatr Med & Gerontol, Pittsburgh, PA USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. RP Pierluissi, E (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave,Room 5H17, San Francisco, CA 94110 USA. EM epierluissi@medsfgh.ucsf.edu FU National Institute on Aging (NIA) [RO1 AG029233]; S.D. Bechtel, Jr. Foundation; NIA [RO1 AG029233, K-01AG025444, AG-10418-03]; NIA, National Institute of Nursing Research, and the National Center for Minority Health and Health Disparities [P30 AG 15272 350]; John A. Hartford Foundation [88277-3G, 2006-0108]; Summa Health System Foundation FX This work was supported by National Institute on Aging (NIA) Grant RO1 AG029233 and a grant from the S.D. Bechtel, Jr. Foundation (Principal Investigator, Dr. Landefeld). Dr. Mehta was supported by a Research Career Scientist Award from the NIA (K-01AG025444). She was an affiliate of the Center for Aging in Diverse Communities at the University of California at San Francisco, a part of the P30 AG 15272 350 Resource Centers for Minority Aging Research Program (NIA, National Institute of Nursing Research, and the National Center for Minority Health and Health Disparities). Dr. Pierluissi was supported by an administrative supplement to NIA Grant RO1 AG029233. The Acute Care for Elders studies were supported by grants from the John A. Hartford Foundation (88277-3G and 2006-0108), the NIA (AG-10418-03), and the Summa Health System Foundation. NR 46 TC 10 Z9 10 U1 6 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2012 VL 60 IS 12 BP 2254 EP 2262 DI 10.1111/jgs.12008 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 056AY UT WOS:000312460500008 PM 23176725 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI Poor Dental Health and Dementia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; MANAGEMENT; LIFE; NUN C1 [Friedlander, Arthur H.] VA Greater Los Angeles, Grad Medicat Educ, Los Angeles, CA 90095 USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles, Grad Medicat Educ, Los Angeles, CA 90095 USA. NR 7 TC 0 Z9 0 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2012 VL 60 IS 12 BP 2382 EP 2383 DI 10.1111/jgs.12017 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 056AY UT WOS:000312460500039 PM 23231568 ER PT J AU Anaya, HD Chan, K Karmarkar, U Asch, SM Goetz, MB AF Anaya, Henry D. Chan, Kee Karmarkar, Uday Asch, Steven M. Goetz, Matthew Bidwell TI Budget Impact Analysis of HIV Testing in the VA Healthcare System SO VALUE IN HEALTH LA English DT Article; Proceedings Paper CT International-Association-of-Physicians in AIDS Care (IAPAC) CY 2009 CL New Orleans, LA SP Int Assoc Phys AIDS Care (IAPAC) DE budget impact analysis; cost-effectiveness; facility costs; HIV testing ID REVISED RECOMMENDATIONS; COST-EFFECTIVENESS; UNITED-STATES; SETTINGS; VETERANS; ERA AB Objectives: The long-term cost effectiveness of routine HIV testing is favorable relative to other medical interventions. Facility-specific costs of expanded HIV testing and care for newly identified patients, however, are less well defined. To aid in resource allocation decisions, we developed a spreadsheet-based budget-impact tool populated with estimates of facility-specific HIV testing and care costs incurred with an expanded testing program. Methods: We modeled intervention effects on quarterly costs of antiretroviral therapy (ART), outpatient resource utilization, and staff expenditures in the Department of Veterans Affairs over a 2-year period of increasing HIV testing rates. We used HIV prevalence estimates, screening rates, counseling, positive tests, Veterans Affairs treatment, and published sources as inputs. We evaluated a single-facility cohort of 20,000 patients and at baseline assumed a serodiagnostic rate of 0.45%. Results: Expanding testing from 2% to 15% annually identified 21 additional HIV-positive patients over 2 years at a cost of approximately $290,000, more than 60% of which was due to providing ART to newly diagnosed patients. While quarterly testing costs decreased longitudinally as fewer persons required testing, quarterly ART costs increased from $10,000 to more than $60,000 over 2 years as more infected patients were identified and started on ART. In sensitivity analyses, serodiagnostic and annual HIV testing rates had the greatest cost impact. Conclusions: Expanded HIV testing costs are greatest during initial implementation and predominantly due to ART for new patients. Cost determinations of expanded HIV testing provide an important tool for managers charged with allocating resources within integrated systems providing both HIV testing and care. C1 [Anaya, Henry D.; Asch, Steven M.; Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, VA Greater Los Angeles Hlth Serv, Res & Dev Ctr Excellence, Los Angeles, CA 90073 USA. [Anaya, Henry D.; Asch, Steven M.; Goetz, Matthew Bidwell] Vet Affairs Qual Enhancement Res Initiat HIV Hepa, Los Angeles, CA 90073 USA. [Anaya, Henry D.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res GIM & HSR, Los Angeles, CA 90095 USA. [Chan, Kee] Boston Univ, Dept Hlth Sci, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA. [Chan, Kee] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Karmarkar, Uday] UCLA Anderson Sch Business, Los Angeles, CA USA. [Asch, Steven M.] RAND Hlth, Santa Monica, CA USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Sect Infect Dis, Los Angeles, CA 90073 USA. RP Anaya, HD (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, VA Greater Los Angeles Hlth Serv, Res & Dev Ctr Excellence, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM hemy.anaya@va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 17 TC 5 Z9 5 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD DEC PY 2012 VL 15 IS 8 BP 1022 EP 1028 DI 10.1016/j.jval.2012.08.2205 PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 055RT UT WOS:000312435300005 PM 23244803 ER PT J AU Lawson, EH Louie, R Zingmond, DS Brook, RH Hall, BL Han, L Rapp, M Ko, CY AF Lawson, Elise H. Louie, Rachel Zingmond, David S. Brook, Robert H. Hall, Bruce L. Han, Lein Rapp, Michael Ko, Clifford Y. TI A Comparison of Clinical Registry Versus Administrative Claims Data for Reporting of 30-Day Surgical Complications SO ANNALS OF SURGERY LA English DT Article DE Administrative claims; clinical registry; complications; postoperative; quality measurement; surgery ID QUALITY IMPROVEMENT PROGRAM; POSTOPERATIVE ADVERSE EVENTS; NSQIP AB Objectives: To compare the recording of 30-day postoperative complications between a national clinical registry and Medicare inpatient claims data and to determine whether the addition of outpatient claims data improves concordance with the clinical registry. Background: Policymakers are increasingly discussing use of postoperative complication rates for value-based purchasing. There is debate regarding the optimal data source for such measures. Methods: Patient records (2005-2008) from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) were linked to Medicare inpatient and outpatient claims data sets. We assessed the ability of (1) Medicare inpatient claims and (2) Medicare inpatient and outpatient claims to detect a core set of ACS-NSQIP 30-day postoperative complications: superficial surgical site infection (SSI), deep/organ-space SSI, any SSI (superficial and/or deep/organ-space), urinary tract infection, pneumonia, sepsis, deep venous thrombosis (DVT), pulmonary embolism, venous thromboembolism (DVT and/or pulmonary embolism), and myocardial infarction. Agreement of patient-level complications by ACS-NSQIP versus Medicare was assessed by. statistics. Results: A total of 117,752 patients from more than 200 hospitals were studied. The sensitivity of inpatient claims data for detecting ACS-NSQIP complications ranged from 0.27 to 0.78; the percentage of false-positives ranged from 48% to 84%. Addition of outpatient claims data improved sensitivity slightly but also greatly increased the percentage of false-positives. Agreement was routinely poor between clinical and claims data for patient-level complications. Conclusions: This analysis demonstrates important differences between ACS-NSQIP and Medicare claims data sets for measuring surgical complications. Poor accuracy potentially makes claims data suboptimal for evaluating surgical complications. These findings have meaningful implications for performance measures currently being considered. C1 [Lawson, Elise H.; Louie, Rachel; Zingmond, David S.; Brook, Robert H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hall, Bruce L.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Hall, Bruce L.] Washington Univ, Sch Med, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Barnes Jewish Hosp, St Louis Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Han, Lein; Rapp, Michael] Ctr Medicare Serv, Baltimore, MD USA. [Han, Lein; Rapp, Michael] Ctr Medicaid Serv, Baltimore, MD USA. [Rapp, Michael] George Washington Univ, Sch Med & Hlth Sci, Dept Emergency Med, Washington, DC 20052 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program; Centers for Medicare & Medicaid Services (CMS) FX E.H.L.'s time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program. This study was funded by a contract from the Centers for Medicare & Medicaid Services (CMS). None of the remaining authors had any conflicts of interests to declare. The views expressed in this article represent the authors' views and do not necessarily represent official policy or opinions of the Department of Health and Human Services, the Centers for Medicare & Medicaid Services. NR 15 TC 106 Z9 106 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD DEC PY 2012 VL 256 IS 6 BP 973 EP 981 DI 10.1097/SLA.0b013e31826b4c4f PG 9 WC Surgery SC Surgery GA 053HC UT WOS:000312261000022 PM 23095667 ER PT J AU Mukkamala, SK Costa, RA Fung, A Sarraf, D Gallego-Pinazo, R Freund, KB AF Mukkamala, Sri Krishna Costa, Rogerio A. Fung, Adrian Sarraf, David Gallego-Pinazo, Roberto Freund, K. Bailey TI Optical Coherence Tomographic Imaging of Sub-Retinal Pigment Epithelium Lipid SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID OCCULT CHOROIDAL NEOVASCULARIZATION; AGE-RELATED MACULOPATHY; DIABETIC-MACULAR-EDEMA; HYPERREFLECTIVE FOCI; APOLIPOPROTEIN-B; BASAL DEPOSITS; DEGENERATION; DRUSEN; CHOLESTEROL; DETACHMENT AB Objective: To describe an optical coherence tomographic finding of layered hyperreflective bands beneath the retinal pigment epithelium (RPE), the so-called onion sign believed to represent lipid within a vascularized pigment epithelial detachment. Methods: This retrospective observational case series involved reviewing clinical histories of patients with the onion sign. Imaging studies analyzed included spectral-domain optical coherence tomography, color and red-free photographs, near infrared reflectance, fundus autofluorescence, and blue-light fundus autofluorescence. Results: A total of 22 eyes of 20 patients with sub-RPE hyperreflective bands were identified. There were 15 women and 5 men with a mean patient age of 76 years (range, 60-92 years). Snellen best-corrected visual acuities ranged from 20/25 to counting fingers, with a median of 20/80. Two patients had bilateral involvement, and 3 of 17 eyes had multifocal onion signs in the same eye. All eyes had neovascular age-related macular degeneration, with type 1 (sub-RPE) neovascularization. In all patients, the onion sign correlated with areas of yellow-gray exudates seen clinically that appeared bright on red-free and near infrared reflectance imaging. No specific fundus autofluorescence or blue-light fundus autofluorescence pattern was identified. Conclusions: The onion sign refers to layered hyperreflective bands in the sub-RPE space usually associated with chronic exudation from type 1 neovascularization in patients with age-related macular degeneration. With an associated bright near infrared reflectance, these bands may correspond to lipid, collagen, or fibrin. Because the onion sign colocalizes to areas of exudation that are known to consist of lipoprotein, we propose that this finding may represent layers of precipitated lipid in the sub-RPE space. To our knowledge, this is the first report of lipid detected in the sub-RPE space on clinical examination. Arch Ophthalmol. 2012;130(12):1547-1553. Published online August 13, 2012. doi:10.1001/archophthalmol.2012.2491 C1 [Mukkamala, Sri Krishna; Fung, Adrian; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA. [Mukkamala, Sri Krishna; Fung, Adrian; Freund, K. Bailey] LuEsther T Mertz Retinal Res Ctr, New York, NY USA. [Mukkamala, Sri Krishna; Freund, K. Bailey] NYU, Dept Ophthalmol, New York, NY 10016 USA. [Mukkamala, Sri Krishna; Freund, K. Bailey] Columbia Univ, Edward S Harkness Eye Inst, New York, NY USA. [Costa, Rogerio A.] Ctr Brasileiro Ciencias Visuais, Belo Horizonte, MG, Brazil. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Gallego-Pinazo, Roberto] Univ & Polytech Hosp, Dept Ophthalmol, Valencia, Spain. RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Fl, New York, NY 10022 USA. EM kbfnyf@aol.com RI Costa, Rogerio/E-6930-2013 OI Costa, Rogerio/0000-0002-0800-2233; Freund, K. Bailey/0000-0002-7888-9773 FU LuEsther T. Mertz Retinal Research Center; Manhattan Eye, Ear, and Throat Institute; Macula Foundation Inc; Karl Kirchgessner Foundation FX This study was supported by funding from the LuEsther T. Mertz Retinal Research Center; the Manhattan Eye, Ear, and Throat Institute; the Macula Foundation Inc; and the Karl Kirchgessner Foundation Ophthalmology Endowment Fund to Dr Sarraf. NR 37 TC 7 Z9 7 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD DEC PY 2012 VL 130 IS 12 BP 1547 EP 1553 DI 10.1001/archophthalmol.2012.2491 PG 7 WC Ophthalmology SC Ophthalmology GA 052KA UT WOS:000312195300007 PM 22892986 ER PT J AU Menda, SA Chen, M Naseri, A AF Menda, Shivali A. Chen, Michael Naseri, Ayman TI Technique for Shortening a Long Clear Corneal Incision SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID CATARACT-SURGERY AB An optimal clear corneal incision creates a self-sealing intrastomal tunnel. Variability in incision length may pose surgical difficulties for subsequent phacoemulsification. An incision that is too long may lead to challenges including decreased instrument mobility, decreased visibility due to corneal striae, stromal hydration, and a difficult angle of approach to the cataract. These sequelae may lead to surgical complications or abandonment of the original incision. We describe a technique for shortening a long clear corneal incision with the intentional creation of a flap of corneal tissue at the posterior internal wound edge. This technique is a simple and quick modification that may avoid the pitfalls of an incision that is too long. Arch Ophthalmol. 2012;130(12):1589-1590 C1 [Naseri, Ayman] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA 94121 USA. [Menda, Shivali A.; Chen, Michael; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. RP Naseri, A (reprint author), San Francisco VA Med Ctr, Dept Ophthalmol, 4150 Clement St, San Francisco, CA 94121 USA. EM ayman.naseri@va.gov NR 5 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD DEC PY 2012 VL 130 IS 12 BP 1589 EP 1590 PG 2 WC Ophthalmology SC Ophthalmology GA 052KA UT WOS:000312195300015 PM 23229702 ER PT J AU Fung, C Chen, X Grandis, JR Duvvuri, U AF Fung, Christopher Chen, Xing Grandis, Jennifer R. Duvvuri, Umamaheswar TI EGFR tyrosine kinase inhibition induces autophagy in cancer cells SO CANCER BIOLOGY & THERAPY LA English DT Article DE EGFR; erlotinib; gefitinib; epidermal; autophagy; TKI; rapamycin ID LUNG-CANCER; CARCINOMA; INDUCTION; HEAD; NECK; RESISTANCE; ERLOTINIB; LINES; APOPTOSIS; SURVIVAL AB The epidermal growth factor receptor (EGFR) signaling pathway is frequently dysregulated in a variety of human malignancies. As a result, agents have been developed to selectively inhibit the tyrosine kinase function of EGFR (EGFR-TKI) for cancer therapy. However, the clinical efficacy of these drugs to date has been limited by both acquired and intrinsic resistance. Macroautophagy, a process of intracellular proteolysis, has been shown to be activated in response to EGFR targeted therapy. However, the specific role of the induction of autophagy remains controversial. Here we show that autophagy is induced in a dose-dependent manner by in vitro treatment of multiple cancer cell lines with EGFR-TKI. Additionally, we find that in cells highly resistant to EGFR-TKI, autophagy is not robustly activated and that co-treatment of these cells with rapamycin, a known inducer of autophagy, can partially restore sensitivity to EGFR-TKI. Finally, we demonstrate that, in resistant cell lines, EGFR-TKI sensitivity can be further inhibited by siRNA-mediated depletion of the critical autophagy protein ATG7. Thus, our data suggests that defective autophagy may be an EGFR-TKI resistance mechanism and that activation of autophagy may be a viable strategy to augment the cytotoxic effect of EGFR-TKIs. C1 [Fung, Christopher; Chen, Xing; Grandis, Jennifer R.; Duvvuri, Umamaheswar] Univ Pittsburgh, Sch Med, Dept Otolaryngol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Grandis, Jennifer R.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. [Fung, Christopher] Howard Hughes Med Inst, Med Fellows Program, Chevy Chase, MD USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM duvvuriu@upmc.edu FU Howard Hughes Medical Institute [57006715]; National Institutes of Health [5P50CA097190, 2R01CA098372]; American Cancer Society [CRP-08-229-01]; United States Department of Veteran's Affairs [CDA-2-057-10S] FX These studies were supported by grants 57006715 (C.F.) from the Howard Hughes Medical Institute, 5P50CA097190 and 2R01CA098372 (J.G.) from the National Institutes of Health, CRP-08-229-01 (J.G.) from the American Cancer Society, and CDA-2-057-10S (U.D.) from the United States Department of Veteran's Affairs. The ideas in this article do not represent the views of the Department of Veteran's Affairs. NR 29 TC 25 Z9 27 U1 2 U2 16 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4047 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD DEC PY 2012 VL 13 IS 14 BP 1417 EP 1424 DI 10.4161/cbt.22002 PG 8 WC Oncology SC Oncology GA 052QD UT WOS:000312212200009 PM 22954701 ER PT J AU Hall, AL Bowden, MG Kautz, SA Neptune, RR AF Hall, A. L. Bowden, M. G. Kautz, S. A. Neptune, R. R. TI Biomechanical variables related to walking performance 6-months following post-stroke rehabilitation SO CLINICAL BIOMECHANICS LA English DT Article DE Hemiparesis; Body-weight supported treadmill training; Gait; Follow-up; Walking speed ID BODY-WEIGHT SUPPORT; CHRONIC STROKE; GAIT SPEED; TREADMILL; RECOVERY; CLASSIFICATION; LOCOMOTOR; SURVIVORS; STEPS AB Background: Body-weight supported treadmill training has been shown to be effective in improving walking speed in post-stroke hemiparetic subjects, and those that have shown improvements generally maintain them after the completion of rehabilitation. However, currently no biomechanical variables are known to be related to those who will either continue to improve or regress in their self-selected walking speed during the 6-month period following rehabilitation. The objective of this study was to identify those biomechanical variables that are associated with subjects who continue (or did not continue) to improve their self-selected walking speed following the completion of rehabilitation. Methods: Experimental kinematic and kinetic data were recorded from 18 hemiparetic subjects who participated in a 6-month follow-up study after completing a 12-week locomotor training program that included stepping on a treadmill with partial body weight support and manual assistance. Pearson correlation coefficients were used to determine which biomechanical variables evaluated during the post-training session were related to changes in self-selected walking speed from post-training to a 6-month follow-up session. Findings: Following the completion of rehabilitation, the majority of subjects increased or retained (i.e., did not change) their self-selected walking speed from post-training to the follow-up session. Post-training step length symmetry and daily step activity were positively related to walking speed improvements. Interpretation: Motor control deficits that lead to persistent step length asymmetry and low daily step activity at the end of rehabilitation are associated with poorer outcomes six months after completion of the program. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Hall, A. L.; Neptune, R. R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Bowden, M. G.; Kautz, S. A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bowden, M. G.; Kautz, S. A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bowden, M. G.; Kautz, S. A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 1 Univ Stn C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu RI Kinney, Allison/J-5814-2013 OI Kinney, Allison/0000-0003-3553-0733; Kautz, Steven/0000-0003-3151-8235 FU NIH [RO1 NS055380]; Rehabilitation Research & Development Service of the VA FX The authors would like to thank Helen Emery, Erin Carr, Dr. Bhavana Raja, Dr. Cameron Nott, Dr. Chitra Balasubramanian, Kelly Rooney and Ryan Knight for help with the data collection and processing and the members of the Neuromuscular Biomechanics Lab at The University of Texas at Austin for their insightful comments on the manuscript. This work was funded by NIH grant RO1 NS055380 and the Rehabilitation Research & Development Service of the VA. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NINDS or VA. NR 32 TC 14 Z9 14 U1 1 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD DEC PY 2012 VL 27 IS 10 BP 1017 EP 1022 DI 10.1016/j.clinbiomech.2012.07.006 PG 6 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 055MO UT WOS:000312420900007 PM 22917626 ER PT J AU Raja, B Neptune, RR Kautz, SA AF Raja, Bhavana Neptune, Richard R. Kautz, Steven A. TI Coordination of the non-paretic leg during hemiparetic gait: Expected and novel compensatory patterns SO CLINICAL BIOMECHANICS LA English DT Article DE Electromyography; Stroke; Walking; Muscle ID RECTUS FEMORIS TRANSFER; GROUND REACTION FORCES; STIFF-KNEE GAIT; POSTSTROKE HEMIPARESIS; STROKE PATIENTS; WALKING; FLEXION; SPEED; SUPPORT; POWER AB Background: Post-stroke hemiparesis is usually considered a unilateral motor control deficit of the paretic leg, while the non-paretic leg is assumed to compensate for paretic leg impairments and have minimal to no deficits. While the non-paretic leg electromyography (EMG) patterns are clearly altered, how the non-paretic leg acts to compensate remains to be established. Methods: Kinesiological data were recorded from sixty individuals with chronic hemiparesis (age: 60.9, SD=12.6 years, 21 females, 28 right hemiparetic, time since stroke: 4.5 years, SD 3.9 years), divided into three speed-based groups, and twenty similarly aged healthy individuals (age: 65.1, SD=10.4 years, 15 females). All walked on an instrumented split-belt treadmill at their self-selected speed and control subjects also walked at slower speeds matching those of the persons with hemiparesis. We determined the differences in magnitude and timing of non-paretic EMG activity relative to healthy control subjects in four pre-defined regions of stance phase of the gait cycle. Findings: Integrated EMG activity and EMG timing in the non-paretic leg were different in many muscles. Multiple compensatory patterns identified included: increased EMG output when the muscle was typically active in controls and novel compensatory EMG patterns that appeared to provide greater propulsion or support with little evidence of impaired motor performance. Interpretation: Most novel compensations were made possible by altered kinematics of the paretic and non-paretic leg (i.e., early stance plantarflexor activity provided propulsion due to the decreased advancement of the non-paretic foot) while others (late single limb stance knee extensor and late stance hamstring activity) appeared to be available mechanisms for increasing propulsion. Published by Elsevier Ltd. C1 [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Neptune, Richard R.] Univ Texas Austin, Austin, TX 78712 USA. [Raja, Bhavana] Univ Florida, Rehabil Sci Doctoral Program, Gainesville, FL USA. [Kautz, Steven A.] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA. [Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. RP Kautz, SA (reprint author), 77 President St,MSC 700, Charleston, SC 29425 USA. EM kautz@musc.edu OI Kautz, Steven/0000-0003-3151-8235 FU NIH [RO1 HD46820]; Rehabilitation Research & Development Service of the VA FX The authors would like to thank Helen Emery, Dr. Mark Bowden, Kelly Rooney, Francis Bergschneider, Dr. Cameron Nott and Ryan Knight for help with the data collection and processing. This work was funded by NIH grant RO1 HD46820 and the Rehabilitation Research & Development Service of the VA The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NICHD, VA or the United States Government. NR 25 TC 12 Z9 13 U1 0 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD DEC PY 2012 VL 27 IS 10 BP 1023 EP 1030 DI 10.1016/j.clinbiomech.2012.08.005 PG 8 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 055MO UT WOS:000312420900008 PM 22981679 ER PT J AU Acharya, D Robertson, P Kay, GN Jackson, L Warnock, DG Plumb, VJ Tallaj, JA AF Acharya, Deepak Robertson, Peter Kay, G. Neal Jackson, Leslie Warnock, David G. Plumb, Vance J. Tallaj, Jose A. TI Arrhythmias in Fabry Cardiomyopathy SO CLINICAL CARDIOLOGY LA English DT Article ID ENZYME REPLACEMENT THERAPY; LEFT-VENTRICULAR HYPERTROPHY; HUMAN ALPHA-GALACTOSIDASE; CARDIAC MANIFESTATIONS; DISEASE; INVOLVEMENT; IMPROVEMENT; PREVALENCE; TRIAL AB Background: Prior studies suggest that the incidence of ventricular arrhythmias is high in patients with Fabry cardiomyopathy. This study evaluated the incidence of significant arrhythmias in a series of patients with Fabry cardiomyopathy. Hypothesis: Arrhythmias are important causes of morbidity and mortality in Fabry Cardiomyopathy. Methods: This study was a retrospective chart review of 19 patients with known Fabry cardiomyopathy. Device interrogation reports were reviewed for those who had implantable devices. Electrocardiogram, Holter monitor, and event monitors were reviewed in those who did not have implantable devices. Results: Eighteen of nineteen patients were on enzyme replacement therapy (ERT). Nine (47%) out of 19 patients had implantable devices. Implant indications included symptomatic bradycardia, nonsustained ventricular tachycardia, conduction abnormalities, palpitations, and syncope. Mean follow-up in the patients with devices was 50 +/- 23 months. Two patients received implantable cardioverter-defibrillator (ICD) shocks, 1 of which was inappropriate for atrial fibrillation. Patients were paced in the atrium 71% +/- 37% of the time and paced in the ventricle 49% +/- 52% of the time. Four patients with devices were paced more than 95% of the time. Patients with an ICD had lower heart rates prior to ICD implant than the group that did not have devices (60 +/- 10 vs 78 +/- 16, P = 0.03). Of the patients without devices, only 1 had sudden cardiac death. Patients with implanted devices had higher left ventricular (LV) mass indices compared to patients without implanted devices (136 +/- 40 g/m2 vs 93 +/- 19 g/m2, P = 0.008). Conclusions: Significant ventricular arrhythmias are uncommon in patients with Fabry cardiomyopathy on ERT, but utilization of pacing is high. Sudden cardiac death in Fabry cardiomyopathy may be related to bradycardia. The authors have no funding, financial relationships, or conflicts of interest to disclose. C1 [Acharya, Deepak; Robertson, Peter; Kay, G. Neal; Plumb, Vance J.; Tallaj, Jose A.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Jackson, Leslie; Warnock, David G.] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL USA. [Tallaj, Jose A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. RP Acharya, D (reprint author), THT 321,1900 Univ Blvd, Birmingham, AL 35226 USA. EM dacharya@cardiology.uab.edu NR 26 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD DEC PY 2012 VL 35 IS 12 BP 738 EP 740 DI 10.1002/clc.22047 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 053CW UT WOS:000312248700008 PM 22886820 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Effects of Birth Cohort on Long-Term Trends in Mortality From Colorectal Cancer SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Colonoscopy Screening; Cohort Study; Epidemiology; Helicobacter pylori ID HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER; RISK; RATES; METAANALYSIS; POLYPECTOMY; PREVENTION; ENDOSCOPY; VETERANS; AUTOPSY AB BACKGROUND & AIMS: The decrease in mortality from colorectal cancer might have begun before widespread use of screening colonoscopy and sigmoidoscopy examinations. We examined long-term time trends in colorectal cancer mortality in 6 European countries to determine when the reduction began. METHODS: We analyzed mortality data from the national statistical offices of the United Kingdom (England and Wales), France, Italy, The Netherlands, Sweden, and Switzerland during the past 66 to 107 years. The data were made available by the national statistical offices of the 6 countries. Age-specific rates of death were plotted against the period of death, as period-age contours, and against the period of birth, as cohort-age contours. RESULTS: Long-term time trends in mortality from cancers of the rectum and colon each increased among generations born from 1800 to 1880, and then decreased among all subsequent generations, in all 6 countries analyzed. Similar temporal patterns also were observed when data from men and women were analyzed separately. The birth cohort patterns of colorectal cancer mortality resemble those of gastric cancer and peptic ulcer. CONCLUSIONS: Time trends of mortality from colorectal cancer, in 6 European countries, are associated with birth cohort patterns: colorectal cancer mortality decreased among all generations since 1880. These patterns indicate that in addition to the use of screening colonoscopy, other factors, such as changes in Helicobacter pylori infection, may have affected mortality. C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, P3-GI,3710 SW US,Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 27 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2012 VL 10 IS 12 BP 1389 EP 1394 DI 10.1016/j.cgh.2012.09.008 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 053IW UT WOS:000312265900017 PM 22982097 ER PT J AU Khan, AM Chirinos, JA Litt, H Yang, W Rosas, SE AF Khan, Abigail May Chirinos, Julio A. Litt, Harold Yang, Wei Rosas, Sylvia E. TI FGF-23 and the Progression of Coronary Arterial Calcification in Patients New to Dialysis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR 23; LEFT-VENTRICULAR HYPERTROPHY; RENAL-TRANSPLANT RECIPIENTS; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; COMPUTED-TOMOGRAPHY; SERUM PHOSPHORUS; CALCIUM; MORTALITY AB Background and objective Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. Design, setting, participants, & measurements FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. Results The mean age of study participants was 50 years; 33% were women, and 64% were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. Conclusions In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD. Clin J Am Soc Nephrol 7: 2017-2022, 2012. doi:10.2215/CJN.02160212 C1 [Khan, Abigail May; Chirinos, Julio A.] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA. [Chirinos, Julio A.; Rosas, Sylvia E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Litt, Harold] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Yang, Wei] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Rosas, Sylvia E.] Univ Penn, Renal Electrolyte & Hypertens Div, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Rosas, SE (reprint author), 3400 Spruce St,1 Founders Bldg, Philadelphia, PA 19010 USA. EM Sylvia.rosas@uphs.upenn.edu FU National Institutes of Health grant [R21 HL 086971]; American Recovery and Reinvestment Act supplement; National Center for Research Resources [UL1RR024134] FX This work was supported by National Institutes of Health grant R21 HL 086971 and an American Recovery and Reinvestment Act supplement. Salary support was also provided by the Veterans Health Administration and R01 DK 080033 (S.E.R). The project described was supported by grant UL1RR024134 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Funding sources had no involvement in study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the paper for publication. NR 32 TC 25 Z9 27 U1 0 U2 31 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD DEC PY 2012 VL 7 IS 12 BP 2017 EP 2022 DI 10.2215/CJN.02160212 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 051FK UT WOS:000312111400016 PM 22997345 ER PT J AU Young, BA Chan, C Blagg, C Lockridge, R Golper, T Finkelstein, F Shaffer, R Mehrotra, R AF Young, Bessie A. Chan, Christopher Blagg, Christopher Lockridge, Robert Golper, Thomas Finkelstein, Fred Shaffer, Rachel Mehrotra, Rajnish CA ASN Dialysis Advisory Grp TI How to Overcome Barriers and Establish a Successful Home HD Program SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; QUALITY-OF-LIFE; IN-CENTER HEMODIALYSIS; PERITONEAL-DIALYSIS PATIENTS; SELF-CARE DIALYSIS; RANDOMIZED CONTROLLED-TRIAL; CHRONIC KIDNEY-DISEASE; NOCTURNAL HEMODIALYSIS; CONVENTIONAL HEMODIALYSIS; UNITED-STATES AB Home hemodialysis (HD) is an underused dialysis modality in the United States, even though it provides an efficient and probably cost-effective way to provide more frequent or longer dialysis. With the advent of newer home HD systems that are easier for patients to learn, use, and maintain, patient and provider interest in home HD is increasing. Although barriers for providers are similar to those for peritoneal dialysis, home HD requires more extensive patient training, nursing education, and infrastructure support in order to maintain a successful program. In addition, because many physicians and patients do not have experience with home HD, reluctance to start home HD programs is widespread. This in-depth review describes barriers to home HD, focusing on patients, individual physicians and practices, and dialysis facilities, and offers suggestions for how to overcome these barriers and establish a successful home HD program. Clin J Am Soc Nephrol 7: 2023-2032, 2012. doi:10.2215/CJN.07080712 C1 [Young, Bessie A.] Univ Washington, Div Nephrol, Kidney Res Inst, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Chan, Christopher] Univ Toronto, Toronto, ON, Canada. [Blagg, Christopher] NW Kidney Ctr, Seattle, WA USA. [Lockridge, Robert] Univ Virginia, Dept Med, Div Nephrol, Lynchburg, VA USA. [Golper, Thomas] Vanderbilt Univ, Nashville, TN USA. [Finkelstein, Fred] St Raphaels Med Ctr, New Haven, CT USA. [Shaffer, Rachel] Amer Soc Nephrol, Washington, DC USA. [Mehrotra, Rajnish] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. RP Young, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst 152 E, 1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu OI Saggi, Subodh/0000-0001-9126-7226 FU Veterans Affairs Puget Sound Health Care System; Baxter Healthcare; DaVita; Mitsubishi; Shire; Takeda; Vifor FX This material is the result of work supported by resources from the Veterans Affairs Puget Sound Health Care System.; C.C. serves as a member of the scientific advisory board for Baxter Healthcare. C.B. is a consultant to DEKA Research and Development Corporation. R.L. serves as a member of the scientific advisory board for Fresenius Medical Care. T.G. conducts consultant activity for Baxter, Fresenius, DaVita, Takeda-Affymax, and Q Source. F.F. serves as a member of the scientific advisory board for NxStage and conducts consultant activity for Baxter Healthcare. R.S. is an employee of the American Society of Nephrology. R.M. has received grant support and/or honoraria from Baxter Healthcare, DaVita, Mitsubishi, Shire, Takeda, and Vifor. NR 97 TC 24 Z9 24 U1 2 U2 16 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD DEC PY 2012 VL 7 IS 12 BP 2023 EP 2032 DI 10.2215/CJN.07080712 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 051FK UT WOS:000312111400017 PM 23037981 ER PT J AU Riegel, B Glaser, D Richards, K Sayers, SL Marzolf, A Weintraub, WS Goldberg, LR AF Riegel, Barbara Glaser, Dale Richards, Kathy Sayers, Steven L. Marzolf, Amy Weintraub, William S. Goldberg, Lee R. TI Modifiable factors associated with sleep dysfunction in adults with heart failure SO EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING LA English DT Article DE Heart failure; sleep; sleep dysfunction; self-rated health; medications; sleep hygiene; depression ID QUALITY-OF-LIFE; GLOBAL PERCEIVED HEALTH; PRIMARY-CARE PATIENTS; SELF-RATED HEALTH; OLDER-ADULTS; DAYTIME SLEEPINESS; BLOOD-PRESSURE; POOR HEALTH; INSOMNIA; POPULATION AB Background: Sleep dysfunction contributes to poor quality of life in adults with heart failure (HF). The purpose of this study was to identify factors associated with sleep dysfunction that may be modifiable. Methods: Data were collected from 266 subjects enrolled from three sites in the U. S. Sleep dysfunction was measured over the past month with the Pittsburgh Sleep Quality Index, using a score > 10 to indicate sleep dysfunction. Potentially modifiable clinical, behavioral, and psychological factors thought to be associated with sleep dysfunction were analyzed with hierarchical logistic regression analysis. Results: When covariates of age, gender, race, data collection site, and New York Heart Association (NYHA) functional class were entered on the first step, only NYHA was a significant correlate of sleep dysfunction. When the clinical, behavioral, and psychological factors were entered, correlates of sleep dysfunction were the number of drugs known to cause daytime somnolence (OR = 2.08), depression (OR = 1.83), worse overall perceived health (OR = 1.64), and better sleep hygiene (OR = 1.40). Although most (54%) subjects had sleep disordered breathing (SDB), SDB was not a significant predictor of sleep dysfunction. Discussion: Factors associated with sleep dysfunction in HF include medications with sleepiness as a side-effect, depression, poorer health perceptions, and better sleep hygiene. Sleep dysfunction may motivate HF patients to address sleep hygiene. Eliminating medications with sleepiness as a side-effect, treating depression and perceptions of poor health may improve sleep quality in HF patients. C1 [Riegel, Barbara] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Glaser, Dale] Glaser Consulting, San Diego, CA USA. [Glaser, Dale] Univ San Diego, Sch Nursing, San Diego, CA 92110 USA. [Richards, Kathy] George Mason Univ, Fairfax, VA 22030 USA. [Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Marzolf, Amy] Univ Penn, Heart Failure & Transplant Ctr, Philadelphia, PA 19104 USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. RP Riegel, B (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA. EM briegel@nursing.upenn.edu OI Goldberg, Lee/0000-0002-7906-9638 FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia Veterans Affairs Medical Center; VISN 4 Mental Illness Research, Education, and Clinical Center (MIREC) FX This work was funded by a grant from the National Heart, Lung & Blood Institute (RO1 HL084394-01A1) and by the Philadelphia Veterans Affairs Medical Center, VISN 4 Mental Illness Research, Education, and Clinical Center (MIREC). NR 60 TC 8 Z9 8 U1 1 U2 13 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1474-5151 J9 EUR J CARDIOVASC NUR JI Eur. J. Cardiovasc. Nurs. PD DEC PY 2012 VL 11 IS 4 BP 402 EP 409 DI 10.1016/j.ejcnurse.2011.02.001 PG 8 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA 054MS UT WOS:000312348500006 PM 21353642 ER PT J AU Lovejoy, TI Turk, DC Morasco, BJ AF Lovejoy, Travis I. Turk, Dennis C. Morasco, Benjamin J. TI Evaluation of the Psychometric Properties of the Revised Short-Form McGill Pain Questionnaire SO JOURNAL OF PAIN LA English DT Article DE Chronic pain; McGill Pain Questionnaire; psychometric reliability; validity ID NEUROPATHIC PAIN; VALIDATION; INVENTORY; SCALE AB The recently revised version of the Short-Form McGill Pain Questionnaire (SF-MPQ-2) was created to assess both neuropathic and non-neuropathic pain. The current study extends prior research by testing the reliability and validity of the SF-MPQ-2 in a sample of U.S. veteran patients with a range of chronic pain diagnoses. Participants (N = 186) completed the SF-MPQ-2, a sociodemographic questionnaire, the Structured Clinical Interview for the DSM-IV, and self-report pain and psychiatric measures. Pain diagnoses were extracted from the electronic medical record. The SF-MPQ-2 total and scale scores demonstrated good-to-excellent internal consistency. Convergent and discriminant validity were supported, and SF-MPQ-2 total and scale scores increased with number of pain diagnoses and pain severity. Confirmatory factor analyses indicated that a 4-factor model fit the data better than a single-factor model. However, high intercorrelations among the 4 latent constructs were observed, and a second-order global pain construct also emerged. Overall, the SF-MPQ-2 demonstrated excellent reliability and validity in a sample of U.S. veteran patients with chronic neuropathic and non-neuropathic pain. Future psychometric studies of the SF-MPQ-2 should employ longitudinal data to evaluate the ability of scale scores to uniquely predict clinical and health service outcomes. Perspective: This article presents the psychometric properties of a revised version of the SF-MPQ-2. This measure may have great utility as a screening tool in clinical practice and as an outcome measure in clinical trials. Published by Elsevier Inc. on behalf of the American Pain Society C1 [Lovejoy, Travis I.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Lovejoy, TI (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, P3MHDC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM travis.lovejoy@va.gov FU United States National Institute on Drug Abuse [K23DA023467]; Endo; Johnson Johnson; Philips Respironics; National Institutes of Health; Eli Lilly; OrthoMcNeill- Janssen; Pfizer; SK LifeScience FX This material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center. This study was supported in part by award K23DA023467 from the United States National Institute on Drug Abuse to Dr. Morasco. Dr. Turk has received research support from Endo, Johnson & Johnson, Philips Respironics, and the National Institutes of Health, and consulting fees from Eli Lilly, OrthoMcNeill- Janssen, Pfizer, Philips Respironics, and SK LifeScience. He is also a Special Government Employee of the U.S. Food and Drug Administration. No other author reports having any potential conflict of interest. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs or the National Institute on Drug Abuse. NR 28 TC 20 Z9 22 U1 3 U2 25 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD DEC PY 2012 VL 13 IS 12 BP 1250 EP 1257 DI 10.1016/j.jpain.2012.09.011 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 053NR UT WOS:000312280200012 PM 23182230 ER PT J AU Milber, JM Noorigian, JV Morley, JF Petrovitch, H White, L Ross, GW Duda, JE AF Milber, Joshua M. Noorigian, Joseph V. Morley, James F. Petrovitch, Helen White, Lon Ross, G. Webster Duda, John E. TI Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease SO NEUROLOGY LA English DT Article ID ALPHA-SYNUCLEIN PATHOLOGY; SUBSTANTIA-NIGRA; BODY DISEASE; DEMENTIA; BRAIN; BODIES; RELEVANCE; DEATH; MEN AB Objective: To determine whether evidence of neuronal dysfunction or demise preceded deposition of Lewy pathology in vulnerable neurons in Parkinson disease (PD). Methods: We examined the extent of nigral dysfunction and degeneration among 63 normal, incidental Lewy body disease (ILBD), and PD cases based on tyrosine hydroxylase (TH) immunoreactivity and neuron densities, respectively. The relationship between these markers and Lewy pathology (LP) burden in the substantia nigra (SN) and Braak PD stage was assessed. Results: Compared with normal subjects, ILBD cases displayed a significantly higher percentage of TH-negative cells and lower neuronal densities in the SN as early as Braak PD stages 1 and 2, before LP deposition in the nigrostriatal system. ILBD nigral neuron densities were intermediate between normal subjects and PD cases, and TH-negative percentages were higher in ILBD than either normal or PD cases. Furthermore, neuron density and neuronal dysfunction levels remained relatively constant across Braak PD stages in ILBD. Conclusions: These results suggest that significant neurodegeneration and cellular dysfunction precede LP in the SN, challenging the pathogenic role of LP in PD and the assumption that ILBD always represents preclinical PD. Neurology (R) 2012; 79: 2307-2314 C1 [Milber, Joshua M.; Noorigian, Joseph V.; Morley, James F.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Morley, James F.; Duda, John E.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Petrovitch, Helen; Ross, G. Webster] Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA. [Petrovitch, Helen; White, Lon; Ross, G. Webster] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96822 USA. [Petrovitch, Helen; White, Lon; Ross, G. Webster] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA. [Petrovitch, Helen; White, Lon; Ross, G. Webster] Kuakini Med Ctr, Honolulu Asian Aging Study, Honolulu, HI USA. RP Duda, JE (reprint author), Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. EM john.duda@va.gov FU Biomedical Laboratory Research and Development Service of the Department of Veterans Affairs; United States Department of the Army [DAMD17-98-1-8621]; National Institutes of Health: National Institute of Neurological Disorders and Stroke [5 R01 NS041265]; National Institute on Aging [1 U01 AG19349, 5 R01 AG017155]; Office of Research and Development, Medical Research Service Department of Veterans Affairs; Department of Defense; NINDS, NIH; NIA, NIH; Northwestern Foundation; Michael J. Fox Foundation; Department of Veterans Affairs; NIH; Michael J. Fox Foundation for Parkinson Research; Samueli Institute FX Supported by a Merit Award from the Biomedical Laboratory Research and Development Service of the Department of Veterans Affairs (J.E. Duda, PI) and by the United States Department of the Army, grant DAMD17-98-1-8621; National Institutes of Health: National Institute of Neurological Disorders and Stroke grant 5 R01 NS041265; National Institute on Aging grants 1 U01 AG19349 and 5 R01 AG017155; and the Office of Research and Development, Medical Research Service Department of Veterans Affairs.; J. Milber and J. Noorigian have no disclosures. J. Morley has received compensation for articles written in the PD Monitor and Commentary, a publication supported by an educational grant from Teva Neuroscience. H. Petrovitch and L. White have no disclosures. G. Webster Ross receives salary support from the Department of Veterans Affairs and research support from the Department of Defense; NINDS, NIH; NIA, NIH; Northwestern Foundation; and the Michael J. Fox Foundation. J. Duda has received research support from the Department of Veterans Affairs, the NIH, the Michael J. Fox Foundation for Parkinson Research, and the Samueli Institute. He holds common stock in C. R. Bard, Inc., Celgene Corp., Clarient, Inc., and Johnson & Johnson. Go to Neurology.org for full disclosures. NR 34 TC 34 Z9 34 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD DEC PY 2012 VL 79 IS 24 BP 2307 EP 2314 DI 10.1212/WNL.0b013e318278fe32 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 053MA UT WOS:000312274500007 PM 23152586 ER PT J AU Williams, EC Bradley, KA Gupta, S Harris, AHS AF Williams, Emily C. Bradley, Katharine A. Gupta, Shalini Harris, Alex H. S. TI Association Between Alcohol Screening Scores and Mortality in Black, Hispanic, and White Male Veterans SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol; Race; Ethnicity; Mortality; AUDIT-C ID ALL-CAUSE MORTALITY; BEHAVIORAL-COUNSELING INTERVENTIONS; DEATH REPORTING SYSTEM; PRIMARY-CARE PATIENTS; UNITED-STATES; HEALTH-STATUS; RACIAL-DIFFERENCES; PROBLEM DRINKING; VIOLENT DEATHS; PUBLIC-HEALTH AB Background Scores on the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaire are associated with mortality, but whether or how associations vary across race/ethnicity is unknown. Methods Self-reported black (n = 13,068), Hispanic (n = 9,466), and white (n = 182,688) male Veterans Affairs (VA) outpatients completed the AUDIT-C via mailed survey. Logistic regression models evaluated whether race/ethnicity modified the association between AUDIT-C scores (0, 1 to 4, 5 to 8, and 9 to 12) and mortality after 24 months, adjusting for demographics, smoking, and comorbidity. Results Adjusted mortality rates were 0.036, 0.033, and 0.054, for black, Hispanic, and white patients with AUDIT-C scores of 1 to 4, respectively. Race/ethnicity modified the association between AUDIT-C scores and mortality (p = 0.0022). Hispanic and white patients with scores of 0, 5 to 8, and 9 to 12 had significantly increased risk of death compared to those with scores of 1 to 4; Hispanic ORs: 1.93, 95% CI 1.50 to 2.49; 1.57, 1.07 to 2.30; 1.82, 1.04 to 3.17, respectively; white ORs: 1.34, 95% CI 1.29 to 1.40; 1.12, 1.03 to 1.21; 1.81, 1.59 to 2.07, respectively. Black patients with scores of 0 and 5 to 8 had increased risk relative to scores of 1 to 4 (ORs 1.28, 1.06 to 1.56 and 1.50, 1.13 to 1.99), but there was no significant increased risk for scores of 9 to 12 (ORs 1.27, 0.77 to 2.09). Post hoc exploratory analyses suggested an interaction between smoking and AUDIT-C scores might account for some of the observed differences across race/ethnicity. Conclusions Among male VA outpatients, associations between alcohol screening scores and mortality varied significantly depending on race/ethnicity. Findings could be integrated into systems with automated risk calculators to provide demographically tailored feedback regarding medical consequences of drinking. C1 [Williams, Emily C.] Vet Affairs VA Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev HSR&D, Seattle, WA USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Williams, Emily C.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, NW Ctr Excellence HSR&D, Seattle, WA 98101 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Gupta, Shalini; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, NW Ctr Excellence HSR&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM emily.williams3@va.gov FU VA Office of Quality and Performance; VA Health Services Research and Development (HSRD); VA Substance Use Disorders Quality Enhancement Research Initiative (SUD-QuERI); National Institute of Alcohol Abuse and Alcoholism [R03 AA016793-01]; NIAAA [1R03AA016793-01A1]; VA Health Services Research and Development; VA Palo Alto Healthcare System Center for Healthcare Evaluation; Substance Use Disorders QUERI FX The authors gratefully acknowledge Rachel M. Thomas, MPH, for assistance with manuscript preparation. This study was supported by the VA Office of Quality and Performance, VA Health Services Research and Development (HSR&D), VA Substance Use Disorders Quality Enhancement Research Initiative (SUD-QuERI), and a grant from the National Institute of Alcohol Abuse and Alcoholism (R03 AA016793-01; Harris, PI). This study was funded by NIAAA 1R03AA016793-01A1 and conducted with support from the VA Health Services Research and Development, VA Palo Alto Healthcare System Center for Healthcare Evaluation, and the Substance Use Disorders QUERI and the VA Office of Quality and Performance. NR 61 TC 4 Z9 4 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD DEC PY 2012 VL 36 IS 12 BP 2132 EP 2140 DI 10.1111/j.1530-0277.2012.01842.x PG 9 WC Substance Abuse SC Substance Abuse GA 051MN UT WOS:000312131400014 PM 22676340 ER PT J AU Luthra, M Khan, H Suhail, MF Avadhani, V AF Luthra, Munish Khan, Hina Suhail, M. Faizul Avadhani, Vaidehi TI Primary pulmonary leiomyosarcoma - A case report SO ARCHIVOS DE BRONCONEUMOLOGIA LA Spanish DT Article DE Leiomyosarcoma; Spindle cell neoplasm; Mesenchymal tumor; Computed tomography ID LUNG AB Sarcomas are mesenchymal tumors that originate from the stromal elements of the bronchial wall or from interstices of lung parenchyma. Pulmonary sarcomatous neoplasms are a rare and diagnostically challenging group of tumors. They constitute only 0.2%-0.5% of all primary lung malignancies. Primary pulmonary leiomyosarcomas are subdivided into those originating from pulmonary parenchyma, bronchial tree or pulmonary arteries. Here we present a case of 43-year-old African-American female who with chronic cough, fatigue and weight loss. Early detection is the key to the successful management of these patients. The available treatment option is complete resection of tumor. These cases provide an interesting juxtaposition to the management of typical lung cancer. (C) 2012 SEPAR. Published by Elsevier Espana, S.L. All rights reserved. C1 [Luthra, Munish] Mt Sinai Sch Med, Dept Crit Care Med, New York, NY USA. [Khan, Hina] Mt Sinai Sch Med, James J Peters VA Med Ctr, Dept Internal Med, Bronx, NY USA. [Suhail, M. Faizul] Albert Einstein Coll Med, Dept Pulm Med, Bronx, NY 10467 USA. [Avadhani, Vaidehi] Columbia Univ, St Lukes Roosevelt Hosp Med Ctr, Dept Pathol, New York, NY 10027 USA. RP Luthra, M (reprint author), Mt Sinai Sch Med, Dept Crit Care Med, New York, NY USA. EM munish74@gmail.com NR 6 TC 0 Z9 0 U1 1 U2 2 PU EDICIONES DOYMA S A PI BARCELONA PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN SN 0300-2896 J9 ARCH BRONCONEUMOL JI Arch. Bronconeumol. PD DEC PY 2012 VL 48 IS 12 BP 476 EP 478 DI 10.1016/j.arbres.2012.01.006 PG 3 WC Respiratory System SC Respiratory System GA 050IG UT WOS:000312046400008 PM 22410283 ER PT J AU Seaquist, ER Lattemann, DF Dixon, RA AF Seaquist, Elizabeth R. Lattemann, Dianne Figlewicz Dixon, Roger A. TI American Diabetes Association Research Symposium: Diabetes and the Brain SO DIABETES LA English DT Article C1 [Seaquist, Elizabeth R.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Lattemann, Dianne Figlewicz] Univ Washington, Seattle, WA 98195 USA. [Lattemann, Dianne Figlewicz] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Dixon, Roger A.] Univ Alberta, Dept Psychol, Edmonton, AB, Canada. RP Seaquist, ER (reprint author), Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. EM seaqu001@umn.edu FU NIDDK NIH HHS [R01 DK040963] NR 0 TC 4 Z9 4 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 2012 VL 61 IS 12 BP 3056 EP 3062 DI 10.2337/db12-0489 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 050GR UT WOS:000312041700003 PM 23172952 ER PT J AU Campbell, JA Walker, RJ Smalls, BL Egede, LE AF Campbell, Jennifer A. Walker, Rebekah J. Smalls, Brittany L. Egede, Leonard E. TI Glucose control in diabetes: the impact of racial differences on monitoring and outcomes SO ENDOCRINE LA English DT Review DE Diabetes; Racial differences; Self-monitoring; Glucose control; Lipids; Blood pressure ID QUALITY-OF-CARE; ETHNIC-DIFFERENCES; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; US ADULTS; MANAGEMENT; HEALTH; RACE; ASSOCIATION; DISPARITIES AB Type 2 diabetes is the seventh leading cause of death in the US and is projected to increase in prevalence globally. Minorities are disproportionately affected by diabetes and data suggest that clinical outcomes consistently fall below American Diabetes Association recommendations. The purpose of this systematic review was to examine ethnic differences in self-monitoring and outcomes in adults with type 2 diabetes. Medline was searched for articles published between January 1990 and January 2012 by means of a reproducible strategy. Inclusion criteria included (1) published in English, (2) targeted African Americans, Hispanic, or Asian adults, ages 18+ years with type 2 diabetes, (3) cross-sectional, cohort, or intervention study, and (4) measured change in glycemic control, BP, lipids, or quality of life by race. Twenty-two papers met the inclusion criteria and were reviewed. Overall, significant racial differences and barriers were found in published studies in diabetes management as it pertains to self-monitoring and outcomes. African Americans tend to consistently exhibit worse outcomes and control when compared to other minority populations and non-Hispanic Whites. In conclusion, significant racial differences and barriers exist in diabetes management as it pertains to self-monitoring and outcomes when compared to non-Hispanic Whites. Explanatory and intervention studies are needed to determine the mechanisms and mediators of these differences and strategies to reduce these disparities. In addition, more research is needed to investigate the impact of racial differences in self-monitoring and outcomes on quality of life. C1 [Campbell, Jennifer A.; Walker, Rebekah J.; Smalls, Brittany L.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA REAP, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699, R01 DK081121] NR 31 TC 31 Z9 31 U1 1 U2 17 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1355-008X J9 ENDOCRINE JI Endocrine PD DEC PY 2012 VL 42 IS 3 BP 471 EP 482 DI 10.1007/s12020-012-9744-6 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 050SE UT WOS:000312073500006 PM 22815042 ER PT J AU Epstein, AJ Johnson, SJ AF Epstein, Andrew J. Johnson, Scott J. TI Physician response to financial incentives when choosing drugs to treat breast cancer SO INTERNATIONAL JOURNAL OF HEALTH CARE FINANCE & ECONOMICS LA English DT Article DE Agency; Physician treatment decisions; Financial incentives; Medicare; Reimbursement ID SEER-MEDICARE DATA; HEALTH-CARE; PRESCRIPTION DECISION; PATIENTS PREFERENCES; CESAREAN DELIVERY; MODELS; ENDOGENEITY; PATTERNS; DOCTORS; CHOICES AB This paper considers physician agency in choosing drugs to treat metastatic breast cancer, a clinical setting in which patients have few protections from physicians' rent seeking. Physicians have explicit financial incentives attached to each potential drug treatment, with profit margins ranging more than a hundred fold. SEER-Medicare claims and Medispan pricing data were formed into a panel of 4,503 patients who were diagnosed with metastatic breast cancer and treated with anti-cancer drugs from 1992 to 2002. We analyzed the effects of product attributes, including profit margin, randomized controlled trial citations, FDA label, generic status, and other covariates on therapy choice. Instruments and drug fixed effects were used to control for omitted variables and possible measurement error associated with margin. We find that increasing physician margin by 10% yields between an 11 and 177% increase in the likelihood of drug choice on average across drugs. Physicians were more likely to use drugs with which they had experience, had more citations, and were FDA-approved to treat breast cancer. Oncologists are susceptible to financial incentives when choosing drugs, though other factors play a large role in their choice of drug. C1 [Johnson, Scott J.] Precis Hlth Econ, Boston, MA 02111 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Epstein, Andrew J.] Univ Penn, Dept Med, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Johnson, SJ (reprint author), Precis Hlth Econ, 711 Atlantic Ave, Boston, MA 02111 USA. EM scott.johnson@precisionhealtheconomics.com NR 44 TC 4 Z9 4 U1 0 U2 16 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1389-6563 J9 INT J HEALTH CARE FI JI Int. J. Health Care Financ. Econ. PD DEC PY 2012 VL 12 IS 4 BP 285 EP 302 DI 10.1007/s10754-012-9117-y PG 18 WC Business, Finance; Economics; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 052GE UT WOS:000312184900003 PM 23124970 ER PT J AU Ratanawongsa, N Korthuis, PT Saha, S Roter, D Moore, RD Sharp, VL Beach, MC AF Ratanawongsa, Neda Korthuis, P. Todd Saha, Somnath Roter, Debra Moore, Richard D. Sharp, Victoria L. Beach, Mary Catherine TI Clinician Stress and Patient-Clinician Communication in HIV Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient; clinician; stress; communication; HIV ID INTERNAL-MEDICINE; PHYSICIAN BURNOUT; PERCEIVED STRESS; WOMEN PHYSICIANS; SATISFACTION; OUTCOMES; EMPATHY; HEALTH; PERFORMANCE; BEHAVIOR AB BACKGROUND: Clinician stress is common, but few studies have examined its relationship with communication behaviors. OBJECTIVE: To investigate associations between clinician stress and patient-clinician communication in primary HIV care. DESIGN: Observational study. PARTICIPANTS: Thirty-three primary HIV clinicians and 350 HIV-infected adult, English-speaking patients at three U.S. HIV specialty clinic sites. MAIN MEASURES: Clinicians completed the Perceived Stress Scale, and we categorized scores in tertiles. Audio-recordings of patient-clinician encounters were coded using the Roter Interaction Analysis System. Patients rated the quality of their clinician's communication and overall quality of medical care. We used regression with generalized estimating equations to examine associations between clinician stress and communication outcomes, controlling for clinician gender, clinic site, and visit length. KEY RESULTS: Among the 33 clinicians, 70 % were physicians, 64 % were women, 67 % were non-Hispanic white, and the mean stress score was 3.9 (SD 2.4, range 0-8). Among the 350 patients, 34 % were women, 55 % were African American, 23 % were non-Hispanic white, 16 % were Hispanic, and 30 % had been with their clinicians > 5 years. Verbal dominance was higher for moderate-stress clinicians (ratio = 1.93, p < 0.01) and high-stress clinicians (ratio = 1.76, p = 0.01), compared with low-stress clinicians (ratio 1.45). More medical information was offered by moderate-stress clinicians (145.5 statements, p < 0.01) and high-stress clinicians (125.9 statements, p = 0.02), compared with low-stress clinicians (97.8 statements). High-stress clinicians offered less psychosocial information (17.1 vs. 19.3, p = 0.02), and patients of high-stress clinicians rated their quality of care as excellent less frequently than patients of low-stress clinicians (49.5 % vs. 66.9 %, p < 0.01). However, moderate-stress clinicians offered more partnering statements (27.7 vs. 18.2, p = 0.04) and positive affect (3.88 vs. 3.78 score, p = 0.02) than low-stress clinicians, and their patients' ratings did not differ. CONCLUSIONS: Although higher stress was associated with verbal dominance and lower patient ratings, moderate stress was associated with some positive communication behaviors. Prospective mixed methods studies should examine the complex relationships across the continuum of clinician well-being and health communication. C1 [Ratanawongsa, Neda] San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Ratanawongsa, Neda] Univ Calif San Francisco, Ctr Trauma, San Francisco, CA 94110 USA. [Korthuis, P. Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Roter, Debra; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Sharp, Victoria L.] St Lukes Roosevelt Hosp, New York, NY USA. RP Ratanawongsa, N (reprint author), San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat, 1001 Potrero Ave,Box 1364, San Francisco, CA 94110 USA. EM ratanawongsan@medsfgh.ucsf.edu RI Roter, Debra/N-8830-2014 FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08 HS013903-05]; National Institute of Drug Abuse [K23 DA019808]; Robert Wood Johnson Generalist Physician Faculty Scholars Awards; Department of Veterans Affairs FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019808). Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08 HS013903-05), and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. Dr. Saha was supported by the Department of Veterans Affairs. NR 63 TC 4 Z9 4 U1 2 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2012 VL 27 IS 12 BP 1635 EP 1642 DI 10.1007/s11606-012-2157-7 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 050RR UT WOS:000312072200012 PM 22821571 ER PT J AU Sudore, RL Karter, AJ Huang, ES Moffet, HH Laiteerapong, N Schenker, Y Adams, A Whitmer, RA Liu, JY Miao, YH John, PM Schillinger, D AF Sudore, Rebecca L. Karter, Andrew J. Huang, Elbert S. Moffet, Howard H. Laiteerapong, Neda Schenker, Yael Adams, Alyce Whitmer, Rachel A. Liu, Jennifer Y. Miao, Yinghui John, Priya M. Schillinger, Dean TI Symptom Burden of Adults with Type 2 Diabetes Across the Disease Course: Diabetes & Aging Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE palliative care; diabetes mellitus type 2; quality of life ID QUALITY-OF-LIFE; NORTHERN CALIFORNIA DISTANCE; PALLIATIVE CARE; ADVANCED CANCER; OLDER-ADULTS; HOSPITALIZED-PATIENTS; COMORBIDITY INDEX; GLYCEMIC CONTROL; KIDNEY-DISEASE; HEART-FAILURE AB BACKGROUND: Reducing symptom burden is paramount at the end-of-life, but typically considered secondary to risk factor control in chronic disease, such as diabetes. Little is known about the symptom burden experienced by adults with type 2 diabetes and the need for symptom palliation. OBJECTIVE: To examine pain and non-pain symptoms of adults with type 2 diabetes over the disease course - at varying time points before death and by age. DESIGN: Survey follow-up study. PARTICIPANTS: 13,171 adults with type 2 diabetes, aged 30-75 years, from Kaiser Permanente, Northern California, who answered a baseline symptom survey in 2005-2006. MAIN MEASURES: Pain and non-pain symptoms were identified by self-report and medical record data. Survival status from baseline was categorized into a parts per thousand currency sign6, > 6-24, or alive > 24 months. KEY RESULTS: Mean age was 60 years; 48 % were women, and 43 % were non-white. Acute pain was prevalent (41.8 %) and 39.7 % reported chronic pain, 24.6 % fatigue, 23.7 % neuropathy, 23.5 % depression, 24.2 % insomnia, and 15.6 % physical/emotional disability. Symptom burden was prevalent in all survival status categories, but was more prevalent among those with shorter survival, p < .001. Adults a parts per thousand yen60 years who were alive > 24 months reported more physical symptoms such as acute pain and dyspnea, whereas participants < 60 years reported more psychosocial symptoms, such as depressed mood and insomnia. Adjustment for duration of diabetes and comorbidity reduced the association between age and pain, but did not otherwise change our results. CONCLUSIONS: In a diverse cohort of adults with type 2 diabetes, pain and non-pain symptoms were common among all patients, not only among those near the end of life. However, symptoms were more prevalent among patients with shorter survival. Older adults reported more physical symptoms, whereas younger adults reported more psychosocial symptoms. Diabetes care management should include not only good cardiometabolic control, but also symptom palliation across the disease course. C1 [Sudore, Rebecca L.; Miao, Yinghui] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sudore, Rebecca L.; Miao, Yinghui] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Karter, Andrew J.; Moffet, Howard H.; Adams, Alyce; Whitmer, Rachel A.; Liu, Jennifer Y.] Kaiser Permanente, Div Res, Oakland, CA USA. [Huang, Elbert S.; Laiteerapong, Neda; John, Priya M.] Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA. [Schenker, Yael] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Schillinger, Dean] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Schillinger, Dean] Univ Calif San Francisco, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. [Schillinger, Dean] Calif Dept Publ Hlth, Calif Diabet Program, Sacramento, CA USA. RP Sudore, RL (reprint author), San Francisco VA Med Ctr, 4150 Clement St 151R, San Francisco, CA 94121 USA. EM rebecca.sudore@ucsf.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, the San Francisco Research Enhancement Award Program; National Institutes of Health (NIH) National Institutes of Diabetes, Digestive and Kidney Diseases (NIDDK) for the Diabetes and Aging Study [RO1-DK-081796]; Diabetes Study of Northern California (DISTANCE) [R01-DK-065664, R01-DK080726, R01-HD46113]; Agency for Healthcare Research and Quality [T32-HS000084]; NIDDK [F32-DK-089973]; NIDDK Diabetes and Research Training Center at the University of Chicago [P60-DK-20595]; NIDDK Centers for Diabetes Translation Research at Kaiser Permanente; University of California, San Francisco [P30 DK092924]; University of Chicago [P30 DK092949] FX Dr. Sudore was supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, the San Francisco Research Enhancement Award Program. This work was performed with support by the National Institutes of Health (NIH) National Institutes of Diabetes, Digestive and Kidney Diseases (NIDDK) for the Diabetes and Aging Study (RO1-DK-081796) and the Diabetes Study of Northern California (DISTANCE) (R01-DK-065664, R01-DK080726 and R01-HD46113). Dr. Laiteerapong was supported by the Agency for Healthcare Research and Quality, T32-HS000084 and the NIDDK F32-DK-089973. Dr. Laiteerapong, Ms. John, and Dr. Huang are members of the NIDDK Diabetes and Research Training Center at the University of Chicago (grant P60-DK-20595). Investigators were also supported by NIDDK Centers for Diabetes Translation Research at Kaiser Permanente and University of California, San Francisco (P30 DK092924) and the University of Chicago (P30 DK092949). The funding organization had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. NR 45 TC 18 Z9 18 U1 3 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2012 VL 27 IS 12 BP 1674 EP 1681 DI 10.1007/s11606-012-2132-3 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 050RR UT WOS:000312072200017 PM 22854982 ER PT J AU Enguidanos, S Vesper, E Lorenz, K AF Enguidanos, Susan Vesper, Evie Lorenz, Karl TI 30-Day Readmissions among Seriously III Older Adults SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID HOSPITAL PALLIATIVE CARE; OF-LIFE; MEDICARE BENEFICIARIES; HEART-FAILURE; LAST YEAR; END; COSTS; DEATH; CANCER; HEALTH AB Background: Inpatient palliative consultation are generally provided to seriously ill hospitalized patients with the intent to alleviate pain and suffering and develop a plan of care for the patient. Although numerous benefits of this service have been documented, little is known about hospital readmission rates and factors associated with these readmissions. Objective: Our aim was to investigate factors associated with 30-day hospital readmission among patients receiving a consultation from an inpatient palliative care (ICP) team. Design: We conducted a retrospective cohort study. Setting/Subjects: Data from 408 managed care patients 65 years old and older were collected in 2007-2009 following an IPC consultation and subsequent hospital discharge. Measurements: IPC and medical service use records were utilized. Results: Among IPC patients, 10% of those discharged from the hospital were readmitted within 30 days. Factors associated with hospital readmission included being discharged from the hospital with no care in the home or to a nursing facility. Receipt of hospice or home-based palliative care post-discharge was associated with significantly lower odds of hospital readmission. Conclusions: This study found that receipt of palliative care following hospital discharge was an important factor in reducing 30-day hospital readmissions. Further study is needed to evaluate the effectiveness of longitudinal palliative care models in reducing 30-day hospital readmissions among seriously ill patients. C1 [Enguidanos, Susan] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA. [Vesper, Evie] Kaiser Permanente, Downey, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. RP Enguidanos, S (reprint author), Univ So Calif, Davis Sch Gerontol, 3715 McClintock Ave,Gero 228-B, Los Angeles, CA 90089 USA. EM Enguidan@usc.edu OI Enguidanos, Susan/0000-0002-5112-288X FU National Palliative Care Research Center (NPCRC) FX This study was supported in full by a career development award from the National Palliative Care Research Center (NPCRC). Evie Vesper was an employee of the health care organization at the time of the study. NR 35 TC 32 Z9 32 U1 2 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD DEC PY 2012 VL 15 IS 12 BP 1356 EP 1361 DI 10.1089/jpm.2012.0259 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 048UB UT WOS:000311937500012 PM 23045990 ER PT J AU Egan, KR Gleason, CE AF Egan, Kelly R. Gleason, Carey E. TI Longer Duration of Hormonal Contraceptive Use Predicts Better Cognitive Outcomes Later in Life SO JOURNAL OF WOMENS HEALTH LA English DT Article ID CONJUGATED EQUINE ESTROGENS; HEALTH INITIATIVE MEMORY; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; ORAL-CONTRACEPTIVES; REPLACEMENT THERAPY; ABILITIES; BRAIN; SEX; PERFORMANCE AB Background: The cognitive effects of postmenopausal hormone therapy (HT) have been studied extensively, but little is known about the relationship between premenopausal hormone use and cognition. Hormonal contraceptive use vs. nonuse may be a potential factor influencing cognitive processes in midlife. The aim of this study is to explore the effect of modification of hormone milieu through use of hormonal contraception in premenopausal women and midlife cognitive function. Methods: Subjects were 261 cognitively normal women, aged 40-65 (mean mu = 52), enrolled in the Wisconsin Registry for Alzheimer's Prevention. All women completed the Women's Health History Questionnaire and a self-report health history questionnaire and were administered a battery of neuropsychologic tests. Cognitive results were analyzed using summary scores for the domains of Verbal Ability, Visuo-spatial Ability, Working Memory, Verbal Learning & Memory, and Speed & Flexibility derived using a confirmatory factor analysis. Results: Hormonal contraceptive ever users performed significantly better than never users in the domains of Visuo-spatial Ability (mu = 0.75, 95% confidence interval [CI] 0.23-1.28, p = 0.005) and Speed & Flexibility (mu = 0.52, 95% CI -0.16-1.04, p = 0.007), with duration-dependent increases in performance, especially in ever users with >= 15 years of use. Conclusions: These data provide preliminary evidence that hormonal contraceptive use may influence cognitive outcomes, even years after use is discontinued. Hormonal contraceptive users scored better in domains of Visuo-spatial Ability and Speed & Flexibility than never users, with a duration-dependent trend. Further research is needed to explore the use of hormonal contraceptives to prevent or delay cognitive decline and to clarify the physiologic basis of this phenomenon. C1 [Egan, Kelly R.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Sci Learning Ctr, Madison, WI 53705 USA. [Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Egan, KR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Hlth Sci Learning Ctr, 750 Highland Ave, Madison, WI 53705 USA. EM kellyegan@wisc.edu RI Egan Huibregtse, Kelly/F-9947-2013 OI Egan Huibregtse, Kelly/0000-0001-5798-9743 FU National Institutes of Health (NIH) [R01 AG027161]; Wisconsin Alzheimer's Disease Research Center [NIH-NIA P50 AG033514] FX This research was supported by National Institutes of Health (NIH) Research Project grant R01 AG027161 and the Wisconsin Alzheimer's Disease Research Center (NIH-NIA P50 AG033514). We thank Drs. Whitney Wharton, Mark Sagar, Asenath LaRue, and Bruce Hermann and Ms. Janet Rowley for their hard work in coordinating and carrying out data collection. We are grateful to Dr. Norca Maritza Dowling, who conducted the factor analysis and developed the factor scores, and Dr. Ron Gangnon for his advice and guidance on statistical analysis. Thank you for the support of the staff of the William S. Middleton Memorial Veterans Hospital and to all Wisconsin Registry for Alzheimer's Prevention study participants. NR 50 TC 4 Z9 4 U1 1 U2 20 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD DEC PY 2012 VL 21 IS 12 BP 1259 EP 1266 DI 10.1089/jwh.2012.3522 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 049AT UT WOS:000311955100009 PM 22994984 ER PT J AU Maguen, S Madden, E Cohen, BE Bertenthal, D Seal, KH AF Maguen, Shira Madden, Erin Cohen, Beth Ellen Bertenthal, Daniel Seal, Karen Hope TI Time to Treatment Among Veterans of Conflicts in Iraq and Afghanistan With Psychiatric Diagnoses SO PSYCHIATRIC SERVICES LA English DT Article ID MENTAL-HEALTH-SERVICES; POSTTRAUMATIC-STRESS-DISORDER; ETHNIC DISPARITIES; GENDER-DIFFERENCES; UNITED-STATES; CARE; BARRIERS; VA; INTERVENTION; BELIEFS AB Objective: Early mental health treatment after military deployment may reduce chronic mental health problems. The authors described time to, and predictors of time to, initiation of a first primary care visit, a first mental health outpatient visit, and minimally adequate mental health care (eight or more outpatient visits within 12 months) among veterans with psychiatric diagnoses. Methods: The authors conducted a retrospective cohort analysis of medical records of veterans of the conflicts in Iraq and Afghanistan who enrolled in Veterans Affairs (VA) health care, had a psychiatric diagnosis, and had used primary or mental health outpatient care between October 7, 2001, and September 30, 2011 (N=314,717). Results: The median time from the end of the last deployment to engagement in mental health care was over two years. More than three years postdeployment, 75% of the veterans in the VA system for at least one year had not engaged in minimally adequate mental health care. There was a median lag of nearly 7.5 years between initial mental health treatment session and initiation of minimally adequate mental health care. Men waited nearly two years longer than women to initiate minimally adequate mental health care. Younger age and minority racial or ethnic status were also associated with greater time to initial mental health outpatient visit and to minimally adequate mental health care. Conclusions: Delays in initiating and completing minimally adequate mental health care by veterans using VA services highlight the importance of attending to the timing of care, particularly among newly returning veterans. (Psychiatric Services 63:1206-1212, 2012; doi: 10.1176/appi.ps.201200051) C1 [Maguen, Shira; Madden, Erin] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Cohen, Beth Ellen; Seal, Karen Hope] San Francisco VA Med Ctr, Med Serv, San Francisco, CA 94121 USA. [Bertenthal, Daniel] San Francisco VA Med Ctr, Mental Illness Res Educ & Clin Ctr, San Francisco, CA 94121 USA. [Maguen, Shira; Seal, Karen Hope] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Cohen, Beth Ellen; Seal, Karen Hope] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St,116-P, San Francisco, CA 94121 USA. EM shira.maguen@va.gov FU U.S. Department of Defense [W81XWH-08-2-0077]; VA Health Services Research and Development Career Development Award RCD [06-042] FX This research was supported by U.S. Department of Defense Concept Award Grant W81XWH-08-2-0077 and by VA Health Services Research and Development Career Development Award RCD 06-042 to Dr. Maguen. NR 29 TC 23 Z9 23 U1 0 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2012 VL 63 IS 12 BP 1206 EP 1212 DI 10.1176/appi.ps.201200051 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 049KS UT WOS:000311982500007 PM 23070131 ER PT J AU Eisen, SV Schultz, MR Mueller, LN Degenhart, C Clark, JA Resnick, SG Christiansen, CL Armstrong, M Bottonari, KA Rosenheck, RA Sadow, D AF Eisen, Susan V. Schultz, Mark R. Mueller, Lisa N. Degenhart, Curt Clark, Jack A. Resnick, Sandra G. Christiansen, Cindy L. Armstrong, Moe Bottonari, Kathryn A. Rosenheck, Robert A. Sadow, Dolly TI Outcome of a Randomized Study of a Mental Health Peer Education and Support Group in the VA SO PSYCHIATRIC SERVICES LA English DT Article ID CONTROLLED-TRIAL; CONSUMER; SERVICES; EMPOWERMENT; ILLNESS; RECOVERY AB Objectives: Study objectives were to compare mental health outcomes of a peer-led recovery group, a clinician-led recovery group, and usual treatment and to examine the effect of group attendance on outcomes. Methods: The study used a randomized design with three groups: a recovery-oriented peer-led group (Vet-to-Vet), a clinician-led recovery group, and usual treatment. The sample included 240 veterans. Recovery and mental health assessments were obtained at enrollment and three months later. Intention-to-treat analysis using mixed-model regression was performed to examine the effect of the intervention. "As treated" analysis was performed to examine the effect of group attendance. Results: There were no statistically significant differences in improvement among the groups. Across groups, depression and functioning, psychotic symptoms, and overall mental health improved significantly. Better group attendance was associated with more improvement. Conclusions: This study adds to the evidence suggesting no short-term incremental benefit (or harm) from peer services beyond usual care. (Psychiatric Services 63: 1243-1246, 2012; doi: 10.1176/appi.ps.201100348) C1 [Eisen, Susan V.; Schultz, Mark R.; Clark, Jack A.; Christiansen, Cindy L.] ENRM Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Eisen, Susan V.; Schultz, Mark R.; Clark, Jack A.; Christiansen, Cindy L.] ENRM Vet Hosp, MIRECC, Vet Integrated Serv Network 1, Bedford, MA 01730 USA. [Eisen, Susan V.; Clark, Jack A.; Christiansen, Cindy L.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Degenhart, Curt] Massachusetts Sch Profess Psychol, Boston, MA USA. [Resnick, Sandra G.] Vet Affairs VA Med Ctr, NE Program Evaluat Ctr, West Haven, CT USA. [Resnick, Sandra G.; Rosenheck, Robert A.] Yale Univ, Sch Med, New Haven, CT USA. [Armstrong, Moe] VA Connecticut Healthcare Syst, Errera Community Care Ctr, West Haven, CT USA. [Bottonari, Kathryn A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bottonari, Kathryn A.] Med Univ S Carolina, Charleston, SC USA. [Rosenheck, Robert A.] VA Connecticut Healthcare Syst, VA New England MIRECC, West Haven, CT USA. [Sadow, Dolly] MedOptions Inc, Bedford, MA USA. RP Eisen, SV (reprint author), ENRM Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd 152, Bedford, MA 01730 USA. EM susan.eisen@va.gov RI Resnick, Sandra/F-3883-2014 OI Resnick, Sandra/0000-0001-6373-1482; Clark, Jack/0000-0002-7424-1670; Christiansen, Cindy/0000-0001-9951-480X FU VA Rehabilitation Research and Development Service [D4464R] FX This study was supported by the VA Rehabilitation Research and Development Service grant D4464R. The views expressed in this report are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors thank Matthew Chinman, Ph.D., Patrick Furlong, B.A., Alexandra Howard, B.A., James Silas, B.A., and Nicole Del Vecchio, M.S., for their contribution to this research. NR 15 TC 14 Z9 14 U1 2 U2 17 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2012 VL 63 IS 12 BP 1243 EP 1246 DI 10.1176/appi.ps.201100348 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 049KS UT WOS:000311982500014 PM 23203360 ER PT J AU Skaron, A Li, K Zhou, XH AF Skaron, Annie Li, Kang Zhou, Xiao-Hua TI Statistical Methods for MRMC ROC Studies SO ACADEMIC RADIOLOGY LA English DT Article DE AUC; classification; ROC; variable selection ID DORFMAN-BERBAUM-METZ; MULTIREADER ROC; READERS; CURVES; MODEL AB Rationale and Objectives: In radiology, multireader, multicase (MRMC) receiver-operating characteristic studies are commonly used to evaluate the accuracy of diagnostic imaging systems. The special feature of an MRMC receiver-operating characteristic study requires that the same set of patients' images be examined by the same set of doctors. One main difficulty of analyzing MRMC data is a complicated correlation structure. Four commonly used methods are available for dealing with this complicated correlation structure. The authors conducted an extensive simulation study to assess the performance of these methods in finite sample sizes. They summarize the relative strengths and weaknesses of these methods and make recommendations on the use of these methods. Materials and Methods: A comprehensive simulation study was conducted to assess finite-sample performance of these methods with continuous data. The use of these methods for magnetic resonance imaging to predict extracapsular extension of prostate gland tumors is also illustrated. Results: The results indicate that when test outcomes are continuous, all four methods perform well for estimating the difference in areas under the curves for two diagnostic tests. On the basis of these results, it seems that any of these approaches is appropriate for analyzing an MRMC data set with continuous or pseudocontinuous data. Conclusions: The Dorfman-Berbaum-Metz method is the most practical analysis method to implement in a wide variety of scenarios. Also, in MRMC studies, radiologists should be encouraged to use the entire rating scale rather than tending toward a binary "diseased" or "not diseased" decision. C1 [Skaron, Annie; Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Li, Kang; Zhou, Xiao-Hua] Harbin Med Univ, Dept Biostat, Harbin, Peoples R China. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. EM azhou@uw.edu NR 16 TC 4 Z9 7 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD DEC PY 2012 VL 19 IS 12 BP 1499 EP 1507 DI 10.1016/j.acra.2012.09.005 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 044WB UT WOS:000311654800009 PM 23122569 ER PT J AU Spira, AP Rebok, GW Stone, KL Kramer, JH Yaffe, K AF Spira, Adam P. Rebok, George W. Stone, Katie L. Kramer, Joel H. Yaffe, Kristine TI Depressive Symptoms in Oldest-Old Women: Risk of Mild Cognitive Impairment and Dementia SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Depression; dementia; mild cognitive impairment; oldest-old; women ID APOLIPOPROTEIN E4 ALLELE; MINI-MENTAL STATE; ALZHEIMER-DISEASE; MAJOR DEPRESSION; LATE-LIFE; NEUROPSYCHIATRIC SYMPTOMS; INFORMANT QUESTIONNAIRE; CARDIOVASCULAR HEALTH; HIPPOCAMPAL VOLUME; ELDERLY IQCODE AB Objectives: Increasing evidence suggests that depression is a risk factor for cognitive impairment, but it is unclear if this is true among the oldest old. We determined whether elevated depressive symptoms predicted 5-year incident mild cognitive impairment (MCI) or dementia, and neuropsychological test performance among oldest-old women. Design: Prospective. Setting: Three study sites. Participants: 302 women >= 85 years (mean, 87 +/- 2). Measurements: Depressive symptoms were measured with the 15-item Geriatric Depression Scale (GDS); scores of 6 or more indicated elevated symptoms. Five years later, participants completed neuropsychological testing and clinical cognitive status was adjudicated. Results: In analyses of MCI versus normal cognition, 70% of women with GDS score 6 or more at baseline developed MCI versus 37% with GDS score less than 6. After adjustment for age, education, alcohol, and benzodiazepine use, and study site, GDS score 6 or more remained independently associated with much greater likelihood of developing MCI (multivariable odds ratio [MOR] = 3.71, 95% confidence interval (CI): 1.30-10.59). In analyses of dementia versus normal cognition, 65% of women with GDS score 6 or more developed dementia compared with 37% of those with GDS score less than 6 (MOR = 3.15, 95% CI: 1.03-9.65). Only 19% of women with GDS score 6 or more had normal cognitive status 5 years later, compared with 46% of those with GDS score less than 6 (MOR = 0.28, 95% CI: 0.11-0.73). Women with elevated depressive symptoms had worse scores on tests of global cognition and working memory. Conclusion: Elevated depressive symptoms are an important risk factor for cognitive disorders and lower cognitive performance among women living to their ninth and tenth decades. (Am J Geriatr Psychiatry 2012; 20:1006-1015) C1 [Spira, Adam P.; Rebok, George W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Kramer, Joel H.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Spira, AP (reprint author), 624 N Broadway,Hampton House,Rm 794, Baltimore, MD 21205 USA. EM aspira@jhsph.edu FU National Institutes of Health [AG026720, AG05394, AG05407, AR35582, AR35583, AR35584, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1, R01 MH086498, NIA K24 AG031155]; Alzheimer's Association [IIRG-08-88872]; National Institute on Aging [1K01AG033195]; NIMH FX This project was supported by National Institutes of Health Grants AG026720, AG05394, AG05407, AR35582, AR35583, AR35584, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1, R01 MH086498, NIA K24 AG031155, and Alzheimer's Association award IIRG-08-88872.; APS is supported by a Mentored Research Scientist Development Award (1K01AG033195) from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. KY is on the data safety monitoring board (DSMB) of the NIMH-funded CitAD trial and on DSMBs for Pfizer and Medivation trials. Other authors have no disclosures to report. NR 56 TC 18 Z9 18 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2012 VL 20 IS 12 BP 1006 EP 1015 DI 10.1097/JGP.0b013e318235b611 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 045RW UT WOS:000311715500002 PM 22015706 ER PT J AU Teng, E Tassniyom, K Lu, PH AF Teng, Edmond Tassniyom, Kanida Lu, Po H. TI Reduced Quality-of-Life Ratings in Mild Cognitive Impairment: Analyses of Subject and Informant Responses SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Cognitive; functional; mild cognitive impairment; neuropsychiatric; quality of life ID ALZHEIMERS-DISEASE SCALE; QOL-AD SCALE; NEUROPSYCHIATRIC SYMPTOMS; CLINICAL SUBTYPES; OLDER ADULTS; DEMENTIA; MCI; COMMUNITY; PATIENT; PROGRESSION AB Objectives: To determine whether quality-of-life (QOL) ratings are reduced in mild cognitive impairment (MCI) and analyze correlations between QOL ratings and cognitive, neuropsychiatric, and functional indices in MCI. Design: Cross-sectional. Setting: The Easton Center for Alzheimer's Disease Research at the University of California, Los Angeles. Participants: A total of 205 individuals who met criteria for normal cognition (n = 97) or MCI (n = 108). The MCI group included amnestic (n = 72) and nonamnestic (n = 36) MCI. Measurements: QOL was assessed using subject and informant ratings on the Quality of Life-Alzheimer's Disease (QOL-AD) scale. Cognitive performance was assessed with the National Alzheimer's Disease Coordinating Center Uniform Data Set neuropsychological battery. Neuropsychiatric symptoms were assessed with the Geriatric Depression Scale (GDS) and the Neuropsychiatric Inventory. Functional abilities were assessed with the Functional Activities Questionnaire (FAQ). Results: The normal cognition group had significantly higher QOL-AD scores than the MCI group on both subject and informant assessments. Individual item analyses indicated that the largest group differences were seen on the mood and memory items. Similar QOL-AD scores were seen in the amnestic and nonamnestic MCI subgroups. Multiple regression analyses within the MCI group indicated that QOL-AD ratings were not correlated with neuropsychological performance. Subject QOL-AD ratings were inversely correlated with GDS scores and informant QOL-AD ratings were inversely correlated with GDS, Neuropsychiatric Inventory, and FAQ scores. Conclusions: Significant declines in QOL are seen in MCI and are associated with neuropsychiatric symptoms and functional decline. Interventions targeting mood symptoms and/or instrumental activities of daily living may improve QOL in MCI. (Am J Geriatr Psychiatry 2012; 201016-1025) C1 [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Teng, Edmond; Lu, Po H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Tassniyom, Kanida] Khon Kaen Univ, Fac Med, Dept Psychiat, Khon Kaen, Thailand. RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit 116AF, Bldg 401,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [P50 AG 16570, K23 AG 028727, K08 AG 34628]; NIA [P50 AG 16570, K23 AG 028727, K08 AG 34628]; AFAR [P50 AG 16570, K23 AG 028727, K08 AG 34628]; John A. Hartford Foundation [P50 AG 16570, K23 AG 028727, K08 AG 34628]; Atlantic Philanthropies [P50 AG 16570, K23 AG 028727, K08 AG 34628]; Starr Foundation [P50 AG 16570, K23 AG 028727, K08 AG 34628]; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation FX This research was supported by grants from the National Institute on Aging (P50 AG 16570, K23 AG 028727 [to PL], and K08 AG 34628 [to ET; jointly sponsored by NIA, AFAR, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation and an anonymous donor]), the Alzheimer's Disease Research Centers of California, and the Sidell-Kagan Foundation. NR 40 TC 23 Z9 24 U1 2 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2012 VL 20 IS 12 BP 1016 EP 1025 DI 10.1097/JGP.0b013e31826ce640 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 045RW UT WOS:000311715500003 PM 23018474 ER PT J AU Munro, CA Longmire, CF Drye, LT Martin, BK Frangakis, CE Meinert, CL Mintzer, JE Porsteinsson, AP Rabins, PV Rosenberg, PB Schneider, LS Weintraub, D Lyketsos, CG AF Munro, Cynthia A. Longmire, Crystal Flynn Drye, Lea T. Martin, Barbara K. Frangakis, Constantine E. Meinert, Curtis L. Mintzer, Jacobo E. Porsteinsson, Anton P. Rabins, Peter V. Rosenberg, Paul B. Schneider, Lon S. Weintraub, Daniel Lyketsos, Constantine G. CA Depression Alzheimer's Dis Study-2 TI Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer disease; clinical trial; cognitive; depression; neuropsychology; sertraline ID EXECUTIVE DYSFUNCTION; MAJOR DEPRESSION; LATE-LIFE; SERTRALINE; PREDICTORS; CRITERIA AB Objectives: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo. Design: Placebo-controlled, randomized, double-blind trial. Setting: Outpatient memory clinics at five academic medical centers in the United States. Participants: A total of 131 patients with dAD (60 men) and Mini-Mental State Examination scores of 10-26. Intervention: Sertraline (n = 67), target dose of 100 mg daily or matching placebo (n = 64). Caregivers received standardized psychosocial intervention throughout the trial. Measurements: Mini-Mental State Examination, cognitive subscale of the Alzheimer's Disease Assessment Scale, letter fluency, backward digit span, Symbol Digit Modalities Test, and Finger Tapping Test, administered at baseline, and 8, 16, and 24 weeks following baseline. Results: A series of linear models indicated no effect of treatment or of depression remission on cognitive test performance at 24 weeks. Regardless of treatment condition, very little change in cognitive test performance was noted in general. Conclusions: Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo. (Am J Geriatr Psychiatry 2012; 20:1036-1044) C1 [Munro, Cynthia A.; Rabins, Peter V.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Sch Med, Baltimore, MD USA. [Drye, Lea T.; Martin, Barbara K.; Frangakis, Constantine E.; Meinert, Curtis L.; Lyketsos, Constantine G.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Longmire, Crystal Flynn; Mintzer, Jacobo E.] Med Univ S Carolina, Charleston, SC USA. [Longmire, Crystal Flynn; Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med, Rochester, NY USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Weintraub, Daniel] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Munro, CA (reprint author), Johns Hopkins Univ Hosp, Dept Psychiat & Behav Sci, 600 N Wolfe St,Meyer 218, Baltimore, MD 21287 USA. EM cmunro@jhmi.edu OI Drye, Lea/0000-0002-2964-1878 FU National Institute of Mental Health [1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066176, 1U01MH066177]; Pfizer; Merck; Wyeth; Lilly; Boehringer Ingelheim; Eli Lilly [PF04494700]; Forest FX This study was supported by National Institute of Mental Health grants 1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066176, and 1U01MH066177. NIMH scientific collaborators participated on the trial's Steering Committee.; These disclosures include any anticipated conflicts through 9/31/11, according to the DIADS-2 Conflict of Interest Policy (available upon request from the study PI). Barbara Martin is involved in another trial for which Pfizer donated a different drug. Paul Rosenberg has received research funds from Pfizer and Merck in amounts greater than $10,000. Jacobo Mintzer is a current grant recipient for Wyeth, Lilly, and Pfizer. Daniel Weintraub has received research support from Boehringer Ingelheim; Dr. Weintraub has also been a paid consultant for Acadia Pharmaceuticals, Novartis Pharmaceuticals, Boehringer Ingelheim, Osmotica Pharmaceutical, BrainCells Inc., EMD Serono, and Sanofi Aventis, and has participated on a Speaker's Bureau for Pfizer. Anton Porsteinsson is involved in research sponsored by Pfizer to study donepezil and PF04494700, Eli Lilly to study atomoxetine, a gamma-secretase inhibitor and a beta amyloid antibody, Wyeth to study a beta amyloid antibody, GSK to study a PPAR inhibitor and Forest to study memantine and neramexane; Dr. Porsteinsson has been a paid consultant and participated on a Speaker's Bureau for Pfizer and Forest. Lon S. Schneider is involved in research sponsored by Pfizer, the manufacturer of sertraline and other drugs used to treatmood disorders; Dr. Schneider has been a paid consultant for Abbott, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Johnson and Johnson, Lundbeck, Merck, and Wyeth, manufacturers of antidepressants or drugs used to treat mood disorders. Constantine Frangakis and Lea Drye have no conflict of interests. Peter Rabins has participated on Speaker's Bureaus for Wyeth, Eli Lilly, and Pfizer for more than 2 years. He has provided legal testimony for Janssen Pharmaceutica. Cynthia Munro has no conflict of interests. Curtis Meinert is involved in another trial for which Pfizer donated a different drug; Dr. Meinert owns shares of GSK stock. Constantine Lyketsos was involved in another trial for which Pfizer donated a different drug; he was also involved in research sponsored by Forest to study escitalopram and citalopram and Pfizer to study sertraline and donepezil. Dr. Lyketsos served as a consultant for Organon, Eisai, GSK, Lilly, Wyeth, and Pfizer. NR 32 TC 20 Z9 20 U1 0 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2012 VL 20 IS 12 BP 1036 EP 1044 DI 10.1097/JGP.0b013e31826ce4c5 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 045RW UT WOS:000311715500005 PM 23032478 ER PT J AU Myaskovsky, L Posluszny, DM Schulz, R DiMartini, AF Switzer, GE Dabbs, AD McNulty, ML Kormos, RL Toyoda, Y Dew, MA AF Myaskovsky, L. Posluszny, D. M. Schulz, R. DiMartini, A. F. Switzer, G. E. Dabbs, A. DeVito McNulty, M. L. Kormos, R. L. Toyoda, Y. Dew, M. A. TI Predictors and Outcomes of Health-Related Quality of Life in Caregivers of Cardiothoracic Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Cardiothoracic transplant; caregivers; psychosocial resources; quality of life ID LUNG-TRANSPLANT; HEART-TRANSPLANT; FAMILY CAREGIVERS; PSYCHOLOGICAL DISTRESS; LIVER-TRANSPLANTATION; COPING STRATEGIES; SOCIAL SUPPORT; CANDIDATES; EXPERIENCE; SPOUSES AB Cardiothoracic transplant programs generally require that transplant recipients have family caregivers to assist them posttransplant. The burden of caregiving on the family members remains poorly understood. If caregivers well-being is compromised by caregiving, it may bode poorly for transplant recipients own health in the long-term posttransplant. We examined caregiver health-related quality of life (HRQOL) during the first year after their family member's transplant, its predictors and its relationship to subsequent patient survival. Adult (aged 18+) caregivers of 242 cardiothoracic transplant recipients (lung = 134; heart = 108) completed assessments of demographics, psychosocial characteristics and caregiver burden at 2 months posttransplant, and HRQOL at 2, 7 and 12 months posttransplant. Recipients survival time was obtained from medical records. Caregiver HRQOL was generally high across the first-year posttransplant in emotional and social functioning; caregiver physical functioning significantly worsened. There were no differences by type of recipient transplant. Greater caregiver burden predicted poorer caregiver HRQOL in several physical domains at 12 months posttransplant. Transplant recipients whose caregivers had lower perceived general health at 12 months posttransplant showed poorer survival rates during the subsequent 7 years of follow up. Transplant teams should identify those caregivers at risk for poorer general health posttransplant to maximize positive outcomes for the entire family. C1 [Myaskovsky, L.; Switzer, G. E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA. [Myaskovsky, L.; Posluszny, D. M.; Switzer, G. E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Myaskovsky, L.; Schulz, R.; DiMartini, A. F.; Switzer, G. E.; McNulty, M. L.; Dew, M. A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Schulz, R.; Dew, M. A.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Schulz, R.] Univ Pittsburgh, Dept Sociol Community Hlth & Hlth & Rehabil Sci, Pittsburgh, PA USA. [DiMartini, A. F.; Kormos, R. L.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Dabbs, A. DeVito] Univ Pittsburgh, Sch Nursing, Dept Acute & Tertiary Care, Pittsburgh, PA 15261 USA. [Toyoda, Y.] Temple Univ, Sch Med, Dept Surg, Pittsburgh, PA USA. [Dew, M. A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Dew, M. A.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA. EM larissa.myaskovsky@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [IIR-06-220]; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK081325]; National Institute of Mental Health [R01 MH59229] FX Work on this manuscript was supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (IIR-06-220; Myaskovsky, PI), the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081325; Myaskovsky, PI) and the National Institute of Mental Health (R01 MH59229; Dew, PI). NR 66 TC 7 Z9 7 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD DEC PY 2012 VL 12 IS 12 BP 3387 EP 3397 DI 10.1111/j.1600-6143.2012.04243.x PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA 047QE UT WOS:000311854800023 PM 22958758 ER PT J AU Morton, LM Gilbert, ES Hall, P Andersson, M Joensuu, H Vaalavirta, L Dores, GM Stovall, M Holowaty, EJ Lynch, CF Curtis, RE Smith, SA Kleinerman, RA Kaijser, M Storm, HH Pukkala, E Weathers, RE Linet, MS Rajaraman, P Fraumeni, JF Brown, LM van Leeuwen, FE Fossa, SD Johannesen, TB Langmark, F Lamart, S Travis, LB Aleman, BMP AF Morton, L. M. Gilbert, E. S. Hall, P. Andersson, M. Joensuu, H. Vaalavirta, L. Dores, G. M. Stovall, M. Holowaty, E. J. Lynch, C. F. Curtis, R. E. Smith, S. A. Kleinerman, R. A. Kaijser, M. Storm, H. H. Pukkala, E. Weathers, R. E. Linet, M. S. Rajaraman, P. Fraumeni, J. F., Jr. Brown, L. M. van Leeuwen, F. E. Fossa, S. D. Johannesen, T. B. Langmark, F. Lamart, S. Travis, L. B. Aleman, B. M. P. TI Risk of treatment-related esophageal cancer among breast cancer survivors SO ANNALS OF ONCOLOGY LA English DT Article DE breast cancer; esophageal cancer; radiotherapy; second cancer ID LUNG-CANCER; RANDOMIZED-TRIALS; RADIATION-THERAPY; 15-YEAR SURVIVAL; HODGKINS-DISEASE; RADIOTHERAPY; MALIGNANCIES; WOMEN; ADENOCARCINOMA; CHEMOTHERAPY AB Radiotherapy for breast cancer may expose the esophagus to ionizing radiation, but no study has evaluated esophageal cancer risk after breast cancer associated with radiation dose or systemic therapy use. Nested case-control study of esophageal cancer among 289 748 >= 5-year survivors of female breast cancer from five population-based cancer registries (252 cases, 488 individually matched controls), with individualized radiation dosimetry and information abstracted from medical records. The largest contributors to esophageal radiation exposure were supraclavicular and internal mammary chain treatments. Esophageal cancer risk increased with increasing radiation dose to the esophageal tumor location (P-trend < 0.001), with doses of >= 35 Gy associated with an odds ratio (OR) of 8.3 [95% confidence interval (CI) 2.7-28]. Patients with hormonal therapy < 5 years preceding esophageal cancer diagnosis had lower risk (OR = 0.4, 95% CI 0.2-0.8). Based on few cases, alkylating agent chemotherapy did not appear to affect risk. Our data were consistent with a multiplicative effect of radiation and other esophageal cancer risk factors (e.g. smoking). Esophageal cancer is a radiation dose-related complication of radiotherapy for breast cancer, but absolute risk is low. At higher esophageal doses, the risk warrants consideration in radiotherapy risk assessment and long-term follow-up. C1 [Morton, L. M.; Gilbert, E. S.; Dores, G. M.; Curtis, R. E.; Kleinerman, R. A.; Linet, M. S.; Rajaraman, P.; Fraumeni, J. F., Jr.; Lamart, S.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Rockville, MD 20892 USA. [Hall, P.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Andersson, M.] Copenhagen Univ Hosp, Dept Oncol, Copenhagen, Denmark. [Joensuu, H.; Vaalavirta, L.] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland. [Dores, G. M.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Stovall, M.; Smith, S. A.; Weathers, R. E.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA. [Holowaty, E. J.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Lynch, C. F.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Kaijser, M.] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden. [Storm, H. H.] Danish Canc Soc, Copenhagen, Denmark. [Pukkala, E.] Finnish Canc Registry, Inst Stat & Epidemiol Canc Res, FIN-00170 Helsinki, Finland. [Brown, L. M.] RTI Int, Stat & Epidemiol, Rockville, MD USA. [van Leeuwen, F. E.] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands. [Fossa, S. D.] Oslo Univ Hosp, Dept Oncol, Oslo, Norway. [Fossa, S. D.] Univ Oslo, Oslo, Norway. [Johannesen, T. B.; Langmark, F.] Canc Registry Norway, Oslo, Norway. [Travis, L. B.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14627 USA. [Aleman, B. M. P.] Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands. RP Morton, LM (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, DHHS, 6120 Execut Blvd,EPS 7040,MSC 7238, Rockville, MD 20892 USA. EM mortonli@mail.nih.gov RI Morton, Lindsay/B-5234-2015 OI Morton, Lindsay/0000-0001-9767-2310; Joensuu, Heikki/0000-0003-0281-2507; Storm, Hans/0000-0001-7223-8198; Kleinerman, Ruth/0000-0001-7415-2478 FU National Cancer Institute, National Institutes of Health, Department of Health and Human Services; National Cancer Institute [NO1-CP-31157]; Danish Cancer Society, Copenhagen, Denmark [NO1-CP-31019]; Finnish Cancer Registry, Helsinki, Finland [NO1-CP-31154]; Information Management Services, Inc., Silver Spring, USA [N01-CP-31003]; Karolinska Institute, Stockholm, Sweden [NO1-CP-31156]; University of Iowa, Iowa City, USA [NO1-CP-31155]; University of Texas MD Anderson Cancer Center, Houston, USA [N02-CP-55503]; Westat, Inc., Rockville, USA [N02-CP-31136] FX This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, and National Cancer Institute contracts to Cancer Care Ontario, Toronto, Canada (NO1-CP-31157); Danish Cancer Society, Copenhagen, Denmark (NO1-CP-31019); Finnish Cancer Registry, Helsinki, Finland (NO1-CP-31154); Information Management Services, Inc., Silver Spring, USA (N01-CP-31003); Karolinska Institute, Stockholm, Sweden (NO1-CP-31156); University of Iowa, Iowa City, USA (NO1-CP-31155); The University of Texas MD Anderson Cancer Center, Houston, USA (N02-CP-55503); and Westat, Inc., Rockville, USA (N02-CP-31136). NR 42 TC 21 Z9 21 U1 0 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD DEC PY 2012 VL 23 IS 12 BP 3081 EP 3091 DI 10.1093/annonc/mds144 PG 11 WC Oncology SC Oncology GA 044RX UT WOS:000311642100013 PM 22745217 ER PT J AU Roussos, P Katsel, P Davis, KL Siever, LJ Haroutunian, V AF Roussos, Panos Katsel, Pavel Davis, Kenneth L. Siever, Larry J. Haroutunian, Vahram TI A System-Level Transcriptomic Analysis of Schizophrenia Using Postmortem Brain Tissue Samples SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID GENOME-WIDE ASSOCIATION; MILD ALZHEIMER-DISEASE; NETWORK ANALYSIS; GENE-EXPRESSION; MICROARRAYS; DISORDER; OLIGODENDROCYTES; ABNORMALITIES; METAANALYSIS; PATHWAYS AB Context: Schizophrenia is a common, highly heritable, neurodevelopmental mental illness, characterized by genetic heterogeneity. Objective: To identify abnormalities in the transcriptome organization among older persons with schizophrenia and controls. Design: Weighted gene coexpression network analysis based on microarray transcriptomic profiling. Setting: Research hospital. Patients: Postmortem brain tissue samples from 4 different cerebrocortical regions (the dorsolateral prefrontal cortex, the middle temporal area, the temporopolar area, and the anterior cingulate cortex) from 21 persons with schizophrenia and 19 controls. Main Outcome Measures: Results from gene expression microarray analysis, from analysis of coexpression networks, and from module eigengene, module preservation, and enrichment analysis of schizophrenia-related genetic variants. Results: The oligodendrocyte, microglial, mitochondrial, and neuronal (GABAergic and glutamatergic) modules were associated with disease status. Enrichment analysis of genome-wide association studies in schizophrenia and other illnesses demonstrated that the neuronal (GABAergic and glutamatergic) and oligodendrocyte modules are enriched for genetically associated variants, whereas the microglial and mitochondrial modules are not, providing independent support for more direct involvement of these gene expression networks in schizophrenia. Interregional coexpression network analysis showed that the gene expression patterns that typically differentiate the frontal, temporal, and cingulate cortices in controls diminish significantly in persons with schizophrenia. Conclusions: These results support the existence of convergent molecular abnormalities in schizophrenia, providing a molecular neuropathological basis for the disease. C1 [Roussos, Panos; Katsel, Pavel; Davis, Kenneth L.; Siever, Larry J.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Roussos, Panos; Siever, Larry J.; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Haroutunian, V (reprint author), Mt Sinai Sch Med, Dept Psychiat, Room 4F-33,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU National Institutes of Health [MH066392, MH064673]; Veterans Administration Mental Illness Research, Education; Clinical Centers award; Clinical Merit award FX This work was supported by National Institutes of Health grants MH066392 and MH064673 (to Dr Haroutunian) and by Veterans Administration Mental Illness Research, Education, and Clinical Centers and Merit awards (to Drs Siever and Haroutunian, respectively). NR 38 TC 31 Z9 31 U1 0 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD DEC PY 2012 VL 69 IS 12 BP 1205 EP 1215 DI 10.1001/archgenpsychiatry.2012.704 PG 11 WC Psychiatry SC Psychiatry GA 046ZL UT WOS:000311804500003 PM 22868662 ER PT J AU Brawner, BM AF Brawner, Bridgette M. TI Attitudes and Beliefs Regarding Depression, HIV/AIDS, and HIV Risk-Related Sexual Behaviors Among Clinically Depressed African American Adolescent Females SO ARCHIVES OF PSYCHIATRIC NURSING LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; REDUCTION INTERVENTIONS; PLANNED BEHAVIOR; PREDICTORS; COMMUNICATION; KNOWLEDGE; SYMPTOMS; VALIDITY; GIRLS AB Individuals' attitudes and beliefs toward behaviors are key indicators of behavioral performance. The purposes of this study were to elucidate attitudes and beliefs about depression, HIV/AIDS, and HIV risk-related sexual behaviors among clinically depressed African American adolescent females and to develop an understanding of their context for HIV risk. For this descriptive qualitative inquiry, semistructured interviews and surveys were employed (N=24). The narratives reveal that behavioral sequelae of depression (i.e., loneliness) can produce risk for HIV. These findings may guide psychiatric nurse educators, scientists, and practitioners to modify HIV risk among clinically depressed African American adolescent females. (C) 2012 Elsevier Inc. All rights reserved. C1 Univ Penn, Ctr Hlth Equ Res, Sch Nursing, Philadelphia, PA 19104 USA. RP Brawner, BM (reprint author), Univ Penn, Ctr Hlth Equ Res, Sch Nursing, 418 Curie Blvd,Floor 2L,Room 236, Philadelphia, PA 19104 USA. EM brawnerb@nursing.upenn.edu FU Substance Abuse and Mental Health Services Administration at the American Nurses Association Minority Fellowship Program [5 SM058566-02]; Hampton-Penn Center for Health Disparities Research [NINR P20NR008361]; Fontaine Society Fellowship at the University of Pennsylvania FX Funding for this research was provided by the Substance Abuse and Mental Health Services Administration at the American Nurses Association Minority Fellowship Program (5 SM058566-02), the Hampton-Penn Center for Health Disparities Research (NINR P20NR008361), and the Fontaine Society Fellowship at the University of Pennsylvania. NR 39 TC 0 Z9 0 U1 1 U2 13 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9417 J9 ARCH PSYCHIAT NURS JI Arch. Psychiatr. Nurs. PD DEC PY 2012 VL 26 IS 6 BP 464 EP 476 DI 10.1016/j.apnu.2012.06.003 PG 13 WC Nursing; Psychiatry SC Nursing; Psychiatry GA 047CD UT WOS:000311814400005 PM 23164403 ER PT J AU Suzuki, E Karam, E Williams, S Watson, DK Gilkeson, G Zhang, XK AF Suzuki, Eiji Karam, Eva Williams, Sarah Watson, Dennis K. Gilkeson, Gary Zhang, Xian K. TI Fli-1 transcription factor affects glomerulonephritis development by regulating expression of monocyte chemoattractant protein-1 in endothelial cells in the kidney SO CLINICAL IMMUNOLOGY LA English DT Article DE Glomerulonephritis; Inflammatory chemokines; Infiltrations; Transcription factors ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; NF-KAPPA-B; RENAL-DISEASE; ETS FAMILY; CHEMOKINE RECEPTOR; MRL-FAS(LPR) MICE; GENE-EXPRESSION; NEPHRITIS; MCP-1; INFLAMMATION AB Expression of transcription factor Fli-1 is implicated in the development of glomerulonephritis. Fli-1 heterozygous knockout (Fli1(+/-)) NZM2410 mice, a murine model of lupus, had significantly improved survival and reduced glomerulonephritis. In this study, we found that infiltrated inflammatory cells were significantly decreased in the kidneys from NZM2410 mice. The expression of monocyte chemoattractant protein-1 (MCP-1) was significantly decreased in kidneys from Fli-1(+/-) NZM2410 mice. The primary endothelial cells isolated from the kidneys of Fli-1(+/-)NZM2410 mice produced significantly less MCP-1. In endothelial cells transfected with specific Fli-1 siRNA the production of MCP-1 was significantly reduced compared to cells transfected with negative control siRNA. By Chromatin Immunoprecipitation (ChIP) assay, we further demonstrated that Fli-1 directly binds to the promoter of the MCP-1 gene. Our data indicate that Fli-1 impacts glomerulonephritis development by regulating expression of inflammatory chemokine MCP-1 and inflammatory cell infiltration in the kidneys in the NZM2410 mice. Published by Elsevier Inc. C1 [Suzuki, Eiji; Karam, Eva; Gilkeson, Gary; Zhang, Xian K.] Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA. [Williams, Sarah; Gilkeson, Gary; Zhang, Xian K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. [Watson, Dennis K.] Med Univ S Carolina, Dept Lab Med & Pathol, Charleston, SC 29425 USA. RP Zhang, XK (reprint author), Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Suite 912,96 Jonathan Lucas St,MSC637, Charleston, SC 29425 USA. EM zhangjo@musc.edu FU National Institutes of Health [R01AR056670]; Medical Research Service, Department of Veterans Affairs FX This study was supported in part by National Institutes of Health grants (R01AR056670 to X.K.Z.) and the Medical Research Service, Department of Veterans Affairs (to G.G. and X.K.Z.). We thank Mr. Jeremy Mathenia and Mr. Emanuel Reyes-Cortes for their excellent technical supports. NR 50 TC 14 Z9 14 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD DEC PY 2012 VL 145 IS 3 BP 201 EP 208 DI 10.1016/j.clim.2012.09.006 PG 8 WC Immunology SC Immunology GA 044YQ UT WOS:000311661500003 PM 23108091 ER PT J AU Hegde, M Santos-Sanchez, C Hess, CP Kabir, AA Garcia, PA AF Hegde, Manu Santos-Sanchez, Carlos Hess, Christopher P. Kabir, Arif A. Garcia, Paul A. TI Seizure exacerbation in two patients with focal epilepsy following marijuana cessation SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy, partial; Cannabis; Marijuana smoking; Tetrahydocannabinol; Cannabidiol ID TEMPORAL-LOBE EPILEPSY; ENDOCANNABINOID SYSTEM; IN-VIVO; CANNABIDIOL; ACTIVATION; MODEL AB While animal models of epilepsy suggest that exogenous cannabinoids may have anticonvulsant properties, scant evidence exists for these compounds' efficacy in humans. Here, we report on two patients whose focal epilepsy was nearly controlled through regular outpatient marijuana use. Both stopped marijuana upon admission to our epilepsy monitoring unit (EMU) and developed a dramatic increase in seizure frequency documented by video-EEG telemetry. These seizures occurred in the absence of other provocative procedures, including changes to anticonvulsant medications. We review these cases and discuss mechanisms for the potentially anticonvulsant properties of cannabis, based on a review of the literature. Published by Elsevier Inc. C1 [Hegde, Manu; Santos-Sanchez, Carlos; Garcia, Paul A.] Univ Calif San Francisco, Epilepsy Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Hess, Christopher P.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Hegde, Manu; Kabir, Arif A.] San Francisco VA Med Ctr, Epilepsy Ctr Excellence, San Francisco, CA USA. RP Hegde, M (reprint author), Univ Calif San Francisco, Epilepsy Ctr, Dept Neurol, 521 Parnassus Ave,Room C-440, San Francisco, CA 94143 USA. EM manu.hegde@ucsf.edu OI Hess, Christopher/0000-0002-5132-5302 NR 17 TC 13 Z9 13 U1 0 U2 19 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD DEC PY 2012 VL 25 IS 4 BP 563 EP 566 DI 10.1016/j.yebeh.2012.09.024 PG 4 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 046SH UT WOS:000311784200017 PM 23159379 ER PT J AU Fung, SJ Xi, MC Zhang, JH Sampogna, S Chase, MH AF Fung, Simon J. Xi, MingChu Zhang, JianHua Sampogna, Sharon Chase, Michael H. TI Apnea produces excitotoxic hippocampal synapses and neuronal apoptosis SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Hypoxia; Rat model; Obstructive sleep apnea; CA1; fEPSP; Excitotoxicity; Neurodegeneration; Plasticity; Cognitive processes ID OBSTRUCTIVE SLEEP-APNEA; PAIRED-PULSE FACILITATION; SYNAPTIC-TRANSMISSION; INTERMITTENT HYPOXIA; CA1 REGION; LONG-TERM; POSTSYNAPTIC MECHANISMS; BRAIN MORPHOLOGY; NMDA RECEPTORS; CARBON-DIOXIDE AB Obstructive sleep apnea (OSA) results in the degeneration of neurons in the hippocampus that eventuates in neurocognitive deficits. We were therefore interested in determining the effects of apnea on monosynaptic excitatory processes in a hippocampal pathway (cornu ammonis 3-cornu ammonis 1, CA3-CA1) that has been shown to mediate the processing of cognitive information. In addition, to substantiate an anatomical basis for the cognitive dysfunction that occurs in OSA patients, we examined the effects of apnea with respect to neurodegenerative changes (apoptosis) in the same hippocampal pathway. In order to determine the effects of apnea, an automated system for the generation and analysis of single and recurrent periods of apnea was developed. Utilizing this system, the field excitatory postsynaptic potential (fEPSP) generated by pyramidal neurons in the CA1 region of the hippocampus was monitored in alpha-chloralose anesthetized rats following stimulation of glutamatergic afferents in the CA3 region. A stimulus-response (input-output) curve for CA3-CA1 synaptic activity was determined. In addition, a paired-pulse paradigm was employed to evaluate, electrophysiologically, the presynaptic release of glutamate. Changes in the synaptic efficacy were assessed following single episodes of apnea induced by ventilatory arrest (60 to 80 s duration, mean = 72 s; mean oxygen desaturation was 53% of normoxia level). Apnea resulted in a significant potentiation of the amplitude (mean = 126%) and slope (mean = 117%) of the baseline CA1 fEPSP. This increase in the fEPSP was accompanied by a significant decrease in the amplitude (71%) and slope (81%) of normalized paired-pulse facilitation (PPF) ratios. Since the potentiation of the fEPSP is inversely proportional to changes in PPF ratio, the potentiated fEPSP accompanied by the reduced PPF reveals that apnea produces an abnormal increase in the preterminal release of glutamate that results in the over-activation (and calcium overloading) of hippocampal CA1 neurons. Thus, we conclude that individual episodes of apnea result in the development of excitotoxic processes in the hippocampal CA3-CA1 pathway that is critically involved in the processing of cognitive information. Morphologically, the deleterious effect of recurrent apnea was substantiated by the finding of apoptosis in CA1 neurons of apneic (but not normoxic) animals. (C) 2012 Elsevier Inc. All rights reserved. C1 [Fung, Simon J.; Xi, MingChu; Zhang, JianHua; Sampogna, Sharon; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA. [Fung, Simon J.; Xi, MingChu; Zhang, JianHua; Chase, Michael H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. RP Fung, SJ (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM sfung@websciences.org FU [1|01BX000819]; [TCS-109219] FX This work was supported by grants 1|01BX000819 and TCS-109219. The authors gratefully acknowledge the expert technical assistance of Vince Lim and John Lopatto. We are indebted to Johnathan Lim for his successful development of the Automated Recurrent Apnea Program which was adopted to regulate the apnea protocols in this study. NR 51 TC 8 Z9 11 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD DEC PY 2012 VL 238 IS 2 BP 107 EP 113 DI 10.1016/j.expneurol.2012.08.006 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 046KE UT WOS:000311763100004 PM 22921462 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Emerging therapies for gout SO EXPERT OPINION ON EMERGING DRUGS LA English DT Review DE emerging therapies; gout; hyperuricemia; rilonacept; canakinumab; lesinurad ID QUALITY-OF-LIFE; EVIDENCE BASED RECOMMENDATIONS; RHEUMATOLOGY GUIDELINES; ACUTE FLARES; TASK-FORCE; PHASE-II; MANAGEMENT; ARTHRITIS; HYPERURICEMIA; HEALTH AB Introduction: Gout is the commonest inflammatory arthritis in adults that affects 4% of the US population. Gout is symptomatic, leading to joint pain and inflammation, frequent acute flares associated with disability, pain and suffering. When not treated optimally, chronic inflammation can lead to chronic pain, joint destruction and deformities and decrements in function and quality of life. Areas covered: Different therapeutic strategies that are being developed in preclinical and clinical settings are discussed. Expert opinion: Multiple new treatment approaches have emerged for gout. Several target acute inflammation of gout flares by inhibiting interleukin-1, either with an antibody or with a molecule that traps interleukin-1. Two drugs in this category are rilonacept and canakinumab. Similarly, new approaches targeting and increasing urate excretion by the kidney are emerging. One such promising drug is lesinurad that decreases serum urate through inhibition of the uric acid transporter (URAT1) in the proximal tubule of the kidney. We hope these and other new treatments and new strategies for gout will lead to additional options. The expansion of the armamentarium for gout treatment will allow clinicians and patients to increase the chances to have gout remission. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Rheumatol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institute of Aging; National Cancer Institute; National Institute of Arthritis and Musculoskeletal Diseases (NIAMS); Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); Birmingham VA Medical Center, Alabama, USA; Takeda; Savient; Ardea; Regeneron; Allergan; URL pharmaceuticals; Novartis FX JA Singh is supported by research grants from National Institute of Aging, National Cancer Institute, National Institute of Arthritis and Musculoskeletal Diseases (NIAMS), Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), and the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA. No funding was received for this manuscript. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis. JA Singh is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. NR 38 TC 4 Z9 4 U1 0 U2 22 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1472-8214 EI 1744-7623 J9 EXPERT OPIN EMERG DR JI Expert Opin Emerg. Drugs PD DEC PY 2012 VL 17 IS 4 BP 511 EP 518 DI 10.1517/14728214.2012.736488 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 044OX UT WOS:000311631100006 PM 23126250 ER PT J AU Sung, RK Massie, BM Varosy, PD Moore, H Rumsfeld, J Lee, BK Keung, E AF Sung, Raphael K. Massie, Barry M. Varosy, Paul D. Moore, Hans Rumsfeld, John Lee, Byron K. Keung, Edmund TI Long-term electrical survival analysis of Riata and Riata ST silicone leads: National Veterans Affairs experience SO HEART RHYTHM LA English DT Article DE ICD; High-voltage leads; Lead failure; Ventricular tachycardia; Lead extraction ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SINGLE-CENTER; PERFORATION; FAILURE; SHOCKS AB BACKGROUND A medical device advisory issued by St Jude Medical in November 2011 estimated 0.63% all-cause abrasion rate on their Riata and Riata ST silicone high-voltage lead families (Riata/ST), leading to Food and Drug Administration class I recall. We performed an independent comparative, long-term electrical survival analysis of Riata/ST and 3 other high-voltage lead families in a large national cohort of patients. OBJECTIVE To evaluate long-term electrical survival of Riata/ST leads relative to other commonly evaluated high-voltage leads. METHODS Failure rates of Riata/ST, Sprint Quattro Secure (Quattro), Sprint Fidelis (Fidelis), and Endotak Reliance G/SG (Endotak) leads from the Veterans Administration's National Cardiac Device Surveillance Center database, consisting of 24,145 patients with remote transmissions since 2003, were analyzed. Survival Probabilities were determined with Kaplan-Meier survival analysis and compared using the log-rank test. RESULTS Of 1,403 Riata/ST, 6,091 Quattro, 5,073 Fidelis, and 2,401 Endotak leads identified, 5-year survival probability of Riata/ST leads (97.5%) was significantly lower than that of Quattro (99.3%) and Endotak (99.4%) leads (P < .0001) but higher than that of Fidelis leads (89.6%) (P < .0001). Riata ST leads showed a 5-year survival of 95.5% (95% confidence interval 92.4-97.4) compared to 98.4% (95% confidence interval 97.1-99.1) in Riata leads (P = .003). CONCLUSIONS There is decreased survival probability of Riata/ST leads compared to other contemporary high-voltage leads, with decreased survival of Riata ST silicone compared to Riata lead series. Careful long-term follow-up should be maintained in patients with Riata/ST leads in order to prevent inappropriate shocks or failed device interventions. Our results were determined in advance of Food and Drug Administration class I recall, which suggested that large-scale remote monitoring may be an effective tool for continued implantable cardioverter-defibrillator system surveillance. C1 [Massie, Barry M.; Keung, Edmund] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA 94121 USA. [Sung, Raphael K.; Lee, Byron K.] Univ Calif San Francisco, Dept Med, Div Cardiol, Electrophysiol Sect, San Francisco, CA 94143 USA. [Varosy, Paul D.; Rumsfeld, John] Univ Colorado, VA Eastern Colorado Hlth Care Syst, Cardiovasc Outcomes Res CCOR Grp, Denver, CO 80202 USA. [Moore, Hans] Washington DC VA Med Ctr, Div Cardiol, Washington, DC USA. [Moore, Hans; Keung, Edmund] VA Natl Cardiac Device Surveillance Program, San Francisco, CA USA. [Moore, Hans; Keung, Edmund] VA Natl Cardiac Device Surveillance Program, Washington, DC USA. RP Keung, E (reprint author), San Francisco VA Med Ctr, Div Cardiol, 4150 Clement Str, San Francisco, CA 94121 USA. EM edmund.keung@ucsf.edu FU VA's Health Services Research and Development Service [IIR 04-046]; Biotronik; Medtronic FX This study was funded by the VA's Health Services Research and Development Service Research Grant IIR 04-046 (to Dr Massie). Dr Lee received moderate consulting fees and honorarium from Biotronik and moderate research funding from Medtronic. Address reprint requests and correspondence: Dr Edmund Keung, MD, Division of Cardiology, San Francisco VA Medical Center, 4150 Clement Str, San Francisco, CA 94121. E-mail address: edmund.keung@ucsf.edu. NR 18 TC 41 Z9 42 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD DEC PY 2012 VL 9 IS 12 BP 1954 EP 1961 DI 10.1016/j.hrthm.2012.08.006 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 046VG UT WOS:000311791900017 PM 22871583 ER PT J AU Dunlap, J Beadling, C Warrick, A Neff, T Fleming, WH Loriaux, M Heinrich, MC Kovacsovics, T Kelemen, K Leeborg, N Gatter, K Braziel, RM Press, R Corless, CL Fan, G AF Dunlap, Jennifer Beadling, Carol Warrick, Andrea Neff, Tanaya Fleming, William H. Loriaux, Marc Heinrich, Michael C. Kovacsovics, Tibor Kelemen, Katalin Leeborg, Nicky Gatter, Ken Braziel, Rita M. Press, Richard Corless, Christopher L. Fan, Guang TI Multiplex high-throughput gene mutation analysis in acute myeloid leukemia SO HUMAN PATHOLOGY LA English DT Article DE Acute myeloid leukemia; Molecular; Genetics; Gene mutation ID INTERNAL TANDEM DUPLICATION; AML; IDH1; FLT3; DIAGNOSIS; PROGNOSIS; CANCER; COHORT; IMPACT AB Classification of acute myeloid leukemia increasingly depends on genetic analysis. However, the number of known mutations in acute myeloid leukemia is expanding rapidly. Therefore, we tested a high-throughput screening method for acute myeloid leukemia mutation analysis using a multiplex mass spectrometry based approach. To our knowledge, this is the first reported application of this approach to genotype leukemias in a clinical setting. One hundred seven acute myeloid leukemia cases were screened for mutations using a panel that covers 344 point mutations across 31 genes known to be associated with leukemia. The analysis was performed by multiplex polymerase chain reaction for mutations in genes of interest followed by primer extension reactions. Products were analyzed on a Sequenom MassARRAY system (San Diego, CA). The multiplex panel yielded mutations in 58% of acute myeloid leukemia cases with normal cytogenetics and 21% of cases with abnormal cytogenetics. Cytogenetics and routine polymerase chain reaction based screening of NPM1, CEBPA, FLT3-ITD, and KIT was also performed on a subset of cases. When combined with the results of these standard polymerase chain reaction based tests, the mutation frequency reached 78% in cases with normal cytogenetics. Of these, 42% harbored multiple mutations primarily involving NPM1 with NRAS, KRAS, CEBPA, PTPN11, IDH1, or FLT3. In contrast, cases with abnormal cytogenetics rarely harbored more than 1 mutation (1.5%), suggesting different underlying biology. This study demonstrates the feasibility and utility of broad-based mutation profiling of acute myeloid leukemia in a clinical setting. This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors. (C) 2012 Elsevier Inc. All rights reserved. C1 [Dunlap, Jennifer; Loriaux, Marc; Kelemen, Katalin; Leeborg, Nicky; Gatter, Ken; Braziel, Rita M.; Press, Richard; Corless, Christopher L.; Fan, Guang] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. [Beadling, Carol; Fleming, William H.; Heinrich, Michael C.; Kovacsovics, Tibor] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA. [Beadling, Carol; Warrick, Andrea; Neff, Tanaya; Fleming, William H.; Loriaux, Marc; Heinrich, Michael C.; Kovacsovics, Tibor; Braziel, Rita M.; Press, Richard; Corless, Christopher L.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA. [Fleming, William H.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Fan, G (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. EM fang@ohsu.edu NR 24 TC 6 Z9 8 U1 0 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD DEC PY 2012 VL 43 IS 12 BP 2167 EP 2176 DI 10.1016/j.humpath.2012.03.002 PG 10 WC Pathology SC Pathology GA 046JY UT WOS:000311762500009 PM 22658276 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Geographic distributions of microscopic colitis and inflammatory bowel disease in the United States SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE collagenous colitis; Crohn's disease; epidemiology of inflammatory bowel disease; geographic distribution; microscopic colitis; ulcerative colitis ID COLLAGENOUS COLITIS; CROHNS-DISEASE; EPIDEMIOLOGY; NORTH AB Background: Crohn's disease (CD) and ulcerative colitis (UC) are characterized by similar geographic distributions. We used a large database of pathology reports to analyze the geographic distribution of microscopic colitis (MC) and compare it with those of UC and CD. Methods: A population of 671,176 individual patients with colonic biopsies was studied stratified by gender and state of residence. The occurrence of each diagnosis MC, UC, or CD, was expressed as proportional rate per 1000 colonoscopies with biopsies from each individual state. Results: UC and CD tended to be common in states in the Northeast or North Central regions of the U.S. and relatively rare among several southern states. MC appeared to follow a somewhat inverse pattern, as it was most common among some states from the Southwest (Colorado, New Mexico, Arizona, Nevada) and other states of southern latitude, such as Florida, Georgia, California, but relatively uncommon among states in the Northeast. The geographic distributions of UC and CD were significantly correlated with each other (R = 0.60 and P = 0.0004). No significant correlation was observed between MC and UC or CD. Conclusions: The differences in epidemiologic behavior point at a dissimilar set of risk factors that shape the occurrence of MC as opposed to UC or CD. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Caris Life Sci, Irving, TX USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU Takeda Pharmaceuticals FX Conflicts of interests: Amnon Sonnenberg is supported by a grant from Takeda Pharmaceuticals. Robert M. Genta is employed by Caris Life Sciences, Irving, TX. Author Contributions: conception and design: Amnon Sonnenberg; Robert M. Genta; pathological interpretation of specimens: Robert M. Genta; analysis of data: Amnon Sonnenberg, Robert M. Genta; writing of article: Amnon Sonnenberg, Robert M. Genta. NR 14 TC 8 Z9 8 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 IS 12 BP 2288 EP 2293 DI 10.1002/ibd.22932 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 039JR UT WOS:000311242400012 PM 22374913 ER PT J AU Cheifetz, AS Melmed, GY Spiegel, B Talley, J Devlin, SM Raffals, L Irving, PM Jones, J Kaplan, GG Kozuch, P Sparrow, M Velayos, F Baidoo, L Bressler, B Siegel, CA AF Cheifetz, A. S. Melmed, G. Y. Spiegel, B. Talley, J. Devlin, S. M. Raffals, L. Irving, P. M. Jones, J. Kaplan, G. G. Kozuch, P. Sparrow, M. Velayos, F. Baidoo, L. Bressler, B. Siegel, C. A. TI Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE comparative effective research; Crohn's disease; ulcerative colitis ID CROHNS-DISEASE AB Background: Comparative effectiveness research (CER) is an emerging field that compares the relative effectiveness of alternative strategies to prevent, diagnose, or treat patients who are typical of day-to-day practice. We developed a priority list of CER topics for inflammatory bowel disease (IBD). Methods: Following the Institute of Medicine's approach, we developed and administered a survey to gastroenterologists asking for important CER topics in IBD. Two patient focus groups were convened to solicit additional CER studies. CER topics were presented to the expert panel using the RAND/UCLA methodology. Following initial ratings, the panel met to discuss and re-rate priorities. The top 10 CER topics were identified using a point-allocation system. Results: Responses were collated into 234 CER topics across 21 categories, of which 87 were prioritized for discussion and re-rated. Disagreement regarding priorities was observed in 5 of 87 studies. We utilized a point-allocation system to prioritize the top-10 CER topics. These related to comparing the effectiveness of: biomarkers in IBD; withdrawal of anti-tumor necrosis factor (TNF) or immunomodulators for Crohn's disease in remission; mucosal healing as an endpoint of treatment; infliximab levels versus standard infliximab dosing; anti-TNF monotherapy versus combination therapy in patients failing thiopurines; safety of long-term treatment options; anti-TNF versus thiopurines for prevention of postoperative recurrence; and treatment options for steroid-refractory UC. Conclusions: We systematically developed a list of high-priority IBD topics for CER based on a survey of gastroenterologists, expert review, and patient input. This list may guide IBD research toward the most important CER studies. C1 [Cheifetz, A. S.] Beth Israel Deaconess Med Ctr, Ctr IBD, Boston, MA 02215 USA. [Melmed, G. Y.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Spiegel, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Talley, J.] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Devlin, S. M.; Kaplan, G. G.] Univ Calgary, Calgary, AB, Canada. [Raffals, L.] Mayo Clin, Rochester, MN USA. [Irving, P. M.] Guys & St Thomas Hosp, London SE1 9RT, England. [Jones, J.] Univ Saskatchewan, Saskatoon, SK, Canada. [Kozuch, P.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Sparrow, M.] Alfred Hosp, Melbourne, Vic, Australia. [Velayos, F.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Baidoo, L.] Univ Pittsburgh, Pittsburgh, PA USA. [Bressler, B.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Siegel, C. A.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. RP Cheifetz, AS (reprint author), Beth Israel Deaconess Med Ctr, Ctr IBD, 330 Brookline Ave,Rabb 425, Boston, MA 02215 USA. EM acheifet@bidmc.harvard.edu OI kozuch, patricia/0000-0002-7465-9671; Kaplan, Gilaad/0000-0003-2719-0556 FU Warner-Chilcott; Abbott; Shire; Salix; UCB; Centocor; Setpoint; Amgen; Celgene; Elan; PG; Merck; GlaxoSmithKline; Millenium Pharmaceuticals; Genentech; Bristol-Myers Squibb; Schering-Plough Canada; UCB Pharma; Ferring Pharmaceuticals; Abbott Pharmaceuticals; Glycominds FX Unrestricted funding for the in-person Scottsdale RAND Appropriateness Panel meeting was generously provided by Warner-Chilcott, Abbott, and Shire. Unrestricted funding for the BRIDGe group is provided by Abbott, Salix, Shire, UCB, and Warner-Chilcott; The authors thank Dr. Harold Sox for contributions in consulting on study design and following IOM methodology and for article review. Disclosures: A. S. C.: Advisory Board (Warner Chilcott, Abbott, UCB); G.Y.M.: Consultant and/or Research Support (Centocor, Setpoint, Amgen, Celgene), Speaker Bureau (Abbott, Prometheus), Advisory Board (UCB); C. A. S.: Advisory Board (Abbott, UCB, P&G), Consultant and Research Support (Elan, P&G), CME activities (Abbott, UCB); B. M. S.: Research (Shire Pharmaceuticals, Ironwood Pharmaceuticals, Takeda Pharma, Rose Pharma A/G), Advisory Board (Prometheus, Salix, Boehringer Inngelheim, Ironwood, AstraZeneca, Pfizer); B. B.: Advisory Board (Abbott, Schering-Plough Canada, Shire, Ferring, Merck, Warner Chilcott, Genentech), Speaker Bureau (Janssen Ortho, Abbott, Merck, Shire, Takeda, Ferring, Warner Chilcott) Research Support (Abbott, Merck, Amgen, GlaxoSmithKline, Millenium Pharmaceuticals, Genentech, Bristol-Myers Squibb); J.J.: Consulting, Speaker's Bureau and Educational Funding (Schering-Plough Canada, UCB Pharma, Shire, P&G and Abbott); M. S.: Research Support (Ferring Pharmaceuticals, Abbott Pharmaceuticals), Advisory Board (Schering-Plough Pharmaceuticals); F. V.: Research Support (P & G); P. M. I.: Advisory Board (Abbott, MSD, Shire, Falk), Speaker's Bureau (Shire, Abbott, MSD, Merck); S. M. D.: Speaker (Schering-Plough, Abbott, Merck, Shire), Advisory Board (Abbott, UCB, Schering-Plough, Shire, Merck); G. G. K.: Advisory Board (Schering-Plough, Abbott, UCB, Shire); L. H.: Consultant (Abbott, Salix), Research support (Glycominds); L. B.: Advisory Board (UCB), Speaker's Bureau (Centocor, Salix); P. K.: None. Contributions: A. S. Cheifetz: study concept and design, drafting of the article, acquisition of data, analysis and interpretation of data, critical revision of the article for important intellectual content of the article; G.Y. Melmed, B. Spiegel, C. A. Siegel: study concept and design, acquisition of data, analysis and interpretation of data, critical revision of the article for important intellectual content of the article; J. Talley: acquisition of data, analysis and interpretation of data, critical revision of the article for important intellectual content of the article; S. M. Devlin, L. Harrell, P. M. Irving, J. Jones, G. G. Kaplan, P. Kozuch, M. Sparrow, F. Velayos, L. Baidoo, B. Bressler: acquisition of data, interpretation of data, critical revision of the article for important intellectual content. NR 9 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 IS 12 BP 2294 EP 2300 DI 10.1002/ibd.22920 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 039JR UT WOS:000311242400013 PM 22337359 ER PT J AU Fang, H Caranto, JD Mendoza, R Taylor, AB Hart, PJ Kurtz, DM AF Fang, Han Caranto, Jonathan D. Mendoza, Rosalinda Taylor, Alexander B. Hart, P. John Kurtz, Donald M., Jr. TI Histidine ligand variants of a flavo-diiron protein: effects on structure and activities SO JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY LA English DT Article DE Non-heme iron; Nitric oxide; Dioxygen; X-ray crystallography; Enzyme kinetics; Site-directed mutagenesis ID NITRIC-OXIDE REDUCTASE; PARASITE GIARDIA-INTESTINALIS; FLAVODIIRON PROTEINS; DESULFOVIBRIO-GIGAS; ESCHERICHIA-COLI; MOORELLA-THERMOACETICA; CRYSTAL-STRUCTURES; SITE STRUCTURE; IN-VIVO; FLAVORUBREDOXIN AB Flavo-diiron proteins (FDPs) contain non-heme diiron and proximal flavin mononucleotide (FMN) active sites and function as terminal components of a nitric oxide reductase (NOR) and/or a four-electron dioxygen reductase (O2R). While most FDPs show similar structural, spectroscopic, and redox properties, O2R and NOR activities vary significantly among FDPs. A potential source of this variability is the iron ligation status of a conserved His residue that provides an iron ligand in all known FDP structures but one, where this His residue is rotated away from iron and replaced by a solvent ligand. In order to test the effect of this His ligation status, we changed this ligating His residue (H90) in Thermotoga maritima (Tm) FDP to either Asn or Ala. The wild-type Tm FDP shows significantly higher O2R than NOR activity. Single crystal X-ray crystallography revealed a remarkably conserved diiron site structure in the H90N and -A variants, differing mainly by either Asn or solvent coordination, respectively, in place of H90. The steady-state activities were minimally affected by the H90 substitutions, remaining significantly higher for O2R versus NOR. The pre-steady-state kinetics of the fully reduced FDP with O-2 were also minimally affected by the H90 substitutions. The results indicate that the coordination status of this His ligand does not significantly modulate the O2R or NOR activities, and that FDPs can retain these activities when the individual iron centers are differentiated by His ligand substitution. This differentiation may have implications for the O2R and NOR mechanisms of FDPs. C1 [Fang, Han; Caranto, Jonathan D.; Mendoza, Rosalinda; Kurtz, Donald M., Jr.] Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Kurtz, DM (reprint author), Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA. EM donald.kurtz@utsa.edu FU National Institute of Health [RO1 GM040388]; Robert A. Welch Foundation [AQ-1399] FX This work was supported by grants from National Institute of Health (RO1 GM040388 to D. M. K. Jr.) and the Robert A. Welch Foundation (AQ-1399 to P. J. H.). Support for the X-ray Crystallography Core Laboratory by the University of Texas Health Sciences Center at San Antonio Executive Research Committee and the Cancer Therapy & Research Center is gratefully acknowledged. We thank Professor Heather Shipley for access to and assistance with the inductively coupled plasma mass spectrometer. NR 36 TC 8 Z9 9 U1 0 U2 21 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0949-8257 J9 J BIOL INORG CHEM JI J. Biol. Inorg. Chem. PD DEC PY 2012 VL 17 IS 8 BP 1231 EP 1239 DI 10.1007/s00775-012-0938-4 PG 9 WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear SC Biochemistry & Molecular Biology; Chemistry GA 045BL UT WOS:000311669200009 PM 22990880 ER PT J AU Holt, CL Schulz, E Williams, B Clark, EM Wang, MQ Southward, PL AF Holt, Cheryl L. Schulz, Emily Williams, Beverly Clark, Eddie M. Wang, Min Qi Southward, Penny L. TI Assessment of Religious and Spiritual Capital in African American Communities SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Social capital; Religious capital; Spiritual capital; Reliability; Validity ID SELF-RATED HEALTH; WOMEN; MODEL AB African American faith communities are an important source of social capital. The present study adapted a theory-based social capital instrument to result in religious (e.g., from organized worship) and spiritual (e.g., from relationship with higher power) capital measures. Data from a national sample of 803 African Americans suggest the instruments have high internal reliability and are distinct from general religiosity. Measurement models confirmed factor structures. Religious capital was positively associated with self-rated health status. Religious and spiritual capital were negatively associated with depressive symptoms, but these associations largely became nonsignificant in multivariate models that controlled for demographic characteristics. An exception is for spiritual capital in the form of community participation, which retained a negative association with depressive symptoms. These instruments may have applied value for health promotion research and practice in African American communities. C1 [Holt, Cheryl L.; Wang, Min Qi] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. [Schulz, Emily] Arizona Sch Hlth Sci, Dept Occupat Therapy, Mesa, AZ USA. [Williams, Beverly] Univ Alabama Birmingham, Dept Med, Birmingham VA Med Ctr, Div Gerontol Geriatr Palliat Care, Birmingham, AL 35294 USA. [Clark, Eddie M.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. [Southward, Penny L.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. RP Holt, CL (reprint author), Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, 2369 Sch Publ Hlth,Bldg 255, College Pk, MD 20742 USA. EM cholt14@umd.edu NR 39 TC 5 Z9 5 U1 1 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 J9 J RELIG HEALTH JI J. Relig. Health PD DEC PY 2012 VL 51 IS 4 BP 1061 EP 1074 DI 10.1007/s10943-012-9635-4 PG 14 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA 040HO UT WOS:000311313500005 PM 22810197 ER PT J AU Lyamin, OI Pavlova, IF Kosenko, PO Mukhametov, LM Siegel, JM AF Lyamin, Oleg I. Pavlova, Ivetta F. Kosenko, Peter O. Mukhametov, Lev M. Siegel, Jerome M. TI Regional differences in cortical electroencephalogram (EEG) slow wave activity and interhemispheric EEG asymmetry in the fur seal SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE interhemispheric EEG asymmetry; local sleep; slow wave activity; unihemispheric sleep; northern fur seal ID SLEEP-DEPRIVATION; RAT; STIMULATION; DYNAMICS; POWER AB Slow wave sleep (SWS) in the northern fur seal (Callorhinus ursinus) is characterized by a highly expressed interhemispheric electroencephalogram (EEG) asymmetry, called unihemispheric or asymmetrical SWS. The aim of this study was to examine the regional differences in slow wave activity (SWA; power in the range of 1.24.0 Hz) within one hemisphere and differences in the degree of interhemispheric EEG asymmetry within this species. Three seals were implanted with 10 EEG electrodes, positioned bilaterally (five in each hemisphere) over the frontal, occipital and parietal cortex. The expression of interhemispheric SWA asymmetry between symmetrical monopolar recordings was estimated based on the asymmetry index [AI = (L-R)/(L+R), where L and R are the power in the left and right hemispheres, respectively]. Our findings indicate an anteriorposterior gradient in SWA during asymmetrical SWS in fur seals, which is opposite to that described for other mammals, including humans, with a larger SWA recorded in the parietal and occipital cortex. Interhemispheric EEG asymmetry in fur seals was recorded across the entire dorsal cerebral cortex, including sensory (visual and somatosensory), motor and associative (parietal or suprasylvian) cortical areas. The expression of asymmetry was greatest in occipitallateral and parietal derivations and smallest in frontalmedial derivations. Regardless of regional differences in SWA, the majority (90%) of SWS episodes with interhemispheric EEG asymmetry meet the criteria for unihemispheric SWS (one hemisphere is asleep while the other is awake). The remaining episodes can be described as episodes of bilateral SWS with a local activation in one cerebral hemisphere. C1 [Lyamin, Oleg I.] VA GLAHS Sepulveda, Ctr Sleep Res, North Hills, CA 91343 USA. [Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Lyamin, Oleg I.; Pavlova, Ivetta F.; Kosenko, Peter O.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow, Russia. [Lyamin, Oleg I.; Mukhametov, Lev M.] Severtsov Inst Ecol & Evolut, Moscow, Russia. [Kosenko, Peter O.] S Fed Univ, Rostov Na Donu, Russia. RP Lyamin, OI (reprint author), VA GLAHS Sepulveda, Ctr Sleep Res, Plummer St 16111, North Hills, CA 91343 USA. EM olyamin@ucla.edu FU NSF [0919929]; NIH [069640]; Utrish Dolphinarium Ltd. FX This study was supported by NSF (0919929), NIH (069640) and Utrish Dolphinarium Ltd. The authors are thankful to J. Lapierre for comments on this manuscript. NR 30 TC 3 Z9 3 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 J9 J SLEEP RES JI J. Sleep Res. PD DEC PY 2012 VL 21 IS 6 BP 603 EP 611 DI 10.1111/j.1365-2869.2012.01023.x PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 045HS UT WOS:000311686700002 PM 22676149 ER PT J AU Huddle, TS Bailey, FA AF Huddle, Thomas S. Bailey, F. Amos TI Pacemaker deactivation: withdrawal of support or active ending of life? SO THEORETICAL MEDICINE AND BIOETHICS LA English DT Article DE Pacemaker deactivation; Withdrawal of support; End of life care; Medical ethics; Physician assisted suicide ID INTENSIVE-CARE; PERSPECTIVES AB In spite of ethical analyses assimilating the palliative deactivation of pacemakers to commonly accepted withdrawings of life-sustaining therapy, many clinicians remain ethically uncomfortable with pacemaker deactivation at the end of life. Various reasons have been posited for this discomfort. Some cardiologists have suggested that reluctance to deactivate pacemakers may stem from a sense that the pacemaker has become part of the patient's "self." The authors suggest that Daniel Sulmasy is correct to contend that any such identification of the pacemaker is misguided. The authors argue that clinicians uncomfortable with pacemaker deactivation are nevertheless correct to see it as incompatible with the traditional medical ethics of withdrawal of support. Traditional medical ethics is presently taken by many to sanction pacemaker deactivation when such deactivation honors the patient's right to refuse treatment. The authors suggest that the right to refuse treatment applies to treatments involving ongoing physician agency. This right cannot underwrite patient demands that physicians reverse the effects of treatments previously administered, in which ongoing physician agency is no longer implicated. The permanently indwelling pacemaker is best seen as such a treatment. As such, its deactivation in the pacemaker-dependent patient is best seen not as withdrawal of support but as active ending of life. That being the case, clinicians adhering to the usual ethical analysis of withdrawal of support are correct to be uncomfortable with pacemaker deactivation at the end of life. C1 [Huddle, Thomas S.] UAB, Div Gen Internal Med, Sch Med, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Bailey, F. Amos] VA Med Ctr, Birmingham, AL 35233 USA. RP Huddle, TS (reprint author), UAB, Div Gen Internal Med, Sch Med, Birmingham VA Med Ctr, FOT 744,1530 3rd Ave S, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 20 TC 9 Z9 9 U1 1 U2 10 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1386-7415 J9 THEOR MED BIOETH JI Theor. Med. Bioeth. PD DEC PY 2012 VL 33 IS 6 BP 421 EP 433 DI 10.1007/s11017-012-9213-5 PG 13 WC Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Social Issues; Biomedical Social Sciences GA 045ED UT WOS:000311676900003 PM 22351107 ER PT J AU Sataranatarajan, K Feliers, D Mariappan, MM Lee, HJ Lee, MJ Day, RT Yalamanchili, HB Choudhury, GG Barnes, JL Van Remmen, H Richardson, A Kasinath, BS AF Sataranatarajan, Kavithalakshmi Feliers, Denis Mariappan, Meenalakshmi M. Lee, Hak Joo Lee, Myung Ja Day, Robert T. Yalamanchili, Hima Bindu Choudhury, Goutam G. Barnes, Jeffrey L. Van Remmen, Holly Richardson, Arlan Kasinath, Balakuntalam S. TI Molecular events in matrix protein metabolism in the aging kidney SO AGING CELL LA English DT Article DE albuminuria; collagen; fibrosis; microRNAs; SMAD3; TGF beta ID MESSENGER-RNA TRANSLATION; RENAL EPITHELIAL-CELLS; HIGH GLUCOSE; DIABETIC-NEPHROPATHY; EXTRACELLULAR-MATRIX; GENE-TRANSFER; FIBROSIS; EXPRESSION; GLOMERULI; KINASE AB We explored molecular events associated with aging-induced matrix changes in the kidney. C57BL6 mice were studied in youth, middle age, and old age. Albuminuria and serum cystatin C level (an index of glomerular filtration) increased with aging. Renal hypertrophy was evident in middle-aged and old mice and was associated with glomerulomegaly and increase in mesangial fraction occupied by extracellular matrix. Content of collagen types I and III and fibronectin was increased with aging; increment in their mRNA varied with the phase of aging. The content of ZEB1 and ZEB2, collagen type I transcription inhibitors, and their binding to the collagen type Ia2 promoter by ChIP assay also showed age-phase-specific changes. Lack of increase in mRNA and data from polysome assay suggested decreased degradation as a potential mechanism for kidney collagen type I accumulation in the middle-aged mice. These changes occurred with increment in TGF beta mRNA and protein and activation of its SMAD3 pathway; SMAD3 binding to the collagen type Ia2 promoter was also increased. TGF beta-regulated microRNAs (miRs) exhibited selective regulation. The renal cortical content of miR-21 and miR-200c, but not miR-192, miR-200a, or miR-200b, was increased with aging. Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively. These data show that aging is associated with complex molecular events in the kidney that are already evident in the middle age and progress to old age. Age-phase-specific regulation of matrix protein synthesis occurs and involves matrix proteinspecific transcriptional and post-transcriptional mechanisms. C1 [Sataranatarajan, Kavithalakshmi; Feliers, Denis; Mariappan, Meenalakshmi M.; Lee, Hak Joo; Lee, Myung Ja; Day, Robert T.; Yalamanchili, Hima Bindu; Choudhury, Goutam G.; Barnes, Jeffrey L.; Van Remmen, Holly; Richardson, Arlan; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Sataranatarajan, Kavithalakshmi; Van Remmen, Holly; Richardson, Arlan; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Mariappan, Meenalakshmi M.; Lee, Hak Joo; Choudhury, Goutam G.; Barnes, Jeffrey L.; Kasinath, Balakuntalam S.] S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. [Choudhury, Goutam G.; Van Remmen, Holly; Richardson, Arlan] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. RP Kasinath, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kasinath@uthscsa.edu FU NIH [RC2AG036613, DK077295, DK050190]; VA Research Service; Juvenile Diabetes Research Foundation; VA FX This study was supported in whole or in part by grants from the NIH RC2AG036613 (BSK, HVR, AR), DK077295 (BSK), DK050190 (GGC), and the VA Research Service (BSK, GGC, JLB) and the Juvenile Diabetes Research Foundation (DF, GGC). GGC is a recipient of Senior Research Career Scientist Award from the VA. We thank Ms. Vivian Diaz for assistance with the animal experiments. NR 45 TC 15 Z9 15 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD DEC PY 2012 VL 11 IS 6 BP 1065 EP 1073 DI 10.1111/acel.12008 PG 9 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 037NP UT WOS:000311113500016 PM 23020145 ER PT J AU Peralta, CA Katz, R Bonventre, JV Sabbisetti, V Siscovick, D Sarnak, M Shlipak, MG AF Peralta, Carmen A. Katz, Ronit Bonventre, Joseph V. Sabbisetti, Venkata Siscovick, David Sarnak, Mark Shlipak, Michael G. TI Associations of Urinary Levels of Kidney Injury Molecule 1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) With Kidney Function Decline in the Multi-Ethnic Study of Atherosclerosis (MESA) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Kidney injury molecule 1 (KIM-1); neutrophil gelatinase-associated lipocalin (NGAL); kidney function decline ID CYSTATIN C; CARDIAC-SURGERY; TUBULOINTERSTITIAL FIBROSIS; DISEASE; BIOMARKERS; RISK; PROGRESSION; MECHANISMS; MORTALITY; HUMANS AB Background: Whether elevations in levels of urinary biomarkers of tubular injury (urine neutrophil gelatinase-associated lipocalin [NGAL] and kidney injury molecule 1 [KIM-1]) are associated with future risk of kidney disease has not been investigated. Study Design: 1: 1 nested case-control study. Setting & Participants: 686 participants in the Multi-Ethnic Study of Atherosclerosis (MESA). Predictor: NGAL and KIM-1 were measured at baseline, expressed as log-transformed continuous variables, and categorized into deciles. Outcomes: Kidney function was estimated by cystatin C level using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. Incident CKD stage 3 was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m(2) and an eGFR decrease > 1 mL/min/1.73 m(2) per year, and rapid kidney function decrease was defined as decrease >= 3 mL/min/1.73 m(2) per year. Measurements: Cases were defined as persons with eGFR > 60 mL/min/1.73 m(2) who subsequently developed incident CKD stage 3 and/or had rapid kidney function decrease by the MESA year-5 visit. Controls were matched for age, sex, race, diabetes, and baseline eGFR. We adjusted for age, hypertension, and presence of albuminuria (albumin-creatinine ratio >= 30 mg/g). Results: Of 343 cases, 145 had incident CKD stage 3, 141 had rapid kidney function decrease, and 57 had both. Mean eGFR for controls was 81 +/- 10 mL/min/1.73 m(2) at baseline and 80 +/- 10 mL/min/1.73 m(2) at follow-up compared with 82 +/- 13 and 58 +/- 10 mL/min/1.73 m(2) for cases. Each doubling of KIM-1 level (in picograms per milliliter) was associated with an OR of 1.15 (95% CI, 1.02-1.29) for incident CKD stage 3 and/or rapid kidney function decrease. Compared with the lowest 90%, the highest decile of KIM-1 level was associated with an OR of 2.02 (95% CI, 1.15-3.56) for the outcome; these associations were independent of albuminuria. NGAL levels (in nanograms per milliliter) were not associated with incident CKD stage 3 and/or rapid kidney function decrease (OR, 1.04; 95% CI, 0.99-1.10). Results were similar when KIM-1 and NGAL levels were standardized for urine creatinine. Limitations: The case-control design limits the ability to account for persons who died or were not available for follow-up. Conclusions: Urinary KIM-1 level is associated with future risk of kidney disease independent of albuminuria. Urinary biomarkers of tubular injury are a promising tool for identifying persons at risk of CKD. Am J Kidney Dis. 60(6): 904-911. (C) 2012 by the National Kidney Foundation, Inc. C1 [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Bonventre, Joseph V.; Sabbisetti, Venkata] Brigham & Womens Hosp, Boston, MA 02115 USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Sarnak, Mark] Tufts Med Ctr, Boston, MA USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; National Institute of Diabetes and Digestive and Kidney Diseases [1K23DK082793-01]; Robert Wood Johnson Foundation; National Institute of Aging [R01 AG027002] FX This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases (1K23DK082793-01, to Dr Peralta), the Robert Wood Johnson Foundation (Harold J. Amos Award; to Dr Peralta), and the National Institute of Aging (R01 AG027002, to Drs Sarnak and Shlipak). These funding sources had no involvement in the design or execution of this study. NR 35 TC 47 Z9 49 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD DEC PY 2012 VL 60 IS 6 BP 904 EP 911 DI 10.1053/j.ajkd.2012.05.014 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 034BM UT WOS:000310845100006 PM 22749388 ER PT J AU Spahillari, A Parikh, CR Sint, K Koyner, JL Patel, UD Edelstein, CL Passik, CS Thiessen-Philbrook, H Swaminathan, M Shlipak, MG AF Spahillari, Aferdita Parikh, Chirag R. Sint, Kyaw Koyner, Jay L. Patel, Uptal D. Edelstein, Charles L. Passik, Cary S. Thiessen-Philbrook, Heather Swaminathan, Madhav Shlipak, Michael G. CA TRIBE-AKI Consortium TI Serum Cystatin C- Versus Creatinine-Based Definitions of Acute Kidney Injury Following Cardiac Surgery: A Prospective Cohort Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Perioperative; acute renal failure; diagnosis; creatinine ID ACUTE-RENAL-FAILURE; GLOMERULAR-FILTRATION-RATE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR EVENTS; SURGICAL-PATIENTS; HEART-FAILURE; RISK; MORTALITY; IMPACT; HEMOFILTRATION AB Background: The primary aim of this study was to compare the sensitivity and rapidity of acute kidney injury (AKI) detection by cystatin C level relative to creatinine level after cardiac surgery. Study Design: Prospective cohort study. Settings & Participants: 1,150 high-risk adult cardiac surgery patients in the TRIBE-AKI (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) Consortium. Predictor: Changes in serum creatinine and cystatin C levels. Outcome: Postsurgical incidence of AKI. Measurements: Serum creatinine and cystatin C were measured at the preoperative visit and daily on postoperative days 1-5. To allow comparisons between changes in creatinine and cystatin C levels, AKI end points were defined by the relative increases in each marker from baseline (25%, 50%, and 100%) and the incidence of AKI was compared based on each marker. Secondary aims were to compare clinical outcomes among patients defined as having AKI by cystatin C and/or creatinine levels. Results: Overall, serum creatinine level detected more cases of AKI than cystatin C level: 35% developed a >= 25% increase in serum creatinine level, whereas only 23% had a >= 25% increase in cystatin C level (P < 0.001). Creatinine level also had higher proportions meeting the 50% (14% and 8%; P < 0.001) and 100% (4% and 2%; P = 0.005) thresholds for AKI diagnosis. Clinical outcomes generally were not statistically different for AKI cases detected by creatinine or cystatin C level. However, for each AKI threshold, patients with AKI confirmed by both markers had a significantly higher risk of the combined mortality/dialysis outcome compared with patients with AKI detected by creatinine level alone (P = 0.002). Limitations: There were few adverse clinical outcomes, limiting our ability to detect differences in outcomes between subgroups of patients based on their definitions of AKI. Conclusions: In this large multicenter study, we found that cystatin C level was less sensitive for AKI detection than creatinine level. However, confirmation by cystatin C level appeared to identify a subset of patients with AKI with a substantially higher risk of adverse outcomes. Am J Kidney Dis. 60(6): 922-929. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Spahillari, Aferdita; Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Parikh, Chirag R.; Sint, Kyaw] Yale Univ, Sch Med, Dept Internal Med, Clin Epidemiol Res Ctr, New Haven, CT 06510 USA. [Koyner, Jay L.] Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA. [Patel, Uptal D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Patel, Uptal D.; Swaminathan, Madhav] Duke Univ, Sch Med, Dept Anesthesiol, Div Cardiothorac Anesthesiol & Crit Care Med, Durham, NC USA. [Edelstein, Charles L.] Univ Colorado, Div Renal Dis, Denver, CO 80202 USA. [Passik, Cary S.] Danbury Hosp, Dept Cardiothorac Surg, Danbury, CT USA. [Thiessen-Philbrook, Heather] Univ Western Ontario, Div Nephrol, Dept Med, London, ON, Canada. RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Rm 219, West Haven, CT 06516 USA. EM Chirag.Parikh@yale.edu FU National Heart, Lung, and Blood Institute [R01HL-085757]; National Center for Research Resources [UL1 RR024139] FX Support: The research reported in this article was supported by grant R01HL-085757 from the National Heart, Lung, and Blood Institute. The study also was supported by a Clinical and Translational Science Award grant (UL1 RR024139) from the National Center for Research Resources. NR 30 TC 35 Z9 36 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD DEC PY 2012 VL 60 IS 6 BP 922 EP 929 DI 10.1053/j.ajkd.2012.06.002 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 034BM UT WOS:000310845100008 PM 22809763 ER PT J AU Ramanathan, V Riosa, S Al-Sharif, AH Mansouri, MD Tranchina, A Kayyal, T Abreo, AP Aslam, S Nassar, G Darouiche, RO AF Ramanathan, Venkataraman Riosa, Sarah Al-Sharif, Atef H. Mansouri, M. David Tranchina, Andrew Kayyal, Talal Abreo, Adrian P. Aslam, Saima Nassar, George Darouiche, Rabih O. TI Characteristics of Biofilm on Tunneled Cuffed Hemodialysis Catheters in the Presence and Absence of Clinical Infection SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Biofilm; hemodialysis; catheter-related bacteremia ID ANTIBIOTIC LOCK; RISK-FACTORS; BACTEREMIA; MANAGEMENT; MORTALITY; PROTOCOL AB Background: Biofilm occurring on the surface of tunneled hemodialysis (HD) catheters is difficult to eradicate and often is associated with recurrent bacteremia. We studied biofilm formation on catheters from patients with and without bacteremia to identify the location of bacterial growth and measure biofilm thickness. Study Design: Prospective observational study. Setting & Participants: 76 adult HD patients; 26 had HD catheters removed for bacteremia and 50 had catheters removed for reasons other than infection. Predictors: Segment of catheter, reason for catheter removal. Outcomes & Measurements: Microbiological growth and biofilm thickness on the outer and luminal surfaces of extravascular and intravascular catheter segments. Results: Catheter cultures were positive in 16 (62%) patients with bacteremia and 15 (30%) when the catheter was removed for non-infection-related reasons. In catheters with positive cultures, the outer surface of the extravascular segment was the most common site of bacterial growth (15/16 [94%] and 11/15 [73%] for bacteremic and nonbacteremic patients, respectively). Bacteremic patients had significantly thicker biofilm on all catheter surfaces, and in bacteremic patients, the biofilm was significantly thicker on the outer compared with the luminal surface for both extravascular (14.53 +/- 6.17 vs 11.97 +/- 5.01 mu m; P < 0.001) and intravascular (12.21 +/- 5.3 vs 9.46 +/- 3.71 mu m; P < 0.001) segments. Extravascular segments had significantly thicker biofilm compared with intravascular segments on both the outer (P < 0.001) and luminal (P < 0.001) surfaces. Similarly, in patients for whom the catheter was removed for non-infection-related reasons, the catheter had thicker biofilm on the outer compared with the inner surface in both extravascular (2.19 +/- 2.84 vs 1.62 +/- 2.33 mu m; P < 0.001) and intravascular (1.92 +/- 2.62 vs 1.29 +/- 2.33 mu m; P < 0.001) segments. Similar to catheters from bacteremic patients, the outer and luminal surfaces of the extravascular segments of the catheters had significantly thicker biofilm compared with their corresponding surfaces on the intravascular segments. Limitations: Observational study. Conclusions: The outer surface of the extravascular segment of tunneled dialysis catheters in both bacteremic and nonbacteremic HD patients has the thickest biofilm and highest microbiological yield, and biofilm is thicker in patients with bacteremia. This knowledge is important for designing preventive strategies and also in the management of patients with catheter infection. Am J Kidney Dis. 60(6): 976-982. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Ramanathan, Venkataraman; Abreo, Adrian P.] Baylor Coll Med, Renal Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Riosa, Sarah; Al-Sharif, Atef H.; Mansouri, M. David; Tranchina, Andrew; Kayyal, Talal; Darouiche, Rabih O.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Aslam, Saima] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA. [Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Nassar, George] Weill Cornell Univ, Doha, Qatar. RP Ramanathan, V (reprint author), Baylor Coll Med, Renal Sect, Michael E DeBakey Vet Affairs Med Ctr, 111J,2002 Holcombe Blvd, Houston, TX 77030 USA. EM ramanath@bcm.edu FU Satellite Healthcare Inc.; National Institutes of Health/National Institute of Allergy and Infectious Diseases FX This research was supported by the Norman S. Coplon Extramural Grant from Satellite Healthcare Inc. Mr Mansouri has received support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. NR 23 TC 16 Z9 16 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD DEC PY 2012 VL 60 IS 6 BP 976 EP 982 DI 10.1053/j.ajkd.2012.06.003 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 034BM UT WOS:000310845100014 PM 22795945 ER PT J AU Lovejoy, TI AF Lovejoy, Travis I. TI Telephone-Delivered Motivational Interviewing Targeting Sexual Risk Behavior Reduces Depression, Anxiety, and Stress in HIV-Positive Older Adults SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE HIV; Motivational interviewing; Randomized controlled trial; Depression; Anxiety; Stress ID SCALES DASS; TRANSMISSION RISK; UNITED-STATES; SYMPTOMS; AGE; INTERVENTIONS; METAANALYSIS; HIV/AIDS; DISEASE; HEALTH AB Few studies have examined the secondary benefits of HIV risk reduction interventions to improve mental health functioning. This study aimed to examine the effectiveness of telephone-delivered motivational interviewing (MI) targeting sexual risk behavior to reduce depression, anxiety, and stress in HIV-positive older adults. Participants were 100 HIV-positive adults 45+ years old enrolled in a sexual risk reduction pilot clinical trial of telephone-delivered MI. Participants were randomly assigned to a one-session MI, four-session MI, or standard of care control condition. Telephone interviews at baseline and 3- and 6-month follow-up assessed sexual behavior, depression, anxiety, and stress. Relative to controls, participants in the one- and four-session MI conditions reported lower levels of depression, anxiety, and stress at 6-month follow-up. No between group differences were observed at 3-month follow-up or between one- and four-session MI participants at 6-month follow-up. Preliminary data suggest that telephone-delivered MI to reduce sexual risk behavior may confer secondary benefits of improving mental health functioning in HIV-positive persons. C1 Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. RP Lovejoy, TI (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd,P3MHDC, Portland, OR 97239 USA. EM travis.lovejoy@va.gov NR 25 TC 8 Z9 8 U1 1 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD DEC PY 2012 VL 44 IS 3 BP 416 EP 421 DI 10.1007/s12160-012-9401-6 PG 6 WC Psychology, Multidisciplinary SC Psychology GA 042TX UT WOS:000311495100015 PM 22956397 ER PT J AU Parrinello, CM Landay, AL Hodis, HN Gange, SJ Norris, PJ Young, M Anastos, K Tien, PC Xue, XN Lazar, J Benning, L Tracy, RP Kaplan, RC AF Parrinello, Christina M. Landay, Alan L. Hodis, Howard N. Gange, Stephen J. Norris, Philip J. Young, Mary Anastos, Kathryn Tien, Phyllis C. Xue, Xiaonan Lazar, Jason Benning, Lorie Tracy, Russell P. Kaplan, Robert C. TI Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study SO ATHEROSCLEROSIS LA English DT Article DE Cardiovascular diseases; Carotid arteries; HAART; HIV; Lipids ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK; POSITIVE PATIENTS; SERUM-LIPIDS; THERAPY; HAART; MEN; PROGRESSION; IMPACT; HDL AB Objective: We examined serum lipids in association with carotid artery intima-media thickness (CIMT) in HIV-infected and HIV-uninfected women. Methods: In 2003-4, among 1827 Women's Interagency HIV Study participants, we measured CIMT and lipids (high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), non-HDL-c). A subset of 520 treated HIV-infected women had pre-1997 lipid measures. We used multivariable linear regression to examine associations between lipids and CIMT. Results: In HIV-uninfected women, higher TC, LDL-c and non-HDL-c were associated with increased CIMT. Among HIV-infected women, associations of lipids with CIMT were observed in treated but not untreated women. Among the HIV-infected women treated in 2003-4, CIMT was associated both with lipids measured a decade earlier in infection, and with late lipid measurements. Conclusion: Among HIV-infected women, hyperlipidemia is most strongly associated with subclinical atherosclerosis in treated women. Among treated women, the association appeared strongest early in the disease course. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Parrinello, Christina M.; Anastos, Kathryn; Xue, Xiaonan; Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA. [Landay, Alan L.] Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA. [Gange, Stephen J.; Benning, Lorie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Norris, Philip J.] Blood Syst Res Inst, San Francisco, CA USA. [Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Norris, Philip J.; Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lazar, Jason] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA. [Tracy, Russell P.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA. RP Kaplan, RC (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Belfer 1306C, Bronx, NY 10461 USA. EM Robert.kaplan@einstein.yu.edu OI Gange, Stephen/0000-0001-7842-512X FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131]; National Heart, Lung and Blood Institute [1R01HL095140, 1R01HL083760]; University of Washington's CVD and Metabolic Complications of HIV/AIDS Data Coordinating Center [5R01HL095126] FX Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington, DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Additional co-funding is provided by the National Heart, Lung and Blood Institute (1R01HL095140, 1R01HL083760 to R. C. K.). Partial funding for laboratory and imaging work as well as assistance with general study coordination was provided by the University of Washington's CVD and Metabolic Complications of HIV/AIDS Data Coordinating Center (5R01HL095126). NR 15 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD DEC PY 2012 VL 225 IS 2 BP 408 EP 411 DI 10.1016/j.atherosclerosis.2012.09.035 PG 4 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 040SV UT WOS:000311344700046 PM 23089369 ER PT J AU Hegarty, CE Foland-Ross, LC Narr, KL Sugar, CA McGough, JJ Thompson, PM Altshuler, LL AF Hegarty, Catherine E. Foland-Ross, Lara C. Narr, Katherine L. Sugar, Catherine A. McGough, James J. Thompson, Paul M. Altshuler, Lori L. TI ADHD comorbidity can matter when assessing cortical thickness abnormalities in patients with bipolar disorder SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; attention-deficit hyperactivity disorder; comorbidity; magnetic resonance imaging; cortical thickness; cortical pattern matching; prefrontal cortex; anterior cingulate cortex; subgenual cingulate cortex; orbitofrontal cortex ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; SUBGENUAL PREFRONTAL CORTEX; VOXEL-BASED MORPHOMETRY; ORBITOFRONTAL CORTEX; VOLUME REDUCTIONS; STRUCTURAL ABNORMALITIES; RESPONSE-INHIBITION; EXECUTIVE FUNCTION; I DISORDER AB Hegarty CE, Foland-Ross LC, Narr KL, Sugar CA, McGough JJ, Thompson PM, Altshuler LL. ADHD comorbidity can matter when assessing cortical thickness abnormalities in patients with bipolar disorder. ?Bipolar Disord 2012: 14: 843855. (C) 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd. Objectives: Attention-deficit hyperactivity disorder (ADHD) is prevalent in patients with bipolar disorder (BP), but very few studies consider this when interpreting magnetic resonance imaging findings. No studies, to our knowledge, have screened for or controlled for the presence of ADHD when examining cortical thickness in patients with BP. We used a 2 x 2 design to evaluate the joint effects of BP and ADHD on cortical thickness and uncover the importance of ADHD comorbidity in BP subjects. Methods: The study included 85 subjects: 31 healthy controls, 17 BP-only, 19 ADHD-only, and 18 BP/ADHD. All patients with BP were subtype I, euthymic, and not taking lithium. Groups did not differ significantly in age or gender distribution. We used cortical thickness measuring tools combined with cortical pattern matching methods to align sulcal/gyral anatomy across participants. Significance maps were used to check for both main effects of BP and ADHD and their interaction. Post-hoc comparisons assessed how the effects of BP on cortical thickness varied as a function of the presence or absence of ADHD. Results: Interactions of BP and ADHD diagnoses were found in the left subgenual cingulate and right orbitofrontal cortex, demonstrating that the effect of BP on cortical thickness depends on ADHD status. Conclusions: Some brain abnormalities attributed to BP may result from the presence of ADHD. Diagnostic interactions were found in regions previously implicated in the pathophysiology of BP, making it vital to control for an ADHD comorbid diagnosis when attempting to isolate neural or genetic abnormalities specific to BP. C1 [Hegarty, Catherine E.; Sugar, Catherine A.; McGough, James J.; Thompson, Paul M.; Altshuler, Lori L.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Foland-Ross, Lara C.] Stanford Univ, Dept Psychol, Mood & Anxiety Disorders Lab, Stanford, CA 94305 USA. [Narr, Katherine L.; Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90095 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Sugar, Catherine A.; Altshuler, Lori L.] W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [McGough, James J.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Altshuler, LL (reprint author), UCLA Mood Disorders Res Program, 300 UCLA Med Plaza,Suite 1544,Box 956968, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu OI Hegarty, Catherine/0000-0003-4976-774X FU Furlotti Family Foundation; National Institute of Mental Health [K24 MH001848, R21 MH075944, 5F31MH078556, EB008432, EB008281, EB007813, HD050735, RR013642]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [RR12169, RR13642, RR00865] FX The authors gratefully acknowledge the Furlotti Family Foundation, (LLA) and the National Institute of Mental Health (K24 MH001848, R21 MH075944) (LLA), 5F31MH078556) (LCF), (EB008432, EB008281, EB007813, HD050735, and RR013642) (PMT) for their financial support of this study. For generous support, the authors also wish to thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, and Northstar Fund. The project described was supported by grant #RR12169, #RR13642, and #RR00865 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The contents of the paper are solely the responsibility of the authors and do not necessarily represent the official views of NIH. NR 77 TC 7 Z9 7 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD DEC PY 2012 VL 14 IS 8 BP 843 EP 855 DI 10.1111/bdi.12024 PG 13 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 041LP UT WOS:000311403600006 PM 23167934 ER PT J AU Small, AC Tsao, CK Moshier, EL Gartrell, BA Wisnivesky, JP Godbold, JH Smith, CB Sonpavde, G Oh, WK Galsky, MD AF Small, Alexander C. Tsao, Che-Kai Moshier, Erin L. Gartrell, Benjamin A. Wisnivesky, Juan P. Godbold, James H. Smith, Cardinale B. Sonpavde, Guru Oh, William K. Galsky, Matthew D. TI Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy SO CANCER LA English DT Article DE metastatic cancer; health care disparities; National Cancer Data Base; untreated; no treatment ID CELL LUNG-CANCER; CHEMOTHERAPY; DIAGNOSIS; SURVIVAL; STAGE; DISPARITIES; SERVICES; BREAST AB BACKGROUND: A subset of patients who present with metastatic solid tumors never receive anticancer therapy. Reasons may include poor functional status, comorbidities, and patient preference. To the authors' knowledge, the prevalence and characteristics of this population have not previously been described. METHODS: The National Cancer Data Base was queried for patients diagnosed with metastatic (stage IV according to the American Joint Committee on Cancer) solid tumors (including those of the breast, cervix, colon, and kidney; small cell and nonsmall cell lung cancer [NSCLC]; and tumors of the prostate, rectum, and uterus) who received neither radiotherapy nor systemic therapy. Log-binomial regression analysis was used to estimate prevalence ratios (PRs) for the percentage of untreated to treated patients with stage IV cancer. RESULTS: Between 2000 and 2008, 773,233 patients with stage IV cancer were identified, 159,284 of whom (20.6%; 95% confidence interval, 20.5%-20.7%) received no anticancer therapy. Patients with NSCLC accounted for 55% of the untreated population. Patients with cancers of the kidney and lung had the highest rates of no treatment at 25.5% and 24.0%, respectively, whereas patients with prostate cancer had the lowest rate of no treatment at 11.1%. Across all cancer types, older age (PR range, 1.37-1.49; all P < .001), black race (PR range, 1.05-1.32; all P < .001), lack of medical insurance (PR range, 1.47-2.46; all P < .001), and lower income (except for cancer of the uterus; PR range, 0.91-0.98 for every $10,000-increase in income [all P < .001]) were associated with a lack of treatment. CONCLUSIONS: Approximately 20% of patients who present with stage IV solid tumors do not receive anticancer therapy. Although there are likely multiple reasons for this lack of treatment, including appropriate indications, these findings have potential implications with regard to health care policy and access to care. Cancer 2012.(c) 2012 American Cancer Society. C1 [Small, Alexander C.; Tsao, Che-Kai; Gartrell, Benjamin A.; Smith, Cardinale B.; Oh, William K.; Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA. [Moshier, Erin L.; Godbold, James H.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA. [Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. [Wisnivesky, Juan P.] Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY 10029 USA. [Sonpavde, Guru] Texas Oncol Deke Slayton Canc Ctr, Houston, TX USA. [Sonpavde, Guru] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Houston, TX 77030 USA. RP Galsky, MD (reprint author), Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM matthew.galsky@mssm.edu RI Oh, William/B-9163-2012 OI Oh, William/0000-0001-5113-8147 FU Doris Duke Charitable Foundation; Novartis Pharmaceuticals; GlaxoSmithKline FX Funding received from the Doris Duke Charitable Foundation.; Dr. Wisnivesky is a member of the research board of EHE International. He has received lecture fees from Novartis Pharmaceuticals, acted as a consultant for United BioSource Corporation, and received a chronic obstructive pulmonary disease grant from GlaxoSmithKline. NR 19 TC 10 Z9 10 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD DEC 1 PY 2012 VL 118 IS 23 BP 5947 EP 5954 DI 10.1002/cncr.27658 PG 8 WC Oncology SC Oncology GA 040EZ UT WOS:000311306000028 PM 22707387 ER PT J AU Albertini, MR Hank, JA Gadbaw, B Kostlevy, J Haldeman, J Schalch, H Gan, J Kim, K Eickhoff, J Gillies, SD Sondel, PM AF Albertini, Mark R. Hank, Jacquelyn A. Gadbaw, Brian Kostlevy, Jordan Haldeman, Jennifer Schalch, Heidi Gan, Jacek Kim, KyungMann Eickhoff, Jens Gillies, Stephen D. Sondel, Paul M. TI Phase II trial of hu14.18-IL2 for patients with metastatic melanoma SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE Immunocytokine; Advanced Melanoma; Immunotherapy; Interleukin-2; Anti-ganglioside antibody; Phase II clinical trial ID RECOMBINANT INTERLEUKIN-2 THERAPY; NEUROBLASTOMA METASTASES; INCREASED EXPRESSION; CLINICAL-TRIAL; KILLER-CELLS; BONE-MARROW; ANTIBODY; IMMUNOCYTOKINE; IMMUNOTHERAPY; EMD-273063 AB Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. In this phase II study, 14 patients with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m(2)/day as 4-h intravenous infusions on Days 1, 2, and 3 of each 28 day cycle. Patients with stable disease (SD) or regression following cycle 2 could receive two additional treatment cycles. The primary objective was to evaluate antitumor activity and response duration. Secondary objectives evaluated adverse events and immunologic activation. All patients received two cycles of treatment. One patient had a partial response (PR) [1 PR of 14 patients = response rate of 7.1 %; confidence interval, 0.2-33.9 %], and 4 patients had SD and received cycles 3 and 4. The PR and SD responses lasted 3-4 months. All toxicities were reversible and those resulting in dose reduction included grade 3 hypotension (2 patients) and grade 2 renal insufficiency with oliguria (1 patient). Patients had a peripheral blood lymphocytosis on Day 8 and increased C-reactive protein. While one PR in 14 patients met protocol criteria to proceed to stage 2 and enter 16 additional patients, we suspended stage 2 due to limited availability of hu14.18-IL2 at that time and the brief duration of PR and SD. We conclude that subsequent testing of hu14.18-IL2 should involve melanoma patients with minimal residual disease based on compelling preclinical data and the confirmed immune activation with some antitumor activity in this study. C1 [Albertini, Mark R.] K6 530 Clin Sci Ctr, Madison, WI 53792 USA. [Albertini, Mark R.; Hank, Jacquelyn A.; Kostlevy, Jordan; Haldeman, Jennifer; Schalch, Heidi; Gan, Jacek; Kim, KyungMann; Eickhoff, Jens; Sondel, Paul M.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Albertini, Mark R.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA. [Hank, Jacquelyn A.; Gan, Jacek; Sondel, Paul M.] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA. [Gadbaw, Brian; Sondel, Paul M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA. [Kim, KyungMann; Eickhoff, Jens] Univ Wisconsin, Dept Biostat, Sch Med & Publ Hlth, Madison, WI USA. [Gillies, Stephen D.] Provenance Biopharmaceut Inc, Waltham, MA USA. RP Albertini, MR (reprint author), K6 530 Clin Sci Ctr, 600 Highland Ave, Madison, WI 53792 USA. EM mralbert@wisc.edu FU National Institutes of Health [CA032685, CA87025]; Midwest Athletes for Childhood Cancer Fund; Crawdaddy Foundation; CTRC grant [GM067386]; National Cancer Institute [P30 CA014520]; Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope Foundation; Jay Van Sloan Memorial from the Steve Leuthold Family; Tim Eagle Memorial FX We thank Barrett P. Wagner for technical assistance and Laddie Johnson for assistance with manuscript preparation. We also thank the nurses on the UW CTRC for outstanding nursing care and for clinical trial support. This material was supported by National Institutes of Health Grants CA032685, CA87025, and grants from the Midwest Athletes for Childhood Cancer Fund, the Crawdaddy Foundation; CTRC grant (GM067386); grant P30 CA014520 from the National Cancer Institute; the Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope Foundation; the Jay Van Sloan Memorial from the Steve Leuthold Family; and the Tim Eagle Memorial. NR 29 TC 19 Z9 19 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD DEC PY 2012 VL 61 IS 12 BP 2261 EP 2271 DI 10.1007/s00262-012-1286-5 PG 11 WC Oncology; Immunology SC Oncology; Immunology GA 045AO UT WOS:000311666600006 PM 22678096 ER PT J AU Hotchkiss, JR Palevsky, PM AF Hotchkiss, John R. Palevsky, Paul M. TI Care of the critically ill patient with advanced chronic kidney disease or end-stage renal disease SO CURRENT OPINION IN CRITICAL CARE LA English DT Review DE chronic kidney disease; critical care; end-stage renal disease; prognosis ID REPLACEMENT THERAPY; DIALYSIS PATIENTS; UREMIC PATIENTS; STAPHYLOCOCCUS-AUREUS; CHRONIC-HEMODIALYSIS; CLINICAL-FEATURES; BLEEDING-TIME; UNIT; FAILURE; OUTCOMES AB Purpose of review The number of individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD) is rising, and these individuals often require intensive care. Recent findings Patients with CKD and ESRD require critical care more frequently than those without these conditions and have similar reasons for requiring critical care as the general population. However, the burden of comorbidities, overall severity of illness as assessed by standard scoring systems, and mortality are higher in patients with ESRD than in the non-ESRD critically ill. After adjustment for demographics, comorbidities, and physiologic variables, the increased mortality risk in patients with ESRD is attenuated. In comparison to patients with dialysis-requiring acute kidney injury (AKI), critically ill patients with ESRD have a more favorable prognosis. Severity of illness scoring systems such as Acute Physiology and Chronic Health Evaluation and Simplified Acute Physiology Score tend to overestimate the risk of death in critically ill ESRD patients. ICU admission does not appear to dramatically affect long-term mortality in those with ESRD who survive their initial acute illness as compared ESRD patients without critical illness. Summary Despite the manifest physiologic derangements attending CKD/ESRD, a higher burden of comorbid conditions and a greater severity of illness on presentation account for much of the increased mortality. There is no justification for therapeutic nihilism in this population. C1 [Hotchkiss, John R.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect,Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Hotchkiss, John R.] VA Pittsburgh Healthcare Syst, Crit Care Med Serv Line, Pittsburgh, PA USA. [Hotchkiss, John R.] VA Pittsburgh Healthcare Syst, Vet Engn Resource Ctr, Pittsburgh, PA USA. [Hotchkiss, John R.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15240 USA. [Hotchkiss, John R.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15240 USA. RP Palevsky, PM (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect,Med Specialty Serv Line, Room 7E123,111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 FU Spectral Diagnostics Inc. FX P.M.P. serves on medical advisory committees for Sanofi-Aventis and Cytopherx and participates in research sponsored by Spectral Diagnostics Inc. NR 34 TC 5 Z9 5 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5295 J9 CURR OPIN CRIT CARE JI Curr. Opin. Crit. Care PD DEC PY 2012 VL 18 IS 6 BP 599 EP 606 DI 10.1097/MCC.0b013e32835a1c59 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 039IA UT WOS:000311237000004 PM 23079618 ER PT J AU Stevens, RJ Ali, R Bankhead, CR Bethel, MA Cairns, BJ Camisasca, RP Crowe, FL Farmer, AJ Harrison, S Hirst, JA Home, P Kahn, SE McLellan, JH Perera, R Pluddemann, A Ramachandran, A Roberts, NW Rose, PW Schweizer, A Viberti, G Holman, RR AF Stevens, R. J. Ali, R. Bankhead, C. R. Bethel, M. A. Cairns, B. J. Camisasca, R. P. Crowe, F. L. Farmer, A. J. Harrison, S. Hirst, J. A. Home, P. Kahn, S. E. McLellan, J. H. Perera, R. Plueddemann, A. Ramachandran, A. Roberts, N. W. Rose, P. W. Schweizer, A. Viberti, G. Holman, R. R. TI Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials (vol 55, pg 2593, 2012) SO DIABETOLOGIA LA English DT Correction C1 [Stevens, R. J.; Bankhead, C. R.; Farmer, A. J.; Harrison, S.; Hirst, J. A.; McLellan, J. H.; Perera, R.; Plueddemann, A.; Roberts, N. W.; Rose, P. W.] Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX2 6GG, England. [Ali, R.; Cairns, B. J.; Crowe, F. L.] Univ Oxford, Canc Epidemiol Unit, Oxford OX2 6GG, England. [Bethel, M. A.; Holman, R. R.] Univ Oxford, Diabet Trials Unit, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX2 6GG, England. [Camisasca, R. P.] Takeda Pharmaceut Co, TGRD Europe, London, England. [Home, P.] Newcastle Univ, Sch Med, ICM Diabet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Kahn, S. E.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. [Ramachandran, A.] Dr A Ramachandrans Diabet Hosp, India Diabet Res Fdn, Chennai, Tamil Nadu, India. [Schweizer, A.] Novartis Pharmaceut, Basel, Switzerland. [Viberti, G.] Kings Coll London, Metab Med Unit, Sch Med, London WC2R 2LS, England. RP Stevens, RJ (reprint author), Univ Oxford, Dept Primary Care Hlth Sci, Woodstock Rd, Oxford OX2 6GG, England. EM richard.stevens@phc.ox.ac.uk OI Roberts, Nia Wyn/0000-0002-1142-6440 NR 1 TC 4 Z9 4 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD DEC PY 2012 VL 55 IS 12 BP 3399 EP 3400 DI 10.1007/s00125-012-2740-9 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 027VJ UT WOS:000310381800030 ER PT J AU Marshall, DF Strutt, AM Williams, AE Simpson, RK Jankovic, J York, MK AF Marshall, D. F. Strutt, A. M. Williams, A. E. Simpson, R. K. Jankovic, J. York, M. K. TI Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE deep brain stimulation; neuropsychology; Parkinson's disease; verbal fluency ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE IMPAIRMENT; PALLIDAL STIMULATION; LOCALIZATION; LESIONS; TASKS; MOOD AB Background and purpose Despite common occurrences of verbal fluency declines following bilateral subthalamic nucleus deep brain stimulation (STN-DBS) for the treatment of Parkinson's disease (PD), alternating fluency measures using cued and uncued paradigms have not been evaluated. Methods Twenty-three STN-DBS patients were compared with 20 non-surgical PD patients on a comprehensive neuropsychological assessment, including cued and uncued intradimensional (phonemic/phonemic and semantic/semantic) and extradimensional (phonemic/semantic) alternating fluency measures at baseline and 6-month follow-up. Results STN-DBS patients demonstrated a greater decline on the cued phonemic/phonemic fluency and the uncued phonemic/semantic fluency tasks compared to the PD patients. For STN-DBS patients, verbal learning and information processing speed accounted for a significant proportion of the variance in declines in alternating phonemic/phonemic and phonemic/semantic fluency scores, respectively, whilst only naming was related to uncued phonemic/semantic performance for the PD patients. Both groups were aided by cueing for the extradimensional task at baseline and follow-up, and the PD patients were also aided by cueing for the phonemic/phonemic task on follow-up. Conclusions These findings suggest that changes in alternating fluency are not related to disease progression alone as STN-DBS patients demonstrated greater declines over time than the PD patients, and this change was related to declines in information processing speed. C1 [Marshall, D. F.; Strutt, A. M.; Williams, A. E.; Jankovic, J.; York, M. K.] Baylor Coll Med, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, Houston, TX 77030 USA. [Simpson, R. K.] Methodist Hosp, Dept Neurosurg, Neurol Inst, Houston, TX 77030 USA. [York, M. K.] Parkinsons Dis Res Educ & Clin Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP York, MK (reprint author), Baylor Coll Med, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, 6550 Fannin,SM1801, Houston, TX 77030 USA. EM myork@bcm.edu FU NIH/NINDS FX The authors wish to thank the National Parkinson's Foundation and the patients who willingly gave their time to participate in this research project and Zack Dorsey for his help in final editing and revisions. Work was funded by an NIH/NINDS K23 grant (PI: York) and supported with resources from the Veterans' Affairs Office of Research and Development. NR 33 TC 12 Z9 12 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD DEC PY 2012 VL 19 IS 12 BP 1525 EP 1531 DI 10.1111/j.1468-1331.2012.03759.x PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 040AI UT WOS:000311290500009 PM 22632922 ER PT J AU de Nijs, L Wolkoff, N Coumans, B Delgado-Escueta, AV Grisar, T Lakaye, B AF de Nijs, Laurence Wolkoff, Nathalie Coumans, Bernard Delgado-Escueta, Antonio V. Grisar, Thierry Lakaye, Bernard TI Mutations of EFHC1, linked to juvenile myoclonic epilepsy, disrupt radial and tangential migrations during brain development SO HUMAN MOLECULAR GENETICS LA English DT Article ID VOXEL-BASED MORPHOMETRY; DEVELOPING CEREBRAL-CORTEX; NEURONAL MIGRATION; GENERALIZED EPILEPSY; RNA INTERFERENCE; PROTEIN; NEOCORTEX; MYOCLONIN1/EFHC1; NUCLEOKINESIS; ABNORMALITIES AB Heterozygous mutations in Myoclonin1/EFHC1 cause juvenile myoclonic epilepsy (JME), the most common form of genetic generalized epilepsies, while homozygous F229L mutation is associated with primary intractable epilepsy in infancy. Heterozygous mutations in adolescent JME patients produce subtle malformations of cortical and subcortical architecture, whereas homozygous F229L mutation in infancy induces severe brain pathology and death. However, the underlying pathological mechanisms for these observations remain unknown. We had previously demonstrated that EFHC1 is a microtubule-associated protein (MAP) involved in cell division and radial migration during cerebral corticogenesis. Here, we show that JME mutations, including F229L, do not alter the ability of EFHC1 to colocalize with the centrosome and the mitotic spindle, but act in a dominant-negative manner to impair mitotic spindle organization. We also found that mutants EFHC1 expression disrupted radial and tangential migration by affecting the morphology of radial glia and migrating neurons. These results show how Myoclonin1/EFHC1 mutations disrupt brain development and potentially produce structural brain abnormalities on which epileptogenesis is established. C1 [de Nijs, Laurence; Wolkoff, Nathalie; Coumans, Bernard; Grisar, Thierry; Lakaye, Bernard] Univ Liege, GIGA Neurosci, B-4000 Liege, Belgium. [Delgado-Escueta, Antonio V.] VA Greater Los Angeles Healthcare Syst, Epilepsy Genet Genom Labs, Neurol & Res Serv, Los Angeles, CA USA. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Lakaye, B (reprint author), Univ Liege, GIGA Neurosci, 1 Ave Hop, B-4000 Liege, Belgium. EM b.lakaye@ulg.ac.be OI Delgado-Escueta, Antonio V./0000-0002-1581-6999 FU Fonds de la Recherche Scientifique-FNRS [FRSM 3.4531.09]; Leon Fredericq Foundation; Fonds speciaux of the University of Liege [C-10/31, C-11/94]; NIH [5R01NS055057]; VA Merit Review grant FX This work was supported by the Fonds de la Recherche Scientifique-FNRS (FRSM 3.4531.09 to T. G. and B. L.); the Leon Fredericq Foundation (to L.d.N.) and the Fonds speciaux of the University of Liege (C-10/31 and C-11/94 to T. G and B. L.). L.d.N. and B. L. are, respectively, postdoctoral researcher and research associates at the Fonds de la Recherche Scientifique-FNRS. A. V. D.-E. is supported by NIH grant 5R01NS055057 and VA Merit Review grant. NR 44 TC 13 Z9 14 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD DEC 1 PY 2012 VL 21 IS 23 BP 5106 EP 5117 DI 10.1093/hmg/dds356 PG 12 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 035SE UT WOS:000310967900007 PM 22926142 ER PT J AU Bodhankar, S Vandenbark, AA Offner, H AF Bodhankar, Sheetal Vandenbark, Arthur A. Offner, Halina TI Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17 beta-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4(+) Foxp3(+) regulatory T cells SO IMMUNOLOGY LA English DT Article DE experimental autoimmune encephalomyelitis; multiple sclerosis; oestrogen and receptors; programmed death-1; programmed death ligand; regulatory B cells ID PREGNANCY HORMONE ESTRIOL; PROGRAMMED DEATH 1; MULTIPLE-SCLEROSIS; EXPRESSION; MICE; MODULATION; SEVERITY AB It is now well accepted that sex hormones have immunoregulatory activity and may prevent exacerbations in multiple sclerosis during pregnancy. Our previous studies demonstrated that oestrogen (17 beta-oestradiol; E2) protection against experimental autoimmune encephalomyelitis (EAE) is mediated mainly through oestrogen receptor-a (ERa) and the membrane receptor G-protein-coupled receptor 30 (GPR30) and is abrogated in the absence of B cells and the co-inhibitory receptor, Programmed Death-1 (PD-1). To critically evaluate the cell source of the E2 and PD-1 co-inhibitory pathways in EAE regulation, we assessed the requirement for ERs on transferred B cells and downstream effects on expression of PD-1/PD-ligand on CD4+ Foxp3+ regulatory T (Treg) cells in B-cell-replenished, E2-treated B-cell-deficient (mu MT-/-) mice with EAE. The results clearly demonstrated involvement of ERa and GPR30 on transferred B cells that mediated the protective E2 treatment effect on EAE and further showed an E2-mediated B-cell-dependent up-regulation of PD-1 on CD4+ Foxp3+ Treg cells. These findings identify regulatory B-cell populations as key players in potentiating Treg-cell activity during E2-mediated protection against EAE. C1 [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Dept Vet Affairs Med Ctr, Res Serv, Portland, OR USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU National Institutes of Health [NS045445]; National Multiple Sclerosis Society [RG3405-C-6]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors thank Lisa Miller and Mary Chase for technical assistance, Danielle Galipeau for assistance in histology images, Zefora Alderman for assistance in preparing the figures and Eva Niehaus for assistance with manuscript preparation. This work was supported by National Institutes of Health grant NS045445 and National Multiple Sclerosis Society grant RG3405-C-6. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the US Government. NR 26 TC 21 Z9 21 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 J9 IMMUNOLOGY JI Immunology PD DEC PY 2012 VL 137 IS 4 BP 282 EP 293 DI 10.1111/imm.12013 PG 12 WC Immunology SC Immunology GA 041HE UT WOS:000311389900002 PM 23039230 ER PT J AU Fukuta, Y Cunningham, CA Harris, PL Wagener, MM Muder, RR AF Fukuta, Yuriko Cunningham, Candace A. Harris, Patricia L. Wagener, Marilyn M. Muder, Robert R. TI Identifying the Risk Factors for Hospital-Acquired Methicillin-Resistant Staphylococcus aureus (MRSA) Infection among Patients Colonized with MRSA on Admission SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INTENSIVE-CARE-UNIT; NASAL COLONIZATION; SURVEILLANCE AB BACKGROUND. Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen in hospital-acquired infections. MRSA-colonized inpatients who may benefit from undergoing decolonization have not been identified. OBJECTIVE. To identify risk factors for MRSA infection among patients who are colonized with MRSA at hospital admission. DESIGN. A case-control study. SETTING. A 146-bed Veterans Affairs hospital. PARTICIPANTS. Case patients were those patients admitted from January 2003 to August 2011 who were found to be colonized with MRSA on admission and then developed MRSA infection. Control subjects were those patients admitted during the same period who were found to be colonized with MRSA on admission but who did not develop MRSA infection. METHODS. A retrospective review. RESULTS. A total of 75 case patients and 150 control subjects were identified. A stay in the intensive care unit (ICU) was the significant risk factor in univariate analysis (P < .001). Prior history of MRSA (P = .03), transfer from a nursing home (P = .002), experiencing respiratory failure (P < .001), and receipt of transfusion (P = .001) remained significant variables in multivariate analysis. Prior history of MRSA colonization or infection (P = .02), difficulty swallowing (P = .04), presence of an open wound (P = .002), and placement of a central line (P = .02) were identified as risk factors for developing MRSA infection for patients in the ICU. Duration of hospitalization, readmission rate, and mortality rate were significantly higher in case patients than in control subjects (P < .001, .001, and <.001, respectively). CONCLUSIONS. MRSA-colonized patients admitted to the ICU or admitted from nursing homes have a high risk of developing MRSA infection. These patients may benefit from undergoing decolonization. Infect Control Hosp Epidemiol 2012;33(12):1219-1225 C1 [Fukuta, Yuriko; Muder, Robert R.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. [Cunningham, Candace A.; Harris, Patricia L.; Muder, Robert R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. [Wagener, Marilyn M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Muder, RR (reprint author), Univ Dr C, Pittsburgh, PA 15240 USA. EM robert.muder@med.va.gov NR 15 TC 13 Z9 14 U1 0 U2 10 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC PY 2012 VL 33 IS 12 BP 1219 EP 1225 DI 10.1086/668420 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 037BP UT WOS:000311076300006 PM 23143359 ER PT J AU Ionov, M Gordiyenko, NV Zukowska, I Tokhtaeva, E Mareninova, OA Baram, N Ziyaev, K Rezhepov, K Zamaraeva, M AF Ionov, Maksim Gordiyenko, Nataliya V. Zukowska, Izabela Tokhtaeva, Elmira Mareninova, Olga A. Baram, Nina Ziyaev, Khairulla Rezhepov, Kuralbay Zamaraeva, Maria TI Stability and antioxidant activity of gossypol derivative immobilized on N-polyvinylpyrrolidone SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES LA English DT Article DE Gossypol derivative; N-polyvinylpyrrolidone antioxidant; CCl4 oxidative damage; Lipid peroxidation; Oxidative phosphorylation ID CARBON-TETRACHLORIDE; LIPID-PEROXIDATION; REACTIVE OXYGEN; IN-VITRO; PHOSPHOLIPIDS; MITOCHONDRIA; ACTIVATION; MECHANISM; FULLERENE; TISSUES AB The objective of this study is analysis of stability and antioxidant and antiradical activities of the gossypol derivative - megosin conjugated with N-polyvinylpyrrolidone (PVP). The results of study have shown the greater stability of megosin + PVP than megosin in aqueous solution of wide range of pH. Here we also demonstrated that megosin + PVP, named rometin, possess high antioxidant activity in the same range as well known antioxidant trolox as determined by its ability to scavenge free ABTS' and DPPH center dot radicals in vitro. In addition, megosin + PVP was able to prevent accumulation of products of lipid peroxidation (thiobarbituric acid reactive substances and diene conjugates) and lysophospholipids formation in mitochondria membranes caused by CCl4-induced oxidative stress in rat liver in vivo. Furthermore, megosin + PVP rescued mitochondrial functions, such as respiration and oxidative phosphorylation, which declined after CCl4 administration. Thus we present that the conjugation of megosin to PVP increase its stability and remain antioxidant activity in vivo and in vitro. (C) 2012 Elsevier B.V. All rights reserved. C1 [Zukowska, Izabela; Zamaraeva, Maria] Univ Bialystok, Dept Biophys, PL-15950 Bialystok, Poland. [Ionov, Maksim] Univ Lodz, Dept Gen Biophys, PL-90237 Lodz, Poland. [Gordiyenko, Nataliya V.; Tokhtaeva, Elmira; Mareninova, Olga A.; Baram, Nina; Ziyaev, Khairulla; Rezhepov, Kuralbay] Uzbek Acad Sci, Inst Bioorgan Chem, Tashkent 100125, Uzbekistan. [Tokhtaeva, Elmira] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Tokhtaeva, Elmira] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. [Mareninova, Olga A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. [Mareninova, Olga A.] Greater Los Angeles Healthcare Syst, Vet Affairs, Los Angeles, CA 90073 USA. RP Zamaraeva, M (reprint author), Univ Bialystok, Dept Biophys, Swierkowa St 208, PL-15950 Bialystok, Poland. EM m.zamaraeva@uwb.edu.pl NR 52 TC 0 Z9 0 U1 0 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0141-8130 J9 INT J BIOL MACROMOL JI Int. J. Biol. Macromol. PD DEC PY 2012 VL 51 IS 5 BP 908 EP 914 DI 10.1016/j.ijbiomac.2012.08.005 PG 7 WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science SC Biochemistry & Molecular Biology; Chemistry; Polymer Science GA 038TD UT WOS:000311196100032 PM 22910577 ER PT J AU Sharff, KA Monecke, S Slaughter, S Forrest, G Pfeiffer, C Ehricht, R Oethinger, M AF Sharff, Katie A. Monecke, Stefan Slaughter, Sarah Forrest, Graeme Pfeiffer, Chris Ehricht, Ralf Oethinger, Margret TI Genotypic Resistance Testing Creates New Treatment Challenges: Two Cases of Oxacillin-Susceptible Methicillin-Resistant Staphylococcus aureus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CASSETTE CHROMOSOME MEC; IN-VIVO; STRAINS; SCCMEC; GENES AB Oxacillin-susceptible, mecA-positive Staphylococcus aureus isolates create a treatment challenge for the clinician. In this article, we describe two cases of bacteremia from isolates that carried the mecA gene but were susceptible to oxacillin ( oxacillin-susceptible methicillin-resistant S. aureus [OS-MRSA]). DNA microarray analysis was used to characterize these isolates as a mecA-positive, clonal complex 5, pediatric strain and a mecA-positive, clonal complex 8, USA300 strain. C1 [Sharff, Katie A.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Monecke, Stefan] Tech Univ Dresden, Inst Med Microbiol & Hyg, D-01062 Dresden, Germany. [Slaughter, Sarah] Prov Portland Med Ctr, Div Infect Dis, Portland, OR USA. [Forrest, Graeme; Pfeiffer, Chris] Portland VA Med Ctr, Div Infect Dis, Portland, OR USA. [Ehricht, Ralf] Alere Technol GmbH, Jena, Germany. [Oethinger, Margret] Prov Hlth & Serv, Dept Lab Serv, Portland, OR USA. RP Sharff, KA (reprint author), Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. EM sharffk@ohsu.edu NR 16 TC 13 Z9 13 U1 3 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2012 VL 50 IS 12 BP 4151 EP 4153 DI 10.1128/JCM.01564-12 PG 3 WC Microbiology SC Microbiology GA 038ZE UT WOS:000311211800062 PM 22993184 ER PT J AU Osman, A Wong, JL Bagge, CL Freedenthal, S Gutierrez, PM Lozano, G AF Osman, Augustine Wong, Jane L. Bagge, Courtney L. Freedenthal, Stacey Gutierrez, Peter M. Lozano, Gregorio TI The Depression Anxiety Stress Scalesu21 (DASS-21): Further Examination of Dimensions, Scale Reliability, and Correlates SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE depression anxiety stress; self1-report inventory; bifactor IRT models; nonclinical ID CONFIRMATORY FACTOR-ANALYSIS; ADOLESCENT PSYCHIATRIC-INPATIENTS; CLINICAL-ASSESSMENT INSTRUMENTS; LARGE NONCLINICAL SAMPLE; PSYCHOMETRIC PROPERTIES; MEASUREMENT INVARIANCE; TRIPARTITE MODEL; PSYCHOLOGICAL-ASSESSMENT; NORMATIVE DATA; VALIDITY AB Objectives We conducted two studies to examine the dimensions, internal consistency reliability estimates, and potential correlates of the Depression Anxiety Stress Scales21 (DASS-21; Lovibond & Lovibond, 1995). Method Participants in Study 1 included 887 undergraduate students (363 men and 524 women, aged 18 to 35 years; mean [M] age = 19.46, standard deviation [SD] = 2.17) recruited from two public universities to assess the specificity of the individual DASS-21 items and to evaluate estimates of internal consistency reliability. Participants in a follow-up study (Study 2) included 410 students (168 men and 242 women, aged 18 to 47 years; M age = 19.65, SD = 2.88) recruited from the same universities to further assess factorial validity and to evaluate potential correlates of the original DASS-21 total and scale scores. Results Item bifactor and confirmatory factor analyses revealed that a general factor accounted for the greatest proportion of common variance in the DASS-21 item scores (Study 1). In Study 2, the fit statistics showed good fit for the bifactor model. In addition, the DASS-21 total scale score correlated more highly with scores on a measure of mixed depression and anxiety than with scores on the proposed specific scales of depression or anxiety. Coefficient omega estimates for the DASS-21 scale scores were good. Conclusions Further investigations of the bifactor structure and psychometric properties of the DASS-21, specifically its incremental and discriminant validity, using known clinical groups are needed. C1 [Osman, Augustine] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA. [Wong, Jane L.] Armstrong Atlantic State Univ, Savannah, GA USA. [Bagge, Courtney L.] Univ Mississippi, Med Ctr, University, MS 38677 USA. [Freedenthal, Stacey] Univ Denver, Denver, CO 80208 USA. [Gutierrez, Peter M.] MIRECC, Denver VA Med Ctr, Denver, CO USA. RP Osman, A (reprint author), Univ Texas San Antonio, Dept Psychol, 1 UTSA Circle, San Antonio, TX 78249 USA. EM augustine.osman@utsa.edu OI Gutierrez, Peter/0000-0001-8981-8404 NR 73 TC 69 Z9 70 U1 8 U2 78 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD DEC PY 2012 VL 68 IS 12 BP 1322 EP 1338 DI 10.1002/jclp.21908 PG 17 WC Psychology, Clinical SC Psychology GA 035UY UT WOS:000310977100009 PM 22930477 ER PT J AU Williams, BR Lewis, DR Burgio, KL Goode, PS AF Williams, Beverly Rosa Lewis, Donna R. Burgio, Kathryn L. Goode, Patricia S. TI "Wrapped in Their Arms'' Next-of-Kin's Perceptions of How Hospital Nursing Staff Support Family Presence Before, During, and After the Death of a Loved One SO JOURNAL OF HOSPICE & PALLIATIVE NURSING LA English DT Article DE end of life; family; nursing care; qualitative analysis ID LIFE CARE; PEOPLE AB Family presence is a vital component of quality end-of-life (EOL) care. We conducted face-to-face, in-depth interviews with next-of-kin of deceased veterans to explore perceptions of how hospital nursing staff supported and facilitated family presence during the actively dying phase, at the time of death, and immediately following the patient's death. We used content analysis to examine respondents' accounts of the role of nursing staff in fostering and sustaining family presence in the hospital setting. We provide exemplary quotes to contextualize nursing staff behaviors that encouraged, supported, and guided families, enabling them to be present and to function adaptively before, during, and after the loved one's death. In particular, we focus on nursing behaviors that were responsive to family members' needs for information, privacy, intimacy, physical comfort, and emotional reassurance. Nurses' effectiveness in optimizing family support required clinical competency in recognizing the actively dying phase of life and engaging in behaviors that facilitated the delivery EOL care, with thoughtful attention to family needs. C1 [Williams, Beverly Rosa; Burgio, Kathryn L.; Goode, Patricia S.] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Williams, Beverly Rosa] Univ Alabama Birmingham, UAB Ctr Aging, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL USA. [Lewis, Donna R.] Emory Univ, Community Living Ctr, Atlanta VA Med Ctr, Atlanta, GA 30322 USA. [Lewis, Donna R.] Emory Univ, Adjunct Fac, Sch Nursing, Atlanta, GA 30322 USA. RP Williams, BR (reprint author), Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham VA Med Ctr, CH 19 218K,1530 3rd Ave S, Birmingham, AL 35294 USA. EM beverly.williams3@va.gov FU Veterans Affairs Health Services Research and Development [IIR 03-126] FX This research was funded by a grant from Veterans Affairs Health Services Research and Development (no. IIR 03-126). NR 24 TC 8 Z9 8 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1522-2179 J9 J HOSP PALLIAT NURS JI J. Hosp. Palliat. Nurs. PD DEC PY 2012 VL 14 IS 8 BP 541 EP 550 DI 10.1097/NJH.0b013e31825d2af1 PG 10 WC Nursing SC Nursing GA 035AJ UT WOS:000310913700007 ER PT J AU Byrd, JB Powers, JD Magid, DJ Tavel, HM Schmittdiel, JA O'Connor, PJ Beck, AL Butler, MG Ho, PJM AF Byrd, James B. Powers, J. David Magid, David J. Tavel, Heather M. Schmittdiel, Julie A. O'Connor, Patrick J. Beck, Arne L. Butler, Melissa G. Ho, Pei-Jai M. TI Detection and recognition of hypertension in anxious and depressed patients SO JOURNAL OF HYPERTENSION LA English DT Article DE anxiety; depression; diagnosis; early diagnosis; hypertension ID SYSTOLIC HYPERTENSION; RISK; SYMPTOMS; ANXIETY; ADHERENCE; DISEASE; TRENDS; IMPACT; CARE AB Objective: Hypertension management requires detection (i.e. confirmation of persistently high blood pressure (BP) after an initial elevated measurement) and recognition of the condition (evidenced by a formal diagnosis and/or initiation of treatment). Our objective was to determine whether disparities exist in detection of elevated BP and recognition (i.e. diagnosis or treatment) of hypertension in patients with depression and anxiety. Methods: Using data from the Cardiovascular Research Network Hypertension Registry, we assessed time-to-detection of elevated BP and recognition of hypertension in patients with comorbid anxiety and depression compared with patients with neither disorder. We performed multivariable survival analysis of time to detection and recognition in patients who entered the registry in 2002-2006. We adjusted for primary care visit rate and other relevant clinical factors. Results: In 168 630 incident hypertension patients, detection occurred earlier among patients with anxiety and depression compared with patients without these diagnoses [adjusted hazard ratio for anxiety and depression 1.30, 95% confidence interval (CI) 1.26-1.35]. Recognition of hypertension within 12 months of the second elevated BP was similar (adjusted hazard ratio for anxiety and depression 0.94, 95% CI 0.89-1.00) or delayed (adjusted hazard ratio for anxiety 0.93, 95% CI 0.88-0.99 and for depression 0.93, 95% CI 0.90-0.97). Conclusions: Detection of elevated BP occurred earlier in patients with anxiety and depression. Time from detection to diagnosis or treatment was similar or delayed in patients with and without these diagnoses. Our findings suggest that as-yet-unidentified factors contribute to disparities in hypertension detection and recognition. C1 [Byrd, James B.] Univ Michigan, Dept Med, Div Cardiol, NCRC,Med Sch, Ann Arbor, MI 48109 USA. [Powers, J. David; Magid, David J.; Tavel, Heather M.; Beck, Arne L.] Kaiser Inst Hlth Res, Denver, CO USA. [Schmittdiel, Julie A.] Kaiser Permanente Div Res, Oakland, CA USA. [O'Connor, Patrick J.] HealthPartners Res Fdn, Minneapolis, MN USA. [Butler, Melissa G.] Kaiser Permanente Georgia, Ctr Hlth Res SE, Atlanta, GA USA. [Ho, Pei-Jai M.] Denver VA Med Ctr, Dept Med, Denver, CO USA. RP Byrd, JB (reprint author), Univ Michigan, Dept Med, Div Cardiol, NCRC,Med Sch, Room 20-209W,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM jbbyrd@umich.edu OI Byrd, J. Brian/0000-0002-0509-3520 FU NIH, Cardiovascular Research Network [U19HL091179, 3U19HL091179-04S1]; Department of Veterans Affairs GME Enhancement Grant FX This work was supported by NIH grants U19HL091179 and 3U19HL091179-04S1 as part of the Cardiovascular Research Network and J.B.B was supported by a Department of Veterans Affairs GME Enhancement Grant. NR 13 TC 3 Z9 4 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2012 VL 30 IS 12 BP 2293 EP 2298 DI 10.1097/HJH.0b013e328359b6e6 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 039VA UT WOS:000311273700008 PM 23032145 ER PT J AU Yoo, JW Nakagawa, S Kim, S AF Yoo, Ji Won Nakagawa, Shunichi Kim, Sulgi TI The Effect Modification of Supplemental Insurance on the Relationship Between Race and Bone Mineral Density Screening in Female Medicare Beneficiaries SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Bone mineral density; Accessibility of health services; Health Insurance for aged and disabled; Women's health service ID AFRICAN-AMERICAN WOMEN; X-RAY ABSORPTIOMETRY; OSTEOPOROSIS; DISPARITIES; WHITE; RISK; CARE; GUIDELINES; FRACTURES; HEALTH AB To determine the effect modification of supplemental insurance on the relationship between race and bone mineral density (BMD) in female Medicare beneficiaries. Retrospectively analyzing hospital administrative claim and clinical data of female Medicare beneficiaries (n = 1,398), we performed multivariate logistic regressions of BMD testing including data from all study participants and the subsets of health insurance. Significantly fewer Black than White female Medicare beneficiaries received the BMD testing in the overall sample (odds ratio, OR = 0.63; p = 0.02) and those without supplementary health insurance (n = 709; OR = 0.38; p = 0.004). By contrast, the magnitude of this racial disparity in the BMD testing was diminished among those with supplementary private health insurance (n = 689). We found a significant racial disparity in BMD testing for Black and White female Medicare beneficiaries. This disparity became more pronounced among those without supplementary private health insurance. C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Yoo, Ji Won] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. [Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Kim, Sulgi] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 N Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA. EM yoojiw@trinity-health.org; nakagas@gmail.com; sulgik@gmail.com NR 33 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD DEC PY 2012 VL 14 IS 6 BP 912 EP 917 DI 10.1007/s10903-012-9629-z PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 036MM UT WOS:000311030400002 PM 22535021 ER PT J AU Sun, HQ Guo, S Chen, DF Yang, FD Zou, YZ Di, XL Cao, YJ Kosten, T Lu, L Zhang, XY AF Sun, Hongqiang Guo, Song Chen, Dafang Yang, Fude Zou, Yizhuang Di, Xiaolan Cao, Yanjun Kosten, Thomas Lu, Lin Zhang, Xiang Yang TI Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE Pharmacogenetics; COMT; Nicotine dependence; Smoking; Dopamine ID CATECHOL-O-METHYLTRANSFERASE; GENETIC-VARIATION; CONTROLLED TRIAL; CHINESE SMOKERS; DOUBLE-BLIND; DEPENDENCE; GENOTYPE; PHARMACOGENETICS; INHIBITORS; INITIATION AB Nicotine replacement treatment (NRT) can be efficacious for smoking cessation, but used by only a minority of smokers in China. Pharmacogenetic matching may improve treatment outcomes for NRT in subgroups of smokers. We evaluated the efficacy and safety of sublingual nicotine tablets (SNT) for smoking cessation and the association of catechol-O-methyltransferase (COMT) genotype with efficacy in this smoking cessation trial among Chinese smokers. We conducted a double-blind, placebo-controlled, 8-week trial of SNT with a follow-up at week 12 among 250 Chinese smokers. Efficacy and safety were evaluated at day 4 and weeks 2, 4, 6, 8, and 12. Abstinence was biochemically verified by exhaled carbon monoxide (CO) and urine cotinine. The COMT Val108Met genotype was determined as a restriction fragment length polymorphism. Our results showed that the success rates for complete abstinence were greater for active versus placebo treatments at 8 weeks (48 vs. 17 %) and 12 weeks (52 vs. 19 %) (both p < 0.0001). Craving was significantly reduced from week 2 on active treatment compared to placebo. Adverse events were mild and tolerable. We found a genotype by treatment interaction at 12 weeks with greater abstinence rates in the COMT Val/Val (50 vs. 15 %) than the Met/Val + Met/Met genotypes (46 vs. 25 %). We found that SNT significantly increased smoking abstinence, reduced craving and was well tolerated, and the COMT Val/Val genotype was associated with a greater improvement in smoking cessation. C1 [Guo, Song] Capital Univ Med Sci, Beijing Anding Hosp, Natl Drug Abuse Treatment Ctr, Beijing 100009, Peoples R China. [Sun, Hongqiang; Yang, Fude; Zou, Yizhuang; Di, Xiaolan; Cao, Yanjun; Zhang, Xiang Yang] Beijing Hui Long Guan Hosp, Beijing, Peoples R China. [Sun, Hongqiang; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100871, Peoples R China. [Guo, Song] Inst Mental Hlth, Addict Med Dept, Singapore, Singapore. [Chen, Dafang] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China. [Kosten, Thomas; Zhang, Xiang Yang] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang] VA Med Ctr, Houston, TX 77030 USA. RP Guo, S (reprint author), Capital Univ Med Sci, Beijing Anding Hosp, Natl Drug Abuse Treatment Ctr, Beijing 100009, Peoples R China. EM guosong23@263.net; xyzhang@bcm.edu FU National Natural Science Foundation of China [81071080]; Training Program Foundation for Excellent Talents by the Beijing Municipal Government, China [2010D003034000026]; Stanley Medical research Institute [03T-459, 05T-726]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This projects was supported by grants from the National Natural Science Foundation of China (No. 81071080) and Training Program Foundation for Excellent Talents by the Beijing Municipal Government, China (No. 2010D003034000026), the Stanley Medical research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 33 TC 3 Z9 4 U1 0 U2 7 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PD DEC PY 2012 VL 119 IS 12 BP 1491 EP 1498 DI 10.1007/s00702-012-0841-8 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 042YW UT WOS:000311509900005 PM 22695756 ER PT J AU Hollingworth, P Sweet, R Sims, R Harold, D Russo, G Abraham, R Stretton, A Jones, N Gerrish, A Chapman, J Ivanov, D Moskvina, V Lovestone, S Priotsi, P Lupton, M Brayne, C Gill, M Lawlor, B Lynch, A Craig, D McGuinness, B Johnston, J Holmes, C Livingston, G Bass, NJ Gurling, H McQuillin, A Holmans, P Jones, L Devlin, B Klei, L Barmada, MM Demirci, FY DeKosky, ST Lopez, OL Passmore, P Owen, MJ O'Donovan, MC Mayeux, R Kamboh, MI Williams, J AF Hollingworth, P. Sweet, R. Sims, R. Harold, D. Russo, G. Abraham, R. Stretton, A. Jones, N. Gerrish, A. Chapman, J. Ivanov, D. Moskvina, V. Lovestone, S. Priotsi, P. Lupton, M. Brayne, C. Gill, M. Lawlor, B. Lynch, A. Craig, D. McGuinness, B. Johnston, J. Holmes, C. Livingston, G. Bass, N. J. Gurling, H. McQuillin, A. Holmans, P. Jones, L. Devlin, B. Klei, L. Barmada, M. M. Demirci, F. Y. DeKosky, S. T. Lopez, O. L. Passmore, P. Owen, M. J. O'Donovan, M. C. Mayeux, R. Kamboh, M. I. Williams, J. CA GERAD Consortium Natl Inst Aging Late-Onset Alzheim TI Genome-wide association study of Alzheimer's disease with psychotic symptoms SO MOLECULAR PSYCHIATRY LA English DT Article DE Alzheimer's disease; psychosis; behavioural symptoms; genome-wide association study; genetic ID INCREASED FAMILIAL RISK; COMPLEMENT RECEPTOR 1; COMMON VARIANTS; BIPOLAR DISORDER; URIC-ACID; NEUROPSYCHIATRIC INVENTORY; COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; IDENTIFIES VARIANTS; NATIONAL INSTITUTE AB Psychotic symptoms occur in similar to 40% of subjects with Alzheimer's disease (AD) and are associated with more rapid cognitive decline and increased functional deficits. They show heritability up to 61% and have been proposed as a marker for a disease subtype suitable for gene mapping efforts. We undertook a combined analysis of three genome-wide association studies (GWASs) to identify loci that (1) increase susceptibility to an AD and subsequent psychotic symptoms; or (2) modify risk of psychotic symptoms in the presence of neurodegeneration caused by AD. In all, 1299 AD cases with psychosis (AD+P), 735 AD cases without psychosis (AD-P) and 5659 controls were drawn from Genetic and Environmental Risk in AD Consortium 1 (GERAD1), the National Institute on Aging Late-Onset Alzheimer's Disease (NIA-LOAD) family study and the University of Pittsburgh Alzheimer Disease Research Center (ADRC) GWASs. Unobserved genotypes were imputed to provide data on > 1.8 million single-nucleotide polymorphisms (SNPs). Analyses in each data set were completed comparing (1) AD+P to AD-P cases, and (2) AD+P cases with controls (GERAD1, ADRC only). Aside from the apolipoprotein E (APOE) locus, the strongest evidence for association was observed in an intergenic region on chromosome 4 (rs753129; 'AD+PvAD-P' P=2.85 x 10(-7); 'AD+PvControls' P=1.11 x 10(-4)). SNPs upstream of SLC2A9 (rs6834555, P=3.0 x 10(-7)) and within VSNL1 (rs4038131, P=5.9 x 10(-7)) showed strongest evidence for association with AD+P when compared with controls. These findings warrant further investigation in larger, appropriately powered samples in which the presence of psychotic symptoms in AD has been well characterized. Molecular Psychiatry (2012) 17, 1316-1327; doi: 10.1038/mp.2011.125; published online 18 October 2011 C1 [Sweet, R.; Devlin, B.; Klei, L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Hollingworth, P.; Sims, R.; Harold, D.; Russo, G.; Abraham, R.; Stretton, A.; Jones, N.; Gerrish, A.; Chapman, J.; Ivanov, D.; Moskvina, V.; Holmans, P.; Owen, M. J.; O'Donovan, M. C.; Williams, J.] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Ctr Neuropsychiat Genet & Genom, Dept Psychol Med & Neurol,Sch Med,MRC, Cardiff, S Glam, Wales. [Sweet, R.; DeKosky, S. T.; Lopez, O. L.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, R.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res 4, Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. [Lovestone, S.; Priotsi, P.; Lupton, M.] Kings Coll London, Dept Neurosci, Inst Psychiat, London WC2R 2LS, England. [Brayne, C.] Univ Cambridge, Inst Publ Hlth, Cambridge, England. [Gill, M.; Lawlor, B.; Lynch, A.] St James Hosp, Mercers Inst Res Aging, Dublin 8, Ireland. [Gill, M.; Lawlor, B.; Lynch, A.] Trinity Coll Dublin, Dublin, Ireland. [Craig, D.; McGuinness, B.; Johnston, J.; Passmore, P.] Queens Univ Belfast, Ageing Grp, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland. [Holmes, C.] Univ Southampton, Div Clin Neurosci, Sch Med, Southampton, Hants, England. [Livingston, G.; Bass, N. J.; Gurling, H.; McQuillin, A.] UCL, Dept Mental Hlth Sci, London, England. [Barmada, M. M.; Mayeux, R.] Columbia Univ, Coll Phys & Surg, Taub Inst, New York, NY USA. [Barmada, M. M.; Mayeux, R.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA. [Demirci, F. Y.; Kamboh, M. I.] Univ Pittsburgh, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [DeKosky, S. T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. RP Sweet, R (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. EM SweetRA@upmc.edu; williamsj@cardiff.ac.uk RI ; Al-Chalabi, Ammar/E-5361-2010; Gurling, Hugh/A-5029-2010; Kowall, Neil/G-6364-2012; Kornhuber, Johannes/B-9613-2014; Singleton, Andrew/C-3010-2009; Holmans, Peter/F-4518-2015; Livingston, Gill/C-7081-2008; Guerreiro, Rita/A-1327-2011; McQuillin, Andrew/C-1623-2008 OI Escott-Price, Valentina/0000-0003-1784-5483; Harold, Denise/0000-0001-5195-0143; O'Donovan, Michael/0000-0001-7073-2379; Nothen, Markus/0000-0002-8770-2464; Livingston, Gill/0000-0001-6741-5516; Ivanov, Dobril/0000-0001-6271-6301; Gill, Michael/0000-0003-0206-5337; Al-Chalabi, Ammar/0000-0002-4924-7712; Kowall, Neil/0000-0002-6624-0213; Kornhuber, Johannes/0000-0002-8096-3987; Holmans, Peter/0000-0003-0870-9412; McQuillin, Andrew/0000-0003-1567-2240; Demirci, F. Yesim/0000-0001-6907-9843; Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M Michael/0000-0002-3604-6460 FU MRC; Wellcome Trust; Alzheimer's Research Trust; Welsh Assembly Government; Alzheimer's Society; Ulster Garden Villages; N Ireland RD Office; Royal College of Physicians/Dunhill Medical Trust; Mercer's Institute for Research on Ageing; Lundbeck SA; MRC [G0800509]; National Institutes of Health [HHSN268200782096C]; NIA-LOAD Family Study [U24AG026395]; University of Pittsburgh [R01AG027224, R01AG030653, P50AG005133]; Rush University Medical Center [P30AG10161]; Boston Universit [P30AG013846]; Columbia University [P50AG08702]; Duke University [P30AG028377]; Indiana University [P30AG010133]; Massachusetts General Hospital [P50AG05134]; Mayo Clinic, Rochester [P50AG165574]; Mayo Clinic, Jacksonville [P50AG165574]; Mount Sinai School of Medicine [P01AG05138, P01AG02219, P50AG05138]; Northwestern University Medical School [P30AG13854]; Oregon Health and Science University [P30AG008017]; University of Alabama at Birmingham [P50AG016582]; David Geffen School of Medicine, University of California, Los Angeles [P50AG016579]; University of Kentucky, Lexington [P30AG028383]; University of Pennsylvania [P30AG10124]; University of Southern California [P50AG05142]; University of Texas Southwestern Medical Center [P30AG12300]; University of Washington [P50AG05136]; Washington University School of Medicine [P50AG05681, P01AG03991]; USPHS [AG027224]; [U24AG021886] FX Professor Williams and Dr Harold have a patent application with respect to genes identified in the GWAS of Harold et al.:2 this study provided data for this manuscript and was funded by the MRC and the Wellcome Trust.; GERAD1: We thank the patients and families who took part in this research. The Cardiff University group was supported by the Wellcome Trust, Medical Research Council, Alzheimer's Research Trust and the Welsh Assembly Government. The Alzheimer's Research Trust also supported and funded DNA sample collections at the Institute of Psychiatry, Cambridge University, University of Nottingham and University of Belfast. The University of Belfast group are supported by the Alzheimer's Society, Alzheimer's Research Trust, Ulster Garden Villages, N Ireland R&D Office and the Royal College of Physicians/Dunhill Medical Trust. The Trinity College Dublin sample was supported by the MRC and Mercer's Institute for Research on Ageing. The LASER-AD study was funded by Lundbeck SA. GR is supported by a program grant from the MRC (G0800509). We also thank Advanced Research Computing @ Cardiff (ARCCA) who facilitated data analysis. NIA-LOAD: Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. Samples used in this study were obtained from the National Cell Repository for Alzheimer's Disease (NCRAD). Jennifer Williamson, Susan LaRusse Eckert and Stephanie Doan (Columbia University), Michele Goodman (Indiana University) and Elise Weamer (University of Pittsburgh) helped coordinate the project across the United States. We especially acknowledge the support and guidance of Creighton H Phelps, PhD, at the National Institute on Aging. ADRC: The following investigators and Alzheimer's Disease Centers participated in the Study: Boston University Robert Green, Neil Kowall, Lindsay Farrer; Columbia University Jennifer Williamson, Vincent Santana; Duke University Donald Schmechel, Peter Gaskel; Indiana University, Bernardino Ghetti, Martin R Farlow, Kelly Horner; Massachusetts General Hospital John H Growdon, Deborah Blacker, Rudolph E Tanzi, Bradley T Hyman; Mayo Clinic-Rochester Bradley Boeve, Karen Kuntz, Lindsay Norgaard, Nathan Larson; Mayo Clinic-Jacksonville Dana Kistler, Fracine Parfitt, Jenny Haddow; Mount Sinai School of Medicine Jeremy Silverman, Michal Schnaider Beeri, Mary Sano, Joy Wang, Rachel Lally; Northwestern University Nancy Johnson, Marcel Mesulum, Sandra Weintraub, Eileen Bigio; Oregon Health and Science University Jeffery Kaye, Patricia Kramer, Jessica Payne-Murphy; Rush University David Bennett, Holli Jacobs, Jeen-Soo Chang, Danielle Arends; University of Alabama at Birmingham Lindy Harrell; University of California, Los Angeles George Bartzokis, Jeffery Cummings, Po H Lu, Usha Toland; University of Kentucky William Markesbery, Charles Smith, Alise Brickhouse; University of Pennsylvania John Trojanowski, Vivianna Van Deerlin, Elisabeth McCarty Wood; University of Pittsburgh Oscar L Lopez, Robert A Sweet; University of Southern California I Helena Chui, Arousiak Varpetian; University of Texas Southwestern Ramon Diaz-Arrastia, Roger Rosenberg, Barbara Davis; University of Washington Thomas Bird, Malia Rumbaugh, Gerard D Schellenberg, Murray Raskind; Washington University at St Louis Alison Goate, John Morris, Joanne Norton, Denise Levitch, Betsy Grant, Mary Coats.; This study was supported by the following federal grants: U24AG026395 (NIA-LOAD Family Study); U24AG021886 (National Cell Repository for Alzheimer's Disease); R01AG027224, R01AG030653 and P50AG005133 University of Pittsburgh; P30AG10161 Rush University Medical Center; P30AG013846 Boston University; P50AG08702 Columbia University; P30AG028377 Duke University; P30AG010133 Indiana University; P50AG05134 Massachusetts General Hospital; P50AG165574 Mayo Clinic, Rochester and Mayo Clinic, Jacksonville; P01AG05138, P01AG02219, and P50AG05138 Mount Sinai School of Medicine; P30AG13854 Northwestern University Medical School; P30AG008017 Oregon Health and Science University; P50AG016582 University of Alabama at Birmingham; P50AG016579 David Geffen School of Medicine, University of California, Los Angeles; P30AG028383 University of Kentucky, Lexington; P30AG10124 University of Pennsylvania; P50AG05142 University of Southern California; P30AG12300 The University of Texas Southwestern Medical Center; P50AG05136 University of Washington; and P50AG05681 and P01AG03991 Washington University School of Medicine. Collection and ascertainment of the ADRC subjects was supported by USPHS grants AG027224. We thank contributors who collected samples used in this study, and we particularly thank the patients and their families, whose help and participation made this work possible. NR 72 TC 33 Z9 33 U1 3 U2 24 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD DEC PY 2012 VL 17 IS 12 BP 1316 EP 1327 DI 10.1038/mp.2011.125 PG 12 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 041UB UT WOS:000311425600023 PM 22005930 ER PT J AU Kivikko, M Nieminen, MS Pollesello, P Pohjanjousi, P Colucci, WS Teerlink, JR Mebazaa, A AF Kivikko, Matti Nieminen, Markku S. Pollesello, Piero Pohjanjousi, Pasi Colucci, Wilson S. Teerlink, John R. Mebazaa, Alexandre TI The clinical effects of levosimendan are not attenuated by sulfonylureas SO SCANDINAVIAN CARDIOVASCULAR JOURNAL LA English DT Article DE levosimendan; acute decompensated heart failure; inodilator; diabetes mellitus; ATP-dependent potassium channels; sulfonylureas ID DECOMPENSATED HEART-FAILURE; SENSITIVE POTASSIUM CHANNELS; INTRAVENOUS LEVOSIMENDAN; CONTINUOUS-INFUSION; DIABETES-MELLITUS; GUINEA-PIG; K-ATP; DOBUTAMINE; PHARMACOKINETICS; POPULATION AB Objectives. Levosimendan is an inodilator indicated for acute heart failure (AHF). Its vasodilatory and anti-ischemic effects are mediated by the opening of ATP-dependent potassium channels (K-ATP channels). Diabetes mellitus is common in AHF patients and sulfonylureas are often prescribed. Sulfonylureas act by blocking the K-ATP channels. An interaction between levosimendan and sulfonylureas has been shown in preclinical models and could be hypothesized in clinical practice. Design. We produced a pooled analysis of six randomized levosimendan trials (in total of 3004 patients of which 1700 were treated with levosimendan and 226 both with levosimendan and sulfonylureas) with the aim to study the influence of concurrent sulfonylurea treatment to the levosimendan effects. Invasive and non-invasive hemodynamics, biomarkers (BNP), adverse events related to myocardial ischemia, and survival were evaluated. Results. In our relatively small data set, we could not detect any clinically relevant interactions between the sulfonylureas and levosimendan. Similar decreases in systolic and diastolic blood pressure, pulmonary capillary wedge pressure and BNP, and similar survival and adverse event profiles were seen in sulfonylurea users and non-users exposed to levosimendan. Conclusions. Concomitant use of sulfonylureas with levosimendan does not attenuate the hemodynamic or other effects of levosimendan. C1 [Kivikko, Matti] Univ Helsinki, Cent Hosp, Div Cardiol, HUS, Helsinki 00029, Finland. [Colucci, Wilson S.] Boston Univ, Med Ctr, Boston, MA USA. [Kivikko, Matti; Pollesello, Piero; Pohjanjousi, Pasi] Orion Pharma, Espoo, Finland. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Mebazaa, Alexandre] Univ Paris 07, Hop Lariboisiere, Assistance Publ Hop Paris, Dept Anesthesiol & Crit Care Med, Paris, France. RP Kivikko, M (reprint author), Univ Helsinki, Cent Hosp, Div Cardiol, HUS, Haartmaninkatu 4,Box 340, Helsinki 00029, Finland. EM matti.kivikko@hus.fi OI pollesello, piero/0000-0001-6994-768X FU Orion Pharma, Finland FX This work was funded by Orion Pharma, Finland. NR 28 TC 2 Z9 2 U1 0 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1401-7431 J9 SCAND CARDIOVASC J JI Scand. Cardiovasc. J. PD DEC PY 2012 VL 46 IS 6 BP 330 EP 338 DI 10.3109/14017431.2012.725206 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 043LF UT WOS:000311544400003 PM 22928945 ER PT J AU Jalbrzikowski, M Carter, C Senturk, D Chow, C Hopkins, JM Green, MF Galvan, A Cannon, TD Bearden, CE AF Jalbrzikowski, Maria Carter, Chelsea Senturk, Damla Chow, Carolyn Hopkins, Jessica M. Green, Michael F. Galvan, Adriana Cannon, Tyrone D. Bearden, Carrie E. TI Social cognition in 22q11.2 microdeletion syndrome: Relevance to psychosis? SO SCHIZOPHRENIA RESEARCH LA English DT Article DE 22q11.2 microdeletion syndrome; Social cognition; Schizophrenia; Prodromal; Psychosis ID CARDIO-FACIAL SYNDROME; DELETION SYNDROME; VELOCARDIOFACIAL SYNDROME; 1ST-DEGREE RELATIVES; NEUROCOGNITIVE ENDOPHENOTYPES; SCHIZOPHRENIA; BRAIN; ADOLESCENTS; RECOGNITION; EMOTION AB 22q11.2 deletion syndrome (22qDS) represents one of the largest known genetic risk factors for schizophrenia. Approximately 30% of individuals with 22qDS develop psychotic illness in adolescence or young adulthood. Given that deficits in social cognition are increasingly viewed as a central aspect of idiopathic schizophrenia, we sought to investigate abilities in this domain as a predictor of psychotic symptoms in 22qDS participants. We assessed multiple domains of social and non-social cognition in 22qDS youth to: 1) characterize performance across these domains in 22qDS, and identify whether 22qDS participants fail to show expected patterns of age-related improvements on these tasks; and 2) determine whether social cognition better predicts positive and negative symptoms than does non-social cognition. Task domains assessed were: emotion recognition and differentiation, Theory of Mind (ToM), verbal knowledge, visuospatial skills, working memory, and processing speed. Positive and negative symptoms were measured using scores obtained from the Structured Interview for Prodromal Symptoms (SIPS). 22qDS participants (N = 31, mean age: 15.9) showed the largest impairment, relative to healthy controls (N = 31, mean age: 15.6), on measures of ToM and processing speed. In contrast to controls, 22qDS participants did not show age-related improvements on measures of working memory and verbal knowledge. Notably, ToM performance was the best predictor of positive symptoms in 22qDS, accounting for 39% of the variance in symptom severity. Processing speed emerged as the best predictor of negative symptoms, accounting for 37% of the variance in symptoms. Given that ToM was a robust predictor of positive symptoms in our sample, these findings suggest that social cognition may be a valuable intermediate trait for predicting the development of psychosis. (C) 2012 Elsevier B.V. All rights reserved. C1 [Jalbrzikowski, Maria; Carter, Chelsea; Hopkins, Jessica M.; Galvan, Adriana; Cannon, Tyrone D.; Bearden, Carrie E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Senturk, Damla] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Chow, Carolyn; Green, Michael F.; Cannon, Tyrone D.; Bearden, Carrie E.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.] VISN22 Mental Illness Res Educ & Clin Ctr, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Bearden, CE (reprint author), UCLA Psychiat & Biobehav Sci, Box 956968,300 Med Pl,Rm 2267, Los Angeles, CA 90095 USA. EM cbearden@mednet.ucla.edu FU National Institute of Mental Health [RO1 MH085953]; NIH/NIMH [5T32MH073526-05]; Heyler Meyer Research Award FX Funding for this study was provided by the National Institute of Mental Health grant RO1 MH085953 (CEB). Funding was also provided by the NIH/NIMH 5T32MH073526-05 (Training Grant in Neurobehavioral Genetics) and Heyler Meyer Research Award given to Ms. Jalbrzikowski. These funding sources had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 78 TC 27 Z9 27 U1 3 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2012 VL 142 IS 1-3 BP 99 EP 107 DI 10.1016/j.schres.2012.10.007 PG 9 WC Psychiatry SC Psychiatry GA 039CR UT WOS:000311220900016 PM 23122739 ER PT J AU Tregellas, JR Smucny, J Eichman, L Rojas, DC AF Tregellas, Jason R. Smucny, Jason Eichman, Lindsay Rojas, Donald C. TI The effect of distracting noise on the neuronal mechanisms of attention in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Distraction; Hippocampus; fMRI; Sensory processing ID AUDITORY ODDBALL TASK; HEMODYNAMIC-RESPONSE; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; SELECTION CONTROL; FMRI; HIPPOCAMPUS; DYSFUNCTION; STIMULUS; BRAIN AB Objective: The inability to ignore irrelevant environmental noise is a common problem for people with schizophrenia. The purpose of this study was to determine if the neuronal response to distracting noise is related to mechanisms of altered attention observed in the illness. Method: Twenty-two outpatients with schizophrenia and seventeen healthy comparison subjects performed a selective attention task in the presence or absence of distracting environmental noise while undergoing functional magnetic resonance imaging at 3 T. A separate condition examining passive response to the distracting noise also was included. Results: Group differences in neuronal response during the attention task were magnified by distracting noise, with the greatest difference being less response by patients, relative to comparison subjects, in the temporoparietal junction. Separate passive listening to distracting noise resulted in greater hippocampal response in patients, relative to comparison subjects. Across all subjects, hippocampal response to noise was inversely related to the degree to which the attention-task-related network was up-regulated to perform the task during distracting noise. Conclusions: Given the observed hippocampal hyperactivity in response to environmental noise in patients and the inverse relationship between hippocampal response to noise and the effects of noise on the task-related network, hippocampal hyperactivity may contribute to impaired recruitment of attention networks in schizophrenia. Published by Elsevier B.V. C1 [Tregellas, Jason R.; Smucny, Jason; Eichman, Lindsay; Rojas, Donald C.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.; Smucny, Jason; Rojas, Donald C.] Univ Colorado, Sch Med, Neurosci Program, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Sch Med, Dept Psychiat, 13001 E 17th Pl,MS F546, Aurora, CO 80045 USA. EM Jason.Tregellas@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616; Smucny, Jason/0000-0001-5656-7987 FU Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service; National Institutes of Mental Health [MH-086383]; National Association for Research in Schizophrenia and Affective Disorders; Blowitz-Ridgeway Foundation FX This work was supported by the Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service, the National Institutes of Mental Health grant MH-086383, the National Association for Research in Schizophrenia and Affective Disorders, and the Blowitz-Ridgeway Foundation. NR 37 TC 13 Z9 13 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2012 VL 142 IS 1-3 BP 230 EP 236 DI 10.1016/j.schres.2012.09.008 PG 7 WC Psychiatry SC Psychiatry GA 039CR UT WOS:000311220900035 PM 23062751 ER PT J AU Mortensen, EM Nakashima, B Cornell, J Copeland, LA Pugh, MJ Anzueto, A Good, C Restrepo, MI Downs, JR Frei, CR Fine, MJ AF Mortensen, Eric M. Nakashima, Brandy Cornell, John Copeland, Laurel A. Pugh, Mary Jo Anzueto, Antonio Good, Chester Restrepo, Marcos I. Downs, John R. Frei, Christopher R. Fine, Michael J. TI Population-Based Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related Outcomes SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; CYTOKINE LEVELS; DISEASE; THERAPY; TRIAL AB Background. Studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors might be beneficial for the treatment of infections. Our purpose was to examine the association of statin, ACE inhibitor, and angiotensin II receptor blocker (ARB) use with pneumonia-related outcomes. Methods. We conducted a retrospective cohort study using Department of Veterans Affairs data of patients aged >= 65 years hospitalized with pneumonia. We performed propensity-score matching for 3 medication classes simultaneously. Results. Of 50 119 potentially eligible patients, we matched 11 498 cases with 11 498 controls. Mortality at 30 days was 13%; 34% used statins, 30% ACE inhibitors, and 4% ARBs. In adjusted models, prior statin use was associated with decreased mortality (odds ratio [OR], 0.74; 95% confidence interval [CI],.68-.82) and mechanical ventilation (OR, 0.81; 95% CI, .70-.94), and inpatient use with decreased mortality (OR, 0.68; 95% CI, .59-.78) and mechanical ventilation (OR, 0.68; 95% CI, .60-.90). Prior (OR, 0.88; 95% CI, .80-.97) and inpatient (OR, 0.58; 95% CI, .48-.69) ACE inhibitor use was associated with decreased mortality. Prior (OR, 0.73; 95% CI, .58-.92) and inpatient ARB use (OR, 0.47; 95% CI, .30-.72) was only associated with decreased mortality. Use of all 3 medications was associated with reduced length of stay. Conclusions. Statins, and to a lesser extent ACE inhibitors and ARBs, are associated with improved pneumonia-related outcomes. Prospective cohort and randomized controlled trials are needed to examine potential mechanisms of action and whether acute initiation at the time of presentation with these infections is beneficial. C1 [Mortensen, Eric M.; Nakashima, Brandy; Pugh, Mary Jo; Anzueto, Antonio; Restrepo, Marcos I.; Downs, John R.] VERDICT Res Program, San Antonio, TX USA. [Mortensen, Eric M.; Nakashima, Brandy; Pugh, Mary Jo; Anzueto, Antonio; Restrepo, Marcos I.; Downs, John R.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Mortensen, Eric M.; Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. [Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA. [Cornell, John; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA. [Cornell, John; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Scott & White Healthcare, Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Good, Chester; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Frei, Christopher R.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Frei, Christopher R.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), Dallas VA Med Ctr, 4500 S Lancaster, Dallas, TX 75216 USA. EM eric.mortensen@utsouthwestern.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU National Institute of Nursing Research [R01NR010828] FX This work was supported by the National Institute of Nursing Research (grant number R01NR010828). This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. NR 26 TC 43 Z9 43 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2012 VL 55 IS 11 BP 1466 EP 1473 DI 10.1093/cid/cis733 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035RR UT WOS:000310966200010 PM 22918991 ER PT J AU Musher, DM AF Musher, Daniel M. TI Pneumococcal Polysaccharide Vaccine Efficacy and Routine Use of Conjugate Vaccines in Infants: There Is No Need for a Vaccine Program in Older Adults at Present Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 Baylor Coll Med, Infect Dis Sect, ME DeBakey VA Med Ctr, Houston, TX 77030 USA. RP Musher, DM (reprint author), Baylor Coll Med, Infect Dis Sect, ME DeBakey VA Med Ctr, 2002 Holcombe, Houston, TX 77030 USA. EM daniel.musher@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2012 VL 55 IS 11 BP 1579 EP 1579 DI 10.1093/cid/cis701 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035RR UT WOS:000310966200027 ER PT J AU Beheshti, M Graber, CJ Goetz, MB Bluestone, GL AF Beheshti, Manie Graber, Christopher J. Goetz, Matthew B. Bluestone, Gary L. TI Clarifying the Role of Adjunctive Metronidazole in the Treatment of Biliary Infections SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID TOKYO GUIDELINES; ANTIMICROBIAL STEWARDSHIP; ACUTE CHOLECYSTITIS; DISEASES SOCIETY; THERAPY; AMERICA C1 [Graber, Christopher J.; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90073 USA. [Beheshti, Manie; Bluestone, Gary L.] Kaiser Permanente, Dept Internal Med, Div Infect Dis, Los Angeles, CA USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, 111F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM christopher.graber@va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 9 TC 0 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2012 VL 55 IS 11 BP 1583 EP 1584 DI 10.1093/cid/cis718 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035RR UT WOS:000310966200030 PM 22942200 ER PT J AU Anaya, JM Castiblanco, J Rojas-Villarraga, A Pineda-Tamayo, R Levy, RA Gomez-Puerta, J Dias, C Mantilla, RD Gallo, JE Cervera, R Shoenfeld, Y Arcos-Burgos, M AF Anaya, Juan-Manuel Castiblanco, John Rojas-Villarraga, Adriana Pineda-Tamayo, Ricardo Levy, Roger A. Gomez-Puerta, Jose Dias, Carlos Mantilla, Ruben D. Esteban Gallo, Juan Cervera, Ricard Shoenfeld, Yehuda Arcos-Burgos, Mauricio TI The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY LA English DT Review DE Autoimmune diseases; Systemic lupus erythematosus; Sjogren's syndrome; Autoimmune thyroid diseases; Genetic association studies; Familial aggregation ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; PEDIGREE DISEQUILIBRIUM TEST; SUSCEPTIBILITY LOCI; COMPLEX DISEASES; CANDIDATE LOCI; LINKAGE; FAMILIES; POLYAUTOIMMUNITY; SCLEROSIS AB The multiple autoimmune syndromes (MAS) consist on the presence of three or more well-defined autoimmune diseases (ADs) in a single patient. The aim of this study was to analyze the clinical and genetic characteristics of a large series of patients with MAS. A cluster analysis and familial aggregation analysis of ADs was performed in 84 patients. A genome-wide microsatellite screen was performed in MAS families, and associated loci were investigated through the pedigree disequilibrium test. Systemic lupus erythematosus (SLE), autoimmune thyroid disease (AITD), and Sjogren's syndrome together were the most frequent ADs encountered. Three main clusters were established. Aggregation for type 1 diabetes, AITD, SLE, and all ADs as a trait was found. Eight loci associated with MAS were observed harboring autoimmunity genes. The MAS represent the best example of polyautoimmunity as well as the effect of a single genotype on diverse phenotypes. Its study provides important clues to elucidate the common mechanisms of ADs (i.e., autoimmune tautology). C1 [Anaya, Juan-Manuel; Rojas-Villarraga, Adriana; Pineda-Tamayo, Ricardo; Mantilla, Ruben D.] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Castiblanco, John; Esteban Gallo, Juan] Univ Rosario, Doctoral Program Biomed Sci, Bogota, Colombia. [Castiblanco, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, S Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX 78229 USA. [Pineda-Tamayo, Ricardo] ART Med IPS, Medellin, Colombia. [Levy, Roger A.] Univ Estado Rio de Janeiro, Discipline Rheumatol, BR-20550011 Rio De Janeiro, Brazil. [Levy, Roger A.] Federico Fdn, Rio De Janeiro, Brazil. [Gomez-Puerta, Jose; Cervera, Ricard] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Catalonia, Spain. [Dias, Carlos] Hosp Sao Joao, Internal Med Serv, Oporto, Portugal. [Mantilla, Ruben D.] Riesgo Fractura CAYRE IPS, Bogota, Colombia. [Shoenfeld, Yehuda] Chaim Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Aviv, Israel. [Arcos-Burgos, Mauricio] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia. RP Anaya, JM (reprint author), Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Carrera 24,63C-69,Piso 3, Bogota, Colombia. EM anayajm@gmail.com RI CASTIBLANCO, JOHN/B-6599-2009; Gomez-Puerta, Jose /H-3550-2015; Anaya, Juan-Manuel/J-1960-2016; Rojas-Villarraga, Adriana/J-2404-2016 OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Anaya, Juan-Manuel/0000-0002-6444-1249; Rojas-Villarraga, Adriana/0000-0003-3145-2440; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Levy, Roger/0000-0001-6393-6031; CASTIBLANCO, JOHN/0000-0003-2556-3697 FU Colciencias [122254531722]; School of Medicine and Health Sciences at the Universidad del Rosario, Bogota, Colombia; Marshfield Foundation, WI, USA FX We thank all patients and participants. This study was financed by Colciencias (122254531722), the School of Medicine and Health Sciences at the Universidad del Rosario, Bogota, Colombia, and Marshfield Foundation, WI, USA. NR 54 TC 19 Z9 20 U1 0 U2 16 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1080-0549 J9 CLIN REV ALLERG IMMU JI Clin. Rev. Allergy Immunol. PD DEC PY 2012 VL 43 IS 3 BP 256 EP 264 DI 10.1007/s12016-012-8317-z PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 034QX UT WOS:000310889100007 PM 22648455 ER PT J AU DiNardo, MM Gibson, JM Siminerio, L Morell, AR Lee, ES AF DiNardo, Monica M. Gibson, Jolynn M. Siminerio, Lara Morell, Allison R. Lee, Edward S. TI Complementary and Alternative Medicine in Diabetes Care SO CURRENT DIABETES REPORTS LA English DT Article DE Complementary and alternative medicine; Herbal supplements; Nutritional supplements; Mind-body therapies; Diabetes mellitus; Type 2 diabetes; Prediabetes; Insulin resistance ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; IMPROVED GLYCEMIC CONTROL; BLIND CLINICAL-TRIAL; OXIDATIVE STRESS; MINDFULNESS MEDITATION; ALMOND CONSUMPTION; INSULIN-RESISTANCE; GYMNEMA-SYLVESTRE; MELLITUS PATIENTS AB Growing numbers of people with diabetes in the U.S. and worldwide use complementary and alternative medicine (CAM) while receiving conventional medical therapy as a means of managing disease and improving quality of life. Although herbal and natural products are the most commonly used forms of CAM, mind-body approaches are also gaining popularity and scientific interest. Current findings suggest that CAM may help to promote an integrative, participatory model of diabetes care that relies upon provider knowledge of evidence-based therapies and patient disclosure of CAM use. Emerging evidence of positive findings with some natural products and mind-body therapies have been reported in glycemic parameters, markers of cardiovascular risk, and quality of life in individuals with type 2 diabetes; however, further investigation in well-designed, adequately powered studies is needed before use of CAM modalities can be recommended as part of clinical care. C1 [DiNardo, Monica M.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [DiNardo, Monica M.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15240 USA. [Gibson, Jolynn M.] UPMC St Margaret Hosp, Pittsburgh, PA 15215 USA. [Morell, Allison R.; Lee, Edward S.] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA 15240 USA. RP DiNardo, MM (reprint author), Univ Pittsburgh, Sch Nursing, 3500 Victoria St, Pittsburgh, PA 15261 USA. EM mmm52@pitt.edu; gibsonjm@upmc.edu; lara.siminerio@gmail.com; allison.morell@va.gov; edward.lee6@va.gov FU VA Integrated Service Network (VISN) 4 for a Competitive Pilot Project Fund FX Conflicts of interest: M. DiNardo, none; J. M. Gibson, none; L. Siminerio, none; A. R. Morell, none. E. S. Lee is a Medical Acupuncture Instructor at the Helms Medical Institute; is Director, Acupuncture Clinic, @ VA Pittsburgh Healthcare System; has received grant support from the VA Integrated Service Network (VISN) 4 for a Competitive Pilot Project Fund, Study on Acupuncture as an adjunctive treatment for poststroke depression (VA VISN 4 Competitive Pilot Fund, 2010); and is a member for the American Academy of Medical Acupuncture, Annual Symposium Planning Committee. NR 68 TC 8 Z9 8 U1 3 U2 62 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 749 EP 761 DI 10.1007/s11892-012-0315-2 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500014 PM 22986889 ER PT J AU Strom, JL Egede, LE AF Strom, Joni L. Egede, Leonard E. TI The Impact of Social Support on Outcomes in Adult Patients with Type 2 Diabetes: A Systematic Review SO CURRENT DIABETES REPORTS LA English DT Review DE Diabetes; Type 2 diabetes; Social support; Glycemic control; Psychosocial factors ID SELF-MANAGEMENT BEHAVIORS; AFRICAN-AMERICAN ADULTS; US-MEXICO BORDER; QUALITY-OF-LIFE; FAMILY SUPPORT; RANDOMIZED-TRIAL; GLYCEMIC CONTROL; GLUCOSE CONTROL; CARE BEHAVIORS; PEER SUPPORT AB Diabetes is one of the fastest growing chronic diseases globally and in the United States. Although preventable, type 2 diabetes accounts for 90 % of all cases of diabetes worldwide and continues to be a source of increased disability, lost productivity, mortality, and amplified health-care costs. Proper disease management is crucial for achieving better diabetes-related outcomes. Evidence suggests that higher levels of social support are associated with improved clinical outcomes, reduced psychosocial symptomatology, and the adaptation of beneficial lifestyle activities; however, the role of social support in diabetes management is not well understood. The purpose of this systematic review is to examine the impact of social support on outcomes in adults with type 2 diabetes. C1 [Strom, Joni L.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Strom, Joni L.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston VA REAP, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM stromjl@musc.edu; egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699, R01 DK081121] NR 52 TC 34 Z9 34 U1 5 U2 53 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 769 EP 781 DI 10.1007/s11892-012-0317-0 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500016 PM 22949135 ER PT J AU Waung, MW Abrams, GM AF Waung, Maggie W. Abrams, Gary M. TI Combat-Related Headache and Traumatic Brain Injury SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Review DE Post-traumatic headache; Blast injury; Traumatic brain injury; Post-traumatic stress disorder; PTSD; Veterans; Migraine; Tension-type headache; Concussion; Combat; Alteration of consciousness; Loss of consciousness ID POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; MILITARY PERSONNEL; CHRONIC PAIN; ENDURING FREEDOM; VETERANS; PREVALENCE; CONCUSSION; SEVERITY; IRAQ AB Post-traumatic headache is a commonly described complication of traumatic brain injury. Recent studies highlight differences between headache features of combat veterans who suffered traumatic brain injury compared to civilians. Not surprisingly, there is a higher rate of associated PTSD and sleep disturbances among veterans. Factors of lower socioeconomic status, rank, and multiple head injuries appear to have a similar effect on post-traumatic headache in combat-related traumatic brain injury. Areas of discordance in the literature include the effect of prolonged loss of consciousness and the prevalence of specific headache phenotypes following head trauma. To date, there have been no randomized trials of treatment for post-traumatic headache. This may be related to the variability of headache features and uncertainty of pathophysiologic mechanisms. Given this lack of data, many practitioners follow treatment guidelines for primary headaches. Additionally, because of mounting data linking PTSD to post-traumatic headache in combat veterans, it may be crucial to choose multimodal agents and take a multidisciplinary approach to combat-related headache. C1 [Waung, Maggie W.; Abrams, Gary M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Abrams, Gary M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Abrams, GM (reprint author), San Francisco VA Med Ctr, 4150 Clement St,MS 117, San Francisco, CA 94121 USA. EM Maggie.Waung@ucsf.edu; Gary.Abrams@ucsf.edu NR 39 TC 5 Z9 5 U1 1 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1531-3433 EI 1534-3081 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD DEC PY 2012 VL 16 IS 6 BP 533 EP 538 DI 10.1007/s11916-012-0294-7 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 035MV UT WOS:000310952200007 PM 22956047 ER PT J AU Bowden, MG Embry, AE Perry, LA Duncan, PW AF Bowden, Mark G. Embry, Aaron E. Perry, Lindsay A. Duncan, Pamela W. TI Rehabilitation of Walking After Stroke SO CURRENT TREATMENT OPTIONS IN NEUROLOGY LA English DT Review DE Walking; Rehabilitation; Stroke; Physical therapy; Strength training; Treadmill training; Speed paradigm; Split-belt paradigm; Locomotor training; External devices ID RANDOMIZED CONTROLLED-TRIAL; NEUROMUSCULAR ELECTRICAL-STIMULATION; BODY-WEIGHT SUPPORT; SUBACUTE STROKE; IMPROVE GAIT; CASE SERIES; OVERGROUND WALKING; TREADMILL; EXERCISE; SPEED AB Rehabilitation of walking after stroke has been investigated with a variety of interventions, which will be outlined in this review. To date, the majority of interventions have demonstrated a positive, but similar effect in the primary clinical outcome of self-selected walking speed. Consistent among the most successful interventions is a focus on the intensity of the intervention and the ability to progress rehabilitation in a structured fashion. Successful progression of rehabilitation of walking likely lies in the ability to combine interventions based on an understanding of contributing underlying deficits (eg, motor control, strength, cardiovascular endurance, and dynamic balance). Rehabilitation programs must account for the need to train dynamic balance for falls prevention. Lastly, clinicians and researchers need to measure the effects of rehabilitation on participation and health related quality of life. C1 [Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bowden, Mark G.; Embry, Aaron E.; Perry, Lindsay A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bowden, Mark G.; Embry, Aaron E.; Perry, Lindsay A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Duncan, Pamela W.] Wake Forest Baptist Med Ctr, Dept Neurol, Winston Salem, NC USA. RP Bowden, MG (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM bowdenm@musc.edu FU VA Rehabilitation, Research, and Development FX This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center and the Medical University of South Carolina in Charleston, SC. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. Dr. Bowden has received VA Rehabilitation, Research, and Development grant support. NR 50 TC 6 Z9 6 U1 3 U2 29 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1092-8480 J9 CURR TREAT OPTION NE JI Curr. Treat. Options Neurol. PD DEC PY 2012 VL 14 IS 6 BP 521 EP 530 DI 10.1007/s11940-012-0198-1 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 038UU UT WOS:000311200400002 PM 22991142 ER PT J AU Egede, LE Gebregziabher, M Dismuke, CE Lynch, CP Axon, RN Zhao, YM Mauldin, PD AF Egede, Leonard E. Gebregziabher, Mulugeta Dismuke, Clara E. Lynch, Cheryl P. Axon, R. Neal Zhao, Yumin Mauldin, Patrick D. TI Medication Nonadherence in Diabetes Longitudinal effects on costs and potential cost savings from improvement SO DIABETES CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL PHARMACIST INTERVENTION; HEALTH-CARE-SYSTEM; ELDERLY OUTPATIENTS; GLYCEMIC CONTROL; ADHERENCE; VETERANS; MANAGEMENT; ADULTS; MELLITUS AB OBJECTIVE-To examine the longitudinal effects of medication nonadherence (MNA) on key costs and estimate potential savings from increased adherence using a novel methodology that accounts for shared correlation among cost categories. RESEARCH DESIGN AND METHODS-Veterans with type 2 diabetes (740,195) were followed from January 2002 until death, loss to follow-up, or December 2006. A novel multivariate, generalized, linear, mixed modeling approach was used to assess the differential effect of MNA, defined as medication possession ratio (MPR) >= 0.8 on healthcare costs. A sensitivity analysis was performed to assess potential cost savings at different MNA levels using the Consumer Price Index to adjust estimates to 2012 dollar value. RESULTS-Mean MPR for the full sample over 5 years was 0.78, with a mean of 0.93 for the adherent group and 0.58 for the MNA group. In fully adjusted models, all annual cost categories increased similar to 3% per year (P = 0.001) during the 5-year study time period. MNA was associated with a 37% lower pharmacy cost, 7% lower outpatient cost, and 41% higher inpatient cost. Based on sensitivity analyses, improving adherence in the MNA group would result in annual estimated cost savings ranging from similar to$661 million (MPR <0.6 vs. >= 0.6) to similar to$1.16 billion (MPR <1 vs. 1). Maximal incremental annual savings would occur by raising MPR from <0.8 to >= 0.8 ($204,530,778) among MNA subjects. CONCLUSIONS-Aggressive strategies and policies are needed to achieve optimal medication adherence in diabetes. Such approaches may further the so-called "triple aim" of achieving better health, better quality care, and lower cost. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Dismuke, Clara E.; Lynch, Cheryl P.; Axon, R. Neal; Mauldin, Patrick D.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.; Dismuke, Clara E.; Lynch, Cheryl P.; Axon, R. Neal; Zhao, Yumin; Mauldin, Patrick D.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Disparities Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU VHA Health Services Research and Development (HSRD) program; [IIR-06-219] FX This study was supported by Grant IIR-06-219 funded by the VHA Health Services Research and Development (HSR&D) program. NR 37 TC 39 Z9 39 U1 2 U2 13 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2012 VL 35 IS 12 BP 2533 EP 2539 DI 10.2337/dc12-0572 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 041UF UT WOS:000311426000037 PM 22912429 ER PT J AU Sharma, A Tian, F Yin, MT Keller, MJ Cohen, M Tien, PC AF Sharma, Anjali Tian, Fang Yin, Michael T. Keller, Marla J. Cohen, Mardge Tien, Phyllis C. TI Association of Regional Body Composition With Bone Mineral Density in HIV-Infected and HIV-Uninfected Women: Women's Interagency HIV Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE body composition; fat redistribution; bone mineral density; HIV; women ID MODERATE ALCOHOL-CONSUMPTION; PROTON MR SPECTROSCOPY; X-RAY ABSORPTIOMETRY; BIOELECTRICAL-IMPEDANCE; ANTIRETROVIRAL THERAPY; ELDERLY-WOMEN; MARROW FAT; NAIVE PATIENTS; MASS; OSTEOPOROSIS AB Objective: To understand how regional body composition affects bone mineral density (BMD) in HIV-infected and HIV-uninfected women. Methods: Dual energy x-ray absorptiometry was used to measure regional lean and fat mass and BMD at lumbar spine (LS), total hip (TH), and femoral neck (FN) in 318 HIV-infected and 122 HIV-uninfected Women's Interagency HIV Study participants at baseline and 2 and 5 years later. Total lean and fat mass were measured using bioimpedance analysis. Multivariate marginal linear regression models assessed the association of HIV status and body composition on BMD change. Results: Compared with HIV-uninfected women, HIV-infected women were older (44 vs. 37 years), more likely to be Hepatitis C virus-infected (32% vs. 14%), and postmenopausal (26% vs. 3%) and had lower baseline total fat mass, trunk fat, and leg fat. In multivariate models, increased total lean mass was independently associated with increased BMD at LS, TH, and FN, and total fat mass was associated with increased BMD at TH and FN (all P < 0.05). When total fat was replaced in multivariate models with trunk fat and leg fat, increased trunk fat (and not leg fat) was associated with increased TH and FN BMD (P < 0.001). Conclusions: Total fat and lean mass are strong independent predictors of TH and FN BMD, and lean mass was associated with greater LS BMD. Regardless of HIV status, greater trunk fat (and not leg fat) was associated with increased TH and FN BMD, suggesting that weight-bearing fat may be a more important predictor of BMD in the hip. C1 [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11205 USA. [Tian, Fang] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Yin, Michael T.] Columbia Univ, Dept Med, New York, NY USA. [Keller, Marla J.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Cohen, Mardge] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Dept Med, Chicago, IL USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Sharma, A (reprint author), Suny Downstate Med Ctr, Dept Med, 450 Clarkson Ave,Box 1240, Brooklyn, NY 11205 USA. EM anjali.sharma@downstate.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources UCSF-CTSI [UL1 RR024131]; NIH [AI-095089]; Robert Wood Johnson Foundation Physician Faculty Scholars Program FX Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases Grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590 and by the National Institute of Child Health and Human Development Gant UO1-HD-32632. The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources UCSF-CTSI Grant UL1 RR024131. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Dr Yin is supported by NIH Grant AI-095089. Dr Sharma is supported by the Robert Wood Johnson Foundation Physician Faculty Scholars Program. NR 51 TC 12 Z9 12 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2012 VL 61 IS 4 BP 469 EP 476 DI 10.1097/QAI.0b013e31826cba6c PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 037DU UT WOS:000311083200013 PM 22895436 ER PT J AU Gros, DF Gros, KS McCabe, RE Antony, MM AF Gros, Daniel F. Gros, Kirstin Stauffacher McCabe, Randi E. Antony, Martin M. TI Psychometric Evaluation of the Factor Structure of the Teasing Questionnaire - Revised (TQ-R) SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Teasing questionnaire-revised; TQ-R; Psychometrics; Factor analyses; Anxiety ID ANXIETY; ADULTS AB Recent literature has focused on the relation between childhood teasing and adulthood psychopathology, with the majority of this work dependent on a single measure, the Teasing Questionnaire-Revised (TQ-R; Storch et al. Journal of Anxiety Disorders 18:681-694, 2004). However, the factor structure and reliability of the TQ-R requires further examination. The present investigation reevaluated the factor structure of the TQ-R in two large samples. In Study 1, three previous factor models were investigated through confirmatory factor analyses (CFAs) in a large clinical sample. Due to their poor fit, exploratory factor analyses (EFAs) were used to investigate alternative factor models. In Study 2, the factor structure of the previous models and new models from Study 1 EFAs were investigated through CFAs and estimates of internal consistency in a large college sample. Together, these findings provided the most support for a new 21-item five factor model, identified in the Study 1 EFAs and supported by the Study 2 CFAs, with the content of the teasing subscales consistent with the constructs of anxiety, appearance, academics, weight, and height. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.; Gros, Kirstin Stauffacher] Med Univ S Carolina, Charleston, SC 29425 USA. [McCabe, Randi E.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [McCabe, Randi E.] McMaster Univ, Hamilton, ON, Canada. [Antony, Martin M.] Ryerson Univ, Toronto, ON, Canada. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu NR 20 TC 1 Z9 1 U1 1 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD DEC PY 2012 VL 34 IS 4 BP 542 EP 551 DI 10.1007/s10862-012-9301-x PG 10 WC Psychology, Clinical SC Psychology GA 035OU UT WOS:000310957600013 ER PT J AU Al-Aly, Z Balasubramanian, S McDonald, JR Scherrer, JF O'Hare, AM AF Al-Aly, Ziyad Balasubramanian, Sumitra McDonald, Jay R. Scherrer, Jeffrey F. O'Hare, Ann M. TI Greater variability in kidney function is associated with an increased risk of death SO KIDNEY INTERNATIONAL LA English DT Article DE acute kidney injury; chronic kidney disease; eGFR slope; longitudinal data; mortality risk; variability ID GLOMERULAR-FILTRATION-RATE; HEMOGLOBIN VARIABILITY; FUNCTION DECLINE; MORTALITY RISK; ADMINISTRATIVE DATABASES; SERUM CREATININE; RENAL-DISEASE; OUTCOMES; CARE; CONSEQUENCES AB Intra-individual variability in kidney function is a common phenomenon; however, predictors of kidney function variability and its prognostic significance are not known. To examine this question, we assembled a cohort of 51,304 US veterans with an estimated glomerular filtration rate (eGFR) <60 ml/min at the end of the study period and who had at least two eGFR measurements during the previous 3 years. Variability in kidney function was defined for each patient as the coefficient of variation of the regression line fitted to all outpatient measures of eGFR during this time frame. In adjusted analyses, blacks, women, and those with Current Procedural Terminology and ICD-9-CM diagnostic codes for hypertension, diabetes, cardiovascular disease, peripheral artery disease, chronic lung disease, hepatitis C, dementia, acute kidney injury, and those with a greater number of hospitalizations had greater variability in eGFR. After a median follow-up of 4.9 years, there were 23.66%, 25.68%, and 31.23% deaths among patients in the lowest, intermediate, and highest tertiles of eGFR variability, respectively. Compared with the referent (those in the lowest tertile), patients in the highest tertile had a significantly increased risk of death with a hazard ratio of 1.34 (1.28-1.40), an association consistently present in all sensitivity analyses. Thus, our results demonstrate that greater variability in kidney function is independently associated with increased risk of death. Kidney International (2012) 82, 1208-1214; doi:10.1038/ki.2012.276; published online 1 August 2012 C1 [Al-Aly, Ziyad] St Louis Vet Affairs Med Ctr, Dept Med, Div Nephrol, St Louis, MO 63106 USA. [Al-Aly, Ziyad; Balasubramanian, Sumitra; McDonald, Jay R.; Scherrer, Jeffrey F.] St Louis Vet Affairs Clin Res & Epidemiol Ctr, St Louis, MO USA. [McDonald, Jay R.] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA. [Scherrer, Jeffrey F.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Div Nephrol, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. RP Al-Aly, Z (reprint author), St Louis Vet Affairs Med Ctr, Dept Med, Div Nephrol, 915 N Grand Blvd,111B-JC, St Louis, MO 63106 USA. EM zalaly@gmail.com RI Al-Aly, Ziyad/S-4439-2016 OI Al-Aly, Ziyad/0000-0002-2600-0434 FU Department of Veterans Affairs VISN 15 Career Development Award FX This work was funded by a Department of Veterans Affairs VISN 15 Career Development Award to ZA-A. NR 54 TC 19 Z9 19 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2012 VL 82 IS 11 BP 1208 EP 1214 DI 10.1038/ki.2012.276 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 038DV UT WOS:000311156300010 PM 22854642 ER PT J AU Zarjou, A Guo, LL Sanders, PW Mannon, RB Agarwal, A George, JF AF Zarjou, Abolfazl Guo, Lingling Sanders, Paul W. Mannon, Roslyn B. Agarwal, Anupam George, James F. TI A reproducible mouse model of chronic allograft nephropathy with vasculopathy SO KIDNEY INTERNATIONAL LA English DT Article DE arteriosclerosis; renal transplantation; transplant pathology; vascular disease ID IMPROVED RENAL-FUNCTION; KIDNEY ALLOGRAFTS; INTIMAL ARTERITIS; TRANSPLANTATION; REJECTION; EXPRESSION AB Although short-term outcomes in kidney transplantation have improved dramatically, long-term survival remains a major challenge. A key component of long-term, chronic allograft injury in solid organ transplants is arteriosclerosis characterized by vascular neointimal hyperplasia and inflammation. Establishing a model of this disorder would provide a unique tool not only to identify mechanisms of disease but also to test potential therapeutics for late graft injury. To this end, we utilized a mouse orthotopic renal transplant model in which C57BL/6J (H-2b) recipients were given either a kidney allograft from a completely mismatched Balb/cJ mouse (H-2d) or an isograft from a littermate. A unilateral nephrectomy was performed at the time of transplant followed by a contralateral nephrectomy on post-transplant day 7. Recipients were treated with daily cyclosporine subcutaneously for 14 days and then studied 8 and 12 weeks post transplantation. Renal function was significantly worse in allograft compared with isograft recipients. Moreover, the allografts had significantly more advanced tubulointerstitial fibrosis and profound vascular disease characterized by perivascular leukocytic infiltration and neointimal hyperplasia affecting the intrarenal blood vessels. Thus, we describe a feasible and reproducible murine model of intrarenal transplant arteriosclerosis that is useful to study allograft vasculopathy. Kidney International (2012) 82, 1231-1235; doi:10.1038/ki.2012.277; published online 8 August 2012 C1 [Agarwal, Anupam] Univ Alabama Birmingham, Div Nephrol, Dept Med, Birmingham, AL 35294 USA. [Zarjou, Abolfazl; Guo, Lingling; Sanders, Paul W.; Mannon, Roslyn B.; Agarwal, Anupam; George, James F.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Sanders, Paul W.; Agarwal, Anupam] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Agarwal, A (reprint author), Univ Alabama Birmingham, Div Nephrol, Dept Med, THT 647,1530 3rd Ave S, Birmingham, AL 35294 USA. EM agarwal@uab.edu; jgeorge@uab.edu OI Sanders, Paul/0000-0002-2915-5714 FU NIH [R01 DK59600, R01 DK75532, R01 DK046199]; UAB-UCSD O'Brien Center [P30 DK079337]; AHA [0655318B] FX This work was supported by NIH grants R01 DK59600 (AA), R01 DK75532 (AA), R01 DK046199 (PWS), the core resource of the UAB-UCSD O'Brien Center (P30 DK079337) (AA), and AHA grant 0655318B (JFG). NR 21 TC 6 Z9 8 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2012 VL 82 IS 11 BP 1231 EP 1235 DI 10.1038/ki.2012.277 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 038DV UT WOS:000311156300013 PM 22874842 ER PT J AU Chen, YX Bodhankar, S Murphy, SJ Vandenbark, AA Alkayed, NJ Offner, H AF Chen, Yingxin Bodhankar, Sheetal Murphy, Stephanie J. Vandenbark, Arthur A. Alkayed, Nabil J. Offner, Halina TI Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice SO METABOLIC BRAIN DISEASE LA English DT Article DE Regulatory B-cells; Experimental stroke; Intrastriatal transfer; mu MT-/- mice ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY RESPONSES; ISCHEMIC-STROKE; BRAIN ISCHEMIA; B10 CELLS; NEUROPROTECTION; LYMPHOCYTES AB Recent evidence emphasizes B-cells as a major regulatory cell type that plays an important role in limiting the pathogenic effects of ischemic stroke. The aim of the current study was to extend this initial observation to specifically examine the infiltration of regulatory B-cells and to determine if the effect of B-cells to limit the inflammatory response to cerebral ischemia is mediated by their action centrally or peripherally. Our data demonstrate the increased presence of a regulatory B-cell subset in the affected hemisphere of wild-type mice after middle cerebral artery occlusion (MCAO). We further explored the use of a novel method of stereotaxic cell delivery to bypass the blood brain barrier (BBB) and introduce CD19(+) B-cells directly into the striatum as compared to peripheral administration of B-cells. Infarct volumes after 60 minutes of MCAO and 48 hours of reperfusion were determined in B-cell deficient mu MT (-/-) mice with and without replacement of either B-cells or medium. Infarct size was significantly decreased in cerebral cortex after intrastriatal transfer of 100,000 B-cells to mu MT-/- mice vs. controls, with a comparable effect on infarct size as obtained by 50 million B-cells transferred intraperitoneally. These findings support the hypothesis that B-cells play a protective role against ischemic brain injury, and suggest that B-cells may serve as a novel therapeutic agent for modulating the immune response in central nervous system inflammation after stroke. C1 [Chen, Yingxin; Murphy, Stephanie J.; Alkayed, Nabil J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Dept Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NS075887]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Drs. Xuefang Ren, Wenri Zhang and Kozaburo Akiyoshi for assistance in some experiments, Ms. Eva Niehaus for assistance with manuscript preparation and Ms. Zefora Alderman for graphics. This work was supported by NIH grant NS075887. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 20 TC 16 Z9 16 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD DEC PY 2012 VL 27 IS 4 BP 487 EP 493 DI 10.1007/s11011-012-9317-7 PG 7 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 040CT UT WOS:000311298300010 PM 22618587 ER PT J AU Shields, RK Nguyen, MH Shullo, MA Silveira, FP Kwak, EJ Massih, RCA Toyoda, Y Bermudez, CA Bhama, JK Kormos, RL Clancy, CJ AF Shields, Ryan K. Nguyen, M. Hong Shullo, Michael A. Silveira, Fernanda P. Kwak, Eun J. Massih, Rima C. Abdel Toyoda, Yoshiya Bermudez, Christian A. Bhama, Jay K. Kormos, Robert L. Clancy, Cornelius J. TI Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Aspergillosis; septic shock; heart transplant ID PULMONARY ASPERGILLOSIS; CARDIAC TRANSPLANTATION; FUNGAL-INFECTIONS; EARLY-DIAGNOSIS; SEVERE SEPSIS; GALACTOMANNAN; PROPHYLAXIS; THERAPIES; RISK AB Between 2000 and 2011, proven or probable invasive aspergillosis (IA) was diagnosed in 1.7% (8/455) of heart transplant (HTx) recipients at our center, in the absence of antifungal prophylaxis. All patients had invasive pulmonary infections and 75% (6/8) were diagnosed during 2 separate 3-month periods. Cases were notable for their association with septic shock and multiple organ dysfunction syndrome (MODS) (75%, 6/8 each), non-specific clinical and radiographic findings, and rapid mortality despite mould-active antifungal therapy (88%, 7/8; occuring at a median 11 days after diagnosis). All patients had predisposing conditions known to be risk factors for IA. For patients with early IA (within 90 days of HTx), conditions included hemodialysis, thoracic re-operation, and the presence of another case in the institution within the preceding 3 months. For late-onset IA, conditions included hemodialysis and receipt of augmented immunosuppression. Clinicians should suspect IA in HTx recipients with risk factors who present with non-specific and unexplained respiratory syndromes, including those in septic shock and MODS, and institute prompt antifungal therapy without waiting for the results of cultures or other diagnostic tests. C1 [Shields, Ryan K.; Nguyen, M. Hong; Silveira, Fernanda P.; Kwak, Eun J.; Massih, Rima C. Abdel; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Shullo, Michael A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Toyoda, Yoshiya; Bermudez, Christian A.; Bhama, Jay K.; Kormos, Robert L.] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA 15261 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, 3550 Terrace St,Scaife Hall,Suite 871, Pittsburgh, PA 15261 USA. EM mhn5@pitt.edu FU NCATS NIH HHS [KL2 TR000146, KL2TR000146]; NCRR NIH HHS [KL2 RR024154, KL2RR024154] NR 21 TC 4 Z9 4 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PD DEC PY 2012 VL 44 IS 12 BP 982 EP 986 DI 10.3109/00365548.2012.705018 PG 5 WC Infectious Diseases SC Infectious Diseases GA 037SW UT WOS:000311127800015 PM 22830948 ER PT J AU Hinton, L Apesoa-Varano, EC Gonzalez, HM Aguilar-Gaxiola, S Dwight-Johnson, M Barker, JC Tran, C Zuniga, R Unutzer, J AF Hinton, Ladson Apesoa-Varano, Ester Carolina Gonzalez, Hector M. Aguilar-Gaxiola, Sergio Dwight-Johnson, Megan Barker, Judith C. Tran, Cindy Zuniga, Ramiro Unuetzer, Juergen TI Falling through the cracks: gaps in depression treatment among older Mexican-origin and white men SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depression; access and quality of care; elderly; men; minorities; primary care ID LATE-LIFE DEPRESSION; PRIMARY-CARE; UNITED-STATES; COLLABORATIVE CARE; DISPARITIES; ADULTS; HEALTH; TRIAL; POPULATIONS; IMPAIRMENT AB Objectives This study aims (i) to compare depression frequency and self-reported depression treatment in Mexican-origin and white men; (ii) to examine ethnic differences in self-reported prior depression diagnosis and types of treatment; and (iii) to determine whether Mexican-origin men (both English and Spanish language preferring) are less likely than white men to report receiving depression treatment after controlling for potential confounders. Methods This is a cross-sectional, observational study of Mexican-origin and white men (60?years old and over) presenting for primary care visits at six outpatient clinics in California's Central Valley. Clinical depression was assessed with the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), module for past-year major depression and questions for chronic depression. Past year, self-reported prior depression diagnosis and treatment (i.e., medication, psychotherapy, mental health referral) were assessed through a structured questionnaire. Results The frequency of past-year clinical depression was similar for both ethnic groups, yet Mexican-origin men were significantly less likely than whites to report receiving a prior diagnosis of depression or prior depression treatment. Compared with whites, the odds of untreated depression in Mexican-origin men was 4.35 (95% CI 1.3514.08) for those interviewed in English and 10.40 (95% CI 2.1151.25) for those interviewed in Spanish. For both ethnic groups, the majority (i.e., approximately two-thirds) of men receiving depression treatment also met criteria for past-year clinical depression. Conclusions Mexican-origin older men in primary care suffer from significant gaps in depression care (i.e., diagnosis and treatment) compared with whites. Delivering effective depression treatment (i.e., so that depression remits) remains elusive for both ethnic groups. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Hinton, Ladson; Apesoa-Varano, Ester Carolina] Univ Calif Davis, Betty Irene Sch Nursing, Sacramento, CA 95817 USA. [Gonzalez, Hector M.] Wayne State Univ, Detroit, MI USA. [Dwight-Johnson, Megan] RAND Corp, Los Angeles, CA USA. [Dwight-Johnson, Megan] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Barker, Judith C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Zuniga, Ramiro] San Joaquin Gen Hosp, French Camp, CA USA. [Unuetzer, Juergen] Univ Washington, Seattle, WA 98195 USA. RP Hinton, L (reprint author), Univ Calif Davis, Betty Irene Sch Nursing, Sacramento, CA 95817 USA. EM ladson.hinton@ucdmc.ucdavis.edu FU National Institute of Mental Health (NIMH) [R01MH080067, R01MH84994]; NHLBI [HC65233] FX The authors are grateful to Eduardo Alvarado and Mauricio Rodriguez who assisted in data collection. This study was supported by Award Number R01MH080067 from the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. Dr Gonzalez is supported by the NIMH (R01MH84994) and NHLBI (HC65233). Results of this study were presented at the American Association of Geriatric Psychiatry meeting in San Antonio in March of 2011. NR 33 TC 4 Z9 4 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD DEC PY 2012 VL 27 IS 12 BP 1283 EP 1290 DI 10.1002/gps.3779 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 033LP UT WOS:000310798300008 PM 22383214 ER PT J AU Gordon, EA Pullatt, RC AF Gordon, Elizabeth A. Pullatt, Rana C. TI Treatment of Biliary Stricture: Stents versus Surgery SO AMERICAN SURGEON LA English DT Article C1 [Gordon, Elizabeth A.] Med Univ S Carolina, Dept Gen Surg, Div Gastrointestinal & Laparoscop Surg, Charleston, SC 29401 USA. [Pullatt, Rana C.] Ralph Johnson VA Med Ctr, Charleston, SC USA. RP Gordon, EA (reprint author), Med Univ S Carolina, Dept Surg, Div Gastrointestinal & Laparoscop Surg, 25 Courtenay Dr, Charleston, SC 29401 USA. EM eag2@musc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD DEC PY 2012 VL 78 IS 12 BP E510 EP E512 PG 3 WC Surgery SC Surgery GA V32MD UT WOS:000208954400006 PM 23265103 ER PT J AU Sugawara, M Ly, T Hershman, JM AF Sugawara, Masahiro Ly, Tran Hershman, Jerome M. TI Medullary Thyroid Cancer-Current Treatment Strategy, Novel Therapies and Perspectives for the Future SO HORMONES & CANCER LA English DT Review AB Medullary thyroid cancer (MTC), an uncommon and slow-growing tumor, is difficult to eradicate when metastasis or recurrence develops. This review describes therapeutic approaches to patients with recurrent sporadic MTC, management of advanced cases of MTC, and future treatment options. A literature review of treatment of MTC in humans was conducted. Surgery is currently the only potentially curative treatment for MTC; complete tumor resection and removal of suspicious nodes is the most important initial treatment to prevent recurrence and metastasis. When recurrence or metastatic MTC develops, the decision for continued observation or initiation of systemic therapy is based on the degree of tumor aggressiveness. Lymph node involvement, calcitonin doubling time, types of RET mutation, and tumor stage are factors that help determine the need for further treatment. Therapeutic options for aggressive and inoperable MTC primarily include tyrosine kinase inhibitors, external beam radiation therapy, or other medications. Among tyrosine kinase inhibitors, vandetanib is the first drug that is FDA approved for treatment of MTC. Focused external beam radiation therapy can be reconsidered for patients with cervical node involvement. Although other targeted drug therapies have been tried, definitive clinical studies are lacking. In recurrent or advanced MTC, when systemic therapy is warranted, vandetanib is available for use in treatment; however, side effects of this drug can be problematic, and impact on overall survival is presently unknown. Newer therapeutics are being studied with the goal of balancing control of tumor growth with maintaining the patient's quality of life. RP Hershman, JM (reprint author), Greater Los Angeles VA Med Ctr, 11307 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 55 TC 1 Z9 2 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-8497 EI 1868-8500 J9 HORM CANCER-US JI Horm. Cancer PD DEC PY 2012 VL 3 IS 5-6 BP 218 EP 226 DI 10.1007/s12672-012-0119-5 PG 9 WC Oncology; Endocrinology & Metabolism SC Oncology; Endocrinology & Metabolism GA 034JO UT WOS:000310869100002 PM 23011723 ER PT J AU Kangovi, S Evans, TL Mitra, N AF Kangovi, Shreya Evans, Tracey L. Mitra, Nandita TI Patient-reported oncology readmission factors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 48 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900048 ER PT J AU Shelton, JB Skolarus, TA Malin, J Antonio, ALM He, R Saigal, C AF Shelton, Jeremy Bradford Skolarus, Ted A. Malin, Jennifer Antonio, Anna Liza M. He, Ren Saigal, Christopher TI Validation of electronic prostate cancer quality-of-care measures in the Veterans Health Administration (VHA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 213 PG 2 WC Oncology SC Oncology GA V32IC UT WOS:000208943900212 ER PT J AU Walling, AM Tisnado, DM Malin, J Asch, SM Pantoja, P Ettner, S Dy, SM Lorenz, KA AF Walling, Anne M. Tisnado, Diana M. Malin, Jennifer Asch, Steven M. Pantoja, Philip Ettner, Susan Dy, Sydney Morss Lorenz, Karl A. TI National evaluation of the VA's quality of supportive care. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 218 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900217 ER PT J AU Morshed, SA Latif, R Davies, TF AF Morshed, Syed A. Latif, Rauf Davies, Terry F. TI Delineating the autoimmune mechanisms in Graves' disease SO IMMUNOLOGIC RESEARCH LA English DT Article DE AITD; GD; HT; Autoimmunity; TSHR; Autoantibody ID REGULATORY T-CELLS; STIMULATING HORMONE-RECEPTOR; HUMAN THYROTROPIN RECEPTOR; OPPOSITE PHENOTYPIC MANIFESTATIONS; FAS-MEDIATED APOPTOSIS; THYROID-DISEASE; TSH-RECEPTOR; MONOCLONAL-ANTIBODIES; GENETIC SUSCEPTIBILITY; DENDRITIC CELLS AB The immunologic processes involved in autoimmune thyroid disease (AITD), particularly Graves' disease (GD), are similar to other autoimmune diseases with the emphasis on the antibodies as the most unique aspect. These characteristics include a lymphocytic infiltrate at the target organs, the presence of antigen-reactive T and B cells and antibodies, and the establishment of animal models of GD by antibody transfer or immunization with antigen. Similar to other autoimmune diseases, risk factors for GD include the presence of multiple susceptibility genes, including certain HLA alleles, and the TSHR gene itself. In addition, a variety of known risk factors and precipitators have been characterized including the influence of sex and sex hormones, pregnancy, stress, infection, iodine and other potential environmental factors. The pathogenesis of GD is likely the result of a breakdown in the tolerance mechanisms, both at central and peripheral levels. Different subsets of T and B cells together with their regulatory populations play important roles in the propagation and maintenance of the disease process. Understanding different mechanistic in the complex system biology interplay will help to identify unique factors contributing to the AITD pathogenesis. C1 [Morshed, Syed A.; Latif, Rauf; Davies, Terry F.] Mt Sinai Sch Med, Thyroid Res Unit, James J Peters VA Med Ctr, New York, NY 10468 USA. RP Morshed, SA (reprint author), Mt Sinai Sch Med, Thyroid Res Unit, James J Peters VA Med Ctr, Room 2F-26,130 W Kingsbridge Rd, New York, NY 10468 USA. EM syed.morshed@mssm.edu OI latif, rauf/0000-0002-4226-3728 FU NIH [DK069713, DK052464]; VA Merit Award Program FX Supported in part by NIH grants DK069713, DK052464 and the VA Merit Award Program. We thank Dr. Xiaoming Yin for help with the manuscript. NR 127 TC 29 Z9 33 U1 0 U2 22 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PD DEC PY 2012 VL 54 IS 1-3 SI SI BP 191 EP 203 DI 10.1007/s12026-012-8312-8 PG 13 WC Immunology SC Immunology GA 025EK UT WOS:000310168100019 PM 22434518 ER PT J AU Hasham, A Tomer, Y AF Hasham, Alia Tomer, Yaron TI Genetic and epigenetic mechanisms in thyroid autoimmunity SO IMMUNOLOGIC RESEARCH LA English DT Article DE Thyroid genetics; Autoimmune thyroid disorders; Epigenetics ID SINGLE-NUCLEOTIDE POLYMORPHISM; GRAVES-DISEASE; SUSCEPTIBILITY LOCI; DIABETES-MELLITUS; CD40 GENE; THYROGLOBULIN; EXPRESSION; ACID; GENOME; REGION AB Autoimmune thyroid diseases (AITD), including Graves' disease and Hashimoto's thyroiditis, are among the commonest autoimmune disorders, affecting approximately 5 % of the population. Epidemiological data support strong genetic influences on the development of AITD. Since the identification of HLA-DR3 as a major AITD susceptibility gene, there have been significant advances made in our understanding of the genetic mechanisms leading to AITD. We have shown that an amino acid substitution of alanine or glutamine with arginine at position 74 in the HLA-DR peptide binding pocket is a critical factor in the development of AITD, and we are continuing to dissect these mechanisms at the molecular level. In addition to the MHC class II genes, there are now several other confirmed gene loci associated with AITD, including immune-regulatory (CD40, CTLA-4, PTPN22, FOXP3, and CD25) and thyroid-specific genes (thyroglobulin and TSHR). Mechanistically, it is postulated that susceptibility genes interact with certain environmental triggers to induce AITD through epigenetic effects. In this review, we summarize some of the recent advances made in our laboratory dissecting the genetic-epigenetic interactions underlying AITD. As shown in our recent studies, epigenetic modifications offer an attractive mechanistic possibility that can provide further insight into the etiology of AITD. C1 [Hasham, Alia; Tomer, Yaron] Mt Sinai Med Ctr, Div Endocrinol, Dept Med, New York, NY 10029 USA. [Hasham, Alia; Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Dept Med, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu FU National Institutes of Health [DK61659, DK067555, DK073681]; Veterans Affairs merit award FX This work was supported in part by National Institutes of Health Grants DK61659, DK067555, and DK073681. This work was also supported by a Veterans Affairs merit award (to Y.T.). NR 35 TC 26 Z9 26 U1 1 U2 43 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X EI 1559-0755 J9 IMMUNOL RES JI Immunol. Res. PD DEC PY 2012 VL 54 IS 1-3 SI SI BP 204 EP 213 DI 10.1007/s12026-012-8302-x PG 10 WC Immunology SC Immunology GA 025EK UT WOS:000310168100020 PM 22457094 ER PT J AU Lee, KB Taghavi, CE Murray, SS Song, KJ Keorochana, G Wang, JC AF Lee, Kwang-Bok Taghavi, Cyrus E. Murray, Samuel S. Song, Kyung-Jin Keorochana, Gun Wang, Jeffrey C. TI BMP induced inflammation: A comparison of rhBMP-7 and rhBMP-2 SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE soft tissue edema; inflammation; rhBMP-7; rhBMP-2; MIPAV ID BONE MORPHOGENETIC PROTEIN; ANTERIOR CERVICAL-SPINE; OSTEOGENIC PROTEIN-1; SAFETY PROFILE; FUSION; SURGERY; RATS AB Concern has been raised because of reports of inflammatory swelling following the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant human bone morphogenetic protein-7 (rhBMP-7). The purpose of this study is to compare the inflammatory action of rhBMP-7 with those of rhBMP-2. ELISA assays (IL-6, TNF-a) were used to measure the cytokine response to different concentrations of rhBMP-7 and -2. Recombinant human BMP-7 was absorbed into absorbable collagen sponges and different amounts were implanted either subcutaneously (SC) or intramuscularly (IM) into the backs of rats. Using MRI and MIPAV software, we measured the degree of soft tissue edema at 3?h and at 2, 4, and 7 days postoperatively. After sacrificing rats on day 7 the inflammatory zone and mass were measured and the tissue examined histologically. Soft tissue edema after rhBMP-7 and rhBMP-2 implantation was dose-dependent and peaked at 3?h for the subcutaneous implants and at 2 days for the intramuscular implants. RhBMP-7 was associated with a significantly smaller soft tissue edema volume than was rhBMP-2 only at the highest dose (20?mu g/ml). Both rhBMP-2 and rhBMP-7 triggered dose-dependent inflammatory reactions. Compared to rhBMP-2, rhBMP-7 is associated with somewhat smaller soft tissue edema volumes. Although rhBMP-7 is associated with an inflammatory reaction leading to soft tissue edema, at high doses this response is significantly less than that seen with rhBMP-2. Our animal model can be used to test materials that could ameliorate this reaction. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:19851994, 2012 C1 [Lee, Kwang-Bok; Taghavi, Cyrus E.; Keorochana, Gun; Wang, Jeffrey C.] Univ Calif Los Angeles, UCLA Comprehens Spine Ctr, Dept Orthopaed Surg, Los Angeles, CA 90404 USA. [Lee, Kwang-Bok; Song, Kyung-Jin] Chonbuk Natl Univ, Sch Med, Chonbuk Natl Univ Hosp, Dept Orthopaed Surg,Res Inst Clin Med, Jeonju, South Korea. [Murray, Samuel S.] VA Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. [Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90404 USA. [Murray, Samuel S.; Wang, Jeffrey C.] Univ Calif Los Angeles, Biomed Engn Interdept Program, Los Angeles, CA 90404 USA. RP Wang, JC (reprint author), Univ Calif Los Angeles, UCLA Comprehens Spine Ctr, Dept Orthopaed Surg, 1250 16th St,7th Floor,Tower 745, Los Angeles, CA 90404 USA. EM jwang@mednet.ucla.edu NR 22 TC 30 Z9 31 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD DEC PY 2012 VL 30 IS 12 BP 1985 EP 1994 DI 10.1002/jor.22160 PG 10 WC Orthopedics SC Orthopedics GA 027XO UT WOS:000310387600017 PM 22674456 ER PT J AU Murray, PS Kirkwood, CM Gray, MC Ikonomovic, MD Paljug, WR Abrahamson, EE Henteleff, RA Hamilton, RL Kofler, JK Klunk, WE Lopez, OL Penzes, P Sweet, RA AF Murray, Patrick S. Kirkwood, Caitlin M. Gray, Megan C. Ikonomovic, Milos D. Paljug, William R. Abrahamson, Eric E. Henteleff, Ruth A. Hamilton, Ronald L. Kofler, Julia K. Klunk, William E. Lopez, Oscar L. Penzes, Peter Sweet, Robert A. TI beta-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis SO NEUROBIOLOGY OF AGING LA English DT Article DE beta-amyloid; Kalirin; Psychosis; Alzheimer disease ID GDP/GTP EXCHANGE FACTOR; LONG-TERM POTENTIATION; SYNAPSE LOSS; IN-VIVO; COGNITIVE IMPAIRMENT; SPINE MORPHOGENESIS; DENDRITIC SPINES; RISK-FACTORS; DBL FAMILY; A-BETA AB Psychosis in Alzheimer disease differentiates a subgroup with more rapid decline, is heritable, and aggregates within families, suggesting a distinct neurobiology. Evidence indicates that greater impairments of cerebral cortical synapses, particularly in dorsolateral prefrontal cortex, may contribute to the pathogenesis of psychosis in Alzheimer disease (AD) phenotype. Soluble beta-amyloid induces loss of dendritic spine synapses through impairment of long-term potentiation. In contrast, the Rho guanine nucleotide exchange factor (GEF) kalirin is an essential mediator of spine maintenance and growth in cerebral cortex. We therefore hypothesized that psychosis in AD would be associated with increased soluble beta-amyloid and reduced expression of kalirin in the cortex. We tested this hypothesis in postmortem cortical gray matter extracts from 52 AD subjects with and without psychosis. In subjects with psychosis, the beta-amyloid(1-42)/beta-amyloid(1-40) ratio was increased, due primarily to reduced soluble beta-amyloid(1-40), and kalirin-7, -9, and -12 were reduced. These findings suggest that increased cortical beta-amyloid(1-42)/beta-amyloid(1-40) ratio and decreased kalirin expression may both contribute to the pathogenesis of psychosis in AD. Published by Elsevier Inc. C1 [Murray, Patrick S.; Kirkwood, Caitlin M.; Gray, Megan C.; Ikonomovic, Milos D.; Henteleff, Ruth A.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Murray, Patrick S.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Ikonomovic, Milos D.; Paljug, William R.; Abrahamson, Eric E.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hamilton, Ronald L.; Kofler, Julia K.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Sweet, RA (reprint author), Biomed Sci Tower,W1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Penzes, Peter/L-3987-2016 OI Penzes, Peter/0000-0001-5449-1640; Murray, Patrick/0000-0002-6525-2888; Klunk, William/0000-0001-5512-0251 FU Veterans Health Administration [5I01BX000452]; National Institute on Aging [5P01AG014449, 5P50AG005133, 5R01AG027224]; National Institute of Mental Health [5T32MH019986] FX This work was supported by the Veterans Health Administration (5I01BX000452 to RAS); and the National Institute on Aging (5P01AG014449 to MDI, 5P50AG005133 to OLL, and 5R01AG027224 to RAS). P. S. M. is supported by the National Institute of Mental Health (5T32MH019986). NR 67 TC 19 Z9 19 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2012 VL 33 IS 12 BP 2807 EP 2816 DI 10.1016/j.neurobiolaging.2012.02.015 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 025OJ UT WOS:000310200000009 PM 22429885 ER PT J AU Nedjat-Haiem, FR Carrion, IV Ell, K Palinkas, L AF Nedjat-Haiem, Frances R. Carrion, Iraida V. Ell, Kathleen Palinkas, Lawrence TI Navigating the advanced cancer experience of underserved Latinas SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Advanced cancer; Cancer burden; Coping; Underserved Latinos; Sociocultural ID AMERICAN WOMEN; CARE; HEALTH; LIFE; END; DISPARITIES; SURVIVORS; FAMILIES AB Previous cancer research does not adequately inform us about the experiences of managing a more serious, life-threatening cancer condition, especially for underserved Latinas. This study was designed to explore the ways in which Latinas navigate through and deal with advanced cancers. A purposive sample of 24 underserved Latina women was selected from a randomized controlled trial. Data were analyzed using a phenomenological approach to explore navigation of the advanced cancer experience. This study outlines a conceptual framework which denotes the interconnectedness of multiple factors that influence the cancer experience for Latina women. Experiences with advanced cancer were embedded within a social, cultural, and systemic framework described as 1) intrapersonal experiences; 2) interpersonal experiences; 3) provider interactions; and 4) medical system factors. This study indicates that underserved Latinas face complex circumstances that interfere with the diagnosis and treatment of cancer. However, women expressed positive attitudes and held beliefs about survival which helped them through their experience with cancer. The implication of these findings is that Latinas have protective attitudes and beliefs that help them to overcome "tragic" circumstances. Providers need to become aware of the complexity of these issues in order to achieve competent, effective, and efficient practice in medical settings with Latinas. C1 [Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, VA Associated Hlth Postdoctoral Fellowship Progra, Off Acad Affiliat, HSR&D Ctr Excellence, Los Angeles, CA 90073 USA. [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL 33612 USA. [Ell, Kathleen; Palinkas, Lawrence] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. RP Nedjat-Haiem, FR (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, VA Associated Hlth Postdoctoral Fellowship Progra, Off Acad Affiliat, HSR&D Ctr Excellence, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM nedjatha@gmail.com OI Carrion, Iraida/0000-0003-4076-6644 FU VA Associated Health Postdoctoral Fellowship Program, HSR&D Center of Excellence; American Cancer Society Doctoral Training Grant in Oncology Social Work [DSW-06-220-01-SW]; National Cancer Institute [R01CA105269] FX This research was supported by the VA Associated Health Postdoctoral Fellowship Program, HSR&D Center of Excellence, the American Cancer Society Doctoral Training Grant in Oncology Social Work DSW-06-220-01-SW (F. R. Nedjat-Haiem, PI), and the National Cancer Institute R01CA105269 (K. Ell, PI). NR 38 TC 11 Z9 11 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD DEC PY 2012 VL 20 IS 12 BP 3095 EP 3104 DI 10.1007/s00520-012-1437-4 PG 10 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 025YD UT WOS:000310232500011 PM 22418600 ER PT J AU Zeiss, A AF Zeiss, Antonette TI Never Turn Your Back on a Wave SO BEHAVIOR THERAPY LA English DT Article DE women's issues; gender differences; women in VA health care AB This article reviews the intersections of personal and professional life development for the author. She offers perspective on three important life lessons that have guided her in this rewarding life path. First, be responsible in fulfilling and seeking professional opportunities. Second, be nice-respectful, warm, collegial, collaborative; treat others with the respect you want to receive yourself. Finally, "Never turn your back on a wave"-face the challenges that life presents, forthrightly, with energy and enthusiasm, and enjoy a full and fulfilling career and personal life. C1 US Dept Vet Affairs, Washington, DC 20420 USA. RP Zeiss, A (reprint author), US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Antonette.Zeiss@va.gov NR 0 TC 2 Z9 2 U1 0 U2 0 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD DEC PY 2012 VL 43 IS 4 BP 712 EP 714 PG 3 WC Psychology, Clinical SC Psychology GA 024HW UT WOS:000310101300006 PM 23213675 ER PT J AU Higashi, RT Tillack, AA Steinman, M Harper, M Johnston, CB AF Higashi, Robin T. Tillack, Allison A. Steinman, Michael Harper, Michael Johnston, C. Bree TI Elder care as "frustrating" and "boring": Understanding the persistence of negative attitudes toward older patients among physicians-in-training SO JOURNAL OF AGING STUDIES LA English DT Article DE Ageism; Medical education; Ethnograpy ID MEDICAL-STUDENTS; HIDDEN CURRICULUM; GERIATRIC-MEDICINE; KNOWLEDGE; EDUCATION; BIOMEDICALIZATION; SCIENCE; LEARN; SEE; AGE AB Objectives: This study explores the attitudes of physicians-in-training toward older patients. Specifically, we examine why, despite increasing exposure to geriatrics in medical school curricula, medical students and residents continue to have negative attitudes toward caring for older patients. Methods: This study used ethnography, a technique used by anthropologists that includes participant-observation, semi-structured interviews, and facilitated group discussions. Research was conducted at two tertiary-care academic hospitals in urban Northern California, and focused on eliciting the opinions, beliefs, and practices of physicians-in-training toward geriatrics. Results: We found that the majority of physicians-in-training in this study expressed a mix of positive and negative views about caring for older patients. We argue that physicians-in-trainings' attitudes toward older patients are shaped by a number of heterogeneous and frequently conflicting factors, including both the formal and so-called "hidden" curricula in medical education, institutional demands on physicians to encourage speed and efficiency of care, and portrayals of the process of aging as simultaneously as a "problem" of inevitable biological decay and an opportunity for medical intervention. Discussion: Efforts to educate medical students and residents about appropriate geriatric care tend to reproduce the paradoxes and uncertainties surrounding aging in biomedicine. These ambiguities contribute to the tendency of physicians-in-training to develop moralizing attitudes about older patients and other patient groups labeled "frustrating" or "boring". (C) 2012 Elsevier Inc. All rights reserved. C1 [Higashi, Robin T.; Tillack, Allison A.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. [Steinman, Michael; Harper, Michael; Johnston, C. Bree] San Francisco VA Med Ctr, Dept Geriatr, San Francisco, CA USA. RP Higashi, RT (reprint author), Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. EM robin.higashi@gmail.com NR 26 TC 13 Z9 13 U1 1 U2 27 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-4065 J9 J AGING STUD JI J. Aging Stud. PD DEC PY 2012 VL 26 IS 4 BP 476 EP 483 DI 10.1016/j.jaging.2012.06.007 PG 8 WC Gerontology SC Geriatrics & Gerontology GA 013NN UT WOS:000309312200012 PM 22939544 ER PT J AU Hirata, H Ueno, K Shahryari, V Tanaka, Y Tabatabai, ZL Hinoda, Y Dahiya, R AF Hirata, Hiroshi Ueno, Koji Shahryari, Varahram Tanaka, Yuichiro Tabatabai, Z. Laura Hinoda, Yuji Dahiya, Rajvir TI Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer SO PLOS ONE LA English DT Article ID BETA-CATENIN ACTIVATION; TUMOR-SUPPRESSOR; SIGNALING ACTIVITY; CARCINOMA CELLS; EXPRESSION; METASTASIS; MICRORNAS; MIR-182; TUMORIGENESIS; RESTORATION AB Onco-miR-182-5p has been reported to be over-expressed in bladder cancer (BC) tissues however a detailed functional analysis of miR-182-5p has not been carried out in BC. Therefore the purpose of this study was to: 1. conduct a functional analysis of miR-182-5p in bladder cancer, 2. assess its usefulness as a tumor marker, 3. identify miR-182-5p target genes in BC. Initially we found that miR-182-5p expression was significantly higher in bladder cancer compared to normal tissues and high miR-182-5p expression was associated with shorter overall survival in BC patients. To study the functional significance of miR-182-5p, we over-expressed miR-182-5p with miR-182-5p precursor and observed that cell proliferation, migration and invasion abilities were increased in BC cells. However cell apoptosis was inhibited by miR-182-5p. We also identified Smad4 and RECK as potential target genes of miR-182-5p using several algorithms. 3'UTR luciferase activity of these target genes was significantly decreased and protein expression of these target genes was significantly up-regulated in miR-182-5p inhibitor transfected bladder cancer cells. MiR-182-5p also increased nuclear beta-catenin expression and while Smad4 repressed nuclear beta-catenin expression. In conclusion, our data suggests that miR-182-5p plays an important role as an oncogene by knocking down RECK and Smad4, resulting in activation of the Wnt-beta-catenin signaling pathway in bladder cancer. C1 [Hirata, Hiroshi; Ueno, Koji; Shahryari, Varahram; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Hirata, Hiroshi; Ueno, Koji; Shahryari, Varahram; Tanaka, Yuichiro; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. EM rdahiya@urology.ucsf.edu FU National Center for Research Resources of the United States National Institutes of Health [RO1CA138642, RO1CA130860, RO1CA160079]; VA Merit Review grants; VA Program Project FX This study was supported by National Center for Research Resources of the United States National Institutes of Health through Grant Number RO1CA138642, RO1CA130860, RO1CA160079, VA Merit Review grants, and VA Program Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 52 Z9 55 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 30 PY 2012 VL 7 IS 11 AR e51056 DI 10.1371/journal.pone.0051056 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 054WM UT WOS:000312376100266 PM 23226455 ER PT J AU Hu, XZ Tomlinson, S Barnum, SR AF Hu, Xianzhen Tomlinson, Stephen Barnum, Scott R. TI Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE SO NEUROSCIENCE LETTERS LA English DT Article DE Experimental autoimmune; encephalomyelitis; Neuroimmunology complement; Immunology; Autoimmune disease ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; COBRA VENOM FACTOR; MULTIPLE-SCLEROSIS; ALTERNATIVE PATHWAY; DISEASE; INJURY; NATALIZUMAB AB Multiple sclerosis (MS) is the most common autoimmune demyelinating disease, affecting millions of individuals worldwide. In the last two decades, many therapeutic options for the treatment of MS have become available, however they are limited in terms of effectiveness and some remain plagued by safety issues. The currently available treatment options target relapsing remitting forms of MS and are not effective against the more progressive forms of the disease. These limitations highlight a significant unmet treatment need for MS. In experimental autoimmune encephalomyelitis (EAE) studies from our laboratory, we have previously shown, using a number of complement mutant and transgenic mice, that inhibition of the alternative complement pathway and the C3 convertase confers significant protection from disease. We report here that targeted inhibition of complement activation using complement receptor 2 (CR2)-conjugated inhibitors significantly attenuates EAE. Administration of CR2-Crry (blocks all complement pathways at C3 activation) and CR2-fH (specifically blocks the alternative pathway) just prior to and during the onset of EAE blocks progression of both acute and chronic disease. These data indicate that inhibition of complement may offer an effective therapeutic approach to treating both acute and chronic forms of demyelinating disease through blocking the alternative pathway or complement convertases. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Hu, Xianzhen; Barnum, Scott R.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Barnum, Scott R.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. RP Barnum, SR (reprint author), Univ Alabama Birmingham, Dept Microbiol, 845 19th St S,BBRB-842, Birmingham, AL 35294 USA. EM tomlinss@musc.edu; sbarnum@uab.edu FU NIH [NS069365, HL082485]; VA Merit Award [IO1BX001201] FX This work was supported by NIH grants NS069365 to SRB and HL082485 to ST and VA Merit Award IO1BX001201 to ST. NR 50 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 30 PY 2012 VL 531 IS 1 BP 35 EP 39 DI 10.1016/j.neulet.2012.10.012 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 052ZN UT WOS:000312239300008 PM 23079547 ER PT J AU Bin Riaz, I Riaz, H Riaz, T Rahman, S Amir, M Badshah, MB Kazi, AN AF Bin Riaz, Irbaz Riaz, Haris Riaz, Talha Rahman, Sophia Amir, Muhammad Badshah, Maaz B. Kazi, Abdul Nafey TI Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: A meta-analysis of randomized controlled trials SO BMC GASTROENTEROLOGY LA English DT Article ID HEPATITIS-C VIRUS; INTERFERON THERAPY; LIVER-CANCER; INHIBITION; ABLATION; GROWTH; ANGIOGENESIS; RESECTION; TUMOR; MENATETRENONE AB Background: Hepatocellular cancer is notorious for recurrence even after curative therapy. High recurrence determines the long term prognosis of the patients. Vitamin K2 has been tested in trials for its effect on prevention of recurrence and improving survival. The results are inconclusive from individual trials and in our knowledge no systematic review which entirely focuses on Vitamin K2 as a chemo preventive agent is available to date. This review is an attempt to pool all the existing trials together and update the existing knowledge on the topic. Methods: Medline, Embase and Cochrane Register of Controlled trials were searched for randomized controlled trials where vitamin K2 or its analogues, in any dosage were compared to placebo or No vitamin K2, for participants of any age or sex. Reference lists and abstracts of conference proceedings were searched by hand. Additional papers were identified by a manual search of the references from the key articles. Attempt was made to contact the authors of primary studies for missing data and with the experts in the field. Trials were assessed for inclusion by two independent reviewers. Primary outcomes were recurrence rates and survival rates. There were no secondary outcomes. Data was synthesized using a random effects model and results presented as relative risk with 95% Confidence Intervals. Result: For recurrence of hepatocellular cancer after hepatic resection or local ablative therapy, compared with controls, participants receiving Vitamin K2, pooled relative risks for hepatocellular cancer were 0.60; 95% CI: 0.28-1.28, p = 0.64) at 1 yr 0.66; 95% CI: 0.47-0.91), p = 0.01) at 2 yr; 0.71; 95% CI: 0.58-0.85, p = 0.004) at 3 yr respectively. The results were combined using the random analysis model. Conclusion: Five RCTs evaluated the preventive efficacy of menatetrenone on HCC recurrence after hepatic resection or local ablative therapy. The meta-analysis of all five studies, failed to confirm significantly better tumor recurrence-free survival at 1 year. Improved tumor recurrence at 2nd and 3rd year may be just due to insufficient data. There was no beneficial effect on the overall survival. However, to confirm the beneficial effect or lack of it, large, higher quality randomized controlled trials are still required. C1 [Bin Riaz, Irbaz] Univ Arizona, Dept Internal Med, Tucson, AZ USA. [Riaz, Haris; Riaz, Talha; Kazi, Abdul Nafey] Dow Univ Hlth Sci, Civil Hosp Karachi, Karachi, Pakistan. [Rahman, Sophia] New York Methodist Hosp, New York, NY USA. [Amir, Muhammad] Albert Einstein Coll Med, New York, NY USA. [Badshah, Maaz B.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. RP Riaz, H (reprint author), Dow Univ Hlth Sci, Civil Hosp Karachi, Karachi, Pakistan. EM harisriaz73@yahoo.com OI Riaz, Irbaz bin/0000-0003-4249-0311 NR 20 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-230X J9 BMC GASTROENTEROL JI BMC Gastroenterol. PD NOV 29 PY 2012 VL 12 AR 170 DI 10.1186/1471-230X-12-170 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096GR UT WOS:000315392700001 ER PT J AU Dick, AAS Mercer, LD Smith, JM McDonald, RA Young, B Healey, PJ AF Dick, A. A. S. Mercer, L. D. Smith, J. M. McDonald, R. A. Young, B. Healey, P. J. TI Donor and Recipient Size Mismatch in Pediatric Living Donor Renal Transplantation Affects Long-Term Graft Survival SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Dick, A. A. S.; Healey, P. J.] Seattle Childrens Hosp, Div Transplant, Surg, Seattle, WA USA. [Mercer, L. D.] Seattle Childrens Res Inst, Core Biomed Stat, Seattle, WA USA. [Smith, J. M.; McDonald, R. A.] Seattle Childrens Hosp, Div Nephrol, Pediat, Seattle, WA USA. [Young, B.] VA Puget Sound Hlth Care Syst, Div Nephrol, Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1735 BP 75 EP 75 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846400139 ER PT J AU Liu, Q Rehman, H Krishnasamy, Y Haque, K Schnellmann, RG Lemasters, JJ Zhong, Z AF Liu, Q. Rehman, H. Krishnasamy, Y. Haque, K. Schnellmann, R. G. Lemasters, J. J. Zhong, Z. TI Role of Amphiregulin in Suppressed Liver Regeneration after Small-For-Size Liver Transplantation in Mice SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ South Carolina, Pharmaceut & Biomed Sci, Charleston, SC USA. [Schnellmann, R. G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 631 BP 376 EP 376 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401492 ER PT J AU Liu, Q Rehman, H Krishnasamy, Y Haque, K Schnellmann, RG Lemasters, JJ Zhong, Z AF Liu, Q. Rehman, H. Krishnasamy, Y. Haque, K. Schnellmann, R. G. Lemasters, J. J. Zhong, Z. TI Role of Amphiregulin in Suppressed Liver Regeneration after Small-For-Size Liver Transplantation in Mice SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ South Carolina, Pharmaceut & Biomed Sci, Charleston, SC USA. [Schnellmann, R. G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 631 BP 649 EP 649 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402556 ER PT J AU Zaman, MS Thamminana, S Shahryari, V Chiyomaru, T Deng, GR Saini, S Majid, S Fukuhara, S Chang, I Arora, S Hirata, H Ueno, K Singh, K Tanaka, Y Dahiya, R AF Zaman, Mohd Saif Thamminana, Sobha Shahryari, Varahram Chiyomaru, Takeshi Deng, Guoren Saini, Sharanjot Majid, Shahana Fukuhara, Shinichiro Chang, Inik Arora, Sumit Hirata, Hiroshi Ueno, Koji Singh, Kamaldeep Tanaka, Yuichiro Dahiya, Rajvir TI Inhibition of PTEN Gene Expression by Oncogenic miR-23b-3p in Renal Cancer SO PLOS ONE LA English DT Article ID CARCINOMA; PROTEIN; MYOFIBROBLASTS; PROGRESSION; MICRORNAS; GENISTEIN; PATHWAY; KINASE; BREAST; CELLS AB Background: miR-23b is located on chromosome number 9 and plays different roles in different organs especially with regards to cancer development. However, the functional significance of miR-23b-3p in renal cell carcinoma (RCC) has not been reported. Methods and Results: We measured miR-23b-3p levels in 29 pairs of renal cell carcinoma and their normal matched tissues using real-time PCR. The expression level of miR-23b-3p was correlated with the 5 year survival rate of renal cancer patients. In 15 cases (52%), miR-23b-3p expression was found to be high. All patients with moderate to low miR-23b-3p expression survived 5 years, while those with high miR-23b-3p expression, only 50% survived. After knocking down miRNA-23b-3p expression in RCC cell lines, there was an induction of apoptosis and reduced invasive capabilities. MiR-23b-3p was shown to directly target PTEN gene through 3'UTR reporter assays. Inhibition of miR-23b-3p induces PTEN gene expression with a concomitant reduction in PI3-kinase, total Akt and IL-32. Immunohistochemistry showed the lack of PTEN protein expression in cancerous regions of tissue samples where the expression of miR-23b-3p was high. We studied the in vitro effects of the dietary chemo preventive agent genistein on miR-23b-3p expression and found that it inhibited expression of miR-23b-3p in RCC cell lines. Conclusions: The current study shows that miR-23b-3p is an oncogenic miRNA and inhibits PTEN tumor suppressor gene in RCC. Therefore, inhibition of miR-23b-3p may be a useful therapeutic target for the treatment of renal cell carcinoma. C1 [Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. EM rdahiya@urology.ucsf.edu FU VA Merit Review; VA Program Project; NIH [RO1CA130860] FX This study was supported by the VA Merit Review, VA Program Project and NIH Grant RO1CA130860 (PI: R. Dahiya). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 35 Z9 36 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 26 PY 2012 VL 7 IS 11 AR e50203 DI 10.1371/journal.pone.0050203 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048RI UT WOS:000311929800064 PM 23189187 ER PT J AU Johansen, KL AF Johansen, Kirsten L. TI The Skinny on Obesity and End-Stage Renal Disease SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID BODY-MASS INDEX; ADOLESCENTS; CHILDREN; RISK C1 San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [HHSN267200700005C]; None [HHSN267200700005C] NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 26 PY 2012 VL 172 IS 21 BP 1651 EP 1652 DI 10.1001/2013.jamainternmed.917 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 042ZY UT WOS:000311513000009 PM 23108610 ER PT J AU Hightower, GK Wong, JK Letendre, SL Umlauf, AA Ellis, RJ Ignacio, CC Heaton, RK Collier, AC Marra, CM Clifford, DB Gelman, BB McArthur, JC Morgello, S Simpson, DM McCutchan, JA Grant, I Little, SJ Richman, DD Pond, SLK Smith, DM AF Hightower, George K. Wong, Joseph K. Letendre, Scott L. Umlauf, Anya A. Ellis, Ronald J. Ignacio, Caroline C. Heaton, Robert K. Collier, Ann C. Marra, Christina M. Clifford, David B. Gelman, Benjamin B. McArthur, Justin C. Morgello, Susan Simpson, David M. McCutchan, J. A. Grant, Igor Little, Susan J. Richman, Douglas D. Pond, Sergei L. Kosakovsky Smith, Davey M. CA CHARTER Study Grp TI Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment SO VIROLOGY LA English DT Article DE HIV; AIDS; Genetic diversity; Neuropsychological impairment; Viral population dynamics ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; CEREBROSPINAL-FLUID; NEUROCOGNITIVE DISORDERS; POSITIVE SELECTION; PRIMARY INFECTION; RNA VIRUS; EVOLUTION; ESCAPE; DISEASE AB Standard methods used to estimate HIV-1 population diversity are often resource intensive (e.g., single genome amplification, clonal amplification and pyrosequencing) and not well suited for large study cohorts. Additional approaches are needed to address the relationships between intraindividual HIV-1 genetic diversity and 2 disease. With a small cohort of individuals, we validated three methods for measuring diversity: Shannon entropy and average pairwise distance (APD) using single genome sequences, and counts of mixed bases (i.e. ambiguous nucleotides) from population based sequences. In a large cohort, we then used the mixed base approach to determine associations between measure HIV-1 diversity and HIV associated disease. Normalized counts of mixed bases correlated with Shannon Entropy at both the nucleotide (rho=0.72, p=0.002) and amino acid level (rho=0.59, p =0.015), and APD (rho=0.75, p=0.001). Among participants who underwent neuropsychological and clinical assessments (n=187), increased HIV-1 population diversity was associated with both a diagnosis of AIDS and neuropsychological impairment. Published by Elsevier Inc. C1 [Hightower, George K.; Letendre, Scott L.; Umlauf, Anya A.; Ellis, Ronald J.; Ignacio, Caroline C.; Heaton, Robert K.; McCutchan, J. A.; Grant, Igor; Little, Susan J.; Richman, Douglas D.; Pond, Sergei L. Kosakovsky; Smith, Davey M.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ellis, Ronald J.; Grant, Igor; Richman, Douglas D.; Smith, Davey M.] Vet Affairs San Diego Healthcare Syst San Diego, San Diego, CA USA. [Collier, Ann C.; Marra, Christina M.] Univ Washington, Seattle, WA 98195 USA. [Clifford, David B.] Washington Univ, St Louis, MO USA. [Gelman, Benjamin B.] Univ Texas Galveston, Med Branch, Galveston, TX 77555 USA. [McArthur, Justin C.] Johns Hopkins Univ, Baltimore, MD USA. [Morgello, Susan; Simpson, David M.] Mt Sinai Sch Med, New York, NY USA. [CHARTER Study Grp] Univ Calif San Diego, CNS HIV Antiretroviral Therapy Effects Res, San Diego, CA 92103 USA. RP Smith, DM (reprint author), Univ Calif San Diego, 9500 Gilman Dr 0679, La Jolla, CA 92093 USA. EM davey@ucsd.edu RI Pond, Sergei/G-9830-2012; Ellis, Ronald/K-3543-2015 OI Pond, Sergei/0000-0003-4817-4029; Ellis, Ronald/0000-0003-4931-752X FU Pendleton Foundation; National Institutes of Health [DA12065, DA034978, MH083552, AI077304, AI69432, MH62512, AI27670, AI38858, AI43638, AI43752, AI047745, NS51132]; UCSD Centers for AIDS Research Translational Virology Core [AI36214, AI29164, AI47745, AI64086, AI57167]; San Diego Veterans Affairs Healthcare System FX This work was supported by the Pendleton Foundation and National Institutes of Health Grants DA12065, DA034978, MH083552, AI077304, AI69432, MH62512, AI27670, AI38858, AI43638, AI43752, AI047745, NS51132, UCSD Centers for AIDS Research Translational Virology Core AI36214, AI29164, AI47745, AI64086, AI57167 and San Diego Veterans Affairs Healthcare System. NR 38 TC 4 Z9 4 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 25 PY 2012 VL 433 IS 2 BP 498 EP 505 DI 10.1016/j.virol.2012.08.028 PG 8 WC Virology SC Virology GA 024FS UT WOS:000310095700024 PM 22999095 ER PT J AU Chintala, H Liu, HB Parmar, R Kamalska, M Kim, YJ Lovett, D Grant, MB Chaqour, B AF Chintala, Hembindu Liu, Haibo Parmar, Rahul Kamalska, Monika Kim, Yoon Ji Lovett, David Grant, Maria B. Chaqour, Brahim TI Connective Tissue Growth Factor Regulates Retinal Neovascularization through p53 Protein-dependent Transactivation of the Matrix Metalloproteinase (MMP)-2 Gene SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROLIFERATIVE DIABETIC-RETINOPATHY; VASCULAR ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VIVO; MATRIX-METALLOPROTEINASE-2 MMP-2; EXTRACELLULAR-MATRIX; FACTOR CYR61; ISCHEMIA; MICE; CCN; PREMATURITY AB Pathological angiogenesis in the retina is driven by dysregulation of hypoxia-driven stimuli that coordinate physiological vessel growth. How the various components of the neovascularization signaling network are integrated to yield pathological changes has not been defined. Connective tissue growth factor (CTGF/CCN2) is an inducible matricellular protein that plays a major role in fibroproliferative disorders. Here, we show that CTGF/CCN2 was dynamically expressed in the developing murine retinal vasculature and was abnormally increased and localized within neovascular tufts in the mouse eye with oxygen-induced retinopathy. Consistent with its propitious vascular localization, ectopic expression of the CTGF/CCN2 gene further accelerated neovascularization, whereas lentivirus-mediated loss-of-function or -expression of CTGF/CCN2 harnessed ischemia-induced neovessel outgrowth in oxygen-induced retinopathy mice. The neovascular effects of CTGF/CCN2 were mediated, at least in part, through increased expression and activity of matrix metalloproteinase (MMP)-2, which drives vascular remodeling through degradation of matrix and non matrix proteins, migration and invasion of endothelial cells, and formation of new vascular patterns. In cultured cells, CTGF/CCN2 activated the MMP-2 promoter through increased expression and tethering of the p53 transcription factor to a highly conserved p53-binding sequence within the MMP-2 promoter. Concordantly, the neovascular effects of CTGF/CCN2 were suppressed by p53 inhibition that culminated in reduced enrichment of the MMP-2 promoter with p53 and decreased MMP-2 gene expression. Our data identified new gene targets and downstream effectors of CTGF/CCN2 and provided the rational basis for targeting the p53 pathway to curtail the effects of CTGF/CCN2 on neovessel formation associated with ischemic retinopathy. C1 [Chintala, Hembindu; Liu, Haibo; Parmar, Rahul; Kamalska, Monika; Kim, Yoon Ji; Chaqour, Brahim] Suny Downstate Med Ctr, Dept Cell Biol, SUNY Eye Inst, Brooklyn, NY 11203 USA. [Chaqour, Brahim] Suny Downstate Med Ctr, Dept Ophthalmol, Brooklyn, NY 11203 USA. [Lovett, David] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Grant, Maria B.] Univ Florida, Dept Pharmacol, Gainesville, FL 32610 USA. [Grant, Maria B.] Univ Florida, Dept Therapeut, Gainesville, FL 32610 USA. RP Chaqour, B (reprint author), Suny Downstate Med Ctr, Dept Cell Biol, SUNY Eye Inst, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA. EM bchaqour@downstate.edu FU National Institutes of Health [EY022091-01, EY019387-01A1]; NEI [DK39776] FX This work was supported, in whole or in part, by National Institutes of Health Grants EY022091-01 and EY019387-01A1 (to B. C.) and DK39776 (to D. L.) from NEI. NR 69 TC 19 Z9 19 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 23 PY 2012 VL 287 IS 48 BP 40570 EP 40585 DI 10.1074/jbc.M112.386565 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 042CM UT WOS:000311448800047 PM 23048035 ER PT J AU Brautigam, H Steele, JW Westaway, D Fraser, PE St George-Hyslop, PH Gandy, S Hof, PR Dickstein, DL AF Brautigam, Hannah Steele, John W. Westaway, David Fraser, Paul E. St George-Hyslop, Peter H. Gandy, Sam Hof, Patrick R. Dickstein, Dara L. TI The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease SO MOLECULAR NEURODEGENERATION LA English DT Article DE Alzheimer's disease; Mouse models; Amyloid beta (A beta); Isotropic fractionator; Neuronal loss ID AMYLOID-BETA OLIGOMERS; TRANSGENIC MICE; ACCUMULATION; BRAIN; TAU AB Background: The accumulation of amyloid beta (A beta) oligomers or fibrils is thought to be one of the main causes of synaptic and neuron loss, believed to underlie cognitive dysfunction in Alzheimer's disease (AD). Neuron loss has rarely been documented in amyloid precursor protein (APP) transgenic mouse models. We investigated whether two APP mouse models characterized by different folding states of amyloid showed different neuronal densities using an accurate method of cell counting. Findings: We examined total cell and neuronal populations in Swedish/Indiana APP mutant mice (TgCRND8) with severe A beta pathology that includes fibrils, plaques, and oligomers, and Dutch APP mutant mice with only A beta oligomer pathology. Using the isotropic fractionator, we found no differences from control mice in regional total cell populations in either TgCRND8 or Dutch mice. However, there were 31.8% fewer hippocampal neurons in TgCRND8 compared to controls, while no such changes were observed in Dutch mice. Conclusions: We show that the isotropic fractionator is a convenient method for estimating neuronal content in milligram quantities of brain tissue and represents a useful tool to assess cell loss efficiently in transgenic models with different types of neuropathology. Our data support the hypothesis that TgCRND8 mice with a spectrum of A beta plaque, fibril, and oligomer pathology exhibit neuronal loss whereas Dutch mice with only oligomers, showed no evidence for neuronal loss. This suggests that the combination of plaques, fibrils, and oligomers causes more damage to mouse hippocampal neurons than A beta oligomers alone. C1 [Brautigam, Hannah; Hof, Patrick R.; Dickstein, Dara L.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Brautigam, Hannah; Steele, John W.; Gandy, Sam; Hof, Patrick R.; Dickstein, Dara L.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Brautigam, Hannah; Gandy, Sam; Hof, Patrick R.; Dickstein, Dara L.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Steele, John W.; Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Steele, John W.] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10065 USA. [Westaway, David] Univ Alberta, Ctr Prions & Prot Folding Dis, Edmonton, AB T6G 2M8, Canada. [Fraser, Paul E.; St George-Hyslop, Peter H.] Univ Toronto, Dept Med Biophys, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada. [Fraser, Paul E.; St George-Hyslop, Peter H.] Univ Toronto, Dept Med Neurol, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada. [St George-Hyslop, Peter H.] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England. [Dickstein, Dara L.] Leon & Norma Hess Ctr Sci & Med, Dept Neurosci, New York, NY 10029 USA. RP Dickstein, DL (reprint author), Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. EM dara.dickstein@mssm.edu RI Dickstein, Dara/F-3036-2013 FU NIH [P50 AG05138, P01 AG10491, F31 AG039890]; Canadian Institutes of Health Research [MOP-115056]; Alberta Heritage Foundation for Medical Research; Wellcome Trust; Medical Research Council; Howard Hughes Medical Institute; Alzheimer Society of Ontario FX This work was supported by NIH grants P50 AG05138 (DLD, SG, PRH), P01 AG10491 (SG), and F31 AG039890 (HB). Support was also provided by the Canadian Institutes of Health Research (MOP-115056, PEF and PHH), Alberta Heritage Foundation for Medical Research (DW), and the Wellcome Trust, Medical Research Council, Howard Hughes Medical Institute, and Alzheimer Society of Ontario (PHH). We would like to thank the members of the Ehrlich, Gandy, and Hof laboratories for help and discussion, and Dr Suzana Herculano-Houzel (Federal University of Rio de Janeiro) for introducing us to the isotropic fractionator. We would like to acknowledge Dr Camilla Butti (Icahn School of Medicine at Mount Sinai) for her help with optimizing the isotropic fractionator protocol. NR 17 TC 8 Z9 8 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD NOV 22 PY 2012 VL 7 AR 58 DI 10.1186/1750-1326-7-58 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 075LT UT WOS:000313888500001 PM 23173713 ER PT J AU Qaseem, A Fihn, SD Williams, S Dallas, P Owens, DK Shekelle, P AF Qaseem, Amir Fihn, Stephan D. Williams, Sankey Dallas, Paul Owens, Douglas K. Shekelle, Paul CA Amer Coll Phys TI Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CORONARY-ARTERY-DISEASE; BUNDLE-BRANCH-BLOCK; EMISSION COMPUTED-TOMOGRAPHY; INCREMENTAL PROGNOSTIC VALUE; HOSPITAL CARDIAC-ARREST; LEFT-VENTRICULAR MASS; SUPINE EXERCISE ELECTROCARDIOGRAPHY; MYOCARDIAL-PERFUSION SCINTIGRAPHY; ADENOSINE STRESS PERFUSION; MEDICALLY TREATED PATIENTS AB Description: The American College of Physicians (ACP) developed this guideline in collaboration with the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, and Society of Thoracic Surgeons to help clinicians diagnose known or suspected stable ischemic heart disease. Methods: Literature on this topic published before November 2011 was identified by using MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS. Searches were limited to human studies published in English. This guideline grades the evidence and recommendations according to a translation of the ACCF/AHA grading system into ACP's clinical practice guidelines grading system. Recommendations: This guideline includes 28 recommendations that address the following issues: the initial diagnosis of the patient who might have stable ischemic heart disease, cardiac stress testing to assess the risk for death or myocardial infarction in patients diagnosed with stable ischemic heart disease, and coronary angiography for risk assessment. Ann Intern Med. 2012; 157: 729-734. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs, Seattle, WA USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. Stanford Univ, Stanford, CA 94305 USA. Virginia Tech, Caril Sch Med, Roanoke, VA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP operating budget FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 127 TC 16 Z9 24 U1 0 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2012 VL 157 IS 10 BP 729 EP + DI 10.7326/0003-4819-157-10-201211200-00010 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 043VZ UT WOS:000311580000018 PM 23165664 ER PT J AU Qaseem, A Fihn, SD Dallas, P Williams, S Owens, DK Shekelle, P AF Qaseem, Amir Fihn, Stephan D. Dallas, Paul Williams, Sankey Owens, Douglas K. Shekelle, Paul CA Amer Coll Phys TI Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; LEFT-VENTRICULAR DYSFUNCTION; LONG-TERM SURVIVAL; CONVERTING-ENZYME-INHIBITOR; PLACEBO-CONTROLLED TRIAL; VIRUS-INFECTED PATIENTS; OPTIMAL MEDICAL THERAPY; IN-HOSPITAL MORTALITY AB Description: The American College of Physicians (ACP) developed this guideline with the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, and Society of Thoracic Surgeons to present the available evidence on the management of stable known or suspected ischemic heart disease. Methods: Literature on this topic published before November 2011 was identified by using MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS. Searches were limited to human studies published in English. This guideline grades the evidence and recommendations according to a translation of the ACCF/AHA grading system into ACP's clinical practice guidelines grading system. Recommendations: The guideline includes 48 specific recommendations that address the following issues: patient education, management of proven risk factors (dyslipidemia, hypertension, diabetes, physical activity body weight, and smoking), risk factor reduction strategies of unproven benefit, medical therapy to prevent myocardial infarction and death and to relieve symptoms, alternative therapy, revascularization to improve survival and symptoms, and patient follow-up. Ann Intern Med. 2012;157:735-743. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs, Seattle, WA USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. Stanford Univ, Stanford, CA 94305 USA. Virginia Tech Caril Sch Med, Roanoke, VA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP operating budget FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 318 TC 32 Z9 34 U1 0 U2 10 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2012 VL 157 IS 10 BP 735 EP + DI 10.7326/0003-4819-157-10-201211200-00011 PG 31 WC Medicine, General & Internal SC General & Internal Medicine GA 043VZ UT WOS:000311580000019 PM 23165665 ER PT J AU Chirinos, JA Kips, JG Jacobs, DR Brumback, L Duprez, DA Kronmal, R Bluemke, DA Townsend, RR Vermeersch, S Segers, P AF Chirinos, Julio A. Kips, Jan G. Jacobs, David R., Jr. Brumback, Lyndia Duprez, Daniel A. Kronmal, Richard Bluemke, David A. Townsend, Raymond R. Vermeersch, Sebastian Segers, Patrick TI Arterial Wave Reflections and Incident Cardiovascular Events and Heart Failure: MESA (Multiethnic Study of Atherosclerosis) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE arterial hemodynamics; cardiovascular risk; heart failure; left ventricular afterload; wave reflections ID LEFT-VENTRICULAR MASS; INPUT IMPEDANCE; ALL-CAUSE; PRESSURE; RECLASSIFICATION; PREDICTION; STIFFNESS; VELOCITY; DISEASE; FORMS AB Objectives This study sought to assess the relationship between central pressure profiles and cardiovascular events (CVEs) in a large community-based sample. Background Experimental and physiologic data mechanistically implicate wave reflections in the pathogenesis of left ventricular failure and cardiovascular disease, but their association with these outcomes in the general population is unclear. Methods Aortic pressure waveforms were derived from a generalized transfer function applied to the radial pressure waveform recorded noninvasively from 5,960 participants in the Multiethnic Study of Atherosclerosis. The central pressure waveform was separated into forward and reflected waves using a physiologic flow waveform. Reflection magnitude (RM = [Reflected/Forward wave amplitude] x 100), augmentation index ([Second/First systolic peak] x 100) and pulse pressure amplification ([Radial/aortic pulse pressure] x 100) were assessed as predictors of CVEs and congestive heart failure (CHF) during a median follow-up of 7.61 years. Results After adjustment for established risk factors, aortic AIx independently predicted hard CVEs (hazard ratio [HR] per 10% increase: 1.08; 95% confidence interval [CI]: 1.01 to 1.14; p = 0.016), whereas PPA independently predicted all CVEs (HR per 10% increase: 0.82; 95% CI: 0.70 to 0.96; p = 0.012). RM was independently predictive of all CVEs (HR per 10% increase: 1.34; 95% CI: 1.08 to 1.67; p = 0.009) and hard CVEs (HR per 10% increase: 1.46; 95% CI: 1.12 to 1.90; p = 0.006) and was strongly predictive of new-onset CHF (HR per 10% increase: 2.69; 95% CI: 1.79 to 4.04; p < 0.0001), comparing favorably to other risk factors for CHF as per various measures of model performance, reclassification, and discrimination. In a fully adjusted model, compared to nonhypertensive subjects with low RM, the HRs (95% CI) for hypertensive subjects with low RM, nonhypertensive subjects with high RM, and hypertensive subjects with high RM were 1.81 (0.85 to 3.86), 2.16 (1.07 to 5.01), and 3.98 (1.96 to 8.05), respectively. Conclusions Arterial wave reflections represent a novel strong risk factor for CHF in the general population. (J Am Coll Cardiol 2012;60:2170-7) (C) 2012 by the American College of Cardiology Foundation C1 [Chirinos, Julio A.] Univ Penn, Sch Med, Dept Cardiol, Philadelphia, PA 19104 USA. [Chirinos, Julio A.; Townsend, Raymond R.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kips, Jan G.; Vermeersch, Sebastian; Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway. [Brumback, Lyndia; Kronmal, Richard] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Duprez, Daniel A.] Univ Minnesota, Sch Med, Div Cardiol, Minneapolis, MN 55455 USA. [Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA. RP Chirinos, JA (reprint author), Univ Penn, Sch Med, Dept Cardiol, Rm 8B111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu OI Bluemke, David/0000-0002-8323-8086 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169]; American Heart Association grants [0885031N, R01-HL-098382]; Atcor Medical; Cardiodynamics; APC cardiovascular; Novartis; Genentech; Amarin; Merck; Pfizer; Boehringer Ingelheim; [RR-024156] FX This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute and RR-024156 as well as American Heart Association grants 0885031N and R01-HL-098382. Dr. Chirinos has received minor support (equipment loans) from Atcor Medical, Cardiodynamics, and APC cardiovascular. Dr. Duprez has received research grants from Novartis, Genentech, and Amarin; and speakers' fees from Merck, Pfizer, Novartis, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 34 TC 138 Z9 138 U1 4 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 20 PY 2012 VL 60 IS 21 BP 2170 EP 2177 DI 10.1016/j.jacc.2012.07.054 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 037CC UT WOS:000311077600007 PM 23103044 ER PT J AU Choucair, WK Lip, GY Waldo, AL Bersohn, MM Martin, DT Akar, JG Wathen, M Neve, N Halperin, JL Ip, J AF Choucair, Wassim K. Lip, Gregory Y. Waldo, Albert L. Bersohn, Malcolm M. Martin, David T. Akar, Joseph G. Wathen, Mark Neve, Nathalie Halperin, Jonathan L. Ip, John TI Atrial Arrhythmias in ICD Versus CRT-D Subjects SO CIRCULATION LA English DT Meeting Abstract DE Atial arrhythmias; Device; CRT C1 [Choucair, Wassim K.] Cardiol Associates Corpus Christi, Corpus Christi, TX USA. [Lip, Gregory Y.] Univ Birmingham, Cntr Cardiovasc Sci, Birmingham, W Midlands, England. [Waldo, Albert L.] Harrington McLaughlin Heart & Vasc Inst Univ Hosp, Div Cardiovasc Med, Cleveland, OH USA. [Bersohn, Malcolm M.] UCLA Cardiol 111E, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Los Angeles, CA USA. [Martin, David T.] Lahey Clin Med Ctr, Dept Cardiovasc Med, Burlington, MA 01803 USA. [Akar, Joseph G.] Yale Univ, Sch Med, Div Cardiol, New Haven, CT USA. [Wathen, Mark] Tennessee Heart PLLC, Heart & Vasc Cntr, Cookeville, TN USA. [Neve, Nathalie] BIOTRONIK, Clin Studies, Lake Oswego, OR USA. [Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA. [Ip, John] Thorac & Cardiovasc Healthcare Fdn, Lansing, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17907 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007332 ER PT J AU Fletcher, RD Amdur, R Papademetriou, V Kheirbek, R Jones, RE AF Fletcher, Ross D. Amdur, Richard Papademetriou, Vasilios Kheirbek, Raya Jones, Ronald E. TI Controlling Hypertension in Blacks - A AVA 10 Year Multicenter Analysis SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Blood pressure C1 [Fletcher, Ross D.; Amdur, Richard; Papademetriou, Vasilios; Kheirbek, Raya; Jones, Ronald E.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14756 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004346 ER PT J AU Cassaday, RD Guthrie, KA Budde, LE Thompson, L Till, BG Press, OW Chauncey, T Pagel, JM Petersdorf, SH Bensinger, WI Holmberg, L Shustov, AR Green, DJ Libby, EN Maloney, DG Gopal, AK AF Cassaday, Ryan D. Guthrie, Katherine A. Budde, Lihua E. Thompson, Leslie Till, Brian G. Press, Oliver W. Chauncey, Thomas Pagel, John M. Petersdorf, Stephen H. Bensinger, William I. Holmberg, Leona Shustov, Andrei R. Green, Damian J. Libby, Edward N., III Maloney, David G. Gopal, Ajay K. TI Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cassaday, Ryan D.; Budde, Lihua E.; Thompson, Leslie; Till, Brian G.; Press, Oliver W.; Pagel, John M.; Petersdorf, Stephen H.; Bensinger, William I.; Holmberg, Leona; Shustov, Andrei R.; Green, Damian J.; Libby, Edward N., III; Maloney, David G.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3082 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601181 ER PT J AU Costa, LJ Lill, M Yeh, RF Stuart, RK Lim, S Waller, EK Shore, TB Craig, M Freytes, CO Shea, TC Rodriguez, TE Flinn, IW Comeau, T Pulsipher, MA Bence-Bruckler, I Laneuville, P Bierman, P Chen, AI Yu, LH Patil, S Sun, YP Armstrong, E Smith, A Elekes, A Kato, K Vaughan, W AF Costa, Luciano J. Lill, Michael Yeh, Rosa F. Stuart, Robert K. Lim, Stephen Waller, Edmund K. Shore, Tsiporah B. Craig, Michael Freytes, Cesar O. Shea, Thomas C. Rodriguez, Tulio E. Flinn, Ian W. Comeau, Terrance Pulsipher, Michael A. Bence-Bruckler, Isabelle Laneuville, Pierre Bierman, Philip Chen, Andy I. Yu, Louie H. Patil, Shiva Sun, Yiping Armstrong, Elizabeth Smith, Angela Elekes, Agnes Kato, Kazunobu Vaughan, William TI Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Costa, Luciano J.; Stuart, Robert K.] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. [Lill, Michael; Lim, Stephen] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Yeh, Rosa F.; Yu, Louie H.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98104 USA. [Waller, Edmund K.] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA. [Shore, Tsiporah B.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Craig, Michael] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Shea, Thomas C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Rodriguez, Tulio E.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Comeau, Terrance] New Brunswick Stem Cell Transplant Program, St John, NB, Canada. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Bence-Bruckler, Isabelle] Univ Ottawa, Ottawa, ON, Canada. [Laneuville, Pierre] McGill Univ, Ctr Hlth, Div Haematol, Montreal, PQ, Canada. [Bierman, Philip] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA. [Chen, Andy I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Patil, Shiva; Sun, Yiping; Armstrong, Elizabeth; Smith, Angela; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. [Vaughan, William] Univ Alabaman Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 813 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838901051 ER PT J AU Dao, KHT Rotelli, MD Yates, JE Brown, B Rantala, J Rathbun, K Tyner, JW Druker, BJ Bagby, GC AF Dao, Kim-Hien T. Rotelli, Michael D. Yates, Jane E. Brown, Brieanna Rantala, Juha Rathbun, Keaney Tyner, Jeffrey W. Druker, Brian J. Bagby, Grover C., Jr. TI Regulation of FANCL by Glycogen Synthase Kinase-3beta Links the Fanconi anemia pathway to Self Renewal and Survival Signals SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Yates, Jane E.; Rathbun, Keaney] NW VA Canc Res Ctr, Portland, OR USA. [Rantala, Juha] Oregon Hlth & Sci Univ, Dept Biomed, Portland, OR 97201 USA. [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell & Dev Biol, Portland, OR 97201 USA. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1263 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902303 ER PT J AU Ettinger, RA Epstein, MS Puranik, K Hughes, RJ Liberman, JA James, E Howard, TE Cole, SS Matthews, DC Pratt, KP AF Ettinger, Ruth A. Epstein, Melinda S. Puranik, Komal Hughes, Richard J. Liberman, Joseph A. James, Eddie Howard, Tom E. Cole, Shelley S. Matthews, Dana C. Pratt, Kathleen P. TI Sequence-Modified Factor VIII Variants Having Reduced Immunogenicity SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Ettinger, Ruth A.; Puranik, Komal; Liberman, Joseph A.; Pratt, Kathleen P.] Puget Sound Blood Ctr Res Inst, Seattle, WA USA. [Epstein, Melinda S.; Hughes, Richard J.] Greater Los Angeles Vet Adm, Los Angeles, CA USA. [James, Eddie] Benaroya Res Inst, Seattle, WA USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Pathol & Lab Med, Los Angeles, CA USA. [Cole, Shelley S.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Matthews, Dana C.] Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 39 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900125 ER PT J AU Frost, P Gera, J Lichtenstein, AK AF Frost, Patrick Gera, Joseph Lichtenstein, Alan K. TI The Internal Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced Apoptosis in Vivo SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Frost, Patrick] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Gera, Joseph] UCLA W LA VA Med Ctr, Los Angeles, CA USA. [Lichtenstein, Alan K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1659 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049600379 ER PT J AU Howard, TE Drigalenko, E Johnson, MP Cole, SS Kim, B Viel, KR Sauna, ZE Curran, JE Blangero, J Almasy, LA Goring, HH AF Howard, Tom E. Drigalenko, Eugene Johnson, Matthew P. Cole, Shelley S. Kim, Benjamin Viel, Kevin R. Sauna, Zuben E. Curran, Joanne E. Blangero, John Almasy, Laura A. Goering, Harald H. TI Common SNPs within or near Three Immune Response Genes Implicated in the Risk of FVIII Immunogenicity in Hemophilia A Do Not Influence Steady-State Levels of Their Encoded mRNAs SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Drigalenko, Eugene; Johnson, Matthew P.; Cole, Shelley S.; Curran, Joanne E.; Blangero, John; Almasy, Laura A.; Goering, Harald H.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Kim, Benjamin] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA. [Viel, Kevin R.] Histonis Inc, Atlanta, GA USA. [Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3366 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602318 ER PT J AU Liao, W Jordaan, G Sharma, S AF Liao, Wei Jordaan, Gwen Sharma, Sanjai TI Rasgrf1 Overexpression Amplifies B Cell Receptor Signaling in Chronic Lymphocytic Leukemia Specimens SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Liao, Wei; Jordaan, Gwen] UCLA W Los Angeles VA, Hematol Oncol, Northridge, CA USA. [Sharma, Sanjai] Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 926 PG 1 WC Hematology SC Hematology GA 074UG UT WOS:000313838902035 ER PT J AU Locke, FL Pidala, J Storer, B Martin, PJ Pulsipher, MA Chauncey, T Jacobsen, N Kroeger, N Walker, I Territo, MC Light, S Laport, GG Nademanee, A Powles, R Keating, A Socie, G Anasetti, C AF Locke, Frederick L. Pidala, Joseph Storer, Barry Martin, Paul J. Pulsipher, Michael A. Chauncey, Thomas Jacobsen, Niels Kroeger, Nikolaus Walker, Irwin Territo, Mary C. Light, Susan Laport, Ginna G. Nademanee, Auayporn Powles, Raymond Keating, Armand Socie, Gerard Anasetti, Claudio TI The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Locke, Frederick L.; Pidala, Joseph] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Storer, Barry; Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Martin, Paul J.] Univ Washington, Seattle, WA 98195 USA. [Pulsipher, Michael A.] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Jacobsen, Niels] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark. [Kroeger, Nikolaus] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Bone Marrow Transplantat Unit, Hamburg, Germany. [Walker, Irwin] McMaster Univ, Hamilton, ON, Canada. [Territo, Mary C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Light, Susan] Bristol Myers Squibb Co, New York, NY 10154 USA. [Laport, Ginna G.] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Nademanee, Auayporn] City Hope Natl Med Ctr, Hematol & Stem Cell Transplantat, Duarte, CA USA. [Powles, Raymond] Parkside Oncol Clin, Wimbledon, England. [Keating, Armand] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Socie, Gerard] Hosp St Louis, Paris, France. [Anasetti, Claudio] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA. [Anasetti, Claudio] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4195 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049604134 ER PT J AU Stadtmauer, EA Ratanatharathorn, V Yeh, RF Freytes, CO Toro, JJ Akpek, G Sahovic, EA Tricot, GJ Shaughnessy, PJ White, DJ Rodriguez, TE Solomon, SR Yu, LH Patil, S Sun, YP Armstrong, E Smith, A Elekes, A Kato, K Reece, D AF Stadtmauer, Edward A. Ratanatharathorn, Voravit Yeh, Rosa F. Freytes, Cesar O. Toro, Juan J. Akpek, Gorgun Sahovic, Entezam A. Tricot, Guido J. Shaughnessy, Paul J. White, Darrell J. Rodriguez, Tulio E. Solomon, Scott R. Yu, Louie H. Patil, Shiva Sun, Yiping Armstrong, Elizabeth Smith, Angela Elekes, Agnes Kato, Kazunobu Reece, Donna TI Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Stadtmauer, Edward A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Ratanatharathorn, Voravit] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. [Yeh, Rosa F.; Yu, Louie H.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98104 USA. [Freytes, Cesar O.] S Vet Hlth Care Syst, BMT, San Antonio, TX USA. [Toro, Juan J.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Akpek, Gorgun] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Sahovic, Entezam A.] Western Penn Canc Inst, Cell Transplantat Program, Pittsburgh, PA USA. [Tricot, Guido J.] Univ Utah, Sch Med, Div Hematol, BMT & Myeloma Program, Salt Lake City, UT USA. [Shaughnessy, Paul J.] Texas Transplant Inst, San Antonio, TX USA. [White, Darrell J.] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada. [Rodriguez, Tulio E.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA. [Solomon, Scott R.] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. [Patil, Shiva; Sun, Yiping; Armstrong, Elizabeth; Smith, Angela; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. [Reece, Donna] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3080 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601183 ER PT J AU Yoo, E Vasuthasawat, A Tran, D Lichtenstein, A Morrison, S AF Yoo, Esther Vasuthasawat, Alex Danh Tran Lichtenstein, Alan Morrison, Sherie TI Anti-CD138-IFN alpha Fusion Proteins Are Effective in Treating Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Lichtenstein, Alan] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Morrison, Sherie] Univ Calif Los Angeles, MIMG, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 939 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902022 ER PT J AU Yoo, E Vasuthasawat, A Tran, D Lichtenstein, A Morrison, S AF Yoo, Esther Vasuthasawat, Alex Danh Tran Lichtenstein, Alan Morrison, Sherie TI Anti-CD138-IFN alpha Fusion Proteins Are Effective in Treating Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Lichtenstein, Alan] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Morrison, Sherie] Univ Calif Los Angeles, MIMG, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 939 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901198 ER PT J AU Pham, MHT Bonello, GB Castiblanco, J Le, T Sigala, J He, WJ Mummidi, S AF Pham, Minh-Hieu T. Bonello, Gregory B. Castiblanco, John Le, Tuan Sigala, Jose He, Weijing Mummidi, Srinivas TI The rs1024611 Regulatory Region Polymorphism Is Associated with CCL2 Allelic Expression Imbalance SO PLOS ONE LA English DT Article ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTIMA-MEDIA THICKNESS; SINGLE-NUCLEOTIDE POLYMORPHISMS; MCP-1 GENE POLYMORPHISM; FUNCTIONAL PROMOTER POLYMORPHISM; TYPE-2 DIABETES-MELLITUS; CORONARY-ARTERY-DISEASE; PULMONARY TUBERCULOSIS; CAROTID ATHEROSCLEROSIS AB CC chemokine ligand 2 (CCL2) is the most potent monocyte chemoattractant and inter-individual differences in its expression level have been associated with genetic variants mapping to the cis-regulatory regions of the gene. An A to G polymorphism in the CCL2 enhancer region at position -2578 (rs1024611; A>G), was found in most studies to be associated with higher serum CCL2 levels and increased susceptibility to a variety of diseases such as HIV-1 associated neurological disorders, tuberculosis, and atherosclerosis. However, the precise mechanism by which rs1024611influences CCL2 expression is not known. To address this knowledge gap, we tested the hypothesis that rs1024611G polymorphism is associated with allelic expression imbalance (AEI) of CCL2. We used haplotype analysis and identified a transcribed SNP in the 3'UTR (rs13900; C>T) can serve as a proxy for the rs1024611 and demonstrated that the rs1024611G allele displayed a perfect linkage disequilibrium with rs13900T allele. Allele-specific transcript quantification in lipopolysaccharide treated PBMCs obtained from heterozygous donors showed that rs13900T allele were expressed at higher levels when compared to rs13900C allele in all the donors examined suggesting that CCL2 is subjected to AEI and that that the allele containing rs1024611G is preferentially transcribed. We also found that AEI of CCL2 is a stable trait and could be detected in newly synthesized RNA. In contrast to these in vivo findings, in vitro assays with haplotype-specific reporter constructs indicated that the haplotype bearing rs1024611G had a lower or similar transcriptional activity when compared to the haplotype containing rs1024611A. This discordance between the in vivo and in vitro expression studies suggests that the CCL2 regulatory region polymorphisms may be functioning in a complex and context-dependent manner. In summary, our studies provide strong functional evidence and a rational explanation for the phenotypic effects of the CCL2 rs1024611G allele. C1 [Pham, Minh-Hieu T.; Bonello, Gregory B.; Castiblanco, John; Le, Tuan; Sigala, Jose; He, Weijing; Mummidi, Srinivas] S Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX 78229 USA. [Pham, Minh-Hieu T.; Bonello, Gregory B.; Castiblanco, John; Le, Tuan; Sigala, Jose; He, Weijing; Mummidi, Srinivas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Mummidi, S (reprint author), S Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX 78229 USA. EM mummidi@uthscsa.edu RI CASTIBLANCO, JOHN/B-6599-2009; Mummidi, Srinivas/C-1004-2008 OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Mummidi, Srinivas/0000-0002-4068-6380; CASTIBLANCO, JOHN/0000-0003-2556-3697 FU Veterans Affairs Office of Research and Development-Biomedical Laboratory Research and Development Service Award [I01BX000975]; Department of Veterans Affairs Career Development Award-2 [1IK2BX001276-01A1]; National Institutes of Health (NIMH and NINDS) FX This work is supported by the Veterans Affairs Office of Research and Development-Biomedical Laboratory Research and Development Service Award (I01BX000975) to SM. TL is supported by a Department of Veterans Affairs Career Development Award-2 (1IK2BX001276-01A1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The brain samples for examining the CCL2 AEI were obtained from National Neurological AIDS bank (5U01MH083500, NS38841), The Manhattan HIV Brain Bank (U01MH083501, R24MH59724), and the Texas Repository for AIDS Neuropathogenesis Research (U01MH083507, R24 NS 38841) that are part of the National NeuroAIDS Tissue Consortium that is funded by the National Institutes of Health (NIMH and NINDS). NR 96 TC 9 Z9 9 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 16 PY 2012 VL 7 IS 11 AR e49498 DI 10.1371/journal.pone.0049498 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048BN UT WOS:000311885300048 PM 23166687 ER PT J AU Sharma, S Dubinett, S Salgia, R AF Sharma, Sherven Dubinett, Steven Salgia, Ravi TI CD14(+)S100A9(+) Myeloid-derived Suppressor Cells Portend Decreased Survival in Patients with Advanced Lung Cancer SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material C1 [Sharma, Sherven; Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Los Angeles, CA 90095 USA. [Sharma, Sherven; Dubinett, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA. [Sharma, Sherven; Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Salgia, Ravi] Univ Chicago, Dept Med, Chicago, IL 60637 USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Los Angeles, CA 90095 USA. FU NCATS NIH HHS [UL1 TR000124] NR 5 TC 2 Z9 3 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 15 PY 2012 VL 186 IS 10 BP 940 EP 941 DI 10.1164/rccm.201209-1597ED PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 046LI UT WOS:000311766100005 PM 23155211 ER PT J AU Woodard, LE Li, XH Malani, N Kaja, A Hice, RH Atkinson, PW Bushman, FD Craig, NL Wilson, MH AF Woodard, Lauren E. Li, Xianghong Malani, Nirav Kaja, Aparna Hice, Robert H. Atkinson, Peter W. Bushman, Frederic D. Craig, Nancy L. Wilson, Matthew H. TI Comparative Analysis of the Recently Discovered hAT Transposon TcBuster in Human Cells SO PLOS ONE LA English DT Article ID INTEGRATION SITE SELECTION; CANCER GENE DISCOVERY; SLEEPING-BEAUTY; IN-VIVO; ELEMENT; GENOME; DNA; MUTAGENESIS; DROSOPHILA; THERAPY AB Background: Transposons are useful tools for creating transgenic organisms, insertional mutagenesis, and genome engineering. TcBuster, a novel hAT-family transposon system derived from the red flour beetle Tribolium castaneum, was shown to be highly active in previous studies in insect embryoes. Methodology/Principal Findings: We tested TcBuster for its activity in human embryonic kidney 293 (HEK-293) cells. Excision footprints obtained from HEK-293 cells contained small insertions and deletions consistent with a hAT-type repair mechanism of hairpin formation and non-homologous end-joining. Genome-wide analysis of 23,417 piggyBac, 30,303 Sleeping Beauty, and 27,985 TcBuster integrations in HEK-293 cells revealed a uniquely different integration pattern when compared to other transposon systems with regards to genomic elements. TcBuster experimental conditions were optimized to assay TcBuster activity in HEK-293 cells by colony assay selection for a neomycin-containing transposon. Increasing transposon plasmid increased the number of colonies, whereas gene transfer activity dependent on codon-optimized transposase plasmid peaked at 100 ng with decreased colonies at the highest doses of transposase DNA. Expression of the related human proteins Buster1, Buster3, and SCAND3 in HEK-293 cells did not result in genomic integration of the TcBuster transposon. TcBuster, Tol2, and piggyBac were compared directly at different ratios of transposon to transposase and found to be approximately comparable while having their own ratio preferences. Conclusions/Significance: TcBuster was found to be highly active in mammalian HEK-293 cells and represents a promising tool for mammalian genome engineering. C1 [Woodard, Lauren E.; Kaja, Aparna; Wilson, Matthew H.] Baylor Coll Med, Dept Med, Div Nephrol, Houston, TX 77030 USA. [Hice, Robert H.; Atkinson, Peter W.] Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA. [Hice, Robert H.; Atkinson, Peter W.] Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA. [Li, Xianghong; Craig, Nancy L.] Johns Hopkins Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD USA. [Malani, Nirav; Bushman, Frederic D.] Univ Penn, Dept Microbiol, Perlman Sch Med, Philadelphia, PA 19104 USA. [Wilson, Matthew H.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. RP Wilson, MH (reprint author), Baylor Coll Med, Dept Med, Div Nephrol, Houston, TX 77030 USA. EM mhwilson@bcm.edu RI Wilson, Matthew/K-3193-2013 OI Bushman, Frederic/0000-0003-4740-4056 FU Department of Veteran's Affairs; National Institutes of Health [AI45741, GM76425, AI52845, 5T32DK062706, R01 DK093660] FX This work was supported by a grant from the Department of Veteran's Affairs [MHW] and by grants from the National Institutes of Health [AI45741 to PWA and NLC, GM76425 to NLC, AI52845 to FDB, and 5T32DK062706 to LEW]. NLC is an Investigator of the Howard Hughes Medical Institute. This work was supported in part by National Institutes of Health R01 DK093660 to MHW and the generous support of Dr. and Mrs. Harold M. Selzman. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 13 Z9 14 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 15 PY 2012 VL 7 IS 11 AR e42666 DI 10.1371/journal.pone.0042666 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 039UP UT WOS:000311272300001 PM 23166581 ER PT J AU McEllistrem, MC Nahm, MH AF McEllistrem, M. Catherine Nahm, Moon H. TI Novel Pneumococcal Serotypes 6C and 6D: Anomaly or Harbinger SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID STREPTOCOCCUS-PNEUMONIAE SEROTYPE; CONJUGATE VACCINE; UNITED-STATES; NASOPHARYNGEAL CARRIAGE; INVASIVE DISEASE; SEROLOGICAL CHARACTERIZATION; MOLECULAR EPIDEMIOLOGY; QUELLUNG REACTION; SOUTH-KOREA; 1ST REPORT AB Clinical use of the 7-valent pneumococcal protein conjugate (PCV7) vaccine, which includes serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, dramatically reduced invasive pneumococcal disease (IPD); however, the effectiveness was diminished due to serotype shift. Although shift due to known serotypes was anticipated, shift by misidentified serotypes was unexpected. We describe the experience with newly recognized serotypes 6C and 6D, which were mistyped as serotypes 6A and 6B, respectively. Although serotype 6D caused only occasional infections, IPD due to serotype 6C disease expanded in the PCV7 era. Subsequent studies showed that PCV7 provided cross-protection against serotype 6A but not serotype 6C. The 13-valent pneumococcal protein conjugate (PCV13) vaccine, which includes PCV7 serotypes plus serotypes 1, 3, 5, 6A, 7F, 19A, may provide protection against IPD due to serotypes 6C and 6D. Regardless, this narrative illustrates the potential impact of unrecognized serotypes on the efficacy of a serotype-specific vaccine. C1 [McEllistrem, M. Catherine] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Nahm, Moon H.] Univ Alabama Birmingham, Birmingham, AL USA. RP McEllistrem, MC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,MS 130-U, Pittsburgh, PA 15240 USA. EM mary.mcellistrem@va.gov OI Nahm, Moon/0000-0002-6922-1042 FU NIH [AI-31473] FX This work was supported by an NIH grant AI-31473. NR 60 TC 14 Z9 14 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1379 EP 1386 DI 10.1093/cid/cis691 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600020 PM 22903767 ER PT J AU Darouiche, RO Hull, RA AF Darouiche, Rabih O. Hull, Richard A. TI Bacterial Interference for Prevention of Urinary Tract Infection SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ESCHERICHIA-COLI 83972; LACTOBACILLUS VAGINAL SUPPOSITORIES; ASYMPTOMATIC BACTERIURIA; MICROBIAL COMMUNITIES; CATHETER ADHERENCE; PILOT TRIAL; PROBIOTICS; COLONIZATION; FIMBRIAE; BLADDER C1 [Darouiche, Rabih O.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Darouiche, Rabih O.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Darouiche, Rabih O.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [Darouiche, Rabih O.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Hull, Richard A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, 1333 Moursund Ave,Ste A221, Houston, TX 77030 USA. EM rdarouiche@aol.com FU ConjuGon FX Both authors are associated with Baylor College of Medicine, which has received grants from ConjuGon. R. O. D. is associated with the Multidisciplinary Alliance Against Device-Related Infections, which has also received grants from ConjuGon. NR 45 TC 16 Z9 16 U1 2 U2 25 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1400 EP 1407 DI 10.1093/cid/cis639 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600024 PM 22828592 ER PT J AU Tomasiewicz, HC Jacobs, MM Wilkinson, MB Wilson, SP Nestler, EJ Hurd, YL AF Tomasiewicz, Hilarie C. Jacobs, Michelle M. Wilkinson, Matthew B. Wilson, Steven P. Nestler, Eric J. Hurd, Yasmin L. TI Proenkephalin Mediates the Enduring Effects of Adolescent Cannabis Exposure Associated with Adult Opiate Vulnerability SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Drug addiction; epigenetics; marijuana; nucleus accumbens; rat; striatopallidal ID HISTONE LYSINE METHYLATION; COCAINE-INDUCED PLASTICITY; CHROMATIN REGULATION; MAMMALIAN CHROMATIN; NUCLEUS-ACCUMBENS; X-CHROMOSOME; DRUG; HETEROCHROMATIN; TRANSCRIPTION; LOCALIZATION AB Background: Marijuana use by teenagers often predates the use of harder drugs, but the neurobiological underpinnings of such vulnerability are unknown. Animal studies suggest enhanced heroin self-administration (SA) and dysregulation of the endogenous opioid system in the nucleus accumbens shell (NAcsh) of adults following adolescent Delta(9)-tetrahydrocannabinol (THC) exposure. However, a causal link between proenkephalin (Penk) expression and vulnerability to heroin has yet to be established. Methods: To investigate the functional significance of NAcsh Penk tone, selective viral-mediated knockdown and overexpression of Penk was performed, followed by analysis of subsequent heroin SA behavior. To determine whether adolescent THC exposure was associated with chromatin alteration, we analyzed levels of histone H3 methylation in the NAcsh via chromatin immunoprecipitation at five sites flanking the Penk gene transcription start site. Results: Here we show that regulation of the Penk opioid neuropeptide gene in NAcsh directly regulates heroin SA behavior. Selective viral-mediated knockdown of Penk in striatopallidal neurons attenuates heroin SA in adolescent THC-exposed rats, whereas Penk overexpression potentiates heroin SA in THC-naive rats. Furthermore, we report that adolescent THC exposure mediates Penk upregulation through reduction of histone H3 lysine 9 (H3K9) methylation in the NAcsh, thereby disrupting the normal developmental pattern of H3K9 methylation. Conclusions: These data establish a direct association between THC-induced NAcsh Penk upregulation and heroin SA and indicate that epigenetic dysregulation of Penk underlies the long-term effects of THC. C1 [Tomasiewicz, Hilarie C.; Jacobs, Michelle M.; Nestler, Eric J.; Hurd, Yasmin L.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Tomasiewicz, Hilarie C.; Wilkinson, Matthew B.; Nestler, Eric J.; Hurd, Yasmin L.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Jacobs, Michelle M.; Nestler, Eric J.; Hurd, Yasmin L.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA. [Tomasiewicz, Hilarie C.; Jacobs, Michelle M.; Wilkinson, Matthew B.; Nestler, Eric J.; Hurd, Yasmin L.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA. [Wilson, Steven P.] Univ S Carolina, Sch Med, Dept Pharmacol Physiol & Neurosci, Columbia, SC 29208 USA. RP Hurd, YL (reprint author), James J Peters VA Med Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. EM Yasmin.hurd@mssm.edu FU National Institute on Drug Abuse [DA024929, T32 DA007135, DA08227, DA030359, DA19350] FX This work was funded by the National Institute on Drug Abuse, Grant Nos. DA024929 (HCT), T32 DA007135 (MMJ), DA08227 (EJN), DA030359 (YLH), and DA19350 (YLH). NR 34 TC 35 Z9 36 U1 0 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 15 PY 2012 VL 72 IS 10 BP 803 EP 810 DI 10.1016/j.biopsych.2012.04.026 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 027KT UT WOS:000310351800007 PM 22683090 ER PT J AU Kocarnik, BM Liu, CF Wong, ES Perkins, M Maciejewski, ML Yano, EM Au, DH Piette, JD Bryson, CL AF Kocarnik, Beverly Mielke Liu, Chuan-Fen Wong, Edwin S. Perkins, Mark Maciejewski, Matthew L. Yano, Elizabeth M. Au, David H. Piette, John D. Bryson, Chris L. TI Does the presence of a pharmacist in primary care clinics improve diabetes medication adherence? SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Pharmacist; Medication adherence; Diabetes mellitus; Oral hypoglycemic agent; Patient-centered medical home ID REFILL COMPLIANCE; GLYCEMIC CONTROL; VETERANS; MANAGEMENT; MELLITUS; HOME; TRANSFORMATION; PROGRAM; SYSTEM; TEAM AB Background: Although oral hypoglycemic agents (OHAs) are an essential element of therapy for the management of type 2 diabetes, OHA adherence is often suboptimal. Pharmacists are increasingly being integrated into primary care as part of the move towards a patient-centered medical home and may have a positive influence on medication use. We examined whether the presence of pharmacists in primary care clinics was associated with higher OHA adherence. Methods: This retrospective cohort study analyzed 280,603 diabetes patients in 196 primary care clinics within the Veterans Affairs healthcare system. Pharmacists presence, number of pharmacist full-time equivalents (FTEs), and the degree to which pharmacy services are perceived as a bottleneck in each clinic were obtained from the 2007 VA Clinical Practice Organizational Survey-Primary Care Director Module. Patient-level adherence to OHAs using medication possession ratios (MPRs) were constructed using refill data from administrative pharmacy databases after adjusting for patient characteristics. Clinic-level OHA adherence was measured as the proportion of patients with MPR >=80%. We analyzed associations between pharmacy measures and clinic-level adherence using linear regression. Results: We found no significant association between pharmacist presence and clinic-level OHA adherence. However, adherence was lower in clinics where pharmacy services were perceived as a bottleneck. Conclusions: Pharmacist presence, regardless of the amount of FTE, was not associated with OHA medication adherence in primary care clinics. The exact role of pharmacists in clinics needs closer examination in order to determine how to most effectively use these resources to improve patient-centered outcomes including medication adherence. C1 [Liu, Chuan-Fen; Wong, Edwin S.; Perkins, Mark; Au, David H.; Bryson, Chris L.] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Liu, Chuan-Fen; Wong, Edwin S.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Kocarnik, Beverly Mielke; Bryson, Chris L.] Univ Washington, Div Gen Internal Med, Seattle, WA 98104 USA. [Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA. [Yano, Elizabeth M.] Los Angeles VA, Ctr Study Healthcare Provider Behav, Los Angeles, CA 91343 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Piette, John D.] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Piette, John D.] Univ Michigan, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA. RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM edwin.wong@va.gov FU Gilead Sciences; Department of Veterans Affairs, Health Services Research and Development [IIR 07-068-2]; VA Health Services Research and Development Postdoctoral Fellowship [TPP 61-024]; VA Career Development Award [03-177] FX DHA reports serving as a consultant for Bosch Inc. and receiving grants from Gilead Sciences. All other authors declare that they have no competing interests.; This research was supported by an Investigator Initiated Research Award (IIR 07-068-2) from the Department of Veterans Affairs, Health Services Research and Development. Dr. Wong is supported by VA Health Services Research and Development Postdoctoral Fellowship TPP 61-024. Dr. Piette is a VA Senior Research Career Scientist; Dr. Maciejewski and Dr. Yano are VA Research Career Scientists. Dr. Bryson was supported by VA Career Development Award 03-177. NR 38 TC 4 Z9 5 U1 0 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD NOV 13 PY 2012 VL 12 AR 391 DI 10.1186/1472-6963-12-391 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 063WZ UT WOS:000313034000001 PM 23148570 ER PT J AU Aragon, K Covinsky, K Miao, YH Boscardin, WJ Flint, L Smith, AK AF Aragon, Katherine Covinsky, Kenneth Miao, Yinghui Boscardin, W. John Flint, Lynn Smith, Alexander K. TI Use of the Medicare Posthospitalization Skilled Nursing Benefit in the Last 6 Months of Life SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID HOME RESIDENTS; PALLIATIVE CARE; HOSPICE; END; HOSPITALIZATION; PAYMENT; DEATH AB Background: In the last 6 months of life, many older adults will experience a hospitalization, followed by a transfer to a skilled nursing facility (SNF) for additional care. We sought to examine patterns of Medicare post-hospitalization SNF use in the last 6 months of life. Methods: We used data from the Health and Retirement Study, a longitudinal survey of older adults, linked to Medicare claims (January 1994 through December 2007). We determined the number of individuals 65 years or older at death who had used the SNF benefit in the last 6 months of life. We report demographic, social, and clinical correlates of SNF use. We examined the relationship between place of death and hospice use for those residing in nursing homes and the community before the last 6 months of life. Results: The mean age at death among 5163 individuals was 82.8 years; 54.5% of the cohort were female, and 23.2% had resided in a nursing home. In total, 30.5% had used the SNF benefit in the last 6 months of life, and 9.2% had died while enrolled in the SNF benefit. The use of the SNF benefit was greater among patients who were 85 years or older, had at least a high school education, did not have cancer, resided in a nursing home, used home health services, and were expected to die soon (P < .01 for all). Of community dwellers who had used the SNF benefit, 42.5% died in a nursing home, 10.7% died at home, 38.8% died in the hospital, and 8.0% died elsewhere. In contrast, of community dwellers who did not use the SNF benefit, 5.3% died in a nursing home, 40.6% died at home, 44.3% died in the hospital, and 9.8% died elsewhere. Conclusions: Almost one-third of older adults receive care in a SNF in the last 6 months of life under the Medicare posthospitalization benefit, and 1 in 11 elders will die while enrolled in the SNF benefit. Palliative care services should be incorporated into SNF-level care. C1 [Covinsky, Kenneth; Boscardin, W. John; Flint, Lynn; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94121 USA. [Aragon, Katherine] Univ Calif San Francisco, Dept Med, Div Palliat Care, San Francisco, CA 94121 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Biostat, San Francisco, CA 94121 USA. [Covinsky, Kenneth; Miao, Yinghui; Boscardin, W. John; Flint, Lynn; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU National Institute on Aging [K24AG029812]; National Center for Research Resources University of California, San Francisco-Clinical and Translational Science Institute [UL1 RR024131] FX This study was supported in part by grants K24AG029812 from the National Institute on Aging (Dr Covinsky) and UL1 RR024131 from the National Center for Research Resources University of California, San Francisco-Clinical and Translational Science Institute (Dr Smith). NR 24 TC 13 Z9 13 U1 1 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 12 PY 2012 VL 172 IS 20 BP 1573 EP 1579 DI 10.1001/archinternmed.2012.4451 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 035XR UT WOS:000310987300008 PM 23026981 ER PT J AU Gellad, W Mor, M Zhao, XH Donohue, J Good, C AF Gellad, Walid Mor, Maria Zhao, Xinhua Donohue, Julie Good, Chester TI Variation in Use of High-Cost Diabetes Mellitus Medications in the VA Healthcare System SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID MEDICARE C1 [Gellad, Walid; Mor, Maria; Zhao, Xinhua; Good, Chester] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Gellad, Walid; Good, Chester] Univ Pittsburgh, Dept Med, Div Gen Med, Pittsburgh, PA USA. [Mor, Maria] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Donohue, Julie] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Gellad, Walid] RAND Corp, Pittsburgh, PA USA. [Good, Chester] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. RP Gellad, W (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM walid.gellad@va.gov OI Donohue, Julie/0000-0003-2418-6017 NR 9 TC 10 Z9 10 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 12 PY 2012 VL 172 IS 20 BP 1608 EP 1609 DI 10.1001/archinternmed.2012.4482 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 035XR UT WOS:000310987300018 PM 23044980 ER PT J AU Albasanz-Puig, A Murray, J Namekata, M Wijelath, ES AF Albasanz-Puig, Adaia Murray, Jacqueline Namekata, Mayumi Wijelath, Errol S. TI Opposing roles of STAT-1 and STAT-3 in regulating vascular endothelial growth factor expression in vascular smooth muscle cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE VEGF; STAT-3; STAT-1; HIF-1 alpha; Oncostatin-M; Smooth muscle cell ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ONCOSTATIN-M; VEGF EXPRESSION; PLAQUE NEOVASCULARIZATION; SIGNALING PATHWAY; EPITHELIAL-CELLS; CARCINOMA CELLS; CAROTID PLAQUE; COLON-CANCER; IN-VIVO AB Increased microvessel density in atherosclerotic plaques plays a major role in promoting plaque destabilization resulting in increased risk of stroke and myocardial infarction. Previously we have shown that expression of the inflammatory cytokine, Oncostatin-M (OSM), in human atherosclerotic plaques correlated with increased microvessel density, indicating a role for OSM in promoting plaque angiogenesis. The purpose of this study was to determine the mechanism by which OSM regulates Vascular Endothelial Growth Factor (VEGF) expression in human coronary artery smooth muscle cells. Using shRNA and overexpression studies, we have shown that the transcription factor, STAT-1 inhibited VEGF expression, while STAT-3 promoted the expression of VEGF. We further show that the mechanism by which STAT-1 and STAT-3 regulates VEGF expression is through modulation of Hypoxia Inducible Factor-1 alpha (HIF-1 alpha). STAT-1 suppresses HIF-1 alpha expression, whereas STAT-3 positively regulates HIF-1 alpha expression. These results provide evidence that activated STAT-1 and STAT-3 regulate VEGF expression indirectly, by modulating HIF-1 alpha activity. Published by Elsevier Inc. C1 VA Puget Sound Hlth Care Syst, Div Vasc Surg, Dept Surg, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. RP Wijelath, ES (reprint author), Dept Vet Affairs Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM errolw@u.washington.edu FU US Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program FX This study was supported by the US Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program. NR 45 TC 12 Z9 13 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 9 PY 2012 VL 428 IS 1 BP 179 EP 184 DI 10.1016/j.bbrc.2012.10.037 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 043DN UT WOS:000311523200031 PM 23068100 ER PT J AU Grapov, D Adams, SH Pedersen, TL Garvey, WT Newman, JW AF Grapov, Dmitry Adams, Sean H. Pedersen, Theresa L. Garvey, W. Timothy Newman, John W. TI Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and Endocannabinoids SO PLOS ONE LA English DT Article ID NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; GLUCOSE-PRODUCTION; PULSATILE INSULIN; BETA-OXIDATION; METABOLISM; PATHOGENESIS; ACTIVATION; DELIVERY; HUMANS AB Type 2 diabetes has profound effects on metabolism that can be detected in plasma. While increases in circulating non-esterified fatty acids (NEFA) are well-described in diabetes, effects on signaling lipids have received little attention. Oxylipins and endocannabinoids are classes of bioactive fatty acid metabolites with many structural members that influence insulin signaling, adipose function and inflammation through autocrine, paracrine and endocrine mechanisms. To link diabetes-associated changes in plasma NEFA and signaling lipids, we quantitatively targeted >150 plasma lipidome components in age- and body mass index-matched, overweight to obese, non-diabetic (n = 12) and type 2 diabetic (n = 43) African-American women. Diabetes related NEFA patterns indicated similar to 60% increase in steroyl-CoA desaturase activity and similar to 40% decrease in very long chain polyunsaturated fatty acid chain shortening, patterns previously associated with the development of nonalcoholic fatty liver disease. Further, epoxides and ketones of eighteen carbon polyunsaturated fatty acids were elevated >80% in diabetes and strongly correlated with changes in NEFA, consistent with their liberation during adipose lipolysis. Endocannabinoid behavior differed by class with diabetes increasing an array of N-acylethanolamides which were positively correlated with pro-inflammatory 5-lipooxygenase-derived metabolites, while monoacylglycerols were negatively correlated with body mass. These results clearly show that diabetes not only results in an increase in plasma NEFA, but shifts the plasma lipidomic profiles in ways that reflect the biochemical and physiological changes of this pathological state which are independent of obesity associated changes. Citation: Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW (2012) Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and Endocannabinoids. PLoS ONE 7(11): e48852. doi: 10.1371/journal.pone.0048852 C1 [Grapov, Dmitry; Adams, Sean H.; Newman, John W.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Grapov, Dmitry; Adams, Sean H.; Pedersen, Theresa L.; Newman, John W.] USDA, Obes & Metab Res Unit, ARS, Western Human Nutr Res Ctr, Davis, CA USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Newman, JW (reprint author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. EM john.newman@ars.usda.gov OI Grapov, Dmitry/0000-0002-7204-3128 FU National Institute of General Medical Sciences-National Institutes of Health (NIGMS-NIH) [T32-GM008799]; intramural United States Department of Agriculture-Agricultural Research Service (USDA-ARS) [5306-51530-019-00D]; National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK) [R01DK078328-01]; NIH [DK-038764, DK-083562, P01 HL-055782]; Merit Review program of the Department of Veterans Affairs; University of Alabama (UAB) Center for Clinical and Translational Science [UL1 RR025777]; UAB Nutrition and Obesity Research Center [P30-DK56336]; UAB Diabetes Research and Training Center [P60 DK079626] FX This work was funded in part by the following: National Institute of General Medical Sciences-National Institutes of Health (NIGMS-NIH) T32-GM008799 (D.G.); intramural United States Department of Agriculture-Agricultural Research Service (USDA-ARS) Project 5306-51530-019-00D (J.W.N. and S.H.A.); National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK) R01DK078328-01 (S.H.A.); NIH grants DK-038764, DK-083562, and P01 HL-055782 and the Merit Review program of the Department of Veterans Affairs (W.T.G.). The authors also acknowledge support from the research core facilities of the University of Alabama (UAB) Center for Clinical and Translational Science (UL1 RR025777), the UAB Nutrition and Obesity Research Center (P30-DK56336), and the UAB Diabetes Research and Training Center (P60 DK079626). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 34 Z9 34 U1 1 U2 31 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 8 PY 2012 VL 7 IS 11 AR e48852 DI 10.1371/journal.pone.0048852 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053KE UT WOS:000312269500039 PM 23144998 ER PT J AU Haile, CN De La Garza, R Mahoney, JJ Nielsen, DA Kosten, TR Newton, TF AF Haile, Colin N. De La Garza, Richard, II Mahoney, James J., III Nielsen, David A. Kosten, Thomas R. Newton, Thomas F. TI The Impact of Disulfiram Treatment on the Reinforcing Effects of Cocaine: A Randomized Clinical Trial SO PLOS ONE LA English DT Article ID DOPAMINE-BETA-HYDROXYLASE; PLACEBO-CONTROLLED TRIAL; ALTERNATIVE REINFORCERS; ALCOHOL DEPENDENCE; FOLLOW-UP; HUMANS; INHIBITION; SEEKING; NOREPINEPHRINE; PSYCHOTHERAPY AB Background: Clinical trials indicate that disulfiram (250 mg/d) reduces cocaine use, though one study found that treatment with lower doses of disulfiram (62.5 and 125 mg/d) increased cocaine use. We conducted the present study to better understand how disulfiram alters the reinforcing effects of cocaine in cocaine users. Methods: Seventeen non-treatment seeking, cocaine-dependent volunteers participated in this double-blind, placebo-controlled, laboratory-based study. A cross-over design was utilized in which participants received placebo in one phase and disulfiram (250 mg/d) in the other. Following three days of study medication participants completed two choice sessions. In one they made 10 choices between receiving an intravenous infusion of saline or money that increased in value (US$ 0.05-16) and in the other cocaine (20 mg) or money. Results: Participants chose cocaine more than saline under both disulfiram and placebo conditions (p<0.05). Unexpectedly, disulfiram increased both the number of cocaine and saline infusion choices (p<0.05). We next examined the relationship between disulfiram dose and cocaine choices. Disulfiram dose (mg/kg bodyweight) was negatively correlated with number of choices for cocaine (p<0.05). Disulfiram also enhanced cocaine-induced increases in cardiovascular measures (p's<0.05-0.01). Conclusions: Disulfiram's impact on the reinforcing effects of cocaine depends on dose relative to body weight. Our results suggest that the use of weight-based medication doses would produce more reliable effects, consistent with weight-based dosing used in pediatrics and in preclinical research. C1 [Haile, Colin N.; De La Garza, Richard, II; Mahoney, James J., III; Nielsen, David A.; Kosten, Thomas R.; Newton, Thomas F.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Newton, TF (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM tnewton@bcm.edu RI De La Garza, Richard/B-2489-2014; Mahoney, James/I-2753-2014 OI De La Garza, Richard/0000-0003-1943-4469; Mahoney, James/0000-0003-0824-1776; Haile, Colin/0000-0001-8293-7291; newton, thomas/0000-0002-3198-5901 FU National Institutes of Health [R01 DA017705, K24 DA017754, M01 RR00188] FX This study was funded by research grants from the National Institutes of Health (R01 DA017705, K24 DA017754, and M01 RR00188). Sterile cocaine HCl for human use was provided by a contractor for National Institute on Drug Abuse's Drug Supply Program (RTI International, North Carolina). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 13 Z9 13 U1 3 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 8 PY 2012 VL 7 IS 11 AR e47702 DI 10.1371/journal.pone.0047702 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053KE UT WOS:000312269500010 PM 23144826 ER PT J AU Papak, J Kansagara, D AF Papak, Joel Kansagara, Devan TI Management of Hyperglycemia in a Hospitalized Patient with Diabetes Mellitus and Cardiovascular Disease SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS; GLUCOSE-INSULIN-POTASSIUM; RANDOMIZED CONTROLLED-TRIAL; TIGHT GLYCEMIC CONTROL; CARE-UNIT PATIENTS; INTENSIVE-CARE; WOUND-INFECTION; FATTY-ACIDS; MORTALITY AB Hyperglycemia in patients with and without known diabetes is a common finding in patients hospitalized with cardiovascular disease, and is associated with poor outcomes. Investigators have been examining the role of insulin to treat patients with acute myocardial infarction since the 1960's. Until the 1990's most studies evaluated fixed doses of glucose-insulin-potassium (GIK) infusions. The Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) trial, published in 1995, evaluated the role of adjustable-dose insulin infusion to lower blood glucose. Its promising results spurred further interest and a number of trials evaluating the use of insulin to lower blood glucose in hospitalized patients - many of which included patients with cardiovascular disease - have been conducted over the last two decades with conflicting results. This manuscript reviews the epidemiology and pathophysiology of hyperglycemia in hospitalized patients, summarizes the evidence for benefits and harms of using insulin to treat hyperglycemic patients hospitalized with cardiovascular disease, and offers some practical management considerations. Published by Elsevier Inc. (Am J Cardiol 2012;110[suppl]:24B-31B) C1 [Kansagara, Devan] Portland VA Med Ctr, Evidence Based Synth Program, Portland, OR USA. [Kansagara, Devan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Kansagara, D (reprint author), 3710 SW US Vet Hosp Rd,P3 Med, Portland, OR 97239 USA. EM kansagar@ohsu.edu FU Novo Nordisk Inc. FX Funding for publication and medical writing assistance were provided by Novo Nordisk Inc. We thank Ruth Kleinpell, PhD, RN, and Mary Lou Briglio (Executive Administrative Assistant to Michael H. Davidson, MD) for assistance in the preparation of this supplement. NR 50 TC 7 Z9 8 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 6 PY 2012 VL 110 IS 9 SU S BP 24B EP 31B DI 10.1016/j.amjcard.2012.08.034 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 036FM UT WOS:000311011800004 PM 23062564 ER PT J AU Wang, CCL Reusch, JEB AF Wang, Cecilia C. Low Reusch, Jane E. B. TI Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CORONARY-HEART-DISEASE; PLACEBO-CONTROLLED TRIAL; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; BLOOD-PRESSURE CONTROL; RISK-FACTORS; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; FOLLOW-UP; ACCORD TRIAL AB Diabetes mellitus (DM) is the fifth-leading cause of death worldwide and contributes to leading causes of death, cancer and cardiovascular disease, including CAD, stroke, peripheral vascular disease, and other vascular disease. While glycemic management remains a cornerstone of DM care, the co-management of hypertension, atherosclerosis, cardiovascular risk reduction, and prevention of long-term consequences associated with DM are now well recognized as essential to improve long-term survival. Clinical trial evidence substantiates the importance of glycemic control, low-density cholesterol lowering therapy, blood pressure lowering, control of albuminuria, and comprehensive approaches targeting multiple risk factors to reduce cardiovascular risk. This article presents a review of the role of DM in the pathogenesis of atherosclerosis and cardiac dysfunction, recent evidence on the degree of glycemic control and mortality, and available evidence for a multifaceted approach to improve long-term outcomes for patients. Published by Elsevier Inc. (Am J Cardiol 2012;110[suppl]:58B-68B) C1 [Wang, Cecilia C. Low] Univ Colorado, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Aurora, CO 80045 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Wang, CCL (reprint author), Univ Colorado, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, MS 8106,Bldg RC-1 S,Room 7103, Aurora, CO 80045 USA. EM cecilia.wang@ucdenver.edu FU Novo Nordisk Inc.; Bristol-Meyers Squibb/Amylin; GlaxoSmithKline FX Funding for publication and medical writing assistance were provided by Novo Nordisk Inc. We thank Ruth Kleinpell, PhD, RN, and Mary Lou Briglio (Executive Administrative Assistant to Michael H. Davidson, MD) for assistance in the preparation of this supplement.; The authors who contributed to this article have disclosed the following industry relationships:; Jane EB Reusch, MD, has received funding from Bristol-Meyers Squibb/Amylin for investigator-initiated trial and GlaxoSmithKline. Dr. Reusch also serves on the advisory board for GlaxoSmithKline. NR 84 TC 28 Z9 30 U1 2 U2 13 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 6 PY 2012 VL 110 IS 9 SU S BP 58B EP 68B DI 10.1016/j.amjcard.2012.08.036 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 036FM UT WOS:000311011800008 PM 23062569 ER PT J AU Kreindler, JL Chen, B Kreitman, Y Kofonow, J Adams, KM Cohen, NA AF Kreindler, James L. Chen, Bei Kreitman, Yael Kofonow, Jennifer Adams, Kelly M. Cohen, Noam A. TI The novel dry extract BNO 1011 stimulates chloride transport and ciliary beat frequency in human respiratory epithelial cultures SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID TRANSMEMBRANE CONDUCTANCE REGULATOR; CHRONIC RHINOSINUSITIS; BICARBONATE SECRETION; CHRONIC SINUSITIS; CELLS; INHIBITION; DIAGNOSIS; CHANNEL; AIRWAYS; NASAL AB Background: Herbal remedies predate written history and continue to be used more frequently than conventional pharmaceutical medications. The novel dry extract BNO 1011 is based on a combination of five herbs that is used to treat acute and chronic rhinosinusitis. We evaluated the pharmacologic effects of the novel dry extract BNO 1011 on human respiratory epithelial cultures specifically addressing electrolyte transport and cilia beat frequency (CBF). Methods: Well-differentiated human bronchial epithelial cultures grown at an air-liquid interface were treated on the apical or basolateral surface with varying concentrations of dry extract BNO 1011. Changes in transepithelial sodium and chloride transport were determined in Ussing chambers under voltage-clamped conditions. Changes in CBF were determined using the Sissons-Ammons Video Analysis system (Ammons Engineering, Mt. Morris, MI). Results: When applied to the apical surface, dry extract BNO 1011 activated forskolin-stimulated chloride secretion and ciliary beat in a dose-dependent fashion. Basolateral application of dry extract BNO 1011 did not alter the measured physiological properties. Conclusion: Apical application of dry extract BNO 1011 stimulates both chloride secretion and CBF and therefore may augment mucociliary clearance. C1 [Kreindler, James L.; Adams, Kelly M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA. [Kreindler, James L.; Adams, Kelly M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Chen, Bei; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Kreitman, Yael] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Kofonow, Jennifer; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU Bionorica SE, Neumarkt, Germany FX Funded by Bionorica SE, Neumarkt, Germany. The company had no role in collecting or analyzing data for inclusion in this article but did participate in its generation. Evaluation of raw data and data interpretation were performed independently by the investigators NR 30 TC 3 Z9 3 U1 0 U2 2 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD NOV-DEC PY 2012 VL 26 IS 6 BP 439 EP 443 DI 10.2500/ajra.2012.26.3821 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 193FK UT WOS:000322543600005 PM 23232192 ER PT J AU Boudreaux, ED Bedek, KL Byrne, NJ Baumann, BM Lord, SA Grissom, G AF Boudreaux, Edwin D. Bedek, Kristyna L. Byrne, Nelson J. Baumann, Brigitte M. Lord, Sherrill A. Grissom, Grant TI The Computer-Assisted Brief Intervention for Tobacco (CABIT) Program: A Pilot Study SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE technology; tobacco use cessation; smoking cessation; referrals ID EMERGENCY-DEPARTMENT PATIENTS; PROMOTING SMOKING-CESSATION; RANDOMIZED-CONTROLLED-TRIAL; NICOTINE DEPENDENCE; PRIMARY-CARE; INTEGRATIVE MODEL; FAGERSTROM TEST; RISK-REDUCTION; HEALTH; PHYSICIANS AB Background: Health care providers do not routinely carry out brief counseling for tobacco cessation despite the evidence for its effectiveness. For this intervention to be routinely used, it must be brief, be convenient, require little investment of resources, require little specialized training, and be perceived as efficacious by providers. Technological advances hold much potential for addressing the barriers preventing the integration of brief interventions for tobacco cessation into the health care setting. Objective: This paper describes the development and initial evaluation of the Computer-Assisted Brief Intervention for Tobacco (CABIT) program, a web-based, multimedia tobacco intervention for use in opportunistic settings. Methods: The CABIT uses a self-administered, computerized assessment to produce personalized health care provider and patient reports, and cue a stage-matched video intervention. Respondents interested in changing their tobacco use are offered a faxed referral to a "best matched" tobacco treatment provider (ie, dynamic referral). During 2008, the CABIT program was evaluated in an emergency department, an employee assistance program, and a tobacco dependence program in New Jersey. Participants and health care providers completed semistructured interviews and satisfaction ratings of the assessment, reports, video intervention, and referrals using a 5-point scale. Results: Mean patient satisfaction scores (n = 67) for all domains ranged from 4.00 (Good) to 5.00 (Excellent; Mean = 4.48). Health care providers completed satisfaction forms for 39 patients. Of these 39 patients, 34 (87%) received tobacco resources and referrals they would not have received under standard care. Of the 45 participants offered a dynamic referral, 28 (62%) accepted. Conclusions: The CABIT program provided a user-friendly, desirable service for tobacco users and their health care providers. Further development and clinical trial testing is warranted to establish its effectiveness in promoting treatment engagement and tobacco cessation. (J Med Internet Res 2012; 14(6): e163) doi: 10.2196/jmir.2074 C1 [Boudreaux, Edwin D.] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA. [Bedek, Kristyna L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Byrne, Nelson J.] Credit Valley Hosp, Mississauga, ON, Canada. [Byrne, Nelson J.] Trillium Hlth Ctr, Mississauga, ON, Canada. [Baumann, Brigitte M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Camden, NJ 08103 USA. [Baumann, Brigitte M.] Cooper Univ Hosp, Dept Emergency Med, Camden, NJ USA. [Lord, Sherrill A.; Grissom, Grant] Polaris Hlth Direct Inc, Langhorne, PA USA. RP Boudreaux, ED (reprint author), Univ Massachusetts, Sch Med, LA 189,55 Lake Ave North, Worcester, MA 01655 USA. EM Edwin.Boudreaux@umassmed.edu OI Boudreaux, Edwin/0000-0002-3223-6371 FU National Institute on Drug Abuse [R41DA019718] FX The study was performed while Edwin Boudreaux, Ph.D., was employed by Cooper Health System and faculty with Robert Wood Johnson Medical School in Camden, NJ. He is currently employed by the University of Massachusetts Medical School. This research was supported by a Small Business Technology Grant from the National Institute on Drug Abuse (R41DA019718) to Polaris Health Directions, Inc. NR 49 TC 2 Z9 2 U1 0 U2 8 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD NOV-DEC PY 2012 VL 14 IS 6 BP 72 EP 87 AR e163 DI 10.2196/jmir.2074 PG 16 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 099TV UT WOS:000315646000006 PM 23208070 ER PT J AU Vodovotz, Y Prelich, J Lagoa, C Barclay, D Zamora, R Murase, N Gandhi, CR AF Vodovotz, Yoram Prelich, John Lagoa, Claudio Barclay, Derek Zamora, Ruben Murase, Noriko Gandhi, Chandrashekhar R. TI Augmenter of Liver Regeneration (ALR) Is a Novel Biomarker of Hepatocellular Stress/Inflammation: In Vitro, In Vivo and In Silico Studies SO MOLECULAR MEDICINE LA English DT Article ID HEPATIC STELLATE CELLS; SULFHYDRYL OXIDASE; HEPATOTROPHIC FACTOR; HUMAN HEPATOCYTES; PORTACAVAL-SHUNT; GROWTH-FACTORS; DNA-SYNTHESIS; CYTOCHROME-C; EXPRESSION; ENDOTOXIN AB The liver is a central organ involved in inflammatory processes, including the elaboration of acute-phase proteins. Augmenter of liver regeneration (ALR) protein, expressed and secreted by hepatocytes, promotes liver regeneration and maintains viability of hepatocytes. ALR also stimulates secretion of inflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) and nitric oxide from Kupffer cells. We hypothesized that ALR may be involved in modulating inflammation induced by various stimuli. We found that hepatic ALR levels are elevated at 24 h, before or about the same time as an increase in the mRNA expression of TNF-alpha and IL-6, after portacaval shunt surgery in rats. Serum ALR also increased, but significantly only on d 4 when pathological changes in the liver become apparent. In rats, serum ALR was elevated after intraperitoneal administration of lipopolysaccharide alone and in a model of gram-negative sepsis. Serum ALP increased before alanine aminotransferase (ALT) in endotoxemia and in the same general time frame as TNF-alpha and IL-6 in the bacterial sepsis model. Furthermore, mathematical prediction of tissue damage correlated strongly with alterations in serum ALP in a mouse model of hemorrhagic shock. In vitro, monomethyl sulfonate. TNF-alpha, actinomycin D and lipopolysaccharide all caused increased release of ALR from rat hepatocytes, which preceded the loss of cell viability and/or inhibition of DNA synthesis. ALR may thus serve as a potential diagnostic marker of hepatocellular stress and/or acute inflammatory conditions. Online address: http://www.molmed.org doi: 10.2119/molmed.2012.00183 C1 [Vodovotz, Yoram; Lagoa, Claudio; Barclay, Derek; Zamora, Ruben; Murase, Noriko; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Gandhi, Chandrashekhar R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Murase, Noriko; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Vodovotz, Yoram; Zamora, Ruben] McGowan Inst Regenerat Med, Ctr Inflammat & Regenerat Modeling, Pittsburgh, PA USA. [Prelich, John] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gandhi, CR (reprint author), Univ Cincinnati, Dept Surg, ML0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA. EM gandhicr@ucmail.uc.edu FU VA Merit Review [1I1BX001174]; NIH [R01-DK54411, R21AA020846] FX This work was supported by VA Merit Review 1I1BX001174 and NIH grants R01-DK54411 and R21AA020846 (CR Gandhi). We thank Adam Kichler for technical assistance. NR 49 TC 6 Z9 7 U1 2 U2 4 PU FEINSTEIN INST MED RES PI MANHASSET PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1076-1551 J9 MOL MED JI Mol. Med. PD NOV PY 2012 VL 18 IS 11 BP 1421 EP 1429 DI 10.2119/molmed.2012.00183 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 087WE UT WOS:000314794300001 ER PT J AU Kennelty, KA Thorpe, JM Chewning, B Mott, DA AF Kennelty, Korey A. Thorpe, Joshua M. Chewning, Betty Mott, David A. TI Use of pharmacists or pharmacies as Medicare Part D information sources SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article DE Medicare Part D; community pharmacies; pharmacists; information sources; rural setting; prescription costs ID BENEFICIARIES; HEALTH AB Objective: To characterize beneficiaries who used a pharmacy or pharmacist as a Medicare Part D information source. Methods: This cross-sectional descriptive study involved 4,724 Medicare Part D beneficiaries who graduated from Wisconsin high schools in 1957. The main outcome measure was beneficiary self-reported use of a pharmacy or pharmacist as a Medicare Part D information source. Results: Only 13% of the total sample and 15% of those with three or more medications used a pharmacy or pharmacist for Medicare Part D information. Adjusted logistic regression revealed that beneficiaries living in rural communities, compared with metropolitan areas, and with higher out-of-pocket prescription costs were more likely to use a pharmacy or pharmacist for Medicare Part D information. Beneficiaries with lower educational attainment were less likely to use a pharmacy or pharmacist for Medicare Part D information. Conclusion: Pharmacists have the knowledge and are in the position in the community to effectively educate beneficiaries about the Medicare Part D program. However, this study suggests that few beneficiaries are using pharmacists or pharmacies for Medicare Part D information. C1 [Kennelty, Korey A.; Thorpe, Joshua M.] Univ Wisconsin, Sch Pharm, Div Social & Adm Sci, Madison, WI 53705 USA. [Thorpe, Joshua M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kennelty, Korey A.; Chewning, Betty; Mott, David A.] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA. [Chewning, Betty] Univ Wisconsin, Sch Pharm, Sonderegger Res Ctr, Madison, WI 53705 USA. RP Kennelty, KA (reprint author), Univ Wisconsin, Sch Pharm, Rennebohm Hall 2506,777 Highland Ave, Madison, WI 53705 USA. EM kennelty@wisc.edu FU Clinical and Translational Science Award program, National Center for Research Resources, National Institutes of Health [1UL1RR025011]; National Institute on Aging [R01 AG09775, R01 AG033285]; Vilas Estate Trust; National Science Foundation; Spencer Foundation; Graduate School of the University of Wisconsin-Madison FX Clinical and Translational Science Award program, National Center for Research Resources, National Institutes of Health (grant no. 1UL1RR025011).; This research uses data from the Wisconsin Longitudinal Study (WLS) of the University of Wisconsin-Madison. Since 1991, the WLS has been supported principally by the National Institute on Aging (R01 AG09775, R01 AG033285), with additional support from the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation, and the Graduate School of the University of Wisconsin-Madison. A public use file of data from the Wisconsin Longitudinal Study is available from the Wisconsin Longitudinal Study, University of Wisconsin-Madison, 1180 Observatory Drive, Madison, WI 53706 and at www.ssc.wisc.edu/wlsresearch/data. The opinions expressed herein are those of the authors. NR 14 TC 0 Z9 0 U1 0 U2 2 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD NOV-DEC PY 2012 VL 52 IS 6 BP E205 EP E209 DI 10.1331/JAPhA.2012.11199 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 082OM UT WOS:000314401500010 PM 23229982 ER PT J AU Mendez, MF AF Mendez, Mario F. TI Early-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD SO ARCHIVES OF MEDICAL RESEARCH LA English DT Review DE Alzheimer's disease; Dementia; Apolipoprotein; Presenilin; Amnestic ID POSTERIOR CORTICAL ATROPHY; MILD COGNITIVE IMPAIRMENT; CEREBRAL GLUCOSE-METABOLISM; APOLIPOPROTEIN-E EPSILON-4; CLINICAL CHARACTERISTICS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; CORTICOBASAL SYNDROME; PROGRESSIVE APHASIA; NATIONAL INSTITUTE AB Patients with Alzheimer's disease (AD), the most prevalent neurodegenerative dementia, are usually elderly; however, similar to 4-5% develop early-onset AD (EOAD) with onset before age 65. Most EOAD is sporadic, but about 5% of patients with EOAD have an autosomal dominant mutation such as Presenilin 1, Presenilin 2, or alterations in the Amyloid Precursor Protein gene. Although most Alzheimer's research has concentrated on older, late-onset AD (LOAD), there is much recent interest and research in EOAD. These recent studies indicate that EOAD is a heterogeneous disorder with significant differences from LOAD. From 22-64% of EOAD patients have a predominant nonamnestic syndrome presenting with deficits in language, visuospatial abilities, praxis, or other non-memory cognition. These nonamnestic patients may differ in several ways from the usual memory or amnestic patients. Patients with nonamnestic EOAD compared to typical amnestic AD have a more aggressive course, lack the apolipoprotein E epsilon 4 (APOE epsilon 4) susceptibility gene for AD, and have a focus and early involvement of non-hippocampal areas of brain, particularly parietal neocortex. These differences in the EOAD subtypes indicate differences in the underlying amyloid cascade, the prevailing pathophysiological theory for the development of AD. Together the results of recent studies suggest that nonamnestic subtypes of EOAD constitute a Type 2 AD distinct from the usual, typical disorder. In sum, the study of EOAD can reveal much about the clinical heterogeneity, predisposing factors, and neurobiology of this disease. (c) 2012 IMSS. Published by Elsevier Inc. C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU NIA NIH HHS [R01 AG034499] NR 102 TC 26 Z9 28 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0188-4409 J9 ARCH MED RES JI Arch. Med. Res. PD NOV PY 2012 VL 43 IS 8 SI SI BP 677 EP 685 DI 10.1016/j.arcmed.2012.11.009 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 082FP UT WOS:000314378000013 PM 23178565 ER PT J AU Antunes, MB Chi, JJ Liu, Z Goldstein-Daruech, N Palmer, JN Zhu, J Cohen, NA AF Antunes, Marcelo B. Chi, John J. Liu, Zhi Goldstein-Daruech, Natalia Palmer, James N. Zhu, Jun Cohen, Noam A. TI Molecular Basis of Tobacco-Induced Bacterial Biofilms: An In Vitro Study SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE chronic rhinosinusitis; biofilm; tobacco; oxidative stress; quorum sensing; virulence factor ID ENDOSCOPIC SINUS SURGERY; ENTEROPATHOGENIC ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA VIRULENCE; BRONCHIAL EPITHELIAL-CELLS; ALGINATE GENE-EXPRESSION; TOXIN-COREGULATED PILI; LUXR-LUXI FAMILY; CHRONIC RHINOSINUSITIS; CYSTIC-FIBROSIS; TWITCHING MOTILITY AB Objective. To evaluate changes in the expression of biofilm-related genes when exposed to tobacco smoke and oxidative stress. Study Design. Experimental, in vitro. Setting. Laboratories of Rhinology and Microbiology, University of Pennsylvania. Subjects and Methods. Bacterial biofilm mass was measured using crystal violet staining and measurement of the optical density. Biofilm-related genes of the Pseudomonas aeruginosa PAO1 strain (pilF, flgK, lasI, lasB, rhlA, and algC) were studied following repetitive exposure to exogenous tobacco smoke and hydrogen peroxide. This was done using a reporter plasmid. Results. After I exposure to smoke, there was no change in biofilm formation. However, after 2 and 3 exposures, the biofilm formed had an increased mass (P < .05). With respect to oxidative stress in the form of H2O2, bacterial cultures demonstrated a dose- and time-dependent induction of biofilm formation compared with control conditions. Gene expression following repetitive smoke exposure demonstrated an increase in expression of pilF, flgK, algC, and lasI genes (P < .05); a decrease in rhlA (P < .05); and no significant change in the lasB gene (P = 0.1). Gene expression following H2O2 exposure demonstrated an increase in pilF (P < .05), whereas the other genes failed to demonstrate a statistical change. Conclusions. Repetitive tobacco smoke exposure leads to molecular changes in biofilm-related genes, and exposure to oxidative stress in the form of H2O2 induces biofilm growth in PAO1. This could represent adaptative changes due to oxidative stress or chemically mediated through any of the several chemicals encountered in tobacco smoke and may explain increased biofilm formation in microbes isolated from smokers. C1 [Antunes, Marcelo B.; Chi, John J.; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Liu, Zhi; Zhu, Jun] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA. [Goldstein-Daruech, Natalia] Pontificia Univ Catolica Chile, Escuela Med, Dept Otorhinolaryngol Head & Neck Surg, Santiago, Chile. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5th Floor,Silverstein Bldg, Philadelphia, PA 19104 USA. EM noam.cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU AAOHNS Foundation Resident Research Grant FX AAOHNS Foundation Resident Research Grant. The funding source had no role in study design and conduct; collection, analysis, and interpretation of the data; and writing or approval of the manuscript. NR 79 TC 7 Z9 9 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD NOV PY 2012 VL 147 IS 5 BP 876 EP 884 DI 10.1177/0194599812447263 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 081AF UT WOS:000314285800012 PM 22597576 ER PT J AU Li, MY Verdijk, LB Sakamoto, K Ely, B van Loon, LJC Musi, N AF Li, Mengyao Verdijk, Lex B. Sakamoto, Kei Ely, Brian van Loon, Luc J. C. Musi, Nicolas TI Reduced AMPK-ACC and mTOR signaling in muscle from older men, and effect of resistance exercise SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Aging; Skeletal muscle; AMPK; mTOR; Resistance exercise ID ACTIVATED PROTEIN-KINASE; HUMAN SKELETAL-MUSCLE; GLUCOSE-UPTAKE; ELDERLY-MEN; MAMMALIAN TARGET; DOSE-RESPONSE; CELL-GROWTH; AMINO-ACID; YOUNG; HYPERTROPHY AB AMP-activated protein kinase (AMPK) is a key energy-sensitive enzyme that controls numerous metabolic and cellular processes. Mammalian target of rapamycin (mTOR) is another energy/nutrient-sensitive kinase that controls protein synthesis and cell growth. In this study we determined whether older versus younger men have alterations in the AMPK and mTOR pathways in skeletal muscle, and examined the effect of a long term resistance type exercise training program on these signaling intermediaries. Older men had decreased AMPK alpha 2 activity and lower phosphorylation of AMPK and its downstream signaling substrate acetyl-CoA carboxylase (ACC). mTOR phosphylation also was reduced in muscle from older men. Exercise training increased AMPK alpha 1 activity in older men, however, AMPK alpha 2 activity, and the phosphorylation of AMPK, ACC and mTOR, were not affected. In conclusion, older men have alterations in the AMPK-ACC and mTOR pathways in muscle. In addition, prolonged resistance type exercise training induces an isoform-selective up regulation of AMPK activity. Published by Elsevier Ireland Ltd. C1 [Li, Mengyao; Ely, Brian; Musi, Nicolas] Audie L Murphy Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Li, Mengyao; Ely, Brian; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Hlth Aging, San Antonio, TX 78229 USA. [Li, Mengyao; Ely, Brian; Musi, Nicolas] Texas Diabet Inst, San Antonio, TX 78207 USA. [Verdijk, Lex B.; van Loon, Luc J. C.] Maastricht Univ, Med Ctr, NUIRIM Sch Nutr Toxicol & Metab, Dept Human Movement Sci, NL-6200 MD Maastricht, Netherlands. [Sakamoto, Kei] Nestle Inst Hlth Sci SA, CH-1015 Lausanne, Switzerland. RP Musi, N (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM musi@uthscsa.edu RI Verdijk, Lex/H-4468-2016 OI van Loon, Luc J.C./0000-0002-6768-9231 FU National Institutes of Health [RO1-DK80157, RO1-DK089229]; Paul B. Beeson Career Development Award from the American Federation for Aging Research and the National Institute on Aging [K23-AG030979]; Anna Foundation (Leiden, the Netherlands); U.K. Medical Research Council FX This work was supported by grants from the National Institutes of Health (RO1-DK80157 and RO1-DK089229 to N.M). N.M. was the recipient of a Paul B. Beeson Career Development Award (K23-AG030979) from the American Federation for Aging Research and the National Institute on Aging. L.V. received support from the Anna Foundation (Leiden, the Netherlands) and K.S. from U.K. Medical Research Council. NR 57 TC 17 Z9 18 U1 2 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD NOV-DEC PY 2012 VL 133 IS 11-12 BP 655 EP 664 DI 10.1016/j.mad.2012.09.001 PG 10 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 077FC UT WOS:000314012300003 PM 23000302 ER PT J AU Mohammed, SF Borlaug, BA Roger, VL Mirzoyev, SA Rodeheffer, RJ Chirinos, JA Redfield, MM AF Mohammed, Selma F. Borlaug, Barry A. Roger, Veronique L. Mirzoyev, Sultan A. Rodeheffer, Richard J. Chirinos, Julio A. Redfield, Margaret M. TI Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction A Community-Based Study SO CIRCULATION-HEART FAILURE LA English DT Article DE anemia; heart failure with preserved ejection fraction; hypertension; diabetes mellitus; renal dysfunction; obesity ID BODY-SIZE; SYSTOLIC HYPERTENSION; REVERSE EPIDEMIOLOGY; DIABETES-MELLITUS; AORTIC DIAMETER; IRON-DEFICIENCY; ANEMIA; OBESITY; IMPACT; DYSFUNCTION AB Background-Patients with heart failure and preserved ejection fraction (HFpEF) display increased adiposity and multiple comorbidities, factors that in themselves may influence cardiovascular structure and function. This has sparked debate as to whether HFpEF represents a distinct disease or an amalgamation of comorbidities. We hypothesized that fundamental cardiovascular structural and functional alterations are characteristic of HFpEF, even after accounting for body size and comorbidities. Methods and Results-Comorbidity-adjusted cardiovascular structural and functional parameters scaled to independently generated and age-appropriate allometric powers were compared in community-based cohorts of HFpEF patients (n=386) and age/sex-matched healthy n=193 and hypertensive, n=386 controls. Within HFpEF patients, body size and concomitant comorbidity-adjusted cardiovascular structural and functional parameters and survival were compared in those with and without individual comorbidities. Among HFpEF patients, comorbidities (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clinical, structural, functional, and prognostic profiles. However, after accounting for age, sex, body size, and comorbidities, greater concentric hypertrophy, atrial enlargement and systolic, diastolic, and vascular dysfunction were consistently observed in HFpEF compared with age/sex-matched normotensive and hypertensive. Conclusions-Comorbidities influence ventricular-vascular properties and outcomes in HFpEF, yet fundamental disease-specific changes in cardiovascular structure and function underlie this disorder. These data support the search for mechanistically targeted therapies in this disease. (Circ Heart Fail. 2012;5:710-719.) C1 [Mohammed, Selma F.; Borlaug, Barry A.; Roger, Veronique L.; Rodeheffer, Richard J.; Redfield, Margaret M.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Roger, Veronique L.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA. [Mirzoyev, Sultan A.] Mayo Clin, Mayo Med Sch, Rochester, MN 55905 USA. [Chirinos, Julio A.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Redfield, MM (reprint author), Mayo Clin, Div Cardiovasc Dis, Guggenheim 9,200 1st St SW, Rochester, MN 55905 USA. EM redfield.margaret@mayo.edu OI Mirzoyev, Sultan/0000-0003-4819-6658 FU National Institutes of Health [HL72435, HL 55502, U01HL 84907, PO1HL 76611, HL080076, T32-HL0711]; American Heart Association [AHA 0885031N]; Mayo Clinic FX This study (HL72435 and HL 55502) and the investigators (Margaret M. Redfield, U01HL 84907, and PO1HL 76611; Julio A. Chirinos, HL080076 and AHA 0885031N; Selma F. Mohammed T32-HL0711) were supported by the National Institutes of Health, American Heart Association, and Mayo Clinic. NR 43 TC 72 Z9 73 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2012 VL 5 IS 6 BP 710 EP 719 DI 10.1161/CIRCHEARTFAILURE.112.968594 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 071GZ UT WOS:000313580100017 PM 23076838 ER PT J AU Carrion, IV Nedjat-Haiem, F Marquez, DX AF Carrion, I. V. Nedjat-Haiem, F. Marquez, D. X. TI OLDER LATINO MEN WITH CANCER: A STUDY OF THEIR TREATMENT DECISIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Carrion, I. V.] Univ S Florida, Tampa, FL USA. [Nedjat-Haiem, F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Marquez, D. X.] Univ Illinois, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 24 EP 24 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201127 ER PT J AU Bonner, L Lanto, A Bolkan, C Watson, G Campbell, DG Zivin, K Rubenstein, L AF Bonner, L. Lanto, A. Bolkan, C. Watson, G. Campbell, D. G. Zivin, K. Rubenstein, L. TI POSTTRAUMATIC STRESS DISORDER AND HELP-SEEKING FROM CLERGY AMONG VETERANS WITH DEPRESSION IN PRIMARY CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bonner, L.; Watson, G.] Vet Affairs Puget Sound, Seattle, WA USA. [Bolkan, C.] Washington State Univ, Vancouver, WA USA. [Campbell, D. G.] Univ Montana, Missoula, MT 59812 USA. [Lanto, A.; Rubenstein, L.] Vet Affairs Greater Los Angeles, Los Angeles, CA USA. [Zivin, K.] Vet Affairs Ann Arbor, Ann Arbor, MI USA. [Zivin, K.] Univ Michigan, Ann Arbor, MI 48109 USA. [Rubenstein, L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Bonner, L.; Watson, G.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 41 EP 41 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201206 ER PT J AU Rivero, T Hughes, J Martin, JL Kramer, B AF Rivero, T. Hughes, J. Martin, J. L. Kramer, B. TI VETERANS HEALTH ADMINISTRATION ADULT DAY HEALTH CARE PROGRAMS: VARIATIONS AND COMMON FEATURES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rivero, T.; Hughes, J.; Martin, J. L.; Kramer, B.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 42 EP 42 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201212 ER PT J AU Stripling, A Dautovich, ND Heesacker, M AF Stripling, A. Dautovich, N. D. Heesacker, M. TI AS DAYS GO BY: AN EXAMINATION OF INTRA-INDIVIDUAL VARIABILITY IN SUBJECTIVE AGING AND SELECT CORRELATES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Stripling, A.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Dautovich, N. D.] Univ Alabama, Tuscaloosa, AL USA. [Heesacker, M.] Univ Florida, Gainesville, FL USA. RI Stripling, Ashley/D-8421-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 47 EP 47 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201234 ER PT J AU Tomko, J Lloyd, A Hennon, JG Hall, SB Husted, J Zana, K Sykes, D AF Tomko, J. Lloyd, A. Hennon, J. G. Hall, S. B. Husted, J. Zana, K. Sykes, D. TI IN-HOME CARE COORDINATION AND INTENSIVE CAREGIVER SUPPORT FOR CAREGIVERS OF VETERANS WITH DEMENTIA SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Tomko, J.; Lloyd, A.; Hennon, J. G.; Hall, S. B.; Husted, J.; Zana, K.; Sykes, D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 52 EP 52 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201255 ER PT J AU Haley, PP Allen, RS AF Haley, P. P. Allen, R. S. TI LONGITUDINAL CHANGES IN EXPECTATIONS FOR NURSING HOME USE IN THE HEALTH AND RETIREMENT STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Haley, P. P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Haley, P. P.; Allen, R. S.] Univ Alabama, Dept Psychol, Ctr Mental Hlth & Aging, Tuscaloosa, AL 35487 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 76 EP 77 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201359 ER PT J AU Santos-Modesitt, W Yaffe, K Byers, AL Simonsick, EM Satterfield, S Cauley, JA Harris, TB Barnes, DE AF Santos-Modesitt, W. Yaffe, K. Byers, A. L. Simonsick, E. M. Satterfield, S. Cauley, J. A. Harris, T. B. Barnes, D. E. TI BRAIN-DERIVED NEUROTROPHIC FACTOR AND DEPRESSIVE SYMPTOMS IN THE HEALTH ABC STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Santos-Modesitt, W.; Yaffe, K.; Byers, A. L.; Barnes, D. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Santos-Modesitt, W.; Yaffe, K.; Byers, A. L.; Barnes, D. E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Simonsick, E. M.; Harris, T. B.] NIA, NIH, Bethesda, MD 20892 USA. [Satterfield, S.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Cauley, J. A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 97 EP 97 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201445 ER PT J AU Barnes, DE Santos-Modesitt, W Byers, AL Poelke, G Goodson, W Middleton, LE Yaffe, K AF Barnes, D. E. Santos-Modesitt, W. Byers, A. L. Poelke, G. Goodson, W. Middleton, L. E. Yaffe, K. TI THE MENTAL ACTIVITY AND EXERCISE (MAX) TRIAL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Barnes, D. E.; Santos-Modesitt, W.; Byers, A. L.; Goodson, W.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Barnes, D. E.; Santos-Modesitt, W.; Byers, A. L.; Poelke, G.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Middleton, L. E.] Univ Waterloo, Waterloo, ON N2L 3G1, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 101 EP 101 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201462 ER PT J AU Barnes, DE Chesney, MA Yaffe, K Flores, C Wu, E Mehling, WE AF Barnes, D. E. Chesney, M. A. Yaffe, K. Flores, C. Wu, E. Mehling, W. E. TI PREVENTING LOSS OF INDEPENDENCE THROUGH EXERCISE (PLIE) FOR OLDER ADULTS WITH DEMENTIA SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chesney, M. A.; Wu, E.; Mehling, W. E.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Barnes, D. E.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Flores, C.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Flores, C.] Inst Aging, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 102 EP 103 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201467 ER PT J AU Roiland, R Heidrich, SM AF Roiland, R. Heidrich, S. M. TI A CROSS-TIME EXPLORATION OF INFLAMMATION, PSYCHOLOGICAL WELL - BEING AND FRAILTY IN OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Roiland, R.] Univ Wisconsin, Sch Nursing, Madison, WI USA. [Heidrich, S. M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 181 EP 181 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888201815 ER PT J AU Mavandadi, S Miller, B Sorkin, D Oslin, D AF Mavandadi, S. Miller, B. Sorkin, D. Oslin, D. TI THE RELATIONSHIP BETWEEN CULTURAL PREFERENCES AND CLINICAL OUTCOMES AMONG OLDER ADULTS RECEIVING MENTAL HEALTH CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mavandadi, S.; Miller, B.; Oslin, D.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Mavandadi, S.; Oslin, D.] Univ Penn, Philadelphia, PA 19104 USA. [Sorkin, D.] Univ Calif Irvine, Irvine, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 186 EP 186 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202014 ER PT J AU Johnson, MD Apesoa-Varano, E Hay, J Unutzer, J Hinton, L AF Johnson, M. D. Apesoa-Varano, E. Hay, J. Unutzer, J. Hinton, L. TI DEPRESSION TREATMENT PREFERENCES OF OLDER WHITE AND MEXICAN AMERICAN MEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Johnson, M. D.] Univ Calif Los Angeles, W Los Angeles VA, Los Angeles, CA USA. [Apesoa-Varano, E.; Hinton, L.] Univ Calif Davis, Davis, CA USA. [Hay, J.] Univ So Calif, Los Angeles, CA USA. [Unutzer, J.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 272 EP 272 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202410 ER PT J AU Barnes, DE Palmer, RM Fortinsky, RH Boscardin, J Kirby, K Mehta, K Counsell, SR Landefeld, C AF Barnes, D. E. Palmer, R. M. Fortinsky, R. H. Boscardin, J. Kirby, K. Mehta, K. Counsell, S. R. Landefeld, C. TI A TOOL TO PREDICT RECOVERY, DEPENDENCE OR DEATH IN OLDER ADULTS WHO BECOME DISABLED DURING HOSPITALIZATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Barnes, D. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Barnes, D. E.; Boscardin, J.; Kirby, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Palmer, R. M.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Fortinsky, R. H.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Boscardin, J.; Kirby, K.; Mehta, K.; Landefeld, C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Mehta, K.] Stanford Univ, Stanford, CA 94305 USA. [Counsell, S. R.] Indiana Univ, Indianapolis, IN 46204 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 282 EP 282 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202460 ER PT J AU Hung, WW Morano, B Boockvar, K AF Hung, W. W. Morano, B. Boockvar, K. TI USE OF HEALTH INFORMATION TECHNOLOGY DURING CARE TRANSITIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.; Morano, B.; Boockvar, K.] James J Peters VA Med Ctr, Bronx, NY USA. [Hung, W. W.; Morano, B.; Boockvar, K.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 310 EP 310 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202605 ER PT J AU Csiszar, A Sosnowska, D Tucsek, Z Toth, P Colman, R Weindruch, R Anderson, R Ungvari, Z AF Csiszar, A. Sosnowska, D. Tucsek, Z. Toth, P. Colman, R. Weindruch, R. Anderson, R. Ungvari, Z. TI CIRCULATING FACTORS INDUCED BY CALORIC RESTRICTION IN THE NON-HUMAN PRIMATE MACACA MULATTA ACTIVATE ANGIOGENIC PROCESSES IN ENDOTHELIAL CELLS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Csiszar, A.; Sosnowska, D.; Tucsek, Z.; Toth, P.; Ungvari, Z.] Univ Oklahoma, Reynolds Oklahoma Ctr Aging, Dept Geriatr Med, Hlth Sci Ctr, Oklahoma City, OK USA. [Colman, R.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI USA. [Weindruch, R.; Anderson, R.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Weindruch, R.; Anderson, R.] Univ Wisconsin, Geriatr Res Educ & Clin Ctr, William S Middleton Mem Vet Hosp, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 316 EP 317 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202634 ER PT J AU Mair, CA Quinones, AR AF Mair, C. A. Quinones, A. R. TI FAMILY AVAILABILITY, NATIONAL HEALTHCARE INFRASTRUCTURE, AND SUPPORT PREFERENCES FOR OLDER ADULTS WITH CHRONIC DISEASE IN EUROPE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mair, C. A.] Univ Maryland Baltimore Cty, Dept Sociol & Anthropol, Baltimore, MD 21228 USA. [Quinones, A. R.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 322 EP 322 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202656 ER PT J AU Shrestha, S Armento, M Zeno, D Stanley, M Wilson, NL AF Shrestha, S. Armento, M. Zeno, D. Stanley, M. Wilson, N. L. TI ENGAGING AFRICAN-AMERICAN ELDERS IN LATE-LIFE ANXIETY TREATMENT RESEARCH SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Shrestha, S.; Armento, M.; Stanley, M.; Wilson, N. L.] Baylor Coll Med, Houston, TX 77030 USA. [Shrestha, S.; Armento, M.; Zeno, D.; Stanley, M.] Michael E DeBakey Vet Affair Med Ctr, Houston, TX USA. [Stanley, M.] S Cent Mental Illness Res Educ & Clin Care, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 345 EP 345 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202753 ER PT J AU Canio, WC Connor, KI Vassar, SD Lee, ML Vickrey, BG Chodosh, J AF Canio, W. C. Connor, K. I. Vassar, S. D. Lee, M. L. Vickrey, B. G. Chodosh, J. TI THE IMPACT OF SOCIAL WORK CONSULTATION ON THE QUALITY OF DEMENTIA CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Canio, W. C.; Vassar, S. D.; Lee, M. L.; Vickrey, B. G.; Chodosh, J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Canio, W. C.; Connor, K. I.; Vassar, S. D.; Lee, M. L.; Vickrey, B. G.; Chodosh, J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Vickrey, B. G.; Chodosh, J.] RAND Hlth, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 351 EP 351 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202776 ER PT J AU Thielke, SM Kaye, J Hayes, T Mattek, NC Quinones, AR AF Thielke, S. M. Kaye, J. Hayes, T. Mattek, N. C. Quinones, A. R. TI DAILY OBSERVED WALKING SPEED AND SELF-REPORTED LOW MOOD IN COMMUNITY-DWELLING OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Thielke, S. M.] Univ Washington, Seattle, WA 98195 USA. [Thielke, S. M.] Puget Sound VA Med Ctr, Seattle, WA USA. [Kaye, J.; Hayes, T.; Mattek, N. C.; Quinones, A. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kaye, J.] Portland VA Med Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 352 EP 352 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888202780 ER PT J AU Huang, DL Chan, KC Young, BA AF Huang, D. L. Chan, K. C. Young, B. A. TI DENTAL CARE AND DENTITION STATUS ARE ASSOCIATED WITH QUALITY OF LIFE IN OLDER VETERANS WITH DIABETES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Huang, D. L.; Young, B. A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Huang, D. L.; Chan, K. C.; Young, B. A.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 378 EP 378 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203053 ER PT J AU Mori, T Crandall, CJ Merkin, S Seeman, T Binkley, N Greendale, GA Karlamangla, AS AF Mori, T. Crandall, C. J. Merkin, S. Seeman, T. Binkley, N. Greendale, G. A. Karlamangla, A. S. TI CHILDHOOD SOCIOECONOMIC STATUS AND ADULT BONE STRENGTH: FINDINGS FROM THE MIDLIFE IN THE US STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mori, T.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Mori, T.] UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA. [Crandall, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Merkin, S.; Seeman, T.; Greendale, G. A.; Karlamangla, A. S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Binkley, N.] Univ Wisconsin, Osteoporosis Clin Ctr, Madison, WI USA. [Binkley, N.] Univ Wisconsin, Res Program, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 378 EP 378 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203054 ER PT J AU Brown, RT Steinman, M AF Brown, R. T. Steinman, M. TI CHARACTERISTICS OF US EMERGENCY DEPARTMENT VISITS BY OLDER HOMELESS ADULTS: RESULTS FROM A NATIONALLY REPRESENTATIVE SURVEY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Brown, R. T.; Steinman, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Brown, R. T.; Steinman, M.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 385 EP 385 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203085 ER PT J AU Boockvar, K Hung, WW Morano, B AF Boockvar, K. Hung, W. W. Morano, B. TI A RHIO ENHANCED CARE TRANSITIONS INTERVENTION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Boockvar, K.; Hung, W. W.; Morano, B.] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 426 EP 426 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203279 ER PT J AU Kind, A Jensen, LL Barczi, S Bridges, AJ Kordahl, B Smith, MA Asthana, S AF Kind, A. Jensen, L. L. Barczi, S. Bridges, A. J. Kordahl, B. Smith, M. A. Asthana, S. TI THE VA COORDINATED-TRANSITIONAL CARE (C-TRAC) PROGRAM: A REGISTERED NURSE TELEPHONE-BASED INITIATIVE TO IMPROVE TRANSITIONS FOR HOSPITALIZED VETERANS WITH DEMENTIA AND OTHER HIGH-RISK CONDITIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kind, A.; Barczi, S.; Asthana, S.] Univ Wisconsin, Dept Med, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA. [Kind, A.; Barczi, S.; Asthana, S.] US Dept Vet Affairs, GRECC, William S Middleton Hosp, Madison, WI USA. [Smith, M. A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA. [Smith, M. A.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA. [Smith, M. A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 426 EP 426 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203278 ER PT J AU Carrion, IV Nedjat-Haiem, F AF Carrion, I. V. Nedjat-Haiem, F. TI CONDUCTING A QUALITATIVE STUDY WITH OLDER LATINO MEN WITH CANCER SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Carrion, I. V.] Univ S Florida, Tampa, FL USA. [Nedjat-Haiem, F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 439 EP 440 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203346 ER PT J AU Byers, AL Neylan, TC Covinsky, K Yaffe, K AF Byers, A. L. Neylan, T. C. Covinsky, K. Yaffe, K. TI CHRONICITY OF PTSD AND RISK OF DISABILITY IN OLDER AMERICANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A. L.; Neylan, T. C.; Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, A. L.; Neylan, T. C.; Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 476 EP 476 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203527 ER PT J AU Nocera, J Yaffe, K Simonsick, EM Williamson, J Newman, AB Caserotti, P Harris, T Shorr, RI AF Nocera, J. Yaffe, K. Simonsick, E. M. Williamson, J. Newman, A. B. Caserotti, P. Harris, T. Shorr, R. I. TI EVALUATION OF BRAIN-DERIVED NEUROTROPHIC FACTOR AND PHYSICAL FUNCTION IN OLDER ADULTS FROM THE HEALTH ABC STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Nocera, J.; Shorr, R. I.] US Dept Vet Affairs, Gainesville, FL USA. [Nocera, J.; Shorr, R. I.] Univ Florida, Gainesville, FL USA. [Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Simonsick, E. M.; Harris, T.] NIH, Bethesda, MD 20892 USA. [Williamson, J.] Wake Forest Baptist Med Ctr, Winston Salem, NC USA. [Newman, A. B.] Univ Pittsburgh, Pittsburgh, PA USA. [Caserotti, P.] Univ So Denmark, Odense, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 508 EP 508 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203688 ER PT J AU Edes, T AF Edes, T. TI HOME BASED PRIMARY CARE: FROM VA EXPERIENCE TO EMERGENCE IN MEDICARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Edes, T.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 509 EP 509 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203693 ER PT J AU King, BJ Mahoney, JE Pecanac, KE Yoon, J Brown, RL AF King, B. J. Mahoney, J. E. Pecanac, K. E. Yoon, J. Brown, R. L. TI FREQUENCY AND DURATION OF NURSE-ASSISTED OLDER PATIENT AMBULATION IN A HOSPITAL SETTING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [King, B. J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Mahoney, J. E.; Pecanac, K. E.; Yoon, J.; Brown, R. L.] Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 569 EP 569 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204096 ER PT J AU Espinoza, SE Hazuda, HP AF Espinoza, S. E. Hazuda, H. P. TI NUMBER OF FRAILTY CHARACTERISTICS IS ASSOCIATED WITH HOSPITALIZATION IN OLDER MEXICAN AMERICANS AND EUROPEAN AMERICANS INDEPENDENTLY OF SOCIODEMOGRAPHIC FACTORS AND DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espinoza, S. E.; Hazuda, H. P.] UT Hlth Sci Ctr, San Antonio, TX USA. [Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 570 EP 570 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204101 ER PT J AU Pecanac, KE King, B Yoon, J Brown, RL Schiefelbein, T Bowers, B AF Pecanac, K. E. King, B. Yoon, J. Brown, R. L. Schiefelbein, T. Bowers, B. TI USE OF HAND HELD COMPUTERS TO DOCUMENT PHASES OF AMBULATION OF OLDER ADULTS IN A HOSPITAL SETTING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Pecanac, K. E.; Yoon, J.; Brown, R. L.; Schiefelbein, T.; Bowers, B.] Univ Wisconsin, Madison, WI USA. [King, B.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 571 EP 571 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204105 ER PT J AU Yoon, J King, BJ Pecanac, KE Bowers, B Brown, RL Schiefelbein, T AF Yoon, J. King, B. J. Pecanac, K. E. Bowers, B. Brown, R. L. Schiefelbein, T. TI A COMPARISON OF TIME-AND-MOTION OBSERVATION AND SELF-REPORT OF NURSE ASSISTED OLDER PATIENT AMBULATION IN HOSPITAL SETTINGS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Yoon, J.; Pecanac, K. E.; Bowers, B.; Brown, R. L.; Schiefelbein, T.] Univ Wisconsin, Sch Nursing, Madison, WI USA. [King, B. J.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 571 EP 571 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204104 ER PT J AU Damron-Rodriguez, J Frank, J Fassbinder, J Kramer, B AF Damron-Rodriguez, J. Frank, J. Fassbinder, J. Kramer, B. TI COMPETENCY-BASED POST-GRADUATE EDUCATION: MEASUREMENT DEVELOPMENT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Frank, J.; Fassbinder, J.; Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Damron-Rodriguez, J.] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA USA. [Fassbinder, J.] Calif Council Gerontol & Geriatr, Los Angeles, CA USA. [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 605 EP 606 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204248 ER PT J AU Quinn, LS Wolden-Hanson, T AF Quinn, L. S. Wolden-Hanson, T. TI ROLE OF INTERLEUKIN-15 IN EXERCISE ENDURANCE, ENERGY METABOLISM, AND BODY COMPOSITION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Quinn, L. S.; Wolden-Hanson, T.] VA Puget Sound Hlth Care Syst, GRECC S182, Seattle, WA USA. [Quinn, L. S.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 608 EP 608 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204261 ER PT J AU Mintzer, J Rosenberg, P Drye, L Scherer, R Herrmann, N Lanctot, K AF Mintzer, J. Rosenberg, P. Drye, L. Scherer, R. Herrmann, N. Lanctot, K. TI APATHY IN DEMENTIA METHYLPHENIDATE TRIAL (ADMET)- PRELIMINARY EFFICACY REPORT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mintzer, J.] Med Univ S Carolina, Alzheimers Res Program, N Charleston, SC USA. [Mintzer, J.] Med Univ S Carolina, Alzheimers Clin Program, N Charleston, SC USA. [Mintzer, J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Herrmann, N.; Lanctot, K.] Univ Toronto, Toronto, ON, Canada. [Herrmann, N.; Lanctot, K.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Rosenberg, P.; Drye, L.; Scherer, R.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 625 EP 625 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204343 ER PT J AU Hughes, J Jouldjian, S Alessi, C Washginton, DL Martin, JL AF Hughes, J. Jouldjian, S. Alessi, C. Washginton, D. L. Martin, J. L. TI SLEEP PROBLEMS AND PROBABLE PTSD AMONGST OLDER FEMALE VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hughes, J.; Jouldjian, S.; Alessi, C.; Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, North Hills, CA USA. [Alessi, C.; Washginton, D. L.; Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 645 EP 646 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204441 ER PT J AU Vuckovic, NH Edes, T Nichols, LO AF Vuckovic, N. H. Edes, T. Nichols, L. O. TI PATIENT EXPERIENCES OF INTERDISCIPLINARY SYMPTOM MANAGEMENT IN VA HOME BASED PRIMARY CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Vuckovic, N. H.] Intel Corp, Beaverton, OR USA. [Edes, T.] US Dept Vet Affairs, Washington, DC USA. [Nichols, L. O.] Vet Affairs Med Ctr, Memphis, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 655 EP 655 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204490 ER PT J AU Park, M Huang, DL AF Park, M. Huang, D. L. TI FINANCIAL SUPPORT AND DEPRESSION OUTCOMES AMONG OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Park, M.] Univ Washington, Seattle, WA 98195 USA. [Huang, D. L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 659 EP 659 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204509 ER PT J AU Allison, TA AF Allison, T. A. TI HOW ELDERS CREATE MEANING THROUGH SONG AND SELF-PRESENTATION IN A NURSING HOME SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Allison, T. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Allison, T. A.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 668 EP 668 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204550 ER PT J AU Puterman, E Epel, E Lin, J Blackburn, E Gross, J Whooley, M Cohen, B AF Puterman, E. Epel, E. Lin, J. Blackburn, E. Gross, J. Whooley, M. Cohen, B. TI A MULTISYSTEM PROTECTIVE PROFILE MODERATES THE DEPRESSION - LEUKOCYTE TELOMERE LENGTH ASSOCIATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Puterman, E.; Epel, E.; Lin, J.; Blackburn, E.; Whooley, M.; Cohen, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Whooley, M.; Cohen, B.] San Francisco VA Med Ctr, San Francisco, CA USA. [Gross, J.] Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 670 EP 670 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204565 ER PT J AU Howe, JL Griffith, JL AF Howe, J. L. Griffith, J. L. TI RURAL INTERDISCIPLINARY TEAM TRAINING FOR RURAL HEALTHCARE PROVIDERS: ENHANCING TEAM SKILLS TO IMPROVE CARE FOR OLDER VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Howe, J. L.; Griffith, J. L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Howe, J. L.; Griffith, J. L.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 680 EP 680 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204617 ER PT J AU Chernoff, R Howe, JL AF Chernoff, R. Howe, J. L. TI WEBINARS: A NEW APPROACH TO PROFESSIONAL EDUCATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chernoff, R.] Cent Arkansas Vet Healthcare Syst, GRECC, Little Rock, AR USA. [Howe, J. L.] VISN 3 GRECC Mt Sinai Sch Med, James J Peters VAMC, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 681 EP 681 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204618 ER PT J AU Stephens, C Sackett, N Schopfer, DW Schmajuk, G Moy, N Pierce, R Wallhagen, MI Lee, S AF Stephens, C. Sackett, N. Schopfer, D. W. Schmajuk, G. Moy, N. Pierce, R. Wallhagen, M. I. Lee, S. TI PATIENT AND PROVIDER PERSPECTIVES OF THE UNIQUE TRANSITIONAL CARE NEEDS OF REHOSPITALIZED VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Stephens, C.; Schopfer, D. W.; Schmajuk, G.; Moy, N.; Pierce, R.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Stephens, C.; Sackett, N.; Schmajuk, G.; Pierce, R.; Wallhagen, M. I.; Lee, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 683 EP 684 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204633 ER PT J AU Jacobson, KK AF Jacobson, K. K. TI WORKING TOGETHER IN A SKILLED NURSING FACILITY? THE IMPORTANCE OF A SPECIALIZED INTERDISCIPLINARY TEAM APPROACH WHEN CARING FOR RESIDENTS WHO ARE BEHAVIORALLY CHALLENGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Jacobson, K. K.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Jacobson, K. K.] John F Kennedy Univ, Pleasant Hill, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 696 EP 696 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204694 ER PT J AU Stripling, A AF Stripling, A. TI QUALITY OF LIFE IN A SKILLED NURSING FACILITY? IMPLEMENTING AND SUSTAINING A NON-PHARMACOLOGICAL INTERVENTION FOR RESIDENTS WHO ARE BEHAVIORALLY CHALLENGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Stripling, A.] San Francisco VA Med Ctr, Dept Geropsychiat, San Francisco, CA USA. RI Stripling, Ashley/D-8421-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 696 EP 696 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204693 ER PT J AU Sutherland, ES AF Sutherland, E. S. TI RAISING THE GAF WITH THE SOCIAL FOCUS COHORT: AN INNOVATIVE CLINICAL PRACTICE TO IMPROVE THE OVERALL QUALITY OF LIFE FOR RESIDENTS IN LONG-TERM CARE WHO ARE BEHAVIORALLY CHALLENGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sutherland, E. S.] San Francisco VA Med Ctr, Dept Geropsychiat, San Francisco, CA USA. [Sutherland, E. S.] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 696 EP 696 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204691 ER PT J AU Sutherland, ES AF Sutherland, E. S. TI BEHAVIORAL ISSUES IN A SKILLED NURSING FACILITY? DEVELOPING AND IMPLEMENTING AN INNOVATIVE CLINICAL PROGRAM FOR RESIDENTS WHO ARE BEHAVIORALLY CHALLENGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sutherland, E. S.] San Francisco VA Med Ctr, Dept Geropsychiat, San Francisco, CA USA. [Sutherland, E. S.] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 696 EP 696 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204692 ER PT J AU Cigolle, C Quinones, AR Bennett, JM Blaum, C Liang, J AF Cigolle, C. Quinones, A. R. Bennett, J. M. Blaum, C. Liang, J. TI ARE RESPONDENTS IN PANEL SURVEYS CONSISTENT IN THEIR SELF-REPORT OF CHRONIC DISEASES? SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Cigolle, C.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Cigolle, C.; Blaum, C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Cigolle, C.; Blaum, C.] VA Ann Arbor Geriatr Res Educ & Clin Ctr GRECC, Ann Arbor, MI USA. [Quinones, A. R.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Quinones, A. R.] Portland VA Med Ctr, Portland, OR USA. [Bennett, J. M.; Liang, J.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 704 EP 704 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204732 ER PT J AU Dodge, HH Bowman, G Katsumata, Y Ohya, Y Yasura, S Kaye, J Todoriki, H AF Dodge, H. H. Bowman, G. Katsumata, Y. Ohya, Y. Yasura, S. Kaye, J. Todoriki, H. TI THE ASSOCIATION BETWEEN SERUM OMEGA-3 FATTY ACIDS AND COGNITIVE FUNCTIONS AMONG THE OLDEST OLD IN OKINAWA, JAPAN: KOCOA PROJECT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dodge, H. H.; Bowman, G.; Katsumata, Y.; Kaye, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dodge, H. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Ohya, Y.; Todoriki, H.] Univ Ryukyus, Nishihara, Okinawa 90301, Japan. [Yasura, S.] Okinawa Int Univ, Okinawa, Japan. [Kaye, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 725 EP 725 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204833 ER PT J AU Ostroff, R Mehan, M Brody, E Stewart, A Williams, S Baron, A Feser, W Franklin, W Wolf, H Miller, Y AF Ostroff, R. Mehan, M. Brody, E. Stewart, A. Williams, S. Baron, A. Feser, W. Franklin, W. Wolf, H. Miller, Y. TI Proteomic Insights in Oncology: What Have We Learned From Measuring Millions of Proteins? SO EUROPEAN JOURNAL OF CANCER LA English DT Meeting Abstract CT 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 06-09, 2012 CL European Org Res & Treatment Canc (EORTC), Dublin, IRELAND SP Natl Canc Inst (NCI), Amer Assoc Canc Res (AACR), Novartis Oncol, TAIHO, Johnson&Johnson, Janssen Pharmaceut Co HO European Org Res & Treatment Canc (EORTC) C1 [Ostroff, R.; Brody, E.; Williams, S.] SomaLogic Inc, Med, Boulder, CO USA. [Mehan, M.; Stewart, A.] SomaLogic Inc, Bioinformat, Boulder, CO USA. [Baron, A.; Feser, W.; Franklin, W.; Wolf, H.; Miller, Y.] Univ Colorado, Ctr Canc, Denver, CO 80262 USA. [Miller, Y.] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PD NOV PY 2012 VL 48 SU 6 MA 460 BP 142 EP 142 PG 1 WC Oncology SC Oncology GA 060FX UT WOS:000312763000453 ER PT J AU Zolak, JS de Andrade, JA AF Zolak, Jason S. de Andrade, Joao A. TI Idiopathic Pulmonary Fibrosis SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA LA English DT Article DE Idiopathic pulmonary fibrosis; Pathogenesis; Diagnosis; Management ID ENDOPLASMIC-RETICULUM STRESS; INTERSTITIAL LUNG-DISEASE; PLACEBO-CONTROLLED TRIAL; ACID GASTROESOPHAGEAL-REFLUX; OXIDATIVE STRESS; ARTERIAL-HYPERTENSION; PREMATURE SENESCENCE; EPITHELIAL-CELLS; PREVALENCE; THERAPY AB Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown cause characterized by progressive scarring of the lung parenchyma and relentless loss of lung function. The diagnosis depends on close collaboration between clinicians, radiologists, and pathologists. No therapies approved by the Food and Drug Administration are available for IPF, and an analysis of completed clinical trials has demonstrated that the clinical course of IPF is largely unpredictable. Until therapies that improve survival become available, measures to preserve function and quality of life should be considered, and gastroesophageal reflux should be treated aggressively. C1 [de Andrade, Joao A.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Interstitial Lung Dis Program, Birmingham, AL 35294 USA. [de Andrade, Joao A.] Birmingham VA Med Ctr, Med Intens Care Unit, Birmingham, AL USA. RP de Andrade, JA (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Interstitial Lung Dis Program, 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA. EM joao@uab.edu FU NIH/NHLBI (IPFnet); Intermune; Actelion; Fibrogen; Centocor; Immuneworks; Gilead; Boehringer-Ingelheim; Celgene FX Funding sources: Dr Zolak: nil; Dr de Andrade: NIH/NHLBI (IPFnet), Intermune, Actelion, Fibrogen, Centocor, Immuneworks, Gilead, Boehringer-Ingelheim, and Celgene. NR 83 TC 1 Z9 2 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8561 J9 IMMUNOL ALLERGY CLIN JI Immunol. Allerg. Clin. North Am. PD NOV PY 2012 VL 32 IS 4 BP 473 EP + DI 10.1016/j.iac.2012.08.006 PG 14 WC Allergy; Immunology SC Allergy; Immunology GA 058FM UT WOS:000312619500004 PM 23102062 ER PT J AU Brody, A Sullivan-Marx, EM AF Brody, Abraham Sullivan-Marx, Eileen M. TI The Patient Protection and Affordable Care Act Implications for Geriatric Nurses and Patients SO JOURNAL OF GERONTOLOGICAL NURSING LA English DT Editorial Material C1 [Brody, Abraham; Sullivan-Marx, Eileen M.] NYU, Coll Nursing, New York, NY USA. [Brody, Abraham] James J Peters Bronx Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Brody, A (reprint author), NYU, Coll Nursing, New York, NY USA. OI Brody, Abraham/0000-0002-3405-7043 NR 10 TC 2 Z9 2 U1 0 U2 4 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0098-9134 J9 J GERONTOL NURS JI J. Gerontol. Nurs. PD NOV PY 2012 VL 38 IS 11 BP 3 EP 5 DI 10.3928/00989134-20121008-01 PG 3 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA 064AF UT WOS:000313042600001 PM 23126510 ER PT J AU Wiler, JL Handel, DA Ginde, AA Aronsky, D Genes, NG Hackman, JL Hilton, JA Hwang, U Kamali, M Pines, JM Powell, E Sattarian, M Fu, RW AF Wiler, Jennifer L. Handel, Daniel A. Ginde, Adit A. Aronsky, Dominik Genes, Nicholas G. Hackman, Jeffrey L. Hilton, Joshua A. Hwang, Ula Kamali, Michael Pines, Jesse M. Powell, Emilie Sattarian, Medhi Fu, Rongwei TI Predictors of patient length of stay in 9 emergency departments SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID AMBULANCE DIVERSION; VARIABLES; TRIAGE; TIME; CARE AB Objectives: Prolonged emergency department (ED) length of stay (LOS) is linked to adverse outcomes, decreased patient satisfaction, and ED crowding. This multicenter study identified factors associated with increased LOS. Methods: This retrospective study included 9 EDs from across the United States. Emergency department daily operational metrics were collected from calendar year 2009. A multivariable linear population average model was used with log-transformed LOS as the dependent variable to identify which ED operational variables are predictors of LOS for ED discharged, admitted, and overall ED patient categories. Results: Annual ED census ranged from 43 000 to 101 000 patients. The number of ED treatment beds ranged from 27 to 95. Median overall LOS for all sites was 5.4 hours. Daily percentage of admitted patients was found to be a significant predictor of discharged and admitted patient LOS. Higher daily percentage of discharged and eloped patients, more hours on ambulance diversion, and weekday (vs weekend) of patient presentation were significantly associated with prolonged LOS for discharged and admitted patients (P < .05). For each percentage of increase in discharged patients, there was a 1% associated decrease in overall LOS, whereas each percentage of increase in eloped patients was associated with a 1.2% increase in LOS. Conclusions: Length of stay was increased on days with higher percentage daily admissions, higher elopements, higher periods of ambulance diversion, and during weekdays, whereas LOS was decreased on days with higher numbers of discharges and weekends. This is the first study to demonstrate this association across a broad group of hospitals. (C) 2012 Elsevier Inc. All rights reserved. C1 [Wiler, Jennifer L.; Ginde, Adit A.] Univ Colorado Denver SOM, Dept Emergency Med, Aurora, CO 80045 USA. [Wiler, Jennifer L.] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63110 USA. [Handel, Daniel A.] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, Portland, OR 97239 USA. [Aronsky, Dominik] Vanderbilt Univ, Dept Biomed Informat & Emergency Med, Nashville, TN 37232 USA. [Genes, Nicholas G.; Hwang, Ula] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Hackman, Jeffrey L.] Univ Missouri, Truman Med Ctr, Dept Emergency Med, Kansas City, MO 64139 USA. [Hilton, Joshua A.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Hwang, Ula] James J Peters VAMC, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Kamali, Michael] Univ Rochester, Dept Emergency Med, Rochester, NY 14642 USA. [Pines, Jesse M.] George Washington Univ, Sch Med, Dept Emergency Med, Washington, DC 20037 USA. [Pines, Jesse M.] George Washington Sch Publ Hlth, Dept Hlth Policy, Washington, DC 20037 USA. [Powell, Emilie] Northwestern Univ, Feinberg Sch Med, Dept Emergency Med, Chicago, IL 60611 USA. [Fu, Rongwei] Oregon Hlth & Sci Univ, Dept Emergency Med & Publ Hlth & Prevent Med, Portland, OR 97239 USA. RP Wiler, JL (reprint author), Univ Colorado Denver SOM, Dept Emergency Med, Aurora, CO 80045 USA. EM jennifer.wiler@ucdenver.edu RI Wiler, Jennifer/G-7676-2016; bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017 OI Genes, Nicholas/0000-0002-9836-2477 FU NIA NIH HHS [K24 AG022345] NR 25 TC 12 Z9 12 U1 1 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD NOV PY 2012 VL 30 IS 9 BP 1860 EP 1864 DI 10.1016/j.ajem.2012.03.028 PG 5 WC Emergency Medicine SC Emergency Medicine GA 049QD UT WOS:000311997600029 PM 22633732 ER PT J AU Vazirani, S Lankarani-Fard, A Liang, LJ Stelzner, M Asch, SM AF Vazirani, Sondra Lankarani-Fard, Azadeh Liang, Li-Jung Stelzner, Matthias Asch, Steven M. TI Perioperative processes and outcomes after implementation of a hospitalist-run preoperative clinic SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID NONCARDIAC SURGERY; CARDIOVASCULAR EVALUATION; MEDICAL CONSULTATION; BETA-BLOCKERS; CARE; GUIDELINES; MANAGEMENT; INPATIENTS; ISSUES; TRIAL AB BACKGROUND: A structured, medical preoperative evaluation may positively impact the perioperative course of medically complex patients. Hospitalists are in a unique position to assist in preoperative evaluations, given their expertise with inpatient medicine and postoperative surgical consultation. OBJECTIVE: To evaluate specific outcomes after addition of a Hospitalist-run, medical Preoperative clinic to the standard Anesthesia preoperative evaluation. DESIGN, SETTING, PATIENTS: A pre/post retrospective, comparative review of outcomes of 5223 noncardiac surgical patients at a tertiary care Veterans Administration (VA) medical center. RESULTS: Length of stay was reduced for inpatients with an American Society of Anesthesia (ASA) score of 3 or higher (P < 0.0001). There was a trend towards a reduction in same-day, medically avoidable surgical cancellations (8.5% vs 4.9%, P = 0.065). More perioperative beta blockers were used (P < 0.0001) and more stress tests were ordered (P = 0.012). Inpatient mortality rates were reduced (1.27% vs 0.36%, P = 0.0158). CONCLUSION: A structured medical preoperative evaluation may benefit medically complex patients and improve perioperative processes and outcomes. Journal of Hospital Medicine 2012. (c) 2012 Society of Hospital Medicine C1 [Vazirani, Sondra; Lankarani-Fard, Azadeh] Univ Calif Los Angeles, David Geffen Sch Med, Hospitalist Div, VA Greater Los Angeles Healthcare Syst,Dept Med, Los Angeles, CA 90073 USA. [Liang, Li-Jung] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90073 USA. [Stelzner, Matthias] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA. [Asch, Steven M.] VA Palo Alto, Hlth Serv Res, Palo Alto, CA USA. RP Vazirani, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Hospitalist Div, VA Greater Los Angeles Healthcare Syst,Dept Med, 11301 Wilshire Blvd,Mail Code 10H1-111, Los Angeles, CA 90073 USA. EM Sondra.vazirani@va.gov NR 19 TC 9 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD NOV-DEC PY 2012 VL 7 IS 9 BP 697 EP 701 DI 10.1002/jhm.1968 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 053AK UT WOS:000312241600006 PM 22961756 ER PT J AU Kangovi, S Grande, D Meehan, P Mitra, N Shannon, R Long, JA AF Kangovi, Shreya Grande, David Meehan, Patricia Mitra, Nandita Shannon, Richard Long, Judith A. TI Perceptions of readmitted patients on the transition from hospital to home SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID SOCIOECONOMIC-STATUS; READMISSIONS; QUALITY; RISK; CARE; REHOSPITALIZATION; MANAGEMENT; DISCHARGE; COVERAGE AB BACKGROUND: Hospital leaders have had mixed success reducing readmissions Little is known about the readmitted patient's perspective. METHODS: A cross-sectional 36-item survey was administered to 1084 readmitted inpatients of The Hospital of the University of Pennsylvania (an urban academic medical center) and Penn Presbyterian Medical Center (an urban community hospital) between November 10, 2010 and July 5, 2011. The survey response rate was 32.9%. RESULTS: The most commonly reported issues contributing to readmission were: 1) feeling unprepared for discharge (11.8%); 2) difficulty performing activities of daily living (ADLs) (10.6%); 3) trouble adhering to discharge medications (5.7%); 4) difficulty accessing discharge medications (5.0%); and 5) lack of social support (4.7%). Low-socioeconomic status (SES) (defined as uninsured or Medicaid) patients were more likely than high-SES patients to report difficulty understanding (odds ratio [OR] 2.7; 95% confidence interval [CI] 1.1, 6.6) and executing (OR 2.2; 95% CI 1.1, 4.4) discharge instructions, difficulty adhering to medications (OR 1.8; 95% CI 1.2, 3.0), lack of social support (OR 2.0; 95% CI 1.2, 3.6), lack of basic resources (OR 2.6; 95% CI 1.1, 6.1), and substance abuse (OR 6.7; 95% CI 2.3, 19.2). CONCLUSIONS: Patients reported transition challenges which they believe contribute to illness relapse and readmission. Interventions designed to address these challenges, and tailored for patient characteristics such as SES, may better address the root causes of readmission. Journal of Hospital Medicine 2012. (c) 2012 Society of Hospital Medicine C1 [Kangovi, Shreya] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Grande, David; Shannon, Richard; Long, Judith A.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Grande, David; Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Meehan, Patricia] Univ Penn Hlth Syst, Dept Social Work, Philadelphia, PA USA. [Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Kangovi, S (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, 423 Guardian Dr,13th Floor,Blockley Hall, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu FU Leonard Davis Institute of Health Economics; HealthWell Foundation; National Human Genome Research Institute; Agency for Healthcare Research and Quality FX Disclosures: Support for this study was provided by a grant from the Leonard Davis Institute of Health Economics. Dr Grande has received honoraria from the Johns Hopkins University CME Program; has a consultancy with the National Nursing Centers Consortium; and has received grant support from, or has grants pending with, the HealthWell Foundation, the National Human Genome Research Institute, and the Agency for Healthcare Research and Quality. Dr Shannon is the founder of a biotech company, Ventrigen, LLC; is a senior fellow at IHI; is on the scientific advisory boards for Glasgow Smith Klein, Pfizer, Merck, and Value Capture; and is a member of the Board of Directors of the ABIM. NR 17 TC 25 Z9 25 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD NOV-DEC PY 2012 VL 7 IS 9 BP 709 EP 712 DI 10.1002/jhm.1966 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 053AK UT WOS:000312241600009 PM 23212980 ER PT J AU Mathias, SD Chren, MM Yim, YM Colwell, HH Reyes, C Chen, DM Fosko, SW AF Mathias, S. D. Chren, M. M. Yim, Y. M. Colwell, H. H. Reyes, C. Chen, D. M. Fosko, S. W. TI ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR ADVANCED BASAL CELL CARCINOMA (ABCC) AND BASAL CELL CARCINOMA NEVUS SYNDROME (BCCNS): DEVELOPMENT OF THE FIRST DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) QUESTIONNAIRE SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Mathias, S. D.; Colwell, H. H.] Hlth Outcomes Solut, Winter Pk, FL USA. [Chren, M. M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Yim, Y. M.; Reyes, C.; Chen, D. M.] Genentech Inc, San Francisco, CA 94080 USA. [Fosko, S. W.] St Louis Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD NOV PY 2012 VL 15 IS 7 BP A430 EP A430 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 055JF UT WOS:000312411100807 ER PT J AU Schlosser, RJ AF Schlosser, Rodney J. TI To Balloon or Not to Balloon? SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article C1 [Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg Otolaryngol, Charleston, SC USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,Ste 1130,POB 250550, Charleston, SC 29425 USA. EM schlossr@musc.edu NR 6 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD NOV PY 2012 VL 138 IS 11 BP 1080 EP 1081 PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 055FH UT WOS:000312400100013 PM 23165384 ER PT J AU Merkow, RP Bilimoria, KY McCarter, MD Phillips, JD DeCamp, MM Sherman, KL Ko, CY Bentrem, DJ AF Merkow, Ryan P. Bilimoria, Karl Y. McCarter, Martin D. Phillips, Joseph D. DeCamp, Malcolm M. Sherman, Karen L. Ko, Clifford Y. Bentrem, David J. TI Short-term Outcomes After Esophagectomy at 164 American College of Surgeons National Surgical Quality Improvement Program Hospitals Effect of Operative Approach and Hospital-Level Variation SO ARCHIVES OF SURGERY LA English DT Article ID LIMITED TRANSHIATAL RESECTION; ESOPHAGUS; ADENOCARCINOMA; CARCINOMA; SURVIVAL; CANCER; IMPACT AB Hypothesis: When assessing the effect of operative approach on outcomes, it may be less relevant whether a transhiatal or an Ivor Lewis esophagectomy was performed and may be more important to focus on patient selection and the quality of the hospital performing the operation. Design: Observational study. Setting: Hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program. Patients: Individuals undergoing esophagectomy were identified from January 1, 2005, to December 31, 2010. The following 4 groups were created based on operative approach: transhiatal, Ivor Lewis, 3-field, and any approach with an intestinal conduit. Main Outcome Measures: Risk-adjusted 30-day outcomes and hospital-level variation in performance. Results: At 164 hospitals, 1738 patients underwent an esophageal resection: 710 (40.9%) were transhiatal, 497 (28.6%) were Ivor Lewis, 361 (20.8%) were 3-field, and 170 (9.8%) were intestinal conduits. Compared with the transhiatal approach, Ivor Lewis esophagectomy was not associated with increased risk for postoperative complications; however, 3-field esophagectomy was associated with increased likelihood of postoperative pneumonia (odds ratio [OR], 1.88; 95% CI, 1.28-2.77) and prolonged ventilation exceeding 48 hours (OR, 1.68; 95% CI, 1.16-2.42). Intestinal conduit use was associated with increased 30-day mortality (OR, 2.65; 95% CI, 1.08-6.47), prolonged ventilation exceeding 48 hours (OR, 1.61; 95% CI, 1.01-2.54), and return to the operating room for any indication (OR, 1.85; 95% CI, 1.16-2.96). Patient characteristics were the strongest predictive factors for 30-day mortality and serious morbidity. After case-mix adjustment, hospital performance varied by 161% for 30-day mortality and by 84% for serious morbidity. Conclusions: Compared with transhiatal dissection, Ivor Lewis esophagectomy did not result in worse postoperative complications. After controlling for case-mix, hospital performance varied widely for all outcomes assessed, indicating that reductions in short-term outcomes will likely result from expanding other aspects of hospital quality beyond a focus on specific technical maneuvers. Arch Surg. 2012;147(11):1009-1016 C1 [Merkow, Ryan P.; Bilimoria, Karl Y.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bilimoria, Karl Y.; Phillips, Joseph D.; DeCamp, Malcolm M.; Sherman, Karen L.; Bentrem, David J.] Northwestern Univ, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Feinberg Sch Med, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA. [Merkow, Ryan P.; McCarter, Martin D.] Univ Colorado Denver Anschutz Med Campus, Dept Surg, Aurora, CO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM rmerkow@facs.org FU American College of Surgeons Clinical Scholars in Residence Program; Career Development Award from the Health Services Research Division, Department of Veterans Affairs FX Dr Merkow is supported by the American College of Surgeons Clinical Scholars in Residence Program. Dr Bentrem is supported by a Career Development Award from the Health Services Research Division, Department of Veterans Affairs. NR 22 TC 19 Z9 19 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD NOV PY 2012 VL 147 IS 11 BP 1009 EP 1016 PG 8 WC Surgery SC Surgery GA 055EG UT WOS:000312397400006 PM 23165615 ER PT J AU Conners, EE Hagedorn, HJ Butler, JN Felmet, K Hoang, T Wilson, P Klima, G Sudzina, E Anaya, HD AF Conners, E. E. Hagedorn, H. J. Butler, J. N. Felmet, K. Hoang, T. Wilson, P. Klima, G. Sudzina, E. Anaya, H. D. TI Evaluating the implementation of nurse-initiated HIV rapid testing in three Veterans Health Administration substance use disorder clinics SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; AIDS; screening; nurse initiated; rapid test; Veterans Health Administration; substance use disorder ID CARE SETTINGS; PHYSICIANS AB Individuals with substance use disorders (SUDs) are at higher risk of HIV infection, yet recent studies show rates of HIV testing are low among this population. We implemented and evaluated a nurse-initiated HIV oral rapid testing (NRT) strategy at three Veterans Health Administration SUD clinics. Implementation of NRT includes streamlined nurse training and a computerized clinical reminder. The evaluation employed qualitative interviews with staff and a quantitative evaluation of HIV testing rates. Barriers to testing included lack of laboratory support and SUD nursing resistance to performing medical procedures. Facilitators included the ease of NAT integration into workflow, engaged management and an existing culture of disease prevention. Six-months post intervention, rapid testing rates at SUD clinics in sites 1, 2, and 3 were 5.0%, 1.1% and 24.0%, respectively. Findings indicate that NAT can be successfully incorporated into some types of SUD subclinics with minimal perceived impact on workflow and time. C1 [Conners, E. E.; Butler, J. N.; Hoang, T.; Anaya, H. D.] VA Greater Los Angeles Healthcare Syst, Vet Affairs Qual Enhancement Res Initiat QUERI HI, Los Angeles, CA USA. [Conners, E. E.; Butler, J. N.; Hoang, T.; Anaya, H. D.] Ctr Excellence Study Healthcare Provider Behav, VA Hlth Serv Res & Dev HSR&D, Los Angeles, CA USA. [Hagedorn, H. J.] Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Hagedorn, H. J.] Minneapolis VA Healthcare Syst, VA QUERI Subst Use Disorders, Minneapolis, MN USA. [Felmet, K.] Georgia State Univ, Atlanta, GA 30303 USA. [Felmet, K.; Wilson, P.; Klima, G.; Sudzina, E.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Anaya, H. D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Anaya, H. D.] VA Chicago Healthcare Syst, VA Ctr Management Complex Chron Condit CMC3, Chicago, IL USA. [Anaya, H. D.] VA Chicago Healthcare Syst, Qual Enhancement Res Initiat Spinal Cord Injury S, Chicago, IL USA. RP Conners, EE (reprint author), 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA. EM conners84@gmail.com FU VA Quality Enhancement Research Initiative (QUERI) [RRP 09-122]; Department of Veterans Affairs, Veterans Health Administration (VHA), Health Services Research and Development Service (HSRD) FX The authors would like to thank Dr Matthew Goetz, Dr Herschel Knapp, Dr Gretchen Haas, Dr Dmitriy Gutkin, and Helen Bonanomi for their invaluable assistance on this project. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. This research was funded by VA Quality Enhancement Research Initiative (QUERI) grant RRP 09-122 awarded to the last author and supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), Health Services Research and Development Service (HSR&D). This study was reviewed and sanctioned by a US Department of Veterans Affairs Institutional Review Board (IRB) process. The last author owns stock in a company that develops biotechnological products, one of which is a RT for diagnosing HIV and is also principal investigator on an external HIV linkage to care grant. NR 17 TC 6 Z9 6 U1 0 U2 6 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD NOV PY 2012 VL 23 IS 11 BP 799 EP 805 DI 10.1258/ijsa.2012.012050 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 054OD UT WOS:000312352200008 PM 23155100 ER PT J AU Liu, XH Yao, S Levine, AC Kirschenbaum, A Pan, JP Wu, Y Qin, WP Collier, L Bauman, WA Cardozo, CP AF Liu, Xin-Hua Yao, Shen Levine, Alice C. Kirschenbaum, Alexander Pan, Jiangping Wu, Yong Qin, Weiping Collier, Lauren Bauman, William A. Cardozo, Christopher P. TI Nandrolone, an Anabolic Steroid, Stabilizes Numb Protein Through Inhibition of mdm2 in C2C12 Myoblasts SO JOURNAL OF ANDROLOGY LA English DT Article DE Androgen receptor; skeleton muscle; notch signaling ID POSTNATAL MYOGENESIS; UBIQUITIN LIGASE; SKELETAL-MUSCLE; CELL ACTIVATION; MAMMALIAN NUMB; NOTCH; DIFFERENTIATION; TESTOSTERONE; HYPERTROPHY; ANDROGENS AB Nandrolone, an anabolic steroid, slows denervation atrophy of rat muscle, prevents denervation-induced nuclear accumulation of intracellular domain of the Notch receptor, and elevates expression of Numb. Numb acts as an inhibitor of Notch signaling and promotes myogenic differentiation of satellite cells. Turnover of Numb is regulated by mdm2, an E3 ubiquitin ligase. With these considerations in mind, we investigated the effects of nandrolone on the expression of Numb and mdm2 proteins and determined the effect of mdm2 on nandrolone-induced alterations in Numb protein in C2C12 myoblasts. When C2C12 cells were cultured in a medium favoring differentiation (Dulbecco modified Eagle medium containing 2% horse serum), nandrolone up-regulated Numb protein levels in a time-dependent manner and prolonged Numb protein half-life from 10 to 18 hours. In contrast, nandrolone reduced the expression of mdm2 protein. To determine whether the decreased mdm2 expression induced by nandrolone was responsible for the increased levels and prolonged half-life of Numb protein in this cell line, mdm2 small interfering RNA (siRNA) was employed to inhibit mdm2 expression. Compared to cells transfected with scrambled siRNA (negative control), transfection with mdm2-siRNA increased basal Numb protein expression but abolished the further increase in Numb protein levels by nandrolone. In addition, transfection of mdm2-siRNA mimicked the effect of nandrolone to prolong the half-life of Numb protein. Moreover, when C2C12 cells were forced to overexpress mdm2, there was a significant decline in the expression of both basal and inducible Numb protein. Our data suggest that nandrolone, by a novel mechanism for this agent in a muscle cell type, increases Numb protein levels in C2C12 myoblasts by stabilizing Numb protein against degradation, at least in part, via suppression of mdm2 expression. C1 [Liu, Xin-Hua; Pan, Jiangping; Wu, Yong; Qin, Weiping; Collier, Lauren; Bauman, William A.; Cardozo, Christopher P.] James J Peter VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA. [Liu, Xin-Hua; Yao, Shen; Levine, Alice C.; Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Levine, Alice C.; Kirschenbaum, Alexander] Mt Sinai Sch Med, Dept Urol, New York, NY USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Cardozo, CP (reprint author), James J Peter VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, F7756R, F6997R] FX Supported by the Veterans Health Administration, Rehabilitation Research and Development Service (grants B4162C, F7756R, and F6997R). NR 29 TC 3 Z9 3 U1 1 U2 5 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 EI 1939-4640 J9 J ANDROL JI J. Androl. PD NOV-DEC PY 2012 VL 33 IS 6 BP 1216 EP 1223 DI 10.2164/jandrol.112.016428 PG 8 WC Andrology SC Endocrinology & Metabolism GA 051GC UT WOS:000312113200021 PM 22700758 ER PT J AU Singh, JA Sperling, JW Schleck, C Harmsen, WS Cofield, RH AF Singh, Jasvinder A. Sperling, John W. Schleck, Cathy Harmsen, William S. Cofield, Robert H. TI Periprosthetic infections after total shoulder arthroplasty: a 33-year perspective SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Total shoulder arthroplasty; periprosthetic infections ID QUALITY-OF-LIFE; HIP-ARTHROPLASTY; REIMPLANTATION; COMPLICATIONS; MORBIDITY AB Background: To examine the rates and predictors of deep periprosthetic infections after primary total shoulder arthroplasty (TSA). Methods: We used prospectively collected data on all primary TSA patients from 1976-2008 at Mayo Clinic Medical Center. We estimated survival free of deep periprosthetic infections after primary TSA using Kaplan-Meier survival. Univariate and multivariable Cox regression was used to assess the association of patient-related factors (age, gender, body mass index), comorbidity (Deyo-Charlson index), American Society of Anesthesiologists class, implant fixation, and underlying diagnosis with risk of infection. Results: A total of 2,207 patients, with a mean age of 65 years (SD, 12 years), 53% of whom were women, underwent 2,588 primary TSAs. Mean follow-up was 7 years (SD, 6 years), and the mean body mass index was 30 kg/m(2) (SD, 6 kg/m(2)). The American Society of Anesthesiologists class was 1 or 2 in 61% of cases. Thirty-two confirmed deep periprosthetic infections occurred during follow-up. In earlier years, Staphylococcus predominated; in recent years, Propionibacterium acnes was almost as common. The 5-, 10-, and 20-year prosthetic infection-free rates were 99.3% (95% confidence interval [CI], 98.9-99.6), 98.5% (95% CI, 97.8-99.1), and 97.2% (95% CI, 96.0-98.4), respectively. On multivariable analysis, a male patient had a significantly higher risk of deep periprosthetic infection (hazard ratio, 2.67 [95% CI, 1.22-5.87]; P = .01) and older age was associated with lower risk (hazard ratio, 0.97 [95% CI, 0.95-1.00] per year; P = .05). Conclusions: The periprosthetic infection rate was low at 20-year follow-up. Male gender and younger age were significant risk factors for deep periprosthetic infections after TSA. Future studies should investigate whether differences in bone morphology, medical comorbidity, or other factors are underlying these associations. Level of evidence: Level IV, Case Series, Treatment Study. (C) 2012 Journal of Shoulder and Elbow Surgery Board of Trustees. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Sperling, John W.; Cofield, Robert H.] Mayo Clin, Dept Orthopaed Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health Clinical Translational Science Award (Mayo Clinic Center for Clinical and Translational Research) [1 KL2 RR024151-01]; Allergan; Takeda; Savient; Wyeth; Amgen; Tornier; URL Pharmaceuticals; Novartis FX This material is the result of work supported by National Institutes of Health Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and the use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA.; There are no financial conflicts related to this work. J.A.S. has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen; and consultant fees from Savient, URL Pharmaceuticals, and Novartis. J.W.S. has received royalties from Aircast and Biomet and consultant fees from Tornier and owns stock in Tornier. R.H.C. has received royalties from Smith & Nephew. NR 17 TC 54 Z9 55 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD NOV PY 2012 VL 21 IS 11 BP 1534 EP 1541 DI 10.1016/j.jse.2012.01.006 PG 8 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 049RH UT WOS:000312000600019 PM 22516570 ER PT J AU Sun, HY Wagener, M Cacciarelli, TV Singh, N AF Sun, Hsin-Yun Wagener, Marilyn Cacciarelli, Thomas V. Singh, Nina TI Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients SO CLINICAL TRANSPLANTATION LA English DT Article DE early post-transplant Infections; hepatic encephalopathy; liver transplant; multidrug-resistant bacteria; rifaximin ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MULTICENTER; EFFICACY; DIARRHEA AB Background: Whether the use of rifaximin for hepatic encephalopathy during liver transplant candidacy has an impact on post-transplant infections is not known. Methods: We compared the frequency and spectrum of infections within 90 d post-transplant in liver transplant recipients who did and did not receive rifaximin for hepatic encephalopathy during transplant candidacy. Results: Of 110 consecutive liver transplant recipients, 30 (27%) received rifaximin. Rifaximin users were more severely ill based on higher Model for End-Stage Liver Disease (MELD) score (p = 0.005). When controlled for MELD (stratified by MELD < 30, MELD >= 30), the risk of infections was significantly lower in rifaximin vs. no rifaximin recipients (OR = 0.269, 95% CI 0.078-0.0.934, p = 0.026). Rifaximin use was not associated with a higher risk of multidrug resistant bacterial infections (OR = 1.8, 95% CI 0.42-8.35, p = 0.40). The probability of post-transplant survival at 90 d did not differ for patients with or without rifaximin use (0.90 for both groups, p = 0.56). Conclusions: Rifaximin appeared to have a protective effect against early post-transplant infections in more severely ill liver transplant recipients. Rifaximin use did not select for multidrug resistant bacteria in these patients. C1 [Sun, Hsin-Yun; Wagener, Marilyn; Cacciarelli, Thomas V.; Singh, Nina] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan. [Wagener, Marilyn; Cacciarelli, Thomas V.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 NR 17 TC 6 Z9 7 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 J9 CLIN TRANSPLANT JI Clin. Transplant. PD NOV-DEC PY 2012 VL 26 IS 6 BP 849 EP 852 DI 10.1111/j.1399-0012.2012.01619.x PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA 051LS UT WOS:000312129100016 PM 22432742 ER PT J AU Liu, ML Xiang, RH Wilk, SA Zhang, N Sloane, LB Azarnoush, K Zhou, LJ Chen, HZ Xiang, GD Walter, CA Austad, SN Musi, N DeFronzo, RA Asmis, R Scherer, PE Dong, LQ Liu, F AF Liu, Meilian Xiang, Ruihua Wilk, Sarah Ann Zhang, Ning Sloane, Lauren B. Azarnoush, Kian Zhou, Lijun Chen, Hongzhi Xiang, Guangda Walter, Christi A. Austad, Steven N. Musi, Nicolas DeFronzo, Ralph A. Asmis, Reto Scherer, Philipp E. Dong, Lily Q. Liu, Feng TI Fat-Specific DsbA-L Overexpression Promotes Adiponectin Multimerization and Protects Mice From Diet-Induced Obesity and Insulin Resistance SO DIABETES LA English DT Article ID COMPLEMENT-RELATED PROTEIN; ADIPOSE-SPECIFIC PROTEIN; COLLAGENOUS DOMAIN; POSTTRANSLATIONAL MODIFICATIONS; METABOLIC SYNDROME; ENDOCRINE ORGAN; ACID OXIDATION; SENSITIVITY; TISSUE; GLUCOSE AB The antidiabetic and antiatherosclerotic effects of adiponectin make it a desirable drug target for the treatment of metabolic and cardiovascular diseases. However, the adiponectin-based drug development approach turns out to be difficult due to extremely high serum levels of this adipokine. On the other hand, a significant correlation between adiponectin multimerization and its insulin-sensitizing effects has been demonstrated, suggesting a promising alternative therapeutic strategy. Here we show that transgenic mice overexpressing disulfide bond A oxidoreductase-like protein in fat (fDsbA-L) exhibited increased levels of total and the high-molecular-weight form of adiponectin compared with wild-type (WT) littermates. The fDsbA-L mice also displayed resistance to diet-induced obesity, insulin resistance, and hepatic steatosis compared with WT control mice. The protective effects of DsbA-L overexpression on diet-induced insulin resistance, but not increased body weight and fat cell size, were significantly decreased in adiponectin-deficient fDsbA-L mice (fDsbA-L/Ad(-/-)). In addition, the fDsbA-L/Ad(-/-) mice displayed greater activity and energy expenditure compared with adiponectin knockout mice under a high-fat diet. Taken together, our results demonstrate that DsbA-L protects mice from diet-induced obesity and insulin resistance through adiponectin-dependent and independent mechanisms. In addition, upregulation of DsbA-L could be an effective therapeutic approach for the treatment of obesity and its associated metabolic disorders. Diabetes 61:2776-2786, 2012 C1 [Liu, Meilian; Liu, Feng] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Xiang, Ruihua; Wilk, Sarah Ann; Sloane, Lauren B.; Azarnoush, Kian; Zhou, Lijun; Xiang, Guangda; Walter, Christi A.; Austad, Steven N.; Dong, Lily Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Zhang, Ning; Musi, Nicolas; DeFronzo, Ralph A.; Liu, Feng] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA. [Chen, Hongzhi; Asmis, Reto; Liu, Feng] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Walter, Christi A.; Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Walter, Christi A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Scherer, Philipp E.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Touchstone Diabet Ctr, Dallas, TX 75390 USA. [Scherer, Philipp E.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA. RP Liu, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. EM liuf@uthscsa.edu FU American Diabetes Association Research Award [1-12-BS-115]; National Institutes of Health [DK-76902, DK-69930, P30-AG-13319-1SSI, DK-80157, DK-89229, HL-70963, R01-DK-55758, R01-CA-112023, RC1-DK-86629, P01-DK-88761] FX This work was supported by an American Diabetes Association Research Award (1-12-BS-115 to F.L.) and by National Institutes of Health RO1 grants DK-76902 (to F.L.), DK-69930 (to L.Q.D.), P30-AG-13319-1SSI (to S.N.A.), DK-80157 and DK-89229 (to N.M.), HL-70963 (to R.A.), and R01-DK-55758, R01-CA-112023, RC1-DK-86629, and P01-DK-88761 (to P.E.S.). NR 50 TC 25 Z9 28 U1 3 U2 32 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD NOV PY 2012 VL 61 IS 11 BP 2776 EP 2786 DI 10.2337/db12-0169 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 050GQ UT WOS:000312041600015 PM 22807031 ER PT J AU Chen, YX Melton, DW Gelfond, JAL McManus, LM Shireman, PK AF Chen, Yongxin Melton, David W. Gelfond, Jonathan A. L. McManus, Linda M. Shireman, Paula K. TI MiR-351 transiently increases during muscle regeneration and promotes progenitor cell proliferation and survival upon differentiation SO PHYSIOLOGICAL GENOMICS LA English DT Article DE microRNA; myogenic progenitor cell; muscle regeneration; muscle differentiation ID SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; CYCLE PROGRESSION; SATELLITE CELLS; MICROARRAY DATA; GENE-REGULATION; MICRORNA; EXPRESSION; E2F; MYOGENESIS AB Chen Y, Melton DW, Gelfond JAL, McManus LM, Shireman PK. MiR-351 transiently increases during muscle regeneration and promotes progenitor cell proliferation and survival upon differentiation. Physiol Genomics 44: 1042-1051, 2012. First published September 11, 2012; doi: 10.1152/physiolgenomics.00052.2012.-Micro-RNAs (miRNAs) regulate many biological processes including muscle development. However, little is known regarding miRNA regulation of muscle regeneration. Murine tibialis anterior muscle was evaluated after cardiotoxin-induced injury and used for global miRNA expression analysis. From day 1 through day 21 following injury, 298 miRNAs were significantly changed at least at one time point, including 86 miRNAs that were altered >10-fold compared with uninjured skeletal muscle. Temporal miRNA expression patterns included inflammation-related miRNAs (miR-223 and -147) that increased immediately after injury; this pattern contrasted to that of mature muscle-specific miRNAs (miR-1, -133a, and -499) that abruptly decreased following injury followed by upregulation in later regenerative events. Another cluster of miRNAs were transiently increased in the early days of muscle regeneration including miR-351, a miRNA that was also transiently expressed during myogenic progenitor cell (MPC) differentiation in vitro. Based on computational predictions, further studies demonstrated that E2f3 was a target of miR-351 in myoblasts. Moreover, knockdown of miR-351 expression inhibited MPC proliferation and promoted apoptosis during MPC differentiation, whereas miR-351 overexpression protected MPC from apoptosis during differentiation. Collectively, these observations suggest that miR-351 is involved in both the maintenance of MPC proliferation and the transition into differentiated myotubes. Thus, a novel, time-dependent sequence of molecular events during muscle regeneration has been identified; miR-351 inhibits E2f3 expression, a key regulator of cell cycle progression and proliferation, and promotes MPC proliferation and protects early differentiating MPC from apoptosis, important events in the hostile tissue environment after acute muscle injury. C1 [Chen, Yongxin; McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Melton, David W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Melton, David W.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Gelfond, Jonathan A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [Melton, David W.; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU National Institutes of Health (NIH) [K01-AR-059096, KL2-R025766, R01-HL-074236, T32-HL-007446, F30-HL-110743]; Veterans Administration Merit Review; University of Texas Health Science Center at San Antonio; NIH-NCI [P30 CA-054174] FX These studies were supported, in part, by National Institutes of Health (NIH) Grants K01-AR-059096, KL2-R025766, R01-HL-074236, T32-HL-007446, and F30-HL-110743 and by Veterans Administration Merit Review. Data were generated in the Core Flow Cytometry Facility, which is supported by the University of Texas Health Science Center at San Antonio and NIH-NCI P30 CA-054174 (Cancer Therapy & Research Center). NR 70 TC 24 Z9 24 U1 0 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD NOV PY 2012 VL 44 IS 21 BP 1042 EP 1051 DI 10.1152/physiolgenomics.00052.2012 PG 10 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 032FU UT WOS:000310699800004 PM 22968638 ER PT J AU Kougias, P Tiwari, V Orcutt, S Chen, A Pisimisis, G Barshes, NR Bechara, CF Berger, DH AF Kougias, Panagiotis Tiwari, Vikram Orcutt, Sonia Chen, Amber Pisimisis, George Barshes, Neal R. Bechara, Carlos F. Berger, David H. TI Derivation and out-of-sample validation of a modeling system to predict length of surgery SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Modeling; Regression; Operative length; Precision ID TIMES; DURATION; THEATER; EXPENDITURES; VARIABILITY AB BACKGROUND: We performed a retrospective study to compare the precision of a regression model (RM) system with the precision of the standard method of surgical length prediction using historical means (HM). METHODS: Data were collected on patients who underwent carotid endarterectomy and lower-extremity bypass. Multiple linear regression was used to model the operative time length (OTL). The precision of the RM versus HM in predicting case length then was compared in a validation dataset. RESULTS: With respect to carotid endarterectomy, surgeon, surgical experience, and cardiac surgical risk were significant predictors of OTL. For lower-extremity bypass, surgeon, use of prosthetic conduit, and performance of a sequential bypass or hybrid procedure were significant predictors of OTL. The precision of out-of-sample prediction was greater for the RM system compared with HM for both procedures. CONCLUSIONS: A regression methodology to predict case length appears promising in decreasing uncertainty about surgical case length. Published by Elsevier Inc. C1 [Kougias, Panagiotis; Orcutt, Sonia; Chen, Amber; Pisimisis, George; Barshes, Neal R.; Bechara, Carlos F.; Berger, David H.] Baylor Coll Med, Houston Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Tiwari, Vikram] Vanderbilt Univ, Nashville, TN USA. RP Kougias, P (reprint author), Baylor Coll Med, Houston Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM pkougias@bcm.edu FU Houston VAMC Health Services Research and Development Center of Excellence FX The authors would like to acknowledge the Houston VAMC Health Services Research and Development Center of Excellence for support provided in this project. NR 20 TC 4 Z9 4 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2012 VL 204 IS 5 BP 563 EP 568 DI 10.1016/j.amjsurg.2012.07.013 PG 6 WC Surgery SC Surgery GA 045YZ UT WOS:000311734000008 PM 23140826 ER PT J AU Stewart, L Griffiss, JM Jarvis, GA Way, LW AF Stewart, Lygia Griffiss, J. McLeod Jarvis, Gary A. Way, Lawrence W. TI The association between body mass index and severe biliary infections: a multivariate analysis SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the Association-of-VA-Surgeons CY APR 01-03, 2012 CL Miami Beach, FL SP Assoc VA Surg DE Biliary infections; Gallstones; Bactibilia; Bacteremia; Cholangitis; Cholecystitis; Obesity; Body mass index (BMI) ID NECROSIS-FACTOR-ALPHA; GALLSTONE DISEASE; PIGMENT GALLSTONES; OBESITY; BACTERIA; PANCREATITIS; MANIFESTATIONS; LIPOPROTEINS; PATHOGENESIS; COMPLEMENT AB BACKGROUND: Obesity has been associated with worse infectious disease outcomes. It is a risk factor for cholesterol gallstones, but little is known about associations between body mass index (BMI) and biliary infections. We studied this using factors associated with biliary infections. METHODS: A total of 427 patients with gallstones were studied. Gallstones, bile, and blood (as applicable) were cultured. Illness severity was classified as follows: none (no infection or inflammation), systemic inflammatory response syndrome (fever, leukocytosis), severe (abscess, cholangitis, empyema), or multi-organ dysfunction syndrome (bacteremia, hypotension, organ failure). Associations between BMI and biliary bacteria, bacteremia, gallstone type, and illness severity were examined using bivariate and multivariate analysis. RESULTS: BMI inversely correlated with pigment stones, biliary bacteria, bacteremia, and increased illness severity on bivariate and multivariate analysis. CONCLUSIONS: Obesity correlated with less severe biliary infections. BMI inversely correlated with pigment stones and biliary bacteria; multivariate analysis showed an independent correlation between lower BMI and illness severity. Most patients with severe biliary infections had a normal BMI, suggesting that obesity may be protective in biliary infections. This study examined the correlation between BMI and biliary infection severity. Published by Elsevier Inc. C1 [Stewart, Lygia; Way, Lawrence W.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. [Stewart, Lygia] San Francisco VA Med Ctr, Dept Surg 112, San Francisco, CA USA. [Griffiss, J. McLeod; Jarvis, Gary A.] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Immunochem, San Francisco, CA 94121 USA. [Griffiss, J. McLeod; Jarvis, Gary A.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94121 USA. RP Stewart, L (reprint author), Univ Calif San Francisco, Dept Surg, 112,4150 Clement St, San Francisco, CA 94121 USA. EM lygia.stewart@med.va.gov NR 29 TC 4 Z9 5 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2012 VL 204 IS 5 BP 574 EP 579 DI 10.1016/j.amjsurg.2012.07.002 PG 6 WC Surgery SC Surgery GA 045YZ UT WOS:000311734000010 PM 22892201 ER PT J AU Cajipe, MD Chu, D Bakaeen, FG Casal, RF LeMaire, SA Coselli, JS Cornwell, LD AF Cajipe, Miguel D. Chu, Danny Bakaeen, Faisal G. Casal, Roberto F. LeMaire, Scott A. Coselli, Joseph S. Cornwell, Lorraine D. TI Video-assisted thoracoscopic lobectomy is associated with better perioperative outcomes than open lobectomy in a veteran population SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the Association-of-VA-Surgeons CY APR 01-03, 2012 CL Miami Beach, FL SP Assoc VA Surg DE Lung cancer; Veterans; Veterans Affairs; Lobectomy; Video-assisted thoracoscopic surgery; Outcomes; VATS; Complications ID CELL LUNG-CANCER; THORACIC-SURGERY LOBECTOMY; THORACOTOMY; TUMORS AB BACKGROUND: We sought to establish the feasibility and efficacy of video-assisted thoracoscopic (VATS) lobectomy in treating lung cancer in a veteran population. METHODS: We retrospectively analyzed preoperative, intraoperative, and postoperative parameters in 46 VATS versus 45 open lobectomy patients at a single center. RESULTS: The 2 groups were similar in preoperative and intraoperative variables. Although surgical mortality was not significantly different after lobectomy performed with VATS (0 of 46) compared with open lobectomy (2 of 45, 4%; P = .2), there were fewer complications in VATS patients (14 of 46, 30%) than their open counterparts (26 of 45, 58%; P = .009). VATS patients also had a shorter chest tube duration and length of stay. In multivariate analysis, VATS was associated independently with a reduced risk of complications (odds ratio,.359; P = .04). CONCLUSIONS: VATS lobectomy in a veteran population is feasible and safe and may lead to better perioperative outcomes than open thoracotomy without compromising oncologic principles. Published by Elsevier Inc. C1 [Cajipe, Miguel D.; Chu, Danny; Bakaeen, Faisal G.; Casal, Roberto F.; LeMaire, Scott A.; Coselli, Joseph S.; Cornwell, Lorraine D.] Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Chu, Danny; Bakaeen, Faisal G.; LeMaire, Scott A.; Coselli, Joseph S.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX USA. RP Cornwell, LD (reprint author), Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM cornwell@bcm.edu NR 22 TC 12 Z9 14 U1 0 U2 6 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2012 VL 204 IS 5 BP 607 EP 612 DI 10.1016/j.amjsurg.2012.07.022 PG 6 WC Surgery SC Surgery GA 045YZ UT WOS:000311734000016 PM 22959921 ER PT J AU Hall, DE Morrison, P Nikolajski, C Fine, M Arnold, R Zickmund, SL AF Hall, Daniel E. Morrison, Penelope Nikolajski, Cara Fine, Michael Arnold, Robert Zickmund, Susan L. TI Informed consent for inguinal herniorrhaphy and cholecystectomy: describing how patients make decisions to have surgery SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the Association-of-VA-Surgeons CY APR 01-03, 2012 CL Miami Beach, FL SP Assoc VA Surg DE Informed consent; Informed decision making; Decision making; iMed consent; Decision aid; Herniorrhaphy; Cholecystectomy ID CLINICAL ANESTHESIA; BACK; COMMUNICATION; PERSPECTIVE; UNDERSTAND; QUALITY; IMPACT; TRIAL; VIDEO AB BACKGROUND: We describe how patients perceive the process of informed consent and its influence on decision making for elective surgery. METHODS: A cohort of 38 patients documented consent for cholecystectomy or inguinal herniorrhaphy using the Veterans Affair's computer-based tool for documenting informed consent for clinical treatment. Participants completed semistructured telephone interviews exploring their attitudes about informed consent, iMed, and the decision-making process. We used qualitative methods to code and analyze the data. RESULTS: Sixty-nine percent of patients decided to have surgery before meeting their surgeon, and 47% stated that the surgeon did not influence their decision. Although the surgeon was an important source of information for most patients (81%), patients frequently described using information gathered before meeting the surgeon, such as other health care providers (81%) or family members (58%). Most (68%) patients perceived iMed as a legal formality with little influence on decision making. CONCLUSIONS: Future research should examine whether patient decision making regarding elective surgery becomes better informed if nonsurgeon clinicians connect patients to educational resources such as iMed closer to the time of initial diagnosis and before meeting the surgeon. Published by Elsevier Inc. C1 [Hall, Daniel E.; Nikolajski, Cara; Fine, Michael; Zickmund, Susan L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Morrison, Penelope] Univ Pittsburgh, RAND Univ Pittsburgh Hlth Inst, Pittsburgh, PA USA. [Nikolajski, Cara] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Fine, Michael; Arnold, Robert] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. RP Hall, DE (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151 C-H, Pittsburgh, PA 15206 USA. EM hallde@upmc.edu RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 NR 35 TC 2 Z9 2 U1 0 U2 5 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2012 VL 204 IS 5 BP 619 EP 625 DI 10.1016/j.amjsurg.2012.07.020 PG 7 WC Surgery SC Surgery GA 045YZ UT WOS:000311734000018 PM 22944389 ER PT J AU Hayman, AV Tarpley, JL Berger, DH Wilson, MA Livingston, EH Kibbe, MR AF Hayman, Amanda V. Tarpley, John L. Berger, David H. Wilson, Mark A. Livingston, Edward H. Kibbe, Melina R. CA Assoc VA Surg TI How is the Department of Veterans Affairs addressing the new Accreditation Council for Graduate Medical Education intern work hour limitations? Solutions from the Association of Veterans Affairs Surgeons SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Intern; Work-hour limitation; ACGME; Veterans Affairs ID COMMUNICATION AB BACKGROUND: The Accreditation Council for Graduate Medical Education implemented new intern work-hour regulations in July 2011 that have unique implications for surgical training at Veterans Affairs (VA) medical centers. Implementation of these new regulations required profound restructuring of trainee night coverage systems at many VA medical centers. This article offers approaches and potential solutions to the Accreditation Council for Graduate Medical Education regulations used by different surgery programs throughout the country that are applicable to the VA training environment. METHODS: The information contained in this article was derived from the opinion of a panel of academic surgical leaders in the VA system and responses to a survey that was sent to national VA surgical leaders. RESULTS: The most common solution chosen by the VA centers was hiring physician extenders (37%). The most common type of extender was a nonphysician extender, that is, nurse practitioner or physician assistant (70%), followed by a surgical hospitalist (33%), and surgical resident moonlighter (24%). Other common solutions included the following: night float for residents (22%) or interns (19%), establishing early versus late shifts (19%), or establishing cross-institutional or disciplinary coverage (19%). CONCLUSIONS: The public expects the medical community to produce safe, experienced surgeons, while demanding they are well rested and directly supervised at all times. The ability to meet these expectations can be challenging. Published by Elsevier Inc. C1 [Hayman, Amanda V.; Kibbe, Melina R.] Jesse Brown VA Med Ctr, Chicago, IL 60611 USA. [Tarpley, John L.] VA Tennessee Valley Hlth Care Syst, Nashville, TN USA. [Berger, David H.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Wilson, Mark A.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Livingston, Edward H.] Univ Texas SW Sch Med, Dallas, TX USA. RP Kibbe, MR (reprint author), Jesse Brown VA Med Ctr, 676 N St Clair,650, Chicago, IL 60611 USA. EM mkibbe@nmh.org NR 6 TC 2 Z9 2 U1 2 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2012 VL 204 IS 5 BP 655 EP 662 DI 10.1016/j.amjsurg.2012.07.009 PG 8 WC Surgery SC Surgery GA 045YZ UT WOS:000311734000024 PM 22906248 ER PT J AU Saul, D Stephens, D Hofstatter, RD Ahmed, L Langhoff, E Heimann, TM AF Saul, Daniel Stephens, Daniel Hofstaetter, Rita de Cassia Ahmed, Leaque Langhoff, Erik Heimann, Tomas M. TI Preliminary outcomes of laparoscopic sleeve gastrectomy in a Veterans Affairs medical center SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 36th Annual Meeting of the Association-of-VA-Surgeons CY APR 01-03, 2012 CL Miami Beach, FL SP Assoc VA Surg DE Bariatric surgery; Morbid obesity; Laparoscopic sleeve gastrectomy; Vertical gastrectomy; Staple line reinforcement; Diabetes; Veterans Affairs ID Y GASTRIC BYPASS; TYPE-2 DIABETES-MELLITUS; MORBIDLY OBESE-PATIENTS; HEALTH-CARE-SYSTEM; HIGH-RISK PATIENTS; BARIATRIC SURGERY; REINFORCEMENT; OPERATION; GHRELIN AB BACKGROUND: Preliminary results of a new bariatric surgery program in a VA Medical Center using laparoscopic sleeve gastrectomy (LSG). METHODS: Prospective review of the first 50 patients who underwent LSG. Percentage change in body mass index (BMI), comorbidities, serum glucose, glycosylated hemoglobin (HbA1c), lipid profiles, and medications were recorded. RESULTS: Mean age was 52 years. Average BMI was 46 kg/m(2). There were no mortalities or staple line leaks. The percentage excess BMI loss was 47% and 54% at 6 and 12 months, respectively. After 6 months, fasting glucose level decreased from 127 to 93 mg/dL, and mean glycosylated hemoglobin decreased from 6.8% to 5.7%. At 1-year follow-up evaluation, serum cholesterol decreased from 182 to 168 mg/dL, mean triglycerides from 179 to 93 mg/dL, low-density lipoprotein from 110 to 94 mg/dL, and high-density lipoprotein increased from 42 to 50 mg/dL. CONCLUSIONS: Laparoscopic sleeve gastrectomy is safe and effective for morbidly obese VA patients and resulted in significant discontinuation of medication for hypertension, diabetes and hyperlipidemia. Published by Elsevier Inc. C1 [Stephens, Daniel] James J Peters VA Med Ctr, Dept Surg, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY USA. RP Stephens, D (reprint author), James J Peters VA Med Ctr, Dept Surg, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM djs979@yahoo.com NR 38 TC 3 Z9 3 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2012 VL 204 IS 5 BP E1 EP E6 DI 10.1016/j.amjsurg.2012.07.005 PG 6 WC Surgery SC Surgery GA 045YZ UT WOS:000311734000001 PM 22902102 ER PT J AU Pierre, JM AF Pierre, Joseph M. TI Mental Illness and Mental Health: Is the Glass Half Empty or Half Full? SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE LA English DT Review DE diagnostic expansion; prevalence inflation; bereavement; adjustment disorder; contextual utility; neuroenhancement; mental illness; mental health ID NATIONAL COMORBIDITY SURVEY; BEREAVEMENT-RELATED DEPRESSION; HARMFUL DYSFUNCTION ANALYSIS; DSM-IV DISORDERS; ADJUSTMENT DISORDER; DIAGNOSTIC-CRITERIA; COMPLICATED GRIEF; COGNITIVE ENHANCEMENT; PSYCHIATRIC DIAGNOSES; CLINICAL-SIGNIFICANCE AB During the past century, the scope of mental health intervention in North America has gradually expanded from an initial focus on hospitalized patients with psychoses to outpatients with neurotic disorders, including the so-called worried well. The Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition, is further embracing the concept of a mental illness spectrum, such that increasing attention to the softer end of the continuum can be expected in the future. This anticipated shift rekindles important questions about how mental illness is defined, how to distinguish between mental disorders and normal reactions, whether psychiatry is guilty of prevalence inflation, and when somatic therapies should be used to treat problems of living. Such debates are aptly illustrated by the example of complicated bereavement, which is best characterized as a form of adjustment disorder. Achieving an overarching definition of mental illness is challenging, owing to the many different contexts in which DSM diagnoses are used. Careful analyses of such contextual utility must inform future decisions about what ends up in DSM, as well as how mental illness is defined by public health policy and society at large. A viable vision for the future of psychiatry should include a spectrum model of mental health (as opposed to exclusively mental illness) that incorporates graded, evidence-based interventions delivered by a range of providers at each point along its continuum. C1 [Pierre, Joseph M.] Univ Calif Los Angeles, Semel Inst Neurosci, Los Angeles, CA USA. [Pierre, Joseph M.] W Los Angeles VA Med Ctr, Schizophrenia Treatment Unit, Los Angeles, CA USA. [Pierre, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Pierre, JM (reprint author), 11301 Wilshire Blvd,Bldg 210,Room 15, Los Angeles, CA 90073 USA. EM joseph.pierre2@va.gov NR 104 TC 4 Z9 4 U1 5 U2 22 PU CANADIAN PSYCHIATRIC ASSOC PI OTTAWA PA 141 LAURIER AVENUE WEST, STE 701, OTTAWA, ONTARIO K1P 5J3, CANADA SN 0706-7437 J9 CAN J PSYCHIAT JI Can. J. Psychiat.-Rev. Can. Psychiat. PD NOV PY 2012 VL 57 IS 11 BP 651 EP 658 PG 8 WC Psychiatry SC Psychiatry GA 044BV UT WOS:000311595300002 PM 23149280 ER PT J AU Thurman, JM Kulik, L Mitchell, LM Hourcade, DE Hannan, JP Coughlin, B Woodell, AS Pickering, MC Rohrer, B Holers, M AF Thurman, Joshua M. Kulik, Liudmila Mitchell, Lynne M. Hourcade, Dennis E. Hannan, Jonathan P. Coughlin, Beth Woodell, Alex S. Pickering, Matthew C. Rohrer, Barbel Holers, Michael TI Novel monoclonal antibodies to C3d that target and identify in living animals sites of complement activation SO IMMUNOBIOLOGY LA English DT Meeting Abstract C1 [Thurman, Joshua M.; Kulik, Liudmila; Hannan, Jonathan P.; Holers, Michael] Univ Colorado, Sch Med, Dept Medicine, Aurora, CO USA. [Mitchell, Lynne M.; Hourcade, Dennis E.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA. [Coughlin, Beth; Rohrer, Barbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Woodell, Alex S.; Rohrer, Barbel] Med Univ S Carolina, Div Res, Dept Neurosci, Charleston, SC 29425 USA. [Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Mol Genet & Rheumatol Sect, London, England. [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0171-2985 J9 IMMUNOBIOLOGY JI Immunobiology PD NOV PY 2012 VL 217 IS 11 MA 177 BP 1191 EP 1191 DI 10.1016/j.imbio.2012.08.179 PG 1 WC Immunology SC Immunology GA 038PY UT WOS:000311187800191 ER PT J AU Hansen, JE Chan, G Liu, Y Gera, J Sweasy, JB Sung, P Rockwell, S Nishimura, RN Weisbart, RH Glazer, PM AF Hansen, J. E. Chan, G. Liu, Y. Gera, J. Sweasy, J. B. Sung, P. Rockwell, S. Nishimura, R. N. Weisbart, R. H. Glazer, P. M. TI A Rare Cell-penetrating Anti-DNA Antibody Inhibits DNA Repair, Sensitizes Tumors To DNA-damaging Therapy, and is Synthetically Lethal to BRCA2-deficient Cancer Cells SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY OCT 28-31, 2012 CL Boston, MA SP Amer Soc Radiat Oncol (ASTRO) C1 [Hansen, J. E.; Liu, Y.; Sweasy, J. B.; Sung, P.; Rockwell, S.; Glazer, P. M.] Yale Univ, Sch Med, New Haven, CT USA. [Chan, G.; Gera, J.; Nishimura, R. N.; Weisbart, R. H.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 4 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD NOV 1 PY 2012 VL 84 IS 3 SU S BP S163 EP S163 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 030BP UT WOS:000310542900406 ER PT J AU Armstrong, AW Wu, J Kovarik, CL Goldyne, ME Oh, DH McKoy, KC Shippy, AM Pak, HS AF Armstrong, April W. Wu, Julie Kovarik, Carrie L. Goldyne, Marc E. Oh, Dennis H. McKoy, Karen C. Shippy, Alison M. Pak, Hon S. TI State of teledermatology programs in the United States SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE live-interactive; practice; real-time; store-and-forward; teledermatology; telehealth; telemedicine ID DERMATOLOGY AB Background: Teledermatology programs in the United States have evolved over the past several decades. No systematic survey of teledermatology programs in the United States is available in peer-reviewed literature. Objective: To provide up-to-date information regarding the state of teledermatology programs in the United States. Methods: Active U.S. teledermatology programs were surveyed in 2011 with regards to practice models, clinical volume, and payment methods. These findings were compared with those from 2003. Results: By January 2012, 37 teledermatology programs were active in the United States. Store-and-forward teledermatology was the most frequent delivery modality offered by 30 (81%) of the programs. The majority of the programs were based at academic institutions (49%), followed by Veterans Administration hospitals (27%), private practice (16%), and health maintenance organizations (HMOs) (8%). The majority of programs (67%) provided services to their home state only, whereas the rest also served additional U. S. states or abroad. The median number of consultations per program was 309 (range, 5-6500) in 2011. The most frequent payer sources were private payers, followed by self-pay, Medicaid, Medicare, and HMOs. Since 2003, with the confirmed discontinuation of 24 previously active programs, the total number of active teledermatology programs in 2011 was 60% of that in 2003. However, the annual consult volume per program nearly doubled for the sustainable programs in 2011. Limitations: Itemized billing information was not uniformly available from all programs. Conclusion: The turnover in teledermatology programs is relatively constant, with an increase in consult volume for sustainable programs. Store-and-forward is the dominant modality of delivery, while hybrid technology model is emerging. (J Am Acad Dermatol 2012;67:939-44.) C1 [Armstrong, April W.] Univ Calif Davis Hlth Syst, Dermatol Clin Res Unit, Dept Dermatol, Sacramento, CA 95816 USA. [Kovarik, Carrie L.] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Kovarik, Carrie L.] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Goldyne, Marc E.; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA USA. [McKoy, Karen C.] Lahey Clin Fdn, Dept Dermatol, Burlington, MA USA. [Pak, Hon S.] HSP Technol, Clarksburg, MD USA. [Armstrong, April W.; Kovarik, Carrie L.; Goldyne, Marc E.; Oh, Dennis H.; Shippy, Alison M.; Pak, Hon S.] Amer Acad Dermatol, Washington, DC USA. [Armstrong, April W.; Kovarik, Carrie L.; Goldyne, Marc E.; Oh, Dennis H.; McKoy, Karen C.; Shippy, Alison M.; Pak, Hon S.] Amer Telemed Assoc, Washington, DC USA. RP Armstrong, AW (reprint author), Univ Calif Davis Hlth Syst, Dermatol Clin Res Unit, Dept Dermatol, 3301 C St,Suite 1400, Sacramento, CA 95816 USA. EM aprilarmstrong@post.harvard.edu NR 12 TC 25 Z9 25 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD NOV PY 2012 VL 67 IS 5 BP 939 EP 944 DI 10.1016/j.jaad.2012.02.019 PG 6 WC Dermatology SC Dermatology GA 033EI UT WOS:000310776600053 PM 22459360 ER PT J AU Tang, JY Fu, T Lau, C Oh, DH Bikle, DD Asgari, MM AF Tang, Jean Y. Fu, Teresa Lau, Christopher Oh, Dennis H. Bikle, Daniel D. Asgari, Maryam M. TI Vitamin D in cutaneous carcinogenesis Part I SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE 25(OH)D levels; cholecalciferol; supplements; vitamin D; ultraviolet radiation ID SUN PROTECTION FACTOR; CELL LUNG-CANCER; SERUM 25-HYDROXYVITAMIN-D LEVELS; RANDOMIZED CONTROLLED-TRIAL; PRIMARY HUMAN KERATINOCYTES; NONMELANOMA SKIN-CANCER; D-ENDOCRINE SYSTEM; BODY-MASS INDEX; D DEFICIENCY; UNITED-STATES AB Skin cancer is the most common cancer in the United States. Exposure to ultraviolet radiation is a known risk factor for skin cancer but is also the principal means by which the body obtains vitamin D. Several studies have suggested that vitamin D plays a protective role in a variety of internal malignancies. With regard to skin cancer, epidemiologic and laboratory studies suggest that vitamin D and its metabolites may have a similar protective effect. These noncalcemic actions of vitamin D have called into question whether the current recommended intake of vitamin D is too low for optimal health and cancer prevention. Part I will review the role of vitamin D in the epidermis; part II will review the role of vitamin D in keratinocyte-derived tumors to help frame the discussion on the possible role of vitamin D in the prevention of skin cancer. (J Am Acad Dermatol 2012;67:803.e1-12.) C1 [Tang, Jean Y.; Fu, Teresa] Stanford Univ, Dept Dermatol, Redwood City, CA 94305 USA. [Lau, Christopher; Asgari, Maryam M.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Oh, Dennis H.; Bikle, Daniel D.; Asgari, Maryam M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Oh, Dennis H.; Bikle, Daniel D.] San Francisco VA Med Ctr, No Calif Inst Res & Educ, San Francisco, CA USA. [Bikle, Daniel D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Tang, JY (reprint author), Stanford Univ, Dept Dermatol, 450 Broadway,Pavil C,MC 5334, Redwood City, CA 94305 USA. EM tangy@stanford.edu RI Asgari, Maryam/O-4947-2016 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR 051037-01, K23 AR 056736-01]; Damon Runyon Clinical Investigator Award FX Supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K23 AR 051037-01 (Dr Asgari) and K23 AR 056736-01 (Dr Tang) and the Damon Runyon Clinical Investigator Award (Dr Tang). NR 121 TC 3 Z9 3 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD NOV PY 2012 VL 67 IS 5 AR 803.e1 DI 10.1016/j.jaad.2012.05.044 PG 12 WC Dermatology SC Dermatology GA 033EI UT WOS:000310776600037 PM 23062903 ER PT J AU Tang, JY Fu, T Lau, C Oh, DH Bikle, DD Asgari, MM AF Tang, Jean Y. Fu, Teresa Lau, Christopher Oh, Dennis H. Bikle, Daniel D. Asgari, Maryam M. TI Vitamin D in cutaneous carcinogenesis Part II SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE 25(OH)D levels; basal cell carcinoma; melanoma; nonmelanoma skin cancer; vitamin D; vitamin D receptor; squamous cell carcinoma; sunlight ID BASAL-CELL CARCINOMAS; PRIMARY HUMAN KERATINOCYTES; NONMELANOMA SKIN-CANCER; INDUCED DNA-DAMAGE; MALIGNANT-MELANOMA; D-RECEPTOR; IN-VITRO; 1,25-DIHYDROXYVITAMIN D-3; MOUSE SKIN; D ANALOGS AB The role of vitamin D in health maintenance and disease prevention in fields ranging from bone metabolism to cancer is currently under intensive investigation. A number of epidemiologic studies have suggested that vitamin D may have a protective effect on cancer risk and cancer-associated mortality. With regard to skin cancer, epidemiologic and laboratory studies suggest that vitamin D and its metabolites may have a similar risk reducing effect. Potential mechanisms of action include inhibition of the hedgehog signaling pathway and upregulation of nucleotide excision repair enzymes. The key factor complicating the association between vitamin D and skin cancer is ultraviolet B radiation. The same spectrum of ultraviolet B radiation that catalyzes the production of vitamin D in the skin also causes DNA damage that can lead to epidermal malignancies. Part II of this continuing medical education article will summarize the literature on vitamin D and skin cancer to identify evidence-based optimal serum levels of vitamin D and to recommend ways of achieving those levels while minimizing the risk of skin cancer. (J Am Acad Dermatol 2012;67:817.e1-11.) C1 [Tang, Jean Y.; Fu, Teresa] Stanford Univ, Dept Dermatol, Redwood City, CA 94305 USA. [Lau, Christopher; Asgari, Maryam M.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Oh, Dennis H.; Bikle, Daniel D.; Asgari, Maryam M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Bikle, Daniel D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Oh, Dennis H.; Bikle, Daniel D.] San Francisco VA Med Ctr, No Calif Inst Res & Educ, San Francisco, CA USA. RP Tang, JY (reprint author), Stanford Univ, Dept Dermatol, 450 Broadway,Pavil C,MC 5334, Redwood City, CA 94305 USA. EM tangy@stanford.edu RI Asgari, Maryam/O-4947-2016 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR 051037-01, K23 AR 056736-01]; Damon Runyon Clinical Investigator Award; VA Office of Research and Development Merit Award [I01BX007080] FX Supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K23 AR 051037-01 (Dr Asgari) and K23 AR 056736-01 ( Dr Tang), the Damon Runyon Clinical Investigator Award ( Dr Tang), and the VA Office of Research and Development Merit Award I01BX007080 ( Dr Oh). NR 82 TC 0 Z9 0 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD NOV PY 2012 VL 67 IS 5 PG 11 WC Dermatology SC Dermatology GA 033EI UT WOS:000310776600038 ER PT J AU Farbota, KDM Sodhi, A Bendlin, BB McLaren, DG Xu, GF Rowley, HA Johnson, SC AF Farbota, Kimberly D. M. Sodhi, Aparna Bendlin, Barbara B. McLaren, Donald G. Xu, Guofan Rowley, Howard A. Johnson, Sterling C. TI Longitudinal Volumetric Changes following Traumatic Brain Injury: A Tensor-Based Morphometry Study SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Longitudinal studies; Recovery of function; Brain injuries; humans; Neurosciences; Magnetic resonance imaging; Chronic brain injuries; Brain mapping; Apoptosis; Necrosis ID INDUCED AXONAL INJURY; WALLERIAN DEGENERATION; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ATROPHY; MILD; AXOTOMY; PATHOBIOLOGY; AUTOPHAGY; ANIMALS AB After traumatic injury, the brain undergoes a prolonged period of degenerative change that is paradoxically accompanied by cognitive recovery. The spatiotemporal pattern of atrophy and the specific relationships of atrophy to cognitive changes are ill understood. The present study used tensor-based morphometry and neuropsychological testing to examine brain volume loss in 17 traumatic brain injury (TBI) patients and 13 controls over a 4-year period. Patients were scanned at 2 months, 1 year, and 4 years post-injury. High-dimensional warping procedures were used to create change maps of each subject's brain for each of the two intervals. TBI patients experienced volume loss in both cortical areas and white matter regions during the first interval. We also observed continuing volume loss in extensive regions of white matter during the second interval. Neuropsychological correlations indicated that cognitive tasks were associated with subsequent volume loss in task-relevant regions. The extensive volume loss in brain white matter observed well beyond the first year post-injury suggests that the injured brain remains malleable for an extended period, and the neuropsychological relationships suggest that this volume loss may be associated with subtle cognitive improvements. (JINS, 2012, 18, 1006-1018) C1 [Farbota, Kimberly D. M.; Sodhi, Aparna; Bendlin, Barbara B.; McLaren, Donald G.; Xu, Guofan; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53792 USA. [Farbota, Kimberly D. M.; McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [Sodhi, Aparna; Bendlin, Barbara B.; Xu, Guofan; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Farbota, KDM (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, J5M-162 CSC,600 Highland Ave, Madison, WI 53792 USA. EM kim.farbota@gmail.com OI Bendlin, Barbara/0000-0002-0580-9875; McLaren, Donald/0000-0002-0566-4610; Johnson, Sterling/0000-0002-8501-545X FU Department of Veterans Affairs; NIH [MH65723, AG000213] FX This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), NIH AG000213, and by the facilities and resources of the William S. Middleton Memorial Veterans Hospital. The authors declare no conflict of interest. The assistance of Robert Dempsey, MD, Jack Sherman, PhD, Tisha Kawahara, Taylor Schmitz, Lisa Newman, Amy Hawley, and Erik Kastman is greatly appreciated. We also greatly appreciate the support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where MR imaging took place. Donald McLaren, PhD, is now affiliated with Harvard University Medical School and the Massachusetts General Hospital, Department of Neurology. Finally, we thank all the patients who took part in this study. The contents of this study do not represent the views of the Department of Veterans Affairs or the United States Government. NR 45 TC 25 Z9 26 U1 3 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD NOV PY 2012 VL 18 IS 6 BP 1006 EP 1018 DI 10.1017/S1355617712000835 PG 13 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 048IT UT WOS:000311905300008 PM 22883443 ER PT J AU Morley, JF Duda, JE AF Morley, James F. Duda, John E. TI Head injury and the risk of Parkinson's disease SO MOVEMENT DISORDERS LA English DT Editorial Material ID ALPHA-SYNUCLEIN; YOUNG-ONSET; EPIDEMIOLOGY; POPULATION; TRAUMA; ETIOLOGY; SMOKING; HISTORY; BRAIN; DRUGS C1 [Morley, James F.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Morley, JF (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM morleyj@uphs.upenn.edu NR 41 TC 0 Z9 0 U1 1 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2012 VL 27 IS 13 BP 1592 EP 1594 DI 10.1002/mds.25230 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 045KU UT WOS:000311695500002 PM 23192921 ER PT J AU Miranda, M Jung, HH Danek, A Walker, RH AF Miranda, Marcelo Jung, Hans H. Danek, Adrian Walker, Ruth H. TI The chorea of McLeod syndrome: Progression to hypokinesia SO MOVEMENT DISORDERS LA English DT Letter ID PHENOTYPE C1 [Miranda, Marcelo] Clin Las Condes, Dept Neurol, Santiago, Chile. [Jung, Hans H.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland. [Danek, Adrian] Univ Munich, Neurol Klin, Munich, Germany. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2012 VL 27 IS 13 BP 1701 EP 1702 DI 10.1002/mds.25224 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 045KU UT WOS:000311695500027 PM 23192927 ER PT J AU Baker, LD Barsness, SM Borson, S Merriam, GR Friedman, SD Craft, S Vitiello, MV AF Baker, Laura D. Barsness, Suzanne M. Borson, Soo Merriam, George R. Friedman, Seth D. Craft, Suzanne Vitiello, Michael V. TI Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults Results of a Controlled Trial SO ARCHIVES OF NEUROLOGY LA English DT Article ID FACTOR-I; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; CEREBROSPINAL-FLUID; VASCULAR DEMENTIA; AEROBIC EXERCISE; IGF-1 RESISTANCE; BODY-COMPOSITION; APOLIPOPROTEIN-E; WORKING-MEMORY AB Background: Growth hormone-releasing hormone (GHRH), growth hormone, and insulin-like growth factor 1 have potent effects on brain function, their levels decrease with advancing age, and they likely play a role in the pathogenesis of Alzheimer disease. Previously, we reported favorable cognitive effects of short-term GHRH administration in healthy older adults and provided preliminary evidence to suggest a similar benefit in adults with mild cognitive impairment (MCI). Objective: To examine the effects of GHRH on cognitive function in healthy older adults and in adults with MCI. Design: Randomized, double-blind, placebo-controlled-trial. Setting: Clinical Research Center, University of Washington School of Medicine in Seattle. Participants: A total of 152 adults (66 with MCI) ranging in age from 55 to 87 years (mean age, 68 years); 137 adults (76 healthy participants and 61 participants with MCI) successfully completed the study. Intervention: Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologies Inc), a stabilized analog of human GHRH (1 mg/d), or placebo 30 minutes before bedtime for 20 weeks. At baseline, at weeks 10 and 20 of treatment, and after a 10-week washout (week 30), blood samples were collected, and parallel versions of a cognitive battery were administered. Before and after the 20-week intervention, participants completed an oral glucose tolerance test and a dual-energy x-ray absorptiometry scan to measure body composition. Main Outcome Measures: Primary cognitive outcomes were analyzed using analysis of variance and included 3 composites reflecting executive function, verbal memory, and visual memory. Executive function was assessed with Stroop Color-Word Interference, Task Switching, the Self-Ordered Pointing Test, and Word Fluency, verbal memory was assessed with Story Recall and the Hopkins Verbal Learning Test, and visual memory was assessed with the Visual-Spatial Learning Test and Delayed Match-to-Sample. Results: The intent-to-treat analysis indicated a favorable effect of GHRH on cognition (P=.03), which was comparable in adults with MCI and healthy older adults. The completer analysis showed a similar pattern, with a more robust GHRH effect (P=.002). Subsequent analyses indicated a positive GHRH effect on executive function (P=.005) and a trend showing a similar treatment-related benefit in verbal memory(P=.08). Treatment with GHRH increased insulinlike growth factor 1 levels by 117% (P<.001), which remained within the physiological range, and reduced percent body fat by 7.4% (P<.001). Treatment with GHRH increased fasting insulin levels within the normal range by 35% in adults with MCI (P<.001) but not in healthy adults. Adverse events were mild and were reported by 68% of GHRH treated adults and 36% of those who received placebo. Conclusions: Twenty weeks of GHRH administration had favorable effects on cognition in both adults with MCI and healthy older adults. Longer-duration treatment trials are needed to further examine the therapeutic potential of GHRH administration on brain health during normal aging and "pathological aging." C1 [Baker, Laura D.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Merriam, George R.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA. [Baker, Laura D.; Borson, Soo; Craft, Suzanne; Vitiello, Michael V.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Baker, LD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, GRECC S182,1660 S Columbian Way, Seattle, WA 98108 USA. EM ldbaker@uw.edu OI Vitiello, Michael/0000-0002-9776-0473 FU National Institutes of Health/National Institute of Aging [AG025515, AG030484]; US Department of Veterans Affairs; National Institutes of Health/National Center for Research Resources [ULRR025014] FX This research was supported by National Institutes of Health/National Institute of Aging grants AG025515 (to Dr Vitiello) and AG030484 (to Dr Friedman) and by the US Department of Veterans Affairs. A portion of this work was conducted through the Clinical Research Center Facility at the University of Washington Medical Center, which is supported by the National Institutes of Health/National Center for Research Resources grant ULRR025014. NR 80 TC 34 Z9 35 U1 1 U2 50 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 EI 1538-3687 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD NOV PY 2012 VL 69 IS 11 BP 1420 EP 1429 DI 10.1001/archneurol.2012.1970 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 035XT UT WOS:000310987500003 PM 22869065 ER PT J AU Molnar, AO Parikh, CR Sint, K Coca, SG Koyner, J Patel, UD Butrymowicz, I Shlipak, M Garg, AX AF Molnar, Amber O. Parikh, Chirag R. Sint, Kyaw Coca, Steven G. Koyner, Jay Patel, Uptal D. Butrymowicz, Isabel Shlipak, Michael Garg, Amit X. TI Association of Postoperative Proteinuria with AKI after Cardiac Surgery among Patients at High Risk SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; GLOMERULAR-FILTRATION-RATE; DISEASE; MORTALITY; OUTCOMES; ALBUMINURIA; BIOMARKERS; DEATH; MICROALBUMINURIA AB Background and objectives Preoperative proteinuria is associated with a higher incidence of postoperative AM. Whether the same is true for postoperative proteinuria is uncertain. This study tested the hypothesis that increased proteinuria after cardiac surgery is associated with an increased risk for AKI. Design, setting, participants, & measurements This prospective cohort study included 1198 adults undergoing cardiac surgery at six hospitals between July 2007 and December 2009. Albuminuria, urine albumin-to-creatinine ratio (ACR), and dipstick proteinuria were measured 0-6 hours after surgery. The primary outcome was AM, defined as a doubling in serum creatinine or receipt of acute dialysis during the hospital stay. Analyses were adjusted for patient characteristics, including preoperative albuminuria. Results Compared with the lowest quintile, the highest quintile of albuminuria and highest grouping of dipstick proteinuria were associated with greatest risk for AKI (adjusted relative risks [RRs], 2.97 [95% confidence interval (0), 1.20-6.91] and 2.46 [95% CI, 1.16-4.97], respectively). Higher ACR was not associated with AKI risk (highest quintile RR, 1.66 [95% Cl, 0.68-3.90]). Of the three proteinuria measures, early postoperative albuminuria improved the prediction of AKI to the greatest degree (clinical model area under the curve, 0.75; 0.81 with albuminuria). Similar improvements with albuminuria were seen for net reclassification index (0.55; P<0.001) and integrated discrimination index (0.036; P<0.001). Conclusions Higher levels of proteinuria after cardiac surgery identify patients at increased risk for AM during their hospital stay. Clin J Am Soc Nepltrol 7: 1749-1760, 2012. doi: 10.2215/CJN.13421211 C1 [Parikh, Chirag R.; Sint, Kyaw; Coca, Steven G.; Butrymowicz, Isabel] Yale Univ, Nephrol Sect, Sch Med, West Haven, CT 06516 USA. [Garg, Amit X.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada. [Molnar, Amber O.; Garg, Amit X.] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. [Koyner, Jay] Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA. [Patel, Uptal D.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Patel, Uptal D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Shlipak, Michael] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, Sch Med, 950 Campbell Ave,Mail Code 151B,Bldg 35A,Room 219, West Haven, CT 06516 USA. EM chirag.parikh@yale.edu FU American Heart Association; National Heart, Lung, and Blood Institute [R01HL-085757]; CTSA grant from the National Center for Research Resources [UL1 RR024139] FX The research in this article was supported by the American Heart Association Clinical Development award and grant R01HL-085757 from the National Heart, Lung, and Blood Institute. The study was also supported by CTSA grant UL1 RR024139 from the National Center for Research Resources. NR 47 TC 14 Z9 14 U1 0 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2012 VL 7 IS 11 BP 1749 EP 1760 DI 10.2215/CJN.13421211 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 033CO UT WOS:000310770600004 PM 22977220 ER PT J AU Crowley-Matoka, M True, G AF Crowley-Matoka, Megan True, Gala TI NO ONE WANTS TO BE THE CANDY MAN: Ambivalent Medicalization and Clinician Subjectivity in Pain Management SO CULTURAL ANTHROPOLOGY LA English DT Article DE [culture of biomedicine; medicalization; subjectivity; pain] ID BODY; MEDICINE AB Pain, despite being an elemental bodily experience and the most common reason for seeking medical care, occupies a place of profound ontological and moral uncertainty in U.S. biomedicine. Taking seriously the highly charged emotionsfrustration, anger, even disgustfrequently expressed by clinicians regarding their patients with pain, this article draws on ethnographic research to explore both the origins and the implications of such anxiously ambivalent responses to pain and pain medications among the clinicians charged with treating it. Set against the recent history of pain medicine as an emergent specialty in the highly fragmented landscape of U.S. biomedicine, we examine at close ethnographic range some of the key ways that U.S. clinicians frame the experience of contending with pain in their everyday practice. Emergent from these clinician experiences are the ways in which pain and pain medications remain both incompletely medicalized and ineffectively medicalizing in U.S. biomedicine, as well as the threatening effects on what we call the pharmaceutical subjectivity of clinicians themselves of this persistently ambivalent medicalization. C1 [Crowley-Matoka, Megan] Northwestern Univ, Evanston, IL 60208 USA. [True, Gala] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [True, Gala] Univ Penn, Philadelphia, PA 19104 USA. RP Crowley-Matoka, M (reprint author), Northwestern Univ, Evanston, IL 60208 USA. NR 46 TC 12 Z9 12 U1 1 U2 11 PU SOC CULTURAL ANTHROPOLOGY PI HOUSTON PA DEPT ANTHROPOLOGY, MS-20, RICE UNIV, PO BOX 1892, HOUSTON, TX 77251 USA SN 0886-7356 EI 1548-1360 J9 CULT ANTHROPOL JI Cult. Anthropol. PD NOV PY 2012 VL 27 IS 4 BP 689 EP 712 DI 10.1111/j.1548-1360.2012.01167.x PG 24 WC Anthropology SC Anthropology GA 037HK UT WOS:000311092600007 ER PT J AU Salinsky, M Evrard, C Storzbach, D Pugh, MJ AF Salinsky, Martin Evrard, Collette Storzbach, Daniel Pugh, Mary Jo TI Psychiatric comorbidity in veterans with psychogenic seizures SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Psychogenic seizures; Veterans; Post-traumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; NONEPILEPTIC SEIZURES; VIDEO-EEG; EPILEPSY; HEALTH; PREVALENCE; DIAGNOSIS; SYMPTOMS; HISTORY AB Psychogenic non-epileptic seizures (PNES) are frequently encountered in epilepsy monitoring units (EMU) at Veterans Affairs Medical Centers (VAMCs) and cause significant long-term disability. An understanding of psychiatric factors associated with PNES could aid in earlier diagnosis and treatment. We studied 50 consecutive veterans diagnosed with PNES and 37 veterans diagnosed with epileptic seizures (ES), evaluated at a VAMC EMU. We reviewed all available mental health evaluations prior to EMU evaluation. Univariate comparisons included axis I diagnoses, axis II diagnoses, and psychiatric hospitalizations. Predictive models of seizure classification were evaluated by logistic regression. A diagnosis of post-traumatic stress disorder (PTSD) preceded the diagnosis of PNES in 58% of patients and the diagnosis of ES in 13.5% (p<0.001). On logistic regression, PTSD was the only significant psychiatric diagnosis (odds ratio 9.2). Major depression and alcohol abuse were common diagnoses but did not differentiate PNES and ES groups. Published by Elsevier Inc. C1 [Salinsky, Martin; Evrard, Collette; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA. [Salinsky, Martin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Pugh, Mary Jo] San Antonio Vet Affairs Med Ctr, San Antonio, TX USA. RP Salinsky, M (reprint author), 3181 SW Sam Jackson Pk Rd,CR 120, Portland, OR 97239 USA. EM Salinsky@ohsu.edu OI Pugh, Mary Jo/0000-0003-4196-7763 FU Portland VA Medical Center FX This material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center. NR 30 TC 18 Z9 19 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD NOV PY 2012 VL 25 IS 3 BP 345 EP 349 DI 10.1016/j.yebeh.2012.07.013 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 035BM UT WOS:000310917000009 PM 23103308 ER PT J AU Fujikawa, DG Licht, EA Jacobsen, RH AF Fujikawa, Denson G. Licht, Eliot A. Jacobsen, Rebecca H. TI Chronic epileptic encephalopathy in adult patients with bilaterally synchronous frequent and/or prolonged subclinical epileptiform discharges SO EPILEPSY & BEHAVIOR LA English DT Article DE Epileptic encephalopathy; Idiopathic generalized epilepsy; Spike and slow-wave discharges; Subclinical epileptiform discharges; Adults ID IDIOPATHIC GENERALIZED EPILEPSY; JUVENILE MYOCLONIC EPILEPSY; COGNITIVE DYSFUNCTION; ONSET; CHILDREN AB We followed four patients with infrequent convulsive seizures for four to 10 years, with periodic EEGs and neuropsychological tests. All four had bursts of frontally predominant, bilaterally synchronous 1.5-3-Hz spike or polyspike and slow-wave discharges (SWDs) that initially comprised 15% to 88% but were reduced to 5% or less of total EEG time with appropriate antiepileptic drugs. Case 1 showed a 30-point improvement in his verbal WAIS-R score and Case 4 a 21-point improvement in his performance WAIS-R score, over nine-and five-year periods, respectively, with normalization of frontal executive function. Cases 2 and 3 showed no improvement in frontal executive dysfunction despite being free of SWDs for nine and five years, respectively. These patients had variable degrees of epileptic encephalopathy and subclinical SWDs. They illustrate the importance of minimizing the occurrence of SWDs with appropriate antiepileptic drugs and long-term monitoring with neuropsychological tests because chronic cognitive deficits are potentially reversible. Published by Elsevier Inc. C1 [Fujikawa, Denson G.; Licht, Eliot A.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA USA. [Jacobsen, Rebecca H.] VA Greater Los Angeles Healthcare Syst, Dept Mental Hlth, North Hills, CA USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA USA. EM dfujikaw@ucla.edu NR 17 TC 2 Z9 2 U1 2 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD NOV PY 2012 VL 25 IS 3 BP 442 EP 448 DI 10.1016/j.yebeh.2012.08.001 PG 7 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 035BM UT WOS:000310917000026 PM 23021092 ER PT J AU Shafer, PO Buelow, JM Noe, K Shinnar, R Dewar, S Levisohn, PM Dean, P Ficker, D Pugh, MJ Barkley, GL AF Shafer, Patricia O. Buelow, Janice M. Noe, Katherine Shinnar, Ruth Dewar, Sandra Levisohn, Paul M. Dean, Patricia Ficker, David Pugh, Mary Jo Barkley, Gregory L. TI A consensus-based approach to patient safety in epilepsy monitoring units: Recommendations for preferred practices SO EPILEPSY & BEHAVIOR LA English DT Article DE Patient safety; Epilepsy monitoring units; Delphi methodology; Epilepsy; Video-EEG telemetry; Expert consensus; Seizure precautions; Seizure observation ID TEMPORAL-LOBE EPILEPSY; LONG-TERM; STATUS EPILEPTICUS; POSTICTAL PSYCHOSIS; SEIZURE OCCURRENCE; FREQUENCY; GUIDELINES; MANAGEMENT; INDUCTION; SYMPTOMS AB Patients in an epilepsy monitoring unit (EMU) with video-EEG telemetry have a risk for seizure emergencies, injuries and adverse events, which emphasizes the need for strategies to prevent avoidable harm. An expert consensus process was used to establish recommendations for patient safety in EMUs. Workgroups analyzed literature and expert opinion regarding seizure observation, seizure provocation, acute seizures, and activity/environment. A Delphi methodology was used to establish consensus for items submitted by these workgroups. Fifty-three items reached consensus and were organized into 30 recommendations. High levels of agreement were noted for items pertaining to orientation, training, communication, seizure precautions, individualized plans, and patient/family education. It was agreed that seizure observation should include direct observation or use of closed-circuit camera. The use of continuous observation was strongest in patients with invasive electrodes, at high risk for injury, or undergoing AED withdrawal. This process provides a first step in establishing EMU safety practices. (C) 2012 Elsevier Inc. All rights reserved. C1 [Shafer, Patricia O.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Buelow, Janice M.] Indiana Univ, Sch Nursing, Indianapolis, IN 46202 USA. [Noe, Katherine] Mayo Clin, Dept Epilepsy & Neurol, Phoenix, AZ 85054 USA. [Shinnar, Ruth] Montefiore Med Ctr, Bronx, NY 10467 USA. [Dewar, Sandra] Univ Calif Los Angeles, Seizure Disorder Ctr, Los Angeles, CA 90025 USA. [Levisohn, Paul M.] Childrens Hosp Colorado, Aurora, CO 80045 USA. [Dean, Patricia] Miami Childrens Hosp, Inst Brain, Epilepsy Program, Miami, FL 33155 USA. [Ficker, David] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH 45267 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Pugh, Mary Jo] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Barkley, Gregory L.] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA. RP Shafer, PO (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. EM poshafer@bidmc.harvard.edu; jbuelow@iupui.edu; noe.katherine@mayo.edu; codell@sprynet.com; sdewar@mednet.ucla.edu; paul.levisohn@childrenscolorado.org; pat.dean@mch.com; fickerdm@ucmail.uc.edu; pughm@uthscsa.edu; barkley@neuro.hfh.edu OI Pugh, Mary Jo/0000-0003-4196-7763 NR 55 TC 20 Z9 20 U1 1 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD NOV PY 2012 VL 25 IS 3 BP 449 EP 456 DI 10.1016/j.yebeh.2012.07.014 PG 8 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 035BM UT WOS:000310917000027 PM 22999858 ER PT J AU Kellogg, DL Zhao, JL Wu, YB Johnson, JM AF Kellogg, Dean L., Jr. Zhao, Joan L. Wu, Yubo Johnson, John M. TI Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE laser-Doppler flowmetry; VPAC2; PAC1; thermoregulation; microdialysis ID CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; SYNTHASE CONTROL MECHANISMS; SKIN BLOOD-FLOW; VASCULAR-RESPONSES; IN-VIVO; PHARMACOLOGY; EXERCISE; INHIBITION; ROLES AB Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans. J Appl Physiol 113: 1512-1518, 2012. First published September 6, 2012; doi:10.1152/japplphysiol.00859.2012.-VPAC2 receptors sensitive to vasoactive intestinal polypeptide (VIP) and pituitary adenylyl cyclase activating polypeptide (PACAP), PAC1 receptors sensitive to PACAP, and nitric oxide (NO) generation by NO synthase (NOS) are all implicated in cutaneous active vasodilation (AVD) through incompletely defined mechanisms. We hypothesized that VPAC2/PAC1 receptor activation and NO are synergistic and interdependent in AVD and tested our hypothesis by examining the effects of VPAC2/PAC1 receptor blockade with and without NOS inhibition during heat stress. The VPAC2/PAC1 antagonist, pituitary adenylate cyclase activating peptide 6-38 (PACAP6-38) and the NOS inhibitor, N-G-nitro-L-arginine methyl ester (L-NAME) were administered by intradermal microdialysis. PACAP6-38, L-NAME, a combination of PACAP6-38 and L-NAME, or Ringer's solution alone were perfused at four separate sites. Skin blood flow was monitored by laser-Doppler flowmetry at each site. Body temperature was controlled with water-perfused suits. Blood pressure was monitored by Finapres, and cutaneous vascular conductance (CVC) calculated (CVC = laser-Doppler flowmetry/mean arterial pressure). The protocol began with a 5- to 10-min baseline period without antagonist perfusion, followed by perfusion of PACAP6-38, L-NAME, or combined PACAP6-38 and L-NAME at the different sites in normothermia (45 min), followed by 3 min of whole body cooling. Whole body heating was then performed to induce heat stress and activate AVD. Finally, 58 mM sodium nitroprusside were perfused at all sites to effect maximal vasodilation for normalization of blood flow data. No significant differences in CVC (normalized to maximum) were found among Ringer's PACAP6-38, L-NAME, or combined antagonist sites during normothermia (P > 0.05 among sites) or cold stress (P > 0.05 among sites). CVC responses at all treated sites were attenuated during AVD (P < 0.05 vs. Ringer's). Attenuation was greater at L-NAME and combined PACAP6-38- and L-NAME-treated sites than at PACAP6-38 sites (P > 0.05). Because responses did not differ between L-NAME and combined treatment sites (P > 0.05), we conclude that VPAC2/PAC1 receptors require NO in series to effect AVD. C1 [Kellogg, Dean L., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, Dept Med, San Antonio, TX 78229 USA. [Kellogg, Dean L., Jr.] Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Kellogg, Dean L., Jr.; Zhao, Joan L.; Wu, Yubo; Johnson, John M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. RP Kellogg, DL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kelloggd@uthscsa.edu NR 48 TC 10 Z9 11 U1 4 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV PY 2012 VL 113 IS 10 BP 1512 EP 1518 DI 10.1152/japplphysiol.00859.2012 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 038XZ UT WOS:000311208700002 PM 22961270 ER PT J AU Bradfield, J Shapiro, S Finch, W Tung, R Boyle, NG Buch, E Mathuria, N Mandapati, R Shivkumar, K Bersohn, M AF Bradfield, Jason Shapiro, Shelley Finch, William Tung, Roderick Boyle, Noel G. Buch, Eric Mathuria, Nilesh Mandapati, Ravi Shivkumar, Kalyanam Bersohn, Malcolm TI Catheter Ablation of Typical Atrial Flutter in Severe Pulmonary Hypertension SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE atrial flutter; catheter ablation; cardiac hypertrophy; pulmonary hypertension AB Atrial Flutter and Pulmonary Hypertension. Background: Radiofrequency ablation is first-line therapy for atrial flutter (AFL). There are no studies of ablation in patients with severe pulmonary arterial hypertension (PAH). Methods: Consecutive patients with severe PAH (systolic pulmonary artery pressure >60 mmHg) and AFL referred for ablation were evaluated. Patients with complex congenital heart disease were excluded. Results: A total of 14 AFL ablation procedures were undertaken in 12 patients. A total of 75% of patients were female; mean age 49 +/- 12 years. SPAP prior to ablation was 99 +/- 35 mmHg. Baseline 6-minute walk distance was 295 +/- 118 m. ECG demonstrated a typical AFL pattern in only 42% of cases. Baseline AFL cycle length was longer in PAH patients compared to controls (295 +/- 53 ms vs 252 +/- 35 ms, P = 0.006). Cavotricuspid isthmus dependence was verified in 86% of cases. Acute success was obtained in 86% of procedures. SPAP decreased from 114 +/- 44 mmHg to 82 +/- 38 mmHg after ablation (P = 0.004). BNP levels were lower postablation (787 +/- 832 pg/mL vs 522 +/- 745 pg/mL, P = 0.02). Complications were seen in 14%. A total of 80% (8/10) of patients were free of AFL at 3 months; 75% (6/8) at 1 year. Conclusion: Ablation of AFL in severe PAH patients is feasible, with good short- and intermediate-term success rates. The ECG pattern is not a reliable marker of isthmus dependence. The SPAP and BNP levels may decrease postablation. AFL may be a marker of poor outcomes in patients with PAH with a 1-year mortality rate of 42% in this study. This rate is higher than expected in the general PAH population. (J Cardiovasc Electrophysiol, Vol. 23, pp. 11851190, November 2012) C1 [Bradfield, Jason; Finch, William; Tung, Roderick; Boyle, Noel G.; Buch, Eric; Mathuria, Nilesh; Mandapati, Ravi; Shivkumar, Kalyanam; Bersohn, Malcolm] Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, UCLA Cardiac Arrhythmia Ctr, Los Angeles, CA 90095 USA. [Shapiro, Shelley; Bersohn, Malcolm] VA Greater Los Angeles Med Ctr, Los Angeles, CA USA. RP Bradfield, J (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, UCLA Cardiac Arrhythmia Ctr, A2-237 CHS,650 Charles E Young Dr S, Los Angeles, CA 90095 USA. EM JBradfield@mednet.ucla.edu OI Shivkumar, Kalyanam/0000-0002-4121-1766 NR 9 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD NOV PY 2012 VL 23 IS 11 BP 1185 EP 1190 DI 10.1111/j.1540-8167.2012.02387.x PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 037HL UT WOS:000311092700006 PM 22734591 ER PT J AU Kobus, AM Smith, DH Morasco, BJ Johnson, ES Yang, XH Petrik, AF Deyo, RA AF Kobus, Amy M. Smith, David H. Morasco, Benjamin J. Johnson, Eric S. Yang, Xiuhai Petrik, Amanda F. Deyo, Richard A. TI Correlates of Higher-Dose Opioid Medication Use for Low Back Pain in Primary Care SO JOURNAL OF PAIN LA English DT Article DE Chronic pain; back pain; opioids; epidemiology; pain/drug therapy ID CHRONIC NONCANCER PAIN; MENTAL-HEALTH DISORDERS; SUBSTANCE USE DISORDERS; PRESCRIBED OPIOIDS; ASSOCIATION; RISK; GUIDELINE; OVERDOSE; TRENDS AB Factors associated with high-dose opioid therapy for noncancer pain are poorly understood. We documented the prevalence of high-dose opioid use as well as associated demographic, clinical, and health service utilization correlates among low back pain patients. Patients prescribed higher doses of opioids (>= 100 mg/day morphine equivalent at last dispensing; n = 453) and receiving opioids for 90+ consecutive days were compared to 2 groups: lower-dose opioid group (1-99 mg/day; n = 4,815) or no-opioid group (n = 10,184). Higher-dose opioid use occurred in 2.9% of patients who received any opioids and in 8.6% of patients who received opioids long-term. The median dose in the higher-dose group was 180.0 mg/day. Compared to the no-opioid group, higher-dose users reported poorer health. Compared to either comparison group, patients in the higher-dose group had higher rates of mental health and substance use disorders, concurrent sedative-hypnotic use (60.5%; n = 274), and health service utilization. After adjusting for select covariates, male gender (odds ratio [OR] = 1.68, 95% confidence interval [CI] = 1.37-2.06), higher comorbidity, Medicare coverage (OR = 1.65, 95% CI = 1.22-2.23), any mental health or substance use diagnosis (OR = 1.58, 95% CI = 1.28-1.95), co-prescriptions of sedative-hypnotics (OR = 1.75, 95% CI = 1.42-2.16), and more emergency department and specialty pain clinic visits were associated with higher likelihood of high-dose prescriptions. Perspective: Higher-dose opioid therapy is being prescribed to 8.6% of back pain patients who receive long-term opioids. These patients had higher mental health and medical comorbidities and co-prescriptions of sedative-hypnotics, raising potential safety concerns. (C) 2012 by the American Pain Society. Published by Elsevier Inc. All rights reserved C1 [Kobus, Amy M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Smith, David H.; Johnson, Eric S.; Yang, Xiuhai; Petrik, Amanda F.; Deyo, Richard A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Morasco, Benjamin J.] Portland VA Med Ctr, Portland, OR USA. RP Kobus, AM (reprint author), Oregon Hlth & Sci Univ, Dept Psychiat, Mail Code OP 02,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM kobusa@ohsu.edu FU Agency of Healthcare Research and Quality [5T32HSO17582]; Oregon Clinical and Translational Research Institute; National Center for Research Resource, National Institutes of Health [UL1 RR024140]; National Institutes of Health Roadmap for Medical Research FX This study was supported in part by an NRSAT32 Fellowship in Health Services Research from the Agency of Healthcare Research and Quality to Dr. Kobus (5T32HSO17582) and a pilot grant from the Oregon Clinical and Translational Research Institute, grant number UL1 RR024140 from the National Center for Research Resources, National Institutes of Health; and the National Institutes of Health Roadmap for Medical Research. NR 33 TC 26 Z9 26 U1 1 U2 12 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD NOV PY 2012 VL 13 IS 11 BP 1131 EP 1138 DI 10.1016/j.jpain.2012.09.003 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 038MT UT WOS:000311179500010 PM 23117108 ER PT J AU Bailey, FA Williams, BR Goode, PS Woodby, LL Redden, DT Johnson, TM Taylor, JW Burgio, KL AF Bailey, F. Amos Williams, Beverly R. Goode, Patricia S. Woodby, Lesa L. Redden, David T. Johnson, Theodore M., II Taylor, Janice W. Burgio, Kathryn L. TI Opioid Pain Medication Orders and Administration in the Last Days of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE End of life; pain; hospice; inpatient; palliative care; opioids ID INTENSIVE-CARE-UNIT; OF-LIFE; HOSPICE CARE; HOSPITALIZED-PATIENTS; PALLIATIVE CARE; IMPROVE CARE; ILL PATIENTS; END; CANCER; QUALITY AB Context. Most patients with serious and life-limiting illness experience pain at some point in the illness trajectory. Objectives. To describe baseline pain management practices for imminently dying patients in Veterans Administration Medical Centers (VAMCs) and examine factors associated with these processes, including presence of opioid orders at the time of death and medication administration in the last seven days, 48 hours, and 24 hours of life. Methods. Data on orders and administration of opioid pain medication at the end of life were abstracted from the medical records of veterans who died in six VAMC hospitals in 2005. Results. Of 1068 patient records, 686 (64.2%) had an active order for an opioid medication at the time of death. Of these, 69.8% of patients had received the medication at some time within the last seven days of life, 61.2% within the last 48 hours, and 47.0% within the last 24 hours. In multivariable models, presence of an order for opioid pain medication at the time of death and administration within the last 24 hours were both significantly associated with having a Do Not Resuscitate (DNR) order (P < 0.0001/0.0002), terminal condition (P < 0.0001/< 0.0001), family presence (P < 0.0001/0.0023), location of death (P = 0.003/0.0005), and having pain noted in the care plan (P = 0.0073/0.0007). Conclusion. Findings indicate a need for improving availability of opioids for end-of-life care in the inpatient setting. Modifiable factors, such as family presence and goals-of-care discussions, suggest potential targets for intervention to improve recognition of the dying process and proactive planning for pain control. J Pain Symptom Manage 2012; 44: 681-691. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee. C1 [Bailey, F. Amos; Williams, Beverly R.; Goode, Patricia S.; Woodby, Lesa L.; Redden, David T.; Johnson, Theodore M., II; Taylor, Janice W.; Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Birmingham, AL USA. [Bailey, F. Amos; Williams, Beverly R.; Goode, Patricia S.; Woodby, Lesa L.; Redden, David T.; Johnson, Theodore M., II; Taylor, Janice W.; Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Atlanta, GA USA. [Bailey, F. Amos; Williams, Beverly R.; Goode, Patricia S.; Woodby, Lesa L.; Redden, David T.; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL USA. [Johnson, Theodore M., II] Emory Univ, Atlanta, GA 30322 USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA. EM kburgio@aging.uab.edu FU Department of Veterans Affairs, VHA, Health Services Research and Development Service [IIR 03-126] FX This research was supported by a Merit Review grant from the Department of Veterans Affairs, VHA, Health Services Research and Development Service (IIR 03-126; K. L. B., principal investigator; F. A. B., co-principal investigator). The funding source had no role in the collection, analysis, interpretation, or presentation of the information contained in this article. The authors do not perceive any conflicts of interest related to the research reported in this article. NR 52 TC 4 Z9 4 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2012 VL 44 IS 5 BP 681 EP 691 DI 10.1016/j.jpainsymman.2011.11.006 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 043TB UT WOS:000311570400007 PM 22765968 ER PT J AU Pugh, MJV Copeland, LA Zeber, JE Wang, CP Amuan, ME Mortensen, EM Tabares, JV Van Cott, AC Cooper, TL Cramer, JA AF Pugh, Mary Jo V. Copeland, Laurel A. Zeber, John E. Wang, Chen-Pin Amuan, Megan E. Mortensen, Eric M. Tabares, Jeffrey V. Van Cott, Anne C. Cooper, Toby L. Cramer, Joyce A. TI Antiepileptic Drug Monotherapy Exposure and Suicide-Related Behavior in Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE suicide; epidemiology; psychiatric disorders; antiepileptic drugs; geriatrics ID NEW-ONSET EPILEPSY; PROPENSITY SCORES; BIPOLAR DISORDER; FDA ALERT; RISK; POPULATION; INDIVIDUALS; DIVALPROEX; DEPRESSION; LITHIUM AB Objectives To examine the association between antiepileptic drug (AED) receipt and suicide-related behavior (SRB) in older veterans. Design Retrospective database analysis. Setting Veterans Health Administration (VHA) inpatient and outpatient care. Participants Veterans aged 65 and older in 2004 to 2006. Measurements SRB was identified using International Classification of Diseases, Ninth Revision, Clinical Modification codes, and new AED monotherapy was identified using the VHA product variable in pharmacy data. Comorbid conditions and medications were also identified as potential confounders using previously validated algorithms. Cox proportional hazards models controlling for the propensity to receive AEDs examined the association between any AED exposure, specific AEDs, and time to SRB. Results Within the eligible sample of 2.15 million individuals, 332 cases of SRB were found. Overall, 98% of participants were male, and 67% were non-Hispanic white. Affective disorders and severe psychiatric conditions were strongly associated with SRB and were included in the propensity score. AED exposure displayed a significant association with SRB (odds ratio = 4.10, 95% confidence interval (CI) = 3.85-6.63) after adjusting for propensity to receive AEDs. Stratified analyses found similar results for those with (hazard ratio (HR) = 4.00, 95% CI = 2.9-5.5) and without (HR = 4.57, 95% CI = 1.15-18.20) mental health comorbidities. Gabapentin, phenytoin, lamotrigine, levetiracetam, topiramate, and valproate were significantly associated with SRB. Conclusion Exposure to five common AEDs was associated with SRB in older VHA beneficiaries. Given the strong associations between psychiatric comorbidity and SRB, clinicians treating elderly adults should weigh this potential adverse effect into their consideration for treatment of those receiving AEDs. Particular attention should be given to depression and suicidality screening in people prescribed AEDs. J Am Geriatr Soc 60: 2042-2047, 2012. C1 [Pugh, Mary Jo V.; Wang, Chen-Pin; Tabares, Jeffrey V.] S Texas Vet Hlth Care Syst VERDICT, San Antonio, TX USA. [Pugh, Mary Jo V.; Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Copeland, Laurel A.; Zeber, John E.] Cent Texas Vet Hlth Care Syst, Temple, TX USA. [Copeland, Laurel A.; Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX USA. [Amuan, Megan E.] Edith Nourse Rogers Mem Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Gen Med, San Antonio, TX 78229 USA. [Mortensen, Eric M.] S Texas Vet Hlth Care Syst, Div Gen Internal Med, San Antonio, TX 78229 USA. [Van Cott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Van Cott, Anne C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Cooper, Toby L.] Carl R Darnall Army Med Ctr, Ft Hood, TX USA. [Cramer, Joyce A.] Yale Univ, Sch Med, New Haven, CT USA. [Cramer, Joyce A.] Epilepsy Therapy Project, Houston, TX USA. RP Pugh, MJV (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, VERDICT 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU VA Health Services Research and Development Service [IIR 06-062]; Central Texas, VA FX This study was funded by VA Health Services Research and Development Service Grant IIR 06-062 (Dr. Pugh, PI).; Laurel Copeland, and John Zeber receive salary from grants through their facility (Central Texas, VA); John Zeber is an editorial board member for the World Journal of Psychiatry, but receives no salary and declares no conflict with this manuscript. NR 42 TC 14 Z9 14 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2012 VL 60 IS 11 BP 2042 EP 2047 DI 10.1111/j.1532-5415.2012.04207.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 037LF UT WOS:000311105000006 PM 23110401 ER PT J AU Min, LL Shekelle, P AF Min, Lillian Shekelle, Paul TI Wanted: A FRAME for Staging Functional Decline in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID VULNERABLE ELDERS SURVEY; PEOPLE; COMMUNITY; FRAILTY C1 [Min, Lillian] Univ Michigan, Sch Med, Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA. [Shekelle, Paul] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. [Shekelle, Paul] RAND Corp Hlth, Santa Monica, CA USA. RP Min, LL (reprint author), Univ Michigan, Sch Med, Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA. NR 7 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2012 VL 60 IS 11 BP 2167 EP 2168 DI 10.1111/j.1532-5415.2012.04215.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 037LF UT WOS:000311105000025 PM 23148420 ER PT J AU Semla, TP Fick, DM AF Semla, Todd P. Fick, Donna M. TI 2012 UPDATED BEERS CRITERIA: GREATER APPLICABILITY TO EUROPE? RESPONSE SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Semla, Todd P.] US Dept Vet Affairs, Natl Pharm Benefits Management Serv, Hines, IL 60141 USA. [Semla, Todd P.] Northwestern Univ, Chicago, IL 60611 USA. [Fick, Donna M.] Penn State Univ, Sch Nursing, University Pk, PA 16802 USA. [Fick, Donna M.] Penn State Univ, Coll Med, University Pk, PA 16802 USA. RP Semla, TP (reprint author), US Dept Vet Affairs, Natl Pharm Benefits Management Serv, Hines, IL 60141 USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2012 VL 60 IS 11 BP 2189 EP 2190 DI 10.1111/j.1532-5415.2012.04218.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 037LF UT WOS:000311105000041 ER PT J AU Semla, TP Fick, DM AF Semla, Todd P. Fick, Donna M. TI CREDULOUS FONDNESS FOR CELECOXIB RESPONSE SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLO-OXYGENASE-2 INHIBITORS; BEERS CRITERIA; ULCER; RISK C1 [Semla, Todd P.] Northwestern Univ, US Dept Vet Affairs, Natl Pharm Benefits Management Serv, Chicago, IL 60611 USA. [Fick, Donna M.] Penn State Univ, Coll Med, Sch Nursing, University Pk, PA 16802 USA. RP Semla, TP (reprint author), Northwestern Univ, US Dept Vet Affairs, Natl Pharm Benefits Management Serv, Chicago, IL 60611 USA. NR 7 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2012 VL 60 IS 11 BP 2190 EP 2191 DI 10.1111/j.1532-5415.2012.04220.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 037LF UT WOS:000311105000043 ER PT J AU Yoshikawa, TT AF Yoshikawa, Thomas T. TI Reply to Response to Gerogeriatrics SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Yoshikawa, Thomas T.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Vet, Los Angeles, CA 90073 USA. [Yoshikawa, Thomas T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Yoshikawa, TT (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Vet, Los Angeles, CA 90073 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2012 VL 60 IS 11 BP 2192 EP 2192 DI 10.1111/j.1532-5415.2012.04221.x PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 037LF UT WOS:000311105000045 ER PT J AU Tafti, BA Berenji, GR Santiago, S Barack, BM AF Tafti, Bashir Akhavan Berenji, Gholam R. Santiago, Silverio Barack, Bruce M. TI Contralateral Decubitus Positioning Enhances Computed Tomographic Angiographic Evaluation of Pulmonary Vasculature in a Patient With a Pulmonary Arteriovenous Malformation SO JOURNAL OF THORACIC IMAGING LA English DT Editorial Material DE pulmonary embolism; arteriovenous malformation; computed tomography angiography; pulmonary angiography; diagnostic pitfall ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; CT; CIRCULATION; EMBOLISM AB Computed tomographic pulmonary angiography has become the diagnostic procedure of choice in patients suspected of having a pulmonary embolus. However, intrapulmonary shunting of blood in a variety of pathologic conditions can cause suboptimal opacification of the pulmonary arterial circulation and result in a suboptimal or even nondiagnostic study. Radiologists should be aware of these conditions and be familiar with positioning techniques to minimize such shunting. We report a patient suspected of having pulmonary embolism, in whom a preexisting unilateral arteriovenous malformation prevented adequate evaluation of the pulmonary circulation. Positioning the patient in the contralateral decubitus position significantly enhanced image quality. C1 [Tafti, Bashir Akhavan; Berenji, Gholam R.; Barack, Bruce M.] Vet Adm Greater Los Angeles Hlth Care Syst, Dept Imaging, Los Angeles, CA 90073 USA. [Santiago, Silverio] Vet Adm Greater Los Angeles Hlth Care Syst, Dept Pulm & Crit Care, Los Angeles, CA 90073 USA. RP Barack, BM (reprint author), Vet Adm Greater Los Angeles Hlth Care Syst, Dept Imaging, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Bruce.Barack@va.gov NR 10 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0883-5993 J9 J THORAC IMAG JI J. Thorac. Imaging PD NOV PY 2012 VL 27 IS 6 BP W193 EP W195 DI 10.1097/RTI.0b013e318242b4b3 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 028OT UT WOS:000310432600012 PM 22437510 ER PT J AU Larauche, M Mulak, A Kim, YS Labus, J Million, M Tache, Y AF Larauche, M. Mulak, A. Kim, Y. S. Labus, J. Million, M. Tache, Y. TI Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE colorectal distension; defecation; estrous cycle; manometry; naloxone; sex difference; stress-related visceral analgesia; water avoidance stress ID IRRITABLE-BOWEL-SYNDROME; CORTICOTROPIN-RELEASING-FACTOR; GENDER-DIFFERENCES; INDUCED ANTINOCICEPTION; INDIVIDUAL-DIFFERENCES; COLORECTAL DISTENSION; PSYCHOLOGICAL STRESS; DISTINCT MECHANISMS; GONADAL-HORMONES; COLONIC FUNCTION AB Background Chronic psychological stress-induced alterations in visceral sensitivity have been predominantly assessed in male rodents. We investigated the effect of acute and repeated water avoidance stress (WAS) on the visceromotor response (VMR) to colorectal distension (CRD) and the role of opioids in male and cycling female Wistar rats using a novel non-invasive manometric technique. Methods After a baseline VMR (1st CRD, day 0), rats were exposed to WAS (1 h day-1) either once or for four consecutive days, without injection or with naloxone (1 mg kg-1) or saline injected subcutaneously before each WAS session. Key Results The VMR to CRD recorded on day 1 or 4 immediately after the last WAS was reduced in both females and males. The visceral analgesia was mainly naloxone-dependent in females, but naloxone-independent in males. In non-injected animals, on days 2 and 5, VMR was not significantly different from baseline in males whereas females exhibited a significant VMR increase at 60 mmHg on day 5. Basal CRD and CRD on days 1, 2, and 5 in both sexes without WAS induced similar VMR. Conclusions & Inferences When monitored non-invasively, psychological stress induces an immediate poststress visceral analgesia mediated by an opiate signaling system in females while naloxone-independent in males, and hyperalgesia at 24 h after repeated stress only in females. These data highlight the importance of sex-specific interventions to modulate visceral pain response to stress. C1 [Larauche, M.] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr Anim Core, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Oppenheimer Family Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90024 USA. RP Larauche, M (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr Anim Core, 11301 Wilshire Blvd,CURE Bldg 115,Room 111, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU National Institutes of Health [P50 DK-64539, DK -41301, R01 DK-33061]; Kosciuszko Foundation; Soongsan Fellowship in Wonkwang University; Career Scientist Award [K01 DK088937, K08 DK071626, R03 DK084169]; [DK 78676] FX This work was supported by National Institutes of Health grants P50 DK-64539 and Center Grant DK -41301 (Animal Core), R01 DK-33061, and VA Career Scientist Award (YT), K01 DK088937 (ML), K08 DK071626 (JL), R03 DK084169 (JL), The Kosciuszko Foundation (AM), The Soongsan Fellowship in Wonkwang University 2009 (YSK), and DK 78676 (MM). NR 62 TC 17 Z9 17 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD NOV PY 2012 VL 24 IS 11 DI 10.1111/j.1365-2982.2012.01980.x PG 12 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 019OG UT WOS:000309748600010 PM 22776034 ER PT J AU Bamne, M Wood, J Chowdari, K Watson, AM Celik, C Mansour, H Klei, L Gur, RC Bradford, LD Calkins, ME Santos, AB Edwards, N Kwentus, J McEvoy, JP Allen, TB Savage, RM Nasrallah, HA Gur, RE Perry, RT Go, RCP Devlin, B Yolken, R Nimgaonkar, VL AF Bamne, Mikhil Wood, Joel Chowdari, Kodavali Watson, Annie M. Celik, Cemil Mansour, Hader Klei, Lambertus Gur, Ruben C. Bradford, L. DiAnne Calkins, Monica E. Santos, Alberto B. Edwards, Neil Kwentus, Joseph McEvoy, Joseph P. Allen, Trina B. Savage, Robert M. Nasrallah, Henry A. Gur, Raquel E. Perry, Rodney T. Go, Rodney C. P. Devlin, Bernie Yolken, Robert Nimgaonkar, Vishwajit L. TI Evaluation of HLA Polymorphisms in Relation to Schizophrenia Risk and Infectious Exposure SO SCHIZOPHRENIA BULLETIN LA English DT Article DE HLA; gene; HSV-1; cytomegalovirus; schizophrenia; African American ID AFRICAN-AMERICANS; COMMON VARIANTS; CONFERRING RISK; EXPLORE RISKS; ASSOCIATION; ANTIBODIES; CYTOMEGALOVIRUS; IMPAIRMENT; PAARTNERS; ANCESTRY AB Background: Genome-wide association studies (C WAS) implicate single nucleotide polymorphisms (SNPs) on chromosome 6p21.3-22.1, the human leukocyte antigen (HLA) region, as common risk factors for schizophrenia (SZ). Other studies implicate viral and protozoan exposure. Our study tests chromosome 6p SNPs for effects on SZ risk with and without exposure. Method: GWAS-significant SNPs and ancestry-informative marker SNPs were analyzed among African American patients with SZ (n = 604) and controls (n = 404). Exposure to herpes simplex virus, type 1 (ISV-1), cytomegalovirus (CMV), and Toxoplasma gondii (TOX) was assayed using specific antibody assays. Results: Five SNPs were nominally associated with SZ, adjusted for population admixture (P<.05, uncorrected for multiple comparisons). These SNPs were next analyzed in relation to infectious exposure. Multivariate analysis indicated significant association between rs3130297 genotype and HSV-1 exposure; the associated allele was different from the SZ risk allele. Conclusions: We propose a model for the genesis of SZ incorporating genomic variation in the HLA region and neurotropic viral exposure for testing in additional, independent African American samples. C1 [Bamne, Mikhil; Wood, Joel; Chowdari, Kodavali; Watson, Annie M.; Celik, Cemil; Mansour, Hader; Devlin, Bernie; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Devlin, Bernie; Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Celik, Cemil] GATA Sch Med, Dept Psychiat, Etlik, Turkey. [Klei, Lambertus] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Computat Genet Program, Pittsburgh, PA 15213 USA. [Gur, Ruben C.; Calkins, Monica E.] Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA. [Gur, Ruben C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Bradford, L. DiAnne] Morehouse Sch Med, Dept Psychiat, Atlanta, GA 30310 USA. [Santos, Alberto B.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Edwards, Neil] Univ Tennessee, Dept Psychiat, Coll Med, Memphis, TN USA. [Kwentus, Joseph] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [McEvoy, Joseph P.; Allen, Trina B.] Duke Univ, Med Ctr, John Umstead Hosp, Butler, NC USA. [Savage, Robert M.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA. [Nasrallah, Henry A.] Univ Cincinnati, Coll Med, Dept Psychiat & Neurosci, Cincinnati, OH USA. [Gur, Raquel E.] Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA. [Go, Rodney C. P.] Univ Alabama Birmingham, Dept Epidemiol & Int Hlth, Birmingham, AL USA. [Yolken, Robert] Johns Hopkins Univ, Med Ctr, Stanley Div Dev Neurovirol, Baltimore, MD 21218 USA. RP Nimgaonkar, VL (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, 3811 Ohara St, Pittsburgh, PA 15213 USA. EM nimga@pitt.edu FU National Institute of Mental Health at the National Institute of Health [MH66006, R01 MH66278, R01 MH066049, R01 MH66181-03, R01 MH66121, R01 MH066005, R01 MH66050, R01 MH66263, R01 MH66004, K08 MH79364]; Stanley Medical Research Institute [07-R1721]; University of Mississippi; Eli Lilly; Astra Zeneca; Pfizer; Bristol Meyers; Johnson Johnson; Takeda; University of Pennsylvania; AstraZeneca; Forest; Lilly; Roche/Genentech; Otsuka; Shire FX National Institute of Mental Health at the National Institute of Health (R01 grant numbers: MH66006 [LDB], R01 MH66278 [BD], R01 MH066049 [NE], R01 MH66181-03 [RCPG], R01 MH66121 [REG], R01 MH066005 [JK], R01 MH66050 [JPM], R01 MH66263 [VLN] and R01 MH66004 [AS], and K08 MH79364 [MC]; The Stanley Medical Research Institute (07-R1721[VLN]).; The authors thank the study participants and research faculty and staff for their time and effort, and they thank the Western Mental Health Center and Dr Thomas Hobbs for their support and contribution to recruitment in Ensley and Birmingham, AL. The following research faculty and staff contributed at the 8 sites: University of Alabama at Birmingham (central administrative site)-Roberta May; Charlie Swanson, Jr, MD; Laura Montgomery-Barefield, MD; Tolulope Aduroja, MD; Ryan Coleman; Rakesha Garner; Lee Prichett, RN; Thomas Kelley, RN; Marguerite Ryan Dickson, PhD; Muktar Aliyu, MD, DrPH; Adrienne Lahti, MD; Duke-Linda Blalock, RN; University of Mississippi-Karen Richardson, MS; Morehouse School of Medicine-Deirdre Evans-Cosby, MD; George W. Woods, MD; Kendaly Meadows, RN; Sandra Cummings, MSW; Cara Stephens, LCSW; and Kent Baker; Medical University of South Carolina-Shirley Hendrix, Cynthia Gilliard, Wanda Smalls-Smith, and Steven McLeod-Bryant; University of Pennsylvania-Felipe Da Silva; Alexandra Duncan-Ramos, MS; Jarrod Gutman; CarlaAnn Henry; Paul Hughett, PhD; Farzin Irani, PhD; Jennifer Jackson Greene, MS; Stephen J. Kanes, MD, PhD; Christian Kohler, MD; David Rice; Devon Seward; Steven Siegel, MD, PhD; Bruce Turetsky, MD; and Robert Witalec; University of Pittsburgh-Mary Miller, LPN; and Frank Fleischer, MBA; University of Tennessee-Kristin Beizai, MD; Marie Tobin, ME); Alyssa English, MD; Richard Sanders, BS; Shelia A. Dempsey, ADN; Martha Velez, CPS; Marianne Smith, BS, MA; Martha Garriott, MS, NCC; Nancy Fowler; Derrick W. Allen, MSSW; Phyllis Meyer, BS, PA; and Lynn Heustess, BS. Drs Allen, Bradford, Calkins, Devlin, Edwards, Go, McEvoy, Nimgaonkar, Santos, Weiner, Wood report no competing interests. Dr Kwentus receives grant support through collaborations of the University of Mississippi with Eli Lilly, Astra Zeneca, Pfizer, Bristol Meyers, Johnson & Johnson, and Takeda. Dr Raquel Gur receives grant support through collaborations of the University of Pennsylvania with AstraZeneca and Pfizer. Dr Henry Nasrallah has received research grants from Forest, Lilly, Roche/Genentech, Otsuka, Shire and honoraria for consulting or speaking at Genentech, Grunenthal, Janssen, Lundbeck, Merck, Novartis, Sunovion, and Boehringer-Inglheim. The other authors did not report any competing interests. NR 29 TC 11 Z9 11 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD NOV PY 2012 VL 38 IS 6 BP 1149 EP 1154 DI 10.1093/schbul/sbs087 PG 6 WC Psychiatry SC Psychiatry GA 035KD UT WOS:000310944500010 PM 22966150 ER PT J AU Perez, VB Ford, JM Roach, BJ Loewy, RL Stuart, BK Vinogradov, S Mathalon, DH AF Perez, Veronica B. Ford, Judith M. Roach, Brian J. Loewy, Rachel L. Stuart, Barbara K. Vinogradov, Sophia Mathalon, Daniel H. TI Auditory Cortex Responsiveness During Talking and Listening: Early Illness Schizophrenia and Patients at Clinical High-Risk for Psychosis SO SCHIZOPHRENIA BULLETIN LA English DT Article DE psychosis; clinical high-risk; self-monitoring; forward model; corollary discharge ID COROLLARY DISCHARGE DYSFUNCTION; CORTICAL RESPONSIVENESS; INITIAL PRODROME; HALLUCINATIONS; SPEECH; PERCEPTION; PREDICTION; DISORDERS; RESPONSES; VALIDITY AB Objective: The corollary discharge mechanism is theorized to dampen sensations resulting from our own actions and distinguish them from environmental events. Deficits in this mechanism in schizophrenia may contribute to misperceptions of self-generated sensations as originating from external stimuli. We previously found attenuated speech-related suppression of auditory cortex in chronic patients, consistent with such deficits. Whether this abnormality precedes psychosis onset, emerges early in the illness, and/or progressively worsens with illness chronicity, is unknown. Methods: Event-related potentials (ERPs) were recorded from schizophrenia patients (SZ; n = 75) and age-matched healthy controls (HC; n = 77). A subsample of early illness schizophrenia patients (ESZ; n = 39) was compared with patients at clinical high-risk for psychosis (CHR; n = 35) and to a subgroup of age-matched HC (n = 36) during a Talk-Listen paradigm. The N1 ERP component was elicited by vocalizations as subjects talked (Talk) and heard them played back (Listen). Results: As shown previously, SZ showed attenuated speech-related N1 suppression relative to HC. This was also observed in ESZ. N1 suppression values in CHR were intermediate to HC and ESZ and not statistically distinguishable from either comparison group. Age-corrected N1 Talk-Listen difference Z scores were not correlated with illness duration in the full SZ sample. Conclusions: Putative dysfunction of the corollary discharge mechanism during speech is evident early in the illness and is stable over its course. The intermediate effects in CHR patients may reflect the heterogeneity of this group, requiring longitudinal follow-up data to address if speech-related N1 suppression abnormalities are a risk marker for conversion to psychosis. C1 [Perez, Veronica B.; Ford, Judith M.; Roach, Brian J.; Loewy, Rachel L.; Stuart, Barbara K.; Vinogradov, Sophia; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Perez, Veronica B.; Ford, Judith M.; Roach, Brian J.; Vinogradov, Sophia; Mathalon, Daniel H.] San Francisco Vet Adm Med Ctr, Dept Psychiat, San Francisco, CA USA. RP Mathalon, DH (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974 FU National Institutes of Health [R01MH076989, K02MH067967] FX National Institutes of Health (R01MH076989, K02MH067967). NR 40 TC 7 Z9 7 U1 2 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD NOV PY 2012 VL 38 IS 6 BP 1216 EP 1224 DI 10.1093/schbul/sbr124 PG 9 WC Psychiatry SC Psychiatry GA 035KD UT WOS:000310944500017 PM 21993915 ER PT J AU Hu, XM Li, PY Guo, YL Wang, HY Leak, RK Chen, SE Gao, YQ Chen, J AF Hu, Xiaoming Li, Peiying Guo, Yanling Wang, Haiying Leak, Rehana K. Chen, Songela Gao, Yanqin Chen, Jun TI Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia SO STROKE LA English DT Article DE inflammation macrophage; microglia; phagocytosis; polarization; stroke ID MACROPHAGE POLARIZATION; GENE-EXPRESSION; SPINAL-CORD; MICROGLIA; BRAIN; INFLAMMATION; ACTIVATION; RESPONSES; MOUSE; CELLS AB Background and Purpose-Mononuclear phagocytes are highly plastic cells that assume diverse phenotypes in response to microenvironmental signals. The phenotype-specific roles of microglia/macrophages in ischemic brain injury are poorly understood. A comprehensive characterization of microglia/macrophage polarization after ischemia may advance our knowledge of poststroke damage/recovery. Methods-Focal transient cerebral ischemia was induced in mice for 60 minutes; animals were euthanized at 1 to 14 days of reperfusion. Reverse-transcriptase polymerase chain reaction and immunohistochemical staining for M1 and M2 markers were performed to characterize phenotypic changes in brain cells, including microglia and infiltrating macrophages. In vitro experiments using a transwell system, a conditioned medium transfer system, or a coculture system allowing cell-to-cell contacts were used to further elucidate the effect of neuronal ischemia on microglia/macrophage polarization and, conversely, the effect of microglia/macrophage phenotype on the fate of ischemic neurons. Results-Local microglia and newly recruited macrophages assume the M2 phenotype at early stages of ischemic stroke but gradually transformed into the M1 phenotype in peri-infarct regions. In vitro experiments revealed that ischemic neurons prime microglial polarization toward M1 phenotype. M1-polarized microglia or M1-conditioned media exacerbated oxygen glucose deprivation-induced neuronal death. In contrast, maintaining the M2 phenotype of microglia protected neurons against oxygen glucose deprivation. Conclusions-Our results suggest that microglia/macrophages respond dynamically to ischemic injury, experiencing an early "healthy" M2 phenotype, followed by a transition to a "sick" M1 phenotype. These dual and opposing roles of microglia/macrophages suggest that stroke therapies should be shifted from simply suppressing microglia/macrophage toward adjusting the C1 [Hu, Xiaoming; Li, Peiying; Wang, Haiying; Chen, Songela; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Hu, Xiaoming; Li, Peiying; Wang, Haiying; Chen, Songela; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Hu, Xiaoming; Li, Peiying; Guo, Yanling; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Hu, Xiaoming; Li, Peiying; Guo, Yanling; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Pittsburgh, PA 15219 USA. [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. EM hux2@upmc.edu; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417 FU National Institutes of Health [NS045048, NS36736, NS43802, NS56118]; American Heart Association [10POST4150028]; Chinese Natural Science Foundation [30870794] FX This project was supported by National Institutes of Health grants to J.C. (NS045048, NS36736, NS43802, and NS56118), a grant from the American Heart Association to X.H (10POST4150028), and Chinese Natural Science Foundation grants to Y. Gao. (30870794). NR 27 TC 261 Z9 263 U1 13 U2 72 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD NOV PY 2012 VL 43 IS 11 BP 3063 EP U474 DI 10.1161/STROKEAHA.112.659656 PG 11 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 028OV UT WOS:000310432800300 PM 22933588 ER PT J AU Gan, Y Xing, J Jing, Z Stetler, RA Zhang, F Luo, YM Ji, XM Gao, YQ Cao, GD AF Gan, Yu Xing, Juan Jing, Zheng Stetler, R. Anne Zhang, Feng Luo, Yumin Ji, Xunming Gao, Yanqin Cao, Guodong TI Mutant Erythropoietin Without Erythropoietic Activity Is Neuroprotective Against Ischemic Brain Injury SO STROKE LA English DT Article DE AKT; cerebral ischemia; ERK1/2; erythropoietin; erythropoietin mutant; neuroprotection; neurotoxicity ID CEREBRAL-ISCHEMIA; IN-VIVO; PROTECTS; ASIALOERYTHROPOIETIN; NEURONS AB Background and Purpose-Erythropoietin (EPO) confers potent neuroprotection against ischemic injury. However, treatment for stroke requires high doses and multiple administrations of EPO, which may cause deleterious side effects due to its erythropoietic activity. This study identifies a novel nonerythropoietic mutant EPO and investigates its potential neuroprotective effects and underlying mechanism in an animal model of cerebral ischemia. Methods-We constructed a series of mutant EPOs, each containing a single amino acid mutation within the erythropoietic motif, and tested their erythropoietic activity. Using cortical neuronal cultures exposed to -N--methyl--d--aspartate neurotoxicity and a murine model of transient middle cerebral artery occlusion, neuroprotection and neurofunctional outcomes were assessed as well as activation of intracellular signaling pathways. Results-The serine to isoleucine mutation at position 104 (S104I-EPO) completely abolished the erythropoietic and -platelet--stimulating activity of EPO. Administration of S104-I--EPO significantly inhibited -N--methyl-d--aspartate--induced neuronal death in primary cultures and protected against cerebral infarction and neurological deficits with an efficacy similar to that of -wild--type EPO. Both S104-I--EPO and -wild--type EPO activated similar prosurvival signaling pathways such as phosphatidylinositol 3-kinase/AKT, -mitogen--activated protein kinase/extracellular -signal--regulated kinase 1/2, and STAT5. Inhibition of phosphatidylinositol 3-kinase/AKT or -mitogen--activated protein kinase/extracellular -signal-regulated kinase 1/2 signaling pathways significantly attenuated the neuroprotective effects of S104-I--EPO, indicating that activation of these pathways underlies the neuroprotective mechanism of mutant EPO against cerebral ischemia. Conclusions-S104-I--EPO confers neuroprotective effects comparable to those of -wild--type EPO against ischemic brain in-jury with the added benefit of lacking erythropoietic and -platelet--stimulating side effects. Our novel findings suggest that the nonerythropoietic mutant EPO is a legitimate candidate for ischemic stroke intervention. (Stroke. 2012; 43: 3071-3077.) C1 [Gan, Yu; Xing, Juan; Jing, Zheng; Stetler, R. Anne; Cao, Guodong] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15260 USA. [Gan, Yu; Jing, Zheng; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Luo, Yumin; Ji, Xunming] Capital Univ Med Sci, Xuanwu Hosp, Res Inst, Beijing, Peoples R China. [Stetler, R. Anne; Gao, Yanqin; Cao, Guodong] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. RP Cao, GD (reprint author), Univ Pittsburgh, Dept Neurol, Sch Med, BST S505,3500 Terrace St, Pittsburgh, PA 15260 USA. EM caog@upmc.edu FU Department of Veteran's Affairs Merit Review grant 1I01RX000199; National Institutes of Health/National Institute of Neurological Disorders and Stroke [NS053473]; American Heart Association Scientist Development [06300064N] FX This project was supported by Department of Veteran's Affairs Merit Review grant 1I01RX000199 (to Dr Cao), National Institutes of Health/National Institute of Neurological Disorders and Stroke grant NS053473 (to Dr Cao), and American Heart Association Scientist Development Grant 06300064N (to Dr Cao). NR 15 TC 10 Z9 11 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD NOV PY 2012 VL 43 IS 11 BP 3071 EP 3077 DI 10.1161/STROKEAHA.112.663120 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 028OV UT WOS:000310432800301 PM 22984011 ER PT J AU Durazzo, TC Insel, PS Weiner, MW AF Durazzo, Timothy C. Insel, Philip S. Weiner, Michael W. CA Alzheimer Dis Neuroimaging TI Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; MRI; Brain volumes; Brain reward system; Cigarette smoking; Brain atrophy ID MAGNETIC-RESONANCE SPECTROSCOPY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; SMOKERS; NEUROBIOLOGY; ADDICTION; DEMENTIA; ALCOHOLISM; PATHOLOGY AB Background: Little is known about the effects of cigarette smoking on longitudinal brain morphological changes in the elderly. This study investigated the effects of a history of cigarette smoking on changes in regional brain volumes over 2 years in healthy, cognitively intact elderly individuals. We predicted that individuals with a history of cigarette smoking, compared with never smokers, demonstrate greater rate of atrophy over 2 years in regions that manifest morphological abnormalities in the early stages of Alzheimer's disease (AD), as well as in the extended brain reward/executive oversight system (BREOS), which is implicated in the development and maintenance of substance use disorders. Methods: Participants were healthy, cognitively normal elderly control subjects (75.9 +/- 4.8 years of age) with any lifetime history of cigarette smoking (n = 68) or no history of smoking (n = 118). Data were obtained through the Alzheimer Disease Neuroimaging Initiative from 2005 to 2010. Participants completed four magnetic resonance scans over 2 years. A standardized protocol using high-resolution three-dimensional T1-weighted sequences at 1.5 T was used for structural imaging and regional brain volumetric analyses. Results: Smokers demonstrated a significantly greater atrophy rate over 2 years than nonsmokers in multiple brain regions associated with the early stages of AD, as well as in the BREOS system. Groups did not differ on the rate of global cortical atrophy. Conclusions: A history of cigarette smoking in this healthy elderly cohort was associated with decreased structural integrity of multiple brain regions, which manifested as a greater rate of atrophy over 2 years in regions specifically affected by incipient AD as well as chronic substance abuse. (C) 2012 The Alzheimer's Association. All rights reserved. C1 [Durazzo, Timothy C.; Insel, Philip S.; Weiner, Michael W.] San Francisco VA Med Ctr, CIND, San Francisco, CA USA. [Durazzo, Timothy C.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, CIND, San Francisco, CA USA. EM timothy.durazzo@ucsf.edu FU ADNI; National Institute on Aging [U01 AG024904]; National Institute of Biomedical Imaging and Bioengineering; National Institutes of Health [P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435, K01 DA 024136]; Dana Foundation FX Data collection and sharing for this project was funded by the ADNI. ADNI is funded by the National Institute on Aging (U01 AG024904), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer, Inc., F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., and Wyeth, as well as nonprofit partners-the Alzheimer Association and Alzheimer Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org; http://www.fnih.org; http://www.fnih.org; http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer Disease Cooperative Study at the University of California, San Diego, CA. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles, CA. This research was also supported by National Institutes of Health grants P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435, K01 DA 024136; The Dana Foundation; and by resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco, CA. T.C.D. and P.S.I. completed all statistical analyses. T.C.D., P.S.I., and M.W.W. were responsible for manuscript preparation. T.C.D. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analyses. The authors thank the participants who made this research possible. NR 45 TC 20 Z9 21 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2012 VL 8 IS 6 BP 513 EP 519 DI 10.1016/j.jalz.2011.10.006 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 038KW UT WOS:000311174600007 PM 23102121 ER PT J AU Wild, KV Mattek, NC Maxwell, SA Dodge, HH Jimison, HB Kaye, JA AF Wild, Katherine V. Mattek, Nora C. Maxwell, Shoshana A. Dodge, Hiroko H. Jimison, Holly B. Kaye, Jeffrey A. TI Computer-related self-efficacy and anxiety in older adults with and without mild cognitive impairment SO ALZHEIMERS & DEMENTIA LA English DT Article DE Computer use; Mild cognitive impairment; Older adults ID CONTROLLED-TRIAL; INTERNET USAGE; TECHNOLOGY; ATTITUDES; HEALTH; WOMEN AB Background: This study examines differences in computer-related self-efficacy and anxiety in subgroups of older adults, and changes in those measures after exposure to a systematic training program and subsequent computer use. Methods: Participants were volunteers in the Intelligent Systems for Assessment of Aging Changes study (ISAAC) carried out by the Oregon Center for Aging and Technology. Participants were administered two questionnaires before training and again I year later, which were related to computer self-efficacy and anxiety. Continuous recording of computer use was also assessed for a subset of participants. Results: Baseline comparisons by sex, age, education, living arrangement, and computer proficiency, but not cognitive status, yielded significant differences in confidence and anxiety related to specific aspects of computer use. At 1-year follow-up, participants reported less anxiety and greater confidence. However, the benefits of training and exposure varied by group and task. Comparisons based on cognitive status showed that the cognitively intact participants benefited more from training and/or experience with computers than did participants with mild cognitive impairment (MCI), who after 1 year continued to report less confidence and more anxiety regarding certain aspects of computer use. Conclusion: After I year of consistent computer use, cognitively intact participants in this study reported reduced levels of anxiety and increased self-confidence in their ability to perform specific computer tasks. Participants with MCI at baseline were less likely to demonstrate increased efficacy or confidence than their cognitively intact counterparts. (C) 2012 The Alzheimer's Association. All rights reserved. C1 [Wild, Katherine V.; Mattek, Nora C.; Maxwell, Shoshana A.; Dodge, Hiroko H.; Jimison, Holly B.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Wild, Katherine V.; Mattek, Nora C.; Maxwell, Shoshana A.; Dodge, Hiroko H.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Jimison, Holly B.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. RP Wild, KV (reprint author), Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. EM wildk@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU National Institutes of Health [P30-AG008017, P30-AG024978, R01-AG024059, K01-AG23014]; Department of Veterans Affairs [P30-AG008017, M01-RR000334]; Intel Corporation FX This study was supported by National Institutes of Health grants P30-AG008017, P30-AG024978, R01-AG024059, and K01-AG23014; the Department of Veterans Affairs grants P30-AG008017 and M01-RR000334; and Intel Corporation. NR 29 TC 14 Z9 14 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2012 VL 8 IS 6 BP 544 EP 552 DI 10.1016/j.jalz.2011.12.008 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 038KW UT WOS:000311174600011 PM 23102124 ER PT J AU Erten-Lyons, D Sherbakov, LO Piccinin, AM Hofer, SM Dodge, HH Quinn, JF Woltjer, RL Kramer, PL Kaye, JA AF Erten-Lyons, Deniz Sherbakov, Lena O. Piccinin, Andrea M. Hofer, Scott M. Dodge, Hiroko H. Quinn, Joseph F. Woltjer, Randy L. Kramer, Patricia L. Kaye, Jeffrey A. TI Review of selected databases of longitudinal aging studies SO ALZHEIMERS & DEMENTIA LA English DT Review DE Longitudinal study; Aging; Aged; Biomarkers; Database ID ALZHEIMERS-DISEASE AB One of the recommendations of the 2010 Leon Thal Symposium, organized to develop strategies to prevent Alzheimer's disease, was to build a global database of longitudinal aging studies. Although several databases of longitudinal aging studies exist, none of these are comprehensive or complete. In this article, we review selected databases of longitudinal aging studies. We also make recommendations on future steps to create a comprehensive database. Additionally, we discuss issues related to data harmonization. (C) 2012 The Alzheimer's Association. All rights reserved. C1 [Erten-Lyons, Deniz; Sherbakov, Lena O.; Dodge, Hiroko H.; Quinn, Joseph F.; Woltjer, Randy L.; Kramer, Patricia L.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Erten-Lyons, Deniz; Quinn, Joseph F.; Kaye, Jeffrey A.] Portland VA Med Ctr, Off Res & Dev, Portland, OR USA. [Piccinin, Andrea M.; Hofer, Scott M.] Univ Victoria, Dept Psychol, Victoria, BC, Canada. [Hofer, Scott M.] Univ Victoria, Ctr Aging, Victoria, BC, Canada. RP Erten-Lyons, D (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM ertenlyo@ohsu.edu RI Hofer, Scott/D-9090-2014 OI Hofer, Scott/0000-0001-8923-4337; Kaye, Jeffrey/0000-0002-9971-3478 FU Oregon Clinical and Translational Research Institute; National Center for Research Resources, a component of the NIH [UL1 RR024140]; NIH Road-map for Medical Research; Department of Veterans Affairs; NIH [AG08017] FX This publication was made possible with support from the Oregon Clinical and Translational Research Institute, grant number UL1 RR024140 from the National Center for Research Resources, a component of the NIH, and NIH Road-map for Medical Research; the Department of Veterans Affairs; and the NIH grant number AG08017. NR 15 TC 5 Z9 5 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2012 VL 8 IS 6 BP 584 EP 589 DI 10.1016/j.jalz.2011.09.232 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 038KW UT WOS:000311174600016 PM 23102128 ER PT J AU Liu, Y Rajagopal, M Lee, K Battini, L Flores, D Gusella, GL Pao, AC Rohatgi, R AF Liu, Yu Rajagopal, Madhumitha Lee, Kim Battini, Lorenzo Flores, Daniel Gusella, G. Luca Pao, Alan C. Rohatgi, Rajeev TI Prostaglandin E-2 mediates proliferation and chloride secretion in ADPKD cystic renal epithelia SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE prostanoid; secretory renal epithelia; cystic epithelia; cyclooxygenase ID POLYCYSTIC KIDNEY-DISEASE; COLLECTING DUCT CELLS; RETINAL-PIGMENT EPITHELIUM; REGULATED KINASE PATHWAY; COLORECTAL-CANCER; COLON-CANCER; PROSTANOID PRODUCTION; EP2 RECEPTOR; GROWTH; EXPRESSION AB Liu Y, Rajagopal M, Lee K, Battini L, Flores D, Gusella GL, Pao AC, Rohatgi R. Prostaglandin E-2 mediates proliferation and chloride secretion in ADPKD cystic renal epithelia. Am J Physiol Renal Physiol 303: F1425-F1434, 2012. First published August 29, 2012; doi: 10.1152/ajprenal.00010.2012.-Prostaglandin E-2 (PGE(2)) contributes to cystogenesis in genetically nonorthologous models of autosomal dominant polycystic kidney disease (ADPKD). However, it remains unknown whether PGE(2) induces the classic features of cystic epithelia in genetically orthologous models of ADPKD. We hypothesized that, in ADPKD epithelia, PGE(2) induces proliferation and chloride (Cl-) secretion, two archetypal phenotypic features of ADPKD. To test this hypothesis, proliferation and Cl- secretion were measured in renal epithelial cells deficient in polycystin-1 (PC-1). PC-1-deficient cells increased in cell number (proliferated) faster than PC-1-replete cells, and this proliferative advantage was abrogated by cyclooxygenase inhibition, indicating a role for PGE(2) in cell proliferation. Exogenous administration of PGE(2) increased proliferation of PC-1-deficient cells by 38.8 +/- 5.2% (P < 0.05) but inhibited the growth of PC-1-replete control cells by 49.4 +/- 1.9% (P < 0.05). Next, we tested whether PGE(2)-specific E prostanoid (EP) receptor agonists induce intracellular cAMP and downstream beta-catenin activation. PGE(2) and EP4 receptor agonism (TCS 2510) increased intracellular cAMP concentration and the abundance of active beta-catenin in PC-1-deficient cells, suggesting a mechanism for PGE(2)-mediated proliferation. Consistent with this hypothesis, antagonizing EP4 receptors reverted the growth advantage of PC-1-deficient cells, implicating a central role for the EP4 receptor in proliferation. To test whether PGE(2)-dependent Cl- secretion is also enhanced in PC-1-deficient cells, we used an Ussing chamber to measure short-circuit current (I-sc). Addition of PGE(2) induced a fivefold higher increase in I-sc in PC-1-deficient cells compared with PC-1-replete cells. This PGE(2)-induced increase in I-sc in PC-1-deficient cells was blocked by CFTR-172 and flufenamic acid, indicating that PGE(2) activates CFTR and calcium-activated Cl channels. In conclusion, PGE(2) activates aberrant signaling pathways in PC-1-deficient epithelia that contribute to the proliferative and secretory phenotype characteristic of ADPKD and suggests a therapeutic role for PGE(2) inhibition and EP4 receptor antagonism. C1 [Liu, Yu; Lee, Kim; Battini, Lorenzo; Flores, Daniel; Gusella, G. Luca; Rohatgi, Rajeev] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Liu, Yu; Flores, Daniel; Rohatgi, Rajeev] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Rajagopal, Madhumitha; Pao, Alan C.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Rohatgi, Rajeev] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. RP Rohatgi, R (reprint author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM rajeev.rohatgi@mssm.edu FU Hepato/Renal Fibrocystic Diseases Core Center [P30DK074038]; Department of Veterans Affairs Merit Review [1I01BX000388]; Satellite Healthcare Norman S. Coplon Extramural Grants; National Institutes of Health [5R01DK78231-2]; Department of Defense [W81XWH-09-1-0269] FX This work was supported by Pilot and Feasibility Grant (to R. Rohatgi) from the Hepato/Renal Fibrocystic Diseases Core Center (P30DK074038), Department of Veterans Affairs Merit Review 1I01BX000388 (to R. Rohatgi), Satellite Healthcare Norman S. Coplon Extramural Grants (to A. C. Pao and R. Rohatgi), National Institutes of Health Grant 5R01DK78231-2 and the Department of Defense Grant W81XWH-09-1-0269 to G. L. Gusella. NR 48 TC 15 Z9 15 U1 0 U2 12 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD NOV PY 2012 VL 303 IS 10 BP F1425 EP F1434 DI 10.1152/ajprenal.00010.2012 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 038XU UT WOS:000311208200004 PM 22933297 ER PT J AU Laserna, E Sibila, O Aguilar, PR Mortensen, EM Anzueto, A Blanquer, JM Sanz, F Rello, J Marcos, PJ Velez, MI Aziz, N Restrepo, MI AF Laserna, Elena Sibila, Oriol Aguilar, Patrick R. Mortensen, Eric M. Anzueto, Antonio Blanquer, Jose M. Sanz, Francisco Rello, Jordi Marcos, Pedro J. Velez, Maria I. Aziz, Nivin Restrepo, Marcos I. TI Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia SO CHEST LA English DT Article ID RESEARCH TEAM COHORT; INTENSIVE-CARE-UNIT; CARBON-DIOXIDE; VALIDATION; GUIDELINES; SEVERITY; OUTCOMES; MANAGEMENT; DATABASE; THERAPY AB Objective: The purpose of our study was to examine in patients hospitalized with community-acquired pneumonia (CAP) the association between abnormal PaCO2 and ICU admission and 30-day mortality. Methods: A retrospective cohort study was conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of CAR Arterial blood gas analyses were obtained with measurement of PaCO2 on admission. Multivariate analyses were performed using 30-day mortality and ICU admission as the dependent measures. Results: Data were abstracted on 453 subjects with a documented arterial blood gas analysis. One hundred eighty-nine patients (41%) had normal PaCO2 (35-45 mm Hg), 194 patients (42%) had a PaCO2 <35 mm Hg (hypocapnic), and 70 patients (15%) had a PaCO2 > 45 mm Hg (hypercapnic). In the multivariate analysis, after adjusting for severity of illness, hypocapnic patients had greater 30-day mortality (OR = 2.84; 95% CI, 1.28-6.30) and a higher need for ICU admission (OR = 2.88; 95% CI, 1.68-4.95) compared with patients with normal PaCO2. In addition, hypercapnic patients had a greater 30-day mortality (OR = 3.38; 95% CI, 1.38-8.30) and a higher need for ICU admission (OR = 5.35; 95% CI, 2.80-10.23). When patients with COPD were excluded from the analysis, the differences persisted between groups. Conclusion: In hospitalized patients with CAP, both hypocapnia and hypercapnia were associated with an increased need for ICU admission and higher 30-day mortality. These findings persisted after excluding patients with CAP and with COPD. Therefore, PaCO2 should be considered for inclusion in future severity stratification criteria to appropriate identified patients who will require a higher level of care and are at risk for increased mortality. CHEST 2012; 142(5):1193-1199 C1 [Laserna, Elena; Sibila, Oriol; Aguilar, Patrick R.; Anzueto, Antonio; Velez, Maria I.; Aziz, Nivin; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Laserna, Elena] Hosp Comarcal Mollet, Serv Pneumol, Mollet Del Valles, Spain. [Sibila, Oriol] Hosp Santa Creui & St Pau, Serv Pneumol, Barcelona, Spain. [Mortensen, Eric M.] VA N Texas Hlth Care Syst, Dallas, TX USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Anzueto, Antonio; Velez, Maria I.; Restrepo, Marcos I.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Blanquer, Jose M.] Unidad Cuidados Intens Resp Hosp Clin Univ, Valencia, Spain. [Sanz, Francisco] Consorci Hosp Gen Univ, Serv Neumol, Valencia, Spain. [Rello, Jordi] Univ Autonoma Barcelona, Serv Med Intens, Hosp Vall dHebron, CIBERES,VHICU, E-08193 Barcelona, Spain. [Marcos, Pedro J.] Complejo Hosp Univ A Coruna, Serv Neumol, La Coruna, Spain. Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst ALMD, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014; Marcos, Pedro J/K-9965-2015 OI Marcos, Pedro J/0000-0001-9600-3537; Rello, Jordi/0000-0003-0676-6210; Mortensen, Eric/0000-0002-3880-5563 FU Howard Hughes Medical Institute faculty start-up grant [00378-001]; Department of Veteran Affairs Veterans Integrated Service Network [17]; Sociedad Espanola de Neumologia y Cirugia Toracica; Societat Catalana de Pneumologia; Fundacio Catalana de Pneumologia; Instituto de Salud Carlos III [BAE11/00102]; National Heart, Lung, and Blood Institute [K23HL096054] FX This research was supported by a Howard Hughes Medical Institute faculty start-up grant [00378-001] and a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant. Drs Laserna and Sibila are supported by Sociedad Espanola de Neumologia y Cirugia Toracica, Societat Catalana de Pneumologia, and Fundacio Catalana de Pneumologia. Dr Sibila is supported by Instituto de Salud Carlos III [Grant BAE11/00102]. Dr Restrepo's time is partially protected by an award from the National Heart, Lung, and Blood Institute [K23HL096054]. NR 33 TC 17 Z9 17 U1 1 U2 2 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2012 VL 142 IS 5 BP 1193 EP 1199 DI 10.1378/chest.12-0576 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 036EV UT WOS:000311010100022 PM 22677348 ER PT J AU Maguen, S Metzler, TJ Bosch, J Marmar, CR Knight, SJ Neylan, TC AF Maguen, Shira Metzler, Thomas J. Bosch, Jeane Marmar, Charles R. Knight, Sara J. Neylan, Thomas C. TI KILLING IN COMBAT MAY BE INDEPENDENTLY ASSOCIATED WITH SUICIDAL IDEATION SO DEPRESSION AND ANXIETY LA English DT Article DE suicide; killing; depression; stress disorders; posttraumatic; war; veterans ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH SYMPTOMS; VIETNAM VETERANS; WAR VETERANS; TRAUMATIC STRESS; US VETERANS; RISK; IMPACT; IRAQ; PREVALENCE AB Background The United States military has lost more troops to suicide than to combat for the second year in a row and better understanding combat-related risk factors for suicide is critical. We examined the association of killing and suicide among war veterans after accounting for PTSD, depression, and substance use disorders. Methods We utilized a cross-sectional, retrospective, nationally representative sample of Vietnam veterans from the National Vietnam Veterans Readjustment Study (NVVRS). In order to perform a more in depth analysis, we utilized a subsample of these data, the NVVRS Clinical Interview Sample (CIS), which is representative of 1.3 million veterans who were eligible for the clinical interview by virtue of living in proximity to an interview site, located within 28 standard metropolitan regions throughout the United States. Results Veterans who had higher killing experiences had twice the odds of suicidal ideation, compared to those with lower or no killing experiences (OR = 1.99, 95% CI = 1.073.67), even after adjusting for demographic variables, PTSD, depression, substance use disorders, and adjusted combat exposure. PTSD (OR = 3.42, 95% CI = 1.0910.73), depression (OR = 11.49, 95% CI = 2.1262.38), and substance use disorders (OR = 3.98, 95% CI = 1.0115.60) were each associated with higher odds of suicidal ideation. Endorsement of suicide attempts was most strongly associated with PTSD (OR = 5.52, 95% CI = 1.2125.29). Conclusions Killing experiences are not routinely examined when assessing suicide risk. Our findings have important implications for conducting suicide risk assessments in veterans of war. Depression and Anxiety 00:16, 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Maguen, Shira] San Francisco VA Med Ctr, PTSD Program 116 P, San Francisco, CA 94121 USA. [Maguen, Shira; Metzler, Thomas J.; Knight, Sara J.; Neylan, Thomas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Marmar, Charles R.] NYU, Langone Med Ctr, New York, NY USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, PTSD Program 116 P, 4150 Clement St, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov FU VA Health Services Research and Development Career Development Award [RCD 06-042] FX This research was supported by the VA Health Services Research and Development Career Development Award (RCD 06-042: Maguen). NR 36 TC 34 Z9 34 U1 1 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD NOV PY 2012 VL 29 IS 11 BP 918 EP 923 DI 10.1002/da.21954 PG 6 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 031YS UT WOS:000310679300002 PM 22505038 ER PT J AU Bhattacharya, A Hamilton, R Rios, C Jernigan, AL Zhang, YQ Sabia, M Rahman, MM Li, Y Qi, WB Van Remmen, H AF Bhattacharya, Arunabh Hamilton, Ryan Rios, Carmen Jernigan, Amanda L. Zhang, Yiqiang Sabia, Marian Rahman, Md M. Li, Yan Qi, Wenbo Van Remmen, Holly TI Divergent Roles for 12/15-Lipoxygenase and 5-Lipoxygenase Lipid Metabolic Pathways in Neurogenic Muscle Atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 19th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine (SFRBM) CY NOV 14-18, 2012 CL San Diego, CA SP Soc Free Rad Biol & Med (SFRBM) C1 [Bhattacharya, Arunabh; Hamilton, Ryan; Rios, Carmen; Jernigan, Amanda L.; Zhang, Yiqiang; Sabia, Marian; Rahman, Md M.; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2012 VL 53 SU 2 BP S124 EP S124 DI 10.1016/j.freeradbiomed.2012.10.306 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 031RS UT WOS:000310660600322 ER PT J AU Mashmoushi, AK Hofbauer, AF Gilkeson, GS Oates, JC AF Mashmoushi, Ahmad K. Hofbauer, Ann F. Gilkeson, Gary S. Oates, Jim C. TI Role of Nitric Oxide in Podocyte Physiology in Lupus Nephritis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 19th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine (SFRBM) CY NOV 14-18, 2012 CL San Diego, CA SP Soc Free Rad Biol & Med (SFRBM) C1 [Mashmoushi, Ahmad K.; Hofbauer, Ann F.; Gilkeson, Gary S.; Oates, Jim C.] Med Univ S Carolina, Charleston, SC USA. [Gilkeson, Gary S.; Oates, Jim C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2012 VL 53 SU 2 BP S76 EP S77 DI 10.1016/j.freeradbiomed.2012.10.228 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 031RS UT WOS:000310660600195 ER PT J AU Richardson, A AF Richardson, Arlan TI HOW WELL DOES THE FREE RADICAL THEORY OF AGING STAND UP TO EXPERIMENTAL TESTING? SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 19th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine (SFRBM) CY NOV 14-18, 2012 CL San Diego, CA SP Soc Free Rad Biol & Med (SFRBM) C1 [Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2012 VL 53 SU 2 BP S10 EP S10 DI 10.1016/j.freeradbiomed.2012.10.019 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 031RS UT WOS:000310660600017 ER PT J AU Sonnenberg, A Boardman, CR Williams, JE AF Sonnenberg, Amnon Boardman, Charles R. Williams, Jason E. TI Poor preps and piano tuners: Fermi's approach to quantifying the risk for interval colon cancer SO GASTROINTESTINAL ENDOSCOPY LA English DT Letter ID BOWEL PREPARATION; COLONOSCOPY; IMPACT; INADEQUATE; QUALITY C1 [Sonnenberg, Amnon; Boardman, Charles R.] Portland VA Med Ctr, Dept Med, Div Gastroenterol, Portland, OR USA. [Sonnenberg, Amnon; Boardman, Charles R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Williams, Jason E.] Santa Clara Valley Med Ctr, Dept Med, Div Gastroenterol, San Jose, CA 95128 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Med, Div Gastroenterol, Portland, OR USA. NR 7 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD NOV PY 2012 VL 76 IS 5 BP 1083 EP 1084 DI 10.1016/j.gie.2012.07.022 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 036FJ UT WOS:000311011500044 PM 23078944 ER PT J AU Basile, JN Bloch, MJ AF Basile, Jan N. Bloch, Michael J. TI Exposure to Air Pollution Increases the Incidence of Hypertension and Diabetes in Black Women Living in Los Angeles SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article C1 [Bloch, Michael J.] Univ Nevada, Sch Med, MedSch Associates N, Reno, NV 89557 USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Charleston, SC USA. RP Bloch, MJ (reprint author), Univ Nevada, Sch Med, MedSch Associates N, 1500 E 2nd St,Suite 302, Reno, NV 89557 USA. EM mbloch@aol.com NR 1 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD NOV PY 2012 VL 14 IS 11 BP 819 EP 820 DI 10.1111/jch.12000 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 031YF UT WOS:000310677900017 PM 23126360 ER PT J AU Lam, HTC O'Toole, TG Arola, PE Kashner, TM Chang, BK AF Lam, Hwai-Tai C. O'Toole, Terry G. Arola, Patricia E. Kashner, T. Michael Chang, Barbara K. TI Factors Associated with the Satisfaction of Millennial Generation Dental Residents SO JOURNAL OF DENTAL EDUCATION LA English DT Article DE dental residents; graduate dental education; Millennial generation; academic environment; academic performance; dental education; productivity; dental assistant; operatory; workload ID LEARNERS PERCEPTIONS SURVEY; EDUCATION AB Data from the 2010 Learners' Perceptions Survey (LPS) administered through the Office of Academic Affiliations, Department of Veterans Affairs (VA) were analyzed to identify factors associated with dental residents' satisfaction with the VA as a clinical training environment. Satisfaction scores were linked to clinic workloads, dental procedure complexity levels, staffing patterns, and facility infrastructure data to explore conditions that may improve residents' satisfaction. Findings supported the construct validity of the LPS survey data and underscored the importance of maintaining optimal ratios of attending dentists, dental assistants, and administrative staff to residents so that each trainee will have opportunities to perform an adequate level of dental workload. As programs strive to improve the quality of graduate dental education, findings from this study are vital for setting curriculum design guidelines and for providing infrastructure support for dental resident education. C1 [Lam, Hwai-Tai C.] US Dept Vet Affairs, Off Policy & Planning, Washington, DC 20006 USA. [Kashner, T. Michael] Loma Linda Univ, Sch Med, Off Acad Affiliat, Loma Linda, CA 92350 USA. [Kashner, T. Michael] Loma Linda Univ, Sch Med, Dept Internal Med, Loma Linda, CA 92350 USA. RP Lam, HTC (reprint author), US Dept Vet Affairs, Off Policy & Planning, Room 540E,1717 H St NE, Washington, DC 20006 USA. EM hwai-tai.lam@va.gov NR 19 TC 4 Z9 4 U1 0 U2 1 PU AMER DENTAL EDUCATION ASSOC PI WASHINGTON PA 1400 K STREET, NW, STE 1100, WASHINGTON, DC 20005 USA SN 0022-0337 J9 J DENT EDUC JI J. Dent. Educ. PD NOV PY 2012 VL 76 IS 11 BP 1416 EP 1426 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 035JF UT WOS:000310941900003 PM 23144476 ER PT J AU Gattoni-Celli, S AF Gattoni-Celli, Sebastiano TI Semi-allogeneic Cancer Vaccines SO JOURNAL OF IMMUNOTHERAPY LA English DT Meeting Abstract CT 27th Annual Scientific Meeting of the Society-for-Immunotherapy-of-Cancer (SITC) CY OCT 24-28, 2012 CL North Bethesda, MD SP Soc Immunotherapy Canc (SITC) DE Cancer vaccine; Active immunotherapy; Combination immunotherapy C1 [Gattoni-Celli, Sebastiano] Med Univ S Carolina, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1524-9557 J9 J IMMUNOTHER JI J. Immunother. PD NOV-DEC PY 2012 VL 35 IS 9 BP 741 EP 741 PG 1 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 028OF UT WOS:000310431100067 ER PT J AU Vu, J Mulugeta, M Larauche, M Waschek, JA Tache, Y Pisegna, J Germano, PM AF Vu, John Mulugeta, Million Larauche, Muriel Waschek, James A. Tache, Yvette Pisegna, JosephR. Germano, Patrizia M. TI VIP deficiency has a protective effect against Dextran Sulfate Sodium (DSS) induced colitis SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Meeting Abstract CT Summer Neuropeptide Conference / Meeting of the European-Neuropeptide-Club (ENC) CY MAY 22-25, 2011 CL Boston, MA SP European Neuropeptide Club (ENC) C1 [Vu, John; Mulugeta, Million; Larauche, Muriel; Tache, Yvette; Pisegna, JosephR.; Germano, Patrizia M.] Univ Calif Los Angeles, Div Gastroenterol & Hepatol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Waschek, James A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD NOV PY 2012 VL 48 SU 1 BP S200 EP S201 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 030BC UT WOS:000310541600457 ER PT J AU Vu, J Mulugeta, M Larauche, M Waschek, JA Tache, Y Pisegna, JR Germano, PM AF Vu, John Mulugeta, Million Larauche, Muriel Waschek, James A. Tache, Yvette Pisegna, Joseph R. Germano, Patrizia M. TI VIP deficiency has a protective effect against Dextran Sulfate Sodium (DSS) induced colitis SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Meeting Abstract CT Summer Neuropeptide Conference / Meeting of the European-Neuropeptide-Club (ENC) CY MAY 22-25, 2011 CL Boston, MA SP European Neuropeptide Club (ENC) C1 [Vu, John; Mulugeta, Million; Larauche, Muriel; Tache, Yvette; Pisegna, Joseph R.; Germano, Patrizia M.] Univ Calif Los Angeles, Div Gastroenterol & Hepatol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Waschek, James A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD NOV PY 2012 VL 48 SU 1 BP S193 EP S193 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 030BC UT WOS:000310541600442 ER PT J AU Elder, GA Dorr, NP De Gasperi, R Sosa, MAG Shaughness, MC Maudlin-Jeronimo, E Hall, AA McCarron, RM Ahlers, ST AF Elder, Gregory A. Dorr, Nathan P. De Gasperi, Rita Sosa, Miguel A. Gama Shaughness, Michael C. Maudlin-Jeronimo, Eric Hall, Aaron A. McCarron, Richard M. Ahlers, Stephen T. TI Blast Exposure Induces Post-Traumatic Stress Disorder-Related Traits in a Rat Model of Mild Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE blast; PTSD; rat; stathmin 1; TBI ID STARTLE RESPONSE; INTRACRANIAL-PRESSURE; BEHAVIORAL CRITERIA; VIETNAM VETERANS; SERUM BIOMARKER; WAR VETERANS; MOUSE MODEL; MICE; OVERPRESSURE; PATHOLOGY AB Blast related traumatic brain injury (TBI) has been a major cause of injury in the wars in Iraq and Afghanistan. A striking feature of the mild TBI (mTBI) cases has been the prominent association with post-traumatic stress disorder (PTSD). However, because of the overlapping symptoms, distinction between the two disorders has been difficult. We studied a rat model of mTBI in which adult male rats were exposed to repetitive blast injury while under anesthesia. Blast exposure induced a variety of PTSD-related behavioral traits that were present many months after the blast exposure, including increased anxiety, enhanced contextual fear conditioning, and an altered response in a predator scent assay. We also found elevation in the amygdala of the protein stathmin 1, which is known to influence the generation of fear responses. Because the blast overpressure injuries occurred while animals were under general anesthesia, our results suggest that a blast-related mTBI exposure can, in the absence of any psychological stressor, induce PTSD-related traits that are chronic and persistent. These studies have implications for understanding the relationship of PTSD to mTBI in the population of veterans returning from the wars in Iraq and Afghanistan. C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA. [De Gasperi, Rita; Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA. [Elder, Gregory A.; Dorr, Nathan P.; De Gasperi, Rita; Sosa, Miguel A. Gama] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Ahlers, Stephen T.] USN, Dept Neurotrauma, Operat & Undersea Med Directorate, Med Res Ctr, Silver Spring, MD USA. [Elder, Gregory A.; De Gasperi, Rita; Sosa, Miguel A. Gama] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA. RP Elder, GA (reprint author), James J Peters VA Med Ctr, Neurol Serv 3E16, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@va.gov FU Department of Veterans Affairs [1I01RX000179-01] FX This work was supported by grant 1I01RX000179-01 from the Department of Veterans Affairs. NR 54 TC 55 Z9 55 U1 2 U2 24 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD NOV PY 2012 VL 29 IS 16 BP 2564 EP 2575 DI 10.1089/neu.2012.2510 PG 12 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 035CS UT WOS:000310920900005 PM 22780833 ER PT J AU Yoo, JW Nakagawa, S Kim, S AF Yoo, Ji Won Nakagawa, Shunichi Kim, Sulgi TI Effect of Reimbursement Reductions on Bone Mineral Density Testing for Female Medicare Beneficiaries SO JOURNAL OF WOMENS HEALTH LA English DT Article ID X-RAY ABSORPTIOMETRY; OSTEOPOROSIS SCREENING GUIDELINES; UNITED-STATES; CARE; TRENDS; ADHERENCE; SETTINGS; ACCESS; ADULTS; DXA AB Background: We examined whether the recent reimbursement reductions on the bone mineral density (BMD) test affected BMD testing in female Medicare beneficiaries with or without supplemental private health insurance. Methods: Retrospectively analyzing hospital administrative and clinical data on female Medicare beneficiaries (n = 1320), we reviewed whether participants received BMD testing before (January 2004-December 2006) or after (January 2007-December 2009) reimbursement reductions for BMD testing. After adjusting for demographics and clinical characteristics, we performed Cox proportional hazard regression analyses of the BMD test including data from all study participants; we then performed separate regression analyses using data with or without supplemental private health insurance. Results: In those without supplemental private health insurance (n = 421), less frequent BMD testing occurred after reimbursement reductions for BMD testing (hazard ratio [HR] 0.67, 95% confidence intervals [CI] 0.34-0.98; p = 0.03). By contrast, in the overall participants (n = 1320) and those with supplemental private health insurance (n = 899), the number of BMD tests did not change significantly after reimbursement reductions for BMD testing. Conclusions: We found a significant association between reimbursement reductions and decrease in BMD tests in female Medicare beneficiaries without supplemental private health insurance. C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Yoo, Ji Won] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. [Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Kim, Sulgi] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 N Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA. EM yoojiw@trinity-health.org FU American Geriatrics Society Seed Grant Research Program FX This project was supported by the American Geriatrics Society Seed Grant Research Program. The funding source had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We thank Pil Park, Ph.D. (University of Michigan Medical School), and Daehyun Kim, M.D., M.P.H. (Harvard Medical School), for their valuable feedback on study design, analysis interpretation, and manuscript preparation. NR 25 TC 6 Z9 6 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD NOV PY 2012 VL 21 IS 11 BP 1144 EP 1148 DI 10.1089/jwh.2012.3517 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 034BI UT WOS:000310844700007 PM 22966834 ER PT J AU Lovejoy, TI Dobscha, SK Cavanagh, R Turk, DC Morasco, BJ AF Lovejoy, Travis I. Dobscha, Steven K. Cavanagh, Renee Turk, Dennis C. Morasco, Benjamin J. TI Chronic Pain Treatment and Health Service Utilization of Veterans with Hepatitis C Virus Infection SO PAIN MEDICINE LA English DT Article DE Hepatitis C; Chronic Pain; Veterans; Health Service Utilization ID UNITED-STATES; PRIMARY-CARE; METHADONE-MAINTENANCE; PSYCHIATRIC-DISORDERS; ADMINISTRATIVE DATA; SUBSTANCE USE; PREVALENCE; POPULATION; COMPLEMENTARY; COMORBIDITY AB Objectives. Hepatitis C virus (HCV) infection is estimated to affect 2% of the general U.S. population and chronic pain is a common comorbidity among persons with HCV. The primary purpose of this study was to compare health service utilization of U.S. military veterans with HCV with and without the presence of comorbid chronic pain. Design. Cross-sectional study with retrospective review of patient medical records. Patients. One hundred seventy-one U.S. military veterans with confirmed HCV, recruited through a single U.S. Veterans Administration hospital. Outcome Measures. Medical service utilization data from the past 5 years were extracted from participants' electronic medical records. Results. Sixty-four percent of veterans with HCV (N = 110) had chronic pain. Veterans with HCV and chronic pain utilized more health services including total inpatient stays (odds ratio [OR] = 2.58 [1.46, 4.56]) and days hospitalized for psychiatric services (OR = 5.50 [3.37, 8.99]), compared to participants with HCV and no chronic pain, after statistically adjusting for demographic, psychiatric, substance use, medical comorbidity, and disability covariates. In addition, those with HCV and chronic pain had more total outpatient visits with primary care providers (OR = 1.73 [1.15, 2.59]), physical therapists (OR = 9.57 [4.79, 19.11]), and occupational therapists (OR = 2.72 [1.00, 7.48]). Conclusions. Patients with HCV and chronic pain utilize medical services to a greater extent than patients with HCV but no chronic pain. Future studies that examine the efficacy of both pharmacological and nonpharmacological pain treatment for patients with comorbid HCV and chronic pain appear warranted. C1 [Lovejoy, Travis I.; Dobscha, Steven K.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Dobscha, Steven K.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA. [Cavanagh, Renee] Univ Pacific, Sch Profess Psychol, Hillsboro, OR USA. [Cavanagh, Renee] Portland VA Res Fdn, Portland, OR USA. [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Lovejoy, TI (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, P3MHDC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM travis.lovejoy@va.gov FU United States National Institute on Drug Abuse [K23DA023467] FX No author reports having any financial or other potential conflict of interest with this study. This study was supported in part by award K23DA023467 from the United States National Institute on Drug Abuse to Dr. Morasco. NR 46 TC 4 Z9 4 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV PY 2012 VL 13 IS 11 BP 1407 EP 1416 DI 10.1111/j.1526-4637.2012.01476.x PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 036TQ UT WOS:000311055000005 PM 22958315 ER PT J AU Hoerster, KD Jakupcak, M McFall, M Unutzer, J Nelson, KM AF Hoerster, Katherine D. Jakupcak, Matthew McFall, Miles Unuetzer, Juergen Nelson, Karin M. TI Mental health and somatic symptom severity are associated with reduced physical activity among US Iraq and Afghanistan veterans SO PREVENTIVE MEDICINE LA English DT Article DE Veterans; Exercise; Depression ID FREEDOM VETERANS; RISK-FACTORS; SAMPLE; CARE; DEPRESSION; DIAGNOSES; VALIDITY; OBESITY AB Objective. Ensuring that Iraq and Afghanistan veterans engage in adequate physical activity is essential to prevent metabolic and cardiovascular diseases, and promote psychological well-being. Identifying factors associated with physical activity in this population will yield areas for targeted interventions aimed at increasing activity. Method. Correlates of meeting physical activity recommendations (>= 150 min/week of moderate-to-vigorous physical activity [MVPA]) were examined in Iraq/Afghanistan veterans assessed at intake to VA Puget Sound Healthcare System's post-deployment health clinic (May, 2005-August, 2009; N=266). Results. The majority were male (94.3%) and Caucasian (70.7%), with an average age of 29.8 (SD=7.3) years. Participants engaged in a median of 180 weekly MVPA minutes. Among those meeting (59%) and not meeting (41%) recommendations, median weekly MVPA minutes were 540 and 0, respectively. In multivariate regression models, higher levels of depression (p=.042) and somatic (p=.018) symptom severity were associated with significantly decreased odds of meeting physical activity recommendations. Conclusion. Overall, physical activity engagement among Iraq/Afghanistan veteran VA patients was above the level specified in national recommendations. Those with higher depressive and somatic symptoms were less likely to meet physical activity recommendations and may benefit from targeted physical activity promotion interventions. Published by Elsevier Inc. C1 [Hoerster, Katherine D.; Nelson, Karin M.] VA Puget Sound Healthcare Syst, Seattle Div, Res & Dev Serv, Seattle, WA 98108 USA. [Hoerster, Katherine D.; Jakupcak, Matthew; McFall, Miles; Unuetzer, Juergen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Jakupcak, Matthew; McFall, Miles] VA Puget Sound Healthcare Syst, Seattle Div, Mental Hlth Serv, Seattle, WA 98108 USA. [Unuetzer, Juergen] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Nelson, Karin M.] VA Puget Sound Healthcare Syst, Gen Internal Med Serv, Seattle, WA 98108 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Hoerster, KD (reprint author), 1660 S Columbian Way,S-116, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov; Matthew.Jakupcak@va.gov; Miles.McFall@va.gov; unutzer@u.washington.edu; Karin.Nelson@va.gov FU VA Puget Sound Healthcare System FX This material is the result of work supported by resources from VA Puget Sound Healthcare System. NR 21 TC 6 Z9 6 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD NOV PY 2012 VL 55 IS 5 BP 450 EP 452 DI 10.1016/j.ypmed.2012.08.017 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 036VT UT WOS:000311061100020 PM 22959890 ER PT J AU John, LK Loewenstein, G Volpp, KG AF John, Leslie K. Loewenstein, George Volpp, Kevin G. TI Empirical observations on longer-term use of incentives for weight loss SO PREVENTIVE MEDICINE LA English DT Article DE Weight loss; Obesity; Behavioral economics; Intervention ID CHOICE; HEALTH; RISK AB Behavioral economic-based interventions are emerging as powerful tools to help individuals accomplish their own goals, including weight loss. Deposit contract incentive systems give participants the opportunity to put their money down toward losing weight, which they forfeit if they fail to lose weight; lottery incentive systems enable participants to win money if they attain weight loss goals. In this paper, we pool data from two prior studies to examine a variety of issues that unpublished data from those studies allow us to address. First, examining data from the deposit contract treatments in greater depth, we investigate factors affecting deposit frequency and size, and discuss possible ways of increasing deposits. Next, we compare the effectiveness of both deposit contract and lottery interventions as a function of participant demographic characteristics. These observations may help to guide the design of future, longer-term, behavioral economic-based interventions. (C) 2012 Elsevier Inc. All rights reserved. C1 [John, Leslie K.] Harvard Univ, Sch Business, Mkt Unit, Boston, MA 02163 USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Volpp, Kevin G.] Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn Wharton Sch, Dept Hlth Care Management, Philadelphia, PA USA. RP John, LK (reprint author), Harvard Univ, Sch Business, Mkt Unit, Morgan Hall 169, Boston, MA 02163 USA. EM ljohn@hbs.edu NR 19 TC 10 Z9 10 U1 1 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD NOV 1 PY 2012 VL 55 SU 1 BP S68 EP S74 DI 10.1016/j.ypmed.2012.01.022 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 036VV UT WOS:000311061300011 PM 22342291 ER PT J AU Park, JD Mitra, N Asch, DA AF Park, James D. Mitra, Nandita Asch, David A. TI Public opinion about financial incentives for smoking cessation SO PREVENTIVE MEDICINE LA English DT Article DE Financial incentive; Tobacco cessation; Public opinion ID HEALTH LOCUS; REINFORCEMENT; SMOKERS AB Objective. The aim of this study is to assess public support for a smoking cessation policy involving financial incentives. Methods. We conducted a randomized controlled trial using an experimental survey design. One of four questionnaire versions was distributed to participants. Each version described a smoking cessation treatment costing $750 per success, including an unspecified treatment, medication, or financial incentive paid to the smoker. Participants indicated whether they would support a $25 increase in their annual health insurance premium to pay for the treatment. Questionnaires were distributed to adults waiting at public transportation depots in Philadelphia between May and August 2010. Results. 1010 individuals completed the questionnaires about willingness to support the policy: 53% female, 27% African-American, 18% current smokers, and 46% with a household income below $40,000. The response rate was greater than 50%. Overall support for all smoking cessation treatments was 41.6%. The financial incentive version received the lowest support (393%) but that support did not statistically differ from the treatment (45.8%, p=0.14) or medication (41.7%, p=0.58) versions. Conclusions. Financial incentives were perceived no differently than currently used medications for smoking cessation. Most participants did not support any smoking cessation treatment options. (C) 2012 Elsevier Inc. All rights reserved, C1 [Park, James D.; Asch, David A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr Res 9E, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Mitra, Nandita; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Colonial Penn Ctr, Philadelphia, PA 19104 USA. RP Park, JD (reprint author), Univ Penn, Div Gen Internal Med, 1005 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jdpark@mail.med.upenn.edu; nanditam@mail.med.upenn.edu; asch@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X FU VAL Health; Center for Public Health Initiatives, University of Pennsylvania; [T32-HP-10026-17] FX David Asch received consulting fees from VAL Health. No other conflicts of interest are reported.; Funding/support: T32-HP-10026-17 and the Center for Public Health Initiatives, University of Pennsylvania. The funding sources did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 18 TC 10 Z9 10 U1 0 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD NOV 1 PY 2012 VL 55 SU 1 BP S41 EP S45 DI 10.1016/j.ypmed.2012.06.013 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 036VV UT WOS:000311061300007 PM 22735040 ER PT J AU Schmidt, H Asch, DA Halpern, SD AF Schmidt, Harald Asch, David A. Halpern, Scott D. TI Fairness and wellness incentives: What is the relevance of the process-outcome distinction? SO PREVENTIVE MEDICINE LA English DT Article DE Wellness incentives; Prevention; Fairness; Discrimination; Patient Protection and Affordable Care Act ID FINANCIAL INCENTIVES; SMOKING-CESSATION; PERSONAL RESPONSIBILITY; SOCIAL DETERMINANTS; IMPROVE HEALTH; CONTROLLED-TRIAL; WEIGHT-LOSS; POLICY; CARE; PREFERENCES AB Objective. To determine whether the commonly drawn distinction between the fairness of incentives targeting behavioral processes (or effort) and those targeting outcomes (or achievement) provide suitable grounds for favoring either approach in healthcare research, policy and practice. Methods. Conceptual analysis, literature review. Results. A categorical distinction between process- and outcome-based incentives is less crisp than it seems. Both processes and outcomes involve targets, and both are subject to differences - across and within socio-economic groups - in circumstance and perspective. Thus, a spectrum view is more appropriate, in which the fairness of incentive programs increases with the extent of control that people have. The effectiveness of incentives is a further relevant consideration, and some available evidence suggests that incentives closer to the outcome-end of the spectrum can be more effective. Conclusions. Simple distinctions between processes and outcomes by themselves provide little assurance that programs are effective or fair. Effectiveness can and should be assessed empirically. Assessments of fairness should focus on the extent to which an activity or outcome might be feasible and under an individual's control, not on whether it targets a process or outcome. Rigid uniform targets for all are generally less desirable than those that reward person-specific improvement. (C) 2012 Elsevier Inc. All rights reserved. C1 [Schmidt, Harald; Asch, David A.; Halpern, Scott D.] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Asch, David A.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Halpern, Scott D.] Univ Penn, Med Ctr, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA. RP Schmidt, H (reprint author), Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM schmidth@mail.med.upenn.edu; asch@wharton.upenn.edu; shalpern@exchange.upenn.edu OI Asch, David/0000-0002-7970-286X NR 53 TC 9 Z9 9 U1 0 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD NOV 1 PY 2012 VL 55 SU 1 BP S118 EP S123 DI 10.1016/j.ypmed.2012.03.005 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 036VV UT WOS:000311061300019 PM 22449482 ER PT J AU Tsan, JY Zeber, JE Stock, EM Sun, FF Copeland, LA AF Tsan, Jack Y. Zeber, John E. Stock, Eileen M. Sun, Fangfang Copeland, Laurel A. TI Primary Care Mental Health Integration and Treatment Retention Among Iraq and Afghanistan War Veterans SO PSYCHOLOGICAL SERVICES LA English DT Article DE integrated care; mental health services; primary care; posttraumatic stress disorder; veterans ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DIAGNOSES; RETURNING VETERANS; MEDICAL-CARE; SERVICES; AFFAIRS; PTSD; ACCESS; SYSTEM AB Despite the high prevalence of posttraumatic stress disorder (PTSD) and medical comorbidity among veterans from Iraq/Afghanistan (OEF/OIF), keeping these patients engaged in health care is challenging. Primary Care Mental Health Integration (PC-MHI), an initiative in the Veterans Health Administration (VA), sought to improve access to mental health care from within primary care. This study examined the lag between first PC-MHI visit and next mental/medical care visit, if any, and the relationship of PC-MHI with short-term (subsequent year) and long-term (4 years later) use of VA. We identified 2,470 OEF/OIF veterans receiving care during fiscal year 2006 (FY06) in a regional VA health care system. Unconditional survival analysis modeled time to next mental/medical visit and logistic regression modeled short- and long-term care as a function of PC-MHI, demo-graphics, and clinical covariates. Of 181 patients in the PC-MHI program, 60%/ 18% returned for mental/medical care within 1 month, and 82%/74% within 1 year. Sixty-one percent (1,503) were still using the VA in FY09. Short-term mental care was related to prior-year PC-MHI. Consistent correlates of short- and long-term mental/medical care included physical comorbidity and Priority 1 status. Most patients attended mental health appointments subsequent to PC-MHI, and PC-MHI was correlated with mental health treatment retention in adjusted models for our cohort. Need for treatment, notably VA Priority 1 status and physical comorbidity, were the primary correlates of care-seeking. Developing innovative approaches to engaging new veterans in care remains imperative as multiple options will be necessary to meet the needs of these complex patients. C1 [Tsan, Jack Y.] US Dept Vet Affairs, VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX 76711 USA. [Tsan, Jack Y.] Texas A&M Hlth Sci Ctr, Houston, TX USA. RP Tsan, JY (reprint author), US Dept Vet Affairs, VISN 17 Ctr Excellence Res Returning War Vet, 4800 Mem Dr 151C, Waco, TX 76711 USA. EM Jack.Tsan@va.gov OI Copeland, Laurel/0000-0002-9478-0209 NR 44 TC 8 Z9 8 U1 1 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2012 VL 9 IS 4 SI SI BP 336 EP 348 DI 10.1037/a0028308 PG 13 WC Psychology, Clinical SC Psychology GA 036ZP UT WOS:000311071100002 PM 22545824 ER PT J AU Baker, RR Stenger, C Gurel, L Goldstein, G AF Baker, Rodney R. Stenger, Charles Gurel, Lee Goldstein, Gerald TI Patient Care by VA Psychologists in the 1950s and 1960s SO PSYCHOLOGICAL SERVICES LA English DT Article DE health care of veterans; history of VA psychology; history of psychology AB In 1946, the Veterans Administration, now the Department of Veterans Affairs (VA), underwent extensive organizational and professional changes to accommodate the health care needs of veterans returning from World War Two. In addition to an introduction and brief history of these changes, three psychologists who began their careers in the VA in the first years after that reorganization discuss their patient care experiences, both as trainees and as staff psychologists. C1 [Baker, Rodney R.; Stenger, Charles; Gurel, Lee] US Dept Vet Affairs, Washington, DC USA. [Goldstein, Gerald] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Baker, RR (reprint author), 10710 Old Blue Lane, San Antonio, TX 78230 USA. EM rodbaker@att.net NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2012 VL 9 IS 4 SI SI BP 417 EP 426 DI 10.1037/a0029515 PG 10 WC Psychology, Clinical SC Psychology GA 036ZP UT WOS:000311071100008 PM 22844985 ER PT J AU Mott, JM Graham, DP Teng, EJ AF Mott, Juliette M. Graham, David P. Teng, Ellen J. TI Perceived Threat During Deployment: Risk Factors and Relation to Axis I Disorders SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE perceived threat; veterans; PTSD; Axis I diagnoses ID POSTTRAUMATIC-STRESS-DISORDER; GULF-WAR; TRAUMA; VETERANS; HEALTH; REPRESENTATIONS; INFORMATION; COMORBIDITY; DEPRESSION; EXPOSURE AB This study sought to (a) examine the relation between perceived threat during deployment and the postdeployment presence of Axis I disorders and (b) identify developmental and deployment-related variables that predict level of threat perception during deployment. Participants were 1,740 Operation Enduring Freedom or Operation Iraqi Freedom veterans who completed the Deployment Risk and Resilience Inventory during a postdeployment screening at a large Veterans Affairs hospital. Greater perceived threat during deployment was significantly associated with the postdeployment presence of posttraumatic stress disorder, anxiety disorders, and mood disorders, but not substance use disorders. Perceived threat was also positively associated with the presence of comorbid Axis I diagnoses. Results of a multiple regression analysis indicated that, after controlling for combat exposure, deployment environment and deployment preparation significantly predicted perceived threat during deployment. These findings indicate that veterans' reports of perceived threat during deployment are associated with a wide variety of mental health disorders and suggest that efforts to increase deployment preparation and facilitate adjustment to the deployment environment have the potential to temper troops' threat appraisals. C1 [Mott, Juliette M.; Graham, David P.; Teng, Ellen J.] Michael E DeBakey VA Med Ctr, Minneapolis, MN USA. [Mott, Juliette M.; Graham, David P.; Teng, Ellen J.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Mott, JM (reprint author), Dept Vet Affairs Med Ctr, Mental Hlth Care Line Trauma Recovery Program 116, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Juliette.Mott@va.gov RI Graham, David /J-1158-2014 NR 28 TC 8 Z9 8 U1 1 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD NOV PY 2012 VL 4 IS 6 BP 587 EP 595 DI 10.1037/a0025778 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 036YR UT WOS:000311068700006 ER PT J AU Turner, TH Horner, MD VanKirk, KK Myrick, H Tuerk, PW AF Turner, Travis H. Horner, Michael D. VanKirk, Kathryn K. Myrick, Hugh Tuerk, Peter W. TI A Pilot Trial of Neuropsychological Evaluations Conducted via Telemedicine in the Veterans Health Administration SO TELEMEDICINE AND E-HEALTH LA English DT Article DE military medicine; telepsychiatry; telemedicine ID TRAUMATIC BRAIN-INJURY; SERVICES; RELIABILITY; DEMENTIA; TELEHEALTH; PROVISION; DISORDER; MEMORY; AREAS AB Introduction: Many veterans live in rural areas distant from Veterans Affairs Medical Centers (VAMCs) and receive primary medical care from community-based outpatient clinics (CBOCs). These veterans often must travel great distances to the nearest VAMC for neuropsychological evaluations, resulting in poor access to care, travel reimbursement costs, fee-basis evaluations of uncontrolled quality, and driving safety concerns. Return trips for feedback compound complications. Accordingly, we initiated a pilot trial of neuropsychological evaluation and feedback via telemedicine (i.e., clinical videoconferencing). Subjects and Methods: Participants were veterans referred for neuropsychological evaluation from a rural CBOC 115 miles from the regional VAMC. All veterans were given the choice to undergo evaluation at the CBOC via telemedicine or in-person at the VAMC. Telemedicine equipment allowed presentation of digitized material with simultaneous patient observation. Testing materials were organized in numbered folders and given to veterans by CBOC clerks immediately prior to evaluation. Clerks returned completed materials via facsimile. Results: Fifteen veterans from the rural CBOC were seen for neuropsychological evaluation. Eight chose telemedicine evaluation. Groups based on evaluation modality appeared similar on demographics, referral basis, resulting neuropsychiatric diagnoses, and follow-through on recommendations. No significant technical or clinical difficulties were encountered, and veterans reported satisfaction with telemedicine. All veterans requested feedback via telemedicine. Conclusions: Neuropsychological evaluation via telemedicine is feasible and appears comparable to in-person evaluation. Experiences are encouraging and consistent with the broader literature on the acceptance of and satisfaction with clinical videoconferencing. Future studies will assess possible psychometric issues in clinical populations. C1 [Turner, Travis H.; Horner, Michael D.; VanKirk, Kathryn K.; Myrick, Hugh; Tuerk, Peter W.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC USA. [Turner, Travis H.; Horner, Michael D.; VanKirk, Kathryn K.; Myrick, Hugh; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Turner, Travis H.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA. RP Turner, TH (reprint author), Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv Line, 109 Bee St,MH 116, Charleston, SC 29401 USA. EM turnertr@musc.edu NR 44 TC 7 Z9 7 U1 4 U2 14 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED E-HEALTH JI Telemed. e-Health PD NOV PY 2012 VL 18 IS 9 BP 662 EP 667 DI 10.1089/tmj.2011.0272 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 034BX UT WOS:000310846200002 PM 23050802 ER PT J AU Brooks-Worrell, B Narla, R Palmer, JP AF Brooks-Worrell, Barbara Narla, Radhika Palmer, Jerry P. TI Biomarkers and immune-modulating therapies for Type 2 diabetes SO TRENDS IN IMMUNOLOGY LA English DT Review DE immunotherapy; type 2 diabetes; immunomodulatory drugs; obesity; biomarkers; autoimmunity; inflammation ID ADIPOSE-TISSUE INFLAMMATION; C-REACTIVE PROTEIN; ACTIVATED RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; PANCREATIC BETA-CELL; REGULATORY T-CELLS; INSULIN-RESISTANCE; METABOLIC DISEASE; PPAR-GAMMA; HISTONE DEACETYLASES AB Recent advances in understanding the etiology of obesity, metabolic syndrome, and type 2 diabetes (T2D) have established involvement of the immune system. These developments highlight the potential of immunomodulatory therapies for treatment of these conditions. Here, we discuss current and new immunotherapeutic strategies for the treatment of T2D, the need for stratification of patients based on immune and autoimmune status, and biomarkers for evaluating treatment efficiency. The time has come to re-evaluate the clinical management of T2D patients using metabolic parameters alone, and to realize that patients should be stratified based on their immune and/or autoimmune status prior to initiation of therapy to realize fully the potential of immunomodulatory strategies for T2D. C1 [Brooks-Worrell, Barbara; Palmer, Jerry P.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. [Brooks-Worrell, Barbara; Narla, Radhika; Palmer, Jerry P.] VA Puget Sound Hlth Care Syst, Dept Hosp & Specialty Med, Seattle, WA 98108 USA. [Narla, Radhika] Univ Washington, Dept Gen Internal Med, Seattle, WA 98108 USA. RP Brooks-Worrell, B (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. EM bbrooks@u.washington.edu NR 91 TC 14 Z9 15 U1 2 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4906 J9 TRENDS IMMUNOL JI Trends Immunol. PD NOV PY 2012 VL 33 IS 11 BP 546 EP 553 DI 10.1016/j.it.2012.07.002 PG 8 WC Immunology SC Immunology GA 039PP UT WOS:000311259300003 PM 22897868 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI Clinical Excellence: Make It a Habit SO ACADEMIC MEDICINE LA English DT Editorial Material C1 [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@ucsf.edu NR 3 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD NOV PY 2012 VL 87 IS 11 BP 1473 EP 1473 DI 10.1097/ACM.0b013e31826d68d9 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 030OI UT WOS:000310579600018 PM 23111262 ER PT J AU Nashar, K Fried, LF AF Nashar, Khaled Fried, Linda F. TI Hyperuricemia and the Progression of Chronic Kidney Disease: Is Uric Acid a Marker or an Independent Risk Factor? SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Uric acid; CKD; Hyperuricemia; Progression ID RENAL-DISEASE; CYCLOSPORINE NEPHROPATHY; IGA NEPHROPATHY; BLOOD-PRESSURE; FOLLOW-UP; INCREASES; OUTCOMES; HYPERTENSION; ALLOPURINOL; ASSOCIATION AB Hyperuricemia is seen when kidney function declines. Whether elevated uric acid (UA) levels play a role in the initiation and progression of kidney disease is a subject of a great debate. Animal studies demonstrate that elevated UA level is a risk factor for kidney disease. In humans, the relationship between UA and kidney disease is more complicated. Cross-sectional studies show an association of hyperuricemia with the presence of CKD; however, from cross-sectional studies, one cannot determine which came first the elevated UA level or the kidney disease. UA levels are also associated with other risk factors for kidney disease, including hypertension, metabolic syndrome, and microalbuminuria, but it is not clear whether these are mediators or confounders of a relationship. Observational studies suggest a relationship of UA level with incident CKD, but studies evaluating the relationship with decline in kidney function in established CKD are conflicting. Finally, small clinical trials using allopurinol to lower UA levels provide weak, but potentially promising, evidence that lowering UA levels may retard the progression of CKD. In this article, we will review the evidence of the association of hyperuricemia and CKD. (C) 2012 by the National Kidney Foundation, Inc. All rights reserved. C1 [Nashar, Khaled] Allegheny Gen Hosp, Div Nephrol & Hypertens, Pittsburgh, PA 15212 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Nashar, K (reprint author), Allegheny Gen Hosp, Div Nephrol & Hypertens, 320 East North Ave,4th Floor, Pittsburgh, PA 15212 USA. EM Knashar@wpahs.org NR 32 TC 17 Z9 18 U1 2 U2 22 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD NOV PY 2012 VL 19 IS 6 BP 386 EP 391 DI 10.1053/j.ackd.2012.05.004 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 033TC UT WOS:000310823000006 PM 23089273 ER PT J AU Gukovskaya, AS Gukovsky, I AF Gukovskaya, Anna S. Gukovsky, Ilya TI Autophagy and pancreatitis SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Review DE macroautophagy; lysosome; cathepsin; lysosome-associated membrane protein; pancreatic acinar cell; trypsin ID CERULEIN-INDUCED PANCREATITIS; LYSOSOMAL MEMBRANE-PROTEINS; ACINAR-CELL DEATH; TRYPSINOGEN ACTIVATION; MAMMALIAN-CELLS; EARLY EVENTS; RAT-LIVER; ORGANELLAR DYSFUNCTION; ZYMOGEN ACTIVATION; IMPAIRED AUTOPHAGY AB Acute pancreatitis is an inflammatory disease of the exocrine pancreas that carries considerable morbidity and mortality; its pathophysiology remains poorly understood. Recent findings from experimental models and genetically altered mice summarized in this review reveal that autophagy, the principal cellular degradative pathway, is impaired in pancreatitis and that one cause of autophagy impairment is defective function of lysosomes. We propose that the lysosomal/autophagic dysfunction is a key initiating event in pancreatitis and a converging point of multiple deranged pathways. There is strong evidence supporting this hypothesis. Investigation of autophagy in pancreatitis has just started, and many questions about the "upstream" mechanisms mediating the lysosomal/autophagic dysfunction and the "downstream" links to pancreatitis pathologies need to be explored. Answers to these questions should provide insight into novel molecular targets and therapeutic strategies for treatment of pancreatitis. C1 [Gukovskaya, Anna S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Gukovskaya, Anna S.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Gukovskaya, AS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU Department of Veterans Affairs, National Institutes of Health [R01 DK-59936, AA-19730]; Southern California Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis (National Institutes of Health) [P50 AA-11999] FX Our research is supported by the Department of Veterans Affairs, National Institutes of Health Grants R01 DK-59936 and AA-19730 and, in part, by the Southern California Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis (National Institutes of Health Grant P50 AA-11999). NR 113 TC 34 Z9 38 U1 0 U2 17 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD NOV PY 2012 VL 303 IS 9 BP G993 EP G1003 DI 10.1152/ajpgi.00122.2012 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 032HS UT WOS:000310706900001 PM 22961802 ER PT J AU Hoerster, KD Lehavot, K Simpson, T McFall, M Reiber, G Nelson, KM AF Hoerster, Katherine D. Lehavot, Keren Simpson, Tracy McFall, Miles Reiber, Gayle Nelson, Karin M. TI Health and Health Behavior Differences US Military, Veteran, and Civilian Men SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; QUALITY-OF-LIFE; INSURANCE COVERAGE; COMBAT DEPLOYMENT; PHYSICAL-ACTIVITY; NATIONAL SAMPLE; ALCOHOL-USE; CARE; DEPRESSION; RISK AB Background: Little is known about health and health behavior differences among military service veterans, active duty service members, National Guard/Reserve members, and civilians. Several important differences were identified among U.S. women from these subpopulations; to identify areas for targeted intervention, studies comparing men from these subpopulations are needed. Purpose: To compare veteran, military, and civilian men on leading U.S. health indicators. Methods: Data were from the 2010 Behavioral Risk Factor Surveillance Survey, a U.S. population-based study. In 2011, self-reported health outcomes were compared using multivariable logistic regression across male veterans (n=53,406); active duty service members (n=2144); National Guard/Reserve service members (n=3724); and civilians (n=110,116). Results: Multivariate logistic regression results are presented. Despite better healthcare access, veterans had poorer health and functioning than civilians and National Guard/Reserve members on several indicators. Veterans also were more likely than those on active duty to report diabetes. Veterans were more likely to report current smoking and heavy alcohol consumption than National Guard/Reserve members and civilian men, and lack of exercise compared to active duty men and National Guard/Reserve members. National Guard/Reserve men had higher levels of obesity, diabetes, and cardiovascular disease (versus active duty and veterans, active duty, and civilians, respectively). Active duty men were more likely to report current smoking and heavy alcohol consumption than civilians and National Guard/Reserve members, and reported more smokeless tobacco use than civilians. Conclusions: Veterans have poorer health and health behaviors; increased prevention efforts are needed from veteran-serving organizations. Despite good health, active duty men reported unhealthy lifestyles, indicating an important area for prevention efforts. (Am J Prey Med 2012;43(5):483-489) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Hoerster, Katherine D.; Reiber, Gayle; Nelson, Karin M.] VA Puget Sound Healthcare Syst, Res & Dev Serv, Seattle, WA USA. [Lehavot, Keren; Simpson, Tracy; McFall, Miles] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle, WA USA. [Simpson, Tracy] VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Nelson, Karin M.] VA Puget Sound Healthcare Syst, Gen Internal Med Serv, Seattle, WA USA. [Hoerster, Katherine D.; Lehavot, Keren; Simpson, Tracy; McFall, Miles] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. RP Hoerster, KD (reprint author), 1660 S Columbian Way,S-116, Seattle, WA 98108 USA. EM Hoerster@va.gov FU VA Puget Sound Health Care System, Seattle WA FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle WA. The views expressed in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 37 TC 65 Z9 65 U1 5 U2 31 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2012 VL 43 IS 5 BP 483 EP 489 DI 10.1016/j.amepre.2012.07.029 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 032JI UT WOS:000310713100004 PM 23079170 ER PT J AU Hiremath, SV Ding, D Farringdon, J Cooper, RA AF Hiremath, Shivayogi V. Ding, Dan Farringdon, Jonathan Cooper, Rory A. TI Predicting Energy Expenditure of Manual Wheelchair Users With Spinal Cord Injury Using a Multisensor-Based Activity Monitor SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Arm ergometry test; Energy expenditure; Physical activity; Rehabilitation; Spinal cord injuries; Wheelchairs ID FREE-LIVING ADULTS; PHYSICAL-ACTIVITY; PARAPLEGIA; AGREEMENT AB Objective: To develop and evaluate new energy expenditure (EE) prediction models for manual wheelchair users (MWUs) with spinal cord injury (SCI) based on a commercially available multisensor-based activity monitor. Design: Cross-sectional. Setting: Laboratory. Participants: Volunteer sample of MWUs with SCI (N=45). Intervention: Subjects were asked to perform 4 activities including resting, wheelchair propulsion, arm-ergometer exercise, and deskwork. Criterion EE using a metabolic cart and raw sensor data from a multisensor-based activity monitor was collected during each of these activities. Main Outcome Measures: Two new EE prediction models including a general model and an activity-specific model were developed using enhanced all-possible regressions on 36 MWUs and tested on the remaining 9 MWUs. Results: The activity-specific and general EE prediction models estimated the EE significantly better than the manufacturer's model. The average EE estimation error using the manufacturer's model and the new general and activity-specific models for all activities combined was -55.31% (overestimation), 2.30% (underestimation), and 4.85%, respectively. The average EE estimation error using the manufacturer's model, the new general model, and activity-specific models for various activities varied from -19.10% to -89.85%, -18.13% to 25.13%, and -4.31% to 9.93%, respectively. Conclusions: The predictors for the new models were based on accelerometer and demographic variables, indicating that movement and subject parameters were necessary in estimating the EE. The results indicate that the multisensor activity monitor with new prediction models can be used to estimate EE in MWUs with SCI during wheelchair-related activities mentioned in this study. C1 [Hiremath, Shivayogi V.; Ding, Dan; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs VA, Pittsburgh, PA 15206 USA. [Hiremath, Shivayogi V.; Ding, Dan; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Ding, Dan; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Farringdon, Jonathan] BodyMedia Inc, Pittsburgh, PA USA. RP Ding, D (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs VA, 6425 Penn Ave, Pittsburgh, PA 15206 USA. EM dad5@pitt.edu OI Farringdon, Jonathan/0000-0001-5977-3700 FU Rehabilitation Engineering Research Center on Interactive Exercise Technologies and Exercise Physiology for Persons with Disabilities [H133E070029]; National Institute on Disability and Rehabilitation Research; VA Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering [B3142C] FX Supported by the Rehabilitation Engineering Research Center on Interactive Exercise Technologies and Exercise Physiology for Persons with Disabilities (grant no. H133E070029), funded by the National Institute on Disability and Rehabilitation Research; and by the VA Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering (grant no. B3142C). The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 18 TC 12 Z9 12 U1 1 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2012 VL 93 IS 11 BP 1937 EP 1943 DI 10.1016/j.apmr.2012.05.004 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 031VQ UT WOS:000310671100008 PM 22609119 ER PT J AU Kanwal, F Hoang, T Chrusciel, T Kramer, JR El-Serag, HB Dominitz, JA Asch, SM AF Kanwal, Fasiha Hoang, Tuyen Chrusciel, Timothy Kramer, Jennifer R. El-Serag, Hashem B. Dominitz, Jason A. Asch, Steven M. TI Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Quality of Care; Performance; Chronic Liver Disease; Indicator ID QUALITY-OF-CARE; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; VIRUS-INFECTION; COMBINATION THERAPY; RANDOMIZED-TRIAL; UNITED-STATES; PREDICTORS; MANAGEMENT; DIAGNOSIS AB BACKGROUND & AIMS: Process of care-based measures are used commonly to assess the quality of medical care provided to patients with chronic hepatitis C virus (HCV) infection. However, the links between these processes and patient outcomes are not clear. METHODS: We conducted a large retrospective cohort study of 34,749 patients with HCV infection identified from the national Veterans Administration HCV Clinical Case Registry between 2003 and 2006. We examined the relationship between meeting process-based measures of HCV care (categorized into pretreatment, preventive or comorbid care, and treatment monitoring domains) and antiviral treatment-related outcomes. For each domain, we defined optimum care as receipt of all indicated care processes in that domain. Study end points were rates of antiviral treatment, treatment completion, and sustained virologic response (SVR), adjusted for patient demographics, comorbidities, use of health services, and intrafacility clustering. RESULTS: Patients who received optimum pretreatment care were significantly more likely to receive antiviral treatment (odds ratio [OR], 3.2; 95% confidence interval [CI], 2.9-3.5), complete treatment (OR, 1.26; 95% CI, 1.13-1.43), and achieve an SVR (OR, 1.29; 95% CI, 1.01-1.65), than those with suboptimum pretreatment care. Optimum preventive or comorbidity care also independently was associated with receipt of antiviral treatment (OR, 1.36; 95% CI, 1.23-1.51), but not with completion of treatment or SVR. Optimum treatment monitoring was associated with a nonsignificant trend toward achieving an SVR (OR, 1.22; 95% CI, 0.95-1.56). CONCLUSIONS: Optimum care for HCV infection-particularly the care delivered before treatment-is associated with increased rates of treatment and SVR. These data could be used to guide clinical policy as newer, more-effective treatments become available. C1 [Kanwal, Fasiha; Kramer, Jennifer R.; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston Vet Adm Hlth Serv Res & Dev Ctr Excellenc, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. [Kanwal, Fasiha; Hoang, Tuyen; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Chrusciel, Timothy] Greater Los Angeles VA Healthcare Syst, Dept Med, Los Angeles, CA USA. [Chrusciel, Timothy] John Cochran VA Med Ctr, St Louis, MO USA. [Dominitz, Jason A.] VA Puget Hlth Care Syst, Seattle, WA USA. [Asch, Steven M.] VA Palo Alto, VA Hlth Serv Res & Dev Ctr Excellence, Hlth Serv Res & Dev Serv, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Coll Med, Dept Med, Palo Alto, CA 94304 USA. RP Kanwal, F (reprint author), Michael E DeBakey VA Med Ctr, Houston Vet Adm Hlth Serv Res & Dev Ctr Excellenc, Hlth Serv Res & Dev Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM fasiha.kanwal@va.gov OI Dominitz, Jason/0000-0002-8070-7086 FU Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs [IIR-07-111] FX This material is based on work supported by the Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs, grant IIR-07-111 (F.K.). NR 34 TC 11 Z9 11 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2012 VL 10 IS 11 BP 1270 EP + DI 10.1016/j.cgh.2012.07.015 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 033FS UT WOS:000310780200020 PM 22841970 ER PT J AU Gu, F Molano, I Ruiz, P Sun, LY Gilkeson, GS AF Gu, Fei Molano, Ivan Ruiz, Philip Sun, Lingyun Gilkeson, Gary S. TI Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice SO CLINICAL IMMUNOLOGY LA English DT Article DE Mesenchymal stem cells; Systemic lupus erythematosus; Allogeneic; Syngeneic ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MARROW STROMAL CELLS; T-REGULATORY CELLS; RENAL-DISEASE; MURINE MODEL; PROLIFERATION; SUPPRESSION; EXPRESSION; THERAPY; INHIBIT AB MSC are being explored as a promising novel treatment for SLE. In this study, we: 1) assessed the differential effects of allogeneic versus syngeneic MSC transplantation on lupus-like disease, 2) explored the mechanisms by which MSC modulate disease, and 3) investigated whether lupus-derived-MSC have intrinsic immunomodulatory defects. We showed that in MRL/lpr mice and (NZB/NZW)F1 mice, both B6-MSC and lupus-MSC from young mice ameliorated SLE-like disease and reduced splenic CD3+CD4+ T lymphocytes and CD19+CD21+ B lymphocytes. However, lupus-MSC from older (NZB/NZW)F1 mice did not reduce spleen weights, glomerular IgG deposits, renal pathology, interstitial inflammation, CD3+CD4+ T lymphocytes or CD19+CD21+ B lymphocytes significantly. Thus MSC transplantation ameliorates SLE-like disease partly through decreasing CD4+ T cell and naive mature B cell numbers. Allogeneic MSC may be preferred over syngeneic lupus-derived-MSC given the decreased overall effectiveness of post-lupus-derived-MSC, which appears partially due to disease and not exclusively intrinsic defects in the MSC themselves. Published by Elsevier Inc. C1 [Gu, Fei; Sun, Lingyun] Nanjing Univ, Dept Rheumatol & Immunol, Affiliated Drum Tower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China. [Gu, Fei; Molano, Ivan; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA. [Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. [Ruiz, Philip] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33136 USA. RP Sun, LY (reprint author), Nanjing Univ, Dept Rheumatol & Immunol, Affiliated Drum Tower Hosp, Sch Med, 321 Zhong Shan Rd, Nanjing 210008, Jiangsu, Peoples R China. EM lingyunsun2001@yahoo.com.cn; gilkeson@musc.edu FU Lupus Foundation of America; Major International (Regional) Joint Research Project of China [81120108021]; National Natural Science Foundation of China [30972736] FX This work was supported by a grant from the Lupus Foundation of America, the Major International (Regional) Joint Research Project of China (No. 81120108021), and National Natural Science Foundation of China (No. 30972736). NR 30 TC 28 Z9 31 U1 0 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD NOV PY 2012 VL 145 IS 2 BP 142 EP 152 DI 10.1016/j.clim.2012.08.012 PG 11 WC Immunology SC Immunology GA 031WB UT WOS:000310672200011 PM 23041504 ER PT J AU Ritchie, C Richman, J Sobko, H Bodner, E Phillips, B Houston, T AF Ritchie, Christine Richman, Joshua Sobko, Heather Bodner, Eric Phillips, Barrett Houston, Thomas TI The E-Coach transition support computer telephony implementation study: Protocol of a randomized trial SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Care transitions; Interactive voice response; Telehealth ID INTERACTIVE VOICE RESPONSE; CARE; INTERVENTION AB Background: Patients requiring complex care are at high risk during the transition from one setting of care to another. Effective interventions to support care transitions have been designed but are very resource intensive. Telemonitoring has been considered as an approach to enhance care transition support, but many telemonitoring systems require special equipment or web-based interfaces to interact with patients and caregivers. Methods/design: In this paper we report our protocol for developing and testing E-Coach, an interactive voice response (IVR)-enhanced care transition intervention that monitors patients at home using their personal phone. The elements described include 1) development of an IVR monitoring system that will be based on Coleman's four pillars of care transition support; 2) development of a web-based "dashboard" of IVR responses that alert care transition nurses (CTN) of patient/caregiver concerns after discharge and allow documentation by the CTN when patients/caregivers are called; 3) pilot testing of the IVR system by patients and providers with refinement of the system based on patient/provider input; and 4) a pragmatic protocol for formal testing through a randomized controlled trial (RCT) of the E-Coach intervention in congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) patients admitted to a large tertiary hospital. (C) 2012 Elsevier Inc. All rights reserved. C1 [Ritchie, Christine; Bodner, Eric] Univ Alabama Birmingham UAB, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Richman, Joshua] Birmingham VA Med Ctr, Birmingham, AL 35222 USA. [Sobko, Heather] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35294 USA. [Phillips, Barrett; Houston, Thomas] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA 01655 USA. RP Ritchie, C (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94118 USA. EM critchie@uab.edu; jrichman@mail.dopm.uab.edu; hsobko@uab.edu; ebodner@uab.edu; BarrettD.Phillips@umassmed.edu; thomas.houston@umassmed.edu RI Houston, Thomas/F-2469-2013 FU Agency for Healthcare Research and Quality Care of Complex Patients grant [R18-HS017786-02] FX This project is supported by an Agency for Healthcare Research and Quality Care of Complex Patients grant # R18-HS017786-02. NR 13 TC 5 Z9 5 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2012 VL 33 IS 6 BP 1172 EP 1179 DI 10.1016/j.cct.2012.08.007 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 033UA UT WOS:000310825400008 PM 22922245 ER PT J AU Al-Jiboury, H Kaunitz, JD AF Al-Jiboury, Hala Kaunitz, Jonathan D. TI Gastroduodenal mucosal defense SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Review DE estrogen; gastrointestinal defense; matrix metalloproteinase-2; oxidative stress; trefoil factors ID DUODENAL BICARBONATE SECRETION; GASTRIC OXIDATIVE STRESS; GLUCAGON-LIKE PEPTIDE-2; HELICOBACTER-PYLORI; EPITHELIAL-CELLS; HEME OXYGENASE-1; INJURY; ACTIVATION; MECHANISM; EXPRESSION AB Purpose of review To review recent developments in the field of gastroduodenal mucosal defense. Recent findings Research in the field of gastroduodenal mucosal defense is shifting from animal models of mucosal injury towards the elucidation of molecular mechanisms that protect the mucosa at the cellular level. Accordingly, the recent literature is focused on endogenous antioxidants such as mitochondrial superoxide dismutase (SOD), and heme oxygenase-1, mucosal receptors such as the Toll-like receptors and protease-activated receptors, endogenous proteins with protective effects such as the matrix metalloproteinases, heat-inducible factors and trefoil factors, protective functions of submucosal mononuclear cells, junctional proteins affecting mucosal permeability, and hormone-mediated protective mechanisms mediated by estrogens, vasoactive peptides, and other hormones. Summary These new published findings contribute to our overall understanding of gastroduodenal defense and suggest innovative avenues of future research and possible novel therapeutic targets. C1 [Al-Jiboury, Hala] Cedars Sinai Med Residency Program, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA USA. [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Med, Los Angeles, CA USA. [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Surg, Los Angeles, CA USA. [Kaunitz, Jonathan D.] CURE Digest Dis Res Ctr, Dept Med, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles VAMC, MD Bldg 114,Room 217E, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Department of Veterans Affairs Merit Review Award; NIH-NIDDK [R01 54221] FX The authors declare no competing interests with the content of this article. Supported by a Department of Veterans Affairs Merit Review Award (J.D.K.), and NIH-NIDDK R01 54221 (J.D.K.). NR 34 TC 4 Z9 4 U1 2 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2012 VL 28 IS 6 BP 594 EP 601 DI 10.1097/MOG.0b013e328358d56c PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 027NA UT WOS:000310358200009 PM 22954689 ER PT J AU Levin, MC Lidberg, U Jirholt, P Adiels, M Wramstedt, A Gustafsson, K Greaves, DR Li, S Fazio, S Linton, MF Olofsson, SO Boren, J Gjertsson, I AF Levin, M. C. Lidberg, U. Jirholt, P. Adiels, M. Wramstedt, A. Gustafsson, K. Greaves, D. R. Li, S. Fazio, S. Linton, M. F. Olofsson, S-O Boren, J. Gjertsson, I. TI Evaluation of macrophage-specific promoters using lentiviral delivery in mice SO GENE THERAPY LA English DT Article DE macrophage; promoter; lentivirus ID GENE-THERAPY; INNATE IMMUNITY; DEFICIENT MICE; EXPRESSION; ATHEROSCLEROSIS; CELLS; VECTOR; CD68; TRANSDUCTION; MACROSIALIN AB In gene therapy, tissue-specific promoters are useful tools to direct transgene expression and improve efficiency and safety. Macrophage-specific promoters (MSPs) have previously been published using different delivery systems. In this study, we evaluated five different MSPs fused with green fluorescent protein (GFP) to delineate the one with highest specificity using lentiviral delivery. We compared three variants of the CD68 promoter (full length, the 343-bp proximal part and the 150-bp proximal part) and two variants (in forward and reverse orientation) of a previously characterized synthetic promoter derived from elements of transcription factor genes. We transduced a number of cell lines and primary cells in vitro. In addition, hematopoietic stem cells were transduced with MSPs and transferred into lethally irradiated recipient mice. Fluorescence activated cell sorting analysis was performed to determine the GFP expression in different cell populations both in vitro and in vivo. We showed that MSPs can efficiently be used for lentiviral gene delivery and that the 150-bp proximal part of the CD68 promoter provides primarily macrophage-specific expression of GFP. We propose that this is the best currently available MSP to use for directing transgene expression to macrophage populations in vivo using lentiviral vectors. C1 [Jirholt, P.; Gjertsson, I.] Univ Gothenburg, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden. [Gustafsson, K.] UCL, Inst Child Hlth, Mol Immunol Unit, London, England. [Greaves, D. R.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England. [Li, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Li, S.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Fazio, S.; Linton, M. F.] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN USA. [Levin, M. C.; Lidberg, U.; Adiels, M.; Wramstedt, A.; Olofsson, S-O; Boren, J.; Gjertsson, I.] Univ Gothenburg, Wallenberg Lab, Dept Mol & Clin Med, Gothenburg, Sweden. RP Levin, MC (reprint author), Sahlgrens Univ Hosp, Wallenberg Lab, Gothenburg 41345, Sweden. EM malin.levin@wlab.gu.se OI Greaves, David/0000-0003-2856-9410 FU Swedish Research Council; VINNOVA Foundation; IngaBritt and Arne Lundgren Foundation; Swedish Foundation for Strategic Research; Sahlgrenska University Hospital ALF research grants; NIH [HL105375, HL57986, HL106845, HL65709] FX We thank Louise Henningsson, Kristina Skalen, Elin Stenfeldt and Maria Heyden (Gothenburg University) for expert technical assistance; Yan Ru Su and John Blakemore (Vanderbilt University) for stimulating discussions and technical expertise; and Rosie Perkins (Gothenburg University) for editing the manuscript. This work was supported by the Swedish Research Council; the VINNOVA Foundation; the IngaBritt and Arne Lundgren Foundation; the Swedish Foundation for Strategic Research; the Sahlgrenska University Hospital ALF research grants; and NIH Grants HL105375, HL57986, HL106845 and HL65709. NR 29 TC 9 Z9 9 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 J9 GENE THER JI Gene Ther. PD NOV PY 2012 VL 19 IS 11 BP 1041 EP 1047 DI 10.1038/gt.2011.195 PG 7 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 034AA UT WOS:000310841300001 PM 22130447 ER PT J AU Walker, RJ Smalls, BL Hernandez-Tejada, MA Campbell, JA Davis, KS Egede, LE AF Walker, Rebekah J. Smalls, Brittany L. Hernandez-Tejada, Melba A. Campbell, Jennifer A. Davis, Kimberly S. Egede, Leonard E. TI Effect of diabetes fatalism on medication adherence and self-care behaviors in adults with diabetes SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Fatalism; Medication adherence; Self-care; Diabetes ID AFRICAN-AMERICANS; DEPRESSION; QUESTIONNAIRE; METAANALYSIS; VALIDITY; SCALE AB Objective: Diabetes fatalism is defined as "a complex psychological cycle characterized by perceptions of despair, hopelessness, and powerlessness" and associated with poor glycemic control. This study examined the association between diabetes fatalism and medication adherence and self-care behaviors in adults with diabetes. Methods: Data on 378 subjects with type 2 diabetes recruited from two primary care clinics in the Southeastern United States were examined. Previously validated scales were used to measure diabetes fatalism, medication adherence, diabetes knowledge and diabetes selfcare behaviors (diet, physical activity, blood sugar testing and foot care). Multiple linear regression was used to assess the independent effect of diabetes fatalism on medication adherence and self-care behaviors controlling for relevant covariates. Results: Fatalism correlated significantly with medication adherence (r=0.24, P<.001), diet (r=-0.26, P<.001), exercise (r=-0.20, P<.001) and blood sugar testing (r=-0.19, P<.001). In the linear regression model, diabetes fatalism was significantly associated with medication adherence [beta=0.029, 95% confidence interval (CI) 0.016, 0.043], diabetes knowledge (beta=-0.042, 95% CI -0.001, -0.084), diet (beta=-0.063, 95% CI -0.039, -0.087), exercise (beta=-0.055, 95% CI -0.028, -0.083) and blood sugar testing (beta=-0.055, 95% CI -0.023, -0.087). There was no significant association between diabetes fatalism and foot care (beta=-0.018, 95% CI -0.047, 0.011). The association between diabetes fatalism and medication adherence, diabetes knowledge and diabetes self-care behaviors did not change significantly when depression was added to the models, suggesting that the associations are independent of depression. Conclusion: Diabetes fatalism is associated with poor medication adherence and self-care and may be an important target for education and skills interventions in diabetes care. In addition, the effect of diabetes fatalism is independent of depression, suggesting that interventions that target depression may not be sufficient to deal with diabetes fatalism. (C) 2012 Elsevier Inc. All rights reserved. C1 [Walker, Rebekah J.; Smalls, Brittany L.; Hernandez-Tejada, Melba A.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Davis, Kimberly S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA REAP, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute for Diabetes, Digestive and Kidney Disease [T35DK007431] FX Supported by Grant #T35DK007431 from the National Institute for Diabetes, Digestive and Kidney Disease. NR 25 TC 21 Z9 22 U1 0 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2012 VL 34 IS 6 BP 598 EP 603 DI 10.1016/j.genhosppsych.2012.07.005 PG 6 WC Psychiatry SC Psychiatry GA 031WA UT WOS:000310672100003 PM 22898447 ER PT J AU Maldonado, JR Nguyen, LH Schader, EM Brooks, JO AF Maldonado, Jose R. Nguyen, Long H. Schader, E. Merritt Brooks, John O., III TI Benzodiazepine loading versus symptom-triggered treatment of alcohol withdrawal: a prospective, randomized clinical trial SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Alcohol; Benzodiazepines; Withdrawal; Lorazepam; Diazepam; Symptom triggered; Loading method ID INTENSIVE-CARE-UNIT; PRACTICE GUIDELINE; MANAGEMENT; DEPENDENCE; LORAZEPAM; CHLORDIAZEPOXIDE; DETOXIFICATION; METAANALYSIS; MEDICATIONS; PREVALENCE AB Objectives: The objectives were to compare the efficacy of a benzodiazepine loading versus a symptom-triggered protocol in the management of alcohol withdrawal. Methods: We conducted a prospective, randomized, controlled trial including 47 consecutive patients admitted to one of two tertiary care medical centers who developed alcohol withdrawal syndrome. Patients were randomly assigned to either a benzodiazepine loading protocol or a symptom-triggered treatment protocol. The Clinical Institute Withdrawal Assessment for Alcohol-Revised scale (CIWA-Ar) was recorded throughout the length of stay, along with measures of autonomic system functioning. Results: The average rate of change of CIWA-Ar scores was -1.5 +/- 1.3 for the symptom-triggered group and -2.3 +/- 2.5 for the loading group. Average rate of change for systolic blood pressure was -2.7 +/- 5.3 for the symptom-triggered group and -2.3 +/- 6.4 for the loading group. There was no significant difference between the rates of change for either group on either measure. Similarly, there was no significant difference in total benzodiazepine use between groups. Within 72 h of treatment, 69.6% of patients in the loading group were free of withdrawal symptoms versus 41.7% in the symptom-triggered group, a difference not reaching statistical significance. Conclusions: This study did not reveal clear evidence of a clinical advantage for choosing either treatment method. (C) 2012 Elsevier Inc. All rights reserved. C1 [Maldonado, Jose R.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Nguyen, Long H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schader, E. Merritt] Community Solut, Morgan Hill, CA USA. [Brooks, John O., III] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. RP Maldonado, JR (reprint author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. EM jrm@stanford.edu NR 51 TC 9 Z9 9 U1 4 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2012 VL 34 IS 6 BP 611 EP 617 DI 10.1016/j.genhosppsych.2012.06.016 PG 7 WC Psychiatry SC Psychiatry GA 031WA UT WOS:000310672100005 PM 22898443 ER PT J AU Lu, MW Carlson, KF Duckart, JP Dobscha, SK AF Lu, Mary W. Carlson, Kathleen F. Duckart, Jonathan P. Dobscha, Steven K. TI The effects of age on initiation of mental health treatment after positive PTSD screens among Veterans Affairs primary care patients SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Veterans/psychology; Posttraumatic stress disorders; Mass screening ID POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN; IRAQ; VALIDATION; DEPRESSION; SERVICES AB Objective: The objective was to examine differences by age in mental health treatment initiation in Veterans Health Administration (VA) primary care patients after positive posttraumatic stress disorder (PTSD) screens. Methods: This was a retrospective cohort study of 71,039 veterans who were administered PTSD screens during primary care encounters in 2007 at four Pacific Northwest VA medical center sites and who had no specialty mental health clinic visits or PTSD diagnoses recorded in the year before screening. Main outcome measures were attendance of any specialty mental health clinic visits or receipt of any antidepressant medication in the year after a positive PTSD screen. Results: Older veterans, compared with veterans less than 30 years old, were less likely to attend any specialty mental health visits after positive PTSD screens [adjusted odds ratios (ORs) ranged from .57 to .12, all P<.001], and veterans 75 years and older were less likely to receive any antidepressant medication (adjusted OR=.56, P<.001). Conclusions: Initiation of mental health treatment among veterans who screen positive for PTSD varies significantly by age. Further research should examine whether this is due to differences in base rates of PTSD, treatment preferences, provider responses to screens or other age-related barriers to mental health treatment. Published by Elsevier Inc. C1 [Lu, Mary W.] Portland VA Med Ctr, Mental Hlth & Neurosci Div, Portland, OR 97239 USA. [Lu, Mary W.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Carlson, Kathleen F.; Duckart, Jonathan P.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA. [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Lu, MW (reprint author), Portland VA Med Ctr, Mental Hlth & Neurosci Div, POB 1034,P3MHR, Portland, OR 97239 USA. EM Mary.Lu@va.gov FU VA Health Services Research and Development Service (HSRD) [REA 06-174, CDA 08-025]; Pacific Northwest Mental Illness Research and Education and Clinical Center FX This work was supported by VA Health Services Research and Development Service (HSR&D) grants REA 06-174 and CDA 08-025, and the Pacific Northwest Mental Illness Research and Education and Clinical Center. The authors acknowledge Bentson McFarland, M.D., Ph.D.; Jean O'Malley, M.P.H.; Maya O'Neil, M.S., Ph.D.; Alex Linke, B.S.; Molly DeLorit, B.A.; Sondra K. Long, B.A.; and Linda Ganzini, M.D., for their assistance. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 30 TC 10 Z9 10 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2012 VL 34 IS 6 BP 654 EP 659 DI 10.1016/j.genhosppsych.2012.07.002 PG 6 WC Psychiatry SC Psychiatry GA 031WA UT WOS:000310672100012 PM 22898446 ER PT J AU Pinne, M Matsunaga, J Haake, DA AF Pinne, Marija Matsunaga, James Haake, David A. TI Leptospiral Outer Membrane Protein Microarray, a Novel Approach to Identification of Host Ligand-Binding Proteins SO JOURNAL OF BACTERIOLOGY LA English DT Article ID HUMORAL IMMUNE-RESPONSE; EXTRACELLULAR-MATRIX PROTEINS; GRAM-NEGATIVE BACTERIA; STAPHYLOCOCCUS-AUREUS; BORRELIA-BURGDORFERI; IMMUNODOMINANT ANTIGENS; PATHOGEN INTERACTIONS; CAMPYLOBACTER-JEJUNI; ANTIBODY-RESPONSES; SIGNAL PEPTIDES AB Leptospirosis is a zoonosis with worldwide distribution caused by pathogenic spirochetes belonging to the genus Leptospira. The leptospiral life cycle involves transmission via freshwater and colonization of the renal tubules of their reservoir hosts. Infection requires adherence to cell surfaces and extracellular matrix components of host tissues. These host-pathogen interactions involve outer membrane proteins (OMPs) expressed on the bacterial surface. In this study, we developed an Leptospira interrogans serovar Copenhageni strain Fiocruz L1-130 OMP microarray containing all predicted lipoproteins and transmembrane OMPs. A total of 401 leptospiral genes or their fragments were transcribed and translated in vitro and printed on nitrocellulose-coated glass slides. We investigated the potential of this protein microarray to screen for interactions between leptospiral OMPs and fibronectin (Fn). This approach resulted in the identification of the recently described fibronectin-binding protein, LIC10258 (MFn8, Lsa66), and 14 novel Fn-binding proteins, denoted Microarray Fn-binding proteins (MFns). We confirmed Fn binding of purified recombinant LIC11612 (MFn1), LIC10714 (MFn2), LIC11051 (MFn6), LIC11436 (MFn7), LIC10258 (MFn8, Lsa66), and LIC10537 (MFn9) by far-Western blot assays. Moreover, we obtained specific antibodies to MFn1, MFn7, MFn8 (Lsa66), and MFn9 and demonstrated that MFn1, MFn7, and MFn9 are expressed and surface exposed under in vitro growth conditions. Further, we demonstrated that MFn1, MFn4 (LIC12631, Sph2), and MFn7 enable leptospires to bind fibronectin when expressed in the saprophyte, Leptospira biflexa. Protein microarrays are valuable tools for high-throughput identification of novel host ligand-binding proteins that have the potential to play key roles in the virulence mechanisms of pathogens. C1 [Pinne, Marija; Matsunaga, James] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Pinne, Marija; Matsunaga, James; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. RP Pinne, M (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. EM mpinne@ucla.edu FU VA Medical Research Funds; National Institute of Allergy and Infectious Diseases [AI-034431] FX This study was supported by VA Medical Research Funds (to D.A.H. and J.M.) and grant AI-034431 (to D.A.H.) from the National Institute of Allergy and Infectious Diseases. NR 108 TC 19 Z9 19 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD NOV PY 2012 VL 194 IS 22 BP 6074 EP 6087 DI 10.1128/JB.01119-12 PG 14 WC Microbiology SC Microbiology GA 030SB UT WOS:000310589300007 PM 22961849 ER PT J AU Russo, SB Baicu, CF Van Laer, A Geng, TY Kasiganesan, H Zile, MR Cowart, LA AF Russo, Sarah Brice Baicu, Catalin F. Van Laer, An Geng, Tuoyu Kasiganesan, Harinath Zile, Michael R. Cowart, L. Ashley TI Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID MONOUNSATURATED FATTY-ACIDS; INDUCED INSULIN-RESISTANCE; BETA-CELL TURNOVER; CARDIAC-HYPERTROPHY; HEART-FAILURE; CHAIN-LENGTH; DIABETIC CARDIOMYOPATHY; SUBSTRATE-SPECIFICITY; HEMODYNAMIC STRESS; METABOLIC SYNDROME AB Diabetic cardiomyopathy (DbCM), which consists of cardiac hypertrophy and failure in the absence of traditional risk factors, is a major contributor to increased heart failure risk in type 2 diabetes patients. In rodent models of DbCM, cardiac hypertrophy and dysfunction have been shown to depend upon saturated fatty acid (SFA) oversupply and de novo sphingolipid synthesis. However, it is not known whether these effects are mediated by bulk SFAs and sphingolipids or by individual lipid species. In this report, we demonstrate that a diet high in SFA induced cardiac hypertrophy, left ventricular systolic and diastolic dysfunction, and autophagy in mice. Furthermore, treatment with the SFA myristate, but not palmitate, induced hypertrophy and autophagy in adult primary cardiomyocytes. De novo sphingolipid synthesis was required for induction of all pathological features observed both in vitro and in vivo, and autophagy was required for induction of hypertrophy in vitro. Finally, we implicated a specific ceramide N-acyl chain length in this process and demonstrated a requirement for (dihydro)ceramide synthase 5 in cardiomyocyte autophagy and myristate-mediated hypertrophy. Thus, this report reveals a requirement for a specific sphingolipid metabolic route and dietary SFAs in the molecular pathogenesis of lipotoxic cardiomyopathy and hypertrophy. C1 [Russo, Sarah Brice; Geng, Tuoyu; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA. [Baicu, Catalin F.; Van Laer, An; Kasiganesan, Harinath; Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29403 USA. [Zile, Michael R.; Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 114 Doughty St,Strom Thurmond Bldg,Rm 423, Charleston, SC 29403 USA. EM cowartl@musc.edu FU Cancer Center Support Grant [P30 CA138313]; COBRE in Lipidomics in Pathobiology [NIH P20RR017077]; National Institute of Diabetes and Digestive and Kidney Diseases [F30DK092125]; Department of Veterans Affairs; NIH COBRE in Lipidomics and Pathobiology at MUSC FX We thank Donald Menick for his invaluable support of this project in its early stages; Benjamin Addy and Santhosh Mani for cell culture and technical assistance; Wei Hu for technical assistance; and Yusuf Hannun for helpful comments. Imaging studies were performed using the Cell and Molecular Imaging Shared Resource (supported in part by Cancer Center Support Grant P30 CA138313 to the Hollings Cancer Center at MUSC), with help from Venkat Ramshesh. LC/MS lipid measurements were performed at the Lipidomics Core Facility at MUSC, which is supported by the COBRE in Lipidomics in Pathobiology (NIH P20RR017077). Support for this work was provided by grant number F30DK092125 from the National Institute of Diabetes and Digestive and Kidney Diseases (to S.B. Russo), merit awards from the Department of Veterans Affairs (to L.A. Cowart and M.R. Zile), and the NIH COBRE in Lipidomics and Pathobiology at MUSC (to L.A. Cowart). NR 77 TC 61 Z9 62 U1 0 U2 12 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD NOV PY 2012 VL 122 IS 11 BP 3919 EP 3930 DI 10.1172/JCI63888 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 031WP UT WOS:000310673600022 PM 23023704 ER PT J AU Lee, RJ Xiong, GX Kofonow, JM Chen, B Lysenko, A Jiang, PH Abraham, V Doghramji, L Adappa, ND Palmer, JN Kennedy, DW Beauchamp, GK Doulias, PT Ischiropoulos, H Kreindler, JL Reed, DR Cohen, NA AF Lee, Robert J. Xiong, Guoxiang Kofonow, Jennifer M. Chen, Bei Lysenko, Anna Jiang, Peihua Abraham, Valsamma Doghramji, Laurel Adappa, Nithin D. Palmer, James N. Kennedy, David W. Beauchamp, Gary K. Doulias, Paschalis-Thomas Ischiropoulos, Harry Kreindler, James L. Reed, Danielle R. Cohen, Noam A. TI T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID CILIARY BEAT FREQUENCY; BRONCHIAL EPITHELIAL-CELLS; HUMAN AIRWAY EPITHELIA; PSEUDOMONAS-AERUGINOSA; NITRIC-OXIDE; CHRONIC RHINOSINUSITIS; INTRACELLULAR CALCIUM; BURKHOLDERIA-CEPACIA; IN-VITRO; INDIVIDUAL-DIFFERENCES AB Innate and adaptive defense mechanisms protect the respiratory system from attack by microbes. Here, we present evidence that the bitter taste receptor T2R38 regulates the mucosal innate defense of the human upper airway. Utilizing immunofluorescent and live cell imaging techniques in polarized primary human sinonasal cells, we demonstrate that T2R38 is expressed in human upper respiratory epithelium and is activated in response to acyl-homoserine lactone quorum-sensing molecules secreted by Pseudomonas aeruginosa and other gram-negative bacteria. Receptor activation regulates calcium-dependent NO production, resulting in stimulation of mucociliary clearance and direct antibacterial effects. Moreover, common polymorphisms of the TAS2R38 gene were linked to significant differences in the ability of upper respiratory cells to clear and kill bacteria. Lastly, TAS2R38 genotype correlated with human sinonasal gram-negative bacterial infection. These data suggest that T2R38 is an upper airway sentinel in innate defense and that genetic variation contributes to individual differences in susceptibility to respiratory infection. C1 [Lee, Robert J.; Kofonow, Jennifer M.; Chen, Bei; Doghramji, Laurel; Adappa, Nithin D.; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Xiong, Guoxiang] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA USA. [Lysenko, Anna; Jiang, Peihua; Beauchamp, Gary K.; Reed, Danielle R.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. [Abraham, Valsamma; Doulias, Paschalis-Thomas; Ischiropoulos, Harry; Kreindler, James L.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA. [Doulias, Paschalis-Thomas; Ischiropoulos, Harry] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19004 USA. EM cohenn@uphs.upenn.edu RI Doulias, Paschalis-Thomas/I-7318-2013 OI Cohen, Noam/0000-0002-9462-3932; Reed, Danielle/0000-0002-4374-6107; Lee, Robert/0000-0001-5826-6686 FU Flight Attendants Medical Research Institute [082478]; USPHS [P30DC011735, R01DC004698, P50DC000214, R01DC010842] FX We thank D.M. Sabatini, P.F. Worley, A.S. Cohen, N.M. Cohen, J.C. Saunders, and Y.E. Cohen for critical reading of this manuscript. We also thank B.H. Igelwski and J.M. Schwingel for Pseudomonas strain PAO-JP2, G. O'Toole for Pseudomonas strain Sad36, and D. LaRosa for FLS-1. This work was supported by a grant from the Flight Attendants Medical Research Institute 082478 (to N.A. Cohen), a philanthropic contribution from the RLG Foundation Inc. (to N.A. Cohen), and USPHS grants P30DC011735 (to D.R. Reed), R01DC004698 (to D.R. Reed), P50DC000214 (to G.K. Beauchamp), and R01DC010842 (to P. Jiang). NR 93 TC 136 Z9 137 U1 5 U2 49 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD NOV PY 2012 VL 122 IS 11 BP 4145 EP 4159 DI 10.1172/JCI64240 PG 15 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 031WP UT WOS:000310673600041 PM 23041624 ER PT J AU Gros, DF Magruder, KM Ruggiero, KJ Shaftman, SR Frueh, BC AF Gros, Daniel F. Magruder, Kathryn M. Ruggiero, Kenneth J. Shaftman, Stephanie R. Frueh, B. Christopher TI Comparing the Symptoms of Posttraumatic Stress Disorder With the Distress and Fear Disorders SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE PTSD; anxiety disorders; depressive disorders; comorbidity; transdiagnostic ID PRIMARY-CARE CLINICS; ADMINISTERED PTSD SCALE; VA PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; ANXIETY DISORDERS; DSM-IV; MOOD DISORDERS; VETERANS; COMORBIDITY; PREVALENCE AB New theoretical models of mood and anxiety disorders have been proposed to better understand the relations and patterns leading to their high diagnostic comorbidities. These models have highlighted two new groupings of the disorders, focused on the prevalence of fear and distress symptoms. The present study investigated the fit of the symptoms of posttraumatic stress disorder (PTSD) in these new models. The relations between the two primary sets of symptom scales of PTSD and the diagnoses of other comorbid disorders were examined in a large multisite sample of veterans from primary care clinics. The results suggested that there was no reliable difference in the predictive power of any of the PTSD symptom scales across the two diagnostic groups. New transdiagnostic models, assessment practices, and treatment approaches may provide better understanding of symptom overlap and diagnostic comorbidity in PTSD and related disorders. C1 [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.; Magruder, Kathryn M.; Ruggiero, Kenneth J.; Shaftman, Stephanie R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA. RP Gros, DF (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Veterans Affairs Health Services Research and Development [VCR-99-010-2] FX This study was partially supported by grant VCR-99-010-2 from Veterans Affairs Health Services Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. NR 49 TC 4 Z9 4 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD NOV PY 2012 VL 200 IS 11 BP 967 EP 972 DI 10.1097/NMD.0b013e3182718a36 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 033KN UT WOS:000310794900010 PM 23124181 ER PT J AU Bourdette, D Gilden, D AF Bourdette, Dennis Gilden, Don TI Fingolimod and multiple sclerosis Four cautionary tales SO NEUROLOGY LA English DT Editorial Material ID ORAL FINGOLIMOD; THERAPY C1 [Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Bourdette, Dennis] Portland VA Med Ctr, MS Ctr Excellence W, Portland, OR USA. [Gilden, Don] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Gilden, Don] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO USA. RP Bourdette, D (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM bourdett@ohsu.edu NR 12 TC 18 Z9 18 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV PY 2012 VL 79 IS 19 BP 1942 EP 1943 DI 10.1212/WNL.0b013e3182735edf PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 032US UT WOS:000310745200007 PM 23035058 ER PT J AU Tsuang, D Leverenz, JB Lopez, OL Hamilton, RL Bennett, DA Schneider, JA Buchman, AS Larson, EB Crane, PK Kaye, JA Kramer, P Woltjer, R Kukull, W Nelson, PT Jicha, GA Neltner, JH Galasko, D Masliah, E Trojanowski, JQ Schellenberg, GD Yearout, D Huston, H Fritts-Penniman, A Mata, IF Wan, JY Edwards, KL Montine, TJ Zabetian, CP AF Tsuang, Debby Leverenz, James B. Lopez, Oscar L. Hamilton, Ronald L. Bennett, David A. Schneider, Julie A. Buchman, Aron S. Larson, Eric B. Crane, Paul K. Kaye, Jeffrey A. Kramer, Patricia Woltjer, Randy Kukull, Walter Nelson, Peter T. Jicha, Gregory A. Neltner, Janna H. Galasko, Doug Masliah, Eliezer Trojanowski, John Q. Schellenberg, Gerard D. Yearout, Dora Huston, Haley Fritts-Penniman, Allison Mata, Ignacio F. Wan, Jia Y. Edwards, Karen L. Montine, Thomas J. Zabetian, Cyrus P. TI GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology SO NEUROLOGY LA English DT Article ID GAUCHER-DISEASE; GLUCOCEREBROSIDASE MUTATIONS; PARKINSONS-DISEASE; DEMENTIA; DISORDERS; NEUROPATHOLOGY; ASSOCIATION; CONSORTIUM; DIAGNOSIS; BODIES AB Objectives: Mutations in the GBA gene occur in 7% of patients with Parkinson disease (PD) and are a well-established susceptibility factor for PD, which is characterized by Lewy body disease (LBD) neuropathologic changes (LBDNCs). We sought to determine whether GBA influences risk of dementia with LBDNCs, Alzheimer disease (AD) neuropathologic changes (ADNCs), or both. Methods: We screened the entire GBA coding region for mutations in controls and in subjects with dementia and LBDNCs and no or low levels of ADNCs (pure dementia with Lewy bodies [pDLB]), LBDNCs and high-level ADNCs (LBD-AD), and high-level ADNCs but without LBDNCs (AD). Results: Among white subjects, pathogenic GBA mutations were identified in 6 of 79 pDLB cases (7.6%), 8 of 222 LBD-AD cases (3.6%), 2 of 243 AD cases (0.8%), and 3 of 381 controls (0.8%). Subjects with pDLB and LBD-AD were more likely to carry mutations than controls (pDLB: odds ratio [OR] = 7.6; 95% confidence interval [CI] = 1.8-31.9; p = 0.006; LBD-AD: OR = 4.6; CI = 1.2-17.6; p = 0.025), but there was no significant difference in frequencies between the AD and control groups (OR = 1.1; CI = 0.2-6.6; p = 0.92). There was a highly significant trend test across groups (chi(2)(1) = 19.3; p = 1.1 x 10(-5)), with the likelihood of carrying a GBA mutation increasing in the following direction: control/AD < LBD-AD < pDLB. Conclusions: GBA is a susceptibility gene across the LBD spectrum, but not in AD, and appears to convey a higher risk for PD and pDLB than for LBD-AD. PD and pDLB might be more similar to one another in genetic determinants and pathophysiology than either disease is to LBD-AD. Neurology (R) 2012;79:1944-1950 C1 [Tsuang, Debby; Leverenz, James B.; Yearout, Dora; Huston, Haley; Fritts-Penniman, Allison; Mata, Ignacio F.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Tsuang, Debby; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.; Yearout, Dora; Huston, Haley; Fritts-Penniman, Allison; Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Larson, Eric B.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA. [Kukull, Walter; Wan, Jia Y.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Hamilton, Ronald L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Bennett, David A.; Buchman, Aron S.] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA. [Schneider, Julie A.] Rush Univ, Dept Pathol, Chicago, IL 60612 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Kaye, Jeffrey A.; Kramer, Patricia] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Woltjer, Randy] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Nelson, Peter T.; Jicha, Gregory A.; Neltner, Janna H.] Univ Kentucky, Dept Pathol, Lexington, KY 40506 USA. [Jicha, Gregory A.] Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA. [Galasko, Doug] Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USA. [Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA. [Trojanowski, John Q.; Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. RP Zabetian, CP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. EM dwt1@uw.edu; zabetian@u.washington.edu RI Crane, Paul/C-8623-2014; Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Fernandez Mata, Ignacio/0000-0003-1198-0633; Kaye, Jeffrey/0000-0002-9971-3478; Kukull, Walter/0000-0001-8761-9014; Crane, Paul/0000-0003-4278-7465; Zabetian, Cyrus/0000-0002-7739-4306 FU Department of Veterans Affairs [1I01BX000531]; National Institutes of Health [P30 AG008017, P30 AG028383, P30 AG010124, P30 AG010161, P50 AG005131, P50 NS062684, P50 AG005136, P50 AG005133, R01 AG007584, R01 AG010845, R01 AG015819, R01 AG017917, R01 NS048595, R01 NS065070, U01 AG006781, U01 AG016976]; NARSAD; American Parkinson Disease Association; Michael J. Fox Foundation; Northwest Collaborative Care; Danone Research B.V.; Illinois Department of Public Health; Robert C. Borwell Endowment Fund; Avid Radiopharmaceuticals, Inc.; Alzheimer's Association; Johnson Johnson; Roche; Bristol Myers Squibb; Pfizer; Elan Corporation; Janssen; Medivation, Inc.; Danone; NIH/NIA; National Institute on Aging; Takeda Pharmaceutical Company, Ltd.; NIH (NIA, NINDS); Marian S. Ware Alzheimer Program; Integra-Gen; NIH (NIA, NIMH); Autism Genome Project; Autism Speaks; CurePSP; Rainwater Foundation; Peebler PSP Research Foundation; Parkinson's Disease Foundation FX Supported by grants from the Department of Veterans Affairs (1I01BX000531) and the National Institutes of Health (P30 AG008017, P30 AG028383, P30 AG010124, P30 AG010161, P50 AG005131, P50 NS062684, P50 AG005136, P50 AG005133, R01 AG007584, R01 AG010845, R01 AG015819, R01 AG017917, R01 NS048595, R01 NS065070, U01 AG006781, and U01 AG016976).; D. Tsuang is funded by grants from Department of Veterans Affairs, NARSAD, and NIH. J. Leverenz has served as a consultant for Bayer and Teva Pharmaceuticals and is funded by grants from the American Parkinson Disease Association, Michael J. Fox Foundation, NIH, and Northwest Collaborative Care. O. Lopez is funded by the NIH. R. Hamilton performs diagnostic neuropathology (40% effort) and bills for these procedures. He is partly supported by grants from the NIH. D. Bennett serves on the editorial board of Neurology (R); serves on the scientific advisory board for Vigorous Minds; serves/has served as a consultant to Danone Research B. V., Willmar Schwabe GmbH, Eli Lilly, and Gerson Lehrman Group; and receives research support from Danone Research B.V., the NIH, the Illinois Department of Public Health, and the Robert C. Borwell Endowment Fund. J. Schneider served on a scientific advisory board for GE Healthcare; serves as a consultant for Avid Radiopharmaceuticals, Inc.; and receives research support from Avid Radiopharmaceuticals, Inc. and the NIH. A. Buchman is funded by the NIH. E. Larson receives research support from the NIH. P. Crane is funded by grants from the Alzheimer's Association and NIH. J. Kaye receives research support from the Department of Veterans Affairs and the NIH. Individuals who work in the research centers he directs receive research support from Johnson & Johnson, Roche, and Bristol Myers Squibb. Dr. Kaye is compensated for serving on a data monitoring committee for Eli Lilly; he serves as a paid advisor for Janssen Pharmaceutical. Dr. Kaye receives reimbursement through Medicare or commercial insurance plans for providing clinical assessment and care for patients; is salaried to see patients at the Portland VA Medical Center; and serves as an unpaid Vice-Chair for the International Professional Interest Area Work Group of the International Society to Advance Alzheimer's Research and Treatments (ISTAART) and as an unpaid Commissioner for the Center for Aging Services and Technologies. P. Kramer reports no disclosures. R. Woltjer is funded by the NIH. W. Kukull is funded by grants from the Alzheimer's Association and NIH. P. Nelson is funded by grants from the NIH. G. Jicha serves as a consultant for Pfizer and Eli Lilly, and receives research support from Pfizer, Elan Corporation, Janssen, Medivation, Inc., Danone, and the NIH/NIA. J. Neltner reports no disclosures. D. Galasko serves on safety monitoring committees for clinical trials for Janssen Pharmaceuticals, Elan Pharmaceuticals, and Balance Pharmaceuticals, and has served as a paid advisor to Elan Pharmaceuticals, Phloronol, Inc., and United BioSource. He has received research funding from the National Institute on Aging. E. Masliah is funded by grants from the NIH. J. Trojanowski has received funding for travel and honoraria from Takeda Pharmaceutical Company, Ltd.; ; has received speaker honoraria from Pfizer; may accrue revenue on patents regarding modified avidinbiotin technique, method of stabilizing microtubules to treat Alzheimer disease, method of detecting abnormally phosphorylated tau, method of screening for Alzheimer disease or disease associated with the accumulation of paired helical filaments, compositions and methods for producing and using homogeneous neuronal cell transplants, rat comprising straight filaments in its brain, compositions and methods for producing and using homogeneous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries, diagnostic methods for Alzheimer disease by detection of multiple MRNAs, methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases, compositions and methods for producing and using homogeneous neuronal cell transplants, method of identifying, diagnosing and treating alpha-synuclein positive neurodegenerative disorders, mutation-specific functional impairments in distinct tau isoforms of hereditary frontotemporal dementia and parkinsonism linked to chromosome-17: genotype predicts phenotype, microtubule stabilizing therapies for neurodegenerative disorders, and treatment of Alzheimer and related diseases with an antibody; and receives research support from the NIH (NIA, NINDS) and from the Marian S. Ware Alzheimer Program. G. Schellenberg serves on a scientific advisory board and receives honoraria from the American Health Assistance Foundation; has served as a consultant for and received funding for travel from Integra-Gen; holds/has filed patents regarding chromosome 14 and familial Alzheimer disease genetic markers and assays, chromosome 1 gene and gene products related to Alzheimer disease, and genetic basis of Alzheimer disease and diagnosis and treatment thereof; and receives/has received research support from the NIH (NIA, NIMH), the Autism Genome Project, Autism Speaks, CurePSP, the Rainwater Foundation, and Peebler PSP Research Foundation. He is an uncompensated member (other than travel funds to meetings of these boards) of the Alzheimer's Association Medical and Scientific Advisory Council, CSP #546 Executive Committee, Veterans Affairs Dementia Prevention Study of Vitamin E and Memantine, the Board of the Peebler PSP Research Foundation, and the Medical Advisory Board, Society of Progressive Supranuclear Palsy. D. Yearout and H. Huston receive salary support from the Department of Veterans Affairs and NIH. A. Fritts-Penniman received salary support from the Department of Veterans Affairs and NIH. I. Mata is funded by grants from the Department of Veterans Affairs, NIH, and Parkinson's Disease Foundation. J. Wan receives salary support from the Department of Veterans Affairs and NIH. K. Edwards and T. Montine are funded by grants from the NIH. C. Zabetian is funded by grants from the American Parkinson Disease Association, Department of Veterans Affairs, NIH, Northwest Collaborative Care, and Parkinson's Disease Foundation. Go to Neurology.org for full disclosures. NR 26 TC 51 Z9 51 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV PY 2012 VL 79 IS 19 BP 1944 EP 1950 DI 10.1212/WNL.0b013e3182735e9a PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 032US UT WOS:000310745200008 PM 23035075 ER PT J AU Daniel, E Pistilli, M Pujari, SS Kacmaz, RO Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Kempen, JH AF Daniel, Ebenezer Pistilli, Maxwell Pujari, Siddharth S. Kacmaz, R. Oktay Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Kempen, John H. TI Risk of Hypotony in Noninfectious Uveitis SO OPHTHALMOLOGY LA English DT Article ID INTRAOCULAR-LENS IMPLANTATION; OCULAR COMPLICATIONS; CYTOMEGALOVIRUS RETINITIS; ULTRASOUND BIOMICROSCOPY; CYCLODIALYSIS CLEFT; CATARACT-SURGERY; PHACOEMULSIFICATION; PRESSURE; MACULOPATHY; VITRECTOMY AB Objective: We sought to describe the risk and risk factors for hypotony in a noninfectious uveitis cohort. Design: Retrospective cohort study. Participants: Patients with noninfectious uveitis seen between 1979 and 2007 at 4 academic ocular inflammation specialty clinics. Methods: Data were collected from medical records by trained, certified, expert reviewers. Main Outcome Measures: Hypotony (<5 mmHg) and low intraocular pressure (<8 mmHg), each sustained for >= 2 visits spanning >= 30 days. Results: During follow-up, 126 of 6785 patients (1.86%) developed hypotony at the rate of 0.61% (95% confidence interval [CI], 0.50-0.75%) per eye-year. Cataract surgery was associated with a 7.5-fold risk (adjusted hazard ratio [aHR], 7.51; 95% CI, 3.97-14.23) of incident hypotony. Phacoemulsification, the type of cataract surgery associated with the least hypotony risk still was associated with nearly 5-fold higher hypotony incidence (aHR, 4.87; 95% CI, 2.25-10.55). Increased risk was observed in children (aHR, 2.92; 95% CI, 1.20-7.10) with respect to young adults, and duration of uveitis of >5 years (aHR, 3.08; 95% CI, 1.30-7.31) with respect to uveitis of <6 month duration. Band keratopathy, >= 3+ vitreous cells, exudative retinal detachment, posterior synechia, and a history of pars plana vitrectomy also were associated with greater hypotony incidence. With respect to anterior uveitis, intermediate uveitis (aHR, 0.17; 95% CI, 0.05-0.56) and posterior uveitis (aHR, 0.11; 95% CI, 0.03-0.45) were associated with lower hypotony risk, whereas panuveitis (aHR, 1.25; 95% CI, 0.67-2.35) was similar. Approximately five-sixths (84.1%) of eyes presenting with hypotony had a visual acuity of <20/200 (aOR for visual acuity <20/200, 13.85; 95% CI, 7.23-26.53). Risk factors for prevalent hypotony were similar. Conclusions: The risk of hypotony is low among eyes with noninfectious uveitis, but is more frequently observed in cases with anterior segment inflammation. Signs of present or past inflammation were associated with greater risk, suggesting excellent inflammatory control may reduce the risk of hypotony. Prior ocular surgery also was associated with higher risk; cataract surgery in particular was associated with much higher risk of hypotony. Lower risk of hypotony with phacoemulsification than with alternative cataract surgery approaches suggests the phacoemulsification approach is preferable. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012; 119: 2377-2385 (C) 2012 by the American Academy of Ophthalmology. C1 [Daniel, Ebenezer; Pistilli, Maxwell; Kempen, John H.] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA. [Daniel, Ebenezer; Pistilli, Maxwell; Kempen, John H.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Pujari, Siddharth S.; Kacmaz, R. Oktay; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Pujari, Siddharth S.] Lions Nab Eye Hosp, Miraj, Maharashtra, India. [Kacmaz, R. Oktay] Allergan Pharmaceut Inc, Irvine, CA USA. [Nussenblatt, Robert B.; Levy-Clarke, Grace A.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Daniel, Ebenezer/0000-0002-2027-2316; Pistilli, Maxwell/0000-0002-4266-4150 FU National Eye Institute [EY014943]; Research to Prevent Blindness (RPB); Paul and Evanina Mackall Foundation FX This study was supported primarily by National Eye Institute Grant EY014943 (J.H.K.). Additional support was provided by Research to Prevent Blindness (RPB) and the Paul and Evanina Mackall Foundation. J.H.K. was an RPB James S. Adams Special Scholar Award recipient, J.E.T. was an RPB Harrington Special Scholar Award recipient, and D.A.J. and J.T.R. were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. G. A. L.-C. was previously supported by and R.B.N. continues to be supported by intramural funds of the National Eye Institute. E. B. S. receives support from the Department of Veterans' Affairs. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of this manuscript. NR 25 TC 13 Z9 13 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD NOV PY 2012 VL 119 IS 11 BP 2377 EP 2385 DI 10.1016/j.ophtha.2012.05.032 PG 9 WC Ophthalmology SC Ophthalmology GA 030OH UT WOS:000310579500027 PM 22796306 ER PT J AU Liu, Y Yuan, J Tan, T Jia, W Lugea, A Gukovskaya, AS Pandol, SJ AF Liu, Y. Yuan, J. Tan, T. Jia, W. Lugea, A. Gukovskaya, A. S. Pandol, S. J. TI PKC epsilon is a Critical Mediator of Necrosis in Acute Pancreatitis by Regulation of Mitochondrial and Non-Mitochondrial Death Pathways SO PANCREAS LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. So Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2012 VL 41 IS 8 BP 1380 EP 1380 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 027NV UT WOS:000310360500180 ER PT J AU Mareninova, OA Yakubov, I Yuan, J Lugea, A Gukovsky, I Gukovskaya, AS AF Mareninova, O. A. Yakubov, I. Yuan, J. Lugea, A. Gukovsky, I. Gukovskaya, A. S. TI Rab Disordering in Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. So Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2012 VL 41 IS 8 BP 1383 EP 1383 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 027NV UT WOS:000310360500194 ER PT J AU Hoe, M Nakagami, E Green, MF Brekke, JS AF Hoe, M. Nakagami, E. Green, M. F. Brekke, J. S. TI The causal relationships between neurocognition, social cognition and functional outcome over time in schizophrenia: a latent difference score approach SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Causal relationship; neurocognition; psychosocial rehabilitation; schizophrenia; social cognition ID FACIAL AFFECT RECOGNITION; PSYCHIATRIC RATING-SCALE; NEGATIVE SYMPTOMS; PSYCHOSOCIAL REHABILITATION; EMOTION PERCEPTION; NEURAL BASIS; DEFICITS; INDIVIDUALS; PERFORMANCE; EXPERIENCE AB Background. Social cognition has been identified as a significant construct for schizophrenia research with relevance to diagnosis, assessment, treatment and functional outcome. However, social cognition has not been clearly understood in terms of its relationships with neurocognition and functional outcomes. The present study sought to examine the empirical independence of social cognition and neurocognition; to investigate the possible causal structure among social cognition, neurocognition and psychosocial functioning. Method. The sample consists of 130 individuals diagnosed with schizophrenia. All participants were recruited as they were admitted to four community-based psychosocial rehabilitation programs. Social cognition, neurocognition and psychosocial functioning were measured at baseline and 12 months. The empirical independence of social cognition and neurocognition was tested using confirmatory factor analysis (CFA) and the possible causal structure among social cognition, neurocognition and psychosocial functioning was investigated using latent difference score (LDS) analysis. Results. A two-factor model of social cognition and neurocognition fit the data very well, indicating the empirical independence of social cognition, whereas the longitudinal CFA results show that the empirical independence of neurocognition and social cognition is maintained over time. The results of the LDS analysis support a causal model that indicates that neurocognition underlies and is causally primary to social cognition, and that neurocognition and social cognition are causally primary to functional outcome. Conclusions. Social cognition and neurocognition could have independent and distinct upward causal effects on functional outcome. It is also suggested that the approaches for remediation of neurocognition and social cognition might need to be distinct. C1 [Hoe, M.] Keimyung Univ, Coll Social Sci, Dept Social Welf, Taegu 704701, South Korea. [Nakagami, E.; Brekke, J. S.] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. [Green, M. F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Hoe, M (reprint author), Keimyung Univ, Coll Social Sci, Dept Social Welf, 2800 Dalgubeoldearo, Taegu 704701, South Korea. EM maanse@kmu.ac.kr FU NCATS NIH HHS [UL1 TR000130] NR 81 TC 28 Z9 29 U1 1 U2 23 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD NOV PY 2012 VL 42 IS 11 BP 2287 EP 2299 DI 10.1017/S0033291712000578 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 031HI UT WOS:000310629600005 PM 22475159 ER PT J AU Jin, J Park, M Rengarajan, A Zhang, Q Limburg, S Joshi, SK Patel, S Kim, HT Kuo, AC AF Jin, Jenny Park, Michelle Rengarajan, Arvind Zhang, Qia Limburg, Sonja Joshi, Sunil K. Patel, Shyam Kim, Hubert T. Kuo, Alfred C. TI Functional motor recovery after peripheral nerve repair with an aligned nanofiber tubular conduit in a rat model SO REGENERATIVE MEDICINE LA English DT Article DE longitudinal alignment; nerve conduit; peripheral nerve repair ID CONTROLLED-RELEASE; GUIDANCE CHANNELS; SKELETAL-MUSCLE; REGENERATION; INJURIES; MICROSPHERES; OUTCOMES; GUIDES; ULNAR AB Aim: Current synthetic tubular conduits are inferior to nerve autograft for the repair of segmental peripheral nerve injuries. We examined motor outcomes with the use of longitudinally aligned poly (L-lactide-co-caprolactone) nanofiber conduits for repair of nerve gap injury in a rat model. Methods: Ten-millimeter segments of sciatic nerve were resected in 44 Lewis rats. The gaps were either left unrepaired (n = 6), repaired with nerve autograft (n = 19), or repaired with conduit (n = 19). After 12 weeks, nerve conduction latency, compound muscle action potential amplitude, muscle force and muscle mass were measured. The numbers of axons and axon diameters both within the grafts and distally were determined. Results: After 12 weeks, gastrocnemius isometric tetanic force and muscle mass for the conduit group reached 85 and 82% of autograft values, respectively. Nerve conduction and compound muscle action potential were not significantly different between these two groups, although the latter approached significance. There was no recovery in the unrepaired group. Conclusion: Muscle recovery for the animals treated with this aligned nanofiber conduit approached that of autograft, suggesting the importance of internal conduit structure for nerve repair. C1 [Jin, Jenny; Park, Michelle; Rengarajan, Arvind; Zhang, Qia; Limburg, Sonja; Joshi, Sunil K.; Kim, Hubert T.; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Jin, Jenny; Park, Michelle; Rengarajan, Arvind; Zhang, Qia; Limburg, Sonja; Joshi, Sunil K.; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. [Patel, Shyam] NanoNerve Inc, Berkeley, CA USA. RP Kuo, AC (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA. EM kuoac@orthosurg.ucsf.edu NR 36 TC 8 Z9 9 U1 1 U2 31 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0751 J9 REGEN MED JI Regen. Med. PD NOV PY 2012 VL 7 IS 6 BP 799 EP 806 DI 10.2217/RME.12.87 PG 8 WC Cell & Tissue Engineering; Engineering, Biomedical SC Cell Biology; Engineering GA 031QC UT WOS:000310656000015 PM 23164080 ER PT J AU Gurubhagavatula, I AF Gurubhagavatula, Indira TI Does the Rubber Meet the Road? Addressing Sleep Apnea in Commercial Truck Drivers SO SLEEP LA English DT Editorial Material ID MOTOR-VEHICLE CRASH; RISK; METAANALYSIS C1 [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Div Sleep Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA. [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. RP Gurubhagavatula, I (reprint author), Univ Penn, Med Ctr, Div Sleep Med, Perelman Sch Med, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM gurubhag@mail.med.upenn.edu FU NIOSH CDC HHS [R01 OH009149, R01-OH009149] NR 26 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD NOV 1 PY 2012 VL 35 IS 11 BP 1443 EP 1444 DI 10.5665/sleep.2180 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 030NU UT WOS:000310578200002 PM 23115390 ER PT J AU Morales, CR Hurley, S Wick, LC Staley, B Pack, FM Gooneratne, NS Maislin, G Pack, A Gurubhagavatula, I AF Morales, Christian R. Hurley, Sharon Wick, Lindsay C. Staley, Bethany Pack, Frances M. Gooneratne, Nalaka S. Maislin, Greg Pack, Allan Gurubhagavatula, Indira TI In-Home, Self-Assembled Sleep Studies Are Useful in Diagnosing Sleep Apnea in the Elderly SO SLEEP LA English DT Article DE Aged adults; obstructive sleep apnea; portable sleep studies; screening ID OLDER-ADULTS; DAYTIME SLEEPINESS; APNOEA/HYPOPNOEA SYNDROME; HEART HEALTH; POLYSOMNOGRAPHY; RISK; MEN; AUTOSET(TM); POPULATION; DISORDERS AB Objectives: Obstructive sleep apnea (OSA) is common and treatable among the elderly. Yet, few older adults seek evaluation for OSA at sleep disorders centers. The authors assessed the feasibility of a two-stage screening procedure for obstructive sleep apnea syndrome (OSAS) in a community-based sample of older adults. Design: Prospective cohort study. Setting: Participants' domicile (in-home) and academic sleep research center. Participants: There were 452 Medicare recipients residing in the greater Philadelphia metropolitan area with the complaint of daytime sleepiness. Interventions: None. Measurements and Results: All participants underwent in-home unattended sleep studies that recorded airflow, and standard in-laboratory polysomnography. Additional measures included symptoms of sleep apnea, body mass index, neck circumference, age, and sex. When comparing diagnostic approaches, the best-performing single-stage model was one that combined apnea symptoms with age and neck circumference. This model had an area under the receiver operating characteristic curve (AUC) of 0.774 and negative posttest probability of 1.2%. The best-performing two-stage model combined symptoms, neck circumference, age, and sex in the first stage, followed by an unattended portable study with a corresponding AUC of 0.85 and negative posttest probability of 0.5%. Conclusions: Unattended, self-assembled, in-home sleep studies recording airflow and respiratory effort are most useful if applied in tandem with clinical data, including a carefully obtained sleep history. This two-stage model is accurate in identifying severe OSAS in older adults and represents a practical diagnostic approach for older adults. Incorporating clinical data was vital and increased accuracy well above that of unattended studies of airflow and effort alone. C1 [Morales, Christian R.; Hurley, Sharon; Wick, Lindsay C.; Staley, Bethany; Pack, Frances M.; Gooneratne, Nalaka S.; Maislin, Greg; Pack, Allan; Gurubhagavatula, Indira] Univ Penn, Ctr Sleep & Circadian Neurobiol, Sch Med, Philadelphia, PA 19104 USA. [Gooneratne, Nalaka S.; Pack, Allan; Gurubhagavatula, Indira] Univ Penn, Med Ctr, Div Sleep Med, Dept Med, Philadelphia, PA 19104 USA. [Gooneratne, Nalaka S.] Univ Penn, Div Geriatr Med, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm & Crit Care & Sleep Sect, Philadelphia, PA USA. RP Gurubhagavatula, I (reprint author), Univ Penn, Ctr Sleep & Circadian Neurobiol, Sch Med, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM gu-rubhag@mail.med.upenn.edu FU NIH [T32 HL07713, R01-HL060756, K23 RR16068, R01-OH009149]; Takeda Pharmaceuticals; Respironics; Phillips/Respironics Foundation FX This work was performed at the University of Pennsylvania and supported by NIH T32 HL07713, R01-HL060756, K23 RR16068, and R01-OH009149. ResMed, Inc. provided an unrestricted loan for use of portable diagnostic sleep study equipment (AutoSet (TM)) and had no role in protocol development, data collection, storage, analysis, or manuscript preparation.; This was not an industry supported study; however, ResMed, Inc. provided an unrestricted loan for use of portable diagnostic sleep study equipment (AutoSet (TM)) and had no role in protocol development, data collection, storage, analysis, or manuscript preparation. Dr. Gooneratne has received research grants from Takeda Pharmaceuticals and Respironics. Dr. Gurubhagavatula has been loaned equipment for research purposes from Embla, Inc. Dr. Maislin is the principal bio-statistician of Biomedical Statistical Consulting (BSC). Dr. Pack has been endowed with funds provided by the Phillips/Respironics Foundation. The other authors have indicated no financial conflicts of interest. NR 44 TC 14 Z9 14 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD NOV 1 PY 2012 VL 35 IS 11 BP 1491 EP 1501 DI 10.5665/sleep.2196 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 030NU UT WOS:000310578200010 PM 23115398 ER PT J AU McNicholas, LF Holbrook, AM O'Grady, KE Jones, HE Coyle, MG Martin, PR Heil, SH Stine, SM Kaltenbach, K AF McNicholas, Laura F. Holbrook, Amber M. O'Grady, Kevin E. Jones, Hendree E. Coyle, Mara G. Martin, Peter R. Heil, Sarah H. Stine, Susan M. Kaltenbach, Karol TI Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication SO ADDICTION LA English DT Article DE Buprenorphine; liver transaminases; methadone; opioids; pregnancy ID NEONATAL ABSTINENCE SYNDROME; OPIATE DEPENDENCE; DOUBLE-BLIND; BUPRENORPHINE; METHADONE; ADDICTION; TRIAL; OUTCOMES; SAMPLE; ABUSE AB Aim To examine hepatic enzyme test results throughout the course of pregnancy in women maintained on methadone or buprenorphine. Design Participants were randomized to either methadone or buprenorphine maintenance. Blood chemistry tests, including liver transaminases and hepatitis C virus (HCV) status, were determined every 4 weeks and once postpartum. As part of a planned secondary analysis, generalized mixed linear models were conducted with aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) as the dependent variables. Setting Six US sites and one European site that provided comprehensive treatment to pregnant opioid-dependent women. Participants A total of 175 opioid-dependent pregnant women enrolled in the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study. Findings ALT, AST and GGT levels decreased for all subjects across pregnancy trimesters, rising slightly postpartum. HCV-positive subjects exhibited higher transaminases at all time-points compared to HCV-negative subjects, regardless of medication (all Ps<0.05) condition. Both HCV-positive and negative buprenorphine-maintained participants exhibited lower GGT levels than those who were methadone-maintained (P<0.05). Conclusions Neither methadone nor buprenorphine appear to have adverse hepatic effects in the treatment of pregnant opioid-dependent women. C1 [McNicholas, Laura F.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [McNicholas, Laura F.] Philadelphia VA Med Ctr, Dept Vet Affairs, Philadelphia, PA USA. [Holbrook, Amber M.; Kaltenbach, Karol] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pediat, Philadelphia, PA 19107 USA. [O'Grady, Kevin E.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Jones, Hendree E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Jones, Hendree E.] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA. [Jones, Hendree E.] RTI Int, Res Triangle Pk, NC USA. [Coyle, Mara G.] Brown Univ, Dept Pediat, Warren Alpert Med Sch, Providence, RI 02912 USA. [Martin, Peter R.] Vanderbilt Univ, Sch Med, Dept Psychiat, Vanderbilt Addict Ctr, Nashville, TN 37212 USA. [Martin, Peter R.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Vanderbilt Addict Ctr, Nashville, TN 37212 USA. [Heil, Sarah H.] Univ Vermont, Dept Psychiat, Burlington, VT USA. [Heil, Sarah H.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Stine, Susan M.] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Kaltenbach, Karol] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA. RP Kaltenbach, K (reprint author), 1233 Locust St,401, Philadelphia, PA 19107 USA. EM Karol.Kaltenbach@jefferson.edu RI Martin, Peter/A-7738-2008 OI Stine, Susan/0000-0001-5426-4448 FU National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse (NIDA), Brown University [R01 DA 015778]; National Institute on Drug Abuse (NIDA), Johns Hopkins University [R01 DA 015764]; National Institute on Drug Abuse (NIDA), Medical University of Vienna [R01 DA 018417]; National Institute on Drug Abuse (NIDA), Thomas Jefferson University [R01 DA 015738]; National Institute on Drug Abuse (NIDA), University of Toronto [R01 DA 015741]; National Institute on Drug Abuse (NIDA), University of Vermont [R01 DA 018410, M01 RR 109]; National Institute on Drug Abuse (NIDA), Vanderbilt University [R01 DA 017513, M01 RR 00095]; National Institute on Drug Abuse (NIDA), Wayne State University [R01 DA 15832]; Reckitt Benckiser; Schering Plough; Schering Canada; Government of Ontario FX All MOTHER grants are from the National Institute on Drug Abuse (NIDA) unless noted otherwise: Brown University, R01 DA 015778; Johns Hopkins University, R01 DA 015764; Medical University of Vienna, R01 DA 018417; Thomas Jefferson University, R01 DA 015738; University of Toronto, R01 DA 015741; University of Vermont, R01 DA 018410 and M01 RR 109; Vanderbilt University, R01 DA 017513 and M01 RR 00095, and Wayne State University, R01 DA 15832.; G. F. discloses that she has received financial support and honoraria for presentations from Reckitt Benckiser, as well as financial support and honoraria for presentations from Schering Plough.; P. S. discloses that he has received an unrestricted educational grant from Schering Canada to provide a single training program on buprenorphine treatment in 2000. His hospital receives funds from the Government of Ontario to develop and provide a training program of which he is the course director for all Ontario physicians who wish to treat opioid dependence including in pregnant women. However, the buprenorphine mono product is not available in Canada. NR 26 TC 8 Z9 8 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 J9 ADDICTION JI Addiction PD NOV PY 2012 VL 107 SU 1 SI SI BP 91 EP 97 DI 10.1111/j.1360-0443.2012.04043.x PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 029EN UT WOS:000310477700010 PM 23106931 ER PT J AU Slatore, CG Hansen, L Ganzini, L Press, N Osborne, ML Chesnutt, MS Mularski, RA AF Slatore, Christopher G. Hansen, Lissi Ganzini, Linda Press, Nancy Osborne, Molly L. Chesnutt, Mark S. Mularski, Richard A. TI COMMUNICATION BY NURSES IN THE INTENSIVE CARE UNIT: QUALITATIVE ANALYSIS OF DOMAINS OF PATIENT-CENTERED CARE SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article ID OF-LIFE CARE; PALLIATIVE CARE; IMPROVE COMMUNICATION; FAMILY CONFERENCE; CRITICAL ILLNESS; DECISION-MAKING; PHYSICIANS; PERCEPTIONS; ICU; OPPORTUNITIES AB Background High-quality communication is a key determinant and facilitator of patient-centered care. Nurses engage in most of the communication with patients and patients' families in the intensive care unit. Objective To perform a qualitative analysis of nurses' communications. Methods Ethnographic observations of 315 hours of interactions and 53 semistructured interviews with 33 nurses were conducted in a 26-bed cardiac-medical intensive care unit in an academic hospital and a 26-bed general intensive care unit in a Veterans Affairs hospital in Portland, Oregon. Communication interactions were categorized into 5 domains of patient-centered care. Interviews were analyzed to identify major themes in nurses' roles and preferences for communicating with patients and patients' families within the domains. Results Most communication occurred in the domains of biopsychosocial information exchange, patient as person, and clinician as person. Nurses endorsed the importance of the domains of shared power and responsibility and therapeutic alliance but had relatively few communication interactions in these areas. Communication behaviors were strongly influenced by the nurses' roles as translators of information between physicians and patients and the patients' families and what the nurses were and were not willing to communicate to patients and patients' families. Conclusions Critical care, including communication, is a collaborative effort. Understanding how nurses engage in patient-centered communication in the intensive care unit can guide future interventions to improve patient-centered care. (American Journal of Critical Care. 2012;21:410-418) C1 [Slatore, Christopher G.; Osborne, Molly L.; Chesnutt, Mark S.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.; Osborne, Molly L.; Chesnutt, Mark S.; Mularski, Richard A.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Dept Med, Portland, OR 97201 USA. [Hansen, Lissi; Press, Nancy] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Press, Nancy] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Chesnutt, Mark S.] Portland VA Med Ctr, Patient Care Serv Div, Portland, OR USA. [Mularski, Richard A.] Kaiser Permanente NW, Ctr Hlth Res, Pulm & Crit Care Med, Portland, OR USA. RP Slatore, CG (reprint author), 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Slatore, Christopher/0000-0003-0958-8122 FU National Institute of Nursing Research [R21 NR009845] FX Dr Slatore is a Veterans Affairs Health Services Research and Development Career Development Awardee. This study is the result of work supported by resources from the Portland Veterans Affairs Medical Center. Neither the National Institutes of Health nor the Department of Veterans Affairs had a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the US government.; The study was funded by grant R21 NR009845 to Dr Hansen from the National Institute of Nursing Research. NR 51 TC 21 Z9 23 U1 1 U2 31 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 J9 AM J CRIT CARE JI Am. J. Crit. Care PD NOV 1 PY 2012 VL 21 IS 6 BP 410 EP 418 DI 10.4037/ajcc2012124 PG 9 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 031LO UT WOS:000310642100006 PM 23117904 ER PT J AU Baicu, CF Li, JY Zhang, YH Kasiganesan, H Cooper, G Zile, MR Bradshaw, AD AF Baicu, Catalin F. Li, Jiayu Zhang, Yuhua Kasiganesan, Harinath Cooper, George Zile, Michael R. Bradshaw, Amy D. TI Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE procollagen; SPARC; osteonectin; cardiac fibroblasts; fibrosis ID CAT RIGHT VENTRICLE; CARDIAC-HYPERTROPHY; HEART-FAILURE; COLLAGEN-SYNTHESIS; GENE-EXPRESSION; CYSTEINE SPARC; PROTEIN; DEGRADATION; REGRESSION; RATS AB Baicu CF, Li J, Zhang Y, Kasiganesan H, Cooper G IV, Zile MR, Bradshaw AD. Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. Am J Physiol Heart Circ Physiol 303: H1128-H1134, 2012. First published August 31, 2012; doi:10.1152/ajpheart.00482.2012.-Myocardial fibrillar collagen is considered an important determinant of increased ventricular stiffness in pressure-overload (PO)-induced cardiac hypertrophy. Chronic PO was created in feline right ventricles (RV) by pulmonary artery banding (PAB) to define the time course of changes in fibrillar collagen content after PO using a nonrodent model and to determine whether this time course was dependent on changes in fibroblast function. Total, soluble, and insoluble collagen (hydroxyproline), collagen volume fraction (CVF), and RV end-diastolic pressure were assessed 2 days and 1, 2, 4, and 10 wk following PAB. Fibroblast function was assessed by quantitating the product of postsynthetic processing, insoluble collagen, and levels of SPARC (secreted protein acidic and rich in cysteine), a protein that affects procollagen processing. RV hypertrophic growth was complete 2 wk after PAB. Changes in RV collagen content did not follow the same time course. Two weeks after PAB, there were elevations in total collagen (control RV: 8.84 +/- 1.03 mg/g vs. 2-wk PAB: 11.50 +/- 0.78 mg/g); however, increased insoluble fibrillar collagen, as measured by CVF, was not detected until 4 wk after PAB (control RV CVF: 1.39 +/- 0.25% vs. 4-wk PAB: 4.18 +/- 0.87%). RV end-diastolic pressure was unchanged at 2 wk, but increased until 4 wk after PAB. RV fibroblasts isolated after 2-wk PAB had no changes in either insoluble collagen or SPARC expression; however, increases in insoluble collagen and in levels of SPARC were detected in RV fibroblasts from 4-wk PAB. Therefore, the time course of PO-induced RV hypertrophy differs significantly from myocardial fibrosis and diastolic dysfunction. These temporal differences appear dependent on changes in fibroblast function. C1 [Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, 114 Doughty St, Charleston, SC 29425 USA. EM bradshad@musc.edu FU Research Service of the Department of Veterans Affairs [5101CX000415-02, 5101BX000487-04, 1I01BX001385-01A1]; National Heart, Lung, and Blood Institute [PO1-HL-48788, RO1-HL-094517] FX This study was supported by the Research Service of the Department of Veterans Affairs (M. R. Zile: 5101CX000415-02 and 5101BX000487-04 and A. D. Bradshaw: 1I01BX001385-01A1) and grants from the National Heart, Lung, and Blood Institute (PO1-HL-48788 to G. Cooper and M. R. Zile; RO1-HL-094517 to A. D. Bradshaw). NR 33 TC 14 Z9 14 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD NOV PY 2012 VL 303 IS 9 BP H1128 EP H1134 DI 10.1152/ajpheart.00482.2012 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 031OA UT WOS:000310650300005 PM 22942178 ER PT J AU Kono, Y Muder, RR AF Kono, Yuriko Muder, Robert R. TI Identifying the Incidence of and Risk Factors for Reamputation Among Patients Who Underwent Foot Amputation SO ANNALS OF VASCULAR SURGERY LA English DT Article ID DIABETIC FOOT; LIMB; MORTALITY AB Background: Many patients who have lower-extremity amputations secondary to peripheral vascular disease or diabetes require reamputation eventually. This study was designed to identify the incidence of and risk factors for ipsilateral reamputation after forefoot amputation, to evaluate whether postoperative infection increases the risk of reamputation, and to evaluate whether the risk of reamputation was reduced by the duration of antimicrobial therapy after amputation. Methods: A retrospective analysis of patients who underwent foot amputation for nontraumatic reason from January 2002 to December 2004 at the Veterans Affairs Pittsburgh Healthcare System was performed. Results: Among 116 patients, 57(49.1%) had ipsilateral reamputation within 3 years after their first surgeries; 78.9% received reamputation in the first 6 months; 53 (45.7%) died within 3 years; and 16 (13.8%) developed postoperative infections. Upper level of amputation, long duration of hospitalization, insulin-dependent diabetes, and gangrene on physical examination on admission were risk factors for reamputation in univariate analysis. Gangrene (odds ratio: 3.81, 95% confidence interval: 1.60-9.12, P = 0.003) and insulin-dependent diabetes (odds ratio: 2.93, 95% confidence interval: 1.26-6.78, P = 0.012) were risk factors in multivariate analysis. Postoperative infection did not increase the risk of reamputation. Longer than 2-week course of antibiotic use after amputation did not prevent reamputation. Conclusions: Approximately one-half of patients required ipsilateral reamputation and died in 3 years. Gangrene on admission and history of insulin-dependent diabetes were significant risk factors (P = 0.003, P = 0.028). Long duration of antibiotic use after amputation and postoperative infection did not change the risk of reamputation. C1 [Kono, Yuriko; Muder, Robert R.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA 15240 USA. RP Muder, RR (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA 15240 USA. EM robert.muder@va.gov NR 12 TC 2 Z9 2 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-5096 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD NOV PY 2012 VL 26 IS 8 BP 1120 EP 1126 DI 10.1016/j.avsg.2012.02.011 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 028GB UT WOS:000310409700010 PM 22840342 ER PT J AU Wofsy, D Hillson, JL Diamond, B AF Wofsy, David Hillson, Jan L. Diamond, Betty TI Abatacept for lupus nephritis Alternative definitions of complete response support conflicting conclusions SO ARTHRITIS AND RHEUMATISM LA English DT Article ID MURINE LUPUS; CYCLOPHOSPHAMIDE; ERYTHEMATOSUS; CLASSIFICATION; EFFICACY; THERAPY; CTLA4IG; SAFETY; TRIAL AB Objective Recent clinical trials in lupus nephritis have all used different criteria to assess complete response. The objective of this analysis was to compare several previously proposed criteria, using the same data set from a large trial of abatacept in lupus nephritis (IM101075). In so doing, we sought to determine which criteria are most sensitive to differences among treatment groups and to further examine the potential of abatacept in lupus nephritis. Methods Patients in the IM101075 trial received abatacept at 1 of 2 different dose regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids. Using data from this trial, we assessed rates of complete response at 12 months according to 5 sets of criteria, from 1) the trial protocol, 2) the Aspreva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment with Rituximab (LUNAR) trial of rituximab, 4) an ongoing National Institutes of Health trial of abatacept (Abatacept and Cyclophosphamide Combination: Efficacy and Safety Study [ACCESS]), and 5) published recommendations of the American College of Rheumatology. Results According to the complete response definition from the IM101075 study protocol, there was no difference among treatment groups in the IM101075 study. In contrast, according to the ALMS, LUNAR, and ACCESS criteria, rates of complete response among patients in the IM101075 study were higher in both treatment groups relative to control. The largest differences were obtained with use of the LUNAR criteria (complete response rate of 6% in the control group, compared to 22% and 24% in the 2 abatacept groups). Conclusion The choice of definition of complete response can determine whether a lupus nephritis trial is interpreted as a success or a failure. The results of this analysis provide an evidence-based rationale for choosing among alternative definitions and offer a strong rationale for conducting further studies of abatacept in lupus nephritis. C1 [Wofsy, David] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hillson, Jan L.] Bristol Myers Squibb Co, Princeton, NJ USA. [Diamond, Betty] Feinstein Inst Med Res, Manhasset, NY USA. RP Wofsy, D (reprint author), San Francisco VA Med Ctr, Arthritis Immunol Unit 111R, 4150 Clement St, San Francisco, CA 94121 USA. EM wofsyd@medsch.ucsf.edu FU Rosalind Russell Medical Research Center for Arthritis at the University of California, San Francisco; Bristol-Myers Squibb; Genentech; Vifor Pharma; Pfizer; Merck-Serono; Merck FX Supported by the Rosalind Russell Medical Research Center for Arthritis at the University of California, San Francisco.; Dr. Wofsy has received consulting fees from Bristol-Myers Squibb, Genentech, and Vifor Pharma (less than $10,000 each). Dr. Hillson owns stock or stock options in Bristol-Myers Squibb. Dr. Diamond has received consulting fees and/or honoraria from Genentech, Pfizer, Merck-Serono, and Merck (less than $10,000 each). Drs. Wofsy and Diamond were not compensated for this investigator-initiated analysis. NR 15 TC 72 Z9 74 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD NOV PY 2012 VL 64 IS 11 BP 3660 EP 3665 DI 10.1002/art.34624 PG 6 WC Rheumatology SC Rheumatology GA 030CC UT WOS:000310544500019 PM 22806274 ER PT J AU Schwab, P Harmon, D Bruno, R Fraunfelder, FW Kim, DH AF Schwab, Pascale Harmon, David Bruno, Richard Fraunfelder, Frederick W. Kim, Donna Hyunchung TI A 55-year-old woman with orbital inflammation SO ARTHRITIS CARE & RESEARCH LA English DT Article ID METASTATIC PROSTATE-CANCER; ZOLEDRONIC ACID INFUSION; ACUTE-PHASE RESPONSE; GRAVES OPHTHALMOPATHY; OCULAR INFLAMMATION; RISK-FACTORS; DISEASE; PAMIDRONATE; SARCOIDOSIS; ACTIVATION C1 [Schwab, Pascale] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. [Schwab, Pascale] Portland VA Med Ctr, Portland, OR USA. RP Schwab, P (reprint author), Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland Vet Affairs Med Ctr, 3181 SW Sam Jackson Pk Rd OP09, Portland, OR 97239 USA. EM schwabp@ohsu.edu OI Bruno, Richard/0000-0001-9803-2876 NR 42 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD NOV PY 2012 VL 64 IS 11 BP 1776 EP 1782 DI 10.1002/acr.21822 PG 7 WC Rheumatology SC Rheumatology GA 030CH UT WOS:000310545000020 PM 22933406 ER PT J AU Schwartz, A Weiner, SJ Weaver, F Yudkowsky, R Sharma, G Binns-Calvey, A Preyss, B Jordan, N AF Schwartz, Alan Weiner, Saul J. Weaver, Frances Yudkowsky, Rachel Sharma, Gunjan Binns-Calvey, Amy Preyss, Ben Jordan, Neil TI Uncharted territory: measuring costs of diagnostic errors outside the medical record SO BMJ QUALITY & SAFETY LA English DT Article ID UNANNOUNCED STANDARDIZED PATIENTS; PHYSICIAN PERFORMANCE; CLINICAL VIGNETTES; CONTEXTUAL ERRORS; CHART ABSTRACTION; PRIMARY-CARE; QUALITY AB Context: In a past study using unannounced standardised patients (USPs), substantial rates of diagnostic and treatment errors were documented among internists. Because the authors know the correct disposition of these encounters and obtained the physicians' notes, they can identify necessary treatment that was not provided and unnecessary treatment. They can also discern which errors can be identified exclusively from a review of the medical records. Objective: To estimate the avoidable direct costs incurred by physicians making errors in our previous study. Design: In the study, USPs visited 111 internal medicine attending physicians. They presented variants of four previously validated cases that jointly manipulate the presence or absence of contextual and biomedical factors that could lead to errors in management if overlooked. For example, in a patient with worsening asthma symptoms, a complicating biomedical factor was the presence of reflux disease and a complicating contextual factor was inability to afford the currently prescribed inhaler. Costs of missed or unnecessary services were computed using Medicare cost-based reimbursement data. Setting: Fourteen practice locations, including two academic clinics, two community-based primary care networks with multiple sites, a core safety net provider, and three Veteran Administration government facilities. Main outcome measures: Contribution of errors to costs of care. Results: Overall, errors in care resulted in predicted costs of approximately $174000 across 399 visits, of which only $8745 was discernible from a review of the medical records alone (without knowledge of the correct diagnoses). The median cost of error per visit with an incorrect care plan differed by case and by presentation variant within case. Conclusions: Chart reviews alone underestimate costs of care because they typically reflect appropriate treatment decisions conditional on (potentially erroneous) diagnoses. Important information about patient context is often entirely missing from medical records. Experimental methods, including the use of USPs, reveal the substantial costs of these errors. C1 [Schwartz, Alan; Yudkowsky, Rachel; Binns-Calvey, Amy] Univ Illinois, Dept Med Educ, Chicago, IL 60612 USA. [Weiner, Saul J.; Jordan, Neil] Univ Illinois, US Dept Vet Affairs, Ctr Management Complex Chron Care, Chicago, IL 60612 USA. [Weaver, Frances] Loyola Univ, Stritch Sch Med, US Dept Vet Affairs, Ctr Management Complex Chron Care, Chicago, IL 60611 USA. [Sharma, Gunjan] Univ Illinois, Dept Med, Chicago, IL 60612 USA. [Preyss, Ben] Northwestern Univ, Dept Family Med, Chicago, IL 60611 USA. [Jordan, Neil] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies & Prevent Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Schwartz, A (reprint author), Univ Illinois, Dept Med Educ, 808 S Wood St,986 CME Mail Code 591, Chicago, IL 60612 USA. EM alansz@uic.edu RI Binns, Colin/A-6012-2008 OI Yudkowsky, Rachel/0000-0002-2145-7582; Schwartz, Alan/0000-0003-3809-6637 FU Veteran Affairs, Health Services Research and Development [04-107] FX This study was supported by the Veteran Affairs, Health Services Research and Development. The funding organisation had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review or approval of the manuscript. IIR 04-107. NR 19 TC 7 Z9 7 U1 0 U2 6 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD NOV PY 2012 VL 21 IS 11 BP 918 EP 924 DI 10.1136/bmjqs-2012-000832 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 028VE UT WOS:000310451400005 PM 22773889 ER PT J AU Tomson, TT Kapa, S Bala, R Riley, MP Lin, D Epstein, AE Deo, R Dixit, S AF Tomson, Todd T. Kapa, Suraj Bala, Rupa Riley, Michael P. Lin, David Epstein, Andrew E. Deo, Rajat Dixit, Sanjay TI Risk of stroke and atrial fibrillation after radiofrequency catheter ablation of typical atrial flutter SO HEART RHYTHM LA English DT Article DE Ablation; Catheter ablation; Atrial flutter; Atrial fibrillation; Stroke; Thromboembolism ID TERM-FOLLOW-UP; CAVOTRICUSPID ISTHMUS; CLINICAL-COURSE; COMMON; ARRHYTHMIAS; PREDICTORS AB BACKGROUND Studies suggest that 18%-50% of the patients develop atrial fibrillation (AF) after typical atrial flutter (AFL) ablation. However, little data exist about the incidence of and risk factors for stroke and AF after successful ablation of typical AFL. OBJECTIVES To determine the risk of stroke and AF after radio-frequency ablation of typical AFL. METHODS A retrospective review of patients undergoing AFL ablation between 2002 and 2010 was performed to determine the incidence of and risk factors for stroke and AF after successful ablation of typical AFL. RESULTS The study cohort consisted of 126 patients (age 66 +/- 10 years) with a mean follow-up of 40 +/- 30 months after ablation. Following successful AFL ablation, AF occurred in 46 patients (37%), with an incidence of 104 cases of documented AF per 1000 person-years after AFL ablation. Twenty patients (16%) developed new AF after AFL ablation. Stroke occurred in 8 patients (6%) during follow-up, with an incidence of 21 strokes per 1000 person-years. Six of the 8 patients (75%) with strokes had documented AF occurrences after AFL ablation. The presence of AF after AFL ablation was the only risk factor associated with the risk for future stroke. CONCLUSIONS Patients with typical AFL undergoing successful ablation are at an elevated risk for AF and stroke following the procedure. Because postprocedure AF is the only identifiable risk factor for stroke, rigorous monitoring of patients after typical AFL may help identify those patients who are at an increased risk for stroke. C1 [Dixit, Sanjay] Hosp Univ Penn, Sect Cardiac Electrophysiol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Dixit, S (reprint author), Hosp Univ Penn, Sect Cardiac Electrophysiol, 9 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM sanjay.dixit@uphs.upenn.edu NR 20 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD NOV PY 2012 VL 9 IS 11 BP 1779 EP 1784 DI 10.1016/j.hrthm.2012.07.013 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 029XY UT WOS:000310532300009 PM 22813577 ER PT J AU Doyle, LA Nelson, D Heinrich, MC Corless, CL Hornick, JL AF Doyle, Leona A. Nelson, Dylan Heinrich, Michael C. Corless, Christopher L. Hornick, Jason L. TI Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study SO HISTOPATHOLOGY LA English DT Article DE gastrointestinal stromal tumour; KIT; PDGFRA; soft tissue sarcoma; succinate dehydrogenase ID CARNEY-STRATAKIS-SYNDROME; OF-FUNCTION MUTATIONS; V600E BRAF MUTATIONS; TERM-FOLLOW-UP; FAMILIAL PHEOCHROMOCYTOMA; PULMONARY CHONDROMA; GERMLINE MUTATIONS; MOLECULAR-GENETICS; PARAGANGLIOMA; TRIAD AB Aims: Gastrointestinal stromal tumours (GISTs) typically harbour KIT or PDGFRA mutations; 15% of adult GISTs and >90% in children lack such mutations ('wild-type' GISTs). Paediatric and occasional adult GISTs show similar, distinctive features: multinodular architecture and epithelioid morphology, indolent behaviour with metastases, and imatinib resistance. Recent studies have suggested that these tumours can be identified by loss of succinate dehydrogenase subunit B (SDHB) expression. The aim of this study was to validate the predictive value of SDHB immunohistochemistry in a large genotyped cohort. Methods and results: SDHB expression was examined in GISTs with known genotypes: 179 with KIT mutations, 32 with PDGFRA mutations, and 53 wild type. Histological features were recorded without knowledge of genotype or SDHB status. SDHB was deficient in 22 (42%) wild-type GISTs. All other tumours showed intact SDHB expression. All SDHB-deficient GISTs with known primary sites arose in the stomach, and had multinodular architecture and epithelioid or mixed morphology. None of the wildtype GISTs with intact SDHB showed multinodular architecture, and only four (13%) had epithelioid morphology. Conclusions: SDHB-deficient GISTs are wild-type gastric tumours with distinctive histology. Immunohistochemistry for SDHB can be used to confirm the diagnosis of this tumour class. SDHB expression is retained in all GISTs with KIT and PDGFRA mutations. C1 [Doyle, Leona A.; Hornick, Jason L.] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA. [Nelson, Dylan; Corless, Christopher L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Nelson, Dylan; Heinrich, Michael C.; Corless, Christopher L.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Hornick, JL (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, 75 Francis St, Boston, MA 02115 USA. EM jhornick@partners.org FU Department of Veterans Affairs; Life Raft Group; GIST Cancer Research Fund FX This work was supported in part by a Merit Review Grant from the Department of Veterans Affairs (M. C. Heinrich), and funding from the Life Raft Group (M. C. Heinrich and C. L. Corless) and the GIST Cancer Research Fund (M. C. Heinrich and C. L. Corless). NR 42 TC 36 Z9 40 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0309-0167 J9 HISTOPATHOLOGY JI Histopathology PD NOV PY 2012 VL 61 IS 5 BP 801 EP 809 DI 10.1111/j.1365-2559.2012.04300.x PG 9 WC Cell Biology; Pathology SC Cell Biology; Pathology GA 029GI UT WOS:000310482400007 PM 22804613 ER PT J AU Jacobs, PG Silaski, G Wilmington, D Gordon, S Helt, W McMillan, G Fausti, SA Dille, M AF Jacobs, Peter G. Silaski, Grayson Wilmington, Debra Gordon, Samuel Helt, Wendy McMillan, Garnett Fausti, Stephen A. Dille, Marilyn TI Development and Evaluation of a Portable Audiometer for High-Frequency Screening of Hearing Loss From Ototoxicity in Homes/Clinics SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Hearing screening; high-frequency (HF) audiometry; ototoxicity monitoring ID PRODUCT OTOACOUSTIC EMISSIONS AB Cancer treatment often requires patients to be exposed to drugs that can damage hearing. Drugs such as cisplatin can cause permanent damage to hearing if not detected early. Damage typically occurs first in the more basal regions of the cochlea which are specific for high-frequency (HF) hearing and progresses to more apical regions that are relevant to speech understanding. Monitoring of HF hearing loss can be an effective means for early detection of ototoxicity caused by chemotherapy. Once ototoxicity is detected, the oncology medical team could adjust the drug dosage or switch to medications that are less ototoxic. Telehealth technology may improve access to ototoxicity monitoring. Patients could monitor their own hearing using a device that alerts healthcare professionals in the event of a change in hearing. A portable audiometer is currently not available that is 1) capable of automatic or manual (by an audiologist) operation; 2) designed with precision pure-tone functionality up to 20 kHz; and 3) able to remotely transfer health status information to a healthcare professional. This paper describes the design of a technology, the ototoxicity identification (OtoID), that includes a portable audiometer with HF test functionality that meets ANSI/ASA S3.6-2010 standards and is capable of reliably detecting a person's drug-related hearing changes relative to a baseline period (i.e., before ototoxic drugs) using an automated test. The system includes a wireless cellular modem capable of notifying a remote healthcare professional in the event that a significant change in hearing has occurred in the patient. The system was evaluated on test subjects within a sound-proof booth, a noisy hospital ward, and within their homes. Results indicate that the OtoID system can be used by patients to effectively monitor hearing changes remotely within their home or in a hospital ward, ultimately enabling early detection of ototoxicity and potentially avoiding hearing loss. C1 [Jacobs, Peter G.; Wilmington, Debra; Gordon, Samuel; Helt, Wendy; McMillan, Garnett; Fausti, Stephen A.; Dille, Marilyn] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Silaski, Grayson] GRAYSON SILASKI, Portland, OR 97221 USA. RP Jacobs, PG (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. EM peter.jacobs@va.gov; ncc621@gmail.com; debwilm@comcast.net; samuel.gordon@va.gov; Wendy.Helt@va.gov; garnett.mcmillan@va.gov; sa.fausti@frontier.com; marilyn.dille@va.gov FU U.S. Department of Veterans Affairs [C6373R] FX This work was supported in part by the U.S. Department of Veterans Affairs under Grant C6373R. Asterisk indicates corresponding author. NR 14 TC 6 Z9 6 U1 0 U2 10 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD NOV PY 2012 VL 59 IS 11 BP 3097 EP 3103 DI 10.1109/TBME.2012.2204881 PG 7 WC Engineering, Biomedical SC Engineering GA 025AM UT WOS:000310154700013 PM 22801480 ER PT J AU Hatano, H Scherzer, R Wu, Y Harvill, K Maka, K Hoh, R Sinclair, E Palmer, S Martin, JN Busch, MP Deeks, SG Hsue, PY AF Hatano, Hiroyu Scherzer, Rebecca Wu, Yuaner Harvill, Kara Maka, Kristinalisa Hoh, Rebecca Sinclair, Elizabeth Palmer, Sarah Martin, Jeffrey N. Busch, Michael P. Deeks, Steven G. Hsue, Priscilla Y. TI A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; raltegravir intensification; endothelial function; flow-mediated vasodilation ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL-ACTIVATION; SUPPRESSIVE ANTIRETROVIRAL THERAPY; MYOCARDIAL-INFARCTION RATES; FLOW-MEDIATED VASODILATION; POLYMERASE-CHAIN-REACTION; BRACHIAL-ARTERY; CARDIOVASCULAR-DISEASE; RISK-FACTOR; INDIVIDUALS AB Objectives: To determine whether intensification with raltegravir improves endothelial function in antiretroviral-treated HIV-infected individuals. Design: Randomized, double-blinded, placebo-controlled study. Methods: Fifty-six subjects with treatment-mediated viral suppression for at least 1 year were randomized to add 400 mg of raltegravir twice daily or matching placebo for 24 weeks. The primary endpoint was the difference in rate of change in endothelial function [as assessed by flow-mediated vasodilation (FMD) of the brachial artery] from baseline to week 24 between the raltegravir and placebo groups. Linear mixed models were used to evaluate the association of treatment group with changes in FMD, immune activation, and measures of viral persistence. Results: At baseline, the median CD4(+) T-cell count was 498 cells/mm(3), nadir CD4(+) T-cell count was 191 cells/mm(3), duration of HIV infection was 18 years, FMD was 3.3%, and hyperemic velocity (a marker of microvascular function) was 68.3 cm. There were no significant differences between treatment groups in rate of change in FMD (raltegravir group: +0.032% per week, placebo group: +0.023% per week; P = 0.60). There were also no differences between treatment groups in rate of change in hyperemic velocity, immune activation, or viral persistence. In multivariable analysis, older age, longer duration of HIV infection, and current abacavir use were associated with lower FMD. Lower CD4(+) T-cell count and current abacavir use were associated with lower hyperemic velocity. Conclusions: The addition of raltegravir to suppressive antiretroviral therapy did not have a significant impact on cardiovascular risk, as assessed by endothelial function (ClinicalTrials.gov NCT00843713). C1 [Hatano, Hiroyu; Scherzer, Rebecca; Wu, Yuaner; Harvill, Kara; Maka, Kristinalisa; Hoh, Rebecca; Sinclair, Elizabeth; Deeks, Steven G.; Hsue, Priscilla Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Scherzer, Rebecca] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Palmer, Sarah] Karolinska Inst, Solna, Sweden. [Palmer, Sarah] Swedish Inst Infect Dis Control, Solna, Sweden. [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Busch, Michael P.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA. RP Hatano, H (reprint author), San Francisco Gen Hosp, Bldg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA. EM hhatano@php.ucsf.edu FU National Institutes of Health [K23AI075985, K24AI069994, AI052745, AI055273, RR 16482, R01 HL095130, R01 AI087145, R01 AI057020]; American Foundation for AIDS Research [106710-40-RGRL, 107170-44-RGRL]; University of California; San Francisco/Gladstone Institute of Virology and Immunology Center for AIDS Research (CFAR) [P30 AI027763]; University of California, San Francisco Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; Center for HIV/AIDS Vaccine Immunology [U01 AI067854]; CFAR Network of Integrated Systems Grant [R24 AI067039]; Merck, Inc. FX Supported by National Institutes of Health Grant K23AI075985, K24AI069994, AI052745, AI055273, RR 16482, R01 HL095130, R01 AI087145, and R01 AI057020; American Foundation for AIDS Research Grants 106710-40-RGRL and 107170-44-RGRL; the University of California, San Francisco/Gladstone Institute of Virology and Immunology Center for AIDS Research (CFAR) Grant P30 AI027763; the University of California, San Francisco Clinical and Translational Research Institute Clinical Research Center Grant UL1 RR024131; the Center for AIDS Prevention Studies Grant P30 MH62246; the Center for HIV/AIDS Vaccine Immunology Grant U01 AI067854; and the CFAR Network of Integrated Systems Grant R24 AI067039.; H. Hatano and S. G. Deeks have received research support from Merck, Inc. Study drug provided by Merck at no cost for this study. The other authors have no conflicts of interest to disclose. NR 47 TC 20 Z9 20 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2012 VL 61 IS 3 BP 317 EP 325 DI 10.1097/QAI.0b013e31826e7d0f PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 029TR UT WOS:000310519300014 PM 22918156 ER PT J AU Tien, PC Schneider, MF Cox, C Karim, R Cohen, M Sharma, A Young, M Glesby, MJ AF Tien, Phyllis C. Schneider, Michael F. Cox, Christopher Karim, Roksana Cohen, Mardge Sharma, Anjali Young, Mary Glesby, Marshall J. TI Association of HIV Infection With Incident Diabetes Mellitus: Impact of Using Hemoglobin A1C as a Criterion for Diabetes SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE diabetes mellitus; HIV; women; hemoglobin A1C ID WOMENS INTERAGENCY HIV; ANTIRETROVIRAL THERAPY EXPOSURE; MULTICENTER AIDS COHORT; GLYCATED HEMOGLOBIN; INSULIN-RESISTANCE; RISK; ATHEROSCLEROSIS AB Background: Data regarding the association between HIV and diabetes mellitus (DM) are conflicting, with little known regarding the impact of including hemoglobin A1C (A1C) as a criterion for DM. Methods: Pooled logistic regression was used to quantify the association between HIV and DM in 1501 HIV-infected and 550 HIV-uninfected participants from the Women's Interagency HIV Study. Incident DM was defined using the following 3 criteria, definition I: fasting glucose (FG) >= 126 mg/dL, anti-DM medication or reporting DM diagnosis (with confirmation by FG >= 126 mg/dL or anti-DM medication); definition II: confirmation with a second FG >= 126 mg/dL, and definition III: addition of A1C >= 6.5% confirmed by FG >= 126 mg/dL or anti-DM medication. Results: DM incidence per 100 person-years was 2.44, 1.55, and 1.70 for HIV-infected women; 1.89, 0.85, and 1.13 for HIV-uninfected women, using definition I, II, and III, respectively. After adjustment for traditional DM risk factors, HIV infection was associated with 1.23-, 1.90-, and 1.38-fold higher risk of incident DM, respectively; the association reached statistical significance only when confirmation with a second FG >= 126 mg/dL was required. Older age, obesity, and a family history of DM were each consistently and strongly associated with increased DM risk. Conclusions: HIV infection is consistently associated with greater risk of DM. Inclusion of an elevated A1C to define DM increases the accuracy of the diagnosis and only slightly attenuates the magnitude of the association otherwise observed between HIV and DM. By contrast, a DM diagnosis made without any confirmatory criteria for FG >= 126 mg/dL overestimates the incidence, while also underestimating the effects of HIV on DM risk, and should be avoided. C1 [Tien, Phyllis C.] Univ Calif San Francisco, Vet Adm Med Ctr, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schneider, Michael F.; Cox, Christopher] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Karim, Roksana] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge] Rush Univ, Dept Med, Chicago, IL 60612 USA. [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Glesby, Marshall J.] Weill Cornell Med Coll, Dept Med, New York, NY USA. RP Tien, PC (reprint author), Univ Calif San Francisco, Vet Adm Med Ctr, Infect Dis Sect, Dept Med, 111W,4150 Clement St, San Francisco, CA 94121 USA. EM ptien@ucsf.edu FU National Institute of Allergy and Infectious Diseases [U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, U01-AI-42590, R01 AI087176, K24 AI078884]; Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant [U01-HD-32632]; National Cancer Institute, National Institute on Drug Abuse, and National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131] FX Supported by the National Institute of Allergy and Infectious Diseases Grants U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590; Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant U01-HD-32632. The study is cofunded by the National Cancer Institute, National Institute on Drug Abuse, and National Institute on Deafness and Other Communication Disorders.; Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Drs. Tien and Glesby are supported by the National Institute of Allergy and Infectious Diseases through R01 AI087176 and K24 AI078884, respectively. NR 23 TC 17 Z9 17 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2012 VL 61 IS 3 BP 334 EP 340 DI 10.1097/QAI.0b013e31826bfc32 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 029TR UT WOS:000310519300016 PM 22878421 ER PT J AU Sundararajan, PP AF Sundararajan, Priya Ponnapula TI Transosseous Fixation in Insertional Achilles Tendonitis SO JOURNAL OF FOOT & ANKLE SURGERY LA English DT Article DE Achilles tendon; anchor; bone tunnel; calcaneus; Haglund's deformity ID ROTATOR CUFF REPAIR; ANTERIOR CRUCIATE LIGAMENT; SUTURE ANCHOR FIXATION; TENDON-BONE INTERFACE; IN-VITRO; RETROCALCANEAL BURSITIS; WEAR PARTICLES; RABBIT MODEL; SINGLE-ROW; RECONSTRUCTION AB The surgical approach of severe insertional Achilles tendonitis involves debridement, repair, and reattachment. Previously described techniques for bone-tendon reattachment involved the use of suture anchors in the sparsely trabeculated calcaneus. The following technique tip is a reintroduction of bicortical transosseous fixation previously used in rotator cuff repairs. Bone tunnels are a viable option in the treatment of insertional Achilles tendonitis; however, additional research is necessary to validate its efficacy in this application. (C) 2012 by the American College of Foot and Ankle Surgeons. All rights reserved. C1 [Sundararajan, Priya Ponnapula] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Sundararajan, PP (reprint author), Audie L Murphy Vet Affairs Hosp, 7400 Merton Minter, San Antonio, TX 78229 USA. EM priyaponnapula@gmail.com NR 62 TC 0 Z9 0 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-2516 J9 J FOOT ANKLE SURG JI J. Foot Ankle Surg. PD NOV-DEC PY 2012 VL 51 IS 6 BP 806 EP 812 DI 10.1053/j.jfas.2012.06.020 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 027GT UT WOS:000310341000023 PM 22841157 ER PT J AU Adair, JE Zhao, X Chien, S Fang, M Wohlfahrt, ME Trobridge, GD Taylor, JA Beard, BC Kiem, HP Becker, PS AF Adair, Jennifer E. Zhao, Xin Chien, Sylvia Fang, Min Wohlfahrt, Martin E. Trobridge, Grant D. Taylor, Jason A. Beard, Brian C. Kiem, Hans-Peter Becker, Pamela S. TI Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities SO JOURNAL OF MOLECULAR MEDICINE-JMM LA English DT Article DE Gene therapy; Fanconi anemia; Lentivirus vector; Cyclophosphamide; Autologous transplantation ID BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; HEMATOPOIETIC PROGENITOR CELLS; LOW-DOSE CYCLOPHOSPHAMIDE; DNA CROSS-LINKING; IN-VIVO; GROUP-A; GROUP-C; CONDITIONING REGIMEN; REPOPULATING CELLS AB A major hurdle for hematopoietic stem cell (HSC) gene therapy for inherited bone marrow disorders, including Fanconi anemia (FA), is adequate engraftment of gene-modified cells. A phenotypic defect in DNA repair renders FA patients sensitive to alkylating agents such as cyclophosphamide (Cy); however, at lower doses, Cy is well tolerated in the FA transplant setting. We tested whether non-alkylating agents could replace Cy for pretransplant conditioning to enhance engraftment of FANCA gene-modified hematopoietic cells. We compared Cy preconditioning with fludarabine (Flu) or cytarabine (AraC) or no conditioning as a control in fanca (-/-) mutant mice receiving gene-modified bone marrow cells. Only mice conditioned with Cy exhibited appreciable engraftment of gene-modified cells by PCR and resistance to mitomycin C (MMC). Cy administration following transplantation increased gene marking levels in all animals treated, but highest gene marking and corresponding MMC resistance were observed in mice receiving Cy pre- and posttransplantation. Importantly, no cytogenetic abnormalities were observed in Cy-treated mice. We conclude that Cy is an effective and superior preparative regimen with respect to engraftment of lentivirus-transduced cells and functional correction in fanca (-/-) mice. Thus, appropriately dosed Cy may provide a suitable conditioning regimen for FA patients undergoing HSC gene therapy. C1 [Adair, Jennifer E.; Wohlfahrt, Martin E.; Beard, Brian C.; Kiem, Hans-Peter] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Zhao, Xin; Chien, Sylvia] Univ Washington, Div Hematol, Dept Med, Seattle, WA 98109 USA. [Fang, Min] Seattle Canc Care Alliance, Dept Med, Div Pathol, Seattle, WA 98109 USA. [Trobridge, Grant D.] Washington State Univ, Dept Pharmaceut Sci, Pullman, WA 99164 USA. [Taylor, Jason A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Beard, Brian C.] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA 98195 USA. [Kiem, Hans-Peter] Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA. [Kiem, Hans-Peter] Univ Washington, Sch Med, Div Pathol, Seattle, WA 98195 USA. [Becker, Pamela S.] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA. RP Kiem, HP (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA. EM hkiem@fhcrc.org; pbecker@u.washington.edu FU National Institutes of Health, Bethesda, MD, USA [P30 DK056465, P01 HL036444, R01 HL085693] FX The authors are grateful for research funding from the National Institutes of Health, Bethesda, MD, USA, grants P30 DK056465, P01 HL036444, and R01 HL085693. H.-P. Kiem is a Markey Molecular Medicine Investigator and the recipient of the Jose Carreras/E. Donnall Thomas Endowed Chair for Cancer Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor its subsidiary Institutes and Centers NR 35 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0946-2716 J9 J MOL MED JI J. Mol. Med. PD NOV PY 2012 VL 90 IS 11 BP 1283 EP 1294 DI 10.1007/s00109-012-0905-0 PG 12 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 025XT UT WOS:000310231300006 PM 22660274 ER PT J AU Stone, RA Sevick, MA Rao, RH Macpherson, DS Cheng, CR Kim, S Hough, LJ DeRubertis, FR AF Stone, Roslyn A. Sevick, Mary Ann Rao, R. Harsha Macpherson, David S. Cheng, Chunrong Kim, Sunghee Hough, Linda J. DeRubertis, Frederick R. TI The Diabetes Telemonitoring Study Extension: an exploratory randomized comparison of alternative interventions to maintain glycemic control after withdrawal of diabetes home telemonitoring SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID CONTROLLED-TRIAL; BLOOD-GLUCOSE; TELEMEDICINE SUPPORT; COLLABORATIVE CARE; FOLLOW-UP; MANAGEMENT; TIME; TRANSMISSION; REDUCTION; TELECARE AB Background Telemonitoring interventions featuring transmission of home glucose records to healthcare providers have resulted in improved glycemic control in patients with diabetes. No research has addressed the intensity or duration of telemonitoring required to sustain such improvements. Purpose The DiaTel study (10 January 2005 to 1 November 2007) compared active care management (ACM) with home telemonitoring (n=73) to monthly care coordination (CC) telephone calls (n=77) among veterans with diabetes and suboptimal glycemic control. The purpose of the Dia Tel Extension was to assess whether initial improvements could be sustained with interventions of the same or lower intensity among participants who re-enrolled in a 6-month extension of DiaTel. Methods Dia Tel participants receiving ACM were re-assigned randomly to monthly CC calls with continued telemonitoring but no active medication management (ACM-to-CCHT, n=23) or monthly CC telephone calls (ACM-to-CC, n=21). Dia Tel participants receiving CC were re-assigned randomly to continued CC (CC-to-CC, n=28) or usual care (UC, ie, CC-to-UC, n=29). Hemaglobin A1c (HbA1c) was assessed at 3 and 6 months following re-randomization. Results Marked HbA1c improvements observed in DiaTel ACM participants were sustained 6 months after re-randomization in both ACM-to-CCHT and ACM-to-CC groups. Lesser HbA1c improvements observed in DiaTel CC participants were sustained in both CC-to-CC and CC-to-UC groups. No benefit was apparent for continued transmission of glucose data among DiaTel ACM participants or continued monthly telephone calls among DiaTel CC participants 6 months after re-randomization. Conclusion Significant improvements in HbA1c achieved using home telemonitoring and active medication management for 6 months were sustained 6 months later with interventions of decreased intensity in VA Health System-qualified veterans. C1 [Rao, R. Harsha; DeRubertis, Frederick R.] VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Stone, Roslyn A.; Sevick, Mary Ann; Cheng, Chunrong; Kim, Sunghee] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Stone, Roslyn A.; Cheng, Chunrong; Kim, Sunghee] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann; Rao, R. Harsha; Macpherson, David S.; DeRubertis, Frederick R.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Sevick, Mary Ann] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Macpherson, David S.] VISN 4 Healthcare Network, Pittsburgh, PA USA. [Hough, Linda J.] Vet Res Fdn Pittsburgh, Pittsburgh, PA USA. RP DeRubertis, FR (reprint author), VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Univ Dr C 111-U, Pittsburgh, PA 15240 USA. EM frederick.derubertis@va.gov FU US Air Force [W81XWH-04-2-0030]; Viterion TeleHealthcare, LLC; Tarrytown, New York FX This work was supported by award W81XWH-04-2-0030 from the US Air Force, administered by the US Army Medical Research Acquisition Activity, Fort Detrick, Maryland, and by resources and the use of facilities at the VA Pittsburgh Healthcare System. A portion of the telemonitoring and other equipment costs were supported by Viterion TeleHealthcare, LLC; Tarrytown, New York. The funding agencies played no role in the conduct or reporting of this study. NR 34 TC 11 Z9 12 U1 0 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2012 VL 19 IS 6 BP 973 EP 979 DI 10.1136/amiajnl-2012-000815 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 028FP UT WOS:000310408500009 PM 22610495 ER PT J AU Russ, AL Weiner, M Saleem, JJ Wears, RL AF Russ, Alissa L. Weiner, Michael Saleem, Jason J. Wears, Robert L. TI When 'technically preventable' alerts occur, the design-not the prescriber-has failed SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Letter C1 [Russ, Alissa L.; Weiner, Michael; Saleem, Jason J.] US Dept Vet Affairs, Ctr Excellence Implementing Evidence Based Practi, Richard L Roudebush VA Med Ctr, Vet Hlth Adm,Hlth Serv Res & Dev Serv HFP 04 148, Indianapolis, IN 46254 USA. [Russ, Alissa L.; Weiner, Michael; Saleem, Jason J.] Regenstrief Inst Inc, Indianapolis, IN USA. [Russ, Alissa L.; Weiner, Michael; Saleem, Jason J.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Indianapolis, IN 46204 USA. [Russ, Alissa L.] Purdue Univ, Sch Pharm, Dept Pharm Practice, W Lafayette, IN 47907 USA. [Wears, Robert L.] Univ Florida, Dept Emergency Med, Jacksonville, FL USA. [Wears, Robert L.] Univ London Imperial Coll Sci Technol & Med, Clin Safety Res Unit, London, England. RP Russ, AL (reprint author), US Dept Vet Affairs, Ctr Excellence Implementing Evidence Based Practi, Richard L Roudebush VA Med Ctr, Vet Hlth Adm,Hlth Serv Res & Dev Serv HFP 04 148, Indianapolis, IN 46254 USA. EM alissa.russ@va.gov OI Wears, Robert/0000-0001-9826-954X FU AHRQ HHS [R18 HS017902]; NCATS NIH HHS [UL1 TR000064] NR 5 TC 3 Z9 3 U1 0 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2012 VL 19 IS 6 BP 1119 EP 1119 DI 10.1136/amiajnl-2012-001193 PG 1 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 028FP UT WOS:000310408500030 PM 22847307 ER PT J AU Gellad, WF Aspinall, SL Handler, SM Stone, RA Castle, N Semla, TP Good, CB Fine, MJ Dysken, M Hanlon, JT AF Gellad, Walid F. Aspinall, Sherrie L. Handler, Steven M. Stone, Roslyn A. Castle, Nicholas Semla, Todd P. Good, Chester B. Fine, Michael J. Dysken, Maurice Hanlon, Joseph T. TI Use of Antipsychotics Among Older Residents in VA Nursing Homes SO MEDICAL CARE LA English DT Article DE nursing homes; antipsychotics; Veterans; pharma-coepidemiology ID DRUG-USE; MEDICATION USE; PRESCRIBING RATES; CONTROLLED-TRIAL; DEMENTIA; VETERANS; METAANALYSIS; CARE; PARKINSONISM; POLYPHARMACY AB Background: Antipsychotic medications are commonly prescribed to nursing home residents despite their well-established adverse event profiles. Because little is known about their use in Veterans Affairs (VA) nursing homes [ie, Community Living Centers (CLCs)], we assessed the prevalence and risk factors for antipsychotic use in older residents of VA CLCs. Methods: This cross-sectional study included 3692 Veterans age 65 or older who were admitted between January 2004 and June 2005 to one of 133 VA CLCs and had a stay of >= 90 days. We used VA Pharmacy Benefits Management data to examine antipsychotic use and VA Medical SAS datasets and the Minimum Data Set to identify evidence-based indications for antipsychotic use (eg, schizophrenia, dementia with psychosis). We used multivariable logistic regression and generalized estimating equations to identify factors independently associated with antipsychotic receipt. Results: Overall, 948/3692(25.7%) residents received an antipsychotic, of which 59.3% had an evidence-based indication for use. Residents with aggressive behavior [odds ratio (OR) = 2.74, 95% confidence interval (CI), 2.04-3.67] and polypharmacy (9+ drugs; OR = 1.84, 95% CI, 1.41-2.40) were more likely to receive antipsychotics, as were users of antidepressants (OR = 1.37, 95% CI, 1.14-1.66), anxiolytic/hypnotics (OR = 2.30, 95% CI, 1.64-3.23), or drugs for dementia (OR = 1.52, 95% CI, 1.21-1.92). Those residing in Alzheimer/dementia special care units were also more likely to receive an antipsychotic (OR = 1.66, 95% CI, 1.26-2.21). Veterans with dementia but no documented psychosis were as likely as those with an evidence-based indication to receive an antipsychotic (OR = 1.10, 95% CI, 0.82-1.47). Conclusions: Antipsychotic use is common among VA nursing home residents aged 65 and older, including those without a documented evidence-based indication for use. Further quality improvement efforts are needed to reduce potentially inappropriate antipsychotic prescribing. C1 [Gellad, Walid F.; Aspinall, Sherrie L.; Handler, Steven M.; Stone, Roslyn A.; Good, Chester B.; Fine, Michael J.; Hanlon, Joseph T.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA. [Gellad, Walid F.; Good, Chester B.; Fine, Michael J.] Univ Pittsburgh, Dept Med Gen Med, Pittsburgh, PA USA. [Gellad, Walid F.; Aspinall, Sherrie L.; Handler, Steven M.; Hanlon, Joseph T.] Univ Pittsburgh, Geriatr Pharmaceut & Geroinformat Res & Training, Pittsburgh, PA USA. [Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Semla, Todd P.; Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Handler, Steven M.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA. [Handler, Steven M.; Hanlon, Joseph T.] Univ Pittsburgh, Pittsburgh VA Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Handler, Steven M.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Med Geriatr, Pittsburgh, PA USA. [Stone, Roslyn A.; Castle, Nicholas] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Semla, Todd P.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Behav Sci, Chicago, IL 60611 USA. [Dysken, Maurice; Hanlon, Joseph T.] Minneapolis VA Geriatr Res Educ & Clin Ctr, Minneapolis, MN USA. RP Gellad, WF (reprint author), VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM walid.gellad@va.gov OI Handler, Steven/0000-0002-3940-3224 FU VA Career Development Award [CDA 09-207]; National Institute of Aging [P30AG024827, T32 AG021885, K07AG033174, R01AG034056, R56AG027017, 3U01 AG012553]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01 HS017695, R01 HS018721, K12 HS019461] FX Supported by a VA Career Development Award (CDA 09-207), National Institute of Aging Grants (P30AG024827, T32 AG021885, K07AG033174, R01AG034056, R56AG027017, 3U01 AG012553), a National Institute of Mental Health Grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), and Agency for Healthcare Research and Quality Grants (R01 HS017695, R01 HS018721, K12 HS019461). NR 49 TC 24 Z9 24 U1 3 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD NOV PY 2012 VL 50 IS 11 BP 954 EP 960 DI 10.1097/MLR.0b013e31825fb21d PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 022OL UT WOS:000309968600009 PM 23047785 ER PT J AU Spence, MM Nguyen, LM Hui, RL Chan, J AF Spence, Michele M. Nguyen, Lynda M. Hui, Rita L. Chan, James TI Evaluation of Clinical and Safety Outcomes Associated with Conversion from Brand-Name to Generic Tacrolimus in Transplant Recipients Enrolled in an Integrated Health Care System SO PHARMACOTHERAPY LA English DT Article DE tacrolimus; drugs; generic; drug substitution; therapeutic equivalency ID RENAL-TRANSPLANTATION; IMMUNOSUPPRESSION; MULTICENTER; EXPERIENCE; PROGRAF; DRUGS AB Study Objective To evaluate clinical and safety outcomes among transplant recipients whose tacrolimus was converted from the brand-name formulation to a generic formulation. Design Retrospective analysis. Data Source Clinical databases and electronic records from a large, integrated health care system in California. Patients A total of 234 clinically stable, adult transplant recipients (renal, liver, and heart) whose tacrolimus was converted from the brand-name formulation to a generic formulation between October 1, 2010, and December 31, 2010, according to a physician-approved protocol. Measurements and Main Results For each patient, pre- and postconversion tacrolimus trough concentrations and serum creatinine concentrations were analyzed. Data were also collected on the percentage of patients who required dosage titration, drug cost savings, and rates of reversion to brand-name tacrolimus, biopsy-proved acute allograft rejections, and mortality. No significant differences were noted in mean +/- SD pre- and postconversion tacrolimus trough levels (6.74 +/- 1.61 vs 6.96 +/- 2.31 ng/ml, p=0.137) or serum creatinine concentrations (1.33 +/- 0.48 vs 1.36 +/- 0.82 mg/dl, p=0.302). The mean +/- SD percent change in tacrolimus trough concentration was 5.63 +/- 32.95%. Thirty-six patients (15.4%) required dosage titration. Six patients (2.6%) reverted back to brand-name tacrolimus. No deaths or acute rejections occurred. Use of the generic product saved each patient an average of $45/month in drug acquisition cost and $26/prescription copayment. Conclusion Clinical experience as well as research data show that use of generic tacrolimus results in trough concentrations that are comparable to the brand-name drug. Given the lack of adverse events reported and the cost savings recognized, conversion from brand-name tacrolimus to generic tacrolimus should be encouraged. Since dosage titration may be required, close therapeutic drug monitoring is recommended. C1 [Spence, Michele M.] Kaiser Permanente, Pharm Outcomes Res Grp, Downey, CA 90242 USA. [Nguyen, Lynda M.] San Francisco VA Med Ctr, Dept Pharm, San Francisco, CA USA. [Hui, Rita L.; Chan, James] Kaiser Permanente, Pharm Outcomes Res Grp, Oakland, CA USA. RP Spence, MM (reprint author), Kaiser Permanente, Pharm Outcomes Res Grp, 12254 Bellflower Blvd, Downey, CA 90242 USA. EM michele.m.spence@kp.org NR 20 TC 18 Z9 18 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD NOV PY 2012 VL 32 IS 11 BP 981 EP 987 DI 10.1002/phar.1130 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 030EF UT WOS:000310551200007 PM 23074134 ER PT J AU Moscariello, A Vliegenthart, R Schoepf, UJ Nance, JW Zwerner, PL Meyer, M Townsend, JC Fernandes, V Steinberg, DH Fink, C Oudkerk, M Bonomo, L O'Brien, TX Henzler, T AF Moscariello, Antonio Vliegenthart, Rozemarijn Schoepf, U. Joseph Nance, John W., Jr. Zwerner, Peter L. Meyer, Mathias Townsend, Jacob C. Fernandes, Valerian Steinberg, Daniel H. Fink, Christian Oudkerk, Matthijs Bonomo, Lorenzo O'Brien, Terrence X. Henzler, Thomas TI Coronary CT Angiography versus Conventional Cardiac Angiography for Therapeutic Decision Making in Patients with High Likelihood of Coronary Artery Disease SO RADIOLOGY LA English DT Article ID COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC PERFORMANCE; METAANALYSIS; REVASCULARIZATION; ECHOCARDIOGRAPHY AB Purpose: To assess the efficacy of coronary computed tomographic (CT) angiography for therapeutic decision making in patients with high likelihood of coronary artery disease (CAD)-specifically the ability of coronary CT angiography to help differentiate patients without and patients with a need for revascularization and determine the appropriate revascularization procedure. Materials and Methods: The study protocol was approved by institutional review board, with written informed consent from all patients. The study was conducted in compliance with HIPAA. One hundred eighty-five consecutive symptomatic patients (121 men; mean age, 59.4 years +/- 9.7) with a positive single photon emission computed tomography (SPECT) myocardial perfusion study underwent coronary CT angiography and conventional cardiac angiography (hereafter, cardiac catheterization). The management strategy (conservative treatment vs revascularization) and revascularization procedure (percutaneous coronary intervention [PCI] vs coronary artery bypass graft surgery [CABG]) were prospectively selected on the basis of a combination of coronary CT angiography and SPECT. In addition, the authors calculated the accuracy, sensitivity, specificity, and negative and positive predictive values of coronary CT angiography in the detection of obstructive CAD and the selection of a revascularization strategy. Cardiac catheterization was used as the standard of reference. Results: Of the 185 patients, 113 (61%) did not undergo revascularization and 42 (23%) were free of CAD. In 178 patients (96%), the same therapeutic strategy (conservative treatment vs revascularization) was chosen on the basis of coronary CT angiography and catheterization. All patients in need of revascularization were identified with coronary CT angiography. When revascularization was indicated, the same procedure (PCI vs CABG) was chosen in 66 of 72 patients (92%). Conclusion: In patients with high likelihood of CAD, the performance of coronary CT angiography in the differentiation of patients without and patients with a need for revascularization and the selection of a revascularization strategy was similar to that of cardiac catheterization; accordingly, coronary CT angiography has the potential to limit the number of patients without obstructive CAD who undergo cardiac catheterization and to inform decision making regarding revascularization. C1 [Moscariello, Antonio; Vliegenthart, Rozemarijn; Schoepf, U. Joseph; Nance, John W., Jr.; Zwerner, Peter L.; Meyer, Mathias; Townsend, Jacob C.; Fernandes, Valerian; Steinberg, Daniel H.; O'Brien, Terrence X.; Henzler, Thomas] Med Univ S Carolina, Heart & Vasc Ctr, Charleston, SC 29425 USA. [Moscariello, Antonio; Bonomo, Lorenzo] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Dept Bioimaging & Radiol Sci, I-00168 Rome, Italy. [Vliegenthart, Rozemarijn; Oudkerk, Matthijs] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Ctr Med Imaging NE Netherlands, NL-9700 AB Groningen, Netherlands. [Meyer, Mathias; Fink, Christian; Henzler, Thomas] Univ Heidelberg, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Clin Radiol & Nucl Med, D-6900 Heidelberg, Germany. [Fernandes, Valerian; O'Brien, Terrence X.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Schoepf, UJ (reprint author), Med Univ S Carolina, Heart & Vasc Ctr, Ashley River Tower,25 Courtenay Dr, Charleston, SC 29425 USA. EM schoepf@musc.edu RI Meyer, Mathias/G-6791-2015 FU GE Healthcare; Bracco Diagnostics; Siemens Healthcare; Department of Veterans Affairs; Bayer; Bracco; Medrad; Siemens FX Supported in part through research grants provided by GE Healthcare, Bracco Diagnostics, and Siemens Healthcare, as well as through the Research and Development Program of the Department of Veterans Affairs.; A.M. Financial activities related to the present article: institution received a grant from GE Healthcare, Bracco Diagnostics, and Siemens Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. R. V. No relevant conflicts of interest to disclose. U.J.S. Financial activities related to the present article: institution received a grant from GE Healthcare, Bracco Diagnostics, and Siemens Healthcare. Financial activities not related to the present article: is a paid consultant for Bayer, Bracco, GE Healthcare, Medrad, and Siemens; institution received a grant or has a grant pending from Bayer, Bracco, GE Healthcare, Medrad, and Siemens; receives payment for lectures including service on speakers bureaus from Bayer, Bracco, GE Healthcare, Medrad, and Siemens; institution received payment for development of educational presentations from GE Healthcare. Other relationships: none to disclose. J.W.N. No relevant conflicts of interest to disclose. P.L.Z. Financial activities related to the present article: institution received a grant from GE Healthcare, Bracco Diagnostics, and Siemens Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. M. M. Financial activities related to the present article: institution received a grant from GE Healthcare, Bracco Diagnostics, and Siemens Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. J.C.T. Financial activities related to the present article: institution received a grant from GE Healthcare, Bracco Diagnostics, and Siemens Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. V. F. No relevant conflicts of interest to disclose. D. H. S. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: is a paid consultant for Boston Scientific, Terumo Interventional Systems, Medtronic, Medicine's Company, Abbott Vascular, and Astra Zeneca. Other relationships: none to disclose. C. F. No relevant conflicts of interest to disclose. M.O. No relevant conflicts of interest to disclose. L. B. No relevant conflicts of interest to disclose. T.X.O. No relevant conflicts of interest to disclose. T. H. No relevant conflicts of interest to disclose. NR 17 TC 17 Z9 18 U1 0 U2 4 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD NOV PY 2012 VL 265 IS 2 BP 385 EP 392 DI 10.1148/radiol.12112426 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 029PN UT WOS:000310508000010 PM 22875799 ER PT J AU Kaiser, NC Melrose, RJ Liu, C Sultzer, DL Jimenez, E Su, M Monserratt, L Mendez, MF AF Kaiser, Natalie C. Melrose, Rebecca J. Liu, Collin Sultzer, David L. Jimenez, Elvira Su, Michael Monserratt, Lorena Mendez, Mario F. TI Neuropsychological and Neuroimaging Markers in Early Versus Late-Onset Alzheimer's Disease SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE early onset; late onset; neuropsychology; Alzheimer's disease; dementia; neuroimaging; FDG-PET ID ISCHEMIC VASCULAR DEMENTIA; MENTAL-STATE-EXAMINATION; GLUCOSE-METABOLISM; EXECUTIVE DEFICITS; SENILE DEMENTIA; AGE; PERFORMANCE; POPULATION; PATTERNS; DISTURBANCES AB Background: Early-onset Alzheimer's disease (EOAD) has been overshadowed by the more common late-onset AD (LOAD). Yet, the literature indicates EOAD may have less hippocampal-memory presentations and more focal neocortical localization early in the disease. Objective: To evaluate these proposed differences between these 2 forms of AD and to explore what they inform about differences in AD pathophysiology. Methods: In all, 21 patients with EOAD and 24 patients with LOAD matched for disease progression and severity were compared on neurocognitive measures and resting state fluorodeoxy-glucose positron-emission tomography (FDG-PET). Results: Patients with EOAD had worse executive functions with greater hypometabolism in the parietal regions; whereas patients with LOAD had worse confrontation naming and verbal recognition memory with greater hypometabolism in inferior frontotemporal regions. Conclusions: In addition to highlighting significant differences between EOAD and LOAD, these results reveal dissociation between executive deficits in AD and frontal hypometabolism, suggesting early disturbances of the parietal-frontal network in EOAD. C1 [Kaiser, Natalie C.; Liu, Collin; Sultzer, David L.; Jimenez, Elvira; Monserratt, Lorena; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Melrose, Rebecca J.; Sultzer, David L.; Su, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Kaiser, NC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 401,Room A235, Los Angeles, CA 90073 USA. EM natalie.kaiser@va.gov FU NIH [R01AG034499-3]; Department of Veterans Affairs VA Merit Review; Career Development Award; NIMH [R01-MH56031] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NIH Grant #R01AG034499-3 (M. Mendez PI); Department of Veterans Affairs VA Merit Review (2 separate awards; 1 to M. Mendez and another to D. Sultzer); Career Development Award to R. Melrose; NIMH #R01-MH56031 (D. Sultzer,) PI. NR 47 TC 12 Z9 12 U1 2 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD NOV PY 2012 VL 27 IS 7 BP 520 EP 529 DI 10.1177/1533317512459798 PG 10 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA 022AX UT WOS:000309928500010 PM 22990206 ER PT J AU Lajoie, TM Rich, A AF Lajoie, Travis M. Rich, Anne TI "Bath Salts": A New Drug Epidemic-A Case Report SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article C1 [Lajoie, Travis M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland VA Med Ctr, Portland, OR 97201 USA. [Rich, Anne] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA. RP Lajoie, TM (reprint author), 1052 Emerson Ave, Salt Lake City, UT 84105 USA. EM tmlajoie@hotmail.com NR 6 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD NOV-DEC PY 2012 VL 21 IS 6 BP 572 EP 573 DI 10.1111/j.1521-0391.2012.00286.x PG 2 WC Substance Abuse SC Substance Abuse GA 027ED UT WOS:000310333700013 PM 23082840 ER PT J AU Felker, GM Hasselblad, V Tang, WHW Hernandez, AF Armstrong, PW Fonarow, GC Voors, AA Metra, M McMurray, JJV Butler, J Heizer, GM Dickstein, K Massie, BM Atar, D Troughton, RW Anker, SD Califf, RM Starling, RC O'Connor, CM AF Felker, G. Michael Hasselblad, Vic Tang, W. H. Wilson Hernandez, Adrian F. Armstrong, Paul W. Fonarow, Gregg C. Voors, Adriaan A. Metra, Marco McMurray, John J. V. Butler, Javed Heizer, Gretchen M. Dickstein, Kenneth Massie, Barry M. Atar, Dan Troughton, Richard W. Anker, Stefan D. Califf, Robert M. Starling, Randall C. O'Connor, Christopher M. TI Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Troponin; Biomarkers; Heart failure ID CARDIAC TROPONIN; NATRIURETIC PEPTIDE; RISK STRATIFICATION; SERIAL CHANGES; MYOCARDIAL-INFARCTION; CLINICAL-IMPLICATIONS; OUTCOMES; NESIRITIDE; DIAGNOSIS AB We examined the prognostic importance of cardiac troponin I (cTnI) in a cohort of patients enrolled in the ASCEND-HF study of nesiritide in acute decompensated heart failure (ADHF). Circulating troponins are a prognostic marker in patients with ADHF. Contemporary assays with greater sensitivity require reassessment of the significance of troponin elevation in HF. Cardiac troponin I was measured in a core laboratory in 808 ADHF patients enrolled in the ASCEND-HF biomarkers substudy using a sensitive assay (VITROS Trop I ES, Ortho Clinical Diagnostics) with a lower limit of detection of 0.012 ng/mL and a 99th percentile upper reference limit (URL) of 0.034 ng/mL. Patients with clinical evidence of acute coronary syndrome or troponin 5 the URL were excluded. Multivariable modelling was used to assess the relationship between log(cTnI) and in-hospital and post-discharge outcomes. Baseline cTnI was undetectable in 22 and elevated above the 99th percentile URL in 50 of subjects. cTnI levels did not differ based on HF aetiology. After multivariable adjustment, higher cTnI was associated with worsened in-hospital outcomes such as length of stay (P 0.01) and worsening HF during the index hospitalization (P 0.01), but was not associated with worsened post-discharge outcomes at 30 or 180 days. The relationship between cTnI and outcomes was generally linear and there was no evidence of a threshold effect at any particular level of cTnI. cTnI is elevated above the 99th percentile URL in 50 of ADHF patients and predicts in-hospital outcome, but is not an independent predictor of long-term outcomes. C1 [Felker, G. Michael; Hasselblad, Vic; Hernandez, Adrian F.; Heizer, Gretchen M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA. [Tang, W. H. Wilson; Starling, Randall C.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada. [Fonarow, Gregg C.] Ronald Reagan UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Metra, Marco] Univ Brescia, Dept Cardiol, Brescia, Italy. [McMurray, John J. V.] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland. [Butler, Javed] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA. [Dickstein, Kenneth] Univ Bergen, Stavenger Univ Hosp, Bergen, Norway. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Atar, Dan] Univ Oslo, Ulleval Hosp, Dept Cardiol, N-0316 Oslo, Norway. [Atar, Dan] Univ Oslo, Inst Clin Med, N-0316 Oslo, Norway. [Troughton, Richard W.] Univ Otago, Christchurch, New Zealand. [Anker, Stefan D.] Charite, Dept Cardiol, D-13353 Berlin, Germany. [Anker, Stefan D.] IRCCS San Raffaele, Ctr Clin & Basic Res, Rome, Italy. [Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27705 USA. RP Felker, GM (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA. EM Michael.felker@duke.edu RI Tang, Wai Hong/I-1238-2013; Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616; Metra, Marco/0000-0001-6691-8568; mcmurray, john/0000-0002-6317-3975 FU Johnson Johnson; Roche Diagnostics; Critical Diagnostics; BG Medicine; Ortho Biotech FX Johnson & Johnson.; G.M.F.: research grants from Johnson & Johnson, Roche Diagnostics, Critical Diagnostics, and BG Medicine. A. F. H., K. D., J.J.,V.M., R. M. C., and C.M.O.: research grants from Johnson & Johnson. P. W. A.: research grants from Johnson & Johnson and Ortho Biotech. G. C. F. : consultant/advisory board for Scios and Novartis. A. A. V., J.B., and B. M. M.: consultant/advisory board for Johnson & Johnson. M. M.: consultant/advisory board for Corthera, Daiichi, Novartis, and Serrvier. R. W. T: consultant/advisory board for St. Jude Medical. S. D. A.: honoraria and consultant/advisory board for Alere Inc. (Europe), Thermo Fisher Scientific, and Vifor Pharma. R. C. S.: research support and consultant/advisory board for Johnson & Johnson. All other authors have no conflicts to declare. NR 25 TC 32 Z9 32 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD NOV PY 2012 VL 14 IS 11 BP 1257 EP 1264 DI 10.1093/eurjhf/hfs110 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 025EL UT WOS:000310168200010 PM 22764184 ER PT J AU Harris, JR Burton, P Knoppers, BM Lindpaintner, K Bledsoe, M Brookes, AJ Budin-Ljosne, I Chisholm, R Cox, D Deschenes, M Fortier, I Hainaut, P Hewitt, R Kaye, J Litton, JE Metspalu, A Ollier, B Palmer, LJ Palotie, A Pasterk, M Perola, M Riegman, PHJ van Ommen, GJ Yuille, M Zatloukal, K AF Harris, Jennifer R. Burton, Paul Knoppers, Bartha Maria Lindpaintner, Klaus Bledsoe, Marianna Brookes, Anthony J. Budin-Ljosne, Isabelle Chisholm, Rex Cox, David Deschenes, Mylene Fortier, Isabel Hainaut, Pierre Hewitt, Robert Kaye, Jane Litton, Jan-Eric Metspalu, Andres Ollier, Bill Palmer, Lyle J. Palotie, Aarno Pasterk, Markus Perola, Markus Riegman, Peter H. J. van Ommen, Gert-Jan Yuille, Martin Zatloukal, Kurt TI Toward a roadmap in global biobanking for health SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article ID DATASHAPER APPROACH; TRANSLATION; BIOMARKERS; DATABASES; MEDICINE; GENOMICS; QUALITY; SOCIETY; SCIENCE; ETHICS AB Biobanks can have a pivotal role in elucidating disease etiology, translation, and advancing public health. However, meeting these challenges hinges on a critical shift in the way science is conducted and requires biobank harmonization. There is growing recognition that a common strategy is imperative to develop biobanking globally and effectively. To help guide this strategy, we articulate key principles, goals, and priorities underpinning a roadmap for global biobanking to accelerate health science, patient care, and public health. The need to manage and share very large amounts of data has driven innovations on many fronts. Although technological solutions are allowing biobanks to reach new levels of integration, increasingly powerful data-collection tools, analytical techniques, and the results they generate raise new ethical and legal issues and challenges, necessitating a reconsideration of previous policies, practices, and ethical norms. These manifold advances and the investments that support them are also fueling opportunities for biobanks to ultimately become integral parts of health-care systems in many countries. International harmonization to increase interoperability and sustainability are two strategic priorities for biobanking. Tackling these issues requires an environment favorably inclined toward scientific funding and equipped to address socio-ethical challenges. Cooperation and collaboration must extend beyond systems to enable the exchange of data and samples to strategic alliances between many organizations, including governmental bodies, funding agencies, public and private science enterprises, and other stakeholders, including patients. A common vision is required and we articulate the essential basis of such a vision herein. European Journal of Human Genetics (2012) 20, 1105-1111; doi:10.1038/ejhg. 2012.96; published online 20 June 2012 C1 [Harris, Jennifer R.; Budin-Ljosne, Isabelle] Norwegian Inst Publ Hlth, Dept Genes & Environm, Div Epidemiol, N-0403 Oslo, Norway. [Burton, Paul; Brookes, Anthony J.] Univ Leicester, Leicester, Leics, England. [Burton, Paul; Deschenes, Mylene; Fortier, Isabel] Publ Populat Project Genom P3G, Montreal, PQ, Canada. [Knoppers, Bartha Maria] McGill Univ, Ctr Genom & Policy, Montreal, PQ, Canada. [Lindpaintner, Klaus] SDIX Inc, Newark, NJ USA. [Lindpaintner, Klaus] Lindpaintner Biobanks Consulting, Muttenz, Switzerland. [Bledsoe, Marianna] US Dept Vet Affairs, Washington, DC USA. [Chisholm, Rex] Northwestern Univ, Sch Med, Ctr Genet Med, Chicago, IL USA. [Cox, David] Pfizer Inc, Biotherapeut & Bioinnovat Ctr, San Francisco, CA USA. [Fortier, Isabel] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada. [Hainaut, Pierre; Pasterk, Markus] Int Prevent Res Inst, Lyon, France. [Hewitt, Robert] European Middle Eastern & African Soc Biopreserva, Marseille, France. [Kaye, Jane] Univ Oxford, Dept Publ Hlth, Ctr Hlth Law & Emerging Technol, Oxford, England. [Litton, Jan-Eric] Karolinska Inst, Stockholm, Sweden. [Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia. [Ollier, Bill] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Integrated Genom Med Res, Manchester, Lancs, England. [Palmer, Lyle J.] Ontario Inst Canc Res, Toronto, ON, Canada. [Palmer, Lyle J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Palotie, Aarno] Wellcome Trust Sanger Inst, Hinxton, S Cambs, England. [Palotie, Aarno] Univ Helsinki, Helsinki, Finland. [Palotie, Aarno] Broad Inst MIT & Harvard, Cambridge, MA USA. [Perola, Markus] Natl Inst Hlth & Welf, Helsinki, Finland. [Riegman, Peter H. J.] Erasmus MC, Josephine Nefkens Inst, Dept Pathol, Rotterdam, Netherlands. [van Ommen, Gert-Jan] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands. [van Ommen, Gert-Jan] Ctr Med Syst Biol, Leiden, Netherlands. [Zatloukal, Kurt] Med Univ Graz, Graz, Austria. RP Harris, JR (reprint author), Norwegian Inst Publ Hlth, Dept Genes & Environm, Div Epidemiol, Post Box 4404 Nydalen, N-0403 Oslo, Norway. EM Jennifer.harris@fhi.no RI Palmer, Lyle/K-3196-2014; Hainaut, Pierre /B-6018-2012; Burton, Paul/H-7527-2016; Pasterk, Markus/A-6588-2011 OI Palmer, Lyle/0000-0002-1628-3055; Hainaut, Pierre /0000-0002-1303-1610; Yuille, Martin/0000-0002-4992-5405; Budin-Ljosne, Isabelle/0000-0002-4610-1662; Pasterk, Markus/0000-0002-6127-3323 FU European Union's Seventh Framework Programme (FP7); ENGAGE Consortium [HEALTH-F4-2007-201413]; BioSHaRE-EU [HEALTH-F4-2010-261433]; Biobank Norway - a national infrastructure for biobanks and biobank-related activity in Norway; Norwegian Research Council [NFR 197443/F50]; Public Population Project in Genomics (P3G) and biobanking-related work from FP7 Grant [212111]; Austrian Genome Programme GEN-AU; Canada Research Chair in Law and Medicine; Genome Canada/Genome Quebec GJBvO; Ministry of Education; Netherlands Organization for Scientific Research NWO for the establishment of BBMRI-NL; Netherlands Biobanking infrastructure; Swedish Research Council Grant [8292009-6285]; EU RDF Centre of Excellence in Genomics; The Estonian Biobank at EGC University of Tartu; Ministry of Social Affairs and Ministry of Education and Research and EU FP7 project OPENGENE; Wellcome Trust [096599/2/11/Z]; The Medical Research Council (UDBN, COPDmap); IMI (U-biopred); Technology Strategy Board (STRATUM, ACROPOLIS); The Medical Research Council (COPDmap) EU FP7; GEN2PHEN [200754] FX This work was supported through funds from the European Union's Seventh Framework Programme (FP7/2007-2013), ENGAGE Consortium, grant agreement HEALTH-F4-2007-201413 to JRH and IBL; BioSHaRE-EU, grant agreement HEALTH-F4-2010-261433 to JRH, PB, AJB, and IBL; through funds from Biobank Norway - a national infrastructure for biobanks and biobank-related activity in Norway - funded by the Norwegian Research Council (NFR 197443/F50) to JRH and IBL. We thank the contribution of the Public Population Project in Genomics (P3G) and biobanking-related work from FP7 Grant Agreement number: 212111 (BBMRI) to KZ, and MY, and the Austrian Genome Programme GEN-AU to KZ. BMK acknowledges the Canada Research Chair in Law and Medicine; Genome Canada/Genome Quebec GJBvO gratefully acknowledges support by a grant from the Ministry of Education, through the Netherlands Organization for Scientific Research NWO for the establishment of BBMRI-NL, a consolidated Netherlands Biobanking infrastructure. JEL gratefully acknowledges support by The Swedish Research Council Grant agreement 8292009-6285 for the BBMRI. SE project. AM was supported by EU RDF Centre of Excellence in Genomics; The Estonian Biobank at EGC University of Tartu is funded by Ministry of Social Affairs and Ministry of Education and Research and EU FP7 project OPENGENE. Other sources of support for this work are the Wellcome Trust 096599/2/11/Z to JK, The Medical Research Council (UDBN, COPDmap), IMI (U-biopred) and Technology Strategy Board (STRATUM, ACROPOLIS) to MY, and The Medical Research Council (COPDmap) EU FP7 and (GEN2PHEN (Grant # 200754) to AJB. NR 40 TC 58 Z9 60 U1 1 U2 25 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD NOV PY 2012 VL 20 IS 11 BP 1105 EP 1111 DI 10.1038/ejhg.2012.96 PG 7 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 025TW UT WOS:000310218600002 PM 22713808 ER PT J AU Ahluwalia, SC Gordon, HS AF Ahluwalia, Sangeeta C. Gordon, Howard S. TI Advance Care Planning Safeguards SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Letter C1 [Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Gordon, Howard S.] Univ Illinois, Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA. RP Ahluwalia, SC (reprint author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,111-G, Los Angeles, CA 90073 USA. EM sangeeta.ahluwalia@va.gov RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 3 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2012 VL 27 IS 11 BP 1404 EP 1404 DI 10.1007/s11606-012-2190-6 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 025CJ UT WOS:000310161500005 PM 22878859 ER PT J AU Morris, DA Johnson, KS Ammarell, N Arnold, RM Tulsky, JA Steinhauser, KE AF Morris, Deborah A. Johnson, Kimberly S. Ammarell, Natalie Arnold, Robert M. Tulsky, James A. Steinhauser, Karen E. TI What is Your Understanding of Your Illness? A Communication Tool to Explore Patients' Perspectives of Living with Advanced Illness SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE communication; qualitative research; advanced illness; patient-centered care; palliative care ID OBSTRUCTIVE PULMONARY-DISEASE; OF-LIFE CARE; BREAKING BAD-NEWS; ADVANCED CANCER; HEART-FAILURE; PALLIATIVE-CARE; PROGNOSIS; AWARENESS; PREFERENCES; INFORMATION AB Provider communication courses and guidelines stress the use of open-ended questions, such as "what is your understanding of your illness?," to explore patients' perceptions of their illness severity, yet descriptions of patients' responses are largely absent from the current literature. These questions are most often used by clinicians as they deliver bad news to cancer patients or address code status at the end of life, but have not been well studied in other diseases or earlier in the disease course. To explore the responses of patients living with serious illness to the question "what is your understanding of your illness?" and to identify similarities and differences in themes and language used by cancer and non-cancer patients to discuss their illness. We conducted a qualitative analysis of patients' responses to "what is your understanding of your illness?" Two hundred nine subjects, 69 with cancer, 70 CHF, and 70 COPD, who had an estimated 50 % 2-year survival. Mean age was 66 years. Responses were recorded at the baseline interview of a larger, longitudinal study of patients with advanced life-limiting illness (cancer, CHF, or COPD). After thematic content analysis using open coding, investigators conducted pattern analysis to examine variation associated with diagnosis. We identified five major themes: naming the diagnosis or describing the pathophysiology, illness history, prognosis, symptoms, and causality. Responses varied by diagnosis. Cancer patients' responses more often included specific diagnostic details and prognosis, while non-cancer patients referenced symptoms and causality. Patients' responses to the open-ended question "what is your understanding of your illness?" can provide the clinician with important information and insight on how they view their illness in a non-acute setting. The identified themes can serve as a foundation for patient-centered communication strategies as we strive to build a mutual understanding of illness with patients. C1 [Morris, Deborah A.] VA Med Ctr, Durham, NC 27701 USA. [Morris, Deborah A.] Duke Med Ctr, Durham, NC 27701 USA. [Morris, Deborah A.; Johnson, Kimberly S.; Ammarell, Natalie; Tulsky, James A.; Steinhauser, Karen E.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Johnson, Kimberly S.] Durham Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Durham, NC USA. [Tulsky, James A.; Steinhauser, Karen E.] Duke Univ, Ctr Palliat Care, Durham, NC USA. [Morris, Deborah A.; Johnson, Kimberly S.; Tulsky, James A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA. [Johnson, Kimberly S.] Duke Univ, Sch Med, Div Geriatr, Durham, NC USA. [Ammarell, Natalie; Tulsky, James A.] Duke Univ, Sch Nursing, Durham, NC USA. [Arnold, Robert M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Arnold, Robert M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Morris, DA (reprint author), VA Med Ctr, 411 W Chapel Hill St,Suite 500, Durham, NC 27701 USA. EM damorri1@gmail.com FU Durham NC VA Medical Center; NIH/NINR RFP [PA-00-127]; Beeson Career Development Award in Aging Research [5K08AG028975] FX This material is the result of work supported with resources and the use of facilities at the Durham NC VA Medical Center. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.; This research was supported by a grant from the NIH/NINR RFP PA-00-127 "Trajectories of Serious Illness Patients and Caregivers" and the 5K08AG028975 Beeson Career Development Award in Aging Research (KSJ). NR 37 TC 6 Z9 7 U1 1 U2 24 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2012 VL 27 IS 11 BP 1460 EP 1466 DI 10.1007/s11606-012-2109-2 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 025CJ UT WOS:000310161500014 PM 22638605 ER PT J AU Roy, B Castiglioni, A Kraemer, RR Salanitro, AH Willett, LL Shewchuk, RM Qu, HY Heudebert, G Centor, RM AF Roy, Brita Castiglioni, Analia Kraemer, Ryan R. Salanitro, Amanda H. Willett, Lisa L. Shewchuk, Richard M. Qu, Haiyan Heudebert, Gustavo Centor, Robert M. TI Using Cognitive Mapping to Define Key Domains for Successful Attending Rounds SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medical education; clinical teaching; ward rounds ID NOMINAL GROUP TECHNIQUE; WARD ROUNDS; MEDICINE; PHYSICIAN; RESIDENTS; ATTITUDES; TEACHER AB Ward attending rounds are an integral part of internal medicine education. Being a good teacher is necessary, but not sufficient for successful rounds. Understanding perceptions of successful attending rounds (AR) may help define key areas of focus for enhancing learning, teaching and patient care. We sought to expand the conceptual framework of 30 previously identified attributes contributing to successful AR by: 1) identifying the most important attributes, 2) grouping similar attributes, and 3) creating a cognitive map to define dimensions and domains contributing to successful rounds. Multi-institutional, cross-sectional study design. We recruited residents and medical students from a university-based internal medicine residency program and a community-based family medicine residency program. Faculty attending a regional general medicine conference, affiliated with multiple institutions, also participated. Participants performed an unforced card-sorting exercise, grouping attributes based on perceived similarity, then rated the importance of attributes on a 5-point Likert scale. We translated our data into a cognitive map through multi-dimensional scaling and hierarchical cluster analysis. Thirty-six faculty, 49 residents and 40 students participated. The highest rated attributes (mean rating) were "Teach by example (bedside manner)" (4.50), "Sharing of attending's thought processes" (4.46), "Be approachable-not intimidating" (4.45), "Insist on respect for all team members" (4.43), "Conduct rounds in an organized, efficient & timely fashion" (4.39), and "State expectations for residents/students" (4.37). Attributes were plotted on a two-dimensional cognitive map, and adequate convergence was achieved. We identified five distinct domains of related attributes: 1) Learning Atmosphere, 2) Clinical Teaching, 3) Teaching Style, 4) Communicating Expectations, and 5) Team Management. We identified five domains of related attributes essential to the success of ward attending rounds. C1 [Roy, Brita] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA. [Castiglioni, Analia; Heudebert, Gustavo; Centor, Robert M.] Birmingham VA Med Ctr, Birmingham, AL USA. [Salanitro, Amanda H.] Tennessee Valley Healthcare Syst Geriatr Res Educ, Dept Vet Affairs, Nashville, TN USA. [Salanitro, Amanda H.] Vanderbilt Univ, Sect Hosp Med, Nashville, TN USA. [Willett, Lisa L.] Univ Alabama Birmingham, Dept Med, Div Gen Internal Med, Birmingham, AL 35294 USA. [Shewchuk, Richard M.; Qu, Haiyan] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL USA. [Heudebert, Gustavo] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. RP Roy, B (reprint author), Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA. EM britaroy@uab.edu NR 21 TC 11 Z9 11 U1 1 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2012 VL 27 IS 11 BP 1492 EP 1498 DI 10.1007/s11606-012-2121-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 025CJ UT WOS:000310161500018 PM 22722975 ER PT J AU Huetsch, JC Uman, JE Udris, EM Au, DH AF Huetsch, John C. Uman, Jane E. Udris, Edmunds M. Au, David H. TI Predictors of Adherence to Inhaled Medications Among Veterans with COPD SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medication adherence; pulmonary diseases; health behavior; veterans ID OBSTRUCTIVE PULMONARY-DISEASE; REFILL ADHERENCE; NONADHERENCE; SALMETEROL; THERAPY; FLUTICASONE; PERSISTENCE; TRIAL; DRUGS AB Factors contributing to medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) are poorly understood. To identify patient characteristics that are predictive of adherence to inhaled medications for COPD and, for patients on multiple inhalers, to assess whether adherence to one medication class was associated with adherence to other medication classes. Cohort study using data from Veteran Affairs (VA) electronic databases. This study included 2,730 patients who underwent pulmonary function testing between 2003 and 2007 at VA facilities in the Northwestern United States, and who met criteria for COPD. We used pharmacy records to estimate adherence to inhaled corticosteroids (ICS), ipratropium bromide (IP), and long-acting beta-agonists (LABA) over two consecutive six month periods. We defined patients as adherent if they had refilled medications to have 80 % of drug available over the time period. We also collected information on their demographics, behavioral habits, COPD severity, and comorbidities. Adherence to medications was poor, with 19.8 % adherent to ICS, 30.6 % adherent to LABA, and 25.6 % adherent to IP. Predictors of adherence to inhaled therapies were highly variable and dependent on the medication being examined. In adjusted analysis, being adherent to a medication at baseline was the strongest predictor of future adherence to that same medication [(Odds ratio, 95 % confidence interval) ICS: 4.79 (3.22-7.12); LABA: 6.60 (3.92-11.11); IP: 14.13 (10.00-19.97)], but did not reliably predict adherence to other classes of medication. Among patients with COPD, past adherence to one class of inhaled medication strongly predicted future adherence to the same class of medication, but only weakly predicted adherence to other classes of medication. C1 [Huetsch, John C.; Uman, Jane E.; Udris, Edmunds M.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Huetsch, John C.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM dau@uw.edu FU American Lung Association [CI-51755N]; HSR&D, VA Puget Sound Health Care System; NHLBI; AHRQ; Department of Veterans Affairs; Gilead Sciences FX This project was funded by the American Lung Association, grant # CI-51755N. Dr. Au was funded by HSR&D, VA Puget Sound Health Care System. The views expressed in this manuscript are those of the authors and do not necessarily represent the opinions of the Department of Veterans Affairs.; Dr. Huetsch, Mr. Udris, and Ms. Uman report no conflicts of interest. Dr. Au is a research advisor for Bosch. He also receives grants from NHLBI, AHRQ, the Department of Veterans Affairs, and Gilead Sciences. NR 29 TC 14 Z9 15 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2012 VL 27 IS 11 BP 1506 EP 1512 DI 10.1007/s11606-012-2130-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 025CJ UT WOS:000310161500020 PM 22782274 ER PT J AU Patel, MS Volpp, KG AF Patel, Mitesh S. Volpp, Kevin G. TI Leveraging Insights from Behavioral Economics to Increase the Value of Health-Care Service Provision SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health-care costs; health-care value; restaurant food labeling; asymmetric paternalism; nudges ID RESTAURANTS; CHARGES; CHOICES AB United States health expenditures continue to escalate at unsustainable rates. A recent movement around increasing price transparency has been suggested as a way of reducing the rate of increase in expenditures, with legislative efforts taking place at both the state and federal level. While this seems on the surface like a good idea, simply providing information on prices to physicians, particularly trainees, may not achieve the type of large changes in practice patterns that proponents expect. The manner in which price transparency is implemented will likely play a significant role in its effectiveness as an intervention. In this article, the authors review efforts of transparency and default options from other contexts and leverage insights from behavioral economics to provide recommendations for increasing the likelihood that price transparency will lead to physicians weighing the relative value of interventions. C1 [Patel, Mitesh S.; Volpp, Kevin G.] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Patel, MS (reprint author), Hosp Univ Penn, Dept Med, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA. EM Mitesh.Patel@uphs.upenn.edu NR 24 TC 9 Z9 9 U1 4 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2012 VL 27 IS 11 BP 1544 EP 1547 DI 10.1007/s11606-012-2050-4 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 025CJ UT WOS:000310161500024 PM 22549296 ER PT J AU Khan, M Dhammu, TS Sakakima, H Shunmugavel, A Gilg, AG Singh, AK Singh, I AF Khan, Mushfiquddin Dhammu, Tajinder S. Sakakima, Harutoshi Shunmugavel, Anadakumar Gilg, Anne G. Singh, Avtar K. Singh, Inderjit TI The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE BBB; endothelial dysfunction; GSNO; ischemia reperfusion; peroxynitrite; S-nitrosylation ID FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ACID PHENETHYL ESTER; NEUROPROTECTIVE EFFICACY; PLATELET ACTIVATION; NITROSO-GLUTATHIONE; NEUROVASCULAR UNIT; ENDOTHELIAL-CELLS; DOPAMINE NEURONS AB The hallmark of stroke injury is endothelial dysfunction leading to bloodbrain barrier (BBB) leakage and edema. Among the causative factors of BBB disruption are accelerating peroxynitrite formation and the resultant decreased bioavailability of nitric oxide (NO). S-nitrosoglutathione (GSNO), an S-nitrosylating agent, was found not only to reduce the levels of peroxynitrite but also to protect the integrity of BBB in a rat model of cerebral ischemia and reperfusion (IR). A treatment with GSNO (3 mu mol/kg) after IR reduced 3-nitrotyrosine levels in and around vessels and maintained NO levels in brain. This mechanism protected endothelial function by reducing BBB leakage, increasing the expression of Zonula occludens-1 (ZO-1), decreasing edema, and reducing the expression of matrix metalloproteinase-9 and E-selectin in the neurovascular unit. An administration of the peroxynitrite-forming agent 3-morpholino sydnonimine (3 mu mol/kg) at reperfusion increased BBB leakage and decreased the expression of ZO-1, supporting the involvement of peroxynitrite in BBB disruption and edema. Mechanistically, the endothelium-protecting action of GSNO was invoked by reducing the activity of nuclear factor kappa B and increasing the expression of S-nitrosylated proteins. Taken together, the results support the ability of GSNO to improve endothelial function by reducing nitroxidative stress in stroke. C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Sakakima, Harutoshi; Shunmugavel, Anadakumar; Gilg, Anne G.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu FU NIH [NS-72511, NS-22576, NS-37766]; Veteran Administration; NIH from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR018823, C06 RR015455] FX These studies were supported by grants from NIH (NS-72511, NS-22576 and NS-37766) and Veteran Administration merit awards. This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We are grateful to Dr. Tom Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript. The authors have no conflict of interest and have not received grants etc. from any commercial body. NR 61 TC 19 Z9 19 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD NOV PY 2012 VL 123 SU 2 SI SI BP 86 EP 97 DI 10.1111/j.1471-4159.2012.07947.x PG 12 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 019LK UT WOS:000309740900010 PM 23050646 ER PT J AU Stetler, RA Leak, RK Yin, W Zhang, LL Wang, SP Gao, YQ Chen, J AF Stetler, R. Anne Leak, Rehana K. Yin, Wei Zhang, Lili Wang, Suping Gao, Yanqin Chen, Jun TI Mitochondrial biogenesis contributes to ischemic neuroprotection afforded by LPS pre-conditioning SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE ischemia; ischemic tolerance; mitochondrial biogenesis; neurons; pre-conditioning ID RESPIRATORY FACTOR-I; TOLL-LIKE RECEPTORS; BRAIN-INJURY; NEONATAL-RAT; NEURONS; LIPOPOLYSACCHARIDE; ACTIVATION; GROWTH; DYSFUNCTION; RESISTANCE AB Although alterations in mitochondrial dynamics are associated with cellular responses to injury, the functional role of these dynamic changes in ischemic neurons is underexplored. One of these dynamic responses to injury includes mitochondrial biogenesis. Various sublethal pre-conditioning stimuli that induce an ischemic-tolerant state [e.g., lipopolysaccharide (LPS)] may also induce mitochondrial biogenesis. Using neuron-enriched cultures, we found that sublethal LPS pre-conditioning induced both ischemic tolerance and markers of mitochondrial biogenesis with overlapping doseresponse temporal kinetics. Sublethal LPS transiently increased the expression of critical components of the mitochondrial transcriptional machinery, including nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM), as well as mtDNA copy number, mitochondrial protein levels, and markers of functional mitochondria, such as increased cellular ATP content, citrate synthase activity, and maximal respiration capacity. Importantly, knockdown of TFAM abrogated both the induction of mitochondrial biogenesis and the neuroprotective pre-conditioning effects of LPS. Several signaling pathways coordinated these events. AMPK inhibition suppressed NRF1 and TFAM expression by LPS, whereas PI3K/Akt signaling was necessary for the nuclear translocation of NRF1 and subsequent induction of TFAM. This is the first demonstration that LPS pre-conditioning initiates multiple signaling pathways leading to mitochondrial biogenesis in neurons and that these dynamic changes contribute to ischemic tolerance. C1 [Stetler, R. Anne; Yin, Wei; Zhang, Lili; Wang, Suping; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Stetler, R. Anne; Zhang, Lili; Gao, Yanqin; Chen, Jun] State Key Lab Med Neurobiol, Shanghai, Peoples R China. [Stetler, R. Anne; Zhang, Lili; Gao, Yanqin; Chen, Jun] Inst Brain Sci, Shanghai, Peoples R China. [Stetler, R. Anne; Wang, Suping; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Stetler, R. Anne; Yin, Wei; Zhang, Lili; Wang, Suping; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. EM stetlerra@upmc.edu; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417 FU NIH/NINDS [NS43802, NS45048, NS36736, NS56118]; Chinese Natural Science Foundation [30670642, 30870794, 81020108021]; VA Career Scientist Award FX This project was supported by NIH/NINDS grants NS43802, NS45048, NS36736, and NS56118 (to J.C.); and Chinese Natural Science Foundation grants 30670642, 30870794, and 81020108021 (to Y.G.). J.C. is the RK Mellon Endowed Chair of UPMC and a recipient of the VA Career Scientist Award. We thank Pat Strickler for excellent secretarial support. NR 43 TC 14 Z9 16 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD NOV PY 2012 VL 123 SU 2 SI SI BP 125 EP 137 DI 10.1111/j.1471-4159.2012.07951.x PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 019LK UT WOS:000309740900014 PM 23050650 ER PT J AU Bourdette, D Yadav, V AF Bourdette, Dennis Yadav, Vijayshree TI Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: No SO MULTIPLE SCLEROSIS JOURNAL LA English DT Editorial Material ID UNSUSPECTED MULTIPLE-SCLEROSIS C1 [Bourdette, Dennis; Yadav, Vijayshree] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Bourdette, Dennis; Yadav, Vijayshree] Portland VA Med Ctr, MS Ctr Excellence W, Portland, OR USA. RP Bourdette, D (reprint author), Oregon Hlth & Sci Univ, Dept Neurol L226, Portland, OR 97239 USA. EM bourdett@ohsu.edu NR 10 TC 6 Z9 6 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER J JI Mult. Scler. J. PD NOV PY 2012 VL 18 IS 11 BP 1529 EP 1530 DI 10.1177/1352458512462075 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 026BM UT WOS:000310245100005 PM 23100523 ER PT J AU Stelmack, JA Tang, XYC Reda, DJ Stroupe, KT Rinne, S Massof, RW AF Stelmack, Joan A. Tang, Xiaoyin C. Reda, Domenic J. Stroupe, Kevin T. Rinne, Stephen Massof, Robert W. CA LOVIT II Study Grp TI VA LOVIT II: a protocol to compare low vision rehabilitation and basic low vision SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS LA English DT Article DE low vision; low vision rehabilitation; reading rehabilitation; vision rehabilitation ID QUALITY-OF-LIFE; VISUAL FUNCTIONING QUESTIONNAIRE; INTERVENTION TRIAL LOVIT; VETERANS-AFFAIRS; IMPAIRED VISION; MACULAR DEGENERATION; OLDER-PEOPLE; DEPRESSION; OUTCOMES; HEALTH AB Citation information: Stelmack JA, Tang XC, Reda DJ, Stroupe KT, Rinne S & Massof RW. VA LOVIT II: a protocol to compare low vision rehabilitation and basic low vision. Ophthalmic Physiol Opt 2012, 32, 461471. doi: 10.1111/j.1475-1313.2012.00933.x Abstract Purpose: To compare the effectiveness of low vision rehabilitation (LVR) and basic low vision (LV) in a single masked multicentre randomised controlled trial (RCT). Methods: Three hundred and thirty patients eligible for US. Veterans Affairs (VA) healthcare services with primary eye diagnosis (better-seeing eye) of macular disease and best-corrected distance visual acuity of 0.401.00 logMAR (6/15 to 6/60 or 20/50 to 20/200 Snellen) are being enrolled at seven VA facilities. All participants receive an optometric LV examination; and they are eligible to receive the same LV devices that are provided without charge. In LVR, a LV therapist dispenses devices and provides 2 or 3 (1(1/2) to 2(1/2) h) therapy sessions with assigned homework to teach effective use of remaining vision and LV devices. Contact time with the therapist depends upon the devices prescribed and the patients progress in learning the skills that are taught. In basic LV, devices are dispensed by the optometrist without LV therapy. Contact time for dispensing is one hour or less depending on LV devices prescribed. The primary outcome measure is a comparison of the changes in visual reading ability (estimated from patients difficulty ratings of reading items on the VA LV VFQ-48 questionnaire) between the treatment and control arms from pre-intervention baseline to 4 months (2 months after completion of treatment). Secondary outcome measures are changes in overall visual ability, visual ability domain scores calculated from subsets of items (mobility, visual information processing and visual motor skills), Short Form-36, and Minnesota Low Vision Reading Test scores. Cost-effectiveness analysis will be conducted using VA LV VFQ-48 scores and QALYS computed from EuroQol scores. Results: A total of 137 patients representing 41.5% of the study target of 330 patients were randomised from October 2010 to March 2012. Among those 137 patients, mean age was 80.2 (S.D. +/- 9.9) years at enrollment; 97.1% of the patients were males; 94.2% were white. Mean best corrected VA was 0.65 (S.D. +/- 0.3) logMAR (approximately Snellen 6/27 or 20/90) at baseline. Conclusions: LOVIT II is the first multicentre RCT comparing the effectiveness and cost-effectiveness of LVR and basic LV for patients with macular diseases and near normal or moderate levels of visual impairment. C1 [Stelmack, Joan A.; Tang, Xiaoyin C.; Reda, Domenic J.; Stroupe, Kevin T.; Rinne, Stephen] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Stelmack, Joan A.] Univ Illinois, Chicago Sch Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA. [Stelmack, Joan A.; Rinne, Stephen] Illinois Coll Optometry, Chicago, IL USA. [Massof, Robert W.] Johns Hopkins Wilmer Eye Inst, Baltimore, MD USA. RP Stelmack, JA (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM joan.stelmack@med.va.gov RI Raasch, Thomas/A-3588-2013 FU Department of Veterans Affairs Rehabilitation Research and Development Service [C958R] FX Funding for this research was provided by the Department of Veterans Affairs Rehabilitation Research and Development Service grant C958R. NR 42 TC 5 Z9 5 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0275-5408 J9 OPHTHAL PHYSL OPT JI Ophthalmic Physiol. Opt. PD NOV PY 2012 VL 32 IS 6 BP 461 EP 471 DI 10.1111/j.1475-1313.2012.00933.x PG 11 WC Ophthalmology SC Ophthalmology GA 019NW UT WOS:000309747600004 PM 22958237 ER PT J AU Paik, DY Janzen, DM Schafenacker, AM Velasco, VS Shung, MS Cheng, DH Huang, JT Witte, ON Memarzadeh, S AF Paik, Daniel Y. Janzen, Deanna M. Schafenacker, Amanda M. Velasco, Victor S. Shung, May S. Cheng, Donghui Huang, Jiaoti Witte, Owen N. Memarzadeh, Sanaz TI Stem-Like Epithelial Cells Are Concentrated in the Distal End of the Fallopian Tube: A Site for Injury and Serous Cancer Initiation SO STEM CELLS LA English DT Article DE Adult stem cells; Clonal assays; Self-renewal; Tissue-specific stem cells ID CILIARY BEAT FREQUENCY; OVARIAN-CANCER; PROSTATE-CANCER; MENSTRUAL-CYCLE; ELECTRON-MICROSCOPY; COLORECTAL-CANCER; ANDROGEN RECEPTOR; MULLERIAN DUCT; ORIGIN; MOUSE AB The reproductive role of the fallopian tube is to transport the sperm and egg. The tube is positioned to act as a bridge between the ovary where the egg is released and the uterus where implantation occurs. Throughout reproductive years, the fallopian tube epithelium undergoes repetitive damage and regeneration. Although a reservoir of adult epithelial stem cells must exist to replenish damaged cells, they remain unidentified. Here, we report isolation of a subset of basally located human fallopian tube epithelia (FTE) that lack markers of ciliated (beta-tubulin; TUBB4) or secretory (PAX8) differentiated cells. These undifferentiated cells expressed cell surface antigens: epithelial cell adhesion molecule, CD44, and integrin a 6. This FTE subpopulation was fivefold enriched for cells capable of clonal growth and self-renewal suggesting that they contain the FTE stem-like cells (FTESCs). A twofold enrichment of the FTESC was found in the distal compared to the proximal end of the tube. The distal fimbriated end of the fallopian tube is a well-characterized locus for initiation of serous carcinomas. An expansion of the cells expressing markers of FTESC was detected in tubal intraepithelial carcinomas and in fallopian tubes from patients with invasive serous cancer. These findings suggest that FTESC may play a role in the initiation of serous tumors. Characterization of these stem-like cells will provide new insight into how the FTE regenerate, respond to injury, and may initiate cancer. STEM CELLS2012;30:24872497 C1 [Witte, Owen N.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Paik, Daniel Y.; Janzen, Deanna M.; Schafenacker, Amanda M.; Velasco, Victor S.; Shung, May S.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Dept Obstet & Gynecol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Cheng, Donghui; Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA. [Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, 610 Charles E Young Dr E,3017 Terasaki Life Sci B, Los Angeles, CA 90095 USA. EM smemarzadeh@mednet.ucla.edu FU Veteran Affairs CDA-2 Career Development Award; Mary Kay Foundation Award; Prostate Cancer Foundation Young Investigators Award; STOP Cancer Award; Broad Stem Cell Research Center Research Award; Liz Tilberis Scholars Program from the Ovarian Cancer Research Fund, Inc.; Gynecologic Cancer Foundation St. Louis Ovarian Cancer Awareness Research Grant; Ovarian Cancer Circle FX We thank Brooke Nakamura for technical support. We thank Drs. Andrew Goldstein and Yang Zong for helpful conversations related to this project. We thank the UCLA Tissue Procurement Core Laboratory for their assistance in providing human fallopian tube specimens. S. M. is supported by a Veteran Affairs CDA-2 Career Development Award, a gift from the Scholars in Translational Medicine Program, Mary Kay Foundation Award, Prostate Cancer Foundation Young Investigators Award, STOP Cancer Award, and the Broad Stem Cell Research Center Research Award. This work was also supported by the Liz Tilberis Scholars Program from the Ovarian Cancer Research Fund, Inc., the Gynecologic Cancer Foundation St. Louis Ovarian Cancer Awareness Research Grant, and the Ovarian Cancer Circle inspired by Robin Babbini. O.N.W. is a Howard Hughes Medical Institute investigator. NR 52 TC 35 Z9 37 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 J9 STEM CELLS JI Stem Cells PD NOV PY 2012 VL 30 IS 11 BP 2487 EP 2497 DI 10.1002/stem.1207 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 023ZP UT WOS:000310077000013 PM 22911892 ER PT J AU Kilbourne, AM Greenwald, DE Bauer, MS Charns, MP Yano, EM AF Kilbourne, Amy M. Greenwald, Devra E. Bauer, Mark S. Charns, Martin P. Yano, Elizabeth M. TI Mental Health Provider Perspectives Regarding Integrated Medical Care for Patients with Serious Mental Illness SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Integrated care; Serious mental illness; Quality of care ID QUALITY-OF-CARE; BIPOLAR DISORDER; VETERANS-AFFAIRS; PROGRAMS; DISEASE; ACCESS; SATISFACTION; INCENTIVES; CONTINUITY; SERVICES AB Integrated care for medical conditions is essential for persons with serious mental illness (SMI). This qualitative study describes mental health provider perspectives regarding barriers and facilitators of integrated care for patients with SMI. We interviewed providers from a national sample of Veterans Health Administration facilities that scored in the top or bottom percentile in medical care quality. Providers from high-performing sites reported substantial in-person contacts with general medical providers, while providers from low-performing sites reported stigma and limited communication with medical providers as major concerns. Interventions to improve mental health and medical provider communication may facilitate integrated care for persons with SMI. C1 [Kilbourne, Amy M.] VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Greenwald, Devra E.] VA Pittsburgh Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Bauer, Mark S.; Charns, Martin P.] VA Boston Ctr Org Management & Leadership Res COL, Boston, MA USA. [Bauer, Mark S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Charns, Martin P.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, VA Greater Angeles HSR&D, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Kilbourne, AM (reprint author), VA Ann Arbor Ctr Clin Management Res, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM amykilbo@umich.edu OI Charns, Martin/0000-0002-7102-5331 NR 42 TC 9 Z9 9 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD NOV PY 2012 VL 39 IS 6 BP 448 EP 457 DI 10.1007/s10488-011-0365-9 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 021CM UT WOS:000309862900004 PM 21735302 ER PT J AU Kim, K Brown, EE Choi, CB Alarc, ME Kelly, JA Glenn, SB Ojwang, JO Adler, A Lee, HS Boackle, SA Criswell, LA Alarc, GS Edberg, JC Stevens, AM Jacob, CO Gilkeson, GS Kamen, DL Tsao, BP Anaya, JM Guthridge, JM Nath, SK Richardson, B Sawalha, AH Kang, YM Shim, SC Suh, CH Lee, SK Kim, CS Merrill, JT Petri, M Ramsey-Goldman, R Vil, LM Niewold, TB Martin, J Pons-Estel, BA Vyse, TJ Freedman, BI Moser, KL Gaffney, PM Williams, A Comeau, M Reveille, JD James, JA Eld, RHS Langefeld, CD Kaufman, KM Harley, JB Kang, C Kimberly, RP Bae, SC AF Kim, Kwangwoo Brown, Elizabeth E. Choi, Chan-Bum Alarc, Marta E. Kelly, Jennifer A. Glenn, Stuart B. Ojwang, Joshua O. Adler, Adam Lee, Hye-Soon Boackle, Susan A. Criswell, Lindsey A. Alarc, Graciela S. Edberg, Jeffrey C. Stevens, Anne M. Jacob, Chaim O. Gilkeson, Gary S. Kamen, Diane L. Tsao, Betty P. Anaya, Juan-Manuel Guthridge, Joel M. Nath, Swapan K. Richardson, Bruce Sawalha, Amr H. Kang, Young Mo Shim, Seung Cheol Suh, Chang-Hee Lee, Soo-Kon Kim, Chang-sik Merrill, Joan T. Petri, Michelle Ramsey-Goldman, Rosalind Vil, Luis M. Niewold, Timothy B. Martin, Javier Pons-Estel, Bernardo A. Vyse, Timothy J. Freedman, Barry I. Moser, Kathy L. Gaffney, Patrick M. Williams, Adrienne Comeau, Mary Reveille, John D. James, Judith A. Eld, R. Hal Sco Langefeld, Carl D. Kaufman, Kenneth M. Harley, John B. Kang, Changwon Kimberly, Robert P. Bae, Sang-Cheol CA BIOLUPUS GENLES TI Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID INTERCELLULAR-ADHESION MOLECULE-1; FUNCTIONAL VARIANT; DISEASE-ACTIVITY; CELL-ADHESION; INTEGRIN; ITGAM; GENE; EXPRESSION; METAANALYSIS; SELECTIN AB Objective Systemic lupus erythematosus (SLE; OMIM 152700) is a chronic autoimmune disease for which the aetiology includes genetic and environmental factors. ITGAM, integrin a. (complement component 3 receptor 3 subunit) encoding a ligand for intracellular adhesion molecule (ICAM) proteins, is an established SLE susceptibility locus. This study aimed to evaluate the independent and joint effects of genetic variations in the genes that encode ITGAM and ICAM. Methods The authors examined several markers in the ICAM1-ICAM4-ICAM5 locus on chromosome 19p13 and the single ITGAM polymorphism (rs1143679) using a large-scale case-control study of 17 481 unrelated participants from four ancestry populations. The single-marker association and gene-gene interaction were analysed for each ancestry, and a meta-analysis across the four ancestries was performed. Results The A-allele of ICAM1-ICAM4-ICAM5 rs3093030, associated with elevated plasma levels of soluble ICAM1, and the A-allele of ITGAM rs1143679 showed the strongest association with increased SLE susceptibility in each of the ancestry populations and the trans-ancestry meta-analysis (ORmeta = 1.16, 95% CI 1.11 to 1.22; p = 4.88 x 10(-10) and ORmeta = 1.67, 95% CI 1.55 to 1.79; p = 3.32 x 10(-46), respectively). The effect of the ICAM single-nucleotide polymorphisms (SNPs) was independent of the effect of the ITGAM SNP rs1143679, and carriers of both ICAM rs3093030-AA and ITGAM rs1143679-AA had an OR of 4.08 compared with those with no risk allele in either SNP (95% CI 2.09 to 7.98; p = 3.91 x 10(-5)). Conclusion These findings are the first to suggest that an ICAM-integrin-mediated pathway contributes to susceptibility to SLE. C1 [Kim, Kwangwoo; Kang, Changwon] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea. [Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Med, Dept Epidemiol, Birmingham, AL 35294 USA. [Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA. [Choi, Chan-Bum; Lee, Hye-Soon; Bae, Sang-Cheol] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul 133792, South Korea. [Alarc, Marta E.; Kelly, Jennifer A.; Glenn, Stuart B.; Ojwang, Joshua O.; Adler, Adam; Guthridge, Joel M.; Nath, Swapan K.; Sawalha, Amr H.; Merrill, Joan T.; Moser, Kathy L.; Gaffney, Patrick M.; Kaufman, Kenneth M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Alarc, Marta E.; BIOLUPUS] Univ Granada Junta de Andaluca, Area Human DNA Variabil, Ctr Gen & Invest Oncol GENYO, Granada, Spain. [Boackle, Susan A.] Univ Colorado, Div Rheumatol, Denver Sch Med, Aurora, CO USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA 94143 USA. [Stevens, Anne M.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Jacob, Chaim O.] Univ So Calif, Lupus Genet Grp, Los Angeles, CA USA. [Gilkeson, Gary S.; Kamen, Diane L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Anaya, Juan-Manuel] Univ Nacl Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia. [Richardson, Bruce] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Richardson, Bruce] US Dept Vet Affairs, Med Ctr, Ann Arbor, MI USA. [Sawalha, Amr H.; James, Judith A.; Eld, R. Hal Sco] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Sawalha, Amr H.; Kaufman, Kenneth M.] US Dept Vet Affairs, Dept Med, Med Ctr, Oklahoma City, OK USA. [Kang, Young Mo] Kyungpook Natl Univ, Dept Internal Med Rheumatol, Sch Med, Taegu, South Korea. [Shim, Seung Cheol] Eulji Univ, Div Rheumatol, Dept Med, Eulji Medi Bio Res Inst, Taejon, South Korea. [Suh, Chang-Hee] Ajou Univ, Dept Rheumatol, Sch Med, Suwon 441749, South Korea. [Lee, Soo-Kon] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea. [Kim, Chang-sik] Chungnam Natl Univ, Dept Ophthalmol, Sch Med, Taejon, South Korea. [Petri, Michelle] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vil, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA. [Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. [Martin, Javier] CSIC, Dept Immunol, Inst Biomed Parasitologa L pez Neyra, Granada, Spain. [Pons-Estel, Bernardo A.; GENLES] Sanatorio Parque, Dept Med, Rosario, Argentina. [Vyse, Timothy J.] Kings Coll London, Div Genet, Guys Hosp, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Mol Med, Guys Hosp, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Immunol, Guys Hosp, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Infect & Inammatory Dis, Guys Hosp, London WC2R 2LS, England. [Freedman, Barry I.; Williams, Adrienne; Comeau, Mary; Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Freedman, Barry I.; Williams, Adrienne; Comeau, Mary; Langefeld, Carl D.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Div Rheumatol, Houston, TX USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Kang, C (reprint author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea. EM ckang@kaist.ac.kr; Robert.Kimberly@ccc.uab.edu; scbae@hanyang.ac.kr RI Kang, Changwon/C-1938-2011; Martin, Javier/B-8141-2008; Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Kimberly, Robert/0000-0002-5330-3086; Suh, Chang-Hee/0000-0001-6156-393X; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660 FU US NIH [AR042460, AR043274, AR043814, AR044804, AR048940, AR052300, AR053483, AR058554, AR060366, AR43727, AR62277, CA141700-01, GM063483, HD07463, K08-AI083790, K24-AR002138, M01-RR00079, N01-AR-6-227, P01-AR49084, P30-DK42086, P30-AR055385]; Lupus Foundation of America; Alliance for Lupus Research; Kirkland Scholar Award; US Department of Veterans Affairs; Korean Healthcare Technology Research and Development Project [A111218-11-GM01]; Korea Research Program for New Drug Target Discovery [20090083335]; National Research Foundation of Korea [2010-0014162]; Lupus Research Institute Novel Research Grant; Alliance for Lupus Research Target Identification in Lupus Grant; Arthritis National Research Foundation Eng Tan Scholar Award; ESF in the framework of the Research Networking Programme European Science Foundation-The Identification of Novel Genes and Biomarkers for Systemic Lupus Erythematosus (BIOLUPUS) [07-RNP-083]; Swedish Research Council; Swedish Association against Rheumatism; Swedish International Development Agency; Gustaf Vth 80th-Jubilee Foundation; Instituto de Salud Carlos III [PS09/00129]; FEDER funds of the European Union; Consejer'a de Salud de la Junta de Andaluc'a FX The work was supported by grants from US NIH (AI063622, AI071651, AI082714, AI083194, AI094377, AI24717, AR042460, AR043274, AR043814, AR044804, AR048940, AR052300, AR053483, AR058554, AR060366, AR43727, AR62277, CA141700-01, GM063483, HD07463, K08-AI083790, K24-AR002138, M01-RR00079, N01-AR-6-227, P01-AR49084, P30-DK42086, P30-AR055385, P60-AR049459 P60-AR053308, P60-2-AR30692, PO1-AR49084, PR094002, R01-AR33062, R21-AI070304, RR015577, RR020143, UL1RR024999, UL1RR025005, UL1RR025741, UL1RR029882 and 5UL1RR025777), the Lupus Foundation of America, the Alliance for Lupus Research, a Kirkland Scholar Award, the US Department of Veterans Affairs, the Korean Healthcare Technology Research and Development Project (A111218-11-GM01), the Korea Research Program for New Drug Target Discovery (20090083335), the National Research Foundation of Korea (2010-0014162), the Lupus Research Institute Novel Research Grant, the Alliance for Lupus Research Target Identification in Lupus Grant, the Arthritis National Research Foundation Eng Tan Scholar Award, the ESF in the framework of the Research Networking Programme European Science Foundation-The Identification of Novel Genes and Biomarkers for Systemic Lupus Erythematosus (BIOLUPUS) 07-RNP-083, the Swedish Research Council, the Swedish Association against Rheumatism, the Swedish International Development Agency, the Gustaf Vth 80th-Jubilee Foundation, the Instituto de Salud Carlos III (PS09/00129) partly financed by the FEDER funds of the European Union, and a grant from the Consejer'a de Salud de la Junta de Andaluc'a. NR 30 TC 16 Z9 16 U1 0 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD NOV PY 2012 VL 71 IS 11 BP 1809 EP 1814 DI 10.1136/annrheumdis-2011-201110 PG 6 WC Rheumatology SC Rheumatology GA 018IZ UT WOS:000309654900009 PM 22523428 ER PT J AU Hassija, CM Jakupcak, M Gray, MJ AF Hassija, Christina M. Jakupcak, Matthew Gray, Matt J. TI Numbing and Dysphoria Symptoms of Posttraumatic Stress Disorder Among Iraq and Afghanistan War Veterans: A Review of Findings and Implications for Treatment SO BEHAVIOR MODIFICATION LA English DT Article DE PTSD; numbing; dysphoria; veterans ID CONFIRMATORY FACTOR-ANALYSIS; BORDERLINE PERSONALITY-DISORDER; DIALECTICAL BEHAVIOR-THERAPY; RANDOMIZED CONTROLLED-TRIAL; ADMINISTERED PTSD SCALE; MENTAL-HEALTH PROBLEMS; WORLD-TRADE-CENTER; QUALITY-OF-LIFE; FUNCTIONAL IMPAIRMENT; PROLONGED EXPOSURE AB Iraq and Afghanistan war veterans experience significant rates of posttraumatic stress disorder (PTSD) and other trauma-related mental health conditions. Understanding how specific PTSD symptomatology affects physical health and psychosocial functioning may be useful in improving the conceptualization of PTSD nosology and informing treatment approaches for this population. Confirmatory factor analytic evidence supports four-factor models of PTSD symptoms that classify emotional numbing and/or dysphoria symptoms as a distinct PTSD symptom cluster, and these symptoms appear to be related to poorer psychological adjustment among returning Iraq and Afghanistan war veterans. This review briefly describes current conceptualizations of numbing/dysphoria symptoms of PTSD and summarizes research on the factor structure of PTSD symptoms. Then, the literature on the influence of numbing/dysphoria symptoms on physical and psychological health among these veterans is reviewed, and implications for treatment and directions for future research are presented. C1 [Hassija, Christina M.] Natl Ctr PTSD VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Hassija, Christina M.; Gray, Matt J.] Univ Wyoming, Laramie, WY 82071 USA. [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Jakupcak, Matthew] Univ Washington, Seattle, WA 98195 USA. RP Hassija, CM (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr Posttraumat Stress Disorder, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Christina.Hassija2@va.gov NR 67 TC 10 Z9 10 U1 5 U2 14 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-4455 J9 BEHAV MODIF JI Behav. Modificat. PD NOV PY 2012 VL 36 IS 6 SI SI BP 834 EP 856 DI 10.1177/0145445512453735 PG 23 WC Psychology, Clinical SC Psychology GA 022BP UT WOS:000309930300005 PM 22977267 ER PT J AU Serafini, G Pompili, M Innamorati, M Rihmer, Z Sher, L Girardi, P AF Serafini, Gianluca Pompili, Maurizio Innamorati, Marco Rihmer, Zoltan Sher, Leo Girardi, Paolo TI Can Cannabis Increase the Suicide Risk in Psychosis? A Critical Review SO CURRENT PHARMACEUTICAL DESIGN LA English DT Review DE Cannabis use; suicidal behavior; psychosis; youths; prevention ID DELIBERATE SELF-HARM; SUBSTANCE USE; YOUNG-PEOPLE; AFFECTIVE TEMPERAMENTS; GENERAL-POPULATION; MENTAL-HEALTH; PSYCHIATRIC-PATIENTS; DEPRESSIVE SYMPTOMS; HIGHER HOPELESSNESS; COMPLETED SUICIDE AB Objectives: This paper aimed to critically review the current literature concerning the possible association between cannabis use and suicidal behavior in patients with psychosis and in non-psychotic samples. Methods: We performed a detailed Pubmed/Medline, Scopus, PsycLit, and PsycInfo search to identify all papers and book chapters focusing on the association between cannabis use, and suicidal behavior during the period between 1980 and 2011. Results: Most, but not all studies reported an association between suicidal behavior and cannabis use both in psychotic and non-psychotic samples. However, there were also some studies suggesting a weak (not direct) association between these two phenomena. Overall, those who attempt or complete suicide are characterized by additional risk factors such as mood disorders, stressful life events, interpersonal problems, poor social support, lonely lives, and feelings of hopelessness. Limitations: It was not possible to perform a meta-analysis due to the high heterogeneity of individual data. Conclusions: Cannabis use was a relevant risk factor associated with both suicidal attempts and behaviors in psychotic and non-psychotic samples. Preventive programs should be directed on reducing cannabis use, particularly in psychotic subjects. Evidence suggests that targeted suicide prevention programs can be also developed in specific at-risk subgroups such as those at genetic or clinical high risk of psychosis. C1 [Serafini, Gianluca; Pompili, Maurizio; Girardi, Paolo] Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, I-00189 Rome, Italy. [Pompili, Maurizio; Innamorati, Marco] Harvard Univ, Sch Med, McLean Hosp, Cambridge, MA 02138 USA. [Rihmer, Zoltan] Semmelweis Univ, Dept Clin & Theoret Mental Hlth, Kutvolgyi Clin Ctr, H-1125 Budapest, Hungary. [Rihmer, Zoltan] Semmelweis Univ, Dept Psychiat & Psychotherapy, H-1125 Budapest, Hungary. [Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, Dept Psychiat, New York, NY USA. RP Serafini, G (reprint author), Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, 1035-1039 Via Grottarossa, I-00189 Rome, Italy. EM gianluca.serafini@uniroma1.it RI Innamorati, Marco/H-8877-2013 OI Innamorati, Marco/0000-0003-1389-2290; Pompili, Maurizio/0000-0003-1886-4977 NR 87 TC 12 Z9 12 U1 4 U2 21 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD NOV PY 2012 VL 18 IS 32 BP 5165 EP 5187 PG 23 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 016JA UT WOS:000309512900028 PM 22716157 ER PT J AU Akiba, Y Kaunitz, JD AF Akiba, Yasutada Kaunitz, Jonathan D. TI May the Truth Be with You: Lubiprostone as EP Receptor Agonist/ClC-2 Internalizing "Inhibitor" SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material ID IRRITABLE-BOWEL-SYNDROME; TRANSMEMBRANE CONDUCTANCE REGULATOR; CHLORIDE CHANNEL ACTIVATOR; CYSTIC-FIBROSIS; CLC-2 CHLORIDE; BICARBONATE SECRETION; EPITHELIAL-CELLS; CLINICAL-TRIAL; CONSTIPATION; COLON C1 [Akiba, Yasutada] W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, 11301 Wilshire Blvd,Bldg 114,Suite 217, Los Angeles, CA 90073 USA. EM yakiba@mednet.ucla.edu FU NIDDK NIH HHS [R01 DK54221] NR 32 TC 2 Z9 2 U1 1 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2012 VL 57 IS 11 BP 2740 EP 2742 DI 10.1007/s10620-012-2410-2 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 021EJ UT WOS:000309867800022 PM 23001408 ER PT J AU Lawson, EH Gibbons, MM Ko, CY Shekelle, PG AF Lawson, Elise H. Gibbons, Melinda Maggard Ko, Clifford Y. Shekelle, Paul G. TI The appropriateness method has acceptable reliability and validity for assessing overuse and underuse of surgical procedures SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Review DE Appropriateness; Surgery; Reliability; Validity; Overuse; Underuse ID UPPER GASTROINTESTINAL ENDOSCOPY; CORONARY REVASCULARIZATION; EXPERT PANELS; CAROTID-ENDARTERECTOMY; MYOCARDIAL-INFARCTION; EXPLICIT CRITERIA; PHYSICIAN RATINGS; KNEE REPLACEMENT; CATARACT-SURGERY; GUIDELINES AB Objective: To summarize the findings of methodological studies on the RAND/University of California Los Angeles (RAND/UCLA) appropriateness method, which was developed to assess if variation in the use of surgical procedures is because of overuse and/or underuse. Study Design and Setting: A MEDLINE literature search was performed. Studies were included if they assessed the reliability or validity of the RAND/UCLA appropriateness method for a surgical procedure or the effect of altering panelist composition or eliminating in-person discussion between rating rounds. Information was abstracted on procedure, study design, and findings. Results: One thousand six hundred one titles were identified, and 37 met the inclusion criteria. The test-retest reliability is good to very good (kappa, 0.64-0.81) for total knee and hip joint replacement, coronary artery bypass grafting (CABG), and carotid endarterectomy (CEA). The interpanel reliability is moderate to very good (kappa, 0.52-0.83) for CABG and hysterectomy. Construct validity has been demonstrated by comparing the appropriateness method with guidelines and/or evidence-based approaches for endoscopy, colonoscopy, CABG, hysterectomy, and CEA. Predictive validity has been studied for cardiac revascularization, in which concordance with appropriateness classification is associated with better clinical outcomes. Conclusion: Our findings support use of the appropriateness method to assess variation in the rates of the procedures studied by identifying overuse and underuse. Further methodological research should be conducted as appropriateness criteria are developed and implemented for a broader range of procedures. (C) 2012 Elsevier Inc. All rights reserved. C1 [Lawson, Elise H.] Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Gibbons, Melinda Maggard] Olive View UCLA Med Ctr, Dept Surg, Sylmar, CA 91342 USA. [Ko, Clifford Y.; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA. [Ko, Clifford Y.; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90401 USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, 10833 LeConte Ave,CHS 72-215, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU American College of Surgeons through RWJF CSP FX The authors acknowledge Dr Angela Ingraham for her help with the initial screening of articles. This study received no external funding. Dr Lawson's time was supported by the American College of Surgeons through RWJF CSP. The remaining three authors participated through their roles as advisors to the RWJF CSP. NR 59 TC 24 Z9 24 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD NOV PY 2012 VL 65 IS 11 BP 1133 EP 1143 DI 10.1016/j.jclinepi.2012.07.002 PG 11 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 017DY UT WOS:000309571500002 PM 23017632 ER PT J AU Vomaske, J Denton, M Kreklywich, C Andoh, T Osborn, JM Chen, D Messaoudi, I Orloff, SL Streblow, DN AF Vomaske, Jennifer Denton, Michael Kreklywich, Craig Andoh, Takeshi Osborn, Jessica M. Chen, Daniel Messaoudi, Ilhem Orloff, Susan L. Streblow, Daniel N. TI Cytomegalovirus CC Chemokine Promotes Immune Cell Migration SO JOURNAL OF VIROLOGY LA English DT Article ID TRANSPLANT VASCULAR SCLEROSIS; LATENT HUMAN CYTOMEGALOVIRUS; APOE KNOCKOUT MICE; RAT SMALL-BOWEL; CHRONIC REJECTION; ALLOGRAFT-REJECTION; CARDIAC ALLOGRAFTS; HEART-TRANSPLANTS; INFECTION; RECEPTOR AB Cytomegaloviruses manipulate the host chemokine/receptor axis by altering cellular chemokine expression and by encoding multiple chemokines and chemokine receptors. Similar to human cytomegalovirus (HCMV), rat cytomegalovirus (RCMV) encodes multiple CC chemokine-analogous proteins, including r129 (HCMV UL128 homologue) and r131 (HCMV UL130 and MCMV m129/130 homologues). Although these proteins play a role in CMV entry, their function as chemotactic cytokines remains unknown. In the current study, we examined the role of the RCMV chemokine r129 in promoting cellular migration and in accelerating transplant vascular sclerosis (TVS) in our rat heart transplant model. We determined that r129 protein is released into culture supernatants of infected cells and is expressed with late viral gene kinetics during RCMV infection and highly expressed in heart and salivary glands during in vivo rat infections. Using the recombinant r129 protein, we demonstrated that r129 induces migration of lymphocytes isolated from rat peripheral blood, spleen, and bone marrow and from a rat macrophage cell line. Using antibody-mediated cell sorting of rat splenocytes, we demonstrated that r129 induces migration of naive/central memory CD4(+) T cells. Through ligand-binding assays, we determined that r129 binds rat CC chemokine receptors CCR3, CCR4, CCR5, and CCR7. In addition, mutational analyses identified functional domains of r129 resulting in recombinant proteins that fail to induce migration (r129-Delta NT and -C31A) or alter the chemotactic ability of the chemokine (r129-F43A). Two of the mutant proteins (r129-C31A and -Delta NT) also act as dominant negatives by inhibiting migration induced by wild-type r129. Furthermore, infection of rat heart transplant recipients with RCMV containing the r129-Delta NT mutation prevented CMV-induced acceleration of TVS. Together our findings indicate that RCMV r129 is highly chemotactic, which has important implications during RCMV infection and reactivation and acceleration of TVS. C1 [Vomaske, Jennifer; Denton, Michael; Osborn, Jessica M.; Chen, Daniel; Messaoudi, Ilhem; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Kreklywich, Craig; Andoh, Takeshi; Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Kreklywich, Craig; Andoh, Takeshi; Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA. [Vomaske, Jennifer; Denton, Michael; Osborn, Jessica M.; Chen, Daniel; Messaoudi, Ilhem; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA. RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. EM streblow@ohsu.edu FU National Institutes of Health [HL 083194, HL 66238-01, HL 088603] FX This work was supported by research grants from the National Institutes of Health to D. N. Streblow (HL 083194), S. L. Orloff (HL 66238-01), and J. A. Nelson (HL 088603). NR 55 TC 13 Z9 13 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD NOV PY 2012 VL 86 IS 21 BP 11833 EP 11844 DI 10.1128/JVI.00452-12 PG 12 WC Virology SC Virology GA 018JT UT WOS:000309657100039 PM 22915808 ER PT J AU Rosenbaum, L AF Rosenbaum, Lisa TI How Much Would You Give to Save a Dying Bird? Patient Advocacy and Biomedical Research SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID HIGH-DOSE CHEMOTHERAPY; BREAST-CANCER C1 [Rosenbaum, Lisa] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Rosenbaum, Lisa] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. RP Rosenbaum, L (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 8 TC 2 Z9 2 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 1 PY 2012 VL 367 IS 18 BP 1755 EP 1759 DI 10.1056/NEJMms1207114 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 028RS UT WOS:000310440800016 PM 23113489 ER PT J AU Eckstein, F Mc Culloch, CE Lynch, JA Nevitt, M Kwoh, CK Maschek, S Hudelmaier, M Sharma, L Wirth, W AF Eckstein, F. Mc Culloch, C. E. Lynch, J. A. Nevitt, M. Kwoh, C. K. Maschek, S. Hudelmaier, M. Sharma, L. Wirth, W. CA OA Initiative Investigators Grp TI How do short-term rates of femorotibial cartilage change compare to long-term changes? Four year follow-up data from the osteoarthritis initiative SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Short term; Long term; Knee; Cartilage thickness; Magnetic resonance imaging; Osteoarthritis ID MULTICENTER CLINICAL-TRIAL; SYMPTOMATIC KNEE OSTEOARTHRITIS; QUANTITATIVE MRI; 3 TESLA; PRECISION; PROGRESSION; MORPHOLOGY; SENSITIVITY; MORPHOMETRY; DESIGN AB Objective: To compare unbiased estimates of short- vs long-term cartilage loss in osteoarthritic knees. Method: 441 knees [216 Kellgren Lawrence (KL) grade 2, 225 la grade 3] from participants of the Osteoarthritis Initiative were studied over a 4-year period. Femorotibial cartilage thickness was determined using 3 T double echo steady state magnetic resonance imaging, the readers being blinded to time points. Because common measurement time points bias correlations, short-term change (year-1 to year-2: Y1 -> Y2) was compared with long-term change (baseline to year-4: BL -> Y4), and initial (BL -> Y1) with subsequent (Y2 -> Y4) observation periods. Results: The mean femorotibial cartilage thickness change (standardized response mean) was -1.2%/-0.8% (-0.42/-0.28) over 1 (BL -> Y1/Y1 -> Y2), -2.1%/-2.5% (-0.56/-0.55) over 2 (BL -> Y2/Y2 -> Y4), -3.3% (-0.63) over 3 (Y1 -> Y4), and -4.5% (-0.78) over 4 years. Spearman correlations were 0.33 for Y1 -> Y2 vs BL -> Y4, and 0.17 for BL -> Y1 vs Y2 -> Y4 change. Percent agreement between knees showing progression during Y1 -> Y2 vs BL -> Y4 was 59%, and 64% for BL -> Y1 vs Y2 -> Y4. The area under the receiver operating characteristic curve was 0.66 for using Y1 -> Y2 to predict BL -> Y4, and 0.59 for using BL -> Y1 to predict Y2 -> Y4 change. Conclusion: Weak to moderate correlations and agreement were observed between individual short- vs long-term cartilage loss, and between initial and subsequent observation periods. Hence, longer observation periods are recommended to achieve robust results on cartilage loss in individual knees. At cohort and subcohort level (e.g., KLG3 vs KLG2 knees), the mean cartilage loss increased almost linearly with the length of the observation period and was constant throughout the study. (C) 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Eckstein, F.; Maschek, S.; Hudelmaier, M.; Wirth, W.] Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Salzburg, Austria. [Eckstein, F.; Maschek, S.; Hudelmaier, M.; Wirth, W.] Chondrometr GmbH, Ainring, Germany. [Mc Culloch, C. E.; Lynch, J. A.; Nevitt, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kwoh, C. K.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA. [Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sharma, L.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Evanston, IL 60208 USA. RP Eckstein, F (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria. EM felix.eckstein@pmu.ac.at RI Wirth, Wolfgang/C-8724-2011 OI Wirth, Wolfgang/0000-0002-2297-8283 FU OAI [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; National Institutes of Health, a branch of the Department of Health and Human Services; Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer, Inc.; OAI coordinating center at UCSF [N01-AR-2-2258]; Division of Rheumatology, Feinberg School of Medicine, Northwestern University [R01 AR52918]; University of Pittsburgh [HHSN2682010000 21C] FX The study and image acquisition was funded by the OAI, a public private partnership comprised five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262), funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. The image analysis of this study was funded by a vendor contract from the OAI coordinating center at UCSF (N01-AR-2-2258), an ancillary study to the OAI held by the Division of Rheumatology, Feinberg School of Medicine, Northwestern University (R01 AR52918), and a contract held by the University of Pittsburgh [Pivotal OAI MRI Analyses (POMA), NIH/NHLBI Contract No. HHSN2682010000 21C]. The sponsors were not directly involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. However, the manuscript has received approval of the OAI Publications Committee based on a review of its scientific content and data interpretation. NR 30 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD NOV PY 2012 VL 20 IS 11 BP 1250 EP 1257 DI 10.1016/j.joca.2012.06.019 PG 8 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 020YV UT WOS:000309853400006 PM 22800771 ER PT J AU Hostetler, CM Anacker, AMJ Loftis, JM Ryabinin, AE AF Hostetler, Caroline M. Anacker, Allison M. J. Loftis, Jennifer M. Ryabinin, Andrey E. TI Social housing and alcohol drinking in male-female pairs of prairie voles (Microtus ochrogaster) SO PSYCHOPHARMACOLOGY LA English DT Article DE Prairie voles; Social behavior; Alcohol self-administration; Social influence ID EXTENDED OLFACTORY AMYGDALA; RAT LINES; NUCLEUS-ACCUMBENS; ANXIETY DISORDERS; ETHANOL INTAKE; VOLUNTARY ETHANOL; BEHAVIOR; AMPHETAMINE; MODULATION; AGGRESSION AB Social environment influences alcohol consumption in humans; however, animal models have only begun to address biological underpinnings of these effects. We investigated whether social influences on alcohol drinking in the prairie vole are specific to the sex of the social partner. In Experiment 1, control, sham, and gonadectomized voles were placed either in mesh-divided housing with a same-sex sibling or isolation with access to ethanol. In Experiment 2, animals were given an elevated plus maze test (EPM) and then females were paired with a castrated male followed by isolation or mesh-divided housing with access to ethanol. In Experiment 3, subjects categorized as low or high drinkers based on initial ethanol intake were placed in mesh-divided housing with an opposite-sex partner of the same or opposite drinking group and ethanol access. Subjects were then moved back to isolation for a final ethanol access period. Same-sex pairs showed social facilitation of drinking similar to previous reports. Gonadectomy did not affect alcohol drinking. Opposite-sex paired animals in Experiment 2 did not differ in alcohol drinking based on social housing. EPM measures suggested a relationship between anxiety-like behaviors and drinking that depended on social environment. Experiment 3 identified moderate changes in alcohol preference based on social housing, but these effects were influenced by the animal's own drinking behavior and were independent of their partner's drinking. Social influences on alcohol self-administration in prairie voles differ based on the sex of a social partner, consistent with human drinking behavior. C1 [Hostetler, Caroline M.; Anacker, Allison M. J.; Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. RP Hostetler, CM (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. EM caroline.hostetler@gmail.com FU NIH [5T32AA007468-24, AA016886]; Portland VA Medical Center, Portland, Oregon FX We gratefully acknowledge Davelle Cocking, Lindsay Swanson, and the Veterinary Medical Unit (VMU) animal care staff from the Portland VA Medical Center for assistance on this project. This research was funded by NIH 5T32AA007468-24 (to CMH) and NIH AA016886 (to AER). This material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center, Portland, Oregon. NR 62 TC 15 Z9 15 U1 5 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD NOV PY 2012 VL 224 IS 1 BP 121 EP 132 DI 10.1007/s00213-012-2836-4 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 018SB UT WOS:000309681900011 PM 22903359 ER PT J AU Moyer, CE Delevich, KM Fish, KN Asafu-Adjei, JK Sampson, AR Dorph-Petersen, KA Lewis, DA Sweet, RA AF Moyer, Caitlin E. Delevich, Kristen M. Fish, Kenneth N. Asafu-Adjei, Josephine K. Sampson, Allan R. Dorph-Petersen, Karl-Anton Lewis, David A. Sweet, Robert A. TI Reduced Glutamate Decarboxylase 65 Protein Within Primary Auditory Cortex Inhibitory Boutons in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE GAD65; postmortem human tissue; primary auditory cortex; quantitative microscopy; schizophrenia; stereology ID GAMMA OSCILLATION FREQUENCY; MISMATCH NEGATIVITY GENERATION; DORSOLATERAL PREFRONTAL CORTEX; ACTIVITY-DEPENDENT REGULATION; DENDRITIC SPINE DENSITY; SUPERIOR TEMPORAL GYRUS; STEADY-STATE RESPONSES; SHORT-TERM-MEMORY; VISUAL-CORTEX; ACID DECARBOXYLASE AB Background: Schizophrenia is associated with perceptual and physiological auditory processing impairments that may result from primary auditory cortex excitatory and inhibitory circuit pathology. High-frequency oscillations are important for auditory function and are often reported to be disrupted in schizophrenia. These oscillations may, in part, depend on upregulation of gamma-aminobutyric acid synthesis by glutamate decarboxylase 65 (GAD65) in response to high interneuron firing rates. It is not known whether levels of GAD65 protein or GAD65-expressing boutons are altered in schizophrenia. Methods: We studied two cohorts of subjects with schizophrenia and matched control subjects, comprising 27 pairs of subjects. Relative fluorescence intensity, density, volume, and number of GAD65-immunoreactive boutons in primary auditory cortex were measured using quantitative confocal microscopy and stereologic sampling methods. Bouton fluorescence intensities were used to compare the relative expression of GAD65 protein within boutons between diagnostic groups. Additionally, we assessed the correlation between previously measured dendritic spine densities and GAD65-immunoreactive bouton fluorescence intensities. Results: GAD65-immunoreactive bouton fluorescence intensity was reduced by 40% in subjects with schizophrenia and was correlated with previously measured reduced spine density. The reduction was greater in subjects who were not living independently at time of death. In contrast, GAD65-immunoreactive bouton density and number were not altered in deep layer 3 of primary auditory cortex of subjects with schizophrenia. Conclusions: Decreased expression of GAD65 protein within inhibitory boutons could contribute to auditory impairments in schizophrenia. The correlated reductions in dendritic spines and GAD65 protein suggest a relationship between inhibitory and excitatory synapse pathology in primary auditory cortex. C1 [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Moyer, Caitlin E.; Fish, Kenneth N.; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA. [Asafu-Adjei, Josephine K.; Sampson, Allan R.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15213 USA. [Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network Mental Illness Res 4, Educ & Clin Ctr, Pittsburgh, PA USA. [Dorph-Petersen, Karl-Anton] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark. [Dorph-Petersen, Karl-Anton] Aarhus Univ, Ctr Stochast Geometry & Adv Bioimaging, Aarhus, Denmark. RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Biomed Sci Tower,Room W1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM SweetRA@upmc.edu RI Lewis, David/G-4053-2014; Dorph-Petersen, Karl-Anton/A-9039-2015 OI Lewis, David/0000-0002-3225-6778; Dorph-Petersen, Karl-Anton/0000-0002-6676-034X; Moyer, Caitlin/0000-0002-2571-2595; Delevich, Kristen/0000-0001-5698-0093 FU Bristol-Myers Squibb Foundation; Bristol-Myers Squibb; Curridium Ltd; Pfizer; [MH071533]; [MH084053]; [MH085108] FX This work was supported by Grants MH071533 (RAS), MH084053 (DAL), and MH085108 (KNF).; ARS is a statistical consultant to Johnson & Johnson Pharmaceutical Research and Development. DAL currently receives investigator-initiated research support from the Bristol-Myers Squibb Foundation, Bristol-Myers Squibb, Curridium Ltd, and Pfizer and in 2007 to 2010 served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science. CEM, KMD, KNF, JKA-A, K-AD-P, and RAS have no biomedical financial interests or potential conflicts of interest to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 90 TC 14 Z9 14 U1 3 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 1 PY 2012 VL 72 IS 9 BP 734 EP 743 DI 10.1016/j.biopsych.2012.04.010 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 017SF UT WOS:000309610500005 PM 22624794 ER PT J AU Ho, T Gerber, L Aronson, WJ Terris, MK Presti, JC Kane, CJ Amling, CL Freedland, SJ AF Ho, Tammy Gerber, Leah Aronson, William J. Terris, Martha K. Presti, Joseph C. Kane, Christopher J. Amling, Christopher L. Freedland, Stephen J. TI Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database SO EUROPEAN UROLOGY LA English DT Article DE Prostate cancer; PSA nadir; Obesity; Radical prostatectomy; Biochemical recurrence ID BODY-MASS INDEX; NATURAL-HISTORY; CANCER; RISK; MEN; PROGRESSION; INSULIN; DISEASE; IMPACT; LEVEL AB Background: Obesity is associated with an increased risk of biochemical recurrence (BCR) after radical prostatectomy (RP). It is unclear whether this is due to technical challenges related to operating on obese men or other biologic factors. Objective: To examine whether obesity predicts higher prostate-specific antigen (PSA) nadir (as a measure of residual PSA-producing tissue) after RP and if this accounts for the greater BCR risk in obese men. Design, setting, and participants: A retrospective analysis of 1038 RP patients from 2001 to 2010 in the multicenter US Veterans Administration-based Shared Equal Access Regional Cancer Hospital database with median follow-up of 41 mo. Intervention: All patients underwent RP. Outcome measurements and statistical analysis: We evaluated the relationship between body mass index (BMI) and ultrasensitive PSA nadir within 6 mo after RP. Adjusted proportional hazards models were used to examine the association between BMI and BCR with and without PSA nadir. Results and limitations: Mean BMI was 28.5 kg/m(2). Higher BMI was associated with higher PSA nadir on both univariable (p = 0.001) and multivariable analyses (p < 0.001). Increased BMI was associated with increased BCR risk (hazard ratio [HR]: 1.06; p = 0.007). Adjusting for PSA nadir slightly attenuated, but did not eliminate, this association (HR: 1.04, p = 0.043). When stratified by PSA nadir, obesity only significantly predicted BCR in men with an undetectable nadir (p = 0.006). Unfortunately, other clinically relevant end points such as metastasis or mortality were not available. Conclusions: Obese men are more likely to have a higher PSA nadir, suggesting that either more advanced disease or technical issues confound an ideal operation. However, even after adjusting for the increased PSA nadir, obesity remained predictive of BCR, suggesting that tumors in obese men are growing faster. This provides further support for the idea that obesity is biologically associated with prostate cancer progression. Published by Elsevier B.V. on behalf of European Association of Urology. C1 [Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol, Dept Pathol, Durham, NC 27710 USA. [Ho, Tammy; Gerber, Leah; Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Div Urol Surg,Dept Surg, Durham, NC 27710 USA. [Ho, Tammy; Gerber, Leah; Freedland, Stephen J.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Durham, NC USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Los Angeles Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Presti, Joseph C.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Kane, Christopher J.] Univ Calif San Diego, Sch Med, Div Urol, San Diego, CA 92103 USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Dept Pathol, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU US Department of Veterans Affairs; US Department of Defense Prostate Cancer Research Program; American Urological Association Foundation/Astellas Rising Star in Urology Award; Georgia Cancer Coalition; National Institutes of Health [P50 CA58236, R01CA100938, P50 CA92131-01A1] FX This study was supported by the US Department of Veterans Affairs, US Department of Defense Prostate Cancer Research Program, the American Urological Association Foundation/Astellas Rising Star in Urology Award, National Institutes of Health Specialized Programs of Research Excellence Grant P50 CA58236, the Georgia Cancer Coalition, National Institutes of Health R01CA100938, and National Institutes of Health Specialized Programs of Research Excellence Grant P50 CA92131-01A1. Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense. NR 30 TC 11 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 J9 EUR UROL JI Eur. Urol. PD NOV PY 2012 VL 62 IS 5 BP 910 EP 916 DI 10.1016/j.eururo.2012.08.015 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 016WE UT WOS:000309549700034 PM 22921964 ER PT J AU Xi, MC Fung, SJ Zhang, JH Sampogna, S Chase, MH AF Xi, Mingchu Fung, Simon J. Zhang, Jianhua Sampogna, Sharon Chase, Michael H. TI The amygdala and the pedunculopontine tegmental nucleus: Interactions controlling active (rapid eye movement) sleep SO EXPERIMENTAL NEUROLOGY LA English DT Article DE REM sleep; Amygdala; PPT; Electrical stimulation; Intracellular recording ID ANTERODORSAL PONTINE TEGMENTUM; PARADOXICAL SLEEP; BRAIN-STEM; REM-SLEEP; RETICULAR-FORMATION; PONTOGENICULOOCCIPITAL WAVES; ELECTRICAL-STIMULATION; ACETYLCHOLINE-RELEASE; INDUCTION ZONE; MEDULLA-OBLONGATA AB There is a consensus that active sleep (AS; i.e., REM sleep) is produced by cholinergic projections from the pedunculopontine tegmental nuclei (PPT) that activate AS-on neurons in the nucleus pontis oralis (NPO) that are components of the AS-Generator. However, there is a growing body of evidence indicating that other sites, such as the amygdala, also participate in the control of AS by inducing the discharge of AS-Generator neurons. In this regard, we recently reported that there are direct, excitatory (glutamatergic) projections from the central nucleus of the amygdala (CNA) to presumptive AS-Generator neurons in the NPO. We therefore hypothesized that the CNA and the PPT act alone, as well as in concert, to promote AS. To test this hypothesis, the effects of stimulation of the CNA and the PPT on the activity of NPO neurons, recorded intracellularly, were examined in urethane-anesthetized rats. Stimulation of either the CNA or the PPT evoked short-latency excitatory postsynaptic potentials (EPSPs) in the same neurons within the NPO. The amplitude of PPT-evoked EPSPs that were recorded from NPO neurons increased by 20.1 to 58.6% when stimulation of the PPT was preceded by stimulation of the CNA at an interval of 0 to 12 ms: maximal potentiation occurred at an interval of 4 to 6 ms. Concurrent subthreshold stimulation of the CNA and the PPT resulted in the discharge of NPO neurons. NPO neurons that were activated following CNA and/or PPT stimulation were identified morphologically and found to be multipolar with diameters >20 mu m; similar neurons in the same NPO site have been previously identified as AS-Generator neurons. The present data demonstrate the presence of converging excitatory synaptic inputs from the CNA and the PPT that are capable of promoting the discharge of AS-Generator neurons in the NPO. Therefore, we suggest that the occurrence of AS depends upon interactions between cholinergic projections from the PVT and glutamatergic projections from the CNA as well as inputs from other sites that project to AS-Generator neurons. Published by Elsevier Inc. C1 [Xi, Mingchu; Fung, Simon J.; Zhang, Jianhua; Sampogna, Sharon; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA. [Xi, Mingchu; Fung, Simon J.; Zhang, Jianhua; Chase, Michael H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA. RP Xi, MC (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM mxi@websciences.org FU NIH [NS 60917] FX This research was supported by NIH grant NS 60917. We are grateful to Mr. Vincent Lim, Ms. Nichole Stevens and Mr. Daniel Bronson for their excellent technical assistance. NR 60 TC 8 Z9 8 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD NOV PY 2012 VL 238 IS 1 BP 44 EP 51 DI 10.1016/j.expneurol.2012.08.001 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 017XV UT WOS:000309625400006 PM 22971360 ER PT J AU Hazlett, EA Collazo, T Zelmanova, Y Entis, JJ Chu, KW Goldstein, KE Roussos, P Haznedar, MM Koenigsberg, HW New, AS Buchsbaum, MS Hershowitz, JP Siever, LJ Byne, W AF Hazlett, Erin A. Collazo, Tyson Zelmanova, Yuliya Entis, Jonathan J. Chu, King-Wai Goldstein, Kim E. Roussos, Panos Haznedar, M. Mehmet Koenigsberg, Harold W. New, Antonia S. Buchsbaum, Monte S. Hershowitz, Julian P. Siever, Larry J. Byne, William TI Anterior limb of the internal capsule in schizotypal personality disorder: Fiber-tract counting, volume, and anisotropy SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizotypal personality disorder; Diffusion tensor imaging; Tractography; Magnetic resonance imaging; Anisotropy; Internal capsule ID THALAMIC MEDIODORSAL NUCLEUS; POOR-OUTCOME SCHIZOPHRENIA; WHITE-MATTER ABNORMALITIES; 1ST-EPISODE SCHIZOPHRENIA; TEMPORAL LOBES; BASAL GANGLIA; FRONTAL LOBES; DIFFUSION; MRI; BRAIN AB Mounting evidence suggests that white matter abnormalities and altered subcortical-cortical connectivity may be central to the pathology of schizophrenia (SZ). The anterior limb of the internal capsule (ALIC) is an important thalamo-frontal white-matter tract shown to have volume reductions in SZ and to a lesser degree in schizotypal personality disorder (SPD). While fractional anisotropy (FA) and connectivity abnormalities in the ALIC have been reported in SZ, they have not been examined in SPD. In the current study, magnetic resonance (MRI) and diffusion tensor imaging (DTI) were obtained in age-and sex-matched individuals with SPD (n = 33) and healthy controls (HCs; n = 38). The ALIC was traced bilaterally on five equally spaced dorsal-to-ventral axial slices from each participant's MRI scan and co-registered to DTI for the calculation of FA. Tractography was used to examine tracts between the ALIC and two key Brodmann areas (BAs; BA10, BA45) within the dorsolateral prefrontal cortex (DLPFC). Compared with HCs, the SPD participants exhibited (a) smaller relative volume at the mid-ventral ALIC slice level but not the other levels; (b) normal FA within the ALIC; (c) fewer relative number of tracts between the most-dorsal ALIC levels and BA10 but not BA45 and (d) fewer dorsal ALIC-DLPFC tracts were associated with greater symptom severity in SPD. In contrast to prior SZ studies that report lower FA, individuals with SPD show sparing. Our findings are consistent with a pattern of milder thalamo-frontal dysconnectivity in SPD than schizophrenia. Published by Elsevier B.V. C1 [Hazlett, Erin A.; Collazo, Tyson; Zelmanova, Yuliya; Entis, Jonathan J.; Goldstein, Kim E.; Roussos, Panos; Haznedar, M. Mehmet; Koenigsberg, Harold W.; New, Antonia S.; Hershowitz, Julian P.; Siever, Larry J.; Byne, William] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Hazlett, Erin A.; Chu, King-Wai; Roussos, Panos; New, Antonia S.; Siever, Larry J.; Byne, William] James J Peters VAMC, VISN Mental Illness Res Educ & Clin Ctr MIRECC 3, Bronx, NY 10468 USA. [Haznedar, M. Mehmet; Koenigsberg, Harold W.; New, Antonia S.; Siever, Larry J.; Byne, William] James J Peters VAMC, Dept Psychiat, Bronx, NY 10468 USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Hazlett, EA (reprint author), James J Peters VAMC, Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, 130 W Kingsbridge Rd,Room 6A-45, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU NIMH [1R01MH073911]; Mental Illness Research Education and Clinical Center; VISN3 Veterans Health Administration; National Center for Research Resources, National Institutes of Health [UL1RR029887] FX Funding for this study was provided by NIMH grant 1R01MH073911 to Dr. Erin Hazlett. Partial support was also provided by the Mental Illness Research Education and Clinical Center, VISN3 Veterans Health Administration, and grant UL1RR029887 from the National Center for Research Resources, National Institutes of Health. The funding sources had no role in the study design, collection, analysis, interpretation of data, writing of the manuscript, or in the decision to submit the paper for publication. NR 67 TC 9 Z9 9 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2012 VL 141 IS 2-3 BP 119 EP 127 DI 10.1016/j.schres.2012.08.022 PG 9 WC Psychiatry SC Psychiatry GA 016IN UT WOS:000309511300002 PM 22995934 ER PT J AU Horan, WP Foti, D Hajcak, G Wynn, JK Green, MF AF Horan, William P. Foti, Dan Hajcak, Greg Wynn, Jonathan K. Green, Michael F. TI Intact motivated attention in schizophrenia: Evidence from event-related potentials (vol 135, pg 95, 2012) SO SCHIZOPHRENIA RESEARCH LA English DT Correction C1 [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Foti, Dan; Hajcak, Greg] SUNY Stony Brook, Stony Brook, NY USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 11301 Wilshire Blvd,Bldg 210,Mail Code 210A,Rm 11, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2012 VL 141 IS 2-3 BP 288 EP 289 DI 10.1016/j.schres.2012.08.004 PG 2 WC Psychiatry SC Psychiatry GA 016IN UT WOS:000309511300033 ER PT J AU Knapp, H Anaya, HD AF Knapp, Herschel Anaya, Henry D. TI Implementation Science in the Real World: A Streamlined Model SO JOURNAL FOR HEALTHCARE QUALITY LA English DT Article DE implementation science; organizational change; performance improvement models; process design/redesign/reengineering; quality improvement AB The process of quality improvement may involve enhancing or revising existing practices or the introduction of a novel element. Principles of Implementation Science provide key theories to guide these processes, however, such theories tend to be highly technical in nature and do not provide pragmatic nor streamlined approaches to real-world implementation. This paper presents a concisely comprehensive six step theory-based Implementation Science model that we have successfully used to launch more than two-dozen self-sustaining implementations. In addition, we provide an abbreviated case study in which we used our streamlined theoretical model to successfully guide the development and implementation of an HIV testing/linkage to care campaign in homeless shelter settings in Los Angeles County. C1 [Knapp, Herschel; Anaya, Henry D.] US Dept Vet Affairs, Washington, DC 20422 USA. [Anaya, Henry D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Knapp, H (reprint author), US Dept Vet Affairs, Washington, DC 20422 USA. EM Herschel.Knapp@va.gov NR 14 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1062-2551 EI 1945-1474 J9 J HEALTHC QUAL JI J. Healthc. Qual. PD NOV-DEC PY 2012 VL 34 IS 6 BP 27 EP 35 DI 10.1111/j.1945-1474.2012.00220.x PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V36OQ UT WOS:000209221400004 PM 23163970 ER PT J AU Fields, BG Kuna, ST AF Fields, Barry G. Kuna, Samuel T. TI Comparing methods of respiratory event detection during the treatment of obstructive sleep apnea SO JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH LA English DT Review DE apnea-hypopnea index; automatic event detection; obstructive sleep apnea; polysomnogram; positive airway pressure AB Renewed focus on comparative effectiveness research presents a unique opportunity to develop optimal clinical management pathways for patients with obstructive sleep apnea. With this momentum comes the challenge of measuring treatment effect on sleep-disordered breathing, especially in large, multisite studies. In-laboratory polysomnography, the current gold standard sleep assessment of obstructive sleep apnea severity, is costly and imposes significant participant burden. Alternatives include home unattended sleep testing and overnight pulse oximetry recording. Research studies using positive airway pressure treatment have the additional option of using the information recorded by the patient's positive airway pressure device to assess treatment effectiveness. Recent research has shown relatively good agreement between manual identification of residual respiratory events in overnight in-laboratory polysomnography and the automatic event detection utilized in positive airway pressure machines. In addition to assessing the effects of interventions on sleep disordered breathing, obstructive sleep apnea-related comparative effectiveness studies need to assess the impact of the interventions on patient burden, cost of therapy, timeliness of care, improved quality of life and other clinically relevant outcomes. C1 [Fields, Barry G.] Univ Penn, Philadelphia, PA 19104 USA. [Fields, Barry G.] Philadelphia Vet Affairs Med Ctr, Penn Sleep Ctr, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr 111P, Vet Integrated Serv Network Reg Sleep Ctr 4, Philadelphia, PA 19104 USA. RP Fields, BG (reprint author), Univ Penn, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM barry.fields@uphs.upenn.edu FU Philips-Respironics FX S Kuna receives grant support from Philips-Respironics. The authors have no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 39 TC 0 Z9 0 U1 1 U2 2 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 2042-6305 EI 2042-6313 J9 J COMP EFFECT RES JI J. Comp. Eff. Res. PD NOV PY 2012 VL 1 IS 6 BP 489 EP 499 DI 10.2217/CER.12.58 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA V32SL UT WOS:000208970800012 PM 24236468 ER PT J AU Abbott, KV Li, NYK Branski, RC Rosen, CA Grillo, E Steinhauer, K Hebda, PA AF Abbott, Katherine Verdolini Li, Nicole Y. K. Branski, Ryan C. Rosen, Clark A. Grillo, Elizabeth Steinhauer, Kimberly Hebda, Patricia A. TI Vocal Exercise May Attenuate Acute Vocal Fold Inflammation SO JOURNAL OF VOICE LA English DT Article DE Vocal fold inflammation; Wound healing; Tissue mobilization; Resonant voice ID PHONATION THRESHOLD PRESSURE; FIBEROPTIC LARYNGEAL SURGERY; RANDOMIZED CONTROLLED-TRIAL; CELLS IN-VITRO; MECHANICAL STRAIN; STEROID INJECTION; RABBIT MODEL; AIR-PRESSURE; VOICE; POLYMORPHISMS AB Objectives/Hypotheses. The objective was to assess the utility of selected "resonant voice" (RV) exercises for the reduction of acute vocal fold inflammation. The hypothesis was that relatively large-amplitude, low-impact vocal fold exercises associated with RV would reduce inflammation more than spontaneous speech (SS) and possibly more than voice rest. Study Design. The study design was prospective, randomized, and double blind. Methods. Nine vocally healthy adults underwent a 1-hour vocal loading procedure, followed by randomization to a SS condition, vocal rest condition, or RV exercise condition. Treatments were monitored in clinic for 4 hours and continued extraclinically until the next morning. At baseline (BL), immediately after loading, after the 4-hour in-clinic treatment, and 24 hours post-BL, secretions were suctioned from the vocal folds bilaterally and submitted to enzyme-linked immunosorbent assay to estimate concentrations of key markers of tissue injury and inflammation: interleukin (IL)-1 beta, IL-6, IL-8, tumor necrosis factor a, matrix metalloproteinase (MMP)-8, and IL-10. Results. Complete data sets were obtained for three markers-IL-1 beta, IL-6, and MMP-8-for one subject in each treatment condition. For these markers, results were poorest at 24-hour follow-up in the SS condition, sharply improved in the voice rest condition, and was the best in the RV condition. Average results for all markers and responsive subjects with normal BL mediator concentrations revealed an almost identical pattern. Conclusions. Some forms of tissue mobilization may be useful to attenuate acute vocal fold inflammation. C1 [Abbott, Katherine Verdolini; Rosen, Clark A.; Hebda, Patricia A.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [Abbott, Katherine Verdolini; Rosen, Clark A.] Univ Pittsburgh, Dept Otolaryngol, Voice Ctr, Sch Med, Pittsburgh, PA 15260 USA. [Abbott, Katherine Verdolini; Rosen, Clark A.; Hebda, Patricia A.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA. [Li, Nicole Y. K.] Univ Wisconsin, Dept Surg, Madison, WI USA. [Branski, Ryan C.] NYU, Sch Med, Dept Otolaryngol, New York, NY USA. [Grillo, Elizabeth] W Chester Univ, Dept Commun Disorders, W Chester, PA 19380 USA. [Steinhauer, Kimberly] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hebda, Patricia A.] Univ Pittsburgh, Dept Otolaryngol, Div Pediat, Otolaryngol Wound Healing Lab,Sch Med, Pittsburgh, PA 15260 USA. [Hebda, Patricia A.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA. RP Abbott, KV (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. OI Branski, Ryan/0000-0003-1190-9036 FU National Institute on Deafness and Other Communication Disorders [R01 DC5643] FX The study was supported by R01 DC5643 from the National Institute on Deafness and Other Communication Disorders. Preliminary data were presented at the 34th Symposium: Care of the Professional Voice; June 2005; Philadelphia, PA. The authors acknowledge the substantial contributions of Dr Priya Krishna and Maria Dietrich in data collection and management as well as Dr Elaine Rubenstein for statistical consulting and Mr Neil Szuminsky for the development of software for data analysis. NR 67 TC 4 Z9 4 U1 2 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 EI 1873-4588 J9 J VOICE JI J. Voice PD NOV PY 2012 VL 26 IS 6 AR 814.e1 DI 10.1016/j.jvoice.2012.03.008 PG 13 WC Otorhinolaryngology SC Otorhinolaryngology GA 041VC UT WOS:000311428300030 ER PT J AU Ettenhofer, ML Melrose, RJ Delawalla, Z Castellon, SA Okonek, A AF Ettenhofer, Mark L. Melrose, Rebecca J. Delawalla, Zainab Castellon, Steven A. Okonek, Anna TI Correlates of Functional Status Among OEF/OIF Veterans With a History of Traumatic Brain Injury SO MILITARY MEDICINE LA English DT Article AB This study was conducted to identify factors related to functional status within a clinical sample of Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OFF) with a history of traumatic brain injury (TBI). Medical chart review was conducted for a consecutive group of OEF/OIF Veterans who were referred for neuropsychological evaluation within a Veterans Affairs Medical Center Polytrauma Program related to history of TBI (n = 57). Level of involvement in occupational and academic activity, presence or absence of housing insecurity, and clinician ratings of overall functioning served as indicators of functional status. Reduced functional status was most strongly related to poorer cognitive function, particularly motor function, processing speed, and executive function. Lower levels of functioning were also related to increased severity of postconcussive symptoms, lower levels of education, and ongoing medication treatment for sleep or psychiatric symptoms. Comprehensive evaluation of cognitive, affective, and behavioral functioning among OEF/OIF Veterans with a history of TBI is likely to provide valuable information to inform rehabilitation strategies and identify potential warning signs for poor postdeployment reintegration. Increased awareness of these factors may aid clinicians in identifying patients at risk for poor outcomes and in more effectively targeting symptoms for intervention. C1 [Ettenhofer, Mark L.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA. [Melrose, Rebecca J.; Delawalla, Zainab; Castellon, Steven A.; Okonek, Anna] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Melrose, Rebecca J.; Castellon, Steven A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Okonek, Anna] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Ettenhofer, ML (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. FU VA Greater Los Angeles Healthcare System; Uniformed Services University of the Health Sciences; Department of Veterans Affairs FX Financial support was provided by VA Greater Los Angeles Healthcare System, the Uniformed Services University of the Health Sciences, and the Department of Veterans Affairs (Career Development Award to R. Melrose; Office of Academic Affiliations, Special Fellowship Program in Advanced Geriatrics). NR 50 TC 9 Z9 9 U1 4 U2 7 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD NOV PY 2012 VL 177 IS 11 BP 1272 EP 1278 DI 10.7205/MILMED-D-12-00095 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA V33OF UT WOS:000209027400007 PM 23198501 ER PT J AU Roth, MK Bingham, B Shah, A Joshi, A Frazer, A Strong, R Morilak, DA AF Roth, Megan K. Bingham, Brian Shah, Aparna Joshi, Ankur Frazer, Alan Strong, Randy Morilak, David A. CA STRONG STAR Consortium TI Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, and evoked HPA-axis reactivity SO NEUROPHARMACOLOGY LA English DT Article DE PTSD; Stress; Coping style; Anxiety; HPA-axis ID MEDIAL PREFRONTAL CORTEX; PITUITARY-ADRENOCORTICAL AXIS; NATIONAL COMORBIDITY SURVEY; URINARY CORTISOL EXCRETION; CHRONIC MILD STRESS; LEARNED HELPLESSNESS; BASOLATERAL AMYGDALA; EXTINGUISHED FEAR; STRIA TERMINALIS; MENTAL-DISORDERS AB Exposure to psychological trauma is the precipitating factor for PTSD. In addition, a history of chronic or traumatic stress exposure is a predisposing risk factor. We have developed a Chronic plus Acute Prolonged Stress (CAPS) treatment for rats that models some of the characteristics of stressful events that can lead to PTSD in humans. We have previously shown that CAPS enhances acute fear responses and impairs extinction of conditioned fear. Further, CAPS reduced the expression of glucocorticoid receptors in the medial prefrontal cortex. In this study we examined the effects of CAPS exposure on behavioral stress coping style, anxiety-like behaviors, and acute stress reactivity of the hypothalamic pituitary adrenal (HPA) axis. Male Sprague-Dawley rats were exposed to CAPS treatment, consisting of chronic intermittent cold stress (4 degrees C, 6 h/day, 14,days) followed on day 15 by a single 1-h session of sequential acute stressors (social defeat, immobilization, swim). After CAPS or control treatment, different groups were tested for shock probe defensive burying, novelty suppressed feeding, or evoked activation of adrenocorticotropic hormone (ACTH) and corticosterone release by an acute immobilization stress. CAPS resulted in a decrease in active burying behavior and an increase in immobility in the shock probe test. Further. CAPS-treated rats displayed increases in the latency to feed in the novelty suppressed feeding test, despite an increase in food intake in the home cage. CAPS treatment also reduced the HPA response to a subsequent acute immobilization stress. These results further validate CAPS treatment as a rat model of relevance to PTSD, and together with results reported previously, suggest that CAPS impairs fear extinction, shifts coping behavior from an active to a more passive strategy, increases anxiety, and alters HPA reactivity, resembling many aspects of human PTSD. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Roth, Megan K.; Bingham, Brian; Shah, Aparna; Joshi, Ankur; Frazer, Alan; Strong, Randy; Morilak, David A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Roth, Megan K.; Bingham, Brian; Shah, Aparna; Joshi, Ankur; Frazer, Alan; Strong, Randy; Morilak, David A.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA. [Frazer, Alan; Strong, Randy] S Texas Vet Hlth Care Network, Audie L Murphy Div, San Antonio, TX 78229 USA. RP Morilak, DA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM morilak@uthscsa.edu OI Bingham, Brian/0000-0001-8266-203X FU NIMH [F32 MH090693, R01 MH053851]; Department of Veterans Affairs Office of Research and Development; Department of Defense through the U.S. Army Medical Research and Materiel Command [W81XWH-08-2-0118] FX This work was supported by a NIMH National Research Service Award individual postdoctoral fellowship F32 MH090693 (MKR), NIMH research grant R01 MH053851 (DAM), Department of Veterans Affairs Office of Research and Development (AF, RS), and by funding provided to the STRONG STAR Multidisciplinary PTSD Research Consortium by the Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program award W81XWH-08-2-0118. The views expressed in this paper are solely those of the authors and do not reflect an endorsement by or official policy of the Department of Defense or the U.S. Government. NR 74 TC 23 Z9 24 U1 2 U2 35 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD NOV PY 2012 VL 63 IS 6 BP 1118 EP 1126 DI 10.1016/j.neuropharm.2012.07.034 PG 9 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 015IC UT WOS:000309438600020 PM 22842072 ER PT J AU Varadarajan, P Toro, JJ Lee, S Schneider, D Neumon, B Frye, B Craig, RM Haile, DJ Freytes, CO AF Varadarajan, Prakash Toro, Juan J. Lee, Shuko Schneider, Deanna Neumon, Bonita Frye, Brenda Craig, Robert M. Haile, David J. Freytes, Cesar O. TI Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw: a longitudinal cohort study SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Autologous hematopoietic progenitor cell transplantation; Multiple myeloma; Osteonecrosis of the jaw ID ZOLEDRONIC ACID; CHEMOTHERAPY; TRIAL AB There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantation-associated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p = 0.889) and febrile days, median 1 vs. 3 days, respectively (p = 0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p = 0.0336), but survival between the groups was not significantly different (log-rank p = 0.0818). We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups. C1 [Varadarajan, Prakash; Toro, Juan J.; Lee, Shuko; Schneider, Deanna; Neumon, Bonita; Frye, Brenda; Craig, Robert M.; Haile, David J.; Freytes, Cesar O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Varadarajan, Prakash; Toro, Juan J.; Haile, David J.; Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Varadarajan, P (reprint author), Mail Code 8221,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM varadarajan@uthscsa.edu NR 23 TC 1 Z9 1 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD NOV PY 2012 VL 20 IS 11 BP 2969 EP 2975 DI 10.1007/s00520-012-1429-4 PG 7 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 013YS UT WOS:000309342800038 PM 22418599 ER PT J AU Higgs, MH Kuznetsova, MS Spain, WJ AF Higgs, Matthew H. Kuznetsova, Marina S. Spain, William J. TI Adaptation of Spike Timing Precision Controls the Sensitivity to Interaural Time Difference in the Avian Auditory Brainstem SO JOURNAL OF NEUROSCIENCE LA English DT Article ID COCHLEAR NUCLEUS; COINCIDENCE DETECTION; SOUND LOCALIZATION; TONAL STIMULI; NEURONS; LAMINARIS; CHICKEN; NERVE; OWL; MAGNOCELLULARIS AB While adaptation is widely thought to facilitate neural coding, the form of adaptation should depend on how the signals are encoded. Monaural neurons early in the interaural time difference (ITD) pathway encode the phase of sound input using spike timing rather than firing rate. Such neurons in chicken nucleus magnocellularis (NM) adapt to ongoing stimuli by increasing firing rate and decreasing spike timing precision. We measured NM neuron responses while adapting them to simulated physiological input, and used these responses to construct inputs to binaural coincidence detector neurons in nucleus laminaris (NL). Adaptation of spike timing in NM reduced ITD sensitivity in NL, demonstrating the dominant role of timing in the short-term plasticity as well as the immediate response of this sound localization circuit. C1 [Higgs, Matthew H.; Spain, William J.] Dept Vet Affairs Med Ctr, Neurol Sect, Seattle, WA 98108 USA. [Higgs, Matthew H.; Kuznetsova, Marina S.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Kuznetsova, Marina S.] Univ Washington, Interdisciplinary Grad Program Neurobiol & Behav, Seattle, WA 98195 USA. [Spain, William J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Spain, WJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM spain@u.washington.edu FU US Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program; Veterans Affairs Merit Review; Veterans Affairs Epilepsy Center of Excellence; NIDCD [5F31DC009176] FX This material is based upon work supported in part by the US Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program. Funding was provided by a Veterans Affairs Merit Review to W.J.S., a Veterans Affairs Epilepsy Center of Excellence, and NIDCD Grant No. 5F31DC009176 (M. S. K.). We thank Jason Haensly for help performing the experiments with simulated spontaneous input to NM. We thank Sean Slee, Adrienne Fairhall, Marc Binder, David Perkel, and Ed Rubel for helpful discussions, Fred Rieke for comments on a previous version of the manuscript, and Sue Usher for excellent technical assistance. NR 36 TC 3 Z9 3 U1 0 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD OCT 31 PY 2012 VL 32 IS 44 BP 15489 EP 15494 DI 10.1523/JNEUROSCI.1865-12.2012 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 030LY UT WOS:000310573400025 PM 23115186 ER PT J AU Xiao, YH Isaacs, SN AF Xiao, Yuhong Isaacs, Stuart N. TI Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine serum albumin (BSA)-not all BSAs are alike SO JOURNAL OF IMMUNOLOGICAL METHODS LA English DT Article DE Enzyme-linked immunosorbent assay/methods; False positive reactions; Serum albumin; Bovine/immunology; Protein binding; Vaccinia virus complement control protein ID ANTIBODIES; COMPLEMENT; BINDING AB The enzyme-linked immunosorbent assay (ELISA) is an extremely common and powerful laboratory technique for detecting proteins by antibodies. Researchers frequently use bovine serum albumin (BSA) as a blocking agent to prevent non-specific binding of antigens and antibodies to the microtiter well. While studying the interactions of the vaccinia virus complement control protein (VCP) with complement, we found non-specific binding of VCP to BSA and identify a BSA preparation that did not result in non-specific binding. This work draws attention to the fact that not all BSA preparations are alike. It also highlights the need to perform critical controls to ensure that ELISA reactants do not inappropriately bind to the blocking agent. Published by Elsevier B.V. C1 [Xiao, Yuhong; Isaacs, Stuart N.] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Isaacs, Stuart N.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Isaacs, SN (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, 502 Johnson Pavilion, Philadelphia, PA 19104 USA. EM isaacs@mail.med.upenn.edu FU NIH [U01 AI077913, U01 AI066333]; Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases [U54 AI057168]; Philadelphia Veterans Affairs Medical Center FX We would like to thank John Atkinson (Washington University, St. Louis) for the recombinant VCP. Partial funding of this work is from NIH grants U01 AI077913 and U01 AI066333, the Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases (U54 AI057168), and the Philadelphia Veterans Affairs Medical Center. NR 12 TC 23 Z9 23 U1 0 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-1759 J9 J IMMUNOL METHODS JI J. Immunol. Methods PD OCT 31 PY 2012 VL 384 IS 1-2 BP 148 EP 151 DI 10.1016/j.jim.2012.06.009 PG 4 WC Biochemical Research Methods; Immunology SC Biochemistry & Molecular Biology; Immunology GA 017EG UT WOS:000309572300018 PM 22732194 ER PT J AU Hunzicker-Dunn, ME Lopez-Biladeau, B Law, NC Fiedler, SE Carr, DW Maizels, ET AF Hunzicker-Dunn, Mary E. Lopez-Biladeau, Blanca Law, Nathan C. Fiedler, Sarah E. Carr, Daniel W. Maizels, Evelyn T. TI PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID FOLLICLE-STIMULATING-HORMONE; PROTEIN-KINASE-A; HISTONE H3 PHOSPHORYLATION; GROWTH-FACTOR RECEPTORS; ANCHORING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; ADAPTER PROTEINS; CYCLIC-AMP; ACTIVATION AB Controlled maturation of ovarian follicles is necessary for fertility. Follicles are restrained at an immature stage until stimulated by FSH secreted by pituitary gonadotropes. FSH acts on granulosa cells within the immature follicle to inhibit apoptosis, promote proliferation, stimulate production of steroid and protein hormones, and induce ligand receptors and signaling intermediates. The phosphoinositide 3-kinase (PI3K)/AKT (protein kinase B) pathway is a pivotal signaling corridor necessary for transducing the FSH signal. We report that protein kinase A (PKA) mediates the actions of FSH by signaling through multiple targets to activate PI3K/AKT. PKA uses a route that promotes phosphorylation of insulin receptor substrate-1 (IRS-1) on Tyr(989), a canonical binding site for the 85-kDa regulatory subunit of PI3K that allosterically activates the catalytic subunit. PI3K activation leads to activation of AKT through phosphorylation of AKT on Thr(308) and Ser(473). The adaptor growth factor receptor bound protein 2-associated binding protein 2 (GAB2) is present in a preformed complex with PI3K heterodimer and IRS-1, it is an A-kinase anchoring protein that binds the type I regulatory subunit of PKA, and it is phosphorylated by PKA on Ser(159). Overexpression of GAB2 enhances FSH-stimulated AKT phosphorylation. GAB2, thus, seems to coordinate signals from the FSH-stimulated rise in cAMP that leads to activation of PI3K/AKT. The ability of PKA to commandeer IRS-1 and GAB2, adaptors that normally integrate receptor/nonreceptor tyrosine kinase signaling into PI3K/AKT, reveals a previously unrecognized route for PKA to activate a pathway that promotes proliferation, inhibits apoptosis, enhances translation, and initiates differentiation of granulosa cells. C1 [Hunzicker-Dunn, Mary E.; Lopez-Biladeau, Blanca; Law, Nathan C.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA. [Fiedler, Sarah E.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. [Maizels, Evelyn T.] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA. RP Hunzicker-Dunn, ME (reprint author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA. EM mehd@wsu.edu FU National Institutes of Health [R01HD062053, R03HD068668]; Department of Veterans Affairs FX We thank additional members of the Hunzicker-Dunn laboratory for their technical and intellectual contributions. We thank John Nilson for his critical reading of the manuscript. This work was supported by National Institutes of Health Grants R01HD062053 (to M.E.H.-D.) and R03HD068668 (to D. W. C.) and a Merit Award from the Department of Veterans Affairs (to D.W.C.). NR 56 TC 37 Z9 39 U1 3 U2 12 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 30 PY 2012 VL 109 IS 44 BP E2979 EP E2988 DI 10.1073/pnas.1205661109 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 038BJ UT WOS:000311149900007 PM 23045700 ER PT J AU Adachi, MS Taylor, AB Hart, PJ Fitzpatrick, PF AF Adachi, Mariya S. Taylor, Alexander B. Hart, P. John Fitzpatrick, Paul F. TI Mechanistic and Structural Analyses of the Roles of Active Site Residues in Yeast Polyamine Oxidase Fms1: Characterization of the N195A and D94N Enzymes SO BIOCHEMISTRY LA English DT Article ID AMINO-ACID OXIDASE; MONOAMINE-OXIDASE; KINETIC MECHANISM; PH-DEPENDENCE; SUBSTRATE-SPECIFICITY; OXYGEN ACTIVATION; FLAVOPROTEIN; OXIDATION; METABOLISM; SPERMINE AB Flavoprotein Fms1 from Saccharomyces cerevisiae catalyzes the oxidation of spermine in the biosynthetic pathway for pantothenic acid. The same reaction is catalyzed by the mammalian polyamine and spermine oxidases. The active site of Fms1 contains three amino acid residues positioned to interact with the polyamine substrate, His67, Asn195, and Asp94. These three residues form a hydrogen bonding triad with Asn195 being the central residue. Previous studies of the effects of mutating His67 are consistent with that residue being important both for interacting with the substrate and for maintaining the hydrogen bonds in the triad [Adachi, M. S., Taylor, A. B., Hart, P. J., and Fitzpatrick, P. F. (2012) Biochemistry Si, 4888-4897]. The N195A and D94N enzymes have now been characterized to evaluate their roles in catalysis. Both mutations primarily affect the reductive half-reaction. With N-1-acetylspermine as the substrate, the rate constant for flavin reduction decreases similar to 450-fold for both mutations; the effects with spermine as the substrate are smaller, 20-40-fold. The k(cat)/K-amine- and k(cat)-pH profiles with N-1-acetylspermine are only slightly changed from the profiles for the wild-type enzyme, consistent with the pK(a) values arising from the amine substrate or product and not from active site residues. The structure of the N195A enzyme was determined at a resolution of 2.0 angstrom. The structure shows a molecule of tetraethylene glycol in the active site and establishes that the mutation has no effect on the protein structure. Overall, the results are consistent with the role of Asn195 and Asp94 being to properly position the polyamine substrate for oxidation. C1 [Adachi, Mariya S.; Taylor, Alexander B.; Hart, P. John; Fitzpatrick, Paul F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Audie Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Fitzpatrick, PF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM fitzpatrick@biochem.uthscsa.edu FU National Institutes of Health Grant [R01 GM058698]; Welch Foundation [AQ-1399, AQ1245]; National Center for Research Resources [5P41RR015301-10]; National Institute of General Medical Sciences from the National Institutes of Health [(8 P41 GM103403-10]; U.S. DOE [DE-AC02-06CH11357]; Department of Veterans Affairs, Veterans Health Administration, Office of Research Development, Biomedical Laboratory Research and Development FX This work was supported in part by National Institutes of Health Grant R01 GM058698 (to P.F.F.) and The Welch Foundation Grants AQ-1399 (to R.J.H.) and AQ1245 (to P.F.F.). This work is based upon research conducted at the Advanced Photon Source on the Northeastern Collaborative Access Team beamlines, which are supported by grants from the National Center for Research Resources (5P41RR015301-10) and the National Institute of General Medical Sciences (8 P41 GM103403-10) from the National Institutes of Health. Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE), Office of Science, by Argonne National Laboratory, was supported by the U.S. DOE under Contract DE-AC02-06CH11357.; This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research Development, Biomedical Laboratory Research and Development. Support for the X-ray Crystallography Core Laboratory by the University of Texas Health Science Center at San Antonio Executive Research Committee and the Cancer Therapy Research Center is gratefully acknowledged. NR 35 TC 2 Z9 2 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD OCT 30 PY 2012 VL 51 IS 43 BP 8690 EP 8697 DI 10.1021/bi3011434 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 029GX UT WOS:000310483900020 PM 23034052 ER PT J AU Anderson, ML Peterson, ED Brennan, JM Rao, SV Dai, D Anstrom, KJ Piana, R Popescu, A Sedrakyan, A Messenger, JC Douglas, PS AF Anderson, Monique L. Peterson, Eric D. Brennan, J. Matthew Rao, Sunil V. Dai, David Anstrom, Kevin J. Piana, Robert Popescu, Andra Sedrakyan, Art Messenger, John C. Douglas, Pamela S. TI Short- and Long-Term Outcomes of Coronary Stenting in Women Versus Men Results From the National Cardiovascular Data Registry Centers for Medicare & Medicaid Services Cohort SO CIRCULATION LA English DT Article DE coronary disease; bare metal stents; drug-eluting stents; proportional hazards models; sex factors ID DRUG-ELUTING STENTS; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; IN-HOSPITAL OUTCOMES; BARE-METAL STENTS; GENDER-DIFFERENCES; ARTERY-DISEASE; ELDERLY-PATIENTS; INTERVENTION; SEX AB Background-Conflicting evidence exists on sex-based outcomes after coronary stenting. Methods and Results-Data on 426 996 patients >= 65 years old (42.3% women) from the National Cardiovascular Data Registry CathPCI Registry (2004-2008) were linked to Medicare inpatient claims to compare in-hospital outcomes by sex and long-term outcomes by sex and stent type. In-hospital complications were more frequent in women than in men: death (3869 [2.2%] versus 3737 [1.6%]; adjusted odds ratio, 1.41; 95% confidence interval [CI], 1.33-1.49), myocardial infarction (2365 [1.3%] versus 2858 [1.2%]; odds ratio, 1.19; 95% CI, 1.11-1.27), bleeding (7860 [4.4%] versus 5627 [2.3%]; odds ratio, 1.86; 95% CI, 1.79-1.93), and vascular complications (2381 [1.3%] versus 1648 [0.7%]; odds ratio, 1.85; 95% CI, 1.73-1.99). At 20.4 months, women had a lower adjusted risk of death (hazard ratio [HR], 0.92; 95% CI, 0.90-0.94) but similar rates of myocardial infarction, revascularization, and bleeding. Relative to bare metal stent use, drug-eluting stent use was associated with similar improved long-term outcomes in both sexes: death (women: adjusted HR, 0.78; 95% CI, 0.76-0.81; men: HR, 0.77; 95% CI, 0.74-0.79), myocardial infarction (women: HR, 0.79; 95% CI, 0.74-0.84; men: HR, 0.81; 95% CI, 0.77-0.85), and revascularization (women: HR, 0.93; 95% CI, 0.90-0.97; men: HR, 0.91; 95% CI, 0.88-0.94). There was no interaction between sex and stent type for long-term outcomes. Conclusions-In contemporary coronary stenting, women have a slightly higher procedural risk than men but have better long-term survival. In both sexes, use of a drug-eluting stent is associated with lower long-term likelihood for death, myocardial infarction, and revascularization. (Circulation. 2012; 126: 2190-2199.) C1 [Anderson, Monique L.; Peterson, Eric D.; Brennan, J. Matthew; Rao, Sunil V.; Dai, David; Anstrom, Kevin J.; Douglas, Pamela S.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC USA. [Piana, Robert] Vanderbilt Heart Inst, Nashville, TN USA. [Popescu, Andra] Christiana Care Hlth Syst, Newark, DE USA. [Sedrakyan, Art] Weill Cornell Med Coll, New York, NY USA. [Messenger, John C.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Anderson, ML (reprint author), 7022 N Pavil DUMC,POB 17969, Durham, NC 27715 USA. EM monique.anderson@duke.edu FU Agency for Healthcare Research and Quality, US Department of Health and Human Services, Rockville, MD, as part of the Cardiovascular Consortium [24-EHC-1, HHSAA290-2005-0032-TO4-WA2]; Alexion; AstraZeneca; Bristol Myers Squibb; Lilly; Innocoll Pharmaceuticals; Medtronic; Pfizer; Proctor Gamble; Cordis FX This project was sponsored by the Agency for Healthcare Research and Quality, US Department of Health and Human Services, Rockville, MD, as part of the Cardiovascular Consortium and funded under project 24-EHC-1 and work assignment number HHSAA290-2005-0032-TO4-WA2 as part of the Developing Evidence to Inform Decisions About Effectiveness (DEcIDE) program. The authors are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services. Additional support was obtained from the National Cardiovascular Data Registry, American College of Cardiology, Washington, DC. The funding organization had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.; Dr Anstrom has received research and salary support from Alexion, AstraZeneca, Bristol Myers Squibb, Lilly, Innocoll Pharmaceuticals, Medtronic, Pfizer, and Proctor & Gamble; has served on data safety monitoring boards for Pfizer and Vertex; and has provided consulting services for Pacific Therapeutics, Bristol Myers Squibb, and AstraZeneca. Dr Rao has received research funding from Cordis. Dr Messenger has served as the site principal investigator for the Resolute Study and EDUCATE study (Medtronic, Inc). The other authors report no conflicts. NR 44 TC 21 Z9 22 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 30 PY 2012 VL 126 IS 18 BP 2190 EP + DI 10.1161/CIRCULATIONAHA.112.111369 PG 19 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 028PU UT WOS:000310435400011 PM 22988009 ER PT J AU Ma, YB Sun, CP Haake, DA Churchill, BM Ho, CM AF Ma, Yanbao Sun, Chien-Pin Haake, David A. Churchill, Bernard M. Ho, Chih-Ming TI A high-order alternating direction implicit method for the unsteady convection-dominated diffusion problem SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN FLUIDS LA English DT Article DE high-order method; unsteady convection-dominated diffusion equation; ADI method; finite difference ID FINITE-DIFFERENCE APPROXIMATIONS; ADI METHOD; COMPACT SCHEME; NUMERICAL-SOLUTION; STABILITY ANALYSIS; EQUATION; COEFFICIENTS AB A high-order alternating direction implicit (ADI) method for solving the unsteady convection-dominated diffusion equation is developed. The fourth-order Pade scheme is used for the discretization of the convection terms, while the second-order Pade scheme is used for the diffusion terms. The CrankNicolson scheme and ADI factorization are applied for time integration. After ADI factorization, the two-dimensional problem becomes a sequence of one-dimensional problems. The solution procedure consists of multiple use of a one-dimensional tridiagonal matrix algorithm that produces a computationally cost-effective solver. Von Neumann stability analysis is performed to show that the method is unconditionally stable. An unsteady two-dimensional problem concerning convection-dominated propagation of a Gaussian pulse is studied to test its numerical accuracy and compare it to other high-order ADI methods. The results show that the overall numerical accuracy can reach third or fourth order for the convection-dominated diffusion equation depending on the magnitude of diffusivity, while the computational cost is much lower than other high-order numerical methods. Copyright (c) 2011 John Wiley & Sons, Ltd. C1 [Ma, Yanbao] Univ Calif Merced, Sch Engn, Merced, CA 95343 USA. [Sun, Chien-Pin; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA. [Haake, David A.; Churchill, Bernard M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. [Haake, David A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Ma, YB (reprint author), Univ Calif Merced, Sch Engn, Merced, CA 95343 USA. EM yma5@ucmerced.edu FU National Institute of Biomedical Imaging and Bioengineering, NIH [EB00127]; National Institute of Health [1R33DK070328] FX The authors gratefully acknowledge the reviewers and editor for their precious suggestions and comments. This work was supported in part by Bioengineering Research Partnership grant EB00127 (to B. M. C.) from the National Institute of Biomedical Imaging and Bioengineering, NIH, and in part by grant 1R33DK070328 (to JL) from the National Institute of Health. The authors also thank Drs Donghyun You, Samir Karaa, and Jun Zhang for great help in implementation of boundary conditions. NR 25 TC 5 Z9 5 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-2091 J9 INT J NUMER METH FL JI Int. J. Numer. Methods Fluids PD OCT 30 PY 2012 VL 70 IS 6 BP 703 EP 712 DI 10.1002/fld.2707 PG 10 WC Computer Science, Interdisciplinary Applications; Mathematics, Interdisciplinary Applications; Mechanics; Physics, Fluids & Plasmas SC Computer Science; Mathematics; Mechanics; Physics GA 008PE UT WOS:000308968200003 ER PT J AU Hull, RL Peters, MJ Perigo, SP Chan, CK Wight, TN Kinsella, MG AF Hull, Rebecca L. Peters, Michael J. Perigo, Susan Potter Chan, Christina K. Wight, Thomas N. Kinsella, Michael G. TI Overall Sulfation of Heparan Sulfate from Pancreatic Islet beta-TC3 Cells Increases Maximal Fibril Formation but Does Not Determine Binding to the Amyloidogenic Peptide Islet Amyloid Polypeptide SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FIBROBLAST-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; FORMATION IN-VITRO; TRANSFORMING GROWTH-FACTOR-BETA-1; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; FORMATION RATHER; MOUSE MODEL; PROTEOGLYCAN; PROTEINS AB Islet amyloid, a pathologic feature of type 2 diabetes, contains the islet beta-cell peptide islet amyloid polypeptide (IAPP) as its unique amyloidogenic component. Islet amyloid also contains heparan sulfate proteoglycans (HSPGs) that may contribute to amyloid formation by binding IAPP via their heparan sulfate (HS) chains. We hypothesized that beta-cells produce HS that bind IAPP via regions of highly sulfated disaccharides. Unexpectedly, HS from the beta-cell line beta-TC3 contained fewer regions of highly sulfated disaccharides compared with control normal murine mammary gland (NMuMG) cells. The proportion of HS that bound IAPP was similar in both cell lines ( 65%). The sulfation pattern of IAPP-bound versus non-bound HS from beta-TC3 cells was similar. In contrast, IAPP-bound HS from NMuMG cells contained frequent highly sulfated regions, whereas the nonbound material demonstrated fewer sulfated regions. Fibril formation from IAPP was stimulated equally by IAPP-bound beta-TC3 HS, non-bound beta-TC3 HS, and non-bound NMuMG HS but was stimulated to a greater extent by the highly sulfated IAPP-bound NMuMG HS. Desulfation of HS decreased the ability of both beta-TC3 and NMuMG HS to stimulate IAPP maximal fibril formation, but desulfated HS from both cell types still accelerated fibril formation relative to IAPP alone. In summary, neither binding to nor acceleration of fibril formation from the amyloidogenic peptide IAPP is dependent on overall sulfation in HS synthesized by beta-TC3 cells. This information will be important in determining approaches to reduce HS-IAPP interactions and ultimately prevent islet amyloid formation and its toxic effects in type 2 diabetes. C1 [Hull, Rebecca L.; Peters, Michael J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Hull, Rebecca L.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Wight, Thomas N.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Perigo, Susan Potter; Chan, Christina K.; Wight, Thomas N.; Kinsella, Michael G.] Benaroya Res Inst Virginia Mason, Hope Heart Matrix Biol Program, Seattle, WA 98101 USA. RP Hull, RL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM rhull@u.washington.edu OI Hull, Rebecca/0000-0001-9690-4087 FU Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care System (Seattle, WA); National Institutes of Health [DK74404, HL18645, HL92969, DK17047] FX This work was supported by the Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care System (Seattle, WA) and National Institutes of Health Grants DK74404 (to R. L. H.), HL18645 and HL92969 (to T. N. W.), and DK17047 (to the University of Washington Diabetes Research Center). NR 38 TC 3 Z9 3 U1 0 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 26 PY 2012 VL 287 IS 44 BP 37154 EP 37164 DI 10.1074/jbc.M112.409847 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 030RT UT WOS:000310588500049 PM 22936797 ER PT J AU Halloran, J Hussong, SA Burbank, R Podlutskaya, N Fischer, KE Sloane, LB Austad, SN Strong, R Richardson, A Hart, MJ Galvan, V AF Halloran, J. Hussong, S. A. Burbank, R. Podlutskaya, N. Fischer, K. E. Sloane, L. B. Austad, S. N. Strong, R. Richardson, A. Hart, M. J. Galvan, V. TI CHRONIC INHIBITION OF MAMMALIAN TARGET OF RAPAMYCIN BY RAPAMYCIN MODULATES COGNITIVE AND NON-COGNITIVE COMPONENTS OF BEHAVIOR THROUGHOUT LIFESPAN IN MICE SO NEUROSCIENCE LA English DT Article DE mammalian target of rapamycin; memory; depression; anxiety; brain aging; monoamines ID CALORIC RESTRICTION; ALZHEIMERS-DISEASE; AMYLOID-BETA; MOUSE MODEL; MTOR; ANXIETY; MEMORY; SEROTONIN; MIDBRAIN; DEFICITS AB Aging is, by far, the greatest risk factor for most neurodegenerative diseases. In non-diseased conditions, normal aging can also be associated with declines in cognitive function that significantly affect quality of life in the elderly. It was recently shown that inhibition of Mammalian TOR (mTOR) activity in mice by chronic rapamycin treatment extends lifespan, possibly by delaying aging {Harrison, 2009 #4}{Miller, 2011 #168}. To explore the effect of chronic rapamycin treatment on normal brain aging we determined cognitive and non-cognitive components of behavior throughout lifespan in male and female C57BL/6 mice that were fed control- or rapamycin-supplemented chow. Our studies show that rapamycin enhances cognitive function in young adult mice and blocks age-associated cognitive decline in older animals. In addition, mice fed with rapamycin-supplemented chow showed decreased anxiety and depressive-like behavior at all ages tested. Levels of three major monoamines (norepinephrine, dopamine and 5-hydroxytryptamine) and their metabolites (3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindolacetic acid) were significantly augmented in midbrain of rapamycin-treated mice compared to controls. Our results suggest that chronic, partial inhibition of mTOR by oral rapamycin enhances learning and memory in young adults, maintains memory in old C57BL/6J mice, and has concomitant anxiolytic and antidepressant-like effects, possibly by stimulating major monoamine pathways in brain. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Halloran, J.; Hussong, S. A.; Burbank, R.; Podlutskaya, N.; Fischer, K. E.; Sloane, L. B.; Austad, S. N.; Strong, R.; Richardson, A.; Hart, M. J.; Galvan, V.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78245 USA. [Halloran, J.; Hussong, S. A.; Burbank, R.; Fischer, K. E.; Galvan, V.] Dept Physiol, San Antonio, TX 78229 USA. [Hussong, S. A.; Podlutskaya, N.; Austad, S. N.; Richardson, A.] Dept Cell & Struct Biol, San Antonio, TX 78229 USA. [Strong, R.] Dept Pharmacol, San Antonio, TX 78229 USA. [Hart, M. J.] Dept Mol Med, San Antonio, TX 78245 USA. [Strong, R.; Richardson, A.] Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. [Strong, R.; Richardson, A.] Audie L Murphy Div, S Texas Vet Hlth Care Network, Res Serv, San Antonio, TX 78229 USA. RP Galvan, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, MSC 7755,15355 Lambda Dr, San Antonio, TX 78245 USA. EM galvanv@uthscsa.edu FU Alzheimer's Association [NIRG 04-1054]; New Scholar Award in Aging from the Ellison Medical Foundation [AG-NS-0726-10]; University Research Council Award from UTHSCSA; San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging; NIH Recovery Act Grand Opportunities "GO" Grant [RC2AG036613]; [T32AG21890] FX This work was supported by NIRG 04-1054 from the Alzheimer's Association, AG-NS-0726-10 New Scholar Award in Aging from the Ellison Medical Foundation, and a University Research Council Award from UTHSCSA to VG, the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging to AR and RS, the RC2AG036613 NIH Recovery Act Grand Opportunities "GO" Grant to AR, and T32AG21890 to SAH.; The authors thank Ms. Katrine Krueger for excellent administrative assistance. We are also grateful to Dr. Elisabeth Fernandez and to Ms. Xiang Bai for their help with monoamine measurements, and to Ms. Vanessa Soto and Mr. John Ramos and to the South Texas Center for Biology in Medicine Animal Facility staff for excellent animal care. This work was supported in part by the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging (AR and RS), RC2AG036613 NIH Recovery Act Grand Opportunities "GO" Grant to AR, and by NIRG 04-1054 from the Alzheimer's Association, AG-NS-0726-10 New Scholar Award in Aging from the Ellison Medical Foundation, and a University Research Council Award from UTHSCSA to VG. NR 55 TC 80 Z9 84 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD OCT 25 PY 2012 VL 223 BP 102 EP 113 DI 10.1016/j.neuroscience.2012.06.054 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 018VM UT WOS:000309694700011 PM 22750207 ER PT J AU Gebregziabher, M Egede, L Gilbert, GE Hunt, K Nietert, PJ Mauldin, P AF Gebregziabher, Mulugeta Egede, Leonard Gilbert, Gregory E. Hunt, Kelly Nietert, Paul J. Mauldin, Patrick TI Fitting parametric random effects models in very large data sets with application to VHA national data SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article DE Generalized linear mixed model; Homogeneity; Random effect meta regression; Longitudinal data; Very large dataset ID LINEAR MIXED MODELS; METAANALYSIS; REGRESSION; INFERENCE; TRIALS AB Background: With the current focus on personalized medicine, patient/subject level inference is often of key interest in translational research. As a result, random effects models (REM) are becoming popular for patient level inference. However, for very large data sets that are characterized by large sample size, it can be difficult to fit REM using commonly available statistical software such as SAS since they require inordinate amounts of computer time and memory allocations beyond what are available preventing model convergence. For example, in a retrospective cohort study of over 800,000 Veterans with type 2 diabetes with longitudinal data over 5 years, fitting REM via generalized linear mixed modeling using currently available standard procedures in SAS (e. g. PROC GLIMMIX) was very difficult and same problems exist in Stata's gllamm or R's lme packages. Thus, this study proposes and assesses the performance of a meta regression approach and makes comparison with methods based on sampling of the full data. Data: We use both simulated and real data from a national cohort of Veterans with type 2 diabetes (n=890,394) which was created by linking multiple patient and administrative files resulting in a cohort with longitudinal data collected over 5 years. Methods and results: The outcome of interest was mean annual HbA1c measured over a 5 years period. Using this outcome, we compared parameter estimates from the proposed random effects meta regression (REMR) with estimates based on simple random sampling and VISN (Veterans Integrated Service Networks) based stratified sampling of the full data. Our results indicate that REMR provides parameter estimates that are less likely to be biased with tighter confidence intervals when the VISN level estimates are homogenous. Conclusion: When the interest is to fit REM in repeated measures data with very large sample size, REMR can be used as a good alternative. It leads to reasonable inference for both Gaussian and non-Gaussian responses if parameter estimates are homogeneous across VISNs. C1 [Gebregziabher, Mulugeta; Egede, Leonard; Gilbert, Gregory E.; Hunt, Kelly; Mauldin, Patrick] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Gebregziabher, Mulugeta; Hunt, Kelly; Nietert, Paul J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Egede, Leonard] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Mauldin, Patrick] Med Univ S Carolina, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA. RP Gebregziabher, M (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. EM gebregz@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496; Nietert, Paul/0000-0002-3933-4986; Gebregziabher, Mulugeta/0000-0002-4826-481X FU Veterans Health Administration Health Services Research and Development (HSRD) program [REA 08-261] FX This work was supported, by the Veterans Health Administration Health Services Research and Development (HSR&D) program [grant #REA 08-261, Center for Disease Prevention and Health Interventions for Diverse Populations]. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript. NR 51 TC 2 Z9 2 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD OCT 24 PY 2012 VL 12 AR 163 DI 10.1186/1471-2288-12-163 PG 14 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 071GG UT WOS:000313577700001 PM 23095325 ER PT J AU Hansen, JE Chan, G Liu, YF Hegan, DC Dalal, S Dray, E Kwon, Y Xu, YY Xu, XH Peterson-Roth, E Geiger, E Liu, YL Gera, J Sweasy, JB Sung, P Rockwell, S Nishimura, RN Weisbart, RH Glazer, PM AF Hansen, James E. Chan, Grace Liu, Yanfeng Hegan, Denise C. Dalal, Shibani Dray, Eloise Kwon, Youngho Xu, Yuanyuan Xu, Xiaohua Peterson-Roth, Elizabeth Geiger, Erik Liu, Yilun Gera, Joseph Sweasy, Joann B. Sung, Patrick Rockwell, Sara Nishimura, Robert N. Weisbart, Richard H. Glazer, Peter M. TI Targeting Cancer with a Lupus Autoantibody SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID HOMOLOGY-DIRECTED REPAIR; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; MAMMALIAN-CELLS; PROTEIN THERAPY; ERYTHEMATOSUS; RAD51; BRCA2; INHIBITION; ANTIBODY AB Systemic lupus erythematosus (SLE) is distinct among autoimmune diseases because of its association with circulating autoantibodies reactive against host DNA. The precise role that anti-DNA antibodies play in SLE pathophysiology remains to be elucidated, and potential applications of lupus autoantibodies in cancer therapy have not previously been explored. We report the unexpected finding that a cell-penetrating lupus autoantibody, 3E10, has potential as a targeted therapy for DNA repair-deficient malignancies. We find that 3E10 preferentially binds DNA single-strand tails, inhibits key steps in DNA single-strand and double-strand break repair, and sensitizes cultured tumor cells and human tumor xenografts to DNA-damaging therapy, including doxorubicin and radiation. Moreover, we demonstrate that 3E10 alone is synthetically lethal to BRCA2-deficient human cancer cells and selectively sensitizes such cells to low-dose doxorubicin. Our results establish an approach to cancer therapy that we expect will be particularly applicable to BRCA2-related malignancies such as breast, ovarian, and prostate cancers. In addition, our findings raise the possibility that lupus autoantibodies may be partly responsible for the intrinsic deficiencies in DNA repair and the unexpectedly low rates of breast, ovarian, and prostate cancers observed in SLE patients. In summary, this study provides the basis for the potential use of a lupus anti-DNA antibody in cancer therapy and identifies lupus autoantibodies as a potentially rich source of therapeutic agents. C1 [Hansen, James E.; Liu, Yanfeng; Hegan, Denise C.; Dalal, Shibani; Peterson-Roth, Elizabeth; Geiger, Erik; Sweasy, Joann B.; Sung, Patrick; Rockwell, Sara; Glazer, Peter M.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA. [Hansen, James E.; Sweasy, Joann B.; Sung, Patrick; Rockwell, Sara; Glazer, Peter M.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA. [Chan, Grace; Gera, Joseph; Nishimura, Robert N.; Weisbart, Richard H.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Dray, Eloise; Kwon, Youngho; Xu, Yuanyuan; Sung, Patrick] Yale Univ, Dept Mol Biophys & Biochem, Sch Med, New Haven, CT 06520 USA. [Xu, Xiaohua; Liu, Yilun] City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Biol, Duarte, CA 91010 USA. [Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Sweasy, Joann B.] Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA. [Sweasy, Joann B.; Glazer, Peter M.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA. [Rockwell, Sara] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RP Hansen, JE (reprint author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA. EM james.e.hansen@yale.edu; peter.glazer@yale.edu RI Dray, Eloise/E-3938-2012; xu, xiaohua/D-1152-2011 OI Dray, Eloise/0000-0001-6793-9838 FU Radiological Society of North America [RR1108]; Kalimeris Fund through the Department of Therapeutic Radiology at Yale School of Medicine; Women's Health Research at Yale Pilot Grant; U.S. Public Health Service (USPHS) [1 RO1 NS066845-01, P01CA129186]; Veterans Affairs Merit Review grant FX This work was partially supported by Radiological Society of North America Research Resident grant RR1108 (J.E.H.), the Kalimeris Fund through the Department of Therapeutic Radiology at Yale School of Medicine (J.E.H. and P.M.G.), a Women's Health Research at Yale Pilot Grant (P.M.G.), U.S. Public Health Service (USPHS) grant 1 RO1 NS066845-01 (R.N.N.), a Veterans Affairs Merit Review grant (R.H.W.), and USPHS grant P01CA129186 (P.M.G., J.B.S., P.S., and S.R.). Author contributions: J.E.H. and P.M.G. conceived and designed the study, analyzed the data, and wrote the paper. J.E.H., G.C., Yanfeng Liu, D.C.H., S.D., E.D., Y.K., Y.X., X.X., E.P.-R., E.G., and R.H.W. performed the experiments and analyzed the data. Yilun Liu, J.B.S., and P.S. supervised the DNA binding and repair assays. J.G., S.R., and R.N.N. supervised the xenograft experiments. Competing interests: J.E.H., P.M.G., R.H. W., R.N.N., and G.C. are inventors on the patent application PCT/US2012/031860, "Cell-Penetrating Anti-DNA Antibodies and Uses Thereof to Inhibit DNA Repair." The other authors declare that they have no competing financial interests. The 3E10 antibody and the 3E10 single chain Fv fragment were obtained by Yale University under a material transfer agreement with the University of California, Los Angeles. NR 32 TC 16 Z9 16 U1 0 U2 12 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD OCT 24 PY 2012 VL 4 IS 157 AR 157ra142 DI 10.1126/scitranslmed.3004385 PG 8 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 028WM UT WOS:000310455500004 PM 23100628 ER PT J AU Volpp, KG Loewenstein, G Asch, DA AF Volpp, Kevin G. Loewenstein, George Asch, David A. TI Choosing Wisely Low-Value Services, Utilization, and Patient Cost Sharing SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID INSURANCE DESIGN; COVERAGE; CARE C1 [Volpp, Kevin G.; Asch, David A.] Univ Penn, Perelman Sch Med, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Loewenstein, George; Asch, David A.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Univ Penn, Dept Hlth Care Management, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Penn Med Ctr Innovat, Philadelphia, PA USA. [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. RP Volpp, KG (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X FU NIA NIH HHS [P30 AG034546, RC4 AG039114, RC2 AG036592] NR 7 TC 23 Z9 23 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 24 PY 2012 VL 308 IS 16 BP 1635 EP 1636 DI 10.1001/jama.2012.13616 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 028PI UT WOS:000310434100015 PM 23093160 ER PT J AU Armstrong, E Maddox, T Carey, E Grunwald, G Shunk, K AF Armstrong, Ehrin Maddox, Thomas Carey, Evan Grunwald, Gary Shunk, Kendrick TI Very Late Stent Thrombosis is Associated with Lower Mortality than Early Stent Thrombosis: A Report from the VHA CART Program SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY OCT 22-26, 2012 CL Miami, FL SP ACC C1 [Armstrong, Ehrin] Univ Calif Davis, Sacramento, CA USA. [Maddox, Thomas; Carey, Evan; Grunwald, Gary] Univ Colorado, Denver, CO 80202 USA. [Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 23 PY 2012 VL 60 IS 17 SU S BP B186 EP B186 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 025RM UT WOS:000310210101429 ER PT J AU Madder, R Madden, S Puri, R Hendricks, M Vanoosterhout, S Sum, S Kini, A Sharma, S Rizik, D Brilakis, E Shunk, K Goldstein, J Weisz, G Virmani, R Nicholls, S Maehara, A Mintz, G Stone, G Muller, J AF Madder, Ryan Madden, Sean Puri, Rishi Hendricks, Michael Vanoosterhout, Stacie Sum, Steve Kini, Annapoorna Sharma, Samin Rizik, David Brilakis, Emmanouil Shunk, Kendrick Goldstein, James Weisz, Giora Virmani, Renu Nicholls, Stephen Maehara, Akiko Mintz, Gary Stone, Gregg Muller, James TI Detection by Near-infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients with Acute ST-Segment Elevation Myocardial Infarction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium CY OCT 22-26, 2012 CL Miami, FL SP ACC C1 [Madder, Ryan; Vanoosterhout, Stacie] Frederik Meijer Heart & Vasc Inst Spectrum Hlth, Grand Rapids, MI USA. [Madden, Sean; Hendricks, Michael; Sum, Steve; Muller, James] Infraredx Inc, Burlington, MA USA. [Puri, Rishi; Nicholls, Stephen] Cleveland Clin, Cleveland, OH 44106 USA. [Kini, Annapoorna; Sharma, Samin] Mt Sinai Sch Med, New York, NY USA. [Rizik, David] Scottsdale Healthcare Hosp, Scottsdale, AZ USA. [Brilakis, Emmanouil] VA N Texas Healthcare Syst, Dallas, TX USA. [Brilakis, Emmanouil] UT SW Med Ctr, Dallas, TX USA. [Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA. [Goldstein, James] Beaumont Hosp, Royal Oak, MI USA. [Stone, Gregg] Columbia Univ, Med Ctr, New York, NY USA. [Virmani, Renu] CVPath Inc, Gaithersburg, MD USA. [Maehara, Akiko; Stone, Gregg] Cardiovasc Res Fdn, New York, NY USA. [Mintz, Gary] CRF, Washington, DC USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD OCT 23 PY 2012 VL 60 IS 17 SU S BP B7 EP B7 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 025RM UT WOS:000310210100023 ER PT J AU Schnell, E Bensen, AL Washburn, EK Westbrook, GL AF Schnell, Eric Bensen, AeSoon L. Washburn, Eric K. Westbrook, Gary L. TI Neuroligin-1 Overexpression in Newborn Granule Cells In Vivo SO PLOS ONE LA English DT Article ID NEWLY GENERATED NEURONS; TRAUMATIC BRAIN-INJURY; INHIBITORY SYNAPSE FORMATION; DENTATE GYRUS; PARKINSONS-DISEASE; EXCITATORY SYNAPSES; ADULT HIPPOCAMPUS; ADHESION MOLECULE; NEUROGENESIS; PLASTICITY AB Adult-born dentate granule cells integrate into the hippocampal network, extend neurites and form synapses in otherwise mature tissue. Excitatory and inhibitory inputs innervate these new granule cells in a stereotyped, temporally segregated manner, which presents a unique opportunity to study synapse development in the adult brain. To examine the role of neuroligins as synapse-inducing molecules in vivo, we infected dividing neural precursors in adult mice with a retroviral construct that increased neuroligin-1 levels during granule cell differentiation. By 21 days post-mitosis, exogenous neuroligin-1 was expressed at the tips of dendritic spines and increased the number of dendritic spines. Neuroligin-1-overexpressing cells showed a selective increase in functional excitatory synapses and connection multiplicity by single afferent fibers, as well as an increase in the synaptic AMPA/NMDA receptor ratio. In contrast to its synapse-inducing ability in vitro, neuroligin-1 overexpression did not induce precocious synapse formation in adult-born neurons. However, the dendrites of neuroligin-1-overexpressing cells did have more thin protrusions during an early period of dendritic outgrowth, suggesting enhanced filopodium formation or stabilization. Our results indicate that neuroligin-1 expression selectively increases the degree, but not the onset, of excitatory synapse formation in adult-born neurons. C1 [Schnell, Eric] Portland VA Med Ctr, Portland, OR USA. [Schnell, Eric] OHSU Dept Anesthesiol & Perioperat Med, Portland, OR USA. [Bensen, AeSoon L.; Washburn, Eric K.; Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA. RP Schnell, E (reprint author), Portland VA Med Ctr, Portland, OR USA. EM schneler@ohsu.edu OI Schnell, Eric/0000-0002-5623-5015 FU Oregon Medical Research Foundation; Department of Veteran's Affairs Career Development Award; National Institute of Mental Health [R01MH46613]; NIH [P30 NS06180] FX This work was supported by the Oregon Medical Research Foundation (ES), a Department of Veteran's Affairs Career Development Award (ES), the National Institute of Mental Health (R01MH46613; GLW), and the Jungers Center Light Microscopy Image Core that is supported in part by NIH P30 NS06180. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 79 TC 9 Z9 9 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 22 PY 2012 VL 7 IS 10 AR e48045 DI 10.1371/journal.pone.0048045 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 025MM UT WOS:000310193400031 PM 23110172 ER PT J AU Zhang, YT Steinman, MA Kaplan, CM AF Zhang, Yuting Steinman, Michael A. Kaplan, Cameron M. TI Geographic Variation in Outpatient Antibiotic Prescribing Among Older Adults SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID RESPIRATORY-TRACT INFECTIONS; ADVERSE-REACTIONS; PRIMARY-CARE; QUALITY AB Background: Consequences of antibiotic overuse are substantial, especially among older adults, who are more susceptible to adverse reactions. Findings about variation in antibiotic prescribing can target policy efforts to focused areas; however, little is known about these patterns among older adults. Methods: Using Medicare Part D data from January 1, 2007, through December 31, 2009 (comprising 1.0-1.1 million patients per year), we examined geographic variation in antibiotic use among older adults in 306 Dartmouth Atlas of Health Care hospital referral regions, 50 states and the District of Columbia, and 4 national regions (South, West, Midwest, and Northeast). In addition, we examined the quarterly change in antibiotic use across the 4 regions. Differences in patient demographics, insurance status, and clinical characteristics were adjusted for across regions. Results: Substantial geographic and quarterly variation in outpatient antibiotic prescribing existed across regions after adjusting for population characteristics. This variation could not be explained by differences in the prevalences of the underlying conditions. For example, the ratios of the 75th percentile to the 25th percentile of adjusted annual antibiotic spending were 1.31 across states and 1.32 across regions. The highest antibiotic use was in the South, where 21.4% of patients per quarter used an antibiotic, whereas the lowest antibiotic use was in the West, where 17.4% of patients per quarter used an antibiotic (P < .01). Regardless of region, the rate of antibiotic use was highest in the first quarter (20.9% in January through March) and was lowest in the third quarter (16.9% in July through September) (P < .01). Conclusions: Areas with high rates of antibiotic use may benefit from targeted programs to reduce unnecessary prescription. Quality improvement programs can set attainable targets using the low-prescribing areas as a reference, particularly targeting older adults. C1 [Zhang, Yuting; Kaplan, Cameron M.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Serv Res Enhancement Award Pr, San Francisco, CA USA. RP Zhang, YT (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 De Soto St,Crabtree Hall,Room A664, Pittsburgh, PA 15261 USA. EM ytzhang@pitt.edu OI Zhang, Yuting/0000-0002-6460-6779 FU Centers for Medicare & Medicaid Services and the Institute of Medicine from the National Institute of Mental Health [HHSP22320042509XI, RC1 MH088510]; Agency for Healthcare Research and Quality [R01 HS018657]; National Institute on Aging [1K23-AG030999]; American Federation for Aging Research FX This study was supported in part by grants HHSP22320042509XI from the Centers for Medicare & Medicaid Services and the Institute of Medicine, RC1 MH088510 from the National Institute of Mental Health, and R01 HS018657 from the Agency for Healthcare Research and Quality (Dr Zhang) and by grant 1K23-AG030999 from the National Institute on Aging and the American Federation for Aging Research (Dr Steinman). NR 19 TC 31 Z9 31 U1 0 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 22 PY 2012 VL 172 IS 19 BP 1465 EP 1471 DI 10.1001/archinternmed.2012.3717 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 023XG UT WOS:000310070200007 PM 23007171 ER PT J AU Goldkorn, A Vogelzang, NJ Fink, LM Ely, B Quinn, DI Tangen, CM Tai, YC Twardowski, P Van Veldhuizen, PJ Agarwal, N Carducci, MA Monk, JP Garzotto, M Mack, PC Lara, P Higano, CS Hussain, M Cote, RJ Thompson, IM AF Goldkorn, Amir Vogelzang, Nicholas J. Fink, Louis M. Ely, Benjamin Quinn, David I. Tangen, Catherine M. Tai, Yu-Chong Twardowski, Przemyslaw Van Veldhuizen, Peter J. Agarwal, Neeraj Carducci, Michael Anthony Monk, J. P. Garzotto, Mark Mack, Philip C. Lara, Primo Higano, Celestia S. Hussain, Maha Cote, Richard J. Thompson, Ian Murchie CA Southwest Oncology Grp TI Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. US Oncol Res LLC, McKesson Specialty Hlth, The Woodlands, TX USA. Comprehens Canc Ctr Nevada, Las Vegas, NV USA. Nevada Canc Inst, Las Vegas, NV USA. SWOG Stat Ctr, Seattle, WA USA. CALTECH, Pasadena, CA 91125 USA. City Hope Natl Med Ctr, Duarte, CA USA. Univ Kansas, Ctr Canc, Westwood, KS USA. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Ohio State Univ, Columbus, OH 43210 USA. Portland VA Med Ctr, Portland, OR USA. Univ Calif Davis, Sacramento, CA 95817 USA. Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA. Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. Univ Miami, Leonard M Miller Sch Med, Miami, FL USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 20 PY 2012 VL 30 IS 30 SU S PG 1 WC Oncology SC Oncology GA V31YY UT WOS:000208920100002 ER PT J AU Wang, XF Wang, SZ Lu, YB Gibson, MP Liu, Y Yuan, BZ Feng, JQ Qin, CL AF Wang, Xiaofang Wang, Suzhen Lu, Yongbo Gibson, Monica P. Liu, Ying Yuan, Baozhi Feng, Jian Q. Qin, Chunlin TI FAM20C Plays an Essential Role in the Formation of Murine Teeth SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID DENTIN MATRIX PROTEIN-1; AMELOGENESIS IMPERFECTA PHENOTYPE; TOOTH ROOT DEVELOPMENT; MICE DISPLAY; ODONTOBLAST DIFFERENTIATION; ENAMEL DEFECTS; SIALOPHOSPHOPROTEIN; EXPRESSION; MOUSE; LEADS AB FAM20Cis highly expressed in bone and tooth. Previously, we showed that Fam20C conditional knock-out (KO) mice manifest hypophosphatemic rickets, which highlights the crucial roles of this molecule in promoting bone formation and mediating phosphate homeostasis. In this study, we characterized the dentin, enamel, and cementum of Sox2-Cre-mediated Fam20C KO mice. The KO mice exhibited small malformed teeth, severe enamel defects, very thin dentin, less cementum than normal, and overall hypomineralization in the dental mineralized tissues. In situ hybridization and immunohistochemistry analyses revealed remarkable down-regulation of dentin matrix protein 1 (DMP1) and dentin sialophosphoprotein in odontoblasts, along with a sharply reduced expression of ameloblastin and amelotin in ameloblasts. Collectively, these data indicate that FAM20Cis essential to the differentiation and mineralization of dental tissues through the regulation of molecules critical to the differentiation of tooth-formative cells. C1 [Wang, Xiaofang; Wang, Suzhen; Lu, Yongbo; Gibson, Monica P.; Liu, Ying; Feng, Jian Q.; Qin, Chunlin] Texas A&M Hlth Sci Ctr Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA. [Yuan, Baozhi] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Yuan, Baozhi] William S Middleton Mem Vet Adm Med Ctr, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Qin, CL (reprint author), Texas A&M Hlth Sci Ctr Baylor Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA. EM cqin@bcd.tamhsc.edu FU National Institutes of Health [DE005092] FX This work was supported, in whole or in part, by National Institutes of Health Grant DE005092 (to C. Q.). NR 37 TC 30 Z9 30 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 19 PY 2012 VL 287 IS 43 BP 35934 EP 35942 DI 10.1074/jbc.M112.386862 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 027PA UT WOS:000310364000015 PM 22936805 ER PT J AU Liu, YY Kogai, T Schultz, JJ Mody, K Brent, GA AF Liu, Yan-Yun Kogai, Takahiko Schultz, James J. Mody, Kaizeen Brent, Gregory A. TI Thyroid Hormone Receptor Isoform-specific Modification by Small Ubiquitin-like Modifier (SUMO) Modulates Thyroid Hormone-dependent Gene Regulation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TRANSCRIPTIONAL ACTIVITY; BRAIN-DEVELOPMENT; RESPONSE ELEMENT; BETA; SUMOYLATION; MICE; BINDING; REPRESSOR; PROTEIN; ALPHA AB Thyroid hormone receptor (TR) alpha and beta mediate thyroid hormone action at target tissues. TR isoforms have specific roles in development and in adult tissues. The mechanisms underlying TR isoform-specific action, however, are not well understood. We demonstrate that posttranslational modification of TR by conjugation of smallSUMOtoTR alpha and TR beta plays an important role in triiodothyronine (T3) action and TR isoform specificity. TR alpha was sumoylated at lysines 283 and 389, and TR beta at lysines 50, 146, and 443. Sumoylation of TR beta was ligand-dependent, and sumoylation of TR alpha was ligand-independent. TR alpha-SUMO conjugation utilized the E3 ligase PIASx beta and TR beta-SUMO conjugation utilized predominantly PIAS1. SUMO1 and SUMO3 conjugation to TR was important for T3-dependent gene regulation, as demonstrated in transient transfection assay and studies of endogenous gene regulation. The functional role of SUMO1 and SUMO3 in T3 induction in transient expression assays was closely matched to the pattern of TR and cofactor recruitment to thyroid hormone response elements (TREs) as determined by ChIP assays. SUMO1 was required for the T3-induced recruitment of the co-activator CREB-binding protein (CBP) and release of nuclear receptor co-repressor (NCoR) on a TRE but had no significant effect on TR DNA binding. SUMO1 was required for T3-mediated recruitment of NCoR and release of CBP from the TSH beta-negative TRE. SUMO3 was required for T3-stimulated TR binding to the TSH beta-negative TRE and recruitment of NCoR. These findings demonstrate that conjugation of SUMO to TR has a TR-isoform preference and is important for T3-dependent gene induction and repression. C1 [Liu, Yan-Yun] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Dept Med, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Liu, YY (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Dept Med, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM yyl@ucla.edu; gbrent@ucla.edu FU Veterans Affairs Merit Review Funds FX This work was supported by Veterans Affairs Merit Review Funds. NR 35 TC 10 Z9 10 U1 2 U2 9 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 19 PY 2012 VL 287 IS 43 BP 36499 EP 36508 DI 10.1074/jbc.M112.344317 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 027PA UT WOS:000310364000069 PM 22930759 ER PT J AU Devanand, DP Mintzer, J Schultz, SK Andrews, HF Sultzer, DL de la Pena, D Gupta, S Colon, S Schimming, C Pelton, GH Levin, B AF Devanand, D. P. Mintzer, Jacobo Schultz, Susan K. Andrews, Howard F. Sultzer, David L. de la Pena, Danilo Gupta, Sanjay Colon, Sylvia Schimming, Corbett Pelton, Gregory H. Levin, Bruce TI Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ATYPICAL ANTIPSYCHOTIC MEDICATIONS; PLACEBO-CONTROLLED TRIALS; NURSING-HOME RESIDENTS; DOUBLE-BLIND; CATIE-AD; NEUROPSYCHIATRIC INVENTORY; COGNITIVE DECLINE; RANDOMIZED TRIAL; ELDERLY-PATIENTS; DEMENTIA AB BACKGROUND Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established. METHODS Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse of psychosis or agitation. RESULTS A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily). The severity of psychosis and agitation were reduced, although there was a mild increase in extrapyramidal signs; 112 patients met the criteria for response to treatment, of whom 110 underwent randomization. In the first 16 weeks after randomization, the rate of relapse was higher in the group that received placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33% [23 of 70 in groups 1 and 2]; P = 0.004; hazard ratio with placebo, 1.94; 95% confidence interval [CI], 1.09 to 3.45; P = 0.02). During the next 16 weeks, the rate of relapse was higher in the group that was switched from risperidone to placebo than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15% [2 of 13 in group 1]; P = 0.02; hazard ratio, 4.88; 95% CI, 1.08 to 21.98; P = 0.02). The rates of adverse events and death after randomization did not differ significantly among the groups, although comparisons were based on small numbers of patients, especially during the final 16 weeks. CONCLUSIONS In patients with Alzheimer's disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00417482.) C1 [Devanand, D. P.; Pelton, Gregory H.] Columbia Univ, New York State Psychiat Inst, Div Geriatr Psychiat, New York, NY 10032 USA. [Devanand, D. P.; Andrews, Howard F.; Pelton, Gregory H.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA. [Devanand, D. P.; Andrews, Howard F.; Pelton, Gregory H.] Columbia Univ, Dept Neurol, New York, NY 10032 USA. [Devanand, D. P.; Andrews, Howard F.; Pelton, Gregory H.] Columbia Univ, Coll Physicians & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA. [Andrews, Howard F.; Levin, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Gupta, Sanjay] Global Res & Consulting, Buffalo, NY USA. [Schimming, Corbett] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Mintzer, Jacobo] Med Univ S Carolina, Dept Neurosci, Div Translat Res, Charleston, SC USA. [Mintzer, Jacobo] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC USA. [Schultz, Susan K.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA. [Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Sultzer, David L.] VA Greater Angeles Hlth Syst, Los Angeles, CA USA. [de la Pena, Danilo] Res Ctr Clin Studies, Norwalk, CT USA. [Colon, Sylvia] VA Med Ctr, Dept Psychiat, Tuscaloosa, AL USA. RP Devanand, DP (reprint author), Columbia Univ, New York State Psychiat Inst, Div Geriatr Psychiat, 1051 Riverside Dr,Unit 126, New York, NY 10032 USA. EM dpd3@columbia.edu FU National Institutes of Health [R01 AG021488, R01 AG17761]; Department of Veterans Affairs FX Supported by grants from the National Institutes of Health (R01 AG021488 and R01 AG17761) and the Department of Veterans Affairs. NR 39 TC 47 Z9 49 U1 1 U2 12 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 18 PY 2012 VL 367 IS 16 BP 1497 EP 1507 DI 10.1056/NEJMoa1114058 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 021SA UT WOS:000309904500007 PM 23075176 ER PT J AU Martinez, HG Quinones, MP Jimenez, F Estrada, C Clark, KM Suzuki, K Miura, N Ohno, N Ahuja, SK Ahuja, SS AF Martinez, Hernan G. Quinones, Marlon P. Jimenez, Fabio Estrada, Carlos Clark, Kassandra M. Suzuki, Kazuo Miura, Noriko Ohno, Naohito Ahuja, Sunil K. Ahuja, Seema S. TI Important role of CCR2 in a murine model of coronary vasculitis SO BMC IMMUNOLOGY LA English DT Article DE CCR2; Coronary vasculitis; Treg; Treg/Th17 imbalance ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PERIPHERAL-BLOOD MONOCYTES; ACUTE KAWASAKI-DISEASE; REGULATORY T-CELLS; INTRAVENOUS IMMUNOGLOBULIN; CANDIDA-ALBICANS; KNOCKOUT MICE; PROPAGERMANIUM; RECEPTOR; ATHEROSCLEROSIS AB Background: Chemokines and their receptors play a role in the innate immune response as well as in the disruption of the balance between pro-inflammatory Th17 cells and regulatory T cells (Treg), underlying the pathogenesis of coronary vasculitis in Kawasaki disease (KD). Results: Here we show that genetic inactivation of chemokine receptor (CCR)-2 is protective against the induction of aortic and coronary vasculitis following injection of Candida albicans water-soluble cell wall extracts (CAWS). Mechanistically, both T and B cells were required for the induction of vasculitis, a role that was directly modulated by CCR2. CAWS administration promoted mobilization of CCR2-dependent inflammatory monocytes (iMo) from the bone marrow (BM) to the periphery as well as production of IL-6. IL-6 was likely to contribute to the depletion of Treg and expansion of Th17 cells in CAWS-injected Ccr2(+/+) mice, processes that were ameliorated following the genetic inactivation of CCR2. Conclusion: Collectively, our findings provide novel insights into the role of CCR2 in the pathogenesis of vasculitis as seen in KD and highlight novel therapeutic targets, specifically for individuals resistant to first-line treatments. C1 [Martinez, Hernan G.; Jimenez, Fabio; Estrada, Carlos; Clark, Kassandra M.; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7870, San Antonio, TX 78229 USA. [Martinez, Hernan G.; Jimenez, Fabio; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Quinones, Marlon P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Suzuki, Kazuo] Chiba Univ, Grad Sch Med, Dept Immunol, Inflammat Program, Chiba 2608670, Japan. [Miura, Noriko; Ohno, Naohito] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Immunopharmacol Microbial Prod, Hachioji, Tokyo 1920392, Japan. [Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Ctr Aids & HIV Infect 1, San Antonio, TX USA. RP Ahuja, SS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7870, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ahuja@uthscsa.edu FU Veterans Administration [Merit Review]; National Institutes of Health [R01 AR 052755] FX This work was supported by the Veterans Administration [Merit Review] and National Institutes of Health [R01 AR 052755] to S.S.A. NR 42 TC 10 Z9 10 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2172 J9 BMC IMMUNOL JI BMC Immunol. PD OCT 17 PY 2012 VL 13 AR 56 DI 10.1186/1471-2172-13-56 PG 12 WC Immunology SC Immunology GA 053JU UT WOS:000312268400001 PM 23074996 ER PT J AU Han, S Yang, BZ Kranzler, HR Oslin, D Anton, R Farrer, LA Gelernter, J AF Han, Shizhong Yang, Bao-Zhu Kranzler, Henry R. Oslin, David Anton, Raymond Farrer, Lindsay A. Gelernter, Joel TI Linkage Analysis Followed by Association Show NRG1 Associated with Cannabis Dependence in African Americans SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Association; candidate gene; cannabis dependence; linkage; NRG1; SNP ID GENOME-WIDE LINKAGE; HETEROZYGOUS NEUREGULIN-1 MICE; MULTILOCUS GENOTYPE DATA; USE DISORDERS; ALCOHOL-DEPENDENCE; SEMISTRUCTURED ASSESSMENT; MISSING HERITABILITY; NICOTINE DEPENDENCE; COCAINE DEPENDENCE; DRUG-DEPENDENCE AB Background: A genetic contribution to cannabis dependence (CaD) has been established but susceptibility genes for CaD remain largely unknown. Methods: We employed a multistage design to identify genetic variants underlying CaD. We first performed a genome-wide linkage scan for CaD in 384 African American (AA) and 354 European American families ascertained for genetic studies of cocaine and opioid dependence. We then conducted association analysis under the linkage peak, first using data from a genome-wide association study from the Study of Addiction: Genetics and Environment, followed by replication studies of prioritized single nucleotide polymorphisms (SNPs) in independent samples. Results: We identified the strongest linkage evidence with CaD (logarithm of odds = 2.9) on chromosome 8p21.1 in AAs. In the association analysis of the Study of Addiction: Genetics and Environment sample under the linkage peak, we identified one SNP (rs17664708) associated with CaD in both AAs (odds ratio [OR] = 2.93, p = .0022) and European Americans (OR = 1.38, p = .02). This SNP, located at NRG1, a susceptibility gene for schizophrenia, was prioritized for further study. We replicated the association of rs17664708 with CaD in an independent AAs sample (OR = 2.81, p = .0068). The joint analysis of the two AA samples demonstrated highly significant association between rs17664708 and CaD with adjustment for either global (p = .00044) or local ancestry (p = .00075). Conclusions: Our study shows that NRG1 is probably a susceptibility gene for CaD, based on convergent evidence of linkage and replicated associations in two independent AA samples. C1 [Gelernter, Joel] Yale Univ, Vet Affairs Connecticut Healthcare Ctr, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Kranzler, Henry R.; Oslin, David] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, Henry R.; Oslin, David] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network Mental Illness Res Ed, Philadelphia, PA USA. [Anton, Raymond] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Gelernter, J (reprint author), Yale Univ, Vet Affairs Connecticut Healthcare Ctr, Sch Med, Dept Psychiat, 950 Campbell Ave,116A2, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health (NIH) [R01 DA12690, R01 DA12849, RC2 DA028909, R01 DA18432, R01 AA11330, R01 AA017535, RO1 DA030976, K01 DA24758]; Veterans Affairs (VA) Connecticut Reserve Educational Assistance Program center; VA Merit Grant; VA National Center for Posttraumatic Stress Disorder Research; VA Connecticut and Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center Centers; Alcoholic Beverage Medical Research Foundation; National Institutes of Health [N01-HG-65403]; NIH Genes, Environment and Health Initiative [U01 HG004422, U01HG004438]; Gene Environment Association Studies under the Genes, Environment and Health Initiative; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; NIH [HHSN268200782096C]; Eli Lilly; Alkermes; GlaxoSmithKline; Merck; Lundbeck; Roche; American College of Neuropsychopharmacology Alcohol Clinical Trials Initiative; Alcohol Clinical Trials Initiative FX This study was supported by National Institutes of Health (NIH) Grants R01 DA12690, R01 DA12849, RC2 DA028909, R01 DA18432, R01 AA11330, R01 AA017535, RO1 DA030976, K01 DA24758, and the Veterans Affairs (VA) Connecticut Reserve Educational Assistance Program center, a VA Merit Grant, VA National Center for Posttraumatic Stress Disorder Research, and the VA Connecticut and Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center Centers. It was also partially supported by the Alcoholic Beverage Medical Research Foundation Grant (SH).; We are grateful to the volunteer families and individuals who participated in this research study. We gratefully acknowledge the assistance in recruitment and assessment provided at McLean Hospital by Roger Weiss, M. D., and at the Medical University of South Carolina by Kathleen Brady, M. D., Ph.D. Genotyping services of linkage analysis and our GWAS study were provided by the Center for Inherited Disease Research and Yale University (Keck Center). The Center for Inherited Disease Research is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). We are grateful to Ann Marie Lacobelle, Michelle Cucinelli, Christa Robinson, and Greg Kay for their excellent technical assistance, to the Semi-Structured Assessment for Drug Dependence and Alcoholism interviewers who devoted substantial time and effort to phenotype the study sample, and to John Farrell for database management assistance.; The datasets used for the analyses described in this manuscript were obtained from the database of Genotypes and Phenotypes at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0 00092.v1.p1 through database of Genotypes and Phenotypes accession number phs000092.v1.p. Funding support for the Study of Addiction: Genetics and Environment was provided through the NIH Genes, Environment and Health Initiative (U01 HG004422). The Study of Addiction: Genetics and Environment is one of the genome-wide association studies funded as part of the Gene Environment Association Studies under the Genes, Environment and Health Initiative. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies Coordinating Center (U01 HG004446).; Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392), and the Family Study of Cocaine Dependence (R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH Genes, Environment and Health Initiative (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease" (HHSN268200782096C).; Dr. Kranzler has been a paid consultant for Alkermes, GlaxoSmithKline, Gilead, Eli Lilly, Lundbeck, and Roche. Dr. Anton has received honoraria or grant support from Eli Lilly, Alkermes, GlaxoSmithKline, Merck, Lundbeck, and Roche and is a shareholder in Alcomed. Drs. Kranzler and Anton also report associations with Eli Lilly, Janssen, Schering Plough, Lundbeck, Alkermes, GlaxoSmithKline, Abbott, and Johnson & Johnson, as these companies provide support to the American College of Neuropsychopharmacology Alcohol Clinical Trials Initiative, and both receive support from the Alcohol Clinical Trials Initiative. The other authors reported no biomedical financial interests or potential conflicts of interest. NR 66 TC 12 Z9 12 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2012 VL 72 IS 8 BP 637 EP 644 DI 10.1016/j.biopsych.2012.02.038 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 016UQ UT WOS:000309545400005 PM 22520967 ER PT J AU Zhang, XY Zhang, WF Zhou, DF Chen, DC Xiu, MH Wu, HR Haile, CN Kosten, TA Kosten, TR AF Zhang, Xiang Yang Zhang, Wu-Fang Zhou, Dong-Feng Chen, Da Chun Xiu, Mei Hong Wu, Hao-Ran Haile, Colin N. Kosten, Therese A. Kosten, Thomas R. TI Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Brain-derived neurotrophic factor; extract of ginkgo biloba; genotype; pharmacogenetics; schizophrenia; tardive dyskinesia ID ACTIVITY-DEPENDENT SECRETION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SCHIZOPHRENIC-PATIENTS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; EXTRACT; NEURONS; BDNF; ASSOCIATION AB Background: Tardive dyskinesia (TD) has no well-accepted treatments or known pathophysiology, but low brain-derived neurotrophic factor (BDNF) may play an important role in its pathophysiology. Ginkgo biloba (EGb-761) is a potent antioxidant that has neuroprotective effects mediated through enhancing BDNF levels. We hypothesized that treatment with EGb-761 would increase serum BDNF levels and reduce TD, particularly among schizophrenia patients who have the BDNF valine 66 to methionine (Val66Met) genotype (Val/Val). Methods: Serum BDNF levels and genotyping for the BDNF gene Val66Met polymorphism were assessed in Chinese schizophrenic patients with (n = 368) and without (n = 563) TD as well as healthy control subjects (n = 546). About half of the TD patients (n = 157) then participated in a double-blind, randomized, placebo-control 12-week treatment with 240 mg per day of EGb-761. Serum BDNF levels were measured again at posttreatment. Clinical efficacy was determined using the Abnormal Involuntary Movement Scale (AIMS). Results: TD patients had lower BDNF levels than the non-TD patients and healthy controls. EGb-761 treatment improved symptoms of TD and increased BDNF levels compared with placebo treatment. Moreover, the improvement of AIMS total score correlated with the increase in BDNF levels. Furthermore, improvement in the AIMS score was greatest in those with the Val/Val allele and lowest with the Met/Met allele. Conclusions: The BDNF system may be implicated in the pathophysiology of TD and its improvement with antioxidant treatment. Furthermore, patients with the genetic potential for greater BDNF release (Val/Val at 66) may obtain a greater reduction in TD from EGb-761 treatment. C1 [Zhang, Xiang Yang; Haile, Colin N.; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Kosten, Thomas R.] Beijing HuiLongGuan Hosp, Psychiat Res Ctr, Beijing, Peoples R China. [Zhang, Wu-Fang; Zhou, Dong-Feng] Peking Univ, Inst Mental Hlth, Key Lab Mental Hlth, Minist Hlth, Beijing 100871, Peoples R China. [Wu, Hao-Ran] Hebei Prov Rong Jun Hosp, Baoding, Peoples R China. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu OI Haile, Colin/0000-0001-8293-7291 FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs, South Central VA Health Care Network (VISN 16); Mental Illness Research, Education and Clinical Center (MIRECC); U.S. National Institutes of Health [P50-DA18827, U01-MH79639] FX This study was funded by the Stanley Medical Research Institute (Grant Nos. 03T-459 and 05T-726), the Department of Veterans Affairs, South Central VA Health Care Network (VISN 16); Mental Illness Research, Education and Clinical Center (MIRECC); and U.S. National Institutes of Health Grant Nos. P50-DA18827 and U01-MH79639. NR 43 TC 22 Z9 25 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2012 VL 72 IS 8 BP 700 EP 706 DI 10.1016/j.biopsych.2012.04.032 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 016UQ UT WOS:000309545400014 PM 22695185 ER PT J AU Bashir, T Cloninger, C Artinian, N Anderson, L Bernath, A Holmes, B Benavides-Serrato, A Sabha, N Nishimura, RN Guha, A Gera, J AF Bashir, Tariq Cloninger, Cheri Artinian, Nicholas Anderson, Lauren Bernath, Andrew Holmes, Brent Benavides-Serrato, Angelica Sabha, Nesrin Nishimura, Robert N. Guha, Abhijit Gera, Joseph TI Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice SO PLOS ONE LA English DT Article ID GROWTH-FACTOR RECEPTOR; NEURAL STEM-CELLS; MOUSE ASTROCYTOMA MODEL; ADULT MAMMALIAN BRAIN; SUBVENTRICULAR ZONE; MTOR COMPLEX; GLIOBLASTOMA-MULTIFORME; CELLULAR COMPOSITION; PTEN LOSS; PATHWAY AB Background: Hyperactivation of the mTORC2 signaling pathway has been shown to contribute to the oncogenic properties of gliomas. Moreover, overexpression of the mTORC2 regulatory subunit Rictor has been associated with increased proliferation and invasive character of these tumor cells. Methodology/Principal Findings: To determine whether Rictor overexpression was sufficient to induce glioma formation in mice, we inserted a Cre-lox-regulated human Rictor transgene into the murine ROSA26 locus. This floxed Rictor strain was crossed with mice expressing the Cre recombinase driven from the glial fibrillary acidic protein (GFAP) promoter whose expression is limited to the glial cell compartment. Double transgenic GFAP-Cre/Rictor(loxP/loxP) mice developed multifocal infiltrating glioma containing elevated mTORC2 activity and typically involved the subventricular zone (SVZ) and lateral ventricle. Analysis of Rictor-dependent signaling in these tumors demonstrated that in addition to elevated mTORC2 activity, an mTORC2-independent marker of cortical actin network function, was also elevated. Upon histological examination of the neoplasms, many displayed oligodendroglioma-like phenotypes and expressed markers associated with oligodendroglial lineage tumors. To determine whether upstream oncogenic EGFRvIII signaling would alter tumor phenotypes observed in the GFAP-Cre/Rictor(loxP/loxP) mice, transgenic GFAP-EGFRvIII; GFAP-Cre/Rictor(loxP/loxP) mice were generated. These mice developed mixed astrocytic-oligodendroglial tumors, however glioma formation was accelerated and correlated with increased mTORC2 activity. Additionally, the subventricular zone within the GFAP-Cre/Rictor(loxP/loxP) mouse brain was markedly expanded, and a further proliferation within this compartment of the brain was observed in transgenic GFAP-EGFRvIII; GFAP-Cre/Rictor(loxP/loxP) mice. Conclusion/Significance: These data collectively establish Rictor as a novel oncoprotein and support the role of dysregulated Rictor expression in gliomagenesis via mTOR-dependent and mTOR-independent mechanisms. Furthermore, oncogenic EGFRvIII signaling appears to potentiate the in vivo proliferative capacity of GFAP-Cre/Rictor(loxP/loxP) gliomas. C1 [Bashir, Tariq; Cloninger, Cheri; Artinian, Nicholas; Anderson, Lauren; Bernath, Andrew; Holmes, Brent; Benavides-Serrato, Angelica; Nishimura, Robert N.; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA. [Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Sabha, Nesrin; Guha, Abhijit] Univ Toronto, Hosp Sick Children, Res Inst, Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada. [Gera, Joseph] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. RP Gera, J (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA. EM jgera@mednet.ucla.edu FU National Institutes of Health [R01CA109312]; Veterans Administration FX This work was supported, in part, by National Institutes of Health grant R01CA109312 and funds from the Veterans Administration. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 17 Z9 19 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 15 PY 2012 VL 7 IS 10 AR e47741 DI 10.1371/journal.pone.0047741 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 022WO UT WOS:000309995100158 PM 23077666 ER PT J AU Manka, JT Vinson, PN Gregory, KJ Zhou, Y Williams, R Gogi, K Days, E Jadhav, S Herman, EJ Lavreysen, H Mackie, C Bartolome, JM Macdonald, GJ Steckler, T Daniels, JS Weaver, CD Niswender, CM Jones, CK Conn, PJ Lindsley, CW Stauffer, SR AF Manka, Jason T. Vinson, Paige N. Gregory, Karen J. Zhou, Ya Williams, Richard Gogi, Kiran Days, Emily Jadhav, Satya Herman, Elizabeth J. Lavreysen, Hilde Mackie, Claire Bartolome, Jose M. Macdonald, Gregor J. Steckler, Thomas Daniels, J. Scott Weaver, C. David Niswender, Colleen M. Jones, Carrie K. Conn, P. Jeffrey Lindsley, Craig W. Stauffer, Shaun R. TI Optimization of an ether series of mGlu(5) positive allosteric modulators: Molecular determinants of MPEP-site interaction crossover SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Metabotropic glutamate receptor 5; mGlu(5); Positive allosteric modulator (PAM); Non-MPEP ID RECEPTOR SUBTYPE 5; METABOTROPIC GLUTAMATE RECEPTORS; RAT BEHAVIORAL-MODELS; IN-VIVO ACTIVITY; CNS DISORDERS; DISCOVERY; MGLUR5; PHARMACOLOGY; PROGRESS; POTENT AB We report the optimization of a series of non-MPEP site metabotropic glutamate receptor 5 (mGlu(5)) positive allosteric modulators (PAMs) based on a simple acyclic ether series. Modifications led to a gain of MPEP site interaction through incorporation of a chiral amide in conjunction with a nicotinamide core. A highly potent PAM, 8v (VU0404251), was shown to be efficacious in a rodent model of psychosis. These studies suggest that potent PAMs within topologically similar chemotypes can be developed to preferentially interact or not interact with the MPEP allosteric binding site. (c) 2012 Elsevier Ltd. All rights reserved. C1 [Manka, Jason T.; Vinson, Paige N.; Gregory, Karen J.; Zhou, Ya; Williams, Richard; Gogi, Kiran; Days, Emily; Jadhav, Satya; Herman, Elizabeth J.; Daniels, J. Scott; Weaver, C. David; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Manka, Jason T.; Vinson, Paige N.; Gregory, Karen J.; Zhou, Ya; Williams, Richard; Gogi, Kiran; Jadhav, Satya; Herman, Elizabeth J.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Manka, Jason T.; Zhou, Ya; Williams, Richard; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Specialized Chem Ctr Probe Dev MLPCN, Nashville, TN 37232 USA. [Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Days, Emily; Weaver, C. David] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA. [Lavreysen, Hilde; Macdonald, Gregor J.; Steckler, Thomas] Janssen Res & Dev, Neurosci, B-2340 Beerse, Belgium. [Mackie, Claire] Janssen Res & Dev, CREATe ADME Tox, B-2340 Beerse, Belgium. [Bartolome, Jose M.] Janssen Res & Dev, Neurosci Med Chem, Toledo 45007, Spain. [Gregory, Karen J.] Monash Univ, MIPS, Parkville, Vic, Australia. [Gregory, Karen J.] Monash Univ, Dept Pharmacol, Parkville, Vic, Australia. [Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Stauffer, SR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM shaun.stauffer@vanderbilt.edu RI Zhou, Ya/F-1220-2013 OI Gregory, Karen/0000-0002-3833-2137 FU NIH [NS031373-15, MH073676-04]; Johnson Johnson; NARSAD; NHMRC FX This work was supported in part by grants from the NIH (NS031373-15, MH073676-04) and from an industry sponsored contract from Johnson & Johnson. K.J.G. thanks NARSAD and NHMRC for fellowship support. The authors thank Daryl F. Venable for technical assistance with radioligand binding assays. NR 33 TC 11 Z9 11 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD OCT 15 PY 2012 VL 22 IS 20 BP 6481 EP 6485 DI 10.1016/j.bmcl.2012.08.043 PG 5 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 017RW UT WOS:000309609500032 PM 22981332 ER PT J AU Sumpter, TL Dangi, A Matta, BM Huang, C Stolz, DB Vodovotz, Y Thomson, AW Gandhi, CR AF Sumpter, Tina L. Dangi, Anil Matta, Benjamin M. Huang, Chao Stolz, Donna B. Vodovotz, Yoram Thomson, Angus W. Gandhi, Chandrashekhar R. TI Hepatic Stellate Cells Undermine the Allostimulatory Function of Liver Myeloid Dendritic Cells via STAT3-Dependent Induction of IDO SO JOURNAL OF IMMUNOLOGY LA English DT Article ID REGULATORY T-CELLS; RAT-LIVER; INDOLEAMINE 2,3-DIOXYGENASE; IN-VIVO; ISCHEMIA/REPERFUSION INJURY; TRANSPLANT RECIPIENTS; TRYPTOPHAN CATABOLISM; ENDOTHELIN RECEPTORS; STAT3 ACTIVATION; UP-REGULATION AB Hepatic stellate cells (HSCs) are critical for hepatic wound repair and tissue remodeling. They also produce cytokines and chemokines that may contribute to the maintenance of hepatic immune homeostasis and the inherent tolerogenicity of the liver. The functional relationship between HSCs and the professional migratory APCs in the liver, that is, dendritic cells (DCs), has not been evaluated. In this article, we report that murine liver DCs colocalize with HSCs in vivo under normal, steady-state conditions, and cluster with HSCs in vitro. In vitro, HSCs secrete high levels of DC chemoattractants, such as M.P-1 alpha and MCP-1, as well as cytokines that modulate DC activation, including TNF-alpha, IL-6, and IL-1 beta. Culture of HSCs with conventional liver myeloid (m) DCs resulted in increased IL-6 and IL-10 secretion compared with that of either cell population alone. Coculture also resulted in enhanced expression of costimulatory (CD80, CD86) and coinhibitory (B7-H1) molecules on mDCs. HSC-induced mDC maturation required cell-cell contact and could be blocked, in part, by neutralizing MIP-1 alpha or MCP-1. HSC-induced mDC maturation was dependent on activation of STAT3 in mDCs and, in part, on HSC-secreted IL-6. Despite upregulation of costimulatory molecules, mDCs conditioned by HSCs demonstrated impaired ability to induce allogeneic T cell proliferation, which was independent of B7-H1, but dependent upon HSC-induced STAT3 activation and subsequent upregulation of IDO. In conclusion, by promoting IDO expression, HSCs may act as potent regulators of liver mDCs and function to maintain hepatic homeostasis and tolerogenicity. The Journal of Immunology, 2012, 189:3848-3858. C1 [Sumpter, Tina L.; Dangi, Anil; Matta, Benjamin M.; Huang, Chao; Vodovotz, Yoram; Thomson, Angus W.; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA 15213 USA. [Sumpter, Tina L.] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15213 USA. [Dangi, Anil; Huang, Chao; Gandhi, Chandrashekhar R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Matta, Benjamin M.; Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA. [Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15213 USA. [Gandhi, Chandrashekhar R.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA. RP Gandhi, CR (reprint author), Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg, E-1540 BST,200 Lothrop St, Pittsburgh, PA 15213 USA. EM Gandhics@upmc.edu FU National Institutes of Health [PO1AI81678, T32 AI74490]; Veterans Administration Merit Review Award; American Society of Transplantation Basic Science Fellowship; American Liver Foundation Roger Jenkins Fellowship FX This work was supported by National Institutes of Health Grants PO1AI81678 (to A.W.T. and C.R.G.) and T32 AI74490 (to A.W.T.), a Veterans Administration Merit Review Award (to C.R.G.), and an American Society of Transplantation Basic Science Fellowship and an American Liver Foundation Roger Jenkins Fellowship (to T.L.S.). NR 85 TC 14 Z9 15 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD OCT 15 PY 2012 VL 189 IS 8 BP 3848 EP 3858 DI 10.4049/jimmunol.1200819 PG 11 WC Immunology SC Immunology GA 017LH UT WOS:000309590900012 PM 22962681 ER PT J AU Wylie, KP Rojas, DC Tanabe, J Martin, LF Tregellas, JR AF Wylie, Korey P. Rojas, Donald C. Tanabe, Jody Martin, Laura F. Tregellas, Jason R. TI Nicotine increases brain functional network efficiency SO NEUROIMAGE LA English DT Article DE Nicotine; Acetylcholine; Graph theory; Small-world; Network; fMRI ID SMALL-WORLD NETWORKS; ALZHEIMERS-DISEASE; ACETYLCHOLINE-RECEPTOR; TRANSDERMAL NICOTINE; BIPOLAR DISORDER; SCHIZOPHRENIA; CONNECTIVITY; MATTER; ATTENTION; COGNITION AB Despite the use of cholinergic therapies in Alzheimer's disease and the development of cholinergic strategies for schizophrenia, relatively little is known about how the system modulates the connectivity and structure of large-scale brain networks. To better understand how nicotinic cholinergic systems alter these networks, this study examined the effects of nicotine on measures of whole-brain network communication efficiency. Resting state fMRI was acquired from fifteen healthy subjects before and after the application of nicotine or placebo transdermal patches in a single blind, crossover design. Data, which were previously examined for default network activity, were analyzed with network topology techniques to measure changes in the communication efficiency of whole-brain networks. Nicotine significantly increased local efficiency, a parameter that estimates the network's tolerance to local errors in communication. Nicotine also significantly enhanced the regional efficiency of limbic and paralimbic areas of the brain, areas which are especially altered in diseases such as Alzheimer's disease and schizophrenia. These changes in network topology may be one mechanism by which cholinergic therapies improve brain function. Published by Elsevier Inc. C1 [Wylie, Korey P.; Rojas, Donald C.; Martin, Laura F.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. [Tanabe, Jody] Univ Colorado, Dept Radiol, Aurora, CO 80045 USA. [Tregellas, Jason R.] Eastern Colorado Hlth Syst, Res Serv 151, Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Tregellas, JR (reprint author), Anschutz Med Campus Bldg 500,Mail Stop F546,13001, Aurora, CO 80045 USA. EM Jason.Tregellas@UCDenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616 FU VA Biomedical Laboratory and Clinical Science Research and Development Service; National Association for Research in Schizophrenia and Affective Disorders (NARSAD); Blowitz-Ridgeway Foundation; NIH/NIDDK [R01 DK089095]; NIH/NIMH [P50 MH-086383] FX The research was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service, the National Association for Research in Schizophrenia and Affective Disorders (NARSAD), the Blowitz-Ridgeway Foundation, NIH/NIDDK R01 DK089095 and NIH/NIMH P50 MH-086383. NR 53 TC 18 Z9 18 U1 2 U2 29 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD OCT 15 PY 2012 VL 63 IS 1 BP 73 EP 80 DI 10.1016/j.neuroimage.2012.06.079 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 005SN UT WOS:000308770300008 PM 22796985 ER PT J AU Gardner, LI Marks, G Craw, JA Wilson, TE Drainoni, ML Moore, RD Mugavero, MJ Rodriguez, AE Bradley-Springer, LA Holman, S Keruly, JC Sullivan, M Skolnik, PR Malitz, F Metsch, LR Raper, JL Giordano, TP AF Gardner, Lytt I. Marks, Gary Craw, Jason A. Wilson, Tracey E. Drainoni, Mari-Lynn Moore, Richard D. Mugavero, Michael J. Rodriguez, Allan E. Bradley-Springer, Lucy A. Holman, Susan Keruly, Jeanne C. Sullivan, Meg Skolnik, Paul R. Malitz, Faye Metsch, Lisa R. Raper, James L. Giordano, Thomas P. CA Retention Care Study Grp TI A Low-Effort, Clinic-Wide Intervention Improves Attendance for HIV Primary Care SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID MEDICAL-CARE; RETENTION; ENGAGEMENT; PREVENTION; INFECTION AB Background. Retention in care for human immunodeficiency virus (HIV)-infected patients is a National HIV/AIDS Strategy priority. We hypothesized that retention could be improved with coordinated messages to encourage patients' clinic attendance. We report here the results of the first phase of the Centers for Disease Control and Prevention/Health Resources and Services Administration Retention in Care project. Methods. Six HIV-specialty clinics participated in a cross-sectionally sampled pretest-posttest evaluation of brochures, posters, and messages that conveyed the importance of regular clinic attendance. 10 018 patients in 20082009 (preintervention period) and 11 039 patients in 2009-2010 (intervention period) were followed up for clinic attendance. Outcome variables were the percentage of patients who kept 2 consecutive primary care visits and the mean proportion of all primary care visits kept. Stratification variables were: new, reengaging, and active patients, HIV RNA viral load, CD4 cell count, age, sex, race or ethnicity, risk group, number of scheduled visits, and clinic site. Data were analyzed by multivariable log-binomial and linear models using generalized estimation equation methods. Results. Clinic attendance for primary care was significantly higher in the intervention versus preintervention year. Overall relative improvement was 7.0% for keeping 2 consecutive visits and 3.0% for the mean proportion of all visits kept (P < .0001). Larger relative improvement for both outcomes was observed for new or reengaging patients, young patients and patients with elevated viral loads. Improved attendance among the new or reengaging patients was consistent across the 6 clinics, and less consistent across clinics for active patients. Conclusion. Targeted messages on staying in care, which were delivered at minimal effort and cost, improved clinic attendance, especially for new or reengaging patients, young patients, and those with elevated viral loads. C1 [Gardner, Lytt I.; Marks, Gary; Craw, Jason A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Craw, Jason A.] ICF Int, Atlanta, GA USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Dept Community Hlth Sci, Brooklyn, NY 11203 USA. [Holman, Susan] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA. [Holman, Susan] Suny Downstate Med Ctr, Coll Nursing, Brooklyn, NY 11203 USA. [Drainoni, Mari-Lynn] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA. [Drainoni, Mari-Lynn; Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Moore, Richard D.; Keruly, Jeanne C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Malitz, Faye] Hlth Resources & Serv Adm, Div Sci & Policy, Rockville, MD USA. [Moore, Richard D.; Raper, James L.] Univ Alabama Birmingham, HIV AIDS Clin 1917, Birmingham, AL USA. [Mugavero, Michael J.; Raper, James L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA. [Metsch, Lisa R.] Univ Miami, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA. [Bradley-Springer, Lucy A.] Univ Colorado Denver, Sch Med, Denver, CO USA. [Skolnik, Paul R.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Giordano, Thomas P.] DeBakey VA Med Ctr, Houston, TX USA. RP Gardner, LI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Mailstop E-45, Atlanta, GA 30333 USA. EM lig0@cdc.gov FU CDC; HRSA (CDC) [200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687]; SUNY Downstate Medical Center [200-2007-23684]; [200-2007-23692] FX This work was supported by the CDC and the HRSA (CDC contracts 200-2007-23685 to Baylor College of Medicine, 200-2007-23690 to Boston Medical Center, 200-2007-23689 to Johns Hopkins University School of Medicine, 200-2007-23687 to Research Foundation of the State University of New York, SUNY Downstate Medical Center, 200-2007-23684 to University of Alabama at Birmingham, and 200-2007-23692 to University of Miami Miller School of Medicine). NR 26 TC 33 Z9 33 U1 2 U2 18 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2012 VL 55 IS 8 BP 1124 EP 1134 DI 10.1093/cid/cis623 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 010BX UT WOS:000309070500020 PM 22828593 ER PT J AU Demetriou, SK Ona-Vu, K Sullivan, EM Dong, TK Hsu, SW Oh, DH AF Demetriou, Stephanie K. Ona-Vu, Katherine Sullivan, Erin M. Dong, Tiffany K. Hsu, Shu-Wei Oh, Dennis H. TI Defective DNA repair and cell cycle arrest in cells expressing Merkel cell polyomavirus T antigen SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE Merkel cell carcinoma; polyomavirus; DNA repair; cell cycle; ultraviolet radiation ID NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; GLOBAL GENOMIC REPAIR; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; IN-VITRO; CARCINOMA; P53; DEFICIENT; INFECTION AB The pathways by which Merkel cell polyomavirus (MCV) infection contributes to the formation of Merkel cell carcinomas are important for understanding the pathogenesis of these cancers. We hypothesized that MCV T antigen suppresses normal responses to ultraviolet radiation (UVR)-induced DNA damage. An MCV-infected cell line (MKL-1) exhibited UVR hypersensitivity, impaired repair of DNA lesions and cell cycle arrest after UVR, as well as reduced levels of the DNA damage recognition protein, XPC. When ectopically expressed in uninfected UISO cells, mutant but not wild-type T antigen resulted in loss of repair of UVR-induced cyclobutane pyrimidine dimers and reductions in XPC, p53 and p21 levels, whereas both wild-type and mutant T antigen inhibited cell cycle arrest after UVR. Similarly, only mutant T antigen in normal fibroblasts inhibited DNA repair and XPC expression, while both mutant and wild-type T antigens produced cell cycle dysregulation. Wild-type T antigen expression produced large T, 57 kT and small T antigens while mutant T antigen was only detectable as a truncated large T antigen protein. Expression of wild-type large T antigen but not small T antigen inhibited the G1 checkpoint in UISO cells, but neither wild-type large T nor small T antigens affected DNA repair, suggesting that large T antigen generates cell cycle defects, and when mutated may also impair DNA repair. These results indicate that T antigen expression by MCV can inhibit key responses to UVR-induced DNA damage and suggest that progressive MCV-mediated abrogation of genomic stability may be involved in Merkel cell carcinogenesis. C1 [Demetriou, Stephanie K.; Ona-Vu, Katherine; Sullivan, Erin M.; Dong, Tiffany K.; Hsu, Shu-Wei; Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA USA. [Demetriou, Stephanie K.; Ona-Vu, Katherine; Sullivan, Erin M.; Dong, Tiffany K.; Hsu, Shu-Wei; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. RP Oh, DH (reprint author), VA Med Ctr, Dermatol Res Serv 190, 4150 Clement St, San Francisco, CA 94121 USA. EM ohd@derm.ucsf.edu FU National Cancer Institute [P30 CA82103]; University of California Cancer Research Coordinating Committee; Department of Veterans Affairs; Dept. of Veterans Affairs, Office of Research and Development, Biomedical Laboratory FX Grant sponsor: National Cancer Institute; Grant number: P30 CA82103; Grant sponsors: University of California Cancer Research Coordinating Committee, Department of Veterans Affairs; The authors thank Drs. Yuan Chang and Patrick Moore for providing MKL-1 cells, the TAg206, TAg350, LT206 and sT vectors and the CM8E6 antibody; Dr. T. K. Das Gupta for UISO cells; and R. Griby of the Northern California Institute for Research and Education for assistance with flow cytometry. Work was supported by an HIV-associated malignancies pilot project award from NCI (P30 CA82103), a University of California Cancer Research Coordinating Committee grant, and a Dept. of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research and Development (Merit Award) (all to D.H.O.). NR 49 TC 17 Z9 17 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD OCT 15 PY 2012 VL 131 IS 8 BP 1818 EP 1827 DI 10.1002/ijc.27440 PG 10 WC Oncology SC Oncology GA 993XN UT WOS:000307893400009 PM 22261839 ER PT J AU Wilt, TJ Brawer, MK Aronson, WJ AF Wilt, Timothy J. Brawer, Michael K. Aronson, William J. TI Radical Prostatectomy versus Observation for Prostate Cancer REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Wilt, Timothy J.] Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Brawer, Michael K.] Myriad Genet, Salt Lake City, UT USA. [Aronson, William J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Wilt, TJ (reprint author), Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. EM tim.wilt@va.gov NR 5 TC 0 Z9 0 U1 0 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 11 PY 2012 VL 367 IS 15 BP 1468 EP 1469 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 018ID UT WOS:000309652700022 ER PT J AU Lane, RF St George-Hyslop, P Hempstead, BL Small, SA Strittmatter, SM Gandy, S AF Lane, Rachel F. St George-Hyslop, Peter Hempstead, Barbara L. Small, Scott A. Strittmatter, Stephen M. Gandy, Sam TI Vps10 Family Proteins and the Retromer Complex in Aging-Related Neurodegeneration and Diabetes SO JOURNAL OF NEUROSCIENCE LA English DT Article ID AMYLOID PRECURSOR PROTEIN; SPORADIC ALZHEIMERS-DISEASE; QUANTITATIVE TRAIT LOCUS; GENOME-WIDE ASSOCIATION; LR11/SORLA EXPRESSION; SUSCEPTIBILITY LOCI; NEUROTROPHIC FACTOR; PARKINSON DISEASE; BETA PRODUCTION; DOWN-SYNDROME AB Members of the vacuolar protein sorting 10 (Vps10) family of receptors (including sortilin, SorL1, SorCS1, SorCS2, and SorCS3) play pleiotropic functions in protein trafficking and intracellular and intercellular signaling in neuronal and non-neuronal cells. Interactions have been documented between Vps10 family members and the retromer coat complex, a key component of the intracellular trafficking apparatus that sorts cargo from the early endosome to the trans-Golgi network. In recent years, genes encoding several members of the Vps10 family of proteins, as well as components of the retromer coat complex, have been implicated as genetic risk factors for sporadic and autosomal dominant forms of neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease, with risk for type 2 diabetes mellitus and atherosclerosis. In addition to their functions in protein trafficking, the Vps10 family proteins modulate neurotrophic signaling pathways. Sortilin can impact the intracellular response to brain-derived neurotrophic factor (BDNF) by regulating anterograde trafficking of Trk receptors to the synapse and direct control of BDNF levels, while both sortilin and SorCS2 function as cell surface receptors to mediate acute responses to proneurotrophins. This mini-review and symposium will highlight the emerging data from this rapidly growing area of research implicating the Vps10 family of receptors and the retromer in physiological intracellular trafficking signaling by neurotrophins and in the pathogenesis of neurodegeneration. C1 [Lane, Rachel F.] Alzheimers Drug Discovery Fdn, New York, NY 10019 USA. [St George-Hyslop, Peter] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada. [St George-Hyslop, Peter] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England. [St George-Hyslop, Peter] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0XY, England. [Hempstead, Barbara L.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA. [Small, Scott A.] Columbia Univ, Sch Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Small, Scott A.] Columbia Univ, Sch Phys & Surg, Taub Inst, New York, NY 10032 USA. [Strittmatter, Stephen M.] Yale Univ, Sch Med, Cellular Neurosci Neurodegenerat & Repair Program, Dept Neurol, New Haven, CT 06536 USA. [Strittmatter, Stephen M.] Yale Univ, Sch Med, Cellular Neurosci Neurodegenerat & Repair Program, Dept Neurobiol, New Haven, CT 06536 USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Lane, RF (reprint author), Alzheimers Drug Discovery Fdn, 57 W 57th St,Suite 904, New York, NY 10019 USA. EM RLane@alzdiscovery.org; samuel.gandy@mssm.edu RI Strittmatter, Stephen/F-5739-2011 OI Strittmatter, Stephen/0000-0001-8188-3092 FU NIH [NS075685, NS030687, AG025161, NS074319, AG034924]; Wellcome Trust; Canadian Institutes of Health Research; Alzheimer Society of Ontario; Howard Hughes Medical Institute; Cure Alzheimer's Fund; US Department of Veteran Affairs FX We gratefully acknowledge the support of the NIH (NS075685 to S.G., NS030687 to B.L.H., AG025161 to S.A.S., NS074319 and AG034924 to S.M.S.), the Wellcome Trust, Canadian Institutes of Health Research, Alzheimer Society of Ontario, and Howard Hughes Medical Institute (P.StG.-H.), the Cure Alzheimer's Fund (S.G.), and the US Department of Veteran Affairs (S.G.). R.F.L. and S.G.thank Dr. Alan Attie for providing advice and helpful conversations during the preparation of this paper. NR 60 TC 26 Z9 27 U1 2 U2 20 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD OCT 10 PY 2012 VL 32 IS 41 BP 14080 EP 14086 DI 10.1523/JNEUROSCI.3359-12.2012 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 022MO UT WOS:000309963700006 PM 23055476 ER PT J AU Slatore, CG Wiener, RS Cooke, CR AF Slatore, Christopher G. Wiener, Renda Soylemez Cooke, Colin R. TI Is Intensive Care Unit Admission an Indicator of Patient-Centered Care for Patients With Advanced Lung Cancer in SEER-Medicare? Reply SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter ID CODE STATUS C1 [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Cooke, Colin R.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA. [Cooke, Colin R.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. RP Slatore, CG (reprint author), Portland VA Med Ctr, Portland, OR USA. OI Slatore, Christopher/0000-0003-0958-8122 NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 10 PY 2012 VL 30 IS 29 BP 3652 EP 3653 DI 10.1200/JCO.2012.45.0296 PG 3 WC Oncology SC Oncology GA 018IM UT WOS:000309653600019 ER PT J AU Parker, ED Margolis, KL Trower, NK Magid, DJ Tavel, HM Shetterly, SM Ho, PM Swain, BE O'Connor, PJ AF Parker, Emily D. Margolis, Karen L. Trower, Nicole K. Magid, David. J. Tavel, Heather M. Shetterly, Susan M. Ho, P. Michael Swain, Bix E. O'Connor, Patrick J. TI Comparative Effectiveness of 2 beta-Blockers in Hypertensive Patients SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID PROSPECTIVELY-DESIGNED OVERVIEWS; HEART-RATE-VARIABILITY; BLOOD-PRESSURE; RANDOMIZED-TRIAL; CARDIOVASCULAR EVENTS; 1ST-LINE THERAPY; ATENOLOL; PREVENTION; METAANALYSIS; GUIDELINES AB Background: Randomized controlled trials have demonstrated the efficacy of selected beta-blockers for preventing cardiovascular (CV) events in patients following myocardial infarction (MI) or with heart failure (HF). However, the effectiveness of beta-blockers for preventing CV events in patients with hypertension has been questioned recently, but it is unclear whether this is a class effect. Methods: Using electronic medical record and health plan data from the Cardiovascular Research Network Hypertension Registry, we compared incident MI, HF, and stroke in patients who were new beta-blocker users between 2000 and 2009. Patients had no history of CV disease and had not previously filled a prescription for a beta-blocker. Cox proportional hazards regression was used to examine the associations of atenolol and metoprolol tartrate with incident CV events using both standard covariate adjustment (n=120 978) and propensity score-matching methods (n=22 352). Results: During follow-up (median, 5.2 years), there were 3517 incident MI, 3272 incident HF, and 3664 incident stroke events. Hazard ratios for MI, HF, and stroke in metoprolol tartrate users were 0.99 (95% CI, 0.97-1.02), 0.99 (95% CI, 0.96-1.01), and 0.99 (95% CI, 0.97-1.02), respectively. An alternative approach using propensity score matching yielded similar results in 11 176 new metoprolol tartrate users, who were similar to 11 176 new atenolol users with regard to demographic and clinical characteristics. Conclusions: There were no statistically significant differences in incident CV events between atenolol and metoprolol tartrate users with hypertension. Large registries similar to the one used in this analysis may be useful for addressing comparative effectiveness questions that are unlikely to be resolved by randomized trials. C1 [Parker, Emily D.; Margolis, Karen L.; Trower, Nicole K.; O'Connor, Patrick J.] HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA. [Magid, David. J.; Tavel, Heather M.; Shetterly, Susan M.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. [Ho, P. Michael] Univ Colorado, Sch Med, Div Cardiol, Denver, CO USA. [Swain, Bix E.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. RP Parker, ED (reprint author), HealthPartners Inst Educ & Res, Box 1524,Mail Stop 21111R, Minneapolis, MN 55440 USA. EM Emily.D.Parker@Healthpartners.com FU National Heart, Lung, and Blood Institute [NIH/NHLBI/U19 HL091179] FX This project was funded by grant NIH/NHLBI/U19 HL091179 from the National Heart, Lung, and Blood Institute and subcontract to HealthPartners Institute for Education and Research. NR 35 TC 6 Z9 6 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 8 PY 2012 VL 172 IS 18 BP 1406 EP 1412 DI 10.1001/archinternmed.2012.4276 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 016ST UT WOS:000309540500008 PM 22928181 ER PT J AU Su, G Sung, KE Beebe, DJ Friedl, A AF Su, Gui Sung, Kyung E. Beebe, David J. Friedl, Andreas TI Functional Screen of Paracrine Signals in Breast Carcinoma Fibroblasts SO PLOS ONE LA English DT Article ID MATRIX-METALLOPROTEINASE INHIBITORS; MAMMARY-TUMOR GROWTH; STROMAL FIBROBLASTS; GENE-EXPRESSION; CELL-PROLIFERATION; CANCER CELLS; PROGRESSION; HEPARANASE; RECEPTOR; MICROENVIRONMENT AB Stromal fibroblasts actively participate in normal mammary gland homeostasis and in breast carcinoma growth and progression by secreting paracrine factors; however, little is known about the identity of paracrine mediators in individual patients. The purpose of this study was to characterize paracrine signaling pathways between breast carcinoma cells and breast carcinoma-associated fibroblasts (CAF) or normal mammary fibroblasts (NF), respectively. CAF and NF were isolated from breast carcinoma tissue samples and adjacent normal mammary gland tissue of 28 patients. The fibroblasts were grown in 3D collagen gel co-culture with T47D human breast carcinoma cells and T47D cell growth was measured. CAF stimulated T47D cell growth to a significantly greater degree than NF. We detected a considerable inter-individual heterogeneity of paracrine interactions but identified FGF2, HB-EGF, heparanase-1 and SDF1 as factors that were consistently responsible for the activity of carcinoma-associated fibroblasts. CAF from low-grade but not high-grade carcinomas required insulin-like growth factor 1 and transforming growth factor beta 1 to stimulate carcinoma growth. Paradoxically, blocking of membrane-type 1 matrix metalloprotease stimulated T47D cell growth in co-culture with NF. The results were largely mirrored by treating the fibroblasts with siRNA oligonucleotides prior to co-culture, implicating the fibroblasts as principal production site for the secreted mediators. In summary, we identify a paracrine signaling network with inter-individual commonalities and differences. These findings have significant implications for the design of stroma-targeted therapies. C1 [Su, Gui; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Sung, Kyung E.; Beebe, David J.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs, Med Ctr, Madison, WI 53705 USA. RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. EM afriedl@wisc.edu FU National Institutes of Health [RO1 CA107012]; Wisconsin Partnership program FX The work was supported by National Institutes of Health grant RO1 CA107012 and a grant from the Wisconsin Partnership program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 23 Z9 24 U1 0 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 8 PY 2012 VL 7 IS 10 AR e46685 DI 10.1371/journal.pone.0046685 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 020RP UT WOS:000309831500057 PM 23056402 ER PT J AU Cheng, T Yang, C Weber, N Kim, HT Kuo, AC AF Cheng, Tiffany Yang, Christina Weber, Norbert Kim, Hubert T. Kuo, Alfred C. TI Fibroblast growth factor 2 enhances the kinetics of mesenchymal stem cell chondrogenesis SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Mesenchymal stem cell; Chondrogenesis; Fibroblast growth factor 2 ID HYPERTROPHIC CHONDROCYTE KINETICS; BONE-MARROW; IN-VITRO; DIFFERENTIATION; FGF-2; PROGENITORS; POTENTIALS; EXPRESSION; MATURATION; EXPANSION AB Treatment of mesenchymal stem cells (MSCs) with fibroblast growth factor 2 (FGF-2) during monolayer expansion leads to increased expression of cartilage-related molecules during subsequent pellet chondrogenesis. This may be due to faster differentiation and/or a durable change in phenotype. In order to evaluate changes over time, we assessed chondrogenesis of human MSCs at early and late time points during pellet culture using real-time PCR, measurement of glycosaminoglycan accumulation, and histology. Marked enhancement of chondrogenesis was seen early compared to controls. However, the differences from controls in gene expression dramatically diminished over time. Depending on conditions, increases in glycosaminoglycan accumulation were maintained. These results suggest that FGF-2 can enhance the kinetics of MSC chondrogenesis, leading to early differentiation, possibly by a priming mechanism. Published by Elsevier Inc. C1 [Cheng, Tiffany; Yang, Christina; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. [Cheng, Tiffany; Yang, Christina; Kim, Hubert T.; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Weber, Norbert] Musculoskeletal Transplant Fdn, Edison, NJ 08837 USA. RP Kuo, AC (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave,MU 320W, San Francisco, CA 94143 USA. EM kuoac@orthosurg.ucsf.edu FU UCSF Department of Orthopaedic Surgery; UCSF Research Evaluation and Allocation Committee; Musculoskeletal Transplant Foundation FX We thank Eva Grotkopp for statistical assistance and Michelle Park for assistance with immunohistochemistry. This work was supported by the UCSF Department of Orthopaedic Surgery, by a pilot project grant from the UCSF Research Evaluation and Allocation Committee, and by an unrestricted research grant from the Musculoskeletal Transplant Foundation, which was administered by the Northern California Institute for Research and Education. The experiments were performed with the resources of the Veterans Affairs Medical Center, San Francisco, California. NR 27 TC 12 Z9 15 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD OCT 5 PY 2012 VL 426 IS 4 BP 544 EP 550 DI 10.1016/j.bbrc.2012.08.124 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 024HT UT WOS:000310101000018 PM 22982316 ER PT J AU Banks, WA Niehoff, ML Ponzio, NM Erickson, MA Zalcman, SS AF Banks, William A. Niehoff, Michael L. Ponzio, Nicholas M. Erickson, Michelle A. Zalcman, Steven S. TI Pharmacokinetics and modeling of immune cell trafficking: quantifying differential influences of target tissues versus lymphocytes in SJL and lipopolysaccharide-treated mice SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Blood-brain barrier; Brain; Cellular trafficking; Encephalitis; Immune; Lymphocytes; Multiple sclerosis; Neuroinflammation; Neuroimmune; Pharmacokinetics ID BLOOD-BRAIN-BARRIER; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; ENCEPHALITIS; LEUKOCYTE; MIGRATION; TRANSPORT; INVASION; MOUSE; ENTRY AB Background: Immune cell trafficking into the CNS and other tissues plays important roles in health and disease. Rapid quantitative methods are not available that could be used to study many of the dynamic aspects of immune cell-tissue interactions. Methods: We used pharmacokinetics and modeling to quantify and characterize the trafficking of radioactively labeled lymphocytes into brain and peripheral tissues. We used variance from two-way ANOVAs with 2 x 2 experimental designs to model the relative influences of lymphocytes and target tissues in trafficking. Results: We found that in male CD-1 mice, about 1 in 5,000 intravenously injected lymphocytes entered each gram of brain. Uptake by brain was 2 to 3 times higher in naive SJL females, but uptake by spleen and clearance from blood was lower, demonstrating a dichotomy in immune cell distribution. Treatment of CD-1 mice with lipopolysaccharide (LPS) increased immune cell uptake into brain but decreased uptake by spleen and axillary nodes. Conclusions: Differences in brain uptake and in uptake by spleen between SJL and CD-1 mice were primarily determined by lymphocytes, whereas differences in uptake with LPS were primarily determined by lymphocytes for the brain but by the tissues for the spleen and the axillary lymph node. These results show that immune cells normally enter the CNS and that tissues and immune cells interact in ways that can be quantified by pharmacokinetic models. C1 [Banks, William A.; Erickson, Michelle A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Banks, William A.; Erickson, Michelle A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Banks, William A.] VAPSHCS, Seattle, WA 98108 USA. [Niehoff, Michael L.] St Louis Univ, Sch Med, Div Geriatr Med, Dept Internal Med, St Louis, MO 63104 USA. [Ponzio, Nicholas M.] Univ Med & Dent New Jersey, UMDNJ, Newark, NJ USA. [Erickson, Michelle A.] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA. [Zalcman, Steven S.] Univ Med & Dent New Jersey, UMDNJ, Dept Psychiat, Newark, NJ USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. EM wabanks1@uw.edu FU VA Merit Review [NS050547, AG029839, MH74689, MH68021] FX Supported by VA Merit Review (WAB), NS050547 (WAB), AG029839 (WAB), MH74689 (SSZ), and MH68021 (SSZ). NR 30 TC 4 Z9 4 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD OCT 3 PY 2012 VL 9 AR 231 DI 10.1186/1742-2094-9-231 PG 14 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 033OB UT WOS:000310806100001 PM 23034075 ER PT J AU Goldzweig, CL AF Goldzweig, Caroline Lubick TI Pushing the Envelope of Electronic Patient Portals to Engage Patients in Their Care SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Goldzweig, CL (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Caroline.Goldzweig@va.gov NR 7 TC 3 Z9 3 U1 1 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 2 PY 2012 VL 157 IS 7 BP 525 EP 526 DI 10.7326/0003-4819-157-7-201210020-00013 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 016MQ UT WOS:000309523200010 PM 23027322 ER PT J AU Fan, VS Niewoehner, DE Lew, R AF Fan, Vincent S. Niewoehner, Dennis E. Lew, Robert TI A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Niewoehner, Dennis E.] Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN 55417 USA. [Lew, Robert] Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA. RP Fan, VS (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 0 TC 2 Z9 2 U1 2 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 2 PY 2012 VL 157 IS 7 BP 530 EP 531 DI 10.7326/0003-4819-157-7-201210020-00019 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 016MQ UT WOS:000309523200014 ER PT J AU Zollinger, TW Saywell, RM Robinson, JJ Jay, SJ Spitznagle, MH AF Zollinger, Terrell W. Saywell, Robert M., Jr. Robinson, Joshua J. Jay, Stephen J. Spitznagle, Miranda H. TI Effect of Personal Characteristics on Individual Support for Indoor Smoke-Free Air Laws, Indiana, 2008 SO PREVENTING CHRONIC DISEASE LA English DT Article ID PARENTAL SMOKING; POSTNATAL EXPOSURE; RESPIRATORY HEALTH; BANS; RESTAURANTS; PREDICTORS; CHILDREN; BELIEFS; IMPACT; BARS AB Introduction Policy makers should understand the attitudes and beliefs of their constituents regarding smoke-free air legislation. The purpose of this study was to evaluate the effect of selected personal characteristics on attitudes and beliefs about secondhand smoke in Indiana and on support for smoke-free air laws. Methods Data were obtained from the 2008 Indiana Adult Tobacco Survey of 2,140 adults and included 11 sociodemographic variables. Chi-square and multiple logistic regression analyses were used to test for significant associations between sociodemographic characteristics and support for statewide or community smoke-free air legislation. Results Most respondents (72.3%) indicated that they supported laws making work places smoke-free. After adjusting for the effects of the other variables, 3 were found to be significant predictors of support: being a never or former smoker, being female, and being aware of the health hazards of secondhand smoke. Age, race/ethnicity, income, urban or rural county of residence, employment status, and having children in the household were not significant when adjusting for the other characteristics. Conclusion Most Indiana residents support smoke-free air legislation for workplaces. The support was constant among most groups across the state, suggesting policy makers would have the backing of their constituents to pass such legislation. The results of this study suggest that efforts to gain support for smoke-free air laws should focus on men, people unaware of the health hazards from secondhand smoke, and smokers and former smokers. C1 [Zollinger, Terrell W.; Robinson, Joshua J.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Robinson, Joshua J.] US Dept Vet Affairs, Washington, DC USA. [Spitznagle, Miranda H.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. RP Saywell, RM (reprint author), Indiana Univ Sch Med, Bowen Res Ctr, 714 North Senate St,Ste 205, Indianapolis, IN 46202 USA. EM rsaywell@iupui.edu NR 34 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2012 VL 9 AR UNSP 120091 DI 10.5888/pcd9.120091 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 173AR UT WOS:000321050800002 ER PT J AU Swenson, ER AF Swenson, Erik R. TI Normal Exercise Capacity in Chronic Mountain Sickness How High Can the Hematocrit Go Without Consequence? SO CHEST LA English DT Editorial Material ID HIGH-ALTITUDE; GAS-EXCHANGE; HEMODILUTION; POLYCYTHEMIA; TOLERANCE C1 [Swenson, Erik R.] Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA 98108 USA. RP Swenson, ER (reprint author), Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, S-111 PULM,1660 S Columbian Way, Seattle, WA 98108 USA. EM eswenson@u.washington.edu NR 12 TC 2 Z9 3 U1 2 U2 4 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2012 VL 142 IS 4 BP 823 EP 825 DI 10.1378/chest.12-0933 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 120EI UT WOS:000317153200005 PM 23032448 ER PT J AU Metersky, ML Fine, MJ Mortensen, EM AF Metersky, Mark L. Fine, Michael J. Mortensen, Eric M. TI The Effect of Marital Status on the Presentation and Outcomes of Elderly Male Veterans Hospitalized for Pneumonia SO CHEST LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; MORTALITY; EPIDEMIOLOGY; VALIDATION; CARE AB Background: Although marital status has been shown to affect the outcomes of many conditions, there are limited data on the relationships between marital status and the presentation and outcomes of pneumonia. Methods: We used Veterans Affairs administrative databases to identify a retrospective cohort of male veterans age >= 65 years hospitalized for pneumonia between 2002 and 2007. We assessed unadjusted and adjusted associations between marital status and mortality, hospital length of stay, and readmission to the hospital using generalized linear mixed-effect models with admitting hospital as a random effect and adjusted for baseline patient characteristics. Results: There were 48,635 patients (26,558 married and 22,077 unmarried) in the study. Married men had a slightly higher Charlson comorbidity score (3.0 vs 2.8, P<.0001) but were less likely to require ICU admission, ventilator support, and vasopressor treatment during the first 48 h of hospitalization. Married patients had significantly lower crude and adjusted in-hospital mortality (9.4% vs 10.6%; adjusted OR, 0.87; 95% CI, 0.81-0.93) and mortality during the 90 days after hospital discharge (14.7% vs 16.0%; adjusted OR, 0.92; 95% CI, 0.88-0.98). Their adjusted incidence rate ratio length of stay was also lower (0.92; 95% CI, 0.91-0.92). Conclusions: Unmarried elderly men admitted to the hospital with pneumonia have a higher risk of in-hospital and postdischarge mortality, despite having a lower degree of comorbidity. Although marital status may be a surrogate marker for other predictors, it is an easily identifiable one. These results should be considered by those responsible for care-transition decisions for patients hospitalized with pneumonia. C1 [Metersky, Mark L.] Univ Connecticut, Sch Med, Div Pulm & Crit Care Med, Farmington, CT 06030 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, VA North Texas Vet Hlth Care Syst, Dallas, TX 75390 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. RP Metersky, ML (reprint author), Univ Connecticut, Ctr Hlth, Div Pulm & Crit Care Med, 263 Farmington Ave, Farmington, CT 06030 USA. EM Metersky@nso.uchc.edu OI Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828] FX This study was supported by the National Institute of Nursing Research [Grant R01NR010828]. NR 25 TC 6 Z9 6 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2012 VL 142 IS 4 BP 982 EP 987 DI 10.1378/chest.11-3183 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 120EI UT WOS:000317153200025 PM 22459780 ER PT J AU Rincon-Choles, H Abboud, HE Lee, S Shade, RE Rice, KS Carey, KD Comuzzie, AG Barnes, JL AF Rincon-Choles, Hernan Abboud, Hanna E. Lee, Shuko Shade, Robert E. Rice, Karen S. Carey, K. Dee Comuzzie, Anthony G. Barnes, Jeffrey L. TI Renal Histopathology of a Baboon Model with Type 2 Diabetes SO TOXICOLOGIC PATHOLOGY LA English DT Article DE glomerular basement membrane; mesangium; diabetic nephropathy; baboon; renal morphology ID NOCTURNAL BLOOD-PRESSURE; ELDERLY HYPERTENSIVE PATIENTS; PAPIO-HAMADRYAS MODEL; HETEROGENEOUS NATURE; MICROALBUMINURIA; MESANGIOLYSIS; PROGRESSION; LESIONS; KIDNEY; DETERMINANTS AB Naturally occurring type 2 diabetes has been found in a colony of baboons. Ongoing characterization of the baboon colony maintained at the Southwest National Primate Research Center has revealed a significant range of glucose sensitivity with some animals clearly diabetic. Seven baboons, four with diabetes and three without diabetes, underwent histopathological investigation. Three diabetic animals were diagnosed using fasting blood glucose, hemoglobin A1C, and intravenous glucose tolerance test, and a fourth one was known to have hyperglycemia. One control baboon and three baboons with diabetes had microalbuminuria. On kidney biopsy, diabetic baboons had thickening of the glomerular basement membrane and mesangial matrix expansion compared to controls. Immunohistochemistry showed the diabetic animals had increased mesangial expression of cellular fibronectin ED-A. Two diabetic animals with microalbuminuria had evidence of mesangiolysis with the formation of an early nodule. One diabetic animal had a Kimmestiel-Wilson nodule. We conclude that the baboon represents a useful primate model of diabetes and nephropathy that resembles the nephropathy associated with type 2 diabetes in humans. C1 [Rincon-Choles, Hernan; Abboud, Hanna E.; Lee, Shuko; Barnes, Jeffrey L.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Rincon-Choles, Hernan; Abboud, Hanna E.; Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Shade, Robert E.; Rice, Karen S.; Carey, K. Dee; Comuzzie, Anthony G.] Southwest Reg Primate Res Ctr, San Antonio, TX USA. [Comuzzie, Anthony G.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. RP Barnes, JL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MSC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM barnesj@uthscsa.edu FU Research Career Development Award, Veterans Administration; George M. O'Brien Kidney Center, National Institutes of Health [P50-DK-061597]; NIH [4R37-DK-033665-19-23, 5U01-DK-57295-05, HL28972, U10-52636, P51-RR1-13986]; South Texas Veterans Health Care System FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. H. Rincon-Choles is a recipient of a Research Career Development Award from the Veterans Administration. Other sources of support are George M. O'Brien Kidney Center from the National Institutes of Health grant P50-DK-061597, NIH grants 4R37-DK-033665-19-23, 5U01-DK-57295-05, HL28972, U10-52636, and P51-RR1-13986 (to the Southwest Regional Primate Research Center), and Research Enhancement Award Program from the South Texas Veterans Health Care System. NR 34 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-6233 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD OCT PY 2012 VL 40 IS 7 BP 1020 EP 1030 DI 10.1177/0192623312444025 PG 11 WC Pathology; Toxicology SC Pathology; Toxicology GA 119DS UT WOS:000317078200005 PM 22552392 ER PT J AU Swenson, ER Bartsch, P AF Swenson, Erik R. Baertsch, Peter TI High-Altitude Pulmonary Edema SO COMPREHENSIVE PHYSIOLOGY LA English DT Article ID ALVEOLAR EPITHELIAL-CELLS; ACUTE MOUNTAIN-SICKNESS; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; STRESS DOPPLER-ECHOCARDIOGRAPHY; INDUCED PERMEABILITY INCREASES; CARBONIC-ANHYDRASE INHIBITION; RAPID INTRAVENOUS-INFUSION; HYPOXIA-INDUCIBLE FACTOR; I/D GENE POLYMORPHISM AB High-altitude pulmonary edema (HAPE), a not uncommon form of acute altitude illness, can occur within days of ascent above 2500 to 3000 m. Although life-threatening, it is avoidable by slow ascent to permit acclimatization or with drug prophylaxis. The critical pathophysiology is an excessive rise in pulmonary vascular resistance or hypoxic pulmonary vasoconstriction (HPV) leading to increased microvascular pressures. The resultant hydrostatic stress causes dynamic changes in the permeability of the alveolar capillary barrier and mechanical injurious damage leading to leakage of large proteins and erythrocytes into the alveolar space in the absence of inflammation. Bronchoalveolar lavage and hemodynamic pressure measurements in humans confirm that elevated capillary pressure induces a high-permeability noninflammatory lung edema. Reduced nitric oxide availability and increased endothelin in hypoxia are the major determinants of excessive HPV in HAPE-susceptible individuals. Other hypoxia-dependent differences in ventilatory control, sympathetic nervous system activation, endothelial function, and alveolar epithelial active fluid reabsorption likely contribute additionally to HAPE susceptibility. Recent studies strongly suggest nonuniform regional hypoxic arteriolar vasoconstriction as an explanation for how HPV occurring predominantly at the arteriolar level causes leakage. In areas of high blood flow due to lesser HPV, edema develops due to pressures that exceed the dynamic and structural capacity of the alveolar capillary barrier to maintain normal fluid balance. This article will review the pathophysiology of the vasculature, alveolar epithelium, innervation, immune response, and genetics of the lung at high altitude, as well as therapeutic and prophylactic strategies to reduce the morbidity and mortality of HAPE. Published 2012. Compr Physiol 2:2753-2773, 2012. C1 [Swenson, Erik R.; Baertsch, Peter] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Swenson, Erik R.; Baertsch, Peter] Heidelberg Univ, Med Klin, Krehl Klin, Heidelberg, Germany. RP Swenson, ER (reprint author), Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM eswenson@u.washington.edu NR 233 TC 20 Z9 23 U1 4 U2 25 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2040-4603 J9 COMPR PHYSIOL JI Compr. Physiol. PD OCT PY 2012 VL 2 IS 4 BP 2753 EP 2773 DI 10.1002/cphy.c100029 PG 21 WC Physiology SC Physiology GA 085ZN UT WOS:000314652900015 PM 23720264 ER PT J AU Adams, GR Bamman, MM AF Adams, Gregory R. Bamman, Marcas M. TI Characterization and Regulation of Mechanical Loading-Induced Compensatory Muscle Hypertrophy SO COMPREHENSIVE PHYSIOLOGY LA English DT Article ID HUMAN SKELETAL-MUSCLE; MYOSIN HEAVY-CHAIN; GROWTH-FACTOR-I; SATELLITE CELL-PROLIFERATION; SERUM RESPONSE FACTOR; LEUKEMIA INHIBITORY FACTOR; BLOOD-FLOW RESTRICTION; MESSENGER-RNA TRANSLATION; CROSS-SECTIONAL AREA; MYOFIBRILLAR PROTEIN-SYNTHESIS AB In mammalian systems, skeletal muscle exists in a dynamic state that monitors and regulates the physiological investment in muscle size to meet the current level of functional demand. This review attempts to consolidate current knowledge concerning development of the compensatory hypertrophy that occurs in response to a sustained increase in the mechanical loading of skeletal muscle. Topics covered include: defining and measuring compensatory hypertrophy, experimental models, loading stimulus parameters, acute responses to increased loading, hyperplasia, myofiber-type adaptations, the involvement of satellite cells, mRNA translational control, mechanotransduction, and endocrinology. The authors conclude with their impressions of current knowledge gaps in the field that are ripe for future study. (C) 2012 American Physiological Society. Compr Physiol 2:2829-2870, 2012. C1 [Adams, Gregory R.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA. [Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Bamman, Marcas M.] Univ Alabama Birmingham, UAB Ctr Exercise Med, Birmingham, AL USA. [Bamman, Marcas M.] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Adams, GR (reprint author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA. EM gradams@uci.edu NR 524 TC 23 Z9 24 U1 1 U2 22 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2040-4603 J9 COMPR PHYSIOL JI Compr. Physiol. PD OCT PY 2012 VL 2 IS 4 BP 2829 EP 2870 DI 10.1002/cphy.c110066 PG 42 WC Physiology SC Physiology GA 085ZN UT WOS:000314652900018 PM 23720267 ER PT J AU Tobin, MJ Laghi, F Jubran, A AF Tobin, Martin J. Laghi, Franco Jubran, Amal TI Ventilatory Failure, Ventilator Support, and Ventilator Weaning SO COMPREHENSIVE PHYSIOLOGY LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; CONTROLLED MECHANICAL VENTILATION; AIRWAY OCCLUSION PRESSURE; CONGESTIVE-HEART-FAILURE; INSPIRATORY MOTOR OUTPUT; INTENSIVE-CARE-UNIT; CENTRAL SLEEP-APNEA; PROPORTIONAL ASSIST VENTILATION AB The development of acute ventilatory failure represents an inability of the respiratory control system to maintain a level of respiratory motor output to cope with the metabolic demands of the body. The level of respiratory motor output is also the main determinant of the degree of respiratory distress experienced by such patients. As ventilatory failure progresses and patient distress increases, mechanical ventilation is instituted to help the respiratory muscles cope with the heightened workload. While a patient is connected to a ventilator, a physician's ability to align the rhythm of the machine with the rhythm of the patient's respiratory centers becomes the primary determinant of the level of rest accorded to the respiratory muscles. Problems of alignment are manifested as failure to trigger, double triggering, an inflationary gas-flow that fails to match inspiratory demands, and an inflation phase that persists after a patient's respiratory centers have switched to expiration. With recovery from disorders that precipitated the initial bout of acute ventilatory failure, attempts are made to discontinue the ventilator (weaning). About 20% of weaning attempts fail, ultimately, because the respiratory controller is unable to sustain ventilation and this failure is signaled by development of rapid shallow breathing. Substantial advances in the medical management of acute ventilatory failure that requires ventilator assistance are most likely to result from research yielding novel insights into the operation of the respiratory control system. (C) 2012 American Physiological Society. Compr Physiol 2:2871-2921, 2012. C1 [Tobin, Martin J.; Laghi, Franco; Jubran, Amal] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. [Tobin, Martin J.; Laghi, Franco; Jubran, Amal] Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM mtobin2@lumc.edu NR 319 TC 20 Z9 20 U1 0 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2040-4603 J9 COMPR PHYSIOL JI Compr. Physiol. PD OCT PY 2012 VL 2 IS 4 BP 2871 EP 2921 DI 10.1002/cphy.c110030 PG 51 WC Physiology SC Physiology GA 085ZN UT WOS:000314652900019 PM 23720268 ER PT J AU Dennis, M Wang, GY Luo, J Lin, Y Dohadwala, M Abemayor, E Elashoff, DA Sharma, S Dubinett, SM St John, MA AF Dennis, Miranda Wang, Guanyu Luo, Jie Lin, Yuan Dohadwala, Mariam Abemayor, Elliot Elashoff, David A. Sharma, Sherven Dubinett, Steven M. St John, Maie A. TI Snail Controls the Mesenchymal Phenotype and Drives Erlotinib Resistance in Oral Epithelial and Head and Neck Squamous Cell Carcinoma Cells SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE Snail; E-cadherin; epithelial-mesenchymal transition (EMT); erlotinib ID E-CADHERIN; EXPRESSION; TRANSITIONS; CANCER AB Objective. The presence of regional metastases in patients with head and neck squamous cell carcinoma (HNSCC) is a common and adverse event associated with poor prognosis. The authors' recent work on human HNSCC tissues underlies Snail's role as a molecular prognostic marker for HNSCC. Snail positivity is significantly predictive of poorly differentiated, lymphovascular invasive, and regionally metastatic tumors. Here, the authors investigate the capacity of Snail to drive epithelial-mesenchymal transition (EMT) in human oral epithelial cell lines and its ability to confer drug resistance. Study Design. Snail was overexpressed in HNSCC and oral epithelial cell lines. Anchorage independent growth assays, wound healing assays, invasion and migration assays, spheroid modeling, and cell survival assays were performed. Setting. Academic tertiary medical center. Subjects and Methods. Snail overexpressing HNSCC (OSC, Tu212, Tu686) and oral epithelial cell lines (HOK 16-B, OKF-6) were evaluated using assays for wound healing, invasion and migration, 3-dimensional growth, Western blot, and immunofluorescence. Results. The overexpression of Snail in human HNSCC and oral epithelial cell lines drives EMT. The transfection of Snail confers the expression of a mesenchymal molecular signature, including downregulation of the epithelial adherens, such as E-cadherin and beta-catenin, and induction of mesenchymal markers. Snail-overexpressing cell lines demonstrate rapid growth in Anchorage-independent growth assays, a decreased capacity to form tight spheroids, an increased resistance to erlotinib, and an increased capacity for invasion. Conclusion. Snail controls the mesenchymal phenotype and drives erlotinib resistance in HNSCC cells. Snail may prove to be a useful marker in predicting epidermal growth factor receptor inhibitor responsiveness. C1 [Dennis, Miranda; Abemayor, Elliot; St John, Maie A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Los Angeles, CA 90095 USA. [Wang, Guanyu; Luo, Jie; Lin, Yuan; Dohadwala, Mariam; Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA. [Wang, Guanyu; Luo, Jie; Lin, Yuan; Dohadwala, Mariam; Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA. [Abemayor, Elliot; Elashoff, David A.; Dubinett, Steven M.; St John, Maie A.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Elashoff, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. [Sharma, Sherven; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP St John, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mstjohn@mednet.ucla.edu RI lin, yuan/E-6062-2011 FU American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award; Tobacco-Related Disease Research Program of the University of California; STOP Cancer Foundation; Jonsson Cancer Center; NIDCR [K23] FX This study was supported by the American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award (MSJ), the Tobacco-Related Disease Research Program of the University of California (MSJ), the STOP Cancer Foundation (MSJ), The Jonsson Cancer Center, and NIDCR K23 (MSJ). NR 13 TC 7 Z9 7 U1 0 U2 6 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD OCT PY 2012 VL 147 IS 4 BP 726 EP 732 DI 10.1177/0194599812446407 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 080ZL UT WOS:000314283700021 PM 22568942 ER PT J AU Mulligan, JK White, DR Wang, EW Sansoni, SR Moses, H Yawn, RJ Wagner, C Casey, SE Mulligan, RM Schlosser, RJ AF Mulligan, Jennifer K. White, David R. Wang, Eric W. Sansoni, S. Ritter Moses, Helen Yawn, Robert J. Wagner, Carol Casey, Sarah E. Mulligan, Ryan M. Schlosser, Rodney J. TI Vitamin D-3 Deficiency Increases Sinus Mucosa Dendritic Cells in Pediatric Chronic Rhinosinusitis with Nasal Polyps SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE vitamin D; allergic fungal rhinosinusitis; dendritic cell; pediatric chronic rhinosinusitis ID ALLERGIC FUNGAL RHINOSINUSITIS; REGULATORY T-CELLS; CHILDHOOD ASTHMA; MOUSE MODEL; IN-VIVO; DISEASE; HEALTH; PERSPECTIVES; INFLAMMATION; TRAFFICKING AB Objective. Dendritic cells are professional antigen presenting cells, capable of initiating Th1 or Th2 responses, and have been implicated in the pathogenesis of a number of diseases, including sinusitis. Vitamin D-3 is a steroid hormone that acts on dendritic cells in a manner similar to corticosteroids. Investigators examined whether children with allergic fungal rhinosinusitis (AFRS) or chronic rhinosinusitis with nasal polyposis (CRSwNP) were vitamin D-3 deficient and the relationship of vitamin D-3 deficiency to dendritic cell infiltrate in the sinus mucosa. Setting. Tertiary care university hospital. Study Design. Retrospective, controlled study using samples collected from pediatric patients seen from August 2009 to July 2011. Subjects and Methods. Plasma levels of 25-hydroxy vitamin D-3 were measured by enzyme-linked immunosorbent assay in children (<= 18 years old) with AFRS, CRSwNP, or CRS without nasal polyposis (CRSsNP) and in controls undergoing surgery for adenotonsillar hypertrophy. Vitamin D-3 levels were confirmed using clinical diagnostic methods for those with CRSwNP or AFRS. Tissue samples were immunohistochemically stained for the dendritic cell marker CD209 and the costimulatory molecules CD80 and CD86. Results. There was no difference in mean vitamin D-3 levels between control and CRSsNP, whereas mean CRSwNP and AFRS levels were both well below the minimum recommended level of 30 ng/mL and significantly lower than control and CRSsNP levels. CD209(+) dendritic cells inversely correlated with vitamin D-3 but not costimulatory molecule expression. Conclusions. These studies identify that children with CRSwNP or AFRS are vitamin D-3 deficient, which may be linked to increased dendritic cell infiltrate. These results suggest a role for vitamin D-3 as a key player in the immunopathology of pediatric CRSwNP. C1 [Mulligan, Jennifer K.; Mulligan, Ryan M.; Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Med Univ S Carolina, Charleston, SC 29425 USA. [Mulligan, Jennifer K.; White, David R.; Wang, Eric W.; Sansoni, S. Ritter; Moses, Helen; Yawn, Robert J.; Mulligan, Ryan M.; Schlosser, Rodney J.] Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Wagner, Carol] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Casey, Sarah E.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), Med Univ S Carolina, Res Serv, Ralph H Johnson VA Med Ctr, MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA. EM konopa@musc.edu OI Wang, Eric/0000-0002-1180-5854 FU American Society of Pediatric Otolaryngology/Centralized Otolaryngology Research Efforts; Flight Attendant Medical Research Institute (FAMRI); Medtronic; Arthocare; NeilMed FX David R. White, Medtronic, Inc, ad hoc consultant (tonsil product, no relationship to this manuscript); Rodney J. Schlosser, BrainLAB, Olympus, Sunovian, NeilMed, consultant/advisory board; Medtronic, Arthocare, NeilMed, grant support. (These disclosures are not related to this manuscript.).; These studies were funded by grants to JKM from the American Society of Pediatric Otolaryngology/Centralized Otolaryngology Research Efforts and grants to JKM and RJS from the Flight Attendant Medical Research Institute (FAMRI). NR 45 TC 24 Z9 24 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD OCT PY 2012 VL 147 IS 4 BP 773 EP 781 DI 10.1177/0194599812448852 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 080ZL UT WOS:000314283700028 PM 22627120 ER PT J AU Siddiq, DM Darouiche, RO AF Siddiq, Danish M. Darouiche, Rabih O. TI Infectious complications associated with percutaneous nephrostomy catheters: Do we know enough? SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS LA English DT Review DE Percutaneous nephrostomy catheter; Infectious complications; Pyonephrosis; pathogenesis; Diagnosis and treatment ID URINARY-TRACT-INFECTIONS; ANTIBIOTIC-PROPHYLAXIS; BACTERIAL BIOFILM; DISEASES-SOCIETY; TUBE PLACEMENT; NEPHROLITHOTOMY; EXPERIENCE; UROSEPSIS; DRAINAGE; BLADDER AB The percutaneous nephrostomy catheter (PCNC) has evolved since its inception. Over more than half a century, it has gone from a temporary maneuver to a permanent fixture in a large proportion of patients who have incurable illnesses with obstructed renal drainage systems. Unfortunately, the research looking specifically at infectious complications associated with PCNCs suffers from oversimplification as studies predominantly assess sepsis alone. There are no standardized definitions or criteria to define the various infectious complications described in this paper. Although the PCNC has a relative paucity of infectious complications, which represents an excellent marker for patient care, the low rate of infection dictates a large sample size for sufficiently-powered research studies to be able to find a significant impact of interventional measures. In this review article, we discuss various aspects of pathogenesis and treatment of the different subtypes of PCNC-associated infections. C1 [Siddiq, Danish M.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Darouiche, Rabih O.] Spinal Cord Injury & Med Serv, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Siddiq, DM (reprint author), Baylor Coll Med, Dept Med, Infect Dis Sect, BCM 286,Room N-1319,1 Baylor Plaza, Houston, TX 77030 USA. EM siddiq@bcm.edu NR 55 TC 0 Z9 0 U1 0 U2 6 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0391-3988 J9 INT J ARTIF ORGANS JI Int. J. Artif. Organs PD OCT PY 2012 VL 35 IS 10 BP 898 EP 907 DI 10.5301/ijao.5000146 PG 10 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 066LX UT WOS:000313223400023 PM 23065896 ER PT J AU Samedy, K Griffin, MTQ Capitulo, KL Fitzpatrick, JJ AF Samedy, Ketly Griffin, Mary T. Quinn Capitulo, Kathleen Leask Fitzpatrick, Joyce J. TI Perceptions of Structural Empowerment: Differences Between Nationally Certified Perinatal Nurses and Perinatal Nurses Who Are Not Nationally Certified SO JOURNAL OF CONTINUING EDUCATION IN NURSING LA English DT Article ID PSYCHOLOGICAL EMPOWERMENT; MODEL AB Background: Although there has been previous research linking perceptions of empowerment to specialty certification among critical care nurses, no research in this area has been conducted among nationally certified perinatal nurses. Methods: A comparative quantitative survey design was used. Participants included 80 perinatal registered nurses from one community hospital in New York. Results: Registered nurses who were nationally certified in a perinatal specialty had higher total empowerment scores and higher scores on five of the six subscales. Conclusion: This study supports the results of previous studies focused on differences in empowerment among nationally certified nurses and nurses without national certification. Because much of the preparation for certification is done within continuing education, nurse leaders must be cognizant of the value of certification and must develop and implement programs to support certification in the workplace. J Contin Educ Nurs 2012;43(10):463-466. C1 [Griffin, Mary T. Quinn; Fitzpatrick, Joyce J.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Samedy, Ketly] N Shore Long Isl Jewish Hlth Syst, Patient Care Serv Ambulatory OB GYN MFM, Manhasset, NY USA. [Capitulo, Kathleen Leask] James J Peters VA Med Ctr, Bronx, NY USA. RP Fitzpatrick, JJ (reprint author), Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, 10900 Euclid Ave, Cleveland, OH 44106 USA. EM joyce.fitzpatrick@case.edu NR 12 TC 5 Z9 5 U1 1 U2 8 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0022-0124 J9 J CONTIN EDUC NURS JI J. Contin. Educ. Nursing PD OCT PY 2012 VL 43 IS 10 BP 463 EP 466 DI 10.3928/00220124-20120301-74 PG 4 WC Nursing SC Nursing GA 064TD UT WOS:000313097400010 PM 22390162 ER PT J AU Ioannou, G Berry, K AF Ioannou, George Berry, Kristin TI Serum alpha-fetoprotein level can improve eligibility criteria for liver transplantation in patients with hepatocellular carcinoma SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ioannou, George] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George; Berry, Kristin] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 96 BP 240A EP 241A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955601096 ER PT J AU Stewart, RK Huang, C Murase, N Kimura, S Gandhi, CR AF Stewart, Rachel K. Huang, Chao Murase, Noriko Kimura, Shoko Gandhi, Chandrashekhar R. TI Development of a stellate cell-depleted mouse model to investigate their role in liver pathophysiology SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Huang, Chao; Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA USA. [Stewart, Rachel K.; Huang, Chao; Murase, Noriko; Kimura, Shoko; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 242 BP 314A EP 314A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955601242 ER PT J AU Hezode, C Hirschfield, GM Ghesquiere, W Sievert, W Rodriguez-Torres, M Shafran, SD Thuluvath, PJ Tatum, HA Waked, I Esmat, GE Lawitz, E Rustgi, VK Pol, S Weis, N Pockros, P Bourliere, M Serfaty, L Vierling, JM Fried, MW Weiland, O Brunetto, MR Everson, GT Zeuzem, S Kwo, PY Sulkowski, MS Brau, N Wind-Rotolo, M Liu, ZH Hughes, EA Schnittman, SM Yin, PD AF Hezode, Christophe Hirschfield, Gideon M. Ghesquiere, Wayne Sievert, William Rodriguez-Torres, Maribel Shafran, Stephen D. Thuluvath, Paul J. Tatum, Harvey A. Waked, Imam Esmat, Gamal E. Lawitz, Eric Rustgi, Vinod K. Pol, Stanislas Weis, Nina Pockros, Paul Bourliere, Marc Serfaty, Lawrence Vierling, John M. Fried, Michael W. Weiland, Ola Brunetto, Maurizia R. Everson, Gregory T. Zeuzem, Stefan Kwo, Paul Y. Sulkowski, Mark S. Brau, Norbert Wind-Rotolo, Megan Liu, Zhaohui Hughes, Eric A. Schnittman, Steven M. Yin, Philip D. TI Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Hezode, Christophe] Univ Paris Est, Hop Henri Mondor, Creteil, France. [Hirschfield, Gideon M.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada. [Ghesquiere, Wayne] Vancouver Isl Hlth Author, Victoria, BC, Canada. [Sievert, William] Monash Med Ctr, Melbourne, Vic, Australia. [Rodriguez-Torres, Maribel] Fdn Invest, San Juan, PR USA. [Shafran, Stephen D.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada. [Thuluvath, Paul J.] St Johns Mercy Med Ctr, Baltimore, MD USA. [Tatum, Harvey A.] Opt Hlth Res LLC, Tulsa, OK USA. [Waked, Imam] Natl Liver Inst, Shibin Al Kawm, Egypt. [Esmat, Gamal E.] Fac Med Hepatol & Trop Med, Cairo, Egypt. [Lawitz, Eric] Alamo Med Res, San Antonio, TX USA. [Rustgi, Vinod K.] Metropolitan Res, Fairfax, VA USA. [Pol, Stanislas] Univ Paris 05, INSERM, Hop Cochin, U1610, Paris, France. [Pol, Stanislas] Univ Paris 05, Liver Unit, Hop Cochin, Paris, France. [Weis, Nina] Copenhagen Univ Hosp, Hvidovre, Denmark. [Pockros, Paul] Scripps Clin, La Jolla, CA USA. [Bourliere, Marc] St Joseph Hosp, Marseille, France. [Serfaty, Lawrence] Hop St Antoine, F-75571 Paris, France. [Vierling, John M.] Baylor Coll Med, Houston, TX 77030 USA. [Fried, Michael W.] Univ N Carolina, Chapel Hill, NC USA. [Weiland, Ola] Karolinska Univ Hosp, Stockholm, Sweden. [Brunetto, Maurizia R.] Azienda Osped Univ Pisana, Pisa, Italy. [Everson, Gregory T.] Univ Colorado, Denver, CO 80202 USA. [Zeuzem, Stefan] Goethe Univ Frankfurt, Frankfurt, Germany. [Kwo, Paul Y.] Indiana Univ, Indianapolis, IN 46204 USA. [Sulkowski, Mark S.] Johns Hopkins Univ, Baltimore, MD USA. [Brau, Norbert] James J Peters VAMC, New York, NY USA. [Wind-Rotolo, Megan; Liu, Zhaohui] Bristol Myers Squibb Res & Dev, Hopewell, NJ USA. [Hughes, Eric A.] Bristol Myers Squibb Res & Dev, Princeton, NJ USA. [Schnittman, Steven M.; Yin, Philip D.] Bristol Myers Squibb Clin Res & Dev, Wallingford, CT USA. NR 0 TC 31 Z9 31 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 755 BP 553A EP 554A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602134 ER PT J AU Yu, L Morishima, C Ioannou, G AF Yu, Lei Morishima, Chihiro Ioannou, George TI Dietary Cholesterol Intake is Associated with Liver Disease Progression in Hepatitis C Infection: Analysis of the HALT-C trial SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Yu, Lei; Morishima, Chihiro; Ioannou, George] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George] Vet Affairs Puget Sound Healthcare Syst, Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 940 BP 647A EP 648A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602319 ER PT J AU Ho, SB Groessl, EJ Brau, N Cheung, R Weingart, KR Ward, M Sklar, M Phelps, TE Marcus, S Wasil, MM Tisi, AS Huynh, LK Robinson, S AF Ho, Samuel B. Groessl, Erik J. Brau, Norbert Cheung, Ramsey Weingart, Kimberly R. Ward, Megan Sklar, Marisa Phelps, Tyler E. Marcus, Sonja Wasil, Michelene M. Tisi, Amelia S. Huynh, Lia K. Robinson, Shannon TI Multisite randomized trial of an Integrated Care (IC) model for HCV patients with psychiatric and substance use co-morbidities: final results of impact on treatment initiation SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ho, Samuel B.; Groessl, Erik J.; Weingart, Kimberly R.; Ward, Megan; Sklar, Marisa; Wasil, Michelene M.; Robinson, Shannon] VA San Diego Healthcare Syst, San Diego, CA USA. [Ho, Samuel B.; Groessl, Erik J.; Robinson, Shannon] Univ Calif San Diego, San Diego, CA 92103 USA. [Brau, Norbert; Marcus, Sonja; Tisi, Amelia S.] James J Peters VA Med Ctr, Bronx, NY USA. [Cheung, Ramsey; Phelps, Tyler E.; Huynh, Lia K.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Brau, Norbert] Mt Sinai Sch Med, New York, NY USA. [Cheung, Ramsey] Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 3 Z9 3 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1736 BP 1000A EP 1001A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603332 ER PT J AU Hasham, A Zhang, WJ Lotay, V Dieterich, DT Tomer, Y AF Hasham, Alia Zhang, Weijia Lotay, Vaneet Dieterich, Douglas T. Tomer, Yaron TI Chronic Hepatitis C virus (HCV) and interferon-induced thyroiditis (IIT): Mapping susceptibility genes with potential to identify high-risk groups SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Hasham, Alia; Tomer, Yaron] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA. [Lotay, Vaneet] Mt Sinai Med Ctr, Inst Personalized Med, New York, NY 10029 USA. [Dieterich, Douglas T.] Mt Sinai Med Ctr, Dept Med, Div Liver Dis, New York, NY 10029 USA. [Hasham, Alia; Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1783 BP 1024A EP 1024A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603379 ER PT J AU Basu, P Shah, NJ Farhat, S Mittimani, K Siriki, R Rahman, MA Ang, LP Win, S Brown, RS AF Basu, Patrick Shah, Niraj J. Farhat, Sakina Mittimani, Kavya Siriki, Ravi Rahman, Md A. Ang, Lynn P. Win, S. Brown, Robert S. TI Pegylated Interferon Alfa, Nitazoxanide, Telapravir and Ribavirin in prior experienced chronic hepatitis C Genotype 1 patients - A randomized Placebo control clinical Pilot Trial (INTRIGUE-C) SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick; Brown, Robert S.] Columbia Univ, Sch Phys & Surg, New York, NY USA. [Basu, Patrick; Farhat, Sakina; Mittimani, Kavya; Siriki, Ravi; Rahman, Md A.; Ang, Lynn P.; Win, S.] N Shore Forest Hills Hosp, Hofstra Med Sch NY, New York, NY USA. [Shah, Niraj J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1806 BP 1035A EP 1035A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603402 ER PT J AU McGhan, AA Kaplan, DE AF McGhan, Alyson A. Kaplan, David E. TI Cirrhosis diagnosis rates, liver transplantation rates, and Child-Turcotte-Pugh stage critically impact the efficacy of hepatocellular carcinoma surveillance to improve HCC-related survival in a US Veteran population SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [McGhan, Alyson A.; Kaplan, David E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1935 BP 1092A EP 1093A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603528 ER PT J AU McGhan, AA Kaplan, DE AF McGhan, Alyson A. Kaplan, David E. TI Costs of palliative treatments of intermediate and advanced stage hepatocellular carcinoma may exceed usually accepted limits of cost effectiveness SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [McGhan, Alyson A.; Kaplan, David E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1944 BP 1097A EP 1097A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603537 ER PT J AU Brewer, JE Gerry, AB Bennett, AD Pumphrey, NJ Kaplan, DE Jakobsen, BK AF Brewer, Joanna E. Gerry, Andrew B. Bennett, Alan D. Pumphrey, Nick J. Kaplan, David E. Jakobsen, Bent K. TI T-cells from cirrhotic patients transduced with optimized T-cell receptor have potent effector functions against hepatocellular carcinoma-associated antigens in vitro SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Brewer, Joanna E.; Gerry, Andrew B.; Bennett, Alan D.; Pumphrey, Nick J.; Jakobsen, Bent K.] Adaptimmune Ltd, Abingdon, Oxon, England. [Kaplan, David E.] Philadelphia VA Med Ctr, Res Sect, Philadelphia, PA USA. [Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1983 BP 1114A EP 1114A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603576 ER PT J AU Vodovotz, Y Prelich, JG Zamora, R Murase, N Gandhi, CR AF Vodovotz, Yoram Prelich, John G. Zamora, Ruben Murase, Noriko Gandhi, Chandrashekhar R. TI Augmenter of Liver Regeneration (ALR) is a Novel Damage-Associated Molecular Pattern Molecule That Predicts Liver Damage: In Vitro, In Vivo, and In Silico Studies SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Vodovotz, Yoram; Zamora, Ruben; Murase, Noriko; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Pittsburgh, PA USA. [Prelich, John G.; Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 2005 BP 1122A EP 1123A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603598 ER PT J AU Peterson, A Mattek, N Clemons, A Bowman, GL Buracchio, T Kaye, J Quinn, J AF Peterson, A. Mattek, N. Clemons, A. Bowman, G. L. Buracchio, T. Kaye, J. Quinn, J. TI Serum vitamin d concentrations are associated with falling and cognitive function in older adults SO JOURNAL OF NUTRITION HEALTH & AGING LA English DT Article DE Accidental falls; cognitive function; vitamin D ID ALZHEIMERS-DISEASE; MUSCLE FUNCTION; GAIT; RISK AB To elucidate the mechanism through which vitamin D is associated with decreased falls. This was a convenience sample from a larger observational study examining correlations between vitamin D and 1) falls, 2) motor function, and 3) cognition (n=159). Falls data were collected via weekly on-line surveys completed in the participants' homes. Yearly evaluations of motor and cognitive function were conducted in an out-patient setting of a large tertiary medical center. Participants from the Intelligent Systems for Assessment of Aging Changes Study (ISAAC), a community-based cohort study of independently living older adults over age 70, who had vitamin D concentration within 6 months of clinical evaluations were included in the analysis. Participants mean age was 85 years and 74% were women. Fallers (n=37) had significantly lower vitamin D concentration (32.9ng/ml) compared to non-fallers (39.2ng/ml) (p < 0.01). The relationship between vitamin D and falls remained significant after adjusting for age, health status (via CIRS), and supplement use (p=0.004). Vitamin D concentration were significantly associated with cognitive impairment (Clinical Dementia Rating = 0.5) (p=0.02) and MMSE (p < 0.01) after adjusting for age, gender, and education. Vitamin D concentrations did not correlate with any motor measures. Vitamin D concentrations correlated with cognition and falls, but not with motor measures. Further research is needed to demonstrate a causal relationship between vitamin D and cognitive function and determine if cognition plays a role in falls reduction. C1 [Peterson, A.; Buracchio, T.; Kaye, J.; Quinn, J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Buracchio, T.; Kaye, J.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97239 USA. [Peterson, A.; Buracchio, T.; Kaye, J.; Quinn, J.] Portland VA Med Ctr, Portland, OR USA. RP Peterson, A (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Samuel Jackson Pk Rd,Mail Code OP32, Portland, OR 97239 USA. EM peterami@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU National Institute of Health [P30-AG008017, P30-AG024978, R01-AG024059, K01-AG23014, K23- AT004777]; Department of Veterans Affairs [P30-AG008017, M01-RR000334]; Intel Corporation FX Supported by National Institute of Health grants P30-AG008017, P30-AG024978, R01-AG024059, K01-AG23014, K23- AT004777, the Department of Veterans Affairs P30-AG008017 and M01-RR000334, and Intel Corporation. NR 26 TC 20 Z9 21 U1 0 U2 21 PU SPRINGER FRANCE PI PARIS PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE SN 1279-7707 J9 J NUTR HEALTH AGING JI J. Nutr. Health Aging PD OCT PY 2012 VL 16 IS 10 BP 898 EP 901 DI 10.1007/s12603-012-0378-4 PG 4 WC Geriatrics & Gerontology; Nutrition & Dietetics SC Geriatrics & Gerontology; Nutrition & Dietetics GA 052NY UT WOS:000312206100005 PM 23208029 ER PT J AU Kessler, ER Bowles, DW Flaig, TW Lam, ET Jimeno, A AF Kessler, E. R. Bowles, D. W. Flaig, T. W. Lam, E. T. Jimeno, A. TI AXITINIB, A NEW THERAPEUTIC OPTION IN RENAL CELL CARCINOMA SO DRUGS OF TODAY LA English DT Article DE Axitinib; Renal cell carcinoma; Platelet-derived growth factor receptor; Proto-oncogene c-Kit; VHL gene ID ENDOTHELIAL GROWTH-FACTOR; QUALITY-OF-LIFE; TYROSINE KINASE INHIBITOR; ADVANCED SOLID TUMORS; INTERFERON-ALPHA; PHASE-II; JAPANESE PATIENTS; ANGIOGENESIS INHIBITOR; ANTITUMOR-ACTIVITY; CANCER AB Axitinib is a small-molecule protein-tyrosine kinase receptor inhibitor specifically targeting this family of receptors, in addition to platelet-derived growth factor receptor and proto-onco gene c-Kit. Improved knowledge of kidney cancer development, and specifically mutations in the VHL gene, has supported the targeting of angiogenesis pathways. Axitinib is the most recently approved agent for use in metastatic renal cell carcinoma. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical activity of this agent, and describe its place in the current treatment of renal cell carcinoma. C1 [Kessler, E. R.; Bowles, D. W.; Flaig, T. W.; Lam, E. T.; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA. [Bowles, D. W.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Jimeno, A (reprint author), Univ Colorado Denver, Div Med Oncol, 12801 E 17th Ave,MS 8117, Aurora, CO 80045 USA. EM antonio.jimeno@ucdenver.edu NR 63 TC 5 Z9 6 U1 0 U2 7 PU PROUS SCIENCE, SAU-THOMSON REUTERS PI BARCELONA PA 398 PROVENCA, 08025 BARCELONA, SPAIN SN 1699-3993 J9 DRUG TODAY JI Drugs Today PD OCT PY 2012 VL 48 IS 10 BP 633 EP 644 DI 10.1358/dot.2012.48.10.1860768 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 047RX UT WOS:000311860200001 PM 23110259 ER PT J AU Goel, HL Chang, C Pursell, B Leav, I Lyle, S Xi, HS Hsieh, CC Adisetiyo, H Roy-Burman, P Coleman, IM Nelson, PS Vessella, RL Davis, RJ Plymate, SR Mercurio, AM AF Goel, Hira Lal Chang, Cheng Pursell, Bryan Leav, Irwin Lyle, Stephen Xi, Hualin Simon Hsieh, Chung-Cheng Adisetiyo, Helty Roy-Burman, Pradip Coleman, Ilsa M. Nelson, Peter S. Vessella, Robert L. Davis, Roger J. Plymate, Stephen R. Mercurio, Arthur M. TI VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-IR Defi ne a Novel Mechanism of Aggressive Prostate Cancer SO CANCER DISCOVERY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; PTEN EXPRESSION; CARCINOMA CELLS; TUMOR BIOLOGY; MAMMARY-GLAND; NEUROPILIN-2; VEGF; PROGRESSION; TARGET AB We show that the VEGF receptor neuropilin-2 (NRP2) is associated with high-grade, PTEN-null prostate cancer and that its expression in tumor cells is induced by PTEN loss as a consequence of c-Jun activation. VEGF/NRP2 signaling represses insulin-like growth factor-1 receptor (IGF-IR) expression and signaling, and the mechanism involves Bmi-1-mediated transcriptional repression of the IGF-IR. This mechanism has significant functional and therapeutic implications that were evaluated. IGF-IR expression positively correlates with PTEN and inversely correlates with NRP2 in prostate tumors. NRP2 is a robust biomarker for predicting response to IGF-IR therapy because prostate carcinomas that express NRP2 exhibit low levels of IGF-IR. Conversely, targeting NRP2 is only modestly effective because NRP2 inhibition induces compensatory IGF-IR signaling. Inhibition of both NRP2 and IGF-IR, however, completely blocks tumor growth in vivo. C1 [Goel, Hira Lal; Chang, Cheng; Pursell, Bryan; Leav, Irwin; Lyle, Stephen; Hsieh, Chung-Cheng; Mercurio, Arthur M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA. [Xi, Hualin Simon] Univ Massachusetts, Sch Med, Bioinformat Core, Worcester, MA 01605 USA. [Davis, Roger J.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA. [Davis, Roger J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA. [Adisetiyo, Helty; Roy-Burman, Pradip] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Coleman, Ilsa M.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA. [Nelson, Peter S.; Vessella, Robert L.; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Nelson, Peter S.; Vessella, Robert L.; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Goel, HL (reprint author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB 470,364 Plantat St, Worcester, MA 01605 USA. EM hira.goel@umassmed.edu OI /0000-0003-1726-3037 FU DOD Prostate Cancer grant [PC111410]; NIH [R01CA80789, CA89209, R01CA59705, PO1 CA85859]; Pacific Northwest Prostate Cancer SPORE [P50 CA097186]; Veterans Affairs Research Program; Prostate Cancer Foundation FX This work was supported by DOD Prostate Cancer grant PC111410 (A. M. Mercurio); NIH grants R01CA80789 and CA89209 (A. M. Mercurio), R01CA59705 (P. Roy-Burman), PO1 CA85859 and the Pacific Northwest Prostate Cancer SPORE P50 CA097186 (S. R. Plymate, R. L. Vessella, and P. S. Nelson); the Veterans Affairs Research Program (S. R. Plymate); and an award from the Prostate Cancer Foundation (P. S. Nelson). NR 50 TC 32 Z9 35 U1 1 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 J9 CANCER DISCOV JI Cancer Discov. PD OCT PY 2012 VL 2 IS 10 BP 906 EP 921 DI 10.1158/2159-8290.CD-12-0085 PG 16 WC Oncology SC Oncology GA 048IG UT WOS:000311904000023 PM 22777769 ER PT J AU Lin, HZ Zhou, XH Li, G AF Lin, Huazhen Zhou, Xiao-Hua Li, Gang TI A DIRECT SEMIPARAMETRIC RECEIVER OPERATING CHARACTERISTIC CURVE REGRESSION WITH UNKNOWN LINK AND BASELINE FUNCTIONS SO STATISTICA SINICA LA English DT Article DE Diagnostic tests; kernel smoothing; nonparametric; ROC regression; transformation models ID OPTIMUM KERNEL ESTIMATORS; ROC CURVES; TRANSFORMATION MODELS; LIKELIHOOD-ESTIMATION; PLACEMENT VALUES AB In this article, we study a direct receiver operating characteristic (ROC) curve regression model with completely unknown link and baseline functions. A semiparametric procedure is proposed to estimate both the parametric and nonparametric components of the model. The resulting parameter estimates and ROC curve estimates are shown to be consistent, and asymptotically normal with a n(-1/2) convergence rate. With arbitrary link and baseline functions, our model is more robust than existing direct ROC regression models that require either complete or partially complete specification of the link and baseline functions. Moreover, the robustness of our new method is gained at little cost to efficiency, as evidenced by the parametric convergence rate of our estimators and by the simulation study. An illustrative example is given using a hearing test data set. C1 [Lin, Huazhen] SW Univ Finance & Econ, Sch Stat, Chengdu 611130, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China. [Li, Gang] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. RP Lin, HZ (reprint author), SW Univ Finance & Econ, Sch Stat, Chengdu 611130, Peoples R China. EM huazhenlin@hotmail.com; azhou@u.washington.edu; vli@ucla.edu FU National Natural Science Funds for Distinguished Young Scholar [11125104]; National Natural Science Foundation of China [11071197]; Program for New Century Excellent Talents in University FX Lin's research was supported by the National Natural Science Funds for Distinguished Young Scholar (No. 11125104), the National Natural Science Foundation of China (No. 11071197) and Program for New Century Excellent Talents in University. NR 24 TC 1 Z9 1 U1 2 U2 4 PU STATISTICA SINICA PI TAIPEI PA C/O DR H C HO, INST STATISTICAL SCIENCE, ACADEMIA SINICA, TAIPEI 115, TAIWAN SN 1017-0405 EI 1996-8507 J9 STAT SINICA JI Stat. Sin. PD OCT PY 2012 VL 22 IS 4 BP 1427 EP 1456 DI 10.5705/ss.2010.167 PG 30 WC Statistics & Probability SC Mathematics GA 047BN UT WOS:000311812800011 ER PT J AU Braxton, CC AF Braxton, Carla C. TI Defining, Measuring, and Improving Surgical Quality: Beyond Teamwork and Checklists to Systems Redesign and Transformation SO SURGICAL INFECTIONS LA English DT Article ID HEALTH-CARE; POSTOPERATIVE COMPLICATIONS; PROGRAM; HOSPITALS; SURGEONS; NSQIP AB Background: Surgical complications are multifactorial but often are attributable to deficiencies in the quality of care. This review examines how quality is defined in surgery, the modalities employed to measure quality, and the approaches to improving the quality of surgical care. Beyond developing a hospital environment supportive of organizational learning, the next generation of surgical performance improvement will include broader, more innovative approaches. These ideas will create partnerships among patients, clinicians, industry, the arts, hospital leaders, and other sectors to look for ways to reinvent the system rather than simply to make a better hospital. Methods: Review of pertinent English-language literature on surgical quality, definitions of quality, quality measures, performance improvement, and organizational learning in health care. Results: Medical care should be safe, effective, patient-centered, timely, efficient, and equitable, as defined by the Institute of Medicine core values for health care quality. There is substantive lack of agreement as to how to measure the quality of care. Although the goal of each measurement system is to give patients the ability to compare hospitals nationally, most of the methodologies measure widely different aspects of hospital care, resulting in conflicting illustrations of institutional performance and confounded decision making for patients and for purchasers of healthcare services and insurance. Conclusions: The best pathway for surgical quality and performance improvement includes the application of systems engineering and innovation to determine ways to do better what we do currently, and to improve the present system while developing ideas for better delivery of high-quality care in the future. C1 Baylor Coll Med, Dept Surg, DeBakey VA Med Ctr, Houston, TX 77030 USA. RP Braxton, CC (reprint author), Baylor Coll Med, Dept Surg, DeBakey VA Med Ctr, 2002 Holcombe OCL 112, Houston, TX 77030 USA. EM carla.braxton@bcm.edu NR 22 TC 0 Z9 0 U1 1 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 J9 SURG INFECT JI Surg. Infect. PD OCT PY 2012 VL 13 IS 5 BP 312 EP 316 DI 10.1089/sur.2012.182 PG 5 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA 047HR UT WOS:000311830700006 PM 23116188 ER PT J AU Carchman, EH Peitzman, AB Simmons, RL Zuckerbraun, BS AF Carchman, Evie H. Peitzman, Andrew B. Simmons, Richard L. Zuckerbraun, Brian S. TI The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article ID FULMINANT PSEUDOMEMBRANOUS COLITIS; HUMAN-ANTIBODY RESPONSE; SACCHAROMYCES-BOULARDII; HOSPITALIZED-PATIENTS; HYPERVIRULENT STRAIN; EMERGENCY COLECTOMY; ACID SUPPRESSION; UNITED-STATES; RISK-FACTORS; TOXIN-A AB Clostridium difficile associated disease (CDAD) is the result of colonic bacterial overgrowth with this gram positive anaerobic organism and the production of toxins that typically induce diarrhea. Most patients with CDAD respond to treatment with oral metronidazole or vancomycin, but a subset of patients will develop a severe systemic illness, multiple organ failure, and death. There are no reliable combinations of clinical or laboratory findings that will distinguish patients who will respond to medical therapy and those who will progress to a more complicated state. Early surgical consultation should be considered in patients with ileus, severe abdominal pain, significant tenderness, immunosuppression, advanced age, high white blood cell or band counts, acute renal failure, mental status changes, or cardiopulmonary compromise. The standard operation for fulminant colitis is subtotal colectomy but the high mortality of the operation, and the long-term morbidity even in survivors combine to act as deterrents to early surgical consultation and operation. Novel operative approaches that preserve the colon and minimize operative morbidity may prove to remove the barriers to earlier surgical treatment for fulminant CDAD and improve outcomes. C1 [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), F1271 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu NR 79 TC 11 Z9 11 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 2163-0755 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD OCT PY 2012 VL 73 IS 4 BP 789 EP 800 DI 10.1097/TA.0b013e318265d19f PG 12 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 029OL UT WOS:000310505100001 PM 23026914 ER PT J AU Mathis, KI Wynn, JK Jahshan, C Hellemann, G Darque, A Green, MF AF Mathis, Kristopher I. Wynn, Jonathan K. Jahshan, Carol Hellemann, Gerhard Darque, Alexandra Green, Michael F. TI An electrophysiological investigation of attentional blink in schizophrenia: Separating perceptual and attentional processes SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Article DE P300; ssVEP; Attentional blink; Schizophrenia ID SERIAL VISUAL PRESENTATION; P300; METAANALYSIS; PARADIGM; ERP AB When two visual targets are presented in a rapid serial visual presentation (RSVP) paradigm, the ability to identify the second target is reduced when it is presented 200-500 ms after the initial target. This phenomenon is referred to as the "attentional blink (AB)." Previous behavioral studies have reported aberrant AB in schizophrenia. The underlying cause, however, of the AB deficit in schizophrenia remains ambiguous. Individuals with schizophrenia consistently demonstrate impairments in early visual processing stages and later attentionally-mediated stages, yet the stage of processing that is contributing to patient-control differences on AB is unknown. The current study attempted to resolve this ambiguity by applying electrophysiological methodology to an RSVP paradigm with 70 clinically stable outpatients with schizophrenia and 63 healthy controls. The task was simplified to reduce task demands, and a suppression ratio was employed to control for possible differences between groups in the ability to identify a single stimulus within a visual stream. Early perceptual processing was assessed using the steady-state visual evoked potential (ssVEP), and attentional processing was assessed using the P300 event-related potential. Relative to the healthy controls, patients showed the expected behavioral AB deficits. These deficits coincided with reduced P300 amplitude: both performance and P300 reductions extended beyond the traditional AB window. Mean ssVEP amplitude did not differ between the groups, and the differences in P300 remained after controlling for ssVEP. These results suggest that the observed AB deficits were due to attentional, not perceptual, processing deficits. Published by Elsevier B.V. C1 [Mathis, Kristopher I.; Wynn, Jonathan K.; Jahshan, Carol; Green, Michael F.] W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA 90073 USA. [Wynn, Jonathan K.; Hellemann, Gerhard; Green, Michael F.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Darque, Alexandra] Univ Hosp Geneva, Lab Expt Neuropsychol, Geneva, Switzerland. RP Mathis, KI (reprint author), W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, VA Desert Pacific Mental Illness Res Educ & Clin, 11301 Wilshire Blvd,Bldg 210,Room 117, Los Angeles, CA 90073 USA. EM mathis@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 26 TC 5 Z9 6 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD OCT PY 2012 VL 86 IS 1 BP 108 EP 113 DI 10.1016/j.ijpsycho.2012.06.052 PG 6 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 035GB UT WOS:000310930300011 PM 22771850 ER PT J AU Amorosa, V Umbleja, T Johnson, V Kang, M Luetkemeyer, A Bardin, M Haas, D Chung, R Yesmin, S Coughlin, K Martinez, A Adams, MB Alston-Smith, B Tebas, P Peters, M AF Amorosa, V. Umbleja, T. Johnson, V. Kang, M. Luetkemeyer, A. Bardin, M. Haas, D. Chung, R. Yesmin, S. Coughlin, K. Martinez, A. Adams, M. B. Alston-Smith, B. Tebas, P. Peters, M. TI The addition of nitazoxanide to peginterferon alfa-2a and ribavirin does not significantly improve sustained virologic response in HCV treatment-naive genotype 1 HIV-1/HCV co-infected subjects: results of ACTG 5269 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Amorosa, V.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Amorosa, V.; Tebas, P.] Univ Penn, Philadelphia, PA 19104 USA. [Umbleja, T.; Kang, M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Johnson, V.] Birmingham VA Med Ctr, Birmingham, AL USA. [Johnson, V.] Univ Alabama Birmingham, Birmingham, AL USA. [Luetkemeyer, A.; Peters, M.] Univ San Francisco, San Francisco, CA 94117 USA. [Bardin, M.] Romark, Tampa, FL USA. [Haas, D.] Vanderbilt Univ, Nashville, TN USA. [Chung, R.] Harvard Univ, Sch Med, Boston, MA USA. [Yesmin, S.] ACTG Operat Ctr, Bethesda, MD USA. [Coughlin, K.] Frontiers Sci & Technol Res Fdn, Amherst, NY USA. [Martinez, A.; Alston-Smith, B.] NIAID, DAIDS, NIH, Bethesda, MD 20892 USA. [Adams, M. B.] Univ Rochester, Rochester, NY 14627 USA. EM marion.peters@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 47 EP 48 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200105 ER PT J AU Lo Re, V Tate, J Kallan, M Lim, J Goetz, M Klein, M Rimland, D Rodriguez-Barradas, M Butt, A Gibert, C Brown, S Kostman, J Strom, B Reddy, R Justice, A Localio, R AF Lo Re, V. Tate, J. Kallan, M. Lim, J. Goetz, M. Klein, M. Rimland, D. Rodriguez-Barradas, M. Butt, A. Gibert, C. Brown, S. Kostman, J. Strom, B. Reddy, R. Justice, A. Localio, R. TI Increased risk of hepatic decompensation and hepatocellular carcinoma in HIV/HCV-co-infected patients compared to HCV-mono-infected patients despite combination antiretroviral therapy SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Lo Re, V.; Kallan, M.; Kostman, J.; Strom, B.; Reddy, R.; Localio, R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lo Re, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Tate, J.; Lim, J.; Justice, A.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Tate, J.; Lim, J.; Justice, A.] Yale Univ, Sch Med, New Haven, CT USA. [Goetz, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Klein, M.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Rimland, D.] Atlanta VA Med Ctr, Atlanta, GA USA. [Rodriguez-Barradas, M.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Butt, A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gibert, C.] Washington DC VA Med Ctr, Washington, DC USA. [Brown, S.] James J Peters VA Med Ctr, New York, NY USA. EM vincentl@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 NR 0 TC 0 Z9 0 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 47 EP 47 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200104 ER PT J AU Chitsaz, S Azadani, AN Matthews, PB Chuter, TA Tseng, EE Ge, L AF Chitsaz, S. Azadani, A. N. Matthews, P. B. Chuter, T. A. Tseng, E. E. Ge, L. TI Hemodynamic determinants of aortic dissection propagation by 2D computational modeling: implications for endovascular stent-grafting SO JOURNAL OF CARDIOVASCULAR SURGERY LA English DT Article DE Aortic diseases; Molecular dynamics simulation; Aneurysm ID DESCENDING THORACIC AORTA; B DISSECTION; INTERNATIONAL REGISTRY; FLUID-DYNAMICS; PLACEMENT; REPAIR; COMPLICATIONS; ANEURYSMS; DISEASE; EXPERIENCE AB Aim. Aortic dissection is a life-threatening aortic catastrophe where layers of the aortic wall are separated allowing blood flow within the layers. Propagation of aortic dissection is strongly linked to the rate of rise of pressure (dp/dt) experienced by the aortic wall but the hemodynamics is poorly understood. The purpose of this study was to perform computational fluid dynamics (CFD) simulations to determine the relationship between dissection propagation in the distal longitudinal direction (the tearing force) and dp/dt. Methods. Five computational models of aortic dissection in a 2D pipe were constructed. Initiation of dissection and propagation were represented in 4 single entry tear models, 3 of which investigated the role of length of dissection and antegrade propagation, 1 of which investigated retrograde propagation. The 5th model included a distal re-entry tear. Impact of pressure field distribution on tearing force was determined. Results. Tearing force in the longitudinal direction for dissections with a single entry tear was approximately proportional to dp/dt and L-2 where L is the length of dissection. Tearing force was much lower under steady flow than pulsatile flow conditions. Introduction of a second tear distally along the dissection away from the primary entry tear significantly reduced tearing force. Conclusion. The hemodynamic mechanism for dissection propagation demonstrated in these models support the use of beta-blockers in medical management. Endovascular stent-graft treatment of dissection should ideally cover both entry and re-entry tears to reduce risk of retrograde propagation of aortic dissection. C1 [Chitsaz, S.; Azadani, A. N.; Matthews, P. B.; Tseng, E. E.; Ge, L.] Univ Calif San Francisco, Med Ctr, Dept Surg, Div Cardiothorac Surg, San Francisco, CA 94143 USA. [Chitsaz, S.; Azadani, A. N.; Matthews, P. B.; Chuter, T. A.; Tseng, E. E.; Ge, L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Chuter, T. A.] Univ Calif San Francisco, Med Ctr, Dept Surg, Div Vasc Surg, San Francisco, CA 94143 USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Dept Surg, Div Cardiothorac Surg, 500 Parnassus Ave Suite 405W Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org RI Chitsaz, Sam/C-4586-2008 FU American Heart Association; Northern California Institute for Research and Education FX This work was supported by American Heart Association and Northern California Institute for Research and Education. NR 43 TC 3 Z9 3 U1 1 U2 8 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0021-9509 J9 J CARDIOVASC SURG JI J. Cardiovasc. Surg. PD OCT PY 2012 VL 53 IS 5 BP 631 EP 640 PG 10 WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Surgery GA 033RR UT WOS:000310819000008 PM 22820737 ER PT J AU Singh, JA Sperling, JW Schleck, C Harmsen, W Cofield, RH AF Singh, Jasvinder A. Sperling, John W. Schleck, Cathy Harmsen, William Cofield, Robert H. TI Periprosthetic infections after shoulder hemiarthroplasty SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Shoulder hemiarthroplasty; humeral head replacement; infection; age ID HUMERAL HEAD REPLACEMENT; ARTHROPLASTY; REIMPLANTATION; OBESE AB Background: To examine the rates and predictors of deep periprosthetic infections after shoulder hemiarthroplasty. Methods: We used prospectively collected institutional registry data on all primary shoulder hemiarthroplasty patients from 1976-2008. We estimated survival free of deep periprosthetic infections using Kaplan-Meier survival curves. Using univariate Cox regression analyses, we examined the association of patient-related factors (age, sex, body mass index), comorbidity (Deyo-Charlson index), American Society of Anesthesiologists grade, underlying diagnosis, and implant fixation with the risk of infection. Results: A total of 1,349 patients, with a mean age of 63 years (SD, 16 years), 63% of whom were women, underwent 1,431 primary shoulder hemiarthroplasties. Mean follow-up was 8 years (SD, 7 years). Fourteen deep periprosthetic infections occurred during the follow-up, confirmed by medical record review. The most common organisms were Staphylococcus aureus, coagulase-negative Staphylococcus, and Propionibacterium acnes, each accounting for 3 cases (21% each). The 5-, 10-, and 20-year prosthetic infectionefree rates were 98.9% (95% confidence interval [CI], 98.3%-99.5%), 98.7% (95% CI, 98.1%-99.4%), and 98.7% (95% CI, 98.1%-99.4%), respectively. None of the factors evaluated were significantly associated with risk of prosthetic infection after primary shoulder hemiarthroplasty, except that an underlying diagnosis of trauma was associated with a significantly higher hazard ratio of 3.18 (95% CI, 1.06-9.56) for infection compared with all other diagnoses (P = .04). A higher body mass index showed a nonestatistically significant trend toward an association with higher hazard (P = .13). Conclusion: The periprosthetic infection rate after shoulder hemiarthroplasty was low, estimated at 1.3% at 20-year follow-up. An underlying diagnosis of trauma was associated with a higher risk of periprosthetic infection. These patients should be observed closely for development of infection. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Sperling, John W.; Cofield, Robert H.] Mayo Clin, Dept Orthoped Surg, Sch Med, Rochester, MN USA. [Schleck, Cathy; Harmsen, William] Mayo Clin, Dept Hlth Sci Res, Sch Med, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health Clinical Translational Science Award [1 KL2 RR024151-01]; Allergan; Takeda; Savient; Wyeth; Amgen; URL Pharmaceuticals; Novartis; Tornier and owns stock in Tornier FX This material is the result of work supported by National Institutes of Health Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and use of facilities at the Birmingham VA Medical Center. The study sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.; Jasvinder A. Singh has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen; and consultant fees from Savient, URL Pharmaceuticals, and Novartis.; John W. Sperling has received royalties from Aircast and Biomet and consultant fees from Tornier and owns stock in Tornier. NR 15 TC 24 Z9 25 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD OCT PY 2012 VL 21 IS 10 BP 1304 EP 1309 DI 10.1016/j.jse.2011.08.067 PG 6 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 033EJ UT WOS:000310776700009 PM 22154310 ER PT J AU Weisbart, RH Gera, JF Chan, G Hansen, JE Li, E Cloninger, C Levine, AJ Nishimura, RN AF Weisbart, Richard H. Gera, Joseph F. Chan, Grace Hansen, James E. Li, Erica Cloninger, Cheri Levine, Arnold J. Nishimura, Robert N. TI A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID METASTASIS IN-VIVO; CANCER-CELLS; P53; AUTOANTIBODY; INHIBITORS; EXPRESSION; MDM2 AB The therapeutic use of antibodies is restricted by the limited access of antibodies to intracellular compartments. To overcome this limitation, we developed a cell-penetrating monoclonal antibody, mAb 3E10, as an intracellular delivery vehicle for the intracellular and intranuclear delivery of antibodies constructed as bispecific single-chain Fv fragments. Because MDM2 is an important target in cancer therapy, we selected monoclonal antibody (mAb) 3G5 for intracellular transport. mAb 3G5 binds MDM2 and blocks binding of MDM2 to p53. Here, we show that the resulting 3E10-3G5 bispecific antibody retains cell-penetrating and MDM2-binding activity, increases tumor p53 levels, and inhibits growth of MDM2-addicted tumors. The use of cell-penetrating bispecific antibodies in targeted molecular therapy will significantly broaden the spectrum of accessible intracellular targets and may have a profound impact in cancer therapy. Mol Cancer Ther; 11(10); 2169-73. (C) 2012 AACR. C1 [Weisbart, Richard H.; Gera, Joseph F.; Chan, Grace; Hansen, James E.; Li, Erica; Cloninger, Cheri] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA 91343 USA. [Levine, Arnold J.] Princeton Univ, Inst Adv Study, Princeton, NJ 08544 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. RP Weisbart, RH (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst, 161111 Plummer St, Sepulveda, CA 91343 USA. EM rweisbar@ucla.edu FU Merit Review Grant from the Veterans Affairs FX This work was supported by a Merit Review Grant from the Veterans Affairs awarded to R. H. Weisbart. NR 15 TC 15 Z9 15 U1 1 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD OCT PY 2012 VL 11 IS 10 BP 2169 EP 2173 DI 10.1158/1535-7163.MCT-12-0476-T PG 5 WC Oncology SC Oncology GA 031KP UT WOS:000310638600010 PM 22863609 ER PT J AU Irwin, DJ White, MT Toledo, JB Xie, SX Robinson, JL Van Deerlin, V Lee, VMY Leverenz, JB Montine, TJ Duda, JE Hurtig, HI Trojanowski, JQ AF Irwin, David J. White, Matthew T. Toledo, Jon B. Xie, Sharon X. Robinson, John L. Van Deerlin, Vivianna Lee, Virginia M-Y Leverenz, James B. Montine, Thomas J. Duda, John E. Hurtig, Howard I. Trojanowski, John Q. TI Neuropathologic substrates of Parkinson disease dementia SO ANNALS OF NEUROLOGY LA English DT Article ID LEWY BODY DISEASES; PREDICTS COGNITIVE DECLINE; ARGYROPHILIC GRAIN DISEASE; APOLIPOPROTEIN-E GENOTYPE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; A-BETA; CLINICOPATHOLOGICAL CORRELATIONS; STRIATAL PATHOLOGY; BRAIN PATHOLOGY AB Objective: A study was undertaken to examine the neuropathological substrates of cognitive dysfunction and dementia in Parkinson disease (PD). Methods: One hundred forty patients with a clinical diagnosis of PD and either normal cognition or onset of dementia 2 or more years after motor symptoms (PDD) were studied. Patients with a clinical diagnosis of dementia with Lewy bodies were excluded. Autopsy records of genetic data and semiquantitative scores for the burden of neurofibrillary tangles, senile plaques, Lewy bodies (LBs), and Lewy neurites (LNs) and other pathologies were used to develop a multivariate logistic regression model to determine the independent association of these variables with dementia. Correlates of comorbid Alzheimer disease (AD) were also examined. Results: Niney-two PD patients developed dementia, and 48 remained cognitively normal. Severity of cortical LB (CLB)/LN pathology was positively associated with dementia (p < 0.001), with an odds ratio (OR) of 4.06 (95% confidence interval [CI], 1.878.81), as was apolipoprotein E4 (APOE4) genotype (p = 0.018; OR, 4.19; 95% CI, 1.2813.75). A total of 28.6% of all PD cases had sufficient pathology for comorbid AD, of whom 89.5% were demented. The neuropathological diagnosis of PDD+AD correlated with an older age of PD onset (p = 0.001; OR, 1.12; 95% CI, 1.041.21), higher CLB/LN burden (p = 0.037; OR, 2.48; 95% CI, 1.065.82), and cerebral amyloid angiopathy severity (p = 0.032; OR, 4.16; 95% CI, 1.1315.30). Interpretation: CLB/LN pathology is the most significant correlate of dementia in PD. Additionally, APOE4 genotype may independently influence the risk of dementia in PD. AD pathology was abundant in a subset of patients, and may modify the clinical phenotype. Thus, therapies that target a-synuclein, tau, or amyloid beta could potentially improve cognitive performance in PD. ANN NEUROL 2012;72:587598 C1 [Trojanowski, John Q.] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, HUP,Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Irwin, David J.; Duda, John E.; Hurtig, Howard I.] Parkinsons Dis & Movement Disorders Clin, Dept Neurol, Philadelphia, PA USA. [White, Matthew T.; Xie, Sharon X.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Leverenz, James B.] Univ Washington, Parkinsons Dis Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. RP Trojanowski, JQ (reprint author), Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, HUP,Dept Pathol & Lab Med, Maloney 3rd Floor,36th & Spruce St, Philadelphia, PA 19104 USA. EM trojanow@mail.med.upenn.edu OI White, Matthew/0000-0002-7655-8145; Toledo, Jon/0000-0003-4366-9268 FU NIH [AG05136, T32-AG000255]; Morris K. Udall Center for Parkinson's Disease Research [P50 NS053488, NS062684]; Alfonso Martin Escudero Foundation FX This study was supported by NIH grants AG05136, and Morris K. Udall Center for Parkinson's Disease Research core grants P50 NS053488 and NS062684. D.J.I. is supported by NIH grant T32-AG000255, Training in Age-Related Neurodegenerative Diseases. J.B.T. is supported by a grant of the Alfonso Martin Escudero Foundation. NR 65 TC 121 Z9 123 U1 1 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD OCT PY 2012 VL 72 IS 4 BP 587 EP 598 DI 10.1002/ana.23659 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 030CG UT WOS:000310544900017 PM 23037886 ER PT J AU Siple, JF Morey, JM Gutman, TE Weinberg, KL Collins, PD AF Siple, Jolene F. Morey, Jessica M. Gutman, Tracy E. Weinberg, Kathy L. Collins, Peggie D. TI Proton Pump Inhibitor Use and Association with Spontaneous Bacterial Peritonitis in Patients with Cirrhosis and Ascites SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE ascites; cirrhosis; Clostridium difficile; proton pump inhibitor; spontaneous bacterial peritonitis ID CLOSTRIDIUM-DIFFICILE; MANAGEMENT; DISEASE; VARICES; RISKS AB OBJECTIVE: To evaluate the literature regarding the efficacy and safety of proton pump inhibitors (PP Is) when they are used in patients with cirrhosis and ascites. DATA SOURCES: A literature search was conducted using MEDLINE (1966-May 2012) and Web of Science (1990-May 2012) with the terms proton pump inhibitor, antisecretory therapy, cirrhosis, ascites, spontaneous bacterial peritonitis, and Clostridium difficile. The search was restricted to articles published in English on the use of PPIs in humans. Reference citations from identified published articles were reviewed for relevant information. STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the data sources were evaluated for inclusion. One case series, 8 retrospective case-control trials, and 1 meta-analysis were identified. DATA SYNTHESIS: Cirrhosis may cause complications such as portal hypertension, esophageal varices, and ascites. Patients may be prescribed PPIs without clear indications or because of their propensity to develop upper gastrointestinal symptoms and bleeding. However, gastric acidity is a major nonspecific defense mechanism and there is insufficient evidence on the need for chronic acid suppression in patients with cirrhosis. It is postulated that the portal hypertensive environment in cirrhosis and the acid suppression from PPIs can increase the risk of spontaneous bacterial peritonitis and C. difficile infection in patients with cirrhosis with ascites. Several retrospective studies and 1 meta-analysis have confirmed this association. CONCLUSIONS: Patients with cirrhosis and ascites should be monitored carefully while on PPIs for a possible increased risk of infection from spontaneous bacterial peritonitis and C. difficile. Prospective randomized trials are needed to confirm this association. Clinicians should be aware of this lesser known adverse effect of PPIs. C1 [Siple, Jolene F.; Morey, Jessica M.; Gutman, Tracy E.; Weinberg, Kathy L.; Collins, Peggie D.] Portland VA Med Ctr, Vancouver Primary Care, Vancouver, WA USA. RP Siple, JF (reprint author), Portland VA Med Ctr, Vancouver Primary Care, Vancouver, WA USA. EM jolene.siple@va.gov NR 29 TC 7 Z9 7 U1 0 U2 7 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD OCT PY 2012 VL 46 IS 10 BP 1413 EP 1418 DI 10.1345/aph.1R174 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 022HE UT WOS:000309947700015 PM 23032651 ER PT J AU Czerniecki, JM Turner, AP Williams, RM Hakimi, KN Norvell, DC AF Czerniecki, Joseph M. Turner, Aaron P. Williams, Rhonda M. Hakimi, Kevin N. Norvell, Daniel C. TI Mobility Changes in Individuals With Dysvascular Amputation From the Presurgical Period to 12 Months Postamputation SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Amputation; Outcome assessment (Health Care); Rehabilitation; Walking ID LOWER-LIMB AMPUTATION; LOCOMOTOR CAPABILITIES INDEX; RESPONSE SHIFT; AUDIT-C; RELIABILITY; POPULATION; VALIDATION; VALIDITY; AMPUTEES; PEOPLE AB Czerniecki JM, Turner AP, Williams RM, Hakimi KN, Norvell DC. Mobility changes in individuals with dysvascular amputation from the presurgical period to 12 months postamputation. Arch Phys Med Rehabil 2012;93:1766-73. Objectives: To describe changes in ambulation among individuals with lower-extremity amputation secondary to peripheral artery disease and/or diabetes prior to surgery through 12 months after surgery. To compare differences in ambulation by amputation level and to examine risk factors for change in ambulation over time. Design: Prospective cohort study. Setting: Two Veterans Affairs medical centers, 1 university hospital, and a level 1 trauma center. Participants: Patients with peripheral artery disease or diabetes (N = 239) undergoing a first unilateral major amputation were screened for participation between September 2005 and December 2008. Among these, 57% (n = 136) met study criteria, and of these, 64% (n = 87) participated. Interventions: Standard of care at each facility. Main Outcome Measures: Ambulatory function measured using the Locomotor Capability Index-5. Results: Seventy-five of the 87 (86%) subjects enrolled finished their 12-month follow-up interview. Ambulatory mobility declined during the period immediately prior to surgery (premorbid) and remained low at 6 weeks postsurgery. On average, ambulation improved after surgery but did not return to premorbid levels. In the final multivariate model, age and history of lower-extremity arterial reconstruction were significantly associated with a poorer ambulatory trajectory over time, while other factors, such as amputation level, prior alcohol use, and length of disability prior to amputation, were not. Conclusions: The findings highlight the importance of considering premorbid ambulatory function. Informing providers and patients about the trajectory and time course of changes in ambulation can enhance patient education, patient expectations, and treatment planning. C1 [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA 98405 USA. [Czerniecki, Joseph M.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Czerniecki, Joseph M.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Norvell, DC (reprint author), Spectrum Res Inc, 705 S 9th St,Suite 203, Tacoma, WA 98405 USA. EM dan@specri.com OI Turner, Aaron/0000-0001-6897-8003 FU US Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development [A41241, B4927W] FX Supported by the US Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development (Merit Review A41241 and Career Development Award B34927W). NR 23 TC 10 Z9 10 U1 2 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2012 VL 93 IS 10 BP 1766 EP 1773 DI 10.1016/j.apmr.2012.04.011 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 018FP UT WOS:000309645800011 PM 22543258 ER PT J AU Belsom, R Jain, A Curtis, J Yang, S Mikuls, TR Chen, L Gaffo, AL AF Belsom, Rebecca Jain, Archana Curtis, Jeffrey Yang, Shuo Mikuls, Ted R. Chen, Lang Gaffo, Angelo L. TI Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Belsom, Rebecca; Jain, Archana; Curtis, Jeffrey; Yang, Shuo; Chen, Lang; Gaffo, Angelo L.] Univ Alabama Birmingham, Birmingham, AL USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 402 BP S176 EP S176 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748300403 ER PT J AU Bhangle, S Lo Re, V Pang, WG Chang, KM Amorosa, V Kostman, J Schumacher, HR Ogdie, A AF Bhangle, Samir Lo Re, Vincent Pang, W. Gina Chang, Kyong-Mi Amorosa, Valerianna Kostman, Jay Schumacher, H. Ralph Ogdie, Alexis TI Prevalence, Risk Factors, and Functional Impact of Arthralgias Among Patients with Chronic Hepatitis C Virus Infection. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Bhangle, Samir; Lo Re, Vincent; Pang, W. Gina; Kostman, Jay; Schumacher, H. Ralph; Ogdie, Alexis] Univ Penn, Philadelphia, PA 19104 USA. [Chang, Kyong-Mi; Amorosa, Valerianna] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Schumacher, H. Ralph] VA Med Ctr, Philadelphia, PA USA. RI Lo Re, Vincent/N-7817-2015 NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 174 BP S75 EP S76 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748300175 ER PT J AU Bunni, M Amani, Z Mather, A Schepp, JB Siskind, L Nowling, TK AF Bunni, Marlene Amani, Zainab Mather, Andrew Schepp, Jennifer Berglind Siskind, Leah Nowling, Tamara K. TI Lowering Fli1 Levels Decreases the Levels of Lipid Mediators in the Kidneys and T Cells of MRL/Lpr Lupus Prone Mice. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Bunni, Marlene; Amani, Zainab; Mather, Andrew; Schepp, Jennifer Berglind; Siskind, Leah; Nowling, Tamara K.] Med Univ S Carolina, Charleston, SC 29425 USA. [Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2339 BP S987 EP S987 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305259 ER PT J AU Chou, YK Wu, SL Avendano, C Caldwell, T Maniaci, B Yomogida, K Zhu, Y Chu, CQ AF Chou, Yuan K. Wu, Shili Avendano, Camilo Caldwell, Tom Maniaci, Brian Yomogida, Kentaro Zhu, Yong Chu, Cong-Qiu TI Supercharged Sox9 Protein Induces Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Chou, Yuan K.; Yomogida, Kentaro; Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Wu, Shili; Avendano, Camilo; Caldwell, Tom; Maniaci, Brian; Zhu, Yong] VivoScript Inc, Costa Mesa, CA USA. [Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 8 BP S3 EP S3 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748300009 ER PT J AU Chu, CQ Austin, CR Doyle, TM Goodwin, KA El Torgomen, N Treudler, R Martin, TM AF Chu, Cong-Qiu Austin, Carrie R. Doyle, Trudy M. Goodwin, Kelley A. El Torgomen, Noha Treudler, Regina Martin, Tammy M. TI NLRP3 Gene Analysis for Patients with Schnitzler's Syndrome SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Chu, Cong-Qiu; Austin, Carrie R.; Doyle, Trudy M.; Goodwin, Kelley A.; El Torgomen, Noha; Martin, Tammy M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR USA. [Treudler, Regina] Univ Klinikum Leipzig AoR, Leipzig, Germany. NR 2 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 190 BP S81 EP S81 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748300191 ER PT J AU Davis, LA Polk, BI Mann, AD Kerr, GS Reimold, AM Cannon, GW Mikuls, TR Caplan, L AF Davis, Lisa A. Polk, Brooke Ivan Mann, Alyse D. Kerr, Gail S. Reimold, Andreas M. Cannon, Grant W. Mikuls, Ted R. Caplan, Liron TI Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Davis, Lisa A.; Polk, Brooke Ivan; Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Mann, Alyse D.] Denver VA Med Ctr, Denver, CO USA. [Kerr, Gail S.] Georgetown & Howard Univ, Washington DC VAMC, Washington, DC USA. [Reimold, Andreas M.] Dallas VA, Dallas, TX USA. [Reimold, Andreas M.] Univ Texas SW, Dallas, TX USA. [Cannon, Grant W.] George E Wahlen VA Med Ctr, Salt Lake City, UT USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Caplan, Liron] Denver VA, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2640 BP S1119 EP S1119 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748306150 ER PT J AU Davis, LA Polk, BI Mann, AD Wolff, RK Kerr, GS Reimold, AM Cannon, GW Mikuls, TR Caplan, L AF Davis, Lisa A. Polk, Brooke Ivan Mann, Alyse D. Wolff, Roger K. Kerr, Gail S. Reimold, Andreas M. Cannon, Grant W. Mikuls, Ted R. Caplan, Liron TI Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Davis, Lisa A.; Polk, Brooke Ivan; Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Mann, Alyse D.] Denver VA Med Ctr, Denver, CO USA. [Wolff, Roger K.] Univ Utah, Salt Lake City, UT USA. [Kerr, Gail S.] Georgetown & Howard Univ, Washington DC VAMC, Washington, DC USA. [Reimold, Andreas M.] Univ Texas SW, Dallas, TX USA. [Reimold, Andreas M.] Dallas VA, Dallas, TX USA. [Cannon, Grant W.] George E Wahlen VA Med Ctr, Salt Lake City, UT USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Caplan, Liron] Denver VA, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2483 BP S1047 EP S1048 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305403 ER PT J AU Deng, Y Zhao, J Sakurai, D Kaufman, KM Edberg, JC Kimberly, RP Kamen, DL Gilkeson, GS Jacob, CO Scofield, RH Langefeld, CD Kelly, JA Alarcuun-Riquelme, ME Harley, JB Vyse, TJ Freedman, BI Gaffney, PM Sivils, KM James, JA Niewold, TB Cantor, RM Chen, WL Hahn, BH Brown, EE Tsao, BP AF Deng, Yun Zhao, Jian Sakurai, Daisuke Kaufman, Kenneth M. Edberg, Jeffrey C. Kimberly, Robert P. Kamen, Diane L. Gilkeson, Gary S. Jacob, Chaim O. Scofield, Robert H. Langefeld, Carl D. Kelly, Jennifer A. Alarcuen-Riquelme, Marta E. Harley, John B. Vyse, Timothy J. Freedman, Barry I. Gaffney, Patrick M. Sivils, Kathy Moser James, Judith A. Niewold, Timothy B. Cantor, Rita M. Chen, Weiling Hahn, Bevra H. Brown, Elizabeth E. Tsao, Betty P. CA BIOLUPUS & GENLES Networks PROFILE TI The SLE-Associated TLR7 Variant Confers Differential Gene Expression Modulated by Microrna-3148 SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Deng, Yun; Zhao, Jian; Sakurai, Daisuke; Chen, Weiling; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Edberg, Jeffrey C.; Kimberly, Robert P.; Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kamen, Diane L.; Scofield, Robert H.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Charleston, SC USA. [Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Scofield, Robert H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Scofield, Robert H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Langefeld, Carl D.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Gaffney, Patrick M.; James, Judith A.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Alarcuen-Riquelme, Marta E.] Pfizer Univ Granada Junta de Andalucia, Ctr Genom & Invest Oncol GENYO, Granada, Spain. [Vyse, Timothy J.] Kings Coll London, Div Genet, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Mol Med & Immunol, London WC2R 2LS, England. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Niewold, Timothy B.] Univ Chicago, Sect Rheumatol, Chicago, IL 60637 USA. [Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. [Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. RI Zhao, Jian/E-6292-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 1613 BP S689 EP S689 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748303334 ER PT J AU Domsic, RT Nihtyanova, S Wisniewski, SR Fine, MJ Kwoh, CK Denton, CP Medsger, TA AF Domsic, Robyn T. Nihtyanova, Svetlana Wisniewski, Stephen R. Fine, Michael J. Kwoh, C. Kent Denton, Christopher P. Medsger, Thomas A., Jr. TI External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Nihtyanova, Svetlana] Royal Free Hosp, Sch Med, London, England. [Fine, Michael J.] VA Pittsburgh Healthcare, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kwoh, C. Kent] VA Healthcare Syst, Pittsburgh, PA USA. [Denton, Christopher P.] UCL, London, England. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 698 BP S299 EP S300 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748301236 ER PT J AU Edberg, JC Duarte, CW Patki, A Brown, EE Kaufman, KM Kelly, JA Comeau, ME Alarcon-Riquelme, ME Bae, SC Criswell, LA Freedman, BI Gaffney, PM Gilkeson, GS Jacob, CO James, JA Kamen, DL Sivils, KM Niewold, TB Scofield, RH Tsao, BP Vyse, TJ Harley, JB Langefeld, CD Tiwari, H Kimberly, RP AF Edberg, Jeffrey C. Duarte, Christine W. Patki, Amit Brown, Elizabeth E. Kaufman, Kenneth M. Kelly, Jennifer A. Comeau, Mary E. Alarcon-Riquelme, Marta E. Bae, Sang-Cheol Criswell, Lindsey A. Freedman, Barry I. Gaffney, Patrick M. Gilkeson, Gary S. Jacob, Chaim O. James, Judith A. Kamen, Diane L. Sivils, Kathy Moser Niewold, Timothy B. Scofield, Robert H. Tsao, Betty P. Vyse, Timothy J. Harley, John B. Langefeld, Carl D. Tiwari, Hemant Kimberly, Robert P. CA BIOLUPUS GENLES TI Genetic Interactions Between SNP Variants in C3 Receptor Sub-units in Patients with SLE. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Comeau, Mary E.] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. [GENLES] Univ Granada, Ctr Genom & Oncol Res Pfizer, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Bae, Sang-Cheol] Hanyang Univ Hosp Rheumat Dis, CRCRA, Seoul, South Korea. [Criswell, Lindsey A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Gaffney, Patrick M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Scofield, Robert H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Scofield, Robert H.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Charleston, SC USA. [Scofield, Robert H.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati Childrens Hosp Med Ctr, Oklahoma City, OK USA. [Tsao, Betty P.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Vyse, Timothy J.] Kings Coll London, Div Genet, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Mol Med & Immunol, London WC2R 2LS, England. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 970 BP S420 EP S420 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748302045 ER PT J AU Foering, K Chang, AY Piette, EW Okawa, J Werth, VP AF Foering, Kristen Chang, Aileen Y. Piette, Evan W. Okawa, Joyce Werth, Victoria P. TI Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Okawa, Joyce] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Foering, Kristen] VAMC, Philadelphia, PA USA. [Okawa, Joyce; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 1401 BP S603 EP S603 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748303122 ER PT J AU Garg, V Maranian, P Taylor, MB Paulus, HE Elashoff, D Ranganath, VK AF Garg, Vikram Maranian, Paul Taylor, Mihaela B. Paulus, Harold E. Elashoff, David Ranganath, Veena K. TI DAS28 Is Not a Sufficient Disease Activity Measure for Obese Rheumatoid Arthritis Patients - Don't Leave the Feet Behind SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Garg, Vikram] UCLA David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Maranian, Paul] UCLA Med Sch, Los Angeles, CA USA. [Ranganath, Veena K.] Univ Calif Los Angeles, Western Consortium Practicing Rheumatologists, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 391 BP S170 EP S171 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748300392 ER PT J AU Giles, BM Zhao, J Lough, KM Gaffney, PM Alarcon-Riquelme, ME Brown, EE Criswell, LA Gilkeson, GS Jacob, CO James, JA Merrill, JT Moser, KL Niewold, TB Scofield, RH Vyse, TJ Harley, JB Kaufman, KM Kelly, JA Langefeld, CD Edberg, JC Kimberly, RP Ulgiati, D Tsao, BP Boackle, SA AF Giles, Brendan M. Zhao, Jian Lough, Kara M. Gaffney, Patrick M. Alarcon-Riquelme, Marta E. Brown, Elizabeth E. Criswell, Lindsey A. Gilkeson, Gary S. Jacob, Chaim O. James, Judith A. Merrill, Joan T. Moser, Kathy L. Niewold, Timothy B. Scofield, R. Hal Vyse, Timothy J. Harley, John B. Kaufman, Kenneth M. Kelly, Jennifer A. Langefeld, Carl D. Edberg, Jeffrey C. Kimberly, Robert P. Ulgiati, Daniela Tsao, Betty P. Boackle, Susan A. CA LLAS2 BIOLUPUS PROFILE TI Preferential Association of Complement Receptor 2 Variants with Anti-dsDNA Autoantibodies in Systemic Lupus Erythematosus. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Giles, Brendan M.; Lough, Kara M.; Boackle, Susan A.] Univ Colorado, Sch Med, Aurora, CO USA. [Zhao, Jian] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Alarcon-Riquelme, Marta E.; BIOLUPUS] Univ Granada Junta de Andalucia, Ctr Genom & Oncol Res Pfizer, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Criswell, Lindsey A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Niewold, Timothy B.] Univ Chicago, Chicago, IL 60637 USA. [Vyse, Timothy J.] Kings Coll London, Guys Hosp, London WC2R 2LS, England. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Langefeld, Carl D.] Wake Forest Sch Med, Winston Salem, NC USA. [Ulgiati, Daniela] Univ Western Australia, Perth, WA 6009, Australia. [Tsao, Betty P.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RI Zhao, Jian/E-6292-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2283 BP S965 EP S966 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305203 ER PT J AU Jain, A Belsom, R Curtis, J Yang, S Mikuls, TR Chen, L Gaffo, AL AF Jain, Archana Belsom, Rebecca Curtis, Jeffrey Yang, Shuo Mikuls, Ted R. Chen, Lang Gaffo, Angelo L. TI Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in US Veterans with Rheumatoid Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Jain, Archana; Belsom, Rebecca; Curtis, Jeffrey; Yang, Shuo; Chen, Lang; Gaffo, Angelo L.] Univ Alabama Birmingham, Birmingham, AL USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2106 BP S891 EP S891 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305026 ER PT J AU Kimberly, RP Freedman, BI Langfeld, CD Absher, D Andringa, KK Birmingham, D Brown, EE Comeau, ME Costenbader, KH Criswell, LA Edberg, JC Harley, JB James, JA Kamen, DL Merrill, JT Niewold, TB Patel, N Petri, MA Ramsey-Goldman, R Salmon, JE Segal, M Sivils, KM Tsao, BP Julian, BA AF Kimberly, Robert P. Freedman, Barry I. Langfeld, Carl D. Absher, Devin Andringa, Kelly K. Birmingham, Daniel Brown, Elizabeth E. Comeau, Mary E. Costenbader, Karen H. Criswell, Lindsey A. Edberg, Jeffrey C. Harley, John B. James, Judith A. Kamen, Diane L. Merrill, Joan T. Niewold, Timothy B. Patel, Neha Petri, Michelle A. Ramsey-Goldman, Rosalind Salmon, Jane E. Segal, Mark Sivils, Kathy Moser Tsao, Betty P. Julian, Bruce A. CA Lupus Nephritis-ESRD Consortium TI Apolipoprotein L1 Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Kimberly, Robert P.; Andringa, Kelly K.; Brown, Elizabeth E.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Langfeld, Carl D.; Comeau, Mary E.] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. [Absher, Devin] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. [Birmingham, Daniel] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Costenbader, Karen H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Criswell, Lindsey A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Edberg, Jeffrey C.; Julian, Bruce A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [James, Judith A.; Merrill, Joan T.; Sivils, Kathy Moser] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Kamen, Diane L.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Charleston, SC USA. [Niewold, Timothy B.] Univ Chicago, Chicago, IL 60637 USA. [Patel, Neha] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Salmon, Jane E.] Hosp Special Surg, New York, NY 10021 USA. [Segal, Mark] Univ Florida, Gainesville, FL USA. [Tsao, Betty P.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 729 BP S313 EP S313 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748301266 ER PT J AU Lessard, CJ Li, H Adrianto, I Ice, JA Jonsson, R Illei, GG Rischmueller, M Nordmark, G Mariette, X Miceli-Richard, C Wahren-Herlenius, M Witte, T Brennan, MT Omdal, R Gaffney, PM Lessard, JA Ng, WF Rhodus, NL Segal, BM Scofield, RH James, JA Anaya, JM Harley, JB Montgomery, CG Sivils, KM AF Lessard, Christopher J. Li, He Adrianto, Indra Ice, John A. Jonsson, Roland Illei, Gabor G. Rischmueller, Maureen Nordmark, Gunnel Mariette, Xavier Miceli-Richard, Corinne Wahren-Herlenius, Marie Witte, Torsten Brennan, Michael T. Omdal, Roald Gaffney, Patrick M. Lessard, James A. Ng, Wan-Fai Rhodus, Nelson L. Segal, Barbara M. Scofield, R. Hal James, Judith A. Anaya, Juan-Manuel Harley, John B. Montgomery, Courtney G. Sivils, Kathy Moser TI A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjogren's Syndrome SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Lessard, Christopher J.; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Jonsson, Roland] Univ Bergen, Bergen, Norway. [Illei, Gabor G.] NIDCR, NIH, Bethesda, MD USA. [Rischmueller, Maureen] Queen Elizabeth Hosp, Adelaide, SA, Australia. [Mariette, Xavier] Univ Paris 11, Le Kremlin Bicetre, France. [Miceli-Richard, Corinne] Hop Bicetre, Le Kremlin Bicetre, France. [Wahren-Herlenius, Marie] Karolinska Inst, Stockholm, Sweden. [Witte, Torsten] Hannover Med Sch, Hannover, Germany. [Brennan, Michael T.] Carolinas Med Ctr, Charlotte, NC 28203 USA. [Omdal, Roald] Stavanger Univ Hosp, Clin Immunol Unit, Dept Internal Med, Stavanger, Norway. [Gaffney, Patrick M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Lessard, James A.] Valley Bone & Joint Clin, Grand Forks, ND USA. [Ng, Wan-Fai] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA. [Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Anaya, Juan-Manuel] Univ Rosario Corp Invest Biol, Bogota, Colombia. [Harley, John B.] US Dept Vet Affairs, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. RI Adrianto, Indra/D-4214-2013; Witte, Torsten/B-5783-2016; Anaya, Juan-Manuel/J-1960-2016 OI Adrianto, Indra/0000-0002-9973-3057; Anaya, Juan-Manuel/0000-0002-6444-1249 NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2671 BP S1133 EP S1133 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748306181 ER PT J AU Li, H Hsu, HC Wu, Q Yang, PA Li, J Cua, D Oukka, M Mountz, JD AF Li, Hao Hsu, Hui-Chen Wu, Qi Yang, PingAr Li, Jun Cua, Daniel Oukka, Mohamed Mountz, John D. TI IL-23 Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 Mice SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Li, Hao; Hsu, Hui-Chen; Wu, Qi; Yang, PingAr; Li, Jun; Oukka, Mohamed; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Cua, Daniel] Merck Res Lab, Palo Alto, CA USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2677 BP S1135 EP S1136 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748306187 ER PT J AU Li, H Ice, JA Kelly, JA Adrianto, I Glenn, SB Hefner, KS Vista, EG Stone, DU Gopalakrishnan, R Houston, GD Lewis, DM Rohrer, M Hughes, P Harley, JB Montgomery, CG Chodosh, J Lessard, JA Anaya, JM Segal, BM Rhodus, NL Radfar, L Frank, MB Scofield, RH Lessard, CJ Sivils, KM AF Li, He Ice, John A. Kelly, Jennifer A. Adrianto, Indra Glenn, Stuart B. Hefner, Kimberly S. Vista, Evan G. Stone, Donald U. Gopalakrishnan, Raj Houston, Glen D. Lewis, David M. Rohrer, Michael Hughes, Pamela Harley, John B. Montgomery, Courtney G. Chodosh, James Lessard, James A. Anaya, Juan-Manuel Segal, Barbara M. Rhodus, Nelson L. Radfar, Lida Frank, Mark B. Scofield, R. Hal Lessard, Christopher J. Sivils, Kathy Moser TI Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates for Susceptibility to Sjogren's Syndrome SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Li, He; Lessard, Christopher J.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Hefner, Kimberly S.] Hefner Eye Care & Opt Ctr, Oklahoma City, OK USA. [Vista, Evan G.] Uni Santo Tomas, Taguig City, Philippines. [Gopalakrishnan, Raj; Rohrer, Michael; Hughes, Pamela; Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati Childrens Hosp, Cincinnati, OH USA. [Lessard, James A.] Valley Bone & Joint Clin, Grand Forks, ND USA. [Anaya, Juan-Manuel] Univ Rosario Corp Invest Biol, Bogota, Colombia. [Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. RI Adrianto, Indra/D-4214-2013; Anaya, Juan-Manuel/J-1960-2016 OI Adrianto, Indra/0000-0002-9973-3057; Anaya, Juan-Manuel/0000-0002-6444-1249 NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2674 BP S1134 EP S1134 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748306184 ER PT J AU Li, J Hsu, HC Yang, PA Wu, Q Spalding, DM Chatham, WW Kimberly, RP Bridges, SL Mountz, JD AF Li, Jun Hsu, Hui-Chen Yang, PingAr Wu, Qi Spalding, David M. Chatham, W. Winn Kimberly, Robert P. Bridges, S. Louis, Jr. Mountz, John D. TI Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-alpha Production. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Spalding, David M.; Chatham, W. Winn; Kimberly, Robert P.; Bridges, S. Louis, Jr.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Hsu, Hui-Chen; Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2152 BP S910 EP S911 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305072 ER PT J AU Lo, GH McAlindon, TE Hawker, GA Driban, JB Price, LL Song, J Eaton, C Hochberg, MC Jackson, RD Kwoh, CK Nevitt, MC Dunlop, DD AF Lo, Grace H. McAlindon, Timothy E. Hawker, Gillian A. Driban, Jeffrey B. Price, Lori Lyn Song, Jing Eaton, Charles Hochberg, Marc C. Jackson, Rebecca D. Kwoh, C. Kent Nevitt, Michael C. Dunlop, Dorothy D. TI Knee Osteoarthritis Symptom Assessments That Combine Pain and Physical Activity Are Superior to Pain Alone. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Lo, Grace H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [McAlindon, Timothy E.; Driban, Jeffrey B.; Price, Lori Lyn] Tufts Med Ctr, Boston, MA USA. [Hawker, Gillian A.] Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada. [Song, Jing; Dunlop, Dorothy D.] Northwestern Univ, Chicago, IL 60611 USA. [Eaton, Charles] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Eaton, Charles] Univ Maryland, Baltimore, MD 21201 USA. [Jackson, Rebecca D.] Ohio State Univ, Columbus, OH 43210 USA. [Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, C. Kent] VA Healthcare Syst, Pittsburgh, PA USA. [Nevitt, Michael C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 239 BP S103 EP S103 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748300240 ER EF